

SHAHROKH F. SHARIAT, M.D.



CITIZENSHIP: Austrian

LANGUAGES: Fluent in English, Farsi, French, German, and Spanish

CURRENT POSITIONS

Professor and Chairman 4/2013-present
Department of Urology

Head 11/2022-present
Comprehensive Cancer Center

Medical University of Vienna; Vienna General Hospital
Währinger Gürtel 18-20; A-1090 Vienna, Austria
Tel: +43 1 40400 26150; Cell: +43 664 8001651010; Fax: +43 1 40400 2332
Email: sfshariat@gmail.com or shahrokh.shariat@meduniwien.ac.at

Adjunct Professor of Urology 4/2013-present
Departments of Urology
Weill Cornell Medical College, New York, New York, USA

Adjunct Professor of Urology 5/2013-present
Department of Urology,
University of Texas Southwestern Medical Center, Dallas, Texas, USA

Adjunct Professor of Urology 5/2015-present
Department of Urology
Second Faculty of Medicine, Charles University, Prag, Czech Republic

Adjunct Professor of Urology 2/2019-2/2022
Institute for Urology and Reproductive Health
I.M. Sechenov First Moscow State Medical University, Moscow, Russia

Honorary Professor of Urology 10/2019-present
Department of Urology, The University of Jordan, Amman, Jordan

Doctor Honoris Causa 10/2019
Carol Davila University of Medicine and Pharmacy, Bucarest, Romania

Doctor Honoris Causa 11/2021
Semmelweis University, Budapest, Hungary

ACADEMIC RESUME (status 6/19/2023)

1771 peer-reviewed and >600 non-peer-reviewed research papers

Scopus h-index: 126; number of citations: 65,641; www.scopus.com; accessed 6/19/2023

Google scholar h-index: 148 number of citations: 90,867; www.google scholar.com; accessed 6/19/2023

>30 book chapters; >2000 abstracts at national and international meetings (available on request)

Four patents; >80 national and international awards

Member of >25 academic societies; Editorial board of 26 scientific journals

EDUCATION & MEDICAL TRAINING

UNIVERSITY OF VIENNA MEDICAL SCHOOL, Vienna, Austria <i>Doctor of Medicine</i> <i>Thesis: "Impact of dialysis on serum total PSA, free PSA and free to total PSA ratio: is prostate cancer detection compromised in patients on chronic hemodialysis?"</i>	1993 – 1998
UNIVERSITY OF LA LAGUNA MEDICAL SCHOOL, La Laguna, Spain	1995 – 1996
SWISS FEDERAL INSTITUTE OF TECHNOLOGY, Lausanne, Switzerland <i>Pre-diploma in mathematics, physics, chemistry with distinction</i>	1992 – 1993
LYCEE FRANÇAIS DE VIENNE, Vienna, Austria <i>French Baccalaureate and Austrian Matura with distinction</i>	1979 – 1992

ACADEMIC TRACK

MEDICAL UNIVERSITY OF VIENNA, Vienna, Austria <i>Professor and Chairman of Urology</i> <i>Director, Urologic Oncology Fellowship Program</i> <i>Head of the Comprehensive Cancer Center</i>	4/2013 – present 4/2013 – present 11/2022 - present
WEILL CORNELL MEDICAL COLLEGE / NEW YORK-PRESBYTERIAN HOSPITAL, New York, NY, USA <i>Adjunct Professor of Urology and Medical Oncology</i> <i>Assistant Professor of Urology and Assistant Professor of Medical Oncology</i> <i>Associate Professor of Urology and Associate Professor of Medical Oncology</i> <i>Director, Bladder Cancer Outcomes and Translational Research</i> <i>Director, Urologic Oncology Fellowship Program</i>	4/2013 – present 2010 – 2011 2011 - 2013 2011 - 2013 2012 - 2013
MEMORIAL SLOAN-KETTERING CANCER CENTER, New York, NY, USA <i>Fellow/Faculty Instructor, Urologic Oncology</i>	6/2008 - 7/2010
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, Dallas, TX, USA <i>Adjunct Professor of Urology</i> <i>Chief Resident in Urology</i> <i>Resident in Urology</i> <i>Intern in Surgery</i> <i>Faculty Instructor, Urologic Oncology</i>	2013 - present 2007 - 2008 2004 - 2007 2003 - 2004 2002 - 2003
BAYLOR COLLEGE OF MEDICINE, Houston, TX, USA <i>Faculty Instructor, Urologic Oncology</i> <i>Postdoctoral Fellowship, Urologic Oncology</i> <i>Postdoctoral Frost Fellowship in Gene Therapy for Urologic Diseases</i>	2001 - 2002 1999 - 2000 1998 - 1999

PROFESSIONAL MEMBERSHIPS

• European Association of Urology (Europe)	1999
• Endourological Society (USA)	1999
• American Association for Cancer Research (USA)	1999
• American Society of Clinical Oncology (USA)	1999
• Society of Basic Urologic Research (USA)	2000
• Association of U.S. Trained European Physicians (USA); Founder	2000
• American Association of Clinical Urologists, Inc. (USA)	2001
• Bladder Cancer Research Consortium (International); Founder and Director	2002
• Texas Medical Association (USA)	2003
• American Urological Association (USA)	2004
• Society of Urologic Oncology (USA)	2004
• Bladder Cancer Early Detection Network (International): Founder and Director	2006
• American College of Surgeons (USA)	2008
• Upper Tract Urothelial Carcinoma Collaboration (International); Founder and Director	2008
• International Bladder Cancer Network (IBCN)	2008
• Bladder Cancer Advocacy Network (USA)	2010
• Österreichische Gesellschaft für Urologie und Andrologie (Austria) <i>Arbeitskreis: Geschlechtsspezifische Medizin in der Urologie</i>	2011
• Academic Men's Health Network (International)	2011
• Foundation for Men's Health (FMH); oncology-related advisory committee	2011
• American Society of Men's Health (ASMH); Executive committee and board of directors	2011
• Minimally Invasive Robotic Association (International)	2011
• Society of University Urologists (USA)	2011
• Iranian American Urological Society (North American); Co-founder and member	2012
• New York Academy of Sciences (USA)	2012
• New York Section of the American Urological Association (USA)	2012
• European Academy of Sciences and Arts (Europe)	2014
• Association of Academic European Urologists (Europe)	2014
• European Genito-Urinary Surgeons (Europe)	2015
• Central European Urological Society (CEUS; co-Founder and honorary member)	2017
• Deutsche Gesellschaft der Urologie (DE) korrespondierender Mitglied	2018
• IVALKV (AUT; Schriftfuehrervertreter)	2021
• Korrespondierende Mitgliedschaft in der Deutschen Gesellschaft für Urologie	2022

ADMINISTRATIVE ACTIVITIES

Tissue Bank Steering Committee Urology, Weill Cornell Med College, NY, NY, USA	2010-2013
Bladder Cancer Team Leader, Weill Cornell Med College, NY, NY, USA	2010-2013
Lead of GU section of the Comprehensive Cancer Center, Med Uni Vienna, AUT	2014-present
Ambulatory operations council member, AKH Vienna, AUT	2016-present
Professorship title working group member, Med Uni Vienna, AUT	2016-2020
Habilitations committee surgery member, Med Uni Vienna, AUT	2016-2022
Privat medicine working group lead, Med Uni Vienna, AUT	2018-present
Senat member, Medical University of Vienna, AUT	2019-present
Appointment committee, chair in general surgery, Med Uni Vienna, AUT	2019-2020

Renommee working group member, Med Uni Vienna, AUT	2020-present
Comprehensive cancer center governing body member, Med Uni Vienna, AUT	2020-present
Appointment committee head, prof in bariatric surgery, Med Uni Vienna, AUT	2020-2021
Reviewer committee member, prof in palliative medicine, Med Uni Vienna, AUT	2021
Reviewer committee member, prof in obstetrics, Med Uni Vienna, AUT	2021
Appointment committee, prof in translational oncology, Med Uni Vienna, AUT	2021
Reviewer committee member, prof in neuroradiology, Med Uni Vienna, AUT	2021
Member of the board of international patients, General Hospital Vienna, Vienna, AUT	2021
MD/PhD working group member, Med Uni Vienna, AUT	2021
Cooperation Med Uni Vienna/WIGEV working group member, Med Uni Vienna, AUT	2019-present
Structural development working group member, Comprehensive Cancer Center, Med Uni Vienna, AUT	2020-present
Habilitation Fachbereich chirurgisch committee, Med Uni Vienna, AUT	2019-2022
Task force nursing shortage, Med Uni Vienna, AUT	2022-present
Appointment committee head, chair in gynecology, Med Uni Vienna, AUT	2022-2023
European urological association research foundation member	2017-2022
President of the Central European Urological Society	2022-present
President Austrian Urological Society	2023-present
Appointment committee, chair in anesthesia and critical care, Med Uni Vienna, AUT	2023-present

HONORS & AWARDS (selected)

- **Award for the First Term of Studies** 1995
Dean of the University of Vienna - Medical School (Austria)
- **“Matricula de Honor” Honorary Award for best student in 1995/1996** 1996
University of La Laguna - Medical School (Spain)
- **Award for the Second Term of Studies** 1997
Dean of the University of Vienna - Medical School (Austria)
- **Performance Grant for Outstanding Study Success in 1996/1997** 1997
Dean of the University of Vienna – Medical School (Austria)
- **Performance Grant for Outstanding Study Success in 1997/1998** 1998
Dean of the University of Vienna - Medical School (Austria)
- **Andlinger Educational Fellowship Grant, American-Austrian Foundation (USA)** 1998
- **Young Investigator Award, Hans und Rosa Blanca Foundation (Austria)** 1999
- **Performance Grant for Outstanding Achievements in Research** 1999
Dean of the University of Vienna - Medical School (Austria)
- **Grant, Methods in Clinical Cancer Research. Vail, Colorado** 1999
The American Association for Cancer Research and the American Society of Clinical Oncology
- **Travel Grant, Molecular Biology in Clinical Oncology. Aspen, Colorado** 2000
The American Association for Cancer Research
- **Glaxo SmithKline Scholar Award, for promising clinical/translational cancer research** 2001
American Association of Cancer Research
- **Pfizer Scholar in Urology Award** 2001
- **Winner of the Science Day 2001 Project – Baylor College of Medicine, Houston, TX** 2001
- **First Place Poster** 2001
2nd Alexander Research Symposium, Baylor College of Medicine, Houston, TX
Expression of TGF-β1 and its receptors in transitional cell carcinoma of the bladder.
- **AUA / Praecis Gerald P. Murphy Scholar** 2002
- **American Cancer Society Institutional Research Grant (IRG#93-034-06)** 2002

Development of a nomogram for prediction of the development of distant prostate cancer metastases and mortality.

- **Best Poster** 2002
Society of Urologic Oncology Annual Meeting, National Cancer Institute, December 13 - 14, 2002, National Institutes of Health, Bethesda, MD
Preoperative serum levels of pro-PSA isoforms are associated with biologically aggressive prostate cancer.
- **2000 Outstanding Intellectuals of the 21st Century** 2003
International Biographical Center, Cambridge, England (Registration number 965274)
- **Best Poster** 2004
Society for Urodynamics and Female Urology 2004 Meeting. Scottsdale, Arizona. February 26-29, 2004.
- **“Best Poster” in urothelial cancer** 2004
European Association of Urology Annual Meeting, Vienna, March 26, 2004.
Urine detection of survivin is a sensitive marker for the non-invasive diagnosis of bladder cancer.
- **“Best Poster” in urogenital trauma** 2005
21st European Association of Urology Annual Meeting, Paris, April 5-8, 2006.
Evidence-based validation of the predictive value of the American Association for the Surgery of Trauma kidney injury scale.
- **“Best Poster” in bladder cancer: diagnosis and staging III** 2006
21st European Association of Urology Annual Meeting, Paris, April 5-8, 2006. *Survivin expression is associated with bladder cancer presence, stage, progression, metastasis, and mortality.*
- **AUA / Threshold Pharmaceuticals Gerald P. Murphy Scholar** 2006
- **AUA / Novacea Gerald P. Murphy Scholar** 2007
- **Listed in the “Guide to America’s Top Urologists 2007” – Consumers’ Research** 2007
Council of America is an independent research company based in Washington, DC that evaluated professional services throughout America (www.consumerresearchcncl.org).
- **“Best Poster” in prostate cancer: staging I** 2007
22nd European Association of Urology Annual Meeting, Berlin, March 21-4, 2007.
Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence.
- **Best Poster** 2007
Society of Urologic Oncology Eight Annual Meeting, National Cancer Institute, November 29th-December 1st, 2007, National Institutes of Health, Bethesda, Maryland.
Multiple bio-markers for the prediction of bladder cancer recurrence and mortality.
- **“Best Poster” in prostate cancer: prognostic factors and predictors of outcome** 2008
23rd European Association of Urology Annual Meeting, Milano, Italy. March 26-9, 2008.
Early post-operative plasma transforming growth factor- β 1 is a powerful predictor of biochemical progression after radical prostatectomy.
- **“Best Poster” in diagnosis and staging of urothelial tumours II** 2008
23rd European Association of Urology Annual Meeting, Milano, Italy. March 26-9, 2008.
Multiple bio-markers for the prediction of bladder cancer recurrence and mortality.
- **“Best Poster” in Prostate Cancer: Staging (I)** 2008
American Urological Association Annual Meeting, Orlando, FL, May 17-22, 2008.
Improved prediction of disease relapse after radical prostatectomy using a panel of reoperative blood-based biomarkers.
- **“Best Poster” in Prostate Cancer: Advanced (I)** 2008
American Urological Association Annual Meeting, Orlando, FL, May 17-22, 2008.
J.Urol 179(4): 186, 2008. The effect of androgen deprivation therapy on the rate of subsequent non-cancer morbidities.
- **“Best Poster” in Urothelial Cancer: Surgical Therapy** 2008

American Urological Association Annual Meeting, Orlando, FL, May 17-22, 2008.

More extensive lymphadenectomy improves the prognosis of patients with upper tract urothelial carcinoma without nodal metastases.

- **Reviewer of the month January** – European Urology 2008
- **ASCO Cancer Foundation Merit Award** 2008
American Society of Clinical Oncology Cancer Foundation and the ASCO/National Cancer Institute/EORTC Scientific Committee, Annual Meeting on Molecular Markers in Cancer, Hollywood, FL
- **Listed in the “Guide to America’s Top Urologists 2008”** 2008
- **Best Poster** 2008
Society of Urologic Oncology Annual Meeting, National Cancer Institute, December 4-6th, 2008, National Institutes of Health, Bethesda, MD
Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with bladder cancer.
- **Merit Award** 2009
ASCO Cancer Foundation Board of Directors and the 2009 Genitourinary Cancers Symposium Program Committee, Genitourinary Cancers Symposium, Orlando, FL
Use of pre-treatment biomarker levels to improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence
- **“Best Poster” in Transitional Cell Carcinoma Pathology** 2009
24th European Association of Urology Meeting, Stockholm, Sweden. March 17-1, 2009.
Predictive value of the combination of immunohistochemical markers in patients with pT1 disease at radical cystectomy.
- **“Best Poster” in Management of Advanced Urothelial Pathology** 2009
24th European Association of Urology Annual Meeting, Stockholm, Sweden. March 17-21, 2009.
Improved prediction of clinical outcomes in patients with advanced bladder cancer using a panel of four cell cycle regulators.
- **“Best Poster” in Upper and Lower Urinary Tract Carcinoma** 2009
24th European Association of Urology Annual Meeting, Stockholm, Sweden. March 17-21, 2009.
Proposal for subclassification of pT3 urothelial cancer of the renal pelvis.
- **First Prize for the Best Abstract** 2009
25th European Association of Urology Annual Meeting, Barcelona, Spain. April 16-20, 2010.
Her2 expression status provides independent prognostic information in patients with urothelial carcinoma of the bladder: a rationale for targeted therapy.
- **“Best Poster” in Urothelial Cancer: Natural history and pathophysiology/markers** 2010
American Urological Association Annual Meeting, San Francisco, CA, May 29-June 3, 2010.
J.Urol 183(4): 662-663, 2010.
- **BJU Int Reviewer of Year 2010** 2011
- **Senior author of Merit award to Eugene Cha at 2011 Genitourinary Cancers Symposium from ASCO/ASTRO/SUO.** 2011
February 2011. San Orlando, FL.
Immunocytology is a strong predictor of bladder cancer presence in patients with painless hematuria: a multicentre study
- **“Best Poster” in Hematuria and Bladder Cancer Diagnosis session** 2011
26th Annual EAU Congress. 18-22 March 2011, Vienna, Austria.
Risk assessment of patients who present with asymptomatic hematuria: development and validation of a nomogram for prediction of bladder cancer presence. 3/19/2011. Abstract 149, page 128.
- **“Best Poster”** 2011
26th Annual EAU Congress. 18-22 March 2011, Vienna, Austria.
pT3 substaging is a prognostic indicator in lymph node negative urothelial carcinoma of the bladder 3/19/2011
- **Senior author of “Best Abstract”** 2011

8th Men's Health World Congress & 4th European Men's Health Conference. 2-5 October 2011, Vienna, Austria

Obesity adversely impacts disease-specific outcomes in urothelial carcinoma of the urinary bladder 10/3/2011

- **2011 Men's Health World Congress outstanding contribution award** 2011
8th Men's Health World Congress & 4th European Men's Health Conference. 2-5 October 2011, Vienna, Austria
- **BJU International Reviewer of Year 2011** 2012
- **Senior author of Merit award to Eugene Cha at 2012 Genitourinary Cancers Symposium from ASCO/ASTRO/SUO.** 2012
February 2-4, 2012. San Francisco, CA.
Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma
- **Senior author of Merit award to Michael Rink at 2012 Genitourinary Cancers Symposium from ASCO/ASTRO/SUO.** 2012
February 2-4, 2012. San Francisco, CA.
Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study
- **Co-author of "Best Poster" in Session 75: Prognostic biomarkers in urothelial carcinoma** 2012
27th Annual EAU Congress. 24-28th February 2012
Circulating tumour cells can not predict clinical or nodal stage, but survival after radical cystectomy for urothelial carcinoma of the bladder.
- **Second author of Best Clinical Research Paper Published in European Urology** 2011
Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration
- **Co-author of "Best Poster" in Radical prostatectomy: Pathological issues and surgical margins,** 2012
27th Annual EAU Congress. 24-28th February 2012
Comparative analyses of surgical modalities for the management of prostate cancer: A multi-institutional study of positive surgical margin rates on 22,403 patients operated on in the new millennium
- **Mentor of Ferdinand C. Valentine Student Research Grant in Urology** to medical student Joseph J. Crivelli, New York, NY, USA 2012
Intravesical application of nanoparticle-mediated microwave thermotherapy for treatment of bladder cancer
- **Senior author of "Best Poster" in Bladder Cancer: Metastatic Disease/Staging** 2012
American Urological Association Association Annual Meeting, Atlanata, GA, USA
Tuesday, May 22, 2012 3:30 PM-5:30 PM
Abstract 1904: Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasis
- **Senior author of Dr. Johannes Ritschl Forschungspreis of the Österreichischen Krebshilfe Niederösterreich, Austria** (recipient: Harun Fajkovic, MD) 2012
Prognostic value of extranodal extension and other lymph node parameters in bladder cancer patients
- **Leading Physician of the World & Top Urologic Oncologist in New York, NY, USA** 2012
bestowed by Doctors of Excellence, The Leading Physicians of the World, The International Association of Oncologists.
- **Senior author of Best Clinical Research Paper Published in European Urology in 2012** 2012
Michael Rink: *Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery*
- **Compassionate Doctor Recognition** 2012-2013
by Vitals.com in conjunction with PatientsChoice.org
http://www.vitals.com/doctors/Dr_Shahrokh_Shariat/credentials#ixzz33bEiXwTM

- **Resident's Corner Award for the Best Scientific Paper published in European Urology by a resident in 2012** 2013
 Eugene Cha: *Immunocytology is a strong predictor of bladder cancer presence in patients with painless hematuria: a multicentre study*
 European Urology, Volume 61, Issue 1, January 2012, Pages 185-192
- **European Association of Urology Best Paper published on Clinical Research in the Urological Literature Award.** EAU Scientific Congress Office. 2013
 28th Annual EAU Congress, Milan, Italy. March 15-19th 2013
Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy
- **Senior author of "Best Poster"** in Poster Session 13: Bladder cancer: gene expression and molecular classification; 28th Annual EAU Congress. March 2013, Milan, Italy. 2013
Prediction and reversibility of cisplatin-resistance in bladder cancer: HOXA9 a novel epigenetic biomarker. Abstract number: 156
- **Senior author of "Best Poster"** in Poster Session 47: Urothelial cancer: Transurethral surgery and intravesical recurrence Hematuria and bladder cancer diagnosis session 28th Annual EAU Congress. March 2013, Milan, Italy. 2013
Prediction of cancer-specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: Development of an optimized post-operative nomogram using decision curve analysis Abstract number: 576
- **Senior author of "Best Poster"** in Poster Session 62: Urothelial cancer treatment: Predicting outcomes; 28th Annual EAU Congress. March 2013, Milan, Italy. 2013
Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non muscle-invasive urothelial carcinoma of the bladder. Abstract number: 754
- **Senior author of "Best Poster"** in Poster Session 62: Urothelial cancer treatment: Predicting outcomes; 28th Annual EAU Congress. March 2013, Milan, Italy. 2013
Female gender is associated with higher risk of disease recurrence in patients with primary T1 high grade urothelial carcinoma of the bladder. Abstract number: 752
- **Senior author of "Best Poster"** in Poster Session 58: Urothelial cancer treatment: intravesical approaches; 28th Annual EAU Congress. March 2013, Milan, Italy. 2013
Statin use is not associated with prognosis or BCG-response in patients with non-muscle invasive bladder cancer. Abstract number: 701
- **Senior author of Best Abstract in prostate cancer**, American Urological Association Annual Meeting ,San Diego, CA. May 4-8th 2013 2013
Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical prostatectomy?
- **Senior author of Best Abstract in bladder cancer**, American Urological Association Annual Meeting ,San Diego, CA. May 4-8th 2013 2013
Concordance in molecular marker status between bladder tumors at time of transurethral resection and subsequent radical cystectomy: results of a 5-year prospective study
- **Senior author of Best Abstract in bladder cancer**, American Urological Association Annual Meeting ,San Diego, CA. May 4-8th 2013 2013
Concordance in molecular marker status between bladder tumors at time of transurethral resection and subsequent radical cystectomy: results of a 5-year prospective study
- **Patients' Choice Award** 2013
 by Vitals.com in conjunction with PatientsChoice.org
http://www.vitals.com/doctors/Dr_Shahrokh_Shariat/credentials#ixzz33bEiXwTM
- Senior author of **Third Prize for the Best Abstract by a Resident** 2014
 29th European Association of Urology Annual Meeting, Stockholm, Sweden

- Malte Rieken: *Comparison of the EORTC tables and the newly introduced EAU categories for risk stratification of patients with no-muscle invasive bladder cancer*
- Senior author of **Best Poster Prize** in Upper Tract Urothelial Carcinoma poster session 2014
29th European Association of Urology Annual Meeting, Stockholm, Sweden
Malte Rieken: *Frequency and prognostic value of PTEN loss in patients with upper tract urothelial carcinoma*
 - **Matula Award**, 29th European Association of Urology, Stockholm, Sweden 2014
 - **Gold Cystosocpe Award**, American Urological Association, Boston, USA 2017
 - Senior author of **Best Poster Prize** in Poster Session 46: Prostate cancer biomarkers: 2017
Technical advances and clinical implications at the 32nd European Association of Urology Annual Meeting, London, UK
Elevated preoperative neutrophil-lymphocyte ratio predicts upgrading at radical prostatectomy
 - Senior author of **Best Poster Prize** in Poster Session 88: Upper urinary tract tumour: 2017
Outcomes after radical surgery & peri-operative chemotherapy at the 32nd European Association of Urology Annual Meeting, London, UK
Trends of lymphadenectomy in upper tract urothelial carcinoma patients treated with radical nephroureterectomy: The impact of surgical technique
 - **Honorary member** of the Uro-oncologic Section, Congress of the Polish Urological Association, Katowice, PL 6/20/2017
 - **Honorary member** of the Asutrian patient advocacy/selfhelp group prostate cancer 12/5/2017
 - **Platinum award** of European Urology, Journal of the European Association of Urology 2018
 - **Platinum award** of European Urology, Journal of the European Association of Urology 2019
 - **Honorary member** of the Polish Urological Society 2021
 - Co-author of **Best Poster Prize** by a YAU member at the European Association of Urology Annual Virtual Meeting 2021 2021
Survival outcomes after radical cystectomy versus conservative management for cT1 high grade non-muscle invasive micropapillary bladder cancer
 - Senior-author of **best abstract poster** at EMUC21, Athens, GR 11/2021
P154: Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for non-metastatic urothelial carcinoma of the bladder"
 - **Co-author of Best Paper** published in 2021 by Young Academic Urologists 2022
 - **Best Abstract in bladder cancer**, American Urological Association 2022
"Upper Tract Urothelial Carcinoma in the Lynch Syndrome Tumour Spectrum: A Comprehensive Overview from the European Association of Urology – Young Academic Urologists and the Global Society of Rare Genitourinary Tumors."
 - **Korrespondierender Mitglied** in der Deutschen Gesellschaft für Urologie 2022
 - **Honorary member** of the Iranian Urological Association 2022
 - Co-author of **Best Abstract Prize** by a YAU member at the European Association of Urology Annual Virtual Meeting 2023 2023
Abstract Session 30, A0653: Can we rely on available models to identify candidates for extended Pelvic Lymph Node Dissection (ePLND) in men staged with PSMA-PET? External validation of the Briganti nomograms and development of a novel tool to identify optimal candidates for ePLND

- **Honorary member** of the Slovak Urological Society 2023

GRANT FUNDING

- **Frost gene therapy for urologic diseases fellowship program** 1999
Frost Foundation, Inc. (USD 90,000)
Baylor College of Medicine, Principal Investigators: Lerner S., Slawin K., Shariat S.
- **Gene therapy for urologic diseases** 1999
Max Kade Foundation, Inc. (USD 53,350)
Baylor College of Medicine, Principal Investigator: Shariat S.
- **Gene therapy for urologic diseases fellowship** 2001
Prostate Cancer Research Initiative - PCRI (USD 90,000)
Baylor College of Medicine, Principal Investigators: Lerner S., Slawin K., Shariat S.
- **Identification of blood, urine, and tissue biomarkers associated with presence, pathologic features and/or clinical outcomes in patients with urologic cancers.** 2001
Erwin Schrödinger Scholarship from the Austrian Academy of Science. (USD 50,000)
Principal Investigator: Shariat S.
- **CTSC Pilot award** 6/2012
Metabolomic prognostication and prediction of response to therapy in non-muscle invasive bladder cancer (USD 45,000)
Principal Investigator: Shariat S.
- **Österreichische Nationalbank** 2013 - 2015
A non-invasive genetic and epigenetic biomarker panel for early diagnosis of bladder cancer project number: 15362, 92,600 € Principal Investigator: Shariat S.
- **Medical-Scientific Fund** of the Mayor of the City of Vienna 2014 - 2015
Quality indicators for bladder cancer (project number: 14069/2014, 28,000 €)
Principal Investigator: Shariat S.
- **Jubiläumsfondsprojekt** Nr. 16702 2016 – 2018
Identifizierung von prädiktiven DNA-Methylierungsbiomarkern für BCG-Immuntherapie im Blasenkarzinom (Auftragsnummer: AP16702ONB / KP16702ONB; €74,000)
Principal Investigator: Hassler M. & Shariat S.
- **Sanofi grant** 2017-2019
Identifying men with low-risk prostate cancer who are unlikely to benefit from treatment. 120,000€ Principal Investigator: Shariat S.
- **Roche grant** 2019
Potentiation of Immune checkpoint inhibitors via a pre-stimulation with Azacitidine 47,000€
Investigators: M. Hassler, U. Lemberger Senior Investigator: Shariat S.
- **Österreichische Nationalbank** 2020
Functional relations of FGFR3 and TERT in urothelial carcinomas of the bladder and the upper urinary (#18329). 104,000 € Investigator: I. Ertl Senior Investigator: Shariat S.
- **Movember Golftrophy** 2018-2019 & 2022
Research in prostate cancer 20,000€ Investigator: Shariat S.
- **FWF Austrian Science Fund** 2023

P36435 - Characterization of the transcriptomic landscape of muscle-invasive bladder cancer underlying responsiveness and resistance to clofarabine; € 396,469; Investigator: B. Englinger

PATENTS

- **Method to determine prognosis after therapy for prostate cancer** 2002
 Inventors: Shahrokh Shariat, Kevin Slawin
 A method for prognosis of patients with prostate cancer, e.g., clinically localized prostate cancer, is provided.
 EP1373899 Patent record available from the European Patent Office
 US20030054419 Patent record available from the US Patent Office
 WO02068960 Patent record available from the World Intellectual Property Organization,
 Granted 2002-09-06
- **Methods to determine prognosis after therapy for bladder cancer** 2003
 Inventors: Shahrokh Shariat, Kevin Slawin, Seth Lerner
 A method to diagnose, stage and predict prognosis of bladder cancer patients is provided, e.g., using TGF- β 1, IL-6, IL-6sR, uPA, uPAR and IGFBP-3.
 US20030032074 Patent record available from the US Patent Office
 WO02099114 Patent record available from the World Intellectual Property Organization,
 Granted 2003-06-19
- **Prognostic methods for patients with prostatic disease** 2004
 Inventors: Shahrokh Shariat, Kevin Slawin, Michael Kattan, Peter Scardino
 A method to diagnose, stage and predict prognosis of prostate cancer patients is provided.
 EP1540350 Patent record available from the European Patent Office
 US20030235816 Patent record available from the US Patent Office
 WO2004027432 Patent record available from the World Intellectual Property Organization,
 Granted 2004-08-05
- **Soluble Fas urinary marker for the detection of bladder transitional cell carcinoma** 2010
 Inventor: Shahrokh Shariat
 The present invention is an apparatus, system and method for detecting bladder cancer are provided that includes a substrate including one or more sFas binding agents and one or more reagents that indicate the amount of sFas present in the sample.
 US07759077 Patent record available from the US Patent Office,
 Granted 2010-07-20

PROFESSIONAL RESPONSIBILITIES

EDITORIAL WORK

- Editorial Board Member, European Urology 1/2008 – present
- Editorial Board Member, Immunotherapy 3/2008 – present
- Contributor to Urology, Faculty of 1000 Medicine 5/2008 – 9/2010
- Editorial Board Member, Debates on Bladder Cancer 9/2009 – present
- Contributor, UpToDate 11/2009 – present
- Editorial Board Member, Oncology Reports 12/2009 – present
- Editorial Board Member, BJU Int 2/2010 – present

- Editorial Board, Journal of Men's Health 3/2010 – present
- Editorial Board Member, World Journal of Clinical Oncology 4/2010 – present
- Editorial Board Member, Journal of Molecular Biomarkers and Diagnosis 6/2010 – present
- Editorial Board Member, Journal of Molecular Imaging and Dynamics 8/2010 – present
- Editorial Board Member, World Journal of Clinical Urology 12/2010 – present
- International Scientific Board, Archivos Españoles De Urologia 1/2011 – present
- Consulting Editor, International Brazilian Journal of Urology 1/2011 – present
- Editorial Board Member, ISRN Oncology 2/2011 – present
- Editorial Board Member, Urology: Current Research (OMICS Publishing Group) 3/2011 – present
- Editorial Board Member, World Journal of Urology 7/2011 – present
- Editorial Board Member, Frontiers in Genitourinary Oncology 2/2012 – present
- Co-editor of book on Prostate cancer –original scientific reports and case studies Edited by Spiess P.E. 6/2012
- Scientific board of Spectrum Urologie - offizielle Organ des Berufsverbands der Österreichischen Urologen (BVU) 2/2013-present
- Bladder Cancer Advocacy Network's scientific advisory board 3/2013-present
- Editorial Board Member, Advances in Therapy (ISSN: 0741-238X) 3/2013-present
- Editorial Board Member, Journal of Tumor (ISSN 1819-6187) 4/2013-present
- Editorial Board Member, American Journal of Urology (ISSN 2162-9722) 5/2013-present
- Editorial Board Member, Bladder Cancer 8/2014-present
- *Editor in chief*, Urologie Scan 9/2014-12/2016
- Editorial Board Member, International Journal of Urology & Urological Practice (http://www.journalnetwork.org/journals/international-journal-of-urology-and-urological-practice) 9/2014-present
- Editorial board, Nature Reviews Urology 10/2014-present
- *Editor in chief*, Current Opinion in Urology (ISSN 0963-0643) 11/2014-present
- Editor Focused Issue: Urothelial Carcinoma 1/2013
- Editor Focused Issue: Immunotherapy 12/2017
- Editorial board, Minerva Urologica e Nefrologica (ISSN 0393-2249) 11/2014-present
- Journal Club report from MUW/AKH Wien, Spectrum Urologie 9/2013-present
- Editorial board, Der Urologe (ISSN: 0340-2592) 10/2014-present
- Editorial board, Bladder Cancer (ISSN print 2352-3727, ISSN online 2352-3735) 4/2015-present
- Editor, European Urology Focus 4/2015-12/2016
- Translational Andrology and Urology (ISSN 2223-4683) Vol 5, No 5, October 2016 8/2016
- Editor Focused Issue: Urothelial Carcinoma
- Editorial board, Journal für Urologie und Urogynäkologie 8/2017-present
- International advisory board, Jordan Medical Journal (ISSN: 0446-9283) 6/2021-present
- Clinical Surgery Research Communications (CSRC) 2/2022-present
- Scientific advisory board Owkin (<https://owkin.com/>) 3/2022-present

MODERATED SESSIONS AT MEETINGS

- **Chair of Moderated Poster session:** Urothelial tumours: Basic research I 2008
(Poster session 33) at the 23rd European Association of Urology Annual Meeting, Milano, Italy. March 26-29, 2008.
- **Chair of Moderated Poster session:** Genetics and basic research in urothelial tumours 2009
(Poster session 26) at the 24th European Association of Urology Annual Meeting,

Stockholm, Sweden. March 17-21, 2009.

- **Chair of Moderated Poster session II:** Basic research at the Northeastern Section AUA 61st Annual Meeting, Montreal, Quebec, Canada. October 7-11, 2009. 2009
- **Chair of Moderated Poster session 64:** Prostate cancer: markers II at the American Urological Association Annual Meeting, San Francisco, CA, May 29-June 3, 2010. 2010
- **Chair of Moderated Debate** on *Current Approaches to Bladder Cancer* at Seventh Annual Current Trends in Genitourinary Malignancies, New York, NY (10/16/2010). 2010
- **Chair of Session** – *Does it really matter to consider gender when managing male patients in primary care?* 7th Men’s Health World Congress and 3rd European Men’s Health Conference. 28-30 October 2010, Nice, France. 2010
- **Chair of Session** – *Comprehensive long term outcomes of male urogenital cancers.* 7th Men’s Health World Congress and 3rd European Men’s Health Conference. 28-30 October 2010, Nice, France (10/29/2010) 2010
- **Chair of Panel Discussion** – *Why and how to care for patients with advanced PCA in a multidisciplinary approach.* 7th Men’s Health World Congress and 3rd European Men’s Health Conference. 28-30 October 2010, Nice, France (10/30/2010) 2010
- **Chair of Panel Discussion** – *Developing a men’s health curriculum: teaching men’s health to medical students & health professionals.* 7th Men’s Health World Congress and 3rd European Men’s Health Conference. 28-30 October 2010, Nice, France (10/30/2010) 2010
- **Chair of Moderated Poster Session** at the 7th Men’s Health World Congress and 3rd European Men’s Health Conference. 28-30 October 2010, Nice, France (10/30/2010) 2010
- **Moderator of Prostate Cancer Clinical Case Discussion** at the 4th Journee d’onco-urologie of the Association Marocaine d’Urologie, Fes, Morocco (12/18/2010) 2010
- **Chair of Moderated Poster session 64:** Prostate cancer: markers II at the American Urological Association Annual Meeting, San Francisco, CA, May 29-June 3, 2010. 2010
- **Chair of Moderated Poster session 26:** Prostate cancer diagnosis at the 26th Annual European Association of Urology Congress. 18-22 March 2011, Vienna, Austria. 2011
- **Chair of Session:** Onkologie at the 44. Alpenländische Urologensymposium, Wolkenstein, Bozen, IT, March 30-April 2, 2011. 2011
- **Introduction session** at Young Urological Associates of the European Association of Urology. 9-10 April 2011, Lago Maggiore, Italy (4/9/11) 2011
- **Chair of Sessions** - The Inaugural International Prostate Cancer Symposium. May 10-12, 2011, New York, USA. 2011
Prostate cancer complications and their management.
Surgical training mini-session.
- **Chair of Sessions** - 8th Men’s Health World Congress & 4th European Men’s Health Conference. 2-5 October 2011, Vienna, Austria 2011

*Urologic care for the elderly patient**Debate on PSA screening for prostate cancer*

- **Chair of Session** – Menopause, Andropause, Anti-aging. 8-10 December, Vienna, Austria 2011
Urology and Andrology
- **Chair of moderated poster session 91: Prostate cancer: Active surveillance** 2012
at the 26th Annual European Association of Urology Congress. 24-28 February 2012, Paris, France.
- **Chair of Session** – Fortbildungstagung der Österreichischen Gesellschaft für Urologie 2012
und Andrologie. 9-10 November 2012, Linz, AUT.
Was sollte ich wissen? Leitlinien und Nomogramme
- **Chair of Session - Diagnostics, prognostic factors and risk stratification of upper tract** 2012
urothelial carcinoma at the Summit on Upper Tract Urothelial Carcinoma,
Society of Urologic Oncology Annual Meeting, November 28-30, 2012, Bethesda, MD, USA
- **Chair of session 2**, 19th St Lawrence Urological Group, 1/26/2013
McGill University Health Centre, Montreal, Quebec, Canada 1/25-27, 2013
- **Chair of moderated poster session 62: Urothelial cancer treatment: predicting outcomes** 3/19/2013
28th Annual EAU Congress. March 2013, Milan, Italy.
- **Chair of wissenschaftlichen Sitzung Katheterismus**, Wilhelimenspital, Vienna, Austria 7/3/2013
- **Chair of session, 33rd Congress of the Societe Internationale d'Urologie, Vancouver, Canada**
Surgical Tips 1: Endoscopic Management of Urothelial Cancer 9/9/2013
ICUD Consultation 2013: Upper Tract Urothelial Carcinoma 9/10/2013
- **Chair of local Lilly meeting on prostate cancer**, Hilton Hotel, Vienna, Austria 10/11/2013
- **Organizator/Chair** First Interdisciplinary Prostate Cancer Symposium, Vienna, AUT 11/29/2013
- **Chair of Session VI** at 23rd International Symposium of the Endourology and ESWL 3/8/2014
Section of the Polish Urological Association, Wroclaw, Poland
- **Chair of moderated poster session: in Upper Tract Urothelial Carcinoma** 4/2014
29th Annual EAU Congress. April 2013, Stockholm, Sweden
- **Chair of session, 34th Congress of the Societe Internationale d'Urologie, Glasgow, UK**
Debate: why do women have a worse prognosis from bladder cancer? 10/14/2014
- **Chair of session, 24. Jahrestagung der MKÖ, Linz, AUT** 10/18/2014
Kontinenz und Schmerz – Zukunftsperspektiven
- **Chair of local Lilly meeting on BPH/LUTS/ED**, Albertina, Vienna, Austria 10/24/2014
- **Chair of local Atellas meeting on castration-resistant prostate cancer** 10/25/2014
Aula der Wissenschaften, Vienna, Austria

- **Chair of Session** – Fortbildungstagung der Österreichischen Gesellschaft für Urologie und Andrologie. 7-8 November 2012, Linz, Austria 11/7/2014
Smoking kills- die Rolle der Urologie
- **Chair of Session** – 13th Meeting of the Association of Academic European Urologists (AAEU), 4-7 December 2014, Porto, Portugal 12/5/2014
Bladder cancer session
- **Chair of moderated poster session 62:** Urothelial cancer treatment: predicting outcomes 3/19/2014
28th Annual EAU Congress. March 2013, Milan, Italy.
- **Chair of moderated poster session 62:** Urothelial cancer treatment: predicting outcomes 3/19/2014
28th Annual EAU Congress. March 2013, Milan, Italy.
- **Chair of the poster session MP68:**Bladder Cancer: Basic Research IV at the American Urological Association Annual Meeting 2015, New Orleans, LA, USA 5/19/2015
- **Chair** of Inaugural Friends of Urology Austrian Polish meeting, Vienna, Austria 5/29/2015
- **Chair of Olympus Symposium,** Challenges in Endourology, Paris, France 6/29/2015
Clinical Innovations in Endourology
- **Chair of lecture session,** 7th European Multidisciplinary Meeting on Urological Cancers, Barcelona, Spain 11/14/2015
Management of upper urinary tract urothelial carcinoma
- **Chair of session,** 68. Deutsche Gesellschaft der Urologie Kongress, Leipzig, Germany 29/09/2016
Zystektomie
- **Chair of session,** 36th Congress of the Societe Internationale d’Urologie, Buenos Aires, Argentina 10/23/2016
Moderated Posters 16: Bladder Cancer
- **Chair of session,** Jahreshauptversammlung der ÖGU Fortbildungstagung der Österreichischen Gesellschaft für Urologie und Andrologie 11/5/2016
International Lectures
- **Chair of session** – 15th Meeting of the Association of Academic European Urologists (AAEU), 5-7 December 2016, Warsaw, Poland 12/5/2016
Endourology and more
- **Chair of session** – 2nd Michal J. Marberger Annual Symposium, Vienna, AUT 12/16/2016
Controversies and challenges in lymphadenectomy
- **Chair of moderated poster session:** Ongoing clinical trials 3/26/2017
29th Annual EAU Congress. March 2017, London, UK.
- **Chair of moderated poster session 64:** Prostate cancer: localized surgical therapy at the American Urological Association Annual Meeting, Boston, MA, May 12-6, 2017. 5/14/2017
- **Chair of moderated poster session 64:** Prostate cancer: localized surgical therapy at the American Urological Association Annual Meeting, Boston, MA, May 12-6, 2017. 5/14/2017
- **Chair of moderated session:** Urothelkarzinom 5/19/2017
43. Gemeinsame Tagung der Oesterreichischen Gesellschaft fuer Urologie und Andrologie und der Bayerischen Urologenvereinigung, Wien, AUT
- **Chair of moderated session:** Österreichisches Gesundheitssystem - Quo vadis? 5/31/2017

Gesellschaft der Ärzte in Wien – Billrothhaus, Wien, AUT

- **Chair of meeting:** Europa Uomo Seminar 360 Degree Perspectives on Prostate Cancer, 6/10/2017
Wien, AUT
- **Chair** of the Uro-oncologic Section session, Congress of the Polish Urological Association, Katowice, PL 6/20/2017
- **Chair of session** *Tumor development an promising biomarkers in prostate and renal cancers* of the EAU 17th Central European Meeting in conjunction with the national 63rd conference of the Czech Urological Society, Plzen, Czech Republic 10/19/2017
- **Chair of ESU session** of the EAU 17th Central European Meeting in conjunction with the national 63rd conference of the Czech Urological Society, Plzen, Czech Republic 10/19/2017
- **Chair of session**, Jahreshauptversammlung der ÖGU Fortbildungstagung der Österreichischen Gesellschaft für Urologie und Andrologie, Linz, AUT
International lectures 11/11/2017
- **Chair of session at** 3rd Michal J. Marberger Annual Symposium, Vienna, AUT 12/16/2017
Frontiers in Urology
- **Chair of session** at the 1st ESU/ESOU Masterclass on Non-Muscle Invasive Bladder Cancer, Prag, CZ; *Module 3- En Bloc resection* 1/12/2018
- **Chair of moderated poster session 75:** Urothelial carcinoma of the upper tract: New options, new strategies and personalised management. 32nd Annual EAU Congress. March 2018, Copenhagen, DK. 3/19/2018
- **Chair of moderated poster session 29:** Prostate cancer: localized surgical therapy at the American Urological Association Annual Meeting, San Francisco, CA, 2018. 5/19/2018
- **Chair of session**, Young Scientist Association, Vienna, Austria 6/7/2018
- **Chair of session** at EAU Update on Bladder Cancer, Munich, GE 6/8/2018
High rik non-muscle invasive bladder cancer: from guidelines to future approaches
- **Chair of session**, Erster wissenschaftlicher Kongress iranischer Aerzte in Wien, AUT 7/14/2018
Erkrankungen des Beckenbodens
- **Chair of Expert-Guided Poster Tour 14**, 33rd Annual EAU Congress, Barcelona, SP 3/18/2019
Mini invasive approaches for upper tract urothelial cancer treatment
- **Chair of session**, Jahreshauptversammlung der ÖGU Fortbildungstagung der Österreichischen Gesellschaft für Urologie und Andrologie, Linz, AUT
International lecture Axel Bex 11/9/2019
- **Chair of session** –Meeting of the Association of Academic European Urologists (AAEU), 29-30 November, Bratislava, Slovakia
Bladder cancer session 11/30/2019
- **Chair of meeting** –Dialog 2020 Prostatakarzinom, Vienna, AUT 11/13/2020
- **Chair of session**, Jahreshauptversammlung der ÖGU Fortbildungstagung der Österreichischen Gesellschaft für Urologie und Andrologie, Linz, AUT
International lecture Alex Mottie 2022

COMMITTEES AND GUIDELINE PANEL

- Member, Prognostic factors panel of **The International Consultation on Urological Diseases** and the **EAU** consensus meeting on Kidney Cancer. 2010
- Member of Biomarkers panel of **The WHO International Consultation on Prostate Cancer** 2010
- Chair of Early detection factors and Prognostic factors panel of **The International Consultation on Urological Diseases**, the AUA/EAU consensus meeting on Bladder Cancer. 2011
- Member of **EAU Guidelines panel on New Technologies** 2011-3
- Member of **EAU guidelines on Non-Muscle-invasive Carcinoma of the Bladder** 2011-present
- Guideline chair of **The International Consultation on Urological Diseases** on Upper tract urothelial carcinoma. Presentation at SIU 2013 in Vancouver, Canada 9/2013
Panel chair of the Predictive and prognostic factors and pathology panel
- Member of **EAU guidelines on Upper Tract Urothelial Carcinoma** 2012-present
- Co-chair of **Summit on Upper Tract Urothelial Carcinoma** held under the auspices of the Society of Urologic Oncology at the annual meeting in Bethesda, MD, USA 12/2012 2012
- Chair of **The International Consultation on Urological Diseases** & the SIU consensus meeting on Upper Tract Urothelial Carcinoma. 2013
- Member of Senat of the **Christian Doppler Forschungsgesellschaft**, Vienna, AUT 3/2016-present
- Scientific committee member of the **Open Medical Institute of the Salzburg Foundation of the American Austrian Foundation** 3/2016-present
- Local organising committee and scientific committee member of the **Global Congress on Prostate Cancer 2016**, Vienna, AUT 6/29-7/1/2016
- Scientific organization committee member of the **Global Congress on Bladder Cancer 2016**, Brussels, BE 9/2016
- Wissenschaftlicher Beirat der **Österreichische Krebshilfe Wien**, AUT 11/2015 - present
- Chair of **Privatmedizin Arbeitsgruppe** of the Medical University of Vienna 2016-7
- Chair of scientific organization committee member of the **2nd Michal J. Marberger Annual Symposium**, Vienna, AUT *Controversies and challenges in lymphadenectomy* 12/16/2016
- Chair of Predictive and Prognostic Factors panel of **The International Consultation on Urological Diseases** consensus guidelines on Bladder Cancer. 2017
- Chair of **Europa Uomo Seminar 360 ° Perspectives on Prostate Cancer**, Wien, AUT 6/10/2017

- Chair of scientific organization committee member of the **3rd Michal J. Marberger Annual Symposium**, Vienna, AUT *Frontiers of urology* 12/15/2017
- Chair of scientific organization committee member of the **2nd B2B Bladder and Kidney Cancers**, Vienna, AUT 5/24-5/2018
- Member of scientific organization committee member of the **Erster wissenschaftlicher Kongress iranischer Aerzte** in Wien, AUT 7/13-5, 2018
- Chair of scientific organization committee of the **4th Michal J. Marberger Annual Symposium**, Vienna, AUT 12/14/2018
- Chair of scientific organization committee of the **X-Change** meeting, Vienna, AUT 12/1/2019
- Chair of scientific organization committee member of the **Controversies in Urologic Oncology**, Vienna, AUT 3/30/2019
- Chair of scientific organization committee of the **5th Michal J. Marberger Annual Symposium**, Vienna, AUT 12/13/2019
- Chair of scientific organization committee of the **6th Michal J. Marberger Annual Symposium**, Vienna, AUT 12/13/2020
- Chair of scientific organization committee of the **7th Michal J. Marberger Annual Symposium**, Vienna, AUT 12/13/2021
- Chair of scientific organization committee member of the **Central European Meeting 2022**, Vienna, AUT 4/1-2/2022
- Co-chair of scientific organization committee member of the **Methods in clinical cancer Oncology 2022**, Vienna, AUT 9/15-7/2022
- Chair of scientific organization committee of the **8th Michal J. Marberger Annual Symposium**, Vienna, AUT 12/14/2022
- Member of scientific organization committee member of the **German Urologic Association** in Leipzig, DE 9/20-23/2023
- Chair of scientific organization committee of the **9th Michal J. Marberger Annual Symposium**, Vienna, AUT 12/15/2023

MEETING REVIEWER

- Abstract reviewer for **24th Annual European Association of Urology Congress** 2008
17-21 March 2009, Stockholm, Sweden; Subject: Prostate cancer: PSA and markers
- Abstract reviewer for **25th Annual European Association of Urology Congress** 2009
16-20 April 2010, Barcelona, Spain; Subject: Prostate cancer: PSA and markers
- Abstract reviewer for **7th Men`s Health World Congress** “How To Overcome The Challenges?” 2010
28-30 October 2010, Nice, France; Subject: Oncology
- Abstract reviewer for **26th Annual European Association of Urology Congress** 2010
18-22 March 2011, Vienna, Austria; Subject: Prostate cancer: PSA and markers
- Abstract reviewer for the **8th Men`s Health World Congress** and 2011

- 4th European Men's Health Conference.** 2-5 October 2011, Vienna, Austria
- Abstract reviewer for the **13th Annual Meeting of the Society of Urologic Oncology** 2012
November 28-30, 2012, Bethesda, MD, USA
 - Reviewer for the **National Agency for the Evaluation of Universities and Research Institutes (ANVUR)**. Mission: assessment of research performed in the time frame 2004-2010 by researchers of all Italian universities and research institutes (eValuation of Quality of Research, VQR 2004-2010). 2012
 - Member of **Bladder Cancer Advocacy Network – BCAN's Scientific Review Group** to review applications for the Young Investigator Awards program 2013
 - Abstract reviewer for the **14th Annual Meeting of the Society of Urologic Oncology** 2013
December 4 - 6, 2013, Bethesda, MD, USA
 - Abstract reviewer for **29th Annual European Association of Urology Congress** 2014
11-15 April 2014, Stockholm, Sweden; Subject: urothelial tumours: management of infiltrative/advanced tumors: surgical management
 - Abstract reviewer for **Deutsche Gesellschaft der Urologie** 2014
 - Abstract reviewer for **30th Annual European Association of Urology Annual Congress** 2015
20-24 March, Madrid, Spain; Subject: urothelial tumours: management of infiltrative/advanced tumors: surgical management
 - Abstract reviewer for **35th Societe International d'Urologie Annual Congress** 2015
15-18 October, Melbourne, Australia; Subjects: bladder and urothelial cancer
 - Abstract reviewer for **31st Annual European Association of Urology Annual Congress** 2016
March, Munich, Germany; Subject: urothelial tumours: management of infiltrative/advanced tumors: surgical management
 - Reviewer for the **National Agency for the Evaluation of Universities and Research Institutes (ANVUR)**. Mission: assessment of research performed in the time frame 2006-2012 by researchers of all Italian universities and research institutes (eValuation of Quality of Research, VQR 2006-2012) 2016
 - Abstract reviewer for **Proasca: Global Prostate Cancer Meeting**, June, Vienna, Austria 2016
 - Abstract reviewer for **36th Societe International d'Urologie Annual Congress** 2016
October, Argentina; Subjects: bladder and urothelial cancer
 - Abstract reviewer for **32nd Annual European Association of Urology Annual Congress** 2017
March, London, UK; Subject: urothelial tumours: management of infiltrative/advanced tumors
 - Abstract reviewer for **37th Societe International d'Urologie Annual Congress** 2017
October, Portugal Subjects: bladder and urothelial cancer
 - Abstract reviewer for **33rd Annual European Association of Urology Annual Congress** 2018
March, Copenhagen, DK; Subject: urothelial tumours: management of infiltrative/advanced tumors
 - Abstract reviewer for **38th Societe International d'Urologie Annual Congress** 2018
October, Seoul, South Korea; Subjects: bladder and urothelial cancer
 - Abstract reviewer for **34rd Annual European Association of Urology Annual Congress** 2019
March, Barcelona, SP; Subject: urothelial tumours: management of infiltrative/advanced tumors
 - Abstract reviewer for **39th Societe International d'Urologie Annual Congress** 2019
October, Athens, Greece; Subjects: bladder and urothelial cancer

- Abstract reviewer for **German Urologic Association 2023** meeting in Leipzig, DE 9/20-23/2023

SCIENTIFIC COMMITTEE MEMBER

- **Member of Scientific Committee** of the 7th Men's Health World Congress and 3rd European Men's Health Conference. A multidisciplinary approach to men's health: How to overcome the challenges? 28-30 October 2010, Nice, France 2010
- **Chair of Scientific Committee and Best Poster Award Committee** of the 8th Men's Health World Congress and 4th European Men's Health Conference. 2-5 October 2011, Vienna, Austria 2011
- **Guest Editor** of special issue on bladder cancer of the World Journal of Urology (ISSN: 0724-4983 and 1433-8726) 2011
- **Co-chair of the Best Presentation Award Committee** of 19th Association Marocaine d'Urologie Annual Meeting 2011
- **Chair of the Best Presentation Award Committee** of 20th Association Marocaine d'Urologie Annual Meeting 2012
- **Member of Bladder Cancer Scientific Program Committee** for the 13th Annual Meeting of the Society of Urologic Oncology, November 28-30, Bethesda, MD, USA 2012
- **Co-chair of Summit on Upper Tract Urothelial Carcinoma Program** at the 13th Annual Meeting of the Society of Urologic Oncology, November 28, Bethesda, MD, USA 2012
- **Guest Editor** of special issue on "Prostatakazinom" in Spectrum Urologie 2012
- **Member of Best Presentation Award Committee** 19th St Lawrence Urological Group, McGill University Health Centre, Montreal, Quebec, Canada 1/25-27, 2013 2013
- **Member of Bladder Cancer Scientific Program Committee** for the 14th Annual Meeting of the Society of Urologic Oncology, December 4-6, Bethesda, MD, USA 2013
- **Guest Editor** of special issue on *Biomarkers in Uro-oncology* in Urologic Oncology 2013
- **Guest Editor** of special issue on "Das Harnblasenkarzinom" in Spectrum Urologie 2013
- **Scientific programme committee chair**, First Interdisciplinary Prostate Cancer Symposium, Vienna, AUT 11/29/2013
- **Scientific programme committee member** of the Societe International d'Urologie 11/2013-10/2015
- **Guest Editor** of special issue on "High risk non muscle invasive bladder cancer" Current Opinion in Urology 9/2014
- **Scientific advisory board**, Maennergesundheit verstehen 11/2014
- **Scientific advisory board**, Österreichisch-Iranische Ärztgesellschaft 8/2013-present
- **Scientific programme committee chair**, Inagural International Urothelial Carcinoma Meeting, Vienna, Austria 1/29/2016
- Member of the Scientific Advisory Board of the **Bladder Cancer Advocacy Network (BCAN)** 2016
- **Meeting and scientific program co-chair**, Friends of Urology Austrian Polish meeting, Krakow, Poland 5/2016

- **Local organising committee, 4th Global Congress on Prostate Cancer PROSCA 2016** 6/2016
(29 June- 01 July), Vienna, Austria.
- **Scientific program committee chair, Controversies and challenges in** 12/16/2016
lymphadenectomy for urologic cancers meeting, Vienna, Austria
- **Meeting & Scientific program chair, Bench to Bedside Kidney and** 5/26-7/2017
Urothelial Cancers meeting, Vienna, AUT
- **Scientific program committee chair, Europa Uomo Seminar 360 Degrees** 6/10/2017
Perspectives on Prostate Cancer, Vienna, AUT
- **President of the jury for the PhD Defense of Dr Matthieu Romain, Rennes, FR** 6/28/2017
- **Meeting & Scientific program chair, Frontiers in Urology, Vienna, AUT** 12/15/2017
- **Meeting & Scientific program chair, Bench to Bedside Bladder &** 5/25-6/2018
Kidney Cancers Vienna, AUT
- **Scientific program chair, Frontiers in Urology, Vienna, AUT** 12/14/2018
- **Meeting & scientific program chair, X-change your knowledge, Vienna, AUT** 12/1/2019
- **Meeting & Scientific program chair, Controversies in Urologic Oncology, Vienna, AUT** 3/30/2019
- **Chair of Prostate cancer session, 11th International Conference of the Jordanian** 10/5/2019
Association of Urological Surgeons, Amman, Jordan
- **Meeting & Scientific program chair, 5th M.J.Marberger Meeting: Frontiers in Urology,** 2/14/2019
Vienna, AUT
- **Meeting & Scientific program co-chair, International Conference “New Technologies in** 2/7/2020
Urology: Pro et Contra”, Moscow, RU
- **Chair of Young CCC session, Trio meeting of the Comprehensive Cancer Center of the Medical**
Universty Vienna
- **Meeting & Scientific program chair, 6th M.J.Marberger Virtual Meeting: Frontiers** 12/11/2020
in Urology,Vienna, AUT
- **Meeting & Scientific program chair, 7th M.J.Marberger Virtual Meeting: Frontiers** 12/10/2021
in Urology,Vienna, AUT
- **Meeting & Scientific program chair, Central European Meeting 22, Central European** 4/1-2/2022
Urological Society, Vienna AUT
- **Meeting & Scientific program co-chair, Methods in clinical cancer research 2022,** 9/15-7/2022
Salzburg AUT
- **Meeting & Scientific program chair, 8th M.J.Marberger Meeting: Frontiers** 12/16/2022
in Urology,Vienna, AUT
- **Meeting & Scientific program chair, Controversies in Urologic Oncology 23,** 4/14-15/2023
Vienna AUT
- **Meeting & Scientific program chair, Trio meeting of the Comprehensive Cancer** 4/27-28/2023
Center of the Medical Universty Vienna

JOURNAL REVIEWER

• Urology	1/2001 – present
• Journal of Clinical Oncology	3/2002 – present
• American Journal of Cancer	4/2002 – present
• European Urology	5/2003 – present
• Journal of Urology	1/2004 – present
• Cancer Chemotherapy and Pharmacology	2/2004 – present
• Expert Review of Molecular Diagnostics	4/2004 – present
• Biochimica et Biophysica Acta – Proteins and Proteomics	6/2004 – present
• BioMed Central Urology	7/2004 – present
• International Journal of Cancer	10/2004 – present
• BJU International	7/2005 – present
• European Journal of Cancer	9/2005 – present
• Artificial Intelligence in Medicine	2/2005 – present
• Urologic Oncology: Seminars and Original Investigations	1/2006 – present
• Medical Principles and Practice	2/2006 – present
• EAU – EBU Update Series	8/2006 – present
• International Brazilian Journal of Urology	8/2006 – present
• Cancer Letters	8/2006 – present
• Biomarker Insights	9/2006 – present
• The Scandinavian Journal of Clinical & Laboratory Investigation	10/2006 – present
• Human Pathology	11/2006 – present
• Clinical Cancer Research	12/2006 – present
• Experimental and Molecular Pathology	1/2007 – present
• Clinical Genetics: An International Journal of Genetics and Molecular Medicine	2/2007 – present
• Yonsei Medical Journal	2/2007 – present
• Apoptosis: An International Journal on Programmed Cell Death	3/2007 – present
• Biomarkers in Medicine	4/2007 – present
• European Journal of Surgical Oncology	7/2007 – present
• World Journal of Surgical Oncology	8/2007 – present
• Cleveland Clinic Journal of Medicine	9/2007 – present
• Pathology: The Official Journal of the Royal College of Pathologists of Australasia	9/2007 – present
• Cancer: Interdisciplinary International Journal of the American Cancer Society	9/2007 – present
• Expert Review of Anticancer Therapy	10/2007 – present
• Neoplasia: An International Journal for Oncology Research	10/2007 – present
• Nature Clinical Practice Oncology	11/2007 – present
• Expert Opinion on Therapeutic Targets	11/2007 – present
• Asian Journal of Andrology	11/2007 – present
• Current Opinion in Molecular Therapeutics	12/2007 – present
• Expert Review of Proteomics	1/2008 – present
• Expert Opinion on Medical Diagnostics	2/2008 – present
• World Journal of Urology	3/2008 – present
• Laboratory Investigation	4/2008 – present
• Radiotherapy and Oncology	6/2008 – present
• Cancer Treatment Review	8/2008 – present
• BioMed Central Cancer	1/2009 – present
• Annals of Oncology	3/2009 – present
• International Journal of Urology	3/2009 – present
• Lancet Oncology	7/2009 – present
• The Journal of Sexual Medicine	8/2009 – present

- The Prostate 9/2009 – present
- Molecular Cancer Therapeutics 10/2009 – present
- Nature Reviews Clinical Oncology 11/2009 – present
- Cancer Epidemiology, Biomarkers and Prevention 3/2010 – present
- International Journal of Surgery 3/2010 – present
- Expert Opinion on Investigational Drugs 4/2010 – present
- Tumor Biology - The International Society of Oncology and BioMarkers 5/2010 – present
- Critical Reviews in Oncology/Hematology 6/2010 – present
- The Journal of Proteome Research 6/2010 – present
- Cancer Treatment Reviews 9/2010-present
- Molecular Medicine 11/2010-present
- Journal of Endourology 11/2010-present
- Jama oncology 2015-present
- Lancet 2017- present
- JAMA 2019- present

VISITING PROFESSORSHIPS

- **Visiting Professor**, University of Montreal, Montreal, Quebec, Canada 9/2008
The benefits of early androgen blockade;
Urologic trauma: experience at Parkland Memorial Hospital;
Potential effect of testosterone supplements of prostate cancer biology
- **Visiting Professor**, XXV Jornadas Urologicas De La Filial Sur de la Sociedad Chilena de Urología. 13-15 Agosto 2010, Temuco, Chile 8/2010
Cancer Vesical Sin Invasión Muscular
Role of surgery in invasive and advanced bladder cancer
Perioperative chemotherapy for muscle invasive bladder cancer
Urine biomarkers for bladder cancer detection and surveillance
- **Visiting Professor**, Sociedad Chilena de Urologia, Santiago de Chile, Chile 8/2010
Update on non-muscle invasive bladder cancer
Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider pre-surgical therapy?
- **Visiting Professor**, Department of Urology, University of Hamburg, Hamburg, Germany 11/2010
Evidence-based management of non-muscle invasive bladder cancer (11/3/2010)

Martini Prostate Klinik, University of Hamburg, Hamburg, Germany
Disease state-specific integration of biomarkers for prostate cancer (11/4/2010)
- **Visiting Professor**, Div. of Urology, Maimonides Medical Center, Brooklyn, NY, USA 4/16/2012
Optimal stage-specific management of prostate cancer
- **Visiting Professor**, Division of Urology, Instituto Do Cancer Do Estado De Sao Paulo (ICESP) and Department of Urology, University of Sao Paulo (USP), Sao Paulo, SP, Brazil 4/26-27/2012
How to integrate research in daily clinical setting
- **Visiting Professor**, Dept. of Urology, Universitaetsklinikum Aachen, Aachen, DL 11-12/12/2013
How to optimize outcomes in muscle-invasive bladder cancer: role of surgery and chemotherapy

- **Visiting Professor**, Div. of Urology, Dept. of Surgery, University of Oxford, Oxford, UK 7/2014
Personalized management of bladder cancer: where is the future
- **Visiting Professor**, Dept. of Urology, 2nd Medical Faculty, Charles University, Prag, CZ 4/2015
How to succeed as physician-scientist
- **Visiting Professor**, Dept. of Urology, European Center of Medicine Otwock, PL 2/24-5/2016
- **Visiting Professor**, Kantonspital Luzern, Luzern, Switzerland 1/12/2017
Upper tract urothelial carcinoma: research and progress
- **Visiting Professor**, University of Texas Southwestern Dallas, Dallas, TX, USA 5/10/2017
Upper tract urothelial carcinoma collaboration: a story that started in Dallas
- **Visiting Professor**, University of Tübingen, Tübingen, Germany 7/5/2017
Biomarkers for checkpoint therapy
- **Visiting Professor**, Northwestern University, Chicago, USA 3/29-31/2018
Upper tract urothelial carcinoma: what have learned in the last 10 years
Tips for a successful career in academia
- **Visiting Professor**, Fundación instituto valenciano de oncología, Valencia, SP 9/23-4/2021
Upper tract urothelial carcinoma: what have learned in the last 10 years
Tips for a successful career in academia
Role of local treatment in hormone naïve metastatic prostate cancer
Active surveillance 2021: From bench to bedside
Partial gland ablation (focal therapy) is the treatment of choice for some patients
Genetic Testing in Prostate Cancer
Metastatic bladder cancer
T1 bladder cancer
MRI/TRUS-Fusion Biopsy: Better than TRUS Biopsy?
Metastatic Castration-Sensitive Prostate Cancer – what is the best treatment sequence today?
Upper tract urothelial carcinoma: quality indicators

INVITED PRESENTATIONS AND COURSES

- **Invited Lecturer**, Austrian-Iranian Medical Society, Vienna, AUT 8/14/2007
Genitourinary Oncology: the US perspective
- **Invited Lecturer**, Association des Urologues du Quebec, Montebello, Canada 9/6/2008
Marqueurs urinaires; Déclenchement du hormono-therapy dans le cancer de la prostate non-avancé
- **Invited Lecturer**, Medizinische Universität Wien, Vienna, AUT 9/12/2008
Prostate cancer biomarkers: an update and future perspectives
- **Invited Lecturer**, The International Bladder Cancer Network Meeting, 10/16/2008
Barcelona, Spain. *Statistical needs in marker research*
- **Invited Lecturer**, Society of Urologic Oncology, Bethesda, MD, USA 12/3/2008
Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer.
- **Invited Lecturer**, Grand rounds of the Department of Urology at New York University, 6/17/2009
New York, NY, USA. *Molecular markers for bladder cancer*

- **Invited Lecturer**, Austrian-Iranian Medical Society, Vienna, AUT 8/23/2009
Trends in Prostate Cancer Management
- **Invited Lecturer**, Department of Urology at University of Texas Southwestern Medical Center, Dallas, TX, USA 9/15-16/2009
Integration of biomarkers in a programmatic approach to bladder cancer
Timing and duration of early androgen deprivation therapy
- **Invited Panelist**, Northeastern Section AUA 61st Annual Meeting, Montreal, Canada 10/8/2009
Testosterone supplementation in prostate cancer and its risks.
- **Invited Lecturer**, Northeastern Section AUA 61st Annual Meeting, Montreal, Canada 10/8/2009
Residents' Breakfast: How to Select a Urology Fellowship Program
- **Invited Lecturer**, Glickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA 10/29/2009
Molecular markers can improve the clinical decision-making in patients with bladder cancer
- **Invited Lecturer**, Society of Urologic Oncology, Bethesda, MD, USA 12/4/2009
Her2 expression status provides independent prognostic information in patients with urothelial carcinoma of the bladder
- **Invited Lecturer**, European School of Urology course at the time of the 26th Annual EAU Congress, Barcelona, Spain 4/18/2010
How to write a manuscript and get it published in European Urology.
- **Invited Lecturer**, Resident Forum of the 2010 American Urological Association, San Francisco, CA, USA 5/29/2010
Choosing a fellowship - Getting Started: A Blueprint for Post-Residency Life
- **Invited Lecturer**, 36 Gemeinsame Tagung der Bayerischen Urologenvereinigung und der Österreichischen Gesellschaft für Urologie, Munich, Germany 6/10/2010
Blasenkarzinom: Grundlagen
- **Invited Lecturer**, Sociedad Chilena de Urologia, Santiago de Chile, Chile 8/19/2010
Update on non-muscle invasive bladder cancer
Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider pre-surgical therapy?
- **Invited Lecturer**, Innovations in Urology First Annual Meeting, Milan, Italy 9/18/2010
Pelvic Lymph Node Dissection for Prostate Cancer: extended, limited, or not at all?
- **Invited Lecturer**, Seventh Annual Current Trends in Genitourinary Malignancies, New York, NY, USA 10/16/2010
Surgery for early-stage bladder cancer. Debate: radiation therapy is suboptimal for bladder cancer.
- **Invited Lecturer** at the session Prostate Cancer II of the 7th Men's Health World Congress and 3rd European Men's Health Conference. 28-30 October 2010, Nice, France 10/29/2010
Prostate cancer overview and recent advances - how can a common disease be so controversial
- **Invited Lecturer** at the 7th Men's Health World Congress and 3rd European Men's Health Conference. *Update on the management of bladder cancer in 2010* 10/29/2010
- **Invited Lecturer**, 4th Journee d' onco-urologie of the Association Marocaine d'Urologie, Fes, Morocco 12/18/2010
Recent advances in prostate cancer –a controversial common disease
Management of non-invasive bladder cancer
- **Lecturer**, ICUD-EAU International Consultation on Bladder cancer 2011 3/18/2011

Chapter 3: Markers

- **Lecturer**, European Society of Residents in Urology and Young Urologists Office 3/19/2011
Vienna, AUT
How to make it in Urology
Panel discussion on career challenges in 2011
- **Lecturer**, ESU Course 20 How to write a manuscript and get it published in 3/21/2011
European Urology, Vienna, AUT
Clinical research original article: how to write the best introduction section
Clinical research original article: how to write the results and discussion sections
Review article: the critical interpretation of the summarized evidence: why is the author's touch of class essential to write the perfect manuscript?
- **Lecturer**, Sub-plenary session 8: ICUD-EAU International Consultation Bladder Cancer 3/21/2011
Vienna, AUT
Markers of early detection in bladder cancer
Prognostic/predictive markers in bladder cancer
- **Invited Lecturer**, 44. Alpenländische Urologensymposium, Wolkenstein, Bozen, IT 4/1/2011
Integration neuer Biomarker in der Diagnostik und Therapie von Blasenkarzinom
Optimales Management des invasiven Blasenkarzinoms- Wertigkeit der Chirurgie unter Integration der Chemotherapie
- **Panel** – *Management of the small renal mass.* EAU 4th leading light meeting. 4/9/2011
7-9 April 2011, Lago Maggiore, Italy (4/9/11)
- **Invited Lecturer**, Tumor board at Columbia University College of Physicians 4/19/2011
and Surgeons, NY, NY, AUT
Upper tract urothelial carcinoma: new data and old news
- **Invited Lecturer**, Association Marocaine d'Urologie Annual Meeting 2011 4/28-29/2011
Skhirat, Morocco
Biomarkers for early detection
Management of T1 high grade urothelial carcinoma of the bladder
Panel discussion on bladder cancer
Ablative therapy for small renal cortical tumors
- **Invited Lecturer**, Interactive Genitourinary Cancer Conference (IGUCC) 4/30/2011
Budapest, Hungary
Interpreting trends in prostate cancer
Panel discussion on prostate cancer biomarkers
- **Course lecturer**, American Urological Association Annual Meeting, Washington, DC, US 5/17/2011
Multidisciplinary management of urothelial carcinoma: stage- and site-specific discussions
upper tract urothelial carcinoma
- **Invited Lecturer**, Societa Italiana di Urologia Oncologica (SIUrO), Naples, Italy 6/23-24/11
Clinical utility of nuclear matrix protein 22 for the management of bladder cancer
Lymphadenectomy for prostate cancer: extended, standard, limited or not at all?
- **Course lecturer**, ESU-Weill Cornell Masterclass in General Urology, Salzburg, AUT 7/11-15/2011
Management of localized prostate cancer
Management of metastatic prostate cancer
Management of penile cancer
Management of upper tract urothelial carcinoma

- **Invited lecturer**, AUA Foundation/Society of Basic Urologic Research Conference 7/16-17/2011
AUA Headquarters, Linthicum, MD, USA
Aging and urothelial carcinoma: an oncogeriatric matter
- **Invited lecturer**, New York Section of the American Urological Association 9/11/2011
109th Annual Meeting, Paris, France
Bladder-sparing approaches to invasive bladder cancer
The role of early cystectomy in muscle invasive bladder cancer
- **Invited lecturer**, 8th Men's health world congress and 4th European men's health conference, Vienna, AUT 10/3-4/2011
Early androgen deprivation- what is the evidence?
Integration of multidisciplinary care in the management of high-risk prostate cancer
- **Invited lecturer**, Andrologisch-Onkologisches Herbstseminar 10/8/2011
Arbeitskreise für Andrologie und Onkologie, Berufsverband der Österreichischen Urologen
Das Prostatakarzinom: warum bestehen bei einer so häufigen Erkrankung so viele Kontroversen?
- **Invited lecturer**, 5th Global Uro-Oncology Meeting under the auspices of the World Urological Oncology Federation, Berlin, Germany 10/15-16/2011
Management of invasive bladder cancer in the elderly
- **Course lecturer**, 31st Congress of the Societe International d'Urologie, Berlin, DE 10/19/2011
Updates on upper tract urothelial carcinoma: diagnosis, staging, and management
- **Invited lecturer**, Menopause, Andropause, Anti-aging. 8-10 December, Vienna, AUT 12/ 2011
Das Prostatkarzinom: eine paradoxe Krankheit
- **Invited lecturer**, 5th EAU Leading Lights in Urology Meeting. March 29-30, Madrid, SPA 3/2012
The risks of 5 α -reductase inhibitors for prostate cancer prevention
The role of neoadjuvant and adjuvant treatment in advanced bladder cancer
The future of urologic oncology research
- **Invited Lecturer**, 20th Association Marocaine d'Urologie (AMU) Annual Meeting 4/4-7/2012 and 20th Congres Francophone D' Urologie (FASULF) 2012, Marrakech, Morocco.
Traitement intravésical du cancer de vessie: thérapie de première ligne et algorithme de prise en charge
Cancer du rein de petite taille: place de la radiofréquence, de la cryothérapie
- **Invited Lecturer**, Department of Surgery, Maimonides Medical Center, Brooklyn, NY 4/16/2012
Lymphadenectomy for prostate cancer: extended, standard, limited, or not at all
- **Invited Lecturer**, III Simposio Internacional de Cancer Urologico, Sao Paulo, Brazil 4/20-21/2012
Intravesical therapy for T1high grade (T1G3)
Role of urinary and tissue markers in bladder cancer detection and prognosis
Bladder cancer in elderly: what is different?
Prognostic markers in upper tract urothelial carcinoma: what have we learned in the last 5 years
Upper tract urothelial carcinoma: when is conservative therapy indicated and safe?
Case Discussion: Bladder Cancer
Role of ablative therapy
Case Discussion: Kidney Cancer
The biologic and clinical importance of teratoma
Active surveillance: reasonable or risky?
Case Discussion: Prostate Cancer

- **Invited Lecturer**, Department of Urology, Albert Einstein College of Medicine, Montefiore Medical Center Center, Bronx, NY, USA 5/7/2012
Upper tract urothelial carcinoma: what have we learned in the last 5 years?
- **Invited Lecturer**, Clinical Medicine, Weill Cornell Medical Associates-East Side New York, NY, USA 5/17/2012
Prostate cancer: a thinking man's approach
- **Course Director and Lecturer**, American Urological Association Association Annual Meeting, Atlanta, GA, USA 5/22/2012
0511C: Contemporary Concepts and Controversies in the Diagnosis and Management of Upper Tract Urothelial Carcinoma (UTUC)
- **Invited Lecturer**, Sol and Margaret Berger Department of Urology, Beth Israel Medical Center, New York, NY, USA 6/14/2012
Management of upper tract urothelial carcinoma
- **Course Director and Lecturer**, EAU/Weill Cornell Seminar in "ESU Master Class in Urology", Salzburg, AUA 7/9-14/2012
Non-muscle invasive bladder cancer: diagnosis & overview
Chemotherapy for bladder cancer
Workshop: why & how to publish in European Urology
Workshops: fellows' case presentations
- **Invited Lecturer**, Australian and New Zealand Urogenital and Prostate Clinical Trials Group (ANZUP) Annual Scientific Meeting, Sydney, Australia. 7/16-17/2012
State of the art in the diagnosis and treatment of upper tract urothelial carcinoma
Optimal management of bladder cancer- integrating surgery and systemic therapy
Role of surgery in the treatment of high-risk non-metastatic prostate cancer
Genitourinary carcinoma clinical trial concept development
- **Invited Lecturer**, Weill Cornell Medical College & Eli Lilly & Co 2nd Men's Health Symposium: From Academic Research to New Drug Developments, Weill Cornell Medical College, New York, NY, USA 11/7/2012
Bladder cancer: opportunities for innovation
- **Invited Lecturer**, Fortbildungstagung der Österreichischen Gesellschaft für Urologie und Andrologie. 9-10 November 2012. Linz, AUT 11/10/2012
Radikale Prostatektomie- state of the art surgery
13 Tipps für eine erfolgreiche Karriere in der urologischen Forschung
- **Invited Lecturer**, Society of Basic Urologic Research Annual Symposium, November 15-8, 2012. Miami, FL, USA 11/17/2012
Biomolecular predictors of urothelial cancer behavior and treatment outcomes
- **Panelist**, Summit on Upper Tract Urothelial Carcinoma, Society of Urologic Oncology Annual Meeting, Bethesda, MD, USA 11/ 28/2012
Achieving consensus on clinical risk stratification
Management of localized disease
- **Invited Lecturer**, 19th St Lawrence Urological Group, McGill University Health Centre, Montreal, Quebec, Canada 1/25-27, 2013
My 15 tips for a successful career in academic urology
How to choose a fellowship – a primer for residents
Concepts and controversies in the management of upper tract urothelial carcinoma

Integration surgery and systemic therapy for invasive bladder cancer

- **Invited Lecturer**, Joint session of the European association of urology (EAU) and the Maghreb Union countries. 28th Annual EAU Congress. March 2013, Milan, Italy. 3/15/2013
Management of non invasive bladder tumors
- **Invited Lecturer**, Plenary session 2 – Debate: How much surgery for upper tract urothelial cancer? 28th Annual EAU Congress. March 2013, Milan, Italy. 3/17/2013
Radical nephroureterectomy or partial ureterectomy?
- **Course Director and Lecturer**, 28th Annual EAU Congress. March 2013, Milan, Italy. 3/18/2013
ESU course 31 Current concepts and controversy in the diagnosis and management of upper tract urothelial carcinoma (UTUC)
Prognostic and predictive factors, pathology
Treatment of localized high risk (invasive) and metastatic cancer
- **Course Lecturer**, 28th Annual EAU Congress. March 2013, Milan, Italy. 3/19/2013
ESU course 20 How to write a manuscript and get it published in European Urology
How to write a clinical research article
- **Invited Lecturer**, National Urology Residents Preceptorship Program (NURPP), AUA 2013 Annual Meeting, May 4-8, San Diego, CA 5/5/ 2013
Fellowships- a primer for residents
- **Invited Lecturer**, American Society for Men's Health, AUA 2013 Annual Meeting, May 4-8, San Diego, CA, USA 5/6/2013
Localized Prostate Cancer: Active Surveillance versus Active Treatment?
- **Chair and lecturer**, Association of American-Iranian Urologists (AAIU), AUA 2013 Annual Meeting, May 4-8, San Diego, CA, USA 5/6/2013
T1 bladder cancer: conservative therapy is the initial way to go
- **Course director and lecturer**, American Urological Association Association Annual Meeting 2013, San Diego, CA, USA 5/7/2013
0511C: Contemporary Concepts and Controversies in the Diagnosis and Management of Upper Tract Urothelial Carcinoma (UTUC)
- **Invited lecturer**, 6th EAU Leading Lights in Urology Meeting. June 6-8th, Lisbon, Portugal 6/2013
Prostate cancer screening: pro
- **Invited lecturer**, 1st International uroanatomy congress. June 14th, Izmir, Turkey 6/14-15/2013
Anatomic steps of radical cystectomy and extended lymphadenectomy: rationale and video
Surgical approach to anatomic open prostatectomy- tips and tricks
Robotic urologic surgery and anatomy: against
Radiologic and sectional uroanatomy – challenger
- **Invited lecturer**, Open Medical Institute Satellite Symposium, Urothelial Cancer, 7/5/2013
Under the auspices of Weill Cornell Medical College and the American Austrian Foundation in collaboration with Postgraduate medical Education Center, European Health Center, Otwock, Poland
Non-muscle invasive bladder cancer: diagnosis, risk stratification, and management
Integrating surgery and systemic therapy for invasive bladder cancer
Modern management of upper tract urothelial carcinoma
Bladder cancer cases presentations and discussion

- **Course lecturer**, ESU-Weill Cornell Masterclass in General Urology, Salzburg, AUT 7/8-12/2013
Update on management of advanced and metastatic renal cancer
Testicular cancer: treatment stage by stage
- **Invited lecturer**, World Urologic Oncology Federation, Vancouver, Canada 9/8/2013
Variant histology in urothelial carcinoma: clinical impact
- **Invited lecturer**, International Young Urologists' Association, Vancouver, Canada 9/8/2013
Optimal integration of chemotherapy with surgery
- **Invited lecturer**, 33rd Congress of the Societe Internationale d'Urologie, Vancouver, Canada
Why Optimal Endoscopic Management Matters 9/9/2013
IC06: Management of urothelial carcinoma: stage- and site-specific discussions 9/11/2013
Diagnosis and management of upper tract urothelial carcinoma
IC10: Non-Muscle-Invasive Bladder Cancer Diagnosis and Treatment 9/12/2013
Risk-Based Clinical Decision Making in NMIBC
Intravesical Immunotherapy Today
- **Invited lecturer**, 30 Jahrestagung ACO ASSO 2013, St Wolfgang, AUT 10/3-5/2013
Primumresektion beim metastasierten Nierenzellkarzinom: der Standard?
- **Course lecturer**, ESU- Cornell Masterclass in Genitourinary Oncology, Salzburg, AUT 10/7/2013
Penis cancer: diagnosis, staging and treatment
Diagnosis, risk-stratification and management of bladder cancer
- **Invited lecturer**, Jahrestagung der Deutschen, Österreichischen und Schweizerischen 10/21/2013
Gesellschaften fuer Haematologie und Onkologie, Wien, AUT
Therapiestrategien beim Nicht-Urothelkarzinom
- **Invited lecturer**, 8. Urologisch/Onkologisches Symposium, Interdisziplare Behandlung 11/9/2013
von urogenitalen Karzinomen, Barmherzige Brüder Krankenhaus, Wien, AUT
State of the Art der Diagnose and Therapie des nicht-muskelinvasiven Urothelkarzinoms
- **Invited lecturer**, Prag Urologic Society, Prag, CZ 11/14/2013
Optimal integration of surgery and chemotherapy for the management of muscle-invasive bladder cancer
- **Invited lecturer**, Fortbildungstagung der Oesterreichischen Gesellschaft fuer Urologie 11/16/2013
und Andrologie, Redoutensaele, Linz, AUT
Konstante PDE-5-Hemmung—Welche Patienten profitieren?
- **Invited lecturer**, Update Blasenkarzinom, Landeskrankenhaus Hall i. Tirol, AUT 11/22/2013
Operative Therapiestrategien des muskelinfiltrierenden Blasentumors
- **Invited lecturer**, First Interdisciplinary Prostate Cancer Symposium, Vienna, AUT 11/29/2013
Prostate cancer: a common disease with many faces
- **Invited lecturer**, Pediatric Surgery Postgraduate Seminars, Vienna, AUT 12/4/2013
Neuropathic Bladder, Bladder Reconstruction, Research in Regenerative Urology,
and Pediatric Voiding Disorders
Primer for a successful career as a physician-scientist
- **Invited guest**, 12th Meeting of the Association of Academic European Urologists, 12/7/2013
Paris, FR
Prediction of cisplatin-resistance in bladder cancer: HOXA- as a novel epigenetic biomarker

- **Invited lecturer**, Dept. of Urology, Universitätsklinikum Aachen, Aachen, DL
Upper tract urothelial carcinoma: from diagnosis to therapy 11/12/2013
How to obtain the best results in the management of muscle-invasive bladder cancer 12/12/2013
- **Invited lecturer**, Fun meeting, Semmelweis Klinik, Budapest, Hungary
T1 High Grade Bladder Cancer: How to Separate The Pussycat from the Tiger 2/21/2014
- **Invited lecturer**, State of the art and horizons in oncology, Medical Univ Vienna,
 Comprehensive Cancer Center, Vienna, Austria 3/4/2014
Surgical management of bladder cancer
- **Invited lecturer**, 23rd International Symposium of the Endourology and ESWL 3/8/2014
 Section of the Polish Urological Association, Wroclaw, Poland
Optimal endoscopic management of T1 bladder cancer
Upper tract urothelial carcinoma: role of endoscopy
- **Invited lecturer**, USANZ 67th Annual Scientific Meeting, Brisbane, AUS 3/17-9/2014
Clinical impact of histologic variants urothelial and non-urothelial cancer
Prostate cancer plenary: high-risk
Upper tract tumors: controversies revisited in 2014
Prostate cancer prevention: it is neither possible nor achievable
Prostate cancer and hormone therapy: treating biochemically relapsed prostate cancer
Meet the expert: bladder cancer
- **Invited lecturer**, 2. Fachtagung Prostatakarzinom, Vienna, AUT 3/21/2014
“Darf’s ein bisserl mehr sein”- Chirurgie beim fortgeschrittenen Prostatakarzinom
Interaktive Falldiskussion: Veteranen versus Jungstars
“Wer zuerst kommt...”- Enzalutamide versus Abiraterone
- **Course Director and Lecturer**, 29th Annual EAU Congress, Stockholm, Sweden. 4/13/2014
 ESU course 31 Current concepts and controversy in the diagnosis and management
 of upper tract urothelial carcinoma (UTUC)
Prognostic and predictive factors, pathology
Treatment of localized high risk (invasive) and metastatic cancer
- **Course Lecturer**, 29th Annual EAU Congress, Stockholm, Sweden. 4/14/2014
 ESU course 20 How to write a manuscript and get it published in European Urology
How to write a clinical research article
- **Invited lecturer**, 29th Annual EAU Congress, Stockholm, Sweden. 4/11/2014
 Joint session of the EAU and the Iranian Urological Association (IUA)
Identifying high risk localized prostate cancer
- **Invited lecturer**, 29th Annual EAU Congress, Stockholm, Sweden 4/11/2014 Joint
 session of the EAU and the Maghreb Union Countries
Biomarkers of prostate cancer aggressiveness
Bladder cancer session
Surgical quality indicators of radical cystectomy
- **Invited lecturer**, plenary session, 29th Annual EAU Congress, Stockholm, Sweden 4/13/2014
 Diagnosis and treatment of non-muscl invasive bladder cancer
How to improve the outcome of transurethral resection of bladder tumors
- **Invited lecturer**, 29th Annual EAU Congress, Stockholm, Sweden. 4/11/2014
 Innovation Approaches in Urological Cancers. Satellite Symposium Ipsen
“Think out of the box”: Target tumor microenvironment to improve prostate cancer management

- **Invited lecturer**, Frühjahrstagung des Berufsverbandes der Österreichischen Urologen 2014, Panhans Grand Hotel, NÖ, AUT 2/5/2014
Festvortrag: *Das Blasenkarzinom: aktuelle Therapieoptionen*
- **Invited lecturer**, Wrap-Up EAU 2014, Museumsquartier, Vienna, AUT 9/5/2014
Das Blasenkarzinom
- **Co-chair** of Betmiga™ launch symposium, Sophiensäle, Vienna, AUT 10/5/2014
- **Invited lecture** at 40. Gemeinsame Tagung der Bayerischen Urologenvereinigung und der Österreichischen Gesellschaft Für Urologie and Andrologie, Erlangen, DE. 15/5/2014
Diagnostik und Therapie des oberen Harntraktumors
- **Chair** at 40. Gemeinsame Tagung der Bayerischen Urologenvereinigung und der Österreichischen Gesellschaft Für Urologie and Andrologie, Erlangen, DE. 15/5/2014
Kontroversen in der Urologie
- 2nd Challenges in Endourology, Paris, France
- **Chair** of Workshop entitled Clinical Innovations in Endourology 2/6/2014
- **Chair** of Live Surgery Session II: Upper and Lower Tract 3/6/2014
- The British Association of Urological Surgeons Annual Meeting, Liverpool, UK
- **Invited lecture:** Personalised Therapeutic Strategies in Urothelial Cancer 6/23/2014
- **Course lecture:** *How successful authors approach writing a clinical or surgical paper* 6/24/2014
at BJU International Course - *How to Get Published in a Modern Surgical Journal*
- **Invited lecture:** *Contemporary concepts in upper tract urothelial carcinoma* 6/26/2014
- **Invited lectures**, Friends of Israel Urology, Tel Aviv, Israel 7/3/2014
Saturation biopsy of the prostate: con
Prostatic invasion of the urothelial carcinoma
- **Invited lecture**, Uroforum 2014, Barcelona, Spain 7/8/2014
Future of non-muscle invasive bladder cancer management
- **Course lectures**, ESU-Weill Cornell Masterclass in General Urology, Salzburg, AUT 7/10/2014
High risk prostate cancer: surgery or radiotherapy?
Treatment of biochemical progression after local therapy
Castrate resistant prostate cancer
- **Invited lecture**, FinnBladder 30 year Anniversary Meeting, Turku, Finland 9/1/2014
Unmet needs and objectives in bladder cancer care
- **Invited lecture**, 66.Kongressder Deutschen Gesellschaft für Urologie, Düsseldorf, GE 10/4/2014
Blasenkarzinom- was muss ich 2014 wissen?
- **Invited lectures**, 34th Congress of the Societe Internationale d'Urologie, Glasgow, UK
- *Major observations in upper tract urothelial carcinoma: aristolochia acid* 10/12/2014
- *Oncologic outcomes of organ-sparing surgery for invasive penile cancer* 10/13/2014
- *Disparate twins: biological and clinical differences between bladder and upper tract urothelial carcinoma* 10/14/2014
- **Invited lecture**, 18. Österreich Tag-Wieviel Körper braucht der Mensch, Wien 10/16/2014
Wieviel Potenz macht den Mann zum Mann?
- **Invited lecture**, Urocyclicum 2014, St Wolfgang, Salzkammergut, Österreich 10/17/2014
Trends in der Urologie- die Zukunft

- **Invited lecture**, Czech Urological Society Annual Meeting 2014, Brno, Czech Rep 10/23/2014
Trends and novelties in upper tract urothelial carcinoma
- **Invited lecture** – Fortbildungstagung der Österreichischen Gesellschaft für Urologie und Andrologie. 7-8 November 2012, Linz, Austria 11/7/2014
Rauchen- der Einfluss in der Uro-Onkologie
- **Invited lecture** – 6. Symposium Urologische Forschung der Deutschen Gesellschaft für Urologie, Homburg/Saar, Germany 11/14/2014
15 Tips für eine erfolgreiche Karriere as Physician-scientist
- **Invited lecture** – 14th Belgian Association of Urology (BAU) Annual Meeting 12/12/2014
12-13 December 2014 in Spa, Belgium
Upper tract urothelial carcinoma – what are the standards and frontiers in 2014
- **Invited lecture** - Krebstag 2015, Rathaus Wien, Wien, AUT 2/10/2015
Der Prostatakrebs: Erkennen und Behandeln
- **Invited lecture** - 7 Interdisziplinäres Uro-Onkologisches Symposium am 30/1/2015
Universitätsspital Zürich, Zürich, Swizerland
Improving the quality of surgery for upper tract disease – lymphadenectomy, the bladder cuff and postoperative bladder instillations
- **Invited lecture** – SIU lecture at 30th Annual EAU Congress, Madrid, Spain 3/21/2015
Lymphadenectomy for upper tract urothelial carcinoma
- **Course Director and Lecturer**, 30th Annual EAU Congress, Madrid, Spain. 3/22/2015
ESU course 31 Current concepts and controversy in the diagnosis and management of upper tract urothelial carcinoma (UTUC)
Prognostic and predictive factors, pathology
Treatment of localized high risk (invasive) and metastatic cancer
- **Invited lecture** – Association Marocaine d'Urologie annual meeting, Rabat, Maroc 5/8/2015
Tumeurs T1 de haut grade refractaire a la BCG
Place de la biologie moleculaire dans le traitement des tumeurs de vessie
Therapie focales de la prostate
- **Course director and lecturer**, American Urological Association Association 5/19/2015
Annual Meeting 2015, New Orleans, LA, USA
0471C: Contemporary Concepts and Controversies in the Diagnosis and Management of Upper Tract Urothelial Carcinoma (UTUC)
- **Invited lecturer**, Friends of Urology Austrian Polish inauguration meeting, Vienna, AUT 5/29/2015
Open prostatectomy: tips and tricks, 2015
Education & career
- **Invited lecturer**, LXXX Congreso Nacional de Urología, Salamanca, Spain
Marcadores de tumor urotelial. Limitaciones y aplicabilidad 6/11/2015
Es el tumor Gleason 6 cáncer o no? 6/12/2015
- **Invited lecturer**, 2015 Summer School in Oncology, Bucharest, Rumania 6/17/2015
Prostate cancer- how can such a common disease be so paradox?
Personalized surgery for bladder cancer in 2015
- **Invited lecturer**, Robotische Chirurgie im Landesklinikum Wiener Neustadt 6/19/2015
Festvortrag: Roboter Chirurgie- Notwendigkeit, Verbesserung, Luxus oder Humbug?

- **Invited lecturer**, 5. Urologischer Workshop der LMU am Tegernesse 6/21/2015
Blasenkarzinom bei der Frau – tatsächlich mit schlechterem Outcome assoziiert?
- **Invited lecturer**, 71. Jahresversammlung der Schweizerische Gesellschaft 9/4/2015
für Urologie, St Gallen, Switzerland
State of the Art: Urothelkarzinom - Management des oberen Harntraktes
- **Invited lecturer**, 9th Uroforum, University of Barcelona, Barcelona, Spain 9/17/2015
Impact of new molecular classification in the management of muscle-invasive bladder cancer
- **Invited lecturer**, 67. Kongress der Deutschen Gesellschaft für Urologie Hamburg, Germany 9/25/2015
Invasives Blasenkarzinom: Risiko- und Prognose-faktoren
- **Invited lecturer**, Genitourinary Malignancies European Association of Urology (EAU) 9/29/2015
Session, 18th European Cancer Congress & 40th European Society For Medical Oncology, Vienna,
Austrian
Risk stratification of urothelial cancer in the lower and upper urinary tract
- **Invited lecturer**, Urology Robotic Oncology Paris, Paris, France 10/8/2015
Risk-stratification of urothelial carcinomas
- **Invited lecturer**, Going USA Weiterbildung, Fellowship, and Forschung, Wien, Austria 10/22/2015
Karrierewege in den USA
- **Invited lecturer**, 2015 Shanghai GU Oncology International Symposium, Shanghai, China 11/7/2015
Optimal multidisciplinary management of bladder cancer
- **Invited lecturer**, 7th European Multidisciplinary Meeting on Urological Cancers, Barcelona, Spain 11/14/2015
Update on clinical trails in urothelial carcinoma
- **Invited lecturer**, The 67th Annual Meeting of The Korean Urological Association, Seoul, Korea 11/19/2015
Lymphadenectomy for upper tract urothelial carcinoma
Risk stratification of high risk bladder cancer 11/20/2015
- **Invited lecturer**, Winter Meeting of Urology Sectionn of the Royal Society of Medicine, Austria 1/17/2016
Gleason 6 prostate lesions: cancer or not?
UTUC: what have we learned in the last 5 years? 1/18/2016
- **Invited lecturer**, Inagural International Urothelial Carcinoma Meeting, Vienna, Austria 1/29/2016
Key concerns about the current state of bladder cancer
- **Invited lecturer**, 4th National Bladder and Kidney Cancer Symposium, Melbourne, Australia 2/11/2016
State of the art: Current standards and controversies in upper tract urothelial carcinoma
Improving the quality of surgery for upper tract urothelial carcinoma 2/11/2016
Personalised therapeutic strategies in urothelial cancer 2/12/2016
State of the art lecture: Optimal management of T1G3 urothelial carcinoma 2/12/2016
Clinical impact of variant histology in urothelial carcinoma 2/12/2016
- **Invited lecturer**, Department of Urology, European Center of Medicine Otwock, PL 2/25/2016
Upper tract urothelial carcinoma: standards and the future
Tips for a succesfull career as surgeon-scientist 2/26/2016
- **Invited lecturer**, Postgraduate course of the Dept. of Urology, University of Istanbul, Istanbul, TK 2/27/2016
Radical cystectomy: tips and tricks
The shifting role of surgery in the management of prostate cancer 2/27/2016
New alternatives in the treatment of CRPC: what should be the optimal order? 2/27/2016

- **Invited lecturer**, 31st Annual EAU Congress, Munich, Germany.
When to perform radical cystectomy in T1HG bladder cancer at Joint Session of the EAU and Maghreb Union Countries 3/11/2016
Diagnosis and follow-up of upper tract urothelial carcinoma at Joint Session of the EAU and Korean Urological Association 3/11/2016
Exploring the limits of kidney sparing treatment of upper tract urothelial carcinoma State-of-the-art lecture at Non-muscle-invasive bladder cancer session 3/14/2016
- **Course Director and Lecturer**, 31st Annual EAU Congress, Munich, Germany. 3/14/2016
 ESU course: Current concepts and controversy in the diagnosis and management of upper tract urothelial carcinoma (UTUC)
Prognostic and predictive factors, pathology
Treatment of localized high risk (invasive) and metastatic cancer
- **Lecturer**, UROS 10 ans: Le cancer de la prostate: de A à Z, Oran, Algeria
Le Gleason 6 cancer est-il vraiment un cancer? 3/24/2016
Stratification des patients: comment choisir nos thérapies 3/24/2016
La surveillance active: qui et comment? 3/25/2016
Cas cliniques et discussions avec collègues algériens 3/25/2016
Traitement du recidive biochimique apres prostatectomy ou radiotherapie primaire 3/26/2016
Place de la chirurgie dans le cancer oligo-métastatique de la prostate 3/26/2016
Définition d'un cancer de la prostate résistant à la castration et traitement disponible 3/26/2016
Comment créer une base de donnée sur le cancer de la prostate 3/26/2016
- **Lecturer and panelist**, Novel Imaging Technique and Image-Guided Focal Therapy in Prostate Cancer, Istanbul, Turkey 4/9/2016
The drawbacks of multiparametric MRI in the diagnosis and treatment of prostate cancer
Multiparametric MRI in prostate cancer – Cases Discussions
- **Lecturer**, 2nd Faculty of the Charles University, Motol Hospital, Prague, CZ 4/20/2016
How to become a successful physician-scientist
- **Lecturer and panelist**, 104th Annual Meeting of the Japanese Urological Association, Sendai, Japan
The changing role of surgery in the management of prostate cancer 4/23/2016
Maximizing success for muscle-invasive bladder cancer 4/24/2016
Personalized medicine for bladder cancer in 2016: where are we going? 4/24/2016
Risks and opportunities of kidney-sparing management of UTUC 4/24/2016
Upper tract urothelial carcinoma: lessons learned in the last 10 years 4/24/2016
- **Course director and lecturer**, American Urological Association Association Annual Meeting 2016, San Diego, CA, USA 5/11/2016
0831C: Contemporary Concepts and Controversies in the Diagnosis and Management of Upper Tract Urothelial Carcinoma (UTUC)
- **Chair of session and invited lecturer**, Perioperative Medizin Symposium, AKH & MedUni Wien, Wien, Austria
High Tech I: Roboterchirurgie 5/20/2016
Eras for major urological surgery: a step forward 5/20/2016
- **Chair of session and lecturer**, 2nd Friends of Urology Austrian Polish meeting, Krakow, Poland 5/28-9/2016
Surgery for very high risk prostate cancer
New concepts in the management of metastatic prostate cancer

- **Chair of session and lecturer**, 42. Gemeinsame Tagung der Bayerischen Urologenvereinigung und der Österreichischen Gesellschaft für Urologie und Andrologie, Augsburg, DE 6/2-4/2016
Invited Lecturer, *Die Rolle der Biomarker für individuelle Behandlungsstrategie für Patienten mit metastasiertem Prostatakarzinom* 6/2/2016
Invited Lecturer, *Personalisierte Therapie des Harnblasenkarzinoms* 6/3/2016
Chair of session, *Palliativmedizin* 6/3/2016
Invited Lecturer, *TURB-Machen wir das was wir täglich tun auch wirklich richtig?* 6/3/2016
Invited Lecturer, *TURB: Können wir besser?* 6/3/2016
- **Chair of session and discussant**, 4th Global Congress on Prostate Cancer PROSCA 2016 6/30/2016
Chemotherapy for hormone-naïve metastatic patients: yes or no? Impact on clinical practice
- **Lecturer and live surgery**, Controversies in Urological Surgical Oncology, European Genito-Urinary Surgeons, Molinette Hospital, Turin, IT
Extended lymphadenectomy live surgery 9/23/2016
Conservative versus radical treatment of upper tract urothelial carcinoma 9/23/2016
- **Lecturer**, EAU 16th Central European Meeting, Vienna, AUT 10/7/2016
Surgical management of prostate cancer in the modern era
- **Lecturer**, 36th Congress of the Societe Internationale d'Urologie, Buenos Aires, Argentina
Molecular medicine: shaping the future – bladder cancer 10/21/2016
Follow-up after partial nephrectomy for localized RCC 10/20/2016
- **Lecturer**, World Urological Oncology Federation Symposium (WUOF), Innovation in Urology, Buenos Aires, Argentina
Unmet needs in upper tract urothelial carcinoma 10/20/2016
- **Invited lecturer**, Open Medical Institute Satellite Symposium, 12/7/2016
Under the auspices of Weill Cornell Medical College and the American Austrian Foundation in collaboration with Postgraduate medical Education Center, European Health Center, Otwock, Poland
Penis cancer
Non-muscle invasive bladder cancer: diagnosis, risk stratification, and management
Optimal management of muscle-invasive bladder cancer
Upper tract urothelial carcinoma: what is new!
- **Invited lecturer**, Kantonsspital Luzern, Luzern, Switzerland 1/12/2017
What is new and hot in upper tract urothelial carcinoma
- **Invited lecturer**, Young Scientist Association, Wien, Austria 3/16/2017
Wearing two hats: Bridging the gap between basic science and clinical practice
How to become a successful physician researcher
- **Invited lecturer**, 32nd Annual EAU Congress, London, UK.
Biomarkers for immunotherapy treatment selection 3/26/2017
The future management of bladder cancer 3/25/2017
- **Course Director and Lecturer**, 32nd Annual EAU Congress, London, UK. 3/26/2017
ESU course 31 Current concepts and controversy in the diagnosis and management of upper tract urothelial carcinoma (UTUC)
Prognostic and predictive factors, pathology
Treatment of localized high risk (invasive) and metastatic cancer
- **Invited lecturer**, 2nd Medical School, Motol Hospital, Charles University, Prag, CZ 4/15/2017
Residency training and excellence in medicine
Prostate cancer: diagnosis, risk stratification and management

- **Invited lecturer**, Taiwanese Urological Association, Taipei, Taiwan 4/29/2017
Changing role of radical prostatectomy today
Best of EAU 2017: what's hot and new in oncology
How androgen receptor inhibitors are reshaping the prostate cancer landscape
- **Invited lecturer**, UT Southwestern Dallas, Dallas, TX, USA 5/10/2017
Changing role of radical prostatectomy today
Tips for a successful career in medicine
UTUC Collaboration: an adventure that started at UT Southwestern
- **Invited lecturer**, 43 Gemeinsame Tagung der Oesterreichischen Gesellschaft fuer 5/18/2017
Urologie und Andrologie und der Bayerischen Urologenvereinigung, Wien, AUT
Organerhaltende Therapie beim UrothelKarzinom des oberen Harntrakts
- **Invited lecturer**, 24th Annual Meeting of the Slovak Urological Society, 6/8/2017
Trenčianskych Tepliciach, Slovakia
Upper tract urothelial carcinoma: diagnosis to therapy
Changing role of radical prostatectomy
- **Invited lecturer**, Europa Uomo Seminar 360° Perspectives Prostate Cancer, Wien, AUT 6/10/2017
Optimal treatment of high risk prostate cancer
- **Invited lecturer**, Session of the Uro-oncologic Section, Congress of the Polish 6/20/2017
Urological Association, Katowice, PL
Emerging novel therapies in systemic management of advanced bladder cancer
- **Invited lecturer**, University of Rennes, Rennes, FR 6/28/2017
T1 bladder cancer: tools for smart clinical decision making
- **Invited lecturer**, 15th European Urology Residents Education Programme, Prag, Cz 9/1-6/2017
Metastatic testicular cancer
Perioperative chemotherapy and systemic therapy for metastatic urothelial carcinoma
- **Invited lecturer**, Global Congress on Bladder Cancer, Edinburgh, UK 10/5/2017
Clinical aspects of immunotherapy in urothelial carcinoma
- **Invited lecturer**, 17th Congres Tunisien d'Urologie & 6th Congres Maghrebin d'Urologie, Tunis, TU
Prise en charge des T1 de haut grade: ce que je fais 10/13/2017
Surveillance active en cancer de prostate 10/14/2017
Curage etendu: technique, indications 10/14/2017
Prostatectomie de cyto-reduction dans les forms metastatiques 10/14/2017
- **Invited lecturer** at the EAU 17th Central European Meeting in conjunction with the 10/19/2017
national 63rd conference of the Czech Urological Society, Plzen, Czech Republic
Tips for a successful career in research
- **Invited lecturer** at the Innere Medizin Compact 2017 of the Austrian Society of 10/23/2017
Internal Medicine (OGIM), Vienna, AUT
Prostatakrebs im Überblick
- **Invited lecturer** at the Bleib gesund Mann! Event from the Medical University of 11/4/2017
Vienna, Vienna, AUT
Prostatakrebs heute
- **Invited lecturer**, Sociedad Chilena de Urologia, Pucon, Chile
The changing role of surgery in prostate cancer 11/23/2017
Harnessing heterogeneity in advanced prostate cancer 11/23/2017

- A roadmap to mangment of T1 high grade bladder cancer* 11/24/2017
Round table on the management of prostate cancer: case presentattions 11/24/2017
Upper tract urothelial carcinoma: an update 11/25/2017
The future of non-muscle invasive bladder cancer 11/25/2017
- **Invited lecturer** at the Selbsthilfegruppe Prostatakarzinom Austria, Vienna, AUT 12/5/2017
Prostatakrebs in 2017: was war neu?
 - **Invited lecturer** at the 1st ESU/ESOU Masterclass on Non-Muscle Invasive Bladder Cancer, Prag, CZ
 - The future of NMIBC management* 2/1/2018
 - Definition of GCG failure and treatment options* 2/2/2018
 - Case presentations* 2/2/2018
 - **Invited lecturer**, 32nd Annual European Urologic Association Annua; Congress, Copenhagen, DK. 3/19/2018
Can we rely on urinary markers?
 - **Course director and lecturer**, 32nd Annual EAU Congress, Copenhagen, DE 3/26/2018
 ESU course 25 New perspectives in the management of upper tract urothelial carcinoma (UTUC)
Prognostic and predictive factors, pathology
Treatment of localized high risk (invasive) and metastatic cancer
 - **Invited lecturer**, Motol Hospital, Charles University, Prag, CZ 4/5-6/2018
Prostate cancer: all you need to know
Primer for a career in academia
 - **Invited lecturer and panelist**, Curso de urologia - cancer de prostate, Madrid, Spain 4/26/2018
Por que hago linfadenectomia de rescate?
Tratamiento del paciente metastatico: casos clinicos
 - **Invited lecturer**, American Urological Association Annual Meeting, San Francisco, CA 5/20/2018.
Statistical considerations for clinical utility of a bladder cancer biomarker
 - **Course lecturer**, American Urological Association Annual Meeting, San Francisco, CA 5/20/2018.
053IC - Upper Tract Urothelial Carcinoma Tumor Board: A Case-Based Approach to Management
 - **Invited lecturer**, 2 Interdisziplinaeres Polytraumasymposium, Vienna, AUT 5/25/2018.
Verletzungen des Urogenitalsystems
 - **Course lecturer**, EAU Update on Bladder Cancer, Munich, GE 6/9/2018
Histological variants in bladder cancer in bladder cancer: how to deal with them? 3 x rotating course
 - **Invited lecturer**, Fortbildungstag Schweizerische Gesellschaft für Urologie, Bern, SUI 6/14/2018.
Endourologische Behandlung der Urothelkarzinome des oberen Harntraktes
 - **Course lecturer**, Updates on Onco-urology, Paris, FR
 - Decision-making for T1 bladder cancer* 6/29/2018
 - Role for urinary marker and perspectives* 6/29/2018
 - A role for PDL1-PD1 therapy in NMIBC* 6/29/2018
 - Chemotherapy for metastatic urothelial carcinoma* 6/30/2018
 - Clinical case discussions: urothelial carcinoma* 6/30/2018
 - **Course lecturer** 2018 Salzburg ESU/ Weill Cornell Master Class in Urology, Salzburg, AUT
 - Diagnosis and Pathology in NMIBC: What is the standard and what has to be changed?* 7/3/2018
 - NMIBC Bladder Cancer: What is a TURBT in 2018?* 7/3/2018
 - Immunotherapy in Metastatic Bladder Cancer: Is it really so good?* 7/5/2018

- Treatment of Invasive and Metastatic UTUC* 7/5/2018
- **Invited lecturer**, Erster wissenschaftlicher Kongress der Oesterreichisch-Iranischen Aerzte, Wien, AUT 7/14/2018
Prostate cancer: current evidence and controversies
 - **Invited lecturer**, 16th European Urology Residents Education Programme, Prag, Cz 8/31-9/5/2018
Metastatic testicular cancer
Perioperative chemotherapy and systemic therapy for metastatic urothelial carcinoma
Non-muscle invasive bladder cancer
 - **Invited Lecturer**, 70ter Kongress der Deutschen Gesellschaft fuer Urologie, Dresden, GE 9/27/2018
Role of molecular staging in the management of cT2c bladder urothelial carcinoma 9/27/2018
Die adaequate bildgebende Diagnostik fuer das Urothelkarzinom des oberen Harntraktes? 9/28/2018
 - **Invited lecturer**, 18th Central European Meeting of the EAU, Cluj Napoca, Romania 10/12/2018
Genetic testing in prostate cancer
 - **Invited lecturer**, 55th Urology Course of the Fundacio Puigvert, Barcelona, Spain 10/17/2018
Quality criteria for radical nephroureterectomy
 - **Invited lecturer**, European Society of Medical Oncology, Munich, DE 10/19/2018
Discussion of Keynote 057 -Efficacy of pembrolizumab in Bacillus Calmette Geurin-unresponsive bladder cancer with high risk for disease progression.
 - **Invited lecturer** at the Innere Medizin Compact 2018 of the Austrian Society of Internal Medicine (ÖGIM), Vienna, AUT 10/22/2018
Blasenkrebs im Überblick
 - **Invited chair**, Nightmare session at the European Multidisciplinary Congress on Urological Cancers, Amsterdam, NL 11/10/2018
 - **Invited lecturer**, 1. Onkologisch-Laparoskopischen und Roboterchirurgischen Herbstsymposium, ÖGU Arbeitskreise, Stift Goettweig in Furth, Austria 11/23/2018
Keynote lecture: Genetik bei Prostatakrebs 11/23/2018
Kritisches Denken in der Medizin und darueber hinaus 11/23/2018
 - **Invited lecturer**, 2nd ESU/ESOU Masterclass on Non-Muscle Invasive Bladder Cancer, Prag, CZ 2/22/2019
The future of NMIBC management 2/22/2019
Definition of BCG failure and treatment options 2/22/2019
Moderator of live surgery 2/22/2019
Case presentations 2/21/2019
 - **Invited lecturer**, 33rd Annual European Urologic Association Annual Congress, Barcelona, SP 3/15/2019
European perspective on the management of pT1 high grade bladder tumors 3/15/2019
EAU Young Urologists Office (YUO) & European Society of Residents in Urology (ESRU)
What you need to know about the POUT trial for upper tract urothelial carcinoma 3/16/2019
Guidelines debate: perioperative chemotherapy will become the new standard 3/16/2019
Thematic Session 7: how much do you know about modern imaging 3/17/2019
 - **Course director and lecturer**, 33rd Annual European Urologic Association, Annual Congress, Barcelona, SP 3/17/2019
ESU course 25 New perspectives in the management of upper tract urothelial carcinoma (UTUC)
Prognostic and predictive factors, pathology
Treatment of localized high risk (invasive) and metastatic cancer

- **Invited lecturer** at the Institute for Urology and Reproductive Health I.M. Sechenov, First Moscow State Medical University, Moscow, Russia
Novel standards in the management of prostate cancer 4/26/2019
- **Invited lecturer** at Central European Meeting of the European Association of Urology, Vienna, AUT
How to write a paper course x3 rotating course 5/9/2019
How to become a successful physician researcher 5/10/2019
- **Invited lecturer and chair**, Blasengesundheitstage Meine Blase und Ich, Netdoktor 5/17/2019
Therapiestrategien beim Blasenkarzinom: status quo und die Zukunft
- **Invited lecturer**, EAU Update on Bladder Cancer, Torino, IT 5/18/2019
Histological variants in bladder cancer in bladder cancer: how to deal with them? 3 x rotating course
Emerging role of immunotherapy in neoadjuvant and adjuvant setting
- **Invited lecturer**, ESU course at the 6th Baltic Meeting with the EAU, Tallinn, Estonia 5/24/2019
Prognostic and predictive factors, pathology
Treatment of localized high risk (invasive) and metastatic cancer
- **Invited lecturer**, Österreichische Gesellschaft für Orthopädie und Traumatologie (ÖGÖuT), 6/5/2019
Urogenital Verletzungen bei Polytraumatisierten Patienten
- **Invited Skype lecturer**, 22nd Annual Meeting of the Iranian urological Association (IUA) 6/13/2019
T1 bladder cancer: a mysterious malignancy
- **Invited lecturer**, 17th European Urology Residents Education Programme, Prag, Cz 9/5-9/11/2019
Metastatic testicular cancer
Perioperative chemotherapy and systemic therapy for metastatic urothelial carcinoma
Non-muscle invasive bladder cancer
Upper tract urothelial carcinoma
- **Invited lecturer** at the Institute for Urology and Reproductive Health I.M. Sechenov, 18/9/2019
First Moscow State Medical University, Moscow, Russia
Systemic therapy in the management of urothelial carcinoma
- **Invited lecturer** at Russian Urological Association, Rostov o Don, Russia 18/9/2019
T1 bladder cancer: how to differentiate the tiger from the pussycat
Emerging standards in the management of upper tract urothelial carcinoma
- **Invited lecturer**, ESMO Clinical Practice Guidelines, European Society of Medical 29/9/2019
Oncology, Barcelona, Spain
Urothelial cancer: Bladder-preserving strategies followed by systemic relapse (ID 6211)
- **Invited lecturer**, 11th International Conference of the Jordanian Association of 10/5/2019
Urological Surgeons, Amman, Jordan
Immunotherapy for bladder cancer
- **Invited lecturer**, King Hussein Cancer Center, Amman, Jordan 10/8/2019
Immunotherapy for GU Cancers
- **Invited lecturer**, The Congress of the University of Medicine and Pharmacy Carol 10/10/2019
Davila Bucharest
The UTUC Collaboration: A Roadmap for an International Success Story
- **Invited lecturer**, Hungarian Urological Society, Eger, Hungary 10/13/2019
Tips for a successful career as physician-scientist

- **Invited chair**, International session, Austrian Urological Society, Linz, Austria 11/10/2019
- **Invited lecturer**, Young academic urologists autumn meeting, Vienna, AUT 11/14/2019
Establishing a professional career at a European level: motivation talk
- **Invited discussant**, EMUC 2019, Vienna, AUT 11/15/2019
Challenge the expert- response after neoadjuvant chemotherapy, histologic variant, upper tract recurrence after cystectomy
- **Invited lecture and chair**, EAU Section of Oncological Urology 2020, Dublin, IE 18/1/2020
Urothelial cancer II
Perioperative systemic treatment in upper tract tumor
ESU ESOU session on immunotherapy for the treatment of urological cancers
Immunotherapy for non-muscle invasive bladder cancer
Game of thrones: Battle of nations
- **Invited lecture and chair**, International Conference “New Technologies in Urology: Pro et Contra”, Moscow, RU 2/7/2020
Quality criteria for a perfect TURBT
Robotic assisted radical cystectomy progress or gimmick?
New technologies in RCC management
- **Invited webinar lecture**, Association Marocaine d’Onco-Urologie 6/19/2020
Prise en charge de l’echec du BCG dans les tumeurs nn invasives de la vessie
- **Invited webinar lecture**, European School of Urology/Weill Cornell Medical Center OMInar in Urology 7/9/2020
Bladder cancer
- **Invited lecture and chair at virtual congress**, 34th Annual EAU congress 18/7/2020
Pro – radical cystectomy for high risk non-muscle invasive bladder cancer
Medscape-live: treatment landscape for BCG unresponsive
Sequencing for urothelial carcinoma
- **Invited webinar lecture**, European School of Urology/Weill Cornell Medical Center OMInar in Urology 7/9/2020
Bladder cancer
- **Invited webinar lecture**, Algerian Urological Association 17/9/2020
Cancer de la prostate metastatique hormone-sensible
Cancer de la prostate metastatique resistant a la castration
Role de la therapie locale dans le cancer metastatique
- **Invited webinar lecture**, Grand rounds at Division of Urology, University of Colorado, Denver, CO 10/2/2020
Modern Management of Upper Tract Urothelial Carcinoma
- **Invited webinar lecture**, EAU Urowebinar, 10/13/2020
BCG unresponsive non uscle invasive bladder cancer
- **Invited webinar lecture**, Semmelweis 250 online clinical conference, HU 11/10/2020
Tips for a successful career as a physician researcher
- **Invited webinar lecture**, Sechenov University, Moscow, RU 11/12/2020
Role local therapy for hormone sensitive metastatic prostate cancer
- **Invited webinar lecture**, Dialog 2020 Prostatakarzinom, Wien, AUT 11/13/2020

Lokale Therapie fuer metastastisches Prostatakarzinom

- **Invited webinar lecture**, European Multidisciplinary Urologic Congress
Kidney Sparing in upper tract urothelial carcinoma 11/14/2020
- **Invited webinar lecture**, Innere Medizin Compact Urogenitalsystem
Prostatakarzinom 11/16/2020
- **Invited webinar lecture**, EAU Section of Oncological Urology 2021
Open versus robotic radical nephroureterectomy 1/30/2021
- **Invited webinar lecturer**, ESU/ESOU Masterclass on Non-Muscle Invasive Bladder Cancer
The future of NMIBC management 2/5/2021
- **Invited webinar lecturer**, Joint Academic Meetings from Cambridge Urology Hospitals, University of Cambridge
Introducing Medical University of Vienna 2/11/2021
Quality indicators for UTUC care 2/11/2021
- **Invited webinar lecturer**, Phillipines Urological Association
Surgical management of prostate cancer: challenges and progress 4/22/2021
- **Invited webinar lecturer**, Trio meeting of the Comprehensive Cancer Center of the Medical Universty Vienna
Tip for becoming a surgeon scientist 4/16/2021
- **Invited webinar lecturer**, Iranian Urological Association Annual Meeting, Virtual.
Quality indicators for the management of upper tract urothelial carcinoma 5/21/2021
Therapeutic options for BCG unresponsive non muscle invasive bladder cancer 5/21/2021
- **Invited webinar lecturer**, North African Webinar from the Association Marrocaine d'Urologie, Association Algerienne d'Urologie and Association Tunesienne d'Urologie, Virtual
Quand et comment faire un traitement local pour le cancer de la prostate metastastique 5/21/2021
- **Invited webinar lecturer**, SPIEF 2021 Medical Science. How To Expedite Introduction Into Practical Healthcare, St Petersburg, RU
How can we get more health care workers involved in science 5/21/2021
- **Invited lecture and chair at virtual congress**, 35th Annual EAU congress
Chair: Steering through new treatment landscapes for patients with locally advanced or metastatic urothelial carcinoma 10/7/2021
Lecture: Looking to the horizon: Treatment goals and requirements in LA/mUC 7/10/2021
Chair: Current concepts & controversy in the diagnosis & management of UTUC 7/11/2021
Accurate risk stratification and pathology 7/11/2021
Treatment of metastatic disease 7/11/2021
UTUC: molecular characterisation and modern management; Poster Session 27 7/11/2021
Active surveillance is the best choice, patients can enjoy life before treatment! 7/12/2021
- **Invited lecture**, ESTPU TEACHING, NHS FIFE, UK- online
UTUC: Quality indicators in 2021 9/17/2021
- **Invited lecture**, Algerian community of endourology & lap surgery (ACELAS)- online
Genetic of prostate cancer 9/29/2021
- **Invited lecture**, Interdisciplinary TUMOR Tage, Wien, AUT
Management of locally advanced and metastatic urothelial carcinoma in 2021/2022 10/15/2021

- **Invited lecture**, Turkish Society of Urology - 30th National Urology Congress- online
BCG unresponsive: diagnosis and management 10/20/2021
- **Invited lecture**, 7th Croatian Urology Congress, Pula, Croatia
Changing role of surgery in prostate cancer 10/22/2021
- **Invited lecture**, CHUK Urology Symposium, Hong Kong, China-online
Early cystectomy in high-risk NMIBC: is it justified? 10/30/2021
- **Invited chair**, International session, Austrian Urological Society, Linz, Austria 11/9/2021
- **Invited lecturer**, 15.CCIV Symposium, Vienna, Austria
Value base health care als Loesungsansatz; Sicht eines Klinikers 11/14/2021
- **Invited lecturer**, 18th Symposium Urology Arena, Controversies in urothelial cancer
What is the standard and what is new in therapy of metastatic urothelial carcinoma 12/3/2021
- **Invited lecturer**, Slovak urological society oncurological symposium
Perioperative systemic therapy: what is new 11/17/2021
- **Invited lecturer**, Algerian Urological Association Annual meeting
Cystectomie precoce: qui et quand? 12/3/2021
- **Invited lecturer**, 7th M.J.Marberger Virtual Meeting: Frontiers in Urology, Vienna, AUT
Neo-adjuvant and adjuvant systemic therapy for muscle invasive bladder cancer 12/10/2021
- **Invited lecturer**, Tabriz University of Medical Sciences, Tabriz Iran
Tips how to become a successful physician-scientist 12/14/2021
- **Invited lecturer**, Philadelphia University, Philadelphia, Pennsylvania
Quality indicators in UTUC 2/17/2022
- **Invited lecturer**, Interdisziplinäre T.U.M.O.R. Tage
ASCO-GU Updates Urothelial Carcinoma 3/12/2022
- **Invited lecturer**, PhD students, Semmelweis University Budapest, Hungary
Tips for a successful career as physician scientist 3/25/2022
- **Invited lecturer**, Winthertur hospital, Switzerland
Treatment of locally advanced and metastatic bladder cancer 4/4/2022
- **Invited lecturer**, Oestereichische Gesellschaft fuer klinische Pathologie und Molekularpathologie,
Abteilung der Internationalen Akademie fuer Pathologie, Vienna, AUT
Ohne Pathologie keine Therapie: aus der Sicht des Urologen 30/4/2022
- **Invited lecturer**, Iranian Urologic Association, Iran, Online
Perioperative systemic therapy for clinically localized MIBC
Discussion of muscle invasive case 19/5/2022
- **Invited lecturer**, ESU course at the 7th Baltic Meeting with the EAU, Vilnius, Lithuania
Local therapy for metatstaic prostate cancer
Prognostic and predictive factors, pathology- Upper tract urothelial carcinoma
Treatment of localized high risk (invasive) and metastatic upper tract urothelial carcinoma 5/30/2022
- **Invited lecturer**, Al Ahliya University, Amman, Jordan
How to build a research affine culture and infastructure 6/19/2022
- **Invited lecturer**, Brazilian Urologic Oncology Society, Sao Paulo, Brazil 6/26/2022

Quality criteria for good UTUC care

The future of perioperative systemic therapy for muscle invasive bladder cancer

- **Invited lectures and chair**, 36th Annual EAU congress
 - Controversies in onco-urology: Young surgeons should learn open surgery in the robotic era* 7/2/2022
 - Perioperative treatment of urothelial cancer in 2022: adjuvant therapy* 7/2/2022
 - Chair: Current concepts & controversy in the diagnosis & management of UTUC* 7/3/2022
 - Lecture: Accurate risk stratification and prognostic factors* 7/3/2022
 - Lecture: Treatment of advanced and metastatic disease* 7/3/2022
 - Chair: New insights in the management of UTUC; Poster Session 16* 7/2/2022
 - Common problems in bladder cancer reTUR depends on biology or surgeon skill!* 7/2/2022
 - EAU Young Urologists Office & ESR: Hot updates on UTUC* 7/2/2022
- **Invited lecturer**, European Society of Radiology Annual Meeting, Vienna, AUT
 - Management of bladder cancer: from bench to bedside* 7/15/2022
- **Invited lecturer**, Methods in clinical cancer research 2022, Salzburg, AUT
 - Tips for a successful career as clinician scientist* 9/15/2022
 - How to write a paper* 9/17/2022
- **Invited lecturer**, Swiss Urological Society, Bern, Switzerland
 - Quality indicators of upper tract urothelial carcinoma* 10/5/2022
- **Invited lecturer**, 2nd Faculty of the Charles University, Prag, Czech Republic
 - Metastatic urothelial carcinoma in 2022* 10/12/2022|
 - Career development: science as a motor for success and joy* 10/12/2022
- **Course director and invited lecturer**, Cancer Update CCC Vienna, Vienna, AUT
 - Hodenkrebs: wo kommen wir her und wo gehen wir hin* 11/15/2022
- **Invited lecturer**, Stift Goettweig, Goettweig, AUT
 - Offene Chirurgie: warum sie heute noch notwendig ist* 18/11/2022
- **Invited lecturer**, Fortbildung des Berufsverband der Urologen, Vienna, AUT
 - Intravesikale Therapie fuer nicht-muskel-invasives Blasenkarzinom* 11/24/2022
- **Invited lecturer**, 12th Shanghai Genitourinary Oncology International Symposium
 - Challenges and unmet needs in metastatic hormone sensitive prostate cancer* 11/26/2022
 - Update on metastatic urothelial carcinoma*
- **Invited lecturer**, 5^{te} Internationales Symposium Uro-Onkologie, Magdeburg, DE
 - Robotic versus open radical cystectomy: the data and the reality* 12/2/2022
- **Invited lectures and chair**, 37th Annual EAU congress
 - How basic science revolutionized cancer specific survival in genitourinary oncology* 3/10/2023
 - Lecture: Accurate risk stratification and prognostic factors* 3/10/2023
 - Lecture: Treatment of advanced and metastatic disease* 3/10/2023
 - Clinical staging for bladder cancer: Have imaging techniques reached a point where we can avoid TURBT – at initial diagnosis? After neoadjuvant therapy?* 3/11/2023
 - Chair of Abstract Session 41: Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)* 3/11/2023
 - Adjuvant treatment after radical surgery for high risk bladder cancer makes sense* 3/11/2023
- **Invited lectures and chair**, CEM23 congress, Krakow, PL
 - Chair moderated poster session* 24/3/2023
 - Chair Varial* 25/3/2023
 - Lecture: Unmet met needs of metastatic hormone sensitive prostate cancer* 26/3/2023

- **Invited lectures and chair**, Controversies in Urologic Oncology, Vienna, AUT
The paradox of prostate cancer 4/14/2023
- **Invited lecture**, 30th Slovak Urological Society, Presov, SL
Local therapy of metastatic hormone sensitive prostate cancer 6/14/2023
- **Invited discussant**, Cluster of Medical Imaging, Future potentials, Vienna, AUT
Clusters at the Medical Univ of Vienna – partnerships and strategy 6/15/2023
- **Invited lecturer**, JBI European Symposium, Tabriz, Iran online
Personalized medicine today: bladder cancer as an example 6/22/2023
- **Invited lecturer**, Urotube from the German Urological Association
Triple therapy for mHSPC: standard, rarely or never 9/13/2023
- **Invited lectures and chair**, German Urological Association in Leipzig, DE
Braucht es eine Zystektomie oder gibt es Alternativen? 9/20/2023
Urothelkarzinom TB: Pro Instillationstherapie 2.0-hypertherm! 9/21/2023
Urothelkarzinom TB: Pro Blasenerhalt 2.0: Molekulare Stratifizierung und neue Ansätze 9/21/2023

PEER-REVIEWED PUBLICATIONS

1. Piszczek R, Krajewski W, Subiela JD, Del Giudice F, Nowak Ł, Chorbińska J, Moschini M, Masson-Lecomte A, Bebane S, Cimadamore A, Grobet-Jeandin E, Rouprêt M, D'Andrea D, Mastroianni R, Gutierrez Hidalgo B, Gomez Rivas J, Mori K, Soria F, Laukhtina E, Mari A, Albisinni S, Gallioli A, Mertens LS, Pichler R, Marcq G, Łaszkiwicz J, Haloń A, Carrion DM, Akand M, Pradere B, **Shariat SF**, Palou J, Babjuk M, Burgos Revilla J, Malkiewicz B, Szydełko T; European Association of Urology EAU-Young Academic Urologists YAU Urothelial Cancer Working Party. Prognosis of patients with T1 low-grade urothelial bladder cancer treated with bacillus Calmette-Guérin immunotherapy. *Minerva Urol Nephrol.* 2023 Oct;75(5):591-599. PMID: 37728495
2. Cano Garcia C, Tappero S, Piccinelli ML, Barletta F, Incesu RB, Morra S, Scheipner L, Baudo A, Tian Z, Hoeh B, Chierigo F, Sorce G, Saad F, **Shariat SF**, Carmignani L, Ahyai S, Longo N, Tilki D, Briganti A, De Cobelli O, Dell'Oglio P, Mandel P, Terrone C, Chun FKH, Karakiewicz PI. In-Hospital Venous Thromboembolism and Pulmonary Embolism After Major Urologic Cancer Surgery. *Ann Surg Oncol.* 2023 Sep 18. PMID: 37721691
3. Yanagisawa T, Sato S, Hayashida Y, Okada Y, Fukuokaya W, Iwatani K, Matsukawa A, Shimoda M, Takahashi H, Kimura T, **Shariat SF**, Miki J. Clinical impact of detrusor muscle in en bloc resection for T1 bladder cancer. *Urol Oncol.* 2023 Sep. PMID: 37714725
4. Alam R, Rezaee ME, Pallauf M, Elias R, Yerrapragada A, Enikeev D, Fang D, **Shariat SF**, Woldu SL, Ged YMA, Singla N. Socioeconomic determinants of racial disparities in survival outcomes among patients with renal cell carcinoma. *Urol Oncol.* 2023 Sep 13: PMID: 37709565
5. Marra G, Callaris G, Conte F, Benfant N, Rajwa P, Ahmed M, Abreu A, Cacciamani G, Smith JA, Joniau S, Rodriguez-Sanchez L, Sanchez-Salas R, Cathcart P, Gill I, Karnes RJ, Tilki D, **Shariat SF**, Touijer K, Gontero P. Recurrent Gleason Score 6 Prostate Cancer After Radiotherapy or Ablation: Should We Observe Them All? Results from a Large Multicenter Salvage Radical Prostatectomy Consortium. *Eur Urol Focus.* 2023 Sep PMID: 37704503
6. Yanagisawa T, Quhal F, Kawada T, Bekku K, Laukhtina E, Rajwa P, Deimling MV, Chlosta M, Pradere B, Karakiewicz PI, Mori K, Kimura T, Schmidinger M, **Shariat SF**. Association between

age and efficacy of first-line immunotherapy-based combination therapies for mRCC: a meta-analysis. *Immunotherapy*. 2023 PMID: 37694583

7. Tappero S, Piccinelli ML, Incesu RB, Cano Garcia C, Barletta F, Morra S, Scheipner L, Baudo A, Tian Z, Parodi S, Dell'Oglio P, de Cobelli O, Graefen M, Chun FKH, Briganti A, Longo N, Ahyai S, Carmignani L, Saad F, **Shariat SF**, Suardi N, Borghesi M, Terrone C, Karakiewicz PI. Overall Survival of Metastatic Prostate Cancer Patients According to Location of Visceral Metastatic Sites. *Clin Genitourin Cancer*. 2023 PMID: 37690970
8. Mazzone E, Gandaglia G, Robesti D, Rajwa P, Gomez Rivas J, Ibáñez L, Soeterik TFW, Bianchi L, Afferi L, Kesch C, Darr C, Guo H, Zhuang J, Zattoni F, Fendler WP, Amparore D, Huebner NA, Giesen A, Joniau S, Schiavina R, Brunocilla E, Mattei A, Dal Moro F, Moreno Sierra J, Porpiglia F, Picchio M, Chiti A, van den Bergh R, **Shariat SF**, Montorsi F, Briganti A. Which Patients with Prostate Cancer and Lymph Node Uptake at Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography Scan Are at a Higher Risk of Prostate-specific Antigen Persistence After Radical Prostatectomy? Identifying Indicators of Systemic Disease by Integrating Clinical, Magnetic Resonance Imaging, and Functional Imaging Parameters. *Eur Urol Oncol*. 2023 PMID: 37689506
9. Morra S, Piccinelli ML, Cano Garcia C, Tappero S, Barletta F, Incesu RB, Scheipner L, Baudo A, Tian Z, Saad F, Mirone V, Califano G, Colla' Ruvolo C, **Shariat SF**, de Cobelli O, Musi G, Chun FKH, Terrone C, Briganti A, Tilki D, Ahyai S, Carmignani L, Longo N, Karakiewicz PI. Differences in future life expectancy of testicular germ-cell tumor patients vs. age-matched male population-based controls. *Int Urol Nephrol*. 2023.PMID: 37640983
10. Kafka M, Horninger A, di Santo G, Virgolini I, Neuwirt H, Unterrainer LM, Kunte SC, Deiss E, Paffenholz P, Heidenreich A, Rasul S, Einspieler H, **Shariat SF**, Rajwa P, Dozauer R, Tsaur I, Medlock E, Rölz N, Rausch S, la Fougère C, Trautwein N, Roesch MC, Merseburger AS, Zattoni F, Sepulcri M, Ladurner M, Bektic J, Gandaglia G, Horninger W, Heidegger I. Real-world Outcomes and Predictive Biomarkers for 177Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate Cancer: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Observational Study. *Eur Urol Oncol*. 2023 Aug PMID: 37604763
11. Teoh JY, D'Andrea D, Gallioli A, Yanagisawa T, MacLennan S, Nicoletti R, Fai NC, Maffei D, Hurler R, Lusuardi L, Malavaud B, Miki J, Kramer M, Mostafid H, Enikeev D, Babjuk M, Breda A, **Shariat S**, Gontero P, Herrmann T. En bloc resection of bladder tumour: the rebirth of past through reminiscence. *World J Urol*. 2023.PMID: 37584691
12. Laukhtina E, von Deimling M, Pradere B, Yanagisawa T, Rajwa P, Kawada T, Quhal F, Pallauf M, Bianchi A, Majdoub M, Mostafaei H, Sari Motlagh R, Mori K, Enikeev D, Fisch M, Moschini M, D'Andrea D, Soria F, Albisinni S, Fajkovic H, Rink M, Teoh JY, Gontero P, **Shariat SF**; European Association of Urology-Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Urinary function in female patients after traditional, organ-sparing and nerve-sparing radical cystectomy for bladder cancer: a systematic review and pooled analysis. *BJU Int*. 2023 Aug 10. PMID: 37562831.
13. Incesu RB, Barletta F, Tappero S, Morra S, Garcia CC, Scheipner L, Piccinelli ML, Tian Z, Saad F, **Shariat SF**, de Cobelli O, Ahyai S, Chun FKH, Longo N, Terrone C, Briganti A, Tilki D, Graefen M, Karakiewicz PI. Conditional survival of stage III non-seminoma testis cancer patients. *Urol Oncol*. 2023 PMID: 37558516
14. Ślusarczyk A, Baboudjian M, Zapala P, Yanagisawa T, Miszczyk M, Chlosta M, Krumpoeck P, Moschini M, Gandaglia G, Ploussard G, Rivas JG, Życzkowski M, Karakiewicz PI, Radziszewski

- P, Leapman MS, **Shariat SF**, Rajwa P. Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate-specific antigen concentrations. *Prostate*. 2023 PMID: 37545342
15. D'Andrea D, Soria F, Hurle R, Enikeev D, Kotov S, Régnier S, Xylinas E, Lusuardi L, Heidenreich A, Cai C, Frego N, Taraktin M, Ryabov M, Gontero P, Compérat E, **Shariat SF**; eBLOC Study Team. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. *Eur Urol Oncol*. 2023.PMID: 37543464
 16. Panunzio A, Tappero S, Piccinelli M, Cano Garcia C, Barletta F, Incesu RB, Law KW, Tian Z, Tafuri A, Saad F, **Shariat SF**, Tilki D, Briganti A, Chun FK, DE Cobelli O, Terrone C, Bourdeau I, Cerruto MA, Antonelli A, Karakiewicz PI. Regional differences in stage distribution and rates of treatment for adrenocortical carcinoma across United States SEER registries. *Minerva Urol Nephrol*. 2023.PMID: 37530661
 17. Rebhan K, Stelzer PD, Pradere B, Rajwa P, Kramer G, Hofmann B, Resch I, Yurdakul O, Laccone FA, Bujalkova MG, Smogavec M, Tan YY, Ristl R, **Shariat SF**, Egger G, Hassler MR. Performance of clinical risk scores and prediction models to identify pathogenic germline variants in patients with advanced prostate cancer. *World J Urol*. 2023 PMID: 37528288
 18. Chierigo F, Flammia RS, Sorce G, Hoeh B, Hohenhorst L, Panunzio A, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Montorsi F, Chun FKH, **Shariat SF**, Antonelli A, Guano G, Mantica G, Borghesi M, Suardi N, Terrone C, Karakiewicz PI. Racial/ethnic disparities in the distribution and effect of type and number of high-risk criteria on mortality in prostate cancer patients treated with radiotherapy. *Arab J Urol*. 2022 Nov 21;21(3):135-141. PMID: 37521449.
 19. Scheipner L, Cano Garcia C, Barletta F, Incesu RB, Morra S, Baudo A, Assad A, Tian Z, Saad F, **Shariat SF**, Chun FKH, Briganti A, Tilki D, Longo N, Carmignani L, Leitsmann M, Ahyai S, Karakiewicz PI. Regional differences in penile cancer patient characteristics and treatment rates across the United States. *Cancer Epidemiol*. 2023.PMID: 37506474
 20. Yanagisawa T, Kawada T, von Deimling M, Bekku K, Laukhtina E, Rajwa P, Chlosta M, Pradere B, D'Andrea D, Moschini M, Karakiewicz PI, Teoh JY, Miki J, Kimura T, **Shariat SF**. Repeat Transurethral Resection for Non-muscle-invasive Bladder Cancer: An Updated Systematic Review and Meta-analysis in the Contemporary Era. *Eur Urol Focus*. 2023 PMID: 37495458
 21. Chierigo F, Flammia RS, Sorce G, Hoeh B, Hohenhorst L, Tian Z, Saad F, Gallucci M, Briganti A, Montorsi F, Chun FKH, Graefen M, **Shariat SF**, Guano G, Mantica G, Borghesi M, Suardi N, Terrone C, Karakiewicz PI. The association of the type and number of D'Amico high-risk criteria with rates of pathologically non-organ-confined prostate cancer. *Cent European J Urol*. 2023;76(2):104-108. PMID: 37483849
 22. Laukhtina E, **Shariat SF**. Smoking, ethnicity and bladder cancer - implications for public health and clinical practice. *Nat Rev Urol*. 2023 Jul 18. doi: 10.1038/s41585-023-00804-4. PMID: 37464063
 23. Sari Motlagh R, Ghoreifi A, Yanagisawa T, Kawada T, Kikic Z, Gill I, Daneshmand S, Djaladat H, **Shariat SF**. Survival of Patients with Chronic Kidney Disease Treated with Radical Cystectomy and Risk Factors of Glomerular Filtration Rate Loss Following Radical Cystectomy: Two Systematic Reviews and Meta-analyses of Interplay Between Radical Cystectomy and Renal Function. *Eur Urol Focus*. 2023 PMID: 37442723.
 24. Piccinelli ML, Tappero S, Cano Garcia C, Barletta F, Incesu RB, Morra S, Scheipner L, Tian Z, Luzzago S, Mistretta FA, Ferro M, Saad F, **Shariat SF**, Ahyai S, Longo N, Tilki D, Briganti A,

- Chun FKH, Terrone C, de Cobelli O, Musi G, Karakiewicz PI. Assessment of the VENUSS and GRANT Models for Individual Prediction of Cancer-specific Survival in Surgically Treated Nonmetastatic Papillary Renal Cell Carcinoma. *Eur Urol Open Sci.* 2023 Jun 13;53:109-115. PMID: 37441347
25. Kawada T, Yanagisawa T, Bekku K, Laukhtina E, Deimling MV, Majdoub M, Chlosta M, Pradere B, Babjuk M, Gontero P, Moschini M, Araki M, **Shariat SF**. Low-dose or -number of BCG in non-muscle invasive bladder cancer: updated systematic review and meta-analysis. *Immunotherapy.* 2023 PMID: 37409426
 26. Yanagisawa T, Kawada T, Mori K, Shim SR, Mostafaei H, Sari Motlagh R, Quhal F, Laukhtina E, von Deimling M, Bianchi A, Majdoub M, Pallauf M, Pradere B, Kimura T, **Shariat SF**, Rajwa P. Impact of performance status on efficacy of systemic therapy for prostate cancer: a meta-analysis. *BJU Int.* 2023 Jul 3. PMID: 37395151
 27. Preisser F, Incesu RB, Rajwa P, Chlosta M, Ahmed M, Abreu AL, Cacciamani G, Ribeiro L, Kretschmer A, Westhofen T, Smith JA, Graefen M, Callaris G, Raskin Y, Gontero P, Joniau S, Sanchez-Salas R, **Shariat SF**, Gill I, Karnes RJ, Cathcart P, Van Der Poel H, Marra G, Tilki D. Oncologic Outcomes of Lymph Node Dissection at Salvage Radical Prostatectomy. *Cancers (Basel).* 2023 Jun 9;15(12):3123. PMID: 37370733
 28. Barletta F, Tappero S, Morra S, Incesu RB, Cano Garcia C, Piccinelli ML, Scheipner L, Baudo A, Tian Z, Gandaglia G, Stabile A, Mazzone E, Terrone C, Longo N, Tilki D, Chun FKH, de Cobelli O, Ahyai S, Carmignani L, Saad F, **Shariat SF**, Montorsi F, Briganti A, Karakiewicz PI. Cancer-Specific Mortality Differences in Specimen-Confined Radical Prostatectomy Patients According to Lymph Node Invasion. *Clin Genitourin Cancer.* 2023 May 18:S1558-7673(23)00122-2. PMID: 37365054
 29. Klemm J, Rink M, von Deimling M, Koelker M, Gild P, **Shariat SF**, Dahlem R, Fisch M, Vetterlein MW. Time-to-complication Patterns After Radical Cystectomy: A Secondary Analysis of a 30-day Morbidity Assessment Using the European Association of Urology Quality Criteria for Standardized Reporting. *Eur Urol Focus.* 2023 Jun 20:S2405-4569(23)00145-1. PMID: 37349179
 30. Aydh A, Sari Motlagh R, Alamri A, Yanagisawa T, Ayed A, Rajwa P, Laukhtina E, Alasiri SM, Kawada T, Mostafai H, Ayidh A, Pallauf M, König F, Abufaraj M, Karakiewicz PI, **Shariat SF**. Comparison between different neoadjuvant chemotherapy regimens and local therapy alone for bladder cancer: a systematic review and network meta-analysis of oncologic outcomes. *World J Urol.* 2023 Jun 22. PMID: 37347252
 31. Cano Garcia C, Flammia RS, Piccinelli M, Panunzio A, Tappero S, Barletta F, Incesu RB, Law KW, Morra S, Tian Z, Saad F, Kapoor A, **Shariat SF**, Longo N, Tilki D, Briganti A, Terrone C, Antonelli A, De Cobelli O, Hoeh B, Kluth LA, Chun FKH, Karakiewicz PI. Differences in Survival of Clear Cell Metastatic Renal Cell Carcinoma According to Partial vs. Radical Cytoreductive Nephrectomy. *Clin Genitourin Cancer.* 2023 Jun 12:S1558-7673(23)00142-8. PMID: 37344282
 32. Yanagisawa T, Rajwa P, Kawada T, Mori K, Fukuokaya W, Petrov P, Quhal F, Laukhtina E, von Deimling M, Bianchi A, Majdoub M, Pradere B, Kramer G, Kimura T, **Shariat SF**. Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis. *J Urol.* 2023 PMID: 37339479
 33. D'Andrea D, **Shariat SF**, Soria F, DI Trapani E, Mertens LS, VAN Rhijn BW, Dinney CP, Black PC, Spiess PE, Carrion DM, Pradere B, Tonin E, Pichler R, Filippot R, Mari A, Moschini M; European Association of Urology-Young Academic Urologists (EAU-YAU): Urothelial Carcinoma

- Working Group. Stage-dependent survival in patients treated with neoadjuvant chemotherapy and radical cystectomy. *Minerva Urol Nephrol*. 2023 Jun 14. PMID: 37314813
34. Bacchiani M, Salamone V, Massaro E, Sandulli A, Mariottini R, Cadenar A, Di Maida F, Pradere B, Mertens LS, Longoni M, Krajewski W, Del Giudice F, D'Andrea D, Laukhtina E, **Shariat SF**, Minervini A, Moschini M, Mari A, On Behalf Of European Association Of Urology-Young Academic Urologists Eau-Yau Urothelial Carcinoma Working Group. Cancers (Basel). Assessing the Performance of 18F-FDG PET/CT in Bladder Cancer: A Narrative Review of Current Evidence. 2023 May 28;15(11):2951. PMID: 37296913
 35. von Deimling M, D'Andrea D, Pradere B, Laukhtina E, Yanagisawa T, Kawada T, Majdoub M, Rajwa P, Pallauf M, Singla N, Soria F, Margulis V, Chlostka P, Karakiewicz PI, Roupert M, Teoh JY, Fisch M, Rink M, Moschini M, Lotan Y, **Shariat SF**. Clinical value of cholinesterase in patients treated with radical nephroureterectomy for upper urinary tract carcinoma. *World J Urol*. 2023 Jun 9. PMID: 37294372
 36. Beijert IJ, Cheng L, Liedberg F, Plass K, Williamson SR, Gontero P, Ribal MJ, Babjuk M, Black PC, Kamat AM, Algaba F, Berman DM, Hartmann A, Masson-Lecomte A, Roupert M, Lopez-Beltran A, Samarasinghe H, **Shariat SF**, Mostafid AH, Varma M, Shen S, Burger M, Tsuzuki T, Palou J, Compérat EM, Sylvester RJ, van der Kwast TH, van Rhijn BWG, Downes MR. International Opinions on Grading of Urothelial Carcinoma: A Survey Among European Association of Urology and International Society of Urological Pathology Members. *Eur Urol Open Sci*. 2023 May 10;52:154-165. PMID: 37284047
 37. Gandaglia G, Barletta F, Robesti D, Scuderi S, Rajwa P, Gomez Rivas J, Ibanez L, Soeterik TFW, Bianchi L, Afferi L, Kesch C, Darr C, Guo H, Zhuang J, Zattoni F, Fendler W, Marra G, Stabile A, Amparore D, Huebner NA, Giesen A, Joniau S, Schiavina R, Brunocilla E, Mattei A, Dal Moro F, Sierra JM, Porpiglia F, Picchio M, van den Bergh R, **Shariat SF**, Montorsi F, Briganti A. Identification of the Optimal Candidates for Nodal Staging with Extended Pelvic Lymph Node Dissection Among Prostate Cancer Patients Who Underwent Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography. External Validation of the Memorial Sloan Kettering Cancer Center and Briganti Nomograms and Development of a Novel Tool. *Eur Urol Oncol*. 2023 PMID: 37270378
 38. Piccinelli ML, Panunzio A, Tappero S, Cano Garcia C, Barletta F, Incesu RB, Tian Z, Luzzago S, Mistretta FA, Ferro M, Saad F, **Shariat SF**, Tilki D, Briganti A, Chun FK, Terrone C, Antonelli A, DE Cobelli O, Musi G, Karakiewicz PI. Cancer-specific mortality free survival rates in non-metastatic non-clear cell renal carcinoma patients at intermediate/high risk of recurrence. *Minerva Urol Nephrol*. 2023 Jun;75(3):319-328. PMID: 37221827
 39. Yanagisawa T, Kawada T, Quhal F, Bekku K, Laukhtina E, Rajwa P, von Deimling M, Majdoub M, Chlostka M, Pradere B, Mori K, Kimura T, Schmidinger M, Karakiewicz PI, **Shariat SF**. Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis. *World J Urol*. 2023 May 20. PMID: 37209143
 40. von Deimling M, Mertens LS, van Rhijn BWG, Lotan Y, Spiess PE, Daneshmand S, Black PC, Pallauf M, D'Andrea D, Moschini M, Soria F, Del Giudice F, Afferi L, Laukhtina E, Yanagisawa T, Kawada T, Teoh JY, Abufaraj M, Ploussard G, Roumiguié M, Karakiewicz PI, Babjuk M, Gontero P, Xylinas E, Rink M, **Shariat SF**, Pradere B. Carboplatin Induction Chemotherapy in Clinically Lymph Node-positive Bladder Cancer. *Eur Urol Open Sci*. 2023 Mar 25;51:39-46. PMID: 37187719

41. Quhal F, Bryniarski P, Rivas JG, Gandaglia G, **Shariat SF**, Rajwa P. Salvage lymphadenectomy after primary therapy with curative intent for prostate cancer. *Curr Opin Urol.* 2023 Jul 1;33(4):269-273 PMID: 37166270
42. Laukhtina E, Quhal F, von Deimling M, Kawada T, Yanagisawa T, Rajwa P, Majdoub M, Enikeev D, **Shariat SF**. For Which Patients Should Bladder Preservation Be Considered After a Complete Response to Neoadjuvant Chemotherapy. *Eur Urol Focus.* 2023 PMID: 37150628
43. Tappero S, Cano Garcia C, Incesu RB, Piccinelli ML, Barletta F, Morra S, Scheipner L, Tian Z, Saad F, **Shariat SF**, Borghesi M, Terrone C, Karakiewicz PI. Conditional survival for non-metastatic muscle-invasive adenocarcinoma of the urinary bladder after radical cystectomy. *Surg Oncol.* 2023 PMID: 37141747
44. Kawada T, Yanagisawa T, Bekku K, Laukhtina E, von Deimling M, Chlostka M, Pradere B, Teoh JY, Babjuk M, Araki M, **Shariat SF**. The efficacy and safety outcomes of lower dose BCG compared to intravesical chemotherapy in non-muscle-invasive bladder cancer: A network meta-analysis. *Urol Oncol.* 2023 May 1: PMID: 37137745
45. Yanagisawa T, Rajwa P, Quhal F, Kawada T, Bekku K, Laukhtina E, Deimling MV, Chlostka M, Karakiewicz PI, Kimura T, **Shariat SF**. Neoadjuvant Androgen Receptor Signaling Inhibitors before Radical Prostatectomy for Non-Metastatic Advanced Prostate Cancer: A Systematic Review. *J Pers Med.* 2023 PMID: 37109028
46. Soria F, D'Andrea D, Barale M, Gust KM, Pisano F, Mazzoli S, De Bellis M, Rosazza M, Livoti S, Dutto D, Lillaz B, Pradere B, Moschini M, Tamandl D, **Shariat SF**, Gontero P; European Association of Urology Young Academic Urologists Urothelial Carcinoma Working Group. Sarcopenia Predicts Disease Progression in Patients with T1 High-grade Non-muscle-invasive Bladder Cancer Treated with Adjuvant Intravesical Bacillus Calmette-Guérin: Implications for Decision-making? *Eur Urol Open Sci.* 2023 PMID: 37101772
47. Piccinelli ML, Morra S, Tappero S, Cano Garcia C, Barletta F, Incesu RB, Scheipner L, Baudo A, Tian Z, Luzzago S, Mistretta FA, Ferro M, Saad F, **Shariat SF**, Carmignani L, Ahyai S, Tilki D, Briganti A, Chun FKH, Terrone C, Longo N, de Cobelli O, Musi G, Karakiewicz PI. Critical Appraisal of Leibovich 2018 and GRANT Models for Prediction of Cancer-Specific Survival in Non-Metastatic Chromophobe Renal Cell Carcinoma. *Cancers (Basel).* 2023 Apr 5;15(7):2155: 37046815
48. Panunzio A, Tappero S, Hohenhorst L, Cano Garcia C, Piccinelli M, Barletta F, Tian Z, Tafuri A, Briganti A, De Cobelli O, Chun FKH, Tilki D, Terrone C, Saad F, **Shariat SF**, Bourdeau I, Cerruto MA, Antonelli A, Karakiewicz PI. African American vs. Caucasian race/ethnicity in adrenocortical carcinoma patients. *Endocr Relat Cancer.* 2023 Apr 1: ERC-22-0249. PMID: 37043366
49. Yanagisawa T, Schmidinger M, Fajkovic H, Karakiewicz PI, Kimura T, **Shariat SF**. What is the role of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma? *Expert Rev Anticancer Ther.* 2023 Apr 13:1-5. PMID: 37042747
50. Yanagisawa T, Matsukawa A, Iwatani K, Sato S, Hayashida Y, Okada Y, Yorozu T, Fukuokaya W, Sakanaka K, Urabe F, Kimura S, Tsuzuki S, Shimoda M, Takahashi H, Miki J, **Shariat SF**, Kimura T. ASO Visual Abstract: En Bloc Resection Versus Conventional TURBT for T1HG Bladder Cancer: A Propensity Score-Matched Analysis. *Ann Surg Oncol.* 2023 Apr 11. PMID: 37040049
51. Piccinelli ML, Barletta F, Tappero S, Cano Garcia C, Incesu RB, Morra S, Scheipner L, Tian Z, Luzzago S, Mistretta FA, Ferro M, Saad F, **Shariat SF**, Ahyai S, Longo N, Tilki D, Chun FKH, Terrone C, Briganti A, de Cobelli O, Musi G, Karakiewicz PI. Development and External Validation of a Novel Nomogram Predicting Cancer-specific Mortality-free Survival in Surgically

- Treated Papillary Renal Cell Carcinoma Patients. *Eur Urol Focus*. 2023 Apr 4: S2405-4569(23)00082-2. PMID: 37024421
52. Bekku K, Kawada T, Yanagisawa T, Karakiewicz PI, **Shariat SF**. Role of lymphadenectomy during primary surgery for kidney cancer. *Curr Opin Urol*. 2023 Apr 11. PMID: 37014778
 53. Yanagisawa T, Kawada T, von Deimling M, Laukhtina E, Kimura T, **Shariat SF**. Need for and extent of lymph node dissection for upper tract urothelial carcinoma: an updated review in 2023. *Curr Opin Urol*. 2023 Apr 4. PMID: 37014743
 54. Yanagisawa T, Kawada T, Mostafaei H, Motlagh RS, Quhal F, Laukhtina E, Rajwa P, von Deimling M, Bianchi A, Pallauf M, Pradere B, Karakiewicz PI, Miki J, Kimura T, **Shariat SF**. Role of Pelvic Drain and Timing of Urethral Catheter Removal Following RARP: A Systematic Review and Meta-analysis. *BJU Int*. 2023 Apr 4. PMID: 37014288
 55. Cano Garcia C, Panunzio A, Tappero S, Piccinelli ML, Barletta F, Incesu RB, Law KW, Scheipner L, Tian Z, Saad F, **Shariat SF**, Tilki D, Briganti A, De Cobelli O, Terrone C, Antonelli A, Banek S, Kluth LA, Chun FKH, Karakiewicz PI. Survival of Testicular Pure Embryonal Carcinoma vs. Mixed Germ Cell Tumor Patients across All Stages. *Medicina (Kaunas)*. 2023 Feb 24;59(3):451. PMID: 36984452
 56. Ofner H, Laukhtina E, Hassler MR, Shariat SFBlood-Based Biomarkers as Prognostic Factors of Recurrent Disease after Radical Cystectomy: A Systematic Review and Meta-Analysis. *.Int J Mol Sci*. 2023 Mar 19;24(6):5846. PMID: 36982918
 57. Taratkin M, Singla N, Babaevskaya D, Androsov A, **Shariat SF**, Fajkovic H, Baniel J, Enikeev D. A Review of How Lasers Are Used in UTUC Surgery: Can the Choice of Laser Affect Outcomes? *Cancers (Basel)*. 2023 Mar 21;15(6):1874. PMID: 36980763
 58. Rouprêt M, Seisen T, Birtle AJ, Capoun O, Compérat EM, Dominguez-Escrig JL, Gürses Andersson I, Liedberg F, Mariappan P, Hugh Mostafid A, Pradere B, van Rhijn BWG, **Shariat SF**, Rai BP, Soria F, Soukup V, Wood RG, Xylinas EN, Masson-Lecomte A, Gontero P. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update. *Eur Urol*. 2023 Mar 24;S0302-2838(23)02652-0. PMID: 36967359.
 59. Hoeh B, Flammia RS, Hohenhorst L, Sorce G, Chierigo F, Panunzio A, Tian Z, Saad F, Gallucci M, Briganti A, Terrone C, **Shariat SF**, Graefen M, Tilki D, Antonelli A, Kluth LA, Becker A, Chun FKH, Karakiewicz PI. Regional differences in total hospital costs for radical cystectomy in the United States. *Surg Oncol*. 2023 Mar 9; 48:101924. PMID: 36948042
 60. Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebre T, **Shariat SF**, Park SH, Ye D, Agerbaek M, Enting D, McDermott R, Gajate P, Peer A, Milowsky MI, Nosov A, Antonio JN Jr, Tupikowski K, Toms L, Fischer BS, Qureshi A, Collette S, Unsal-Kacmaz K, Broughton E, Zardavas D, Koon HB, Galsky MD. Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summary. *Future Oncol*. 2023 Mar 15. PMID: 36919916.
 61. Chierigo F, Flammia RS, Sorce G, Hoeh B, Hohenhorst L, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Montorsi F, Chun FKH, **Shariat SF**, Guano G, Mantica G, Borghesi M, Suardi N, Terrone C, Karakiewicz PI. The association of type and number of high-risk criteria with cancer specific mortality in prostate cancer patients treated with radiotherapy. *Prostate*. 2023 Mar 15. PMID: 36919872
 62. Yanagisawa T, Miki J, Matsukawa A, Iwatani K, Sato S, Hayashida Y, Okada Y, Shimoda M, Takahashi H, **Shariat SF**, Kimura T. ASO Author Reflections: Is T1HG Bladder Cancer a Good

- Candidate for En Bloc Resection? *Ann Surg Oncol*. 2023 Mar 12. doi: 10.1245/s10434-023-13291-z. PMID: 36907962
63. Tappero S, Barletta F, Piccinelli ML, Cano Garcia C, Incesu RB, Morra S, Scheipner L, Tian Z, Parodi S, Dell'Oglio P, Palumbo C, Briganti A, De Cobelli O, Chun FKH, Graefen M, Longo N, Ahyai S, Saad F, **Shariat SF**, Suardi N, Borghesi M, Terrone C, Karakiewicz PI. The Association Between Cytoréductive Nephrectomy and Overall Survival in Metastatic Renal Cell Carcinoma with Primary Tumor Size ≤ 4 cm. *Eur Urol Focus*. 2023 Mar 9: S2405-4569(23)00059-7. PMID: 36906483
 64. Flammia RS, Tufano A, Chierigo F, Würnschimmel C, Hoeh B, Sorce G, Tian Z, Anceschi U, Leonardo C, Del Giudice F, Terrone C, Giordano A, Morrione A, Saad F, **Shariat SF**, Briganti A, Montorsi F, Chun FKH, Gallucci M, Karakiewicz PI. The Effect of Sex on Disease Stage and Survival after Radical Cystectomy in Non-Urothelial Variant-Histology Bladder Cancer. *J Clin Med*. 2023 Feb 23;12(5):1776. PMID: 36902562
 65. Grossmann NC, Soria F, Juvet T, Potretzke AM, Djaladat H, Ghoreifi A, Kikuchi E, Mari A, Khene ZE, Fujita K, Raman JD, Breda A, Fontana M, Sfakianos JP, Pfail JL, Laukhtina E, Rajwa P, Pallauf M, Poyet C, Cacciamani GE, van Doeveren T, Boormans JL, Antonelli A, Jamil M, Abdollah F, Ploussard G, Heidenreich A, Storz E, Daneshmand S, Boorjian SA, Rouprêt M, Rink M, **Shariat SF**, Pradere B. Comparing Oncological and Perioperative Outcomes of Open versus Laparoscopic versus Robotic Radical Nephroureterectomy for the Treatment of Upper Tract Urothelial Carcinoma: A Multicenter, Multinational, Propensity Score-Matched Analysis. *Cancers (Basel)*. 2023 Feb 23;15(5): 1409. PMID: 36900201
 66. Yanagisawa T, Matsukawa A, Iwatani K, Sato S, Hayashida Y, Okada Y, Yorozu T, Fukuokaya W, Sakanaka K, Urabe F, Kimura S, Tsuzuki S, Shimoda M, Takahashi H, Miki J, **Shariat SF**, Kimura T. En Bloc Resection Versus Conventional TURBT for T1HG Bladder Cancer: A Propensity Score-Matched Analysis. *Ann Surg Oncol*. 2023 Mar 10. doi: 10.1245/s10434-023-13227-7. PMID: 36897417
 67. Tappero S, Barletta F, Piccinelli ML, Cano Garcia C, Incesu RB, Morra S, Scheipner L, Tian Z, Parodi S, Dell'Oglio P, Briganti A, de Cobelli O, Chun FKH, Graefen M, Mirone V, Ahyai S, Saad F, **Shariat SF**, Suardi N, Borghesi M, Terrone C, Karakiewicz PI. Adenocarcinoma of the Bladder: Assessment of Survival Advantage Associated With Radical Cystectomy and Comparison With Urothelial Bladder Cancer. *Urol Oncol*. 2023 Mar 5:S1078-1439(23)00015-7. PMID: 36882338
 68. Huang J, Chan EO, Liu X, Lok V, Ngai CH, Zhang L, Xu W, Zheng ZJ, Chiu PK, Vasdev N, Enekeev D, **Shariat SF**, Ng CF, Teoh JY, Wong MCS. Global Trends of Prostate Cancer by Age, and Their Associations With Gross Domestic Product (GDP), Human Development Index (HDI), Smoking, and Alcohol Drinking. *Clin Genitourin Cancer*. 2023 Feb 15:S1558-7673(23)00036-8. PMID: 36878752
 69. Muin D, Laukhtina E, Hacker M, **Shariat SF**. PET in bladder cancer imaging. *Curr Opin Urol*. 2023 Mar 7. PMID: 36876730
 70. Brönimann S, Mun DH, Hackl M, Yang L, **Shariat SF**, Waldhoer T. Increase and Plateauing of Testicular Cancer Incidence in Austria-A Time Trend Analysis of the Past Four Decades. *Eur Urol Open Sci*. 2023 Feb 6;49:104-109. PMID: 36874603
 71. Mostafaei H, Salehi-Pourmehr H, Rahnama'i MS, Mostafaei H, **Shariat SF**, Hajebrahimi S. Microbiome in Lower Urinary Tract Symptoms (LUTSs): Mapping the State of the Art with Bibliometric Analysis. *Life (Basel)*. 2023 Feb 16;13(2):552. PMID: 36836909

72. Miszczyk M, Kraszkiewicz M, Moll M, Kaminiów K, Sobel S, Dolla Ł, Wojcieszek P, Rajwa P, Yanagisawa T, Nowicka Z, **Shariat SF**, Goldner G, Miszczyk L, Majewski W. Long-Term Outcomes of Stereotactic Body Radiotherapy (SBRT) for Intraprostatic Relapse after Definitive Radiotherapy for Prostate Cancer: Patterns of Failure and Association between Volume of Irradiation and Late Toxicity. *Cancers (Basel)*. 2023 Feb 13;15(4):1180. PMID: 36831523
73. Yanagisawa T, Rajwa P, Kawada T, Bekku K, Laukhtina E, Deimling MV, Majdoub M, Chlosta M, Karakiewicz PI, Heidenreich A, Kimura T, **Shariat SF**. An Updated Systematic and Comprehensive Review of Cytoreductive Prostatectomy for Metastatic Prostate Cancer. *Curr Oncol*. 2023 Feb 10;30(2):2194-2216. PMID: 36826131
74. Grubmüller B, Huebner NA, Rasul S, Clauser P, Pötsch N, Grubmüller KH, Hacker M, Hartenbach S, **Shariat SF**, Hartenbach M, Baltzer P. Dual-Tracer PET-MRI-Derived Imaging Biomarkers for Prediction of Clinically Significant Prostate Cancer. *Curr Oncol*. 2023 Jan 30;30(2):1683-1691. PMID: 36826090
75. **Shariat SF**. From Avoiding Overtreatment and Undertreatment to Delivering the Right Therapy at the Right Time for the Right Tumor in the Right Patient: The Age of the Thoughtful Urologic Oncologic Surgeon Has Begun. *Eur Urol Focus*. 2023 Feb 21:S2405-4569(23)00042-1. PMID: 36822925
76. Marra G, Marquis A, Yanagisawa T, **Shariat SF**, Touijer K, Gontero P. Salvage Radical Prostatectomy for Recurrent Prostate Cancer After Primary Nonsurgical Treatment: An Updated Systematic Review. *Eur Urol Focus*. 2023 Feb 21:S2405-4569(23)00029-9. PMID: 36822924
77. Cano Garcia C, Piccinelli ML, Tappero S, Panunzio A, Barletta F, Incesu RB, Tian Z, Saad F, Briganti A, Terrone C, **Shariat SF**, Graefen M, Tilki D, Antonelli A, De Cobelli O, Kosiba M, Banek S, Kluth LA, Chun FKH, Karakiewicz PI. Differences in overall survival of T2N0M0 bladder cancer patients vs. population-based controls according to treatment modalities. *Int Urol Nephrol*. 2023 Feb 23. PMID: 36813873
78. Kirk PS, Lotan Y, Zargar H, Fairey AS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobson NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Kassouf W, Dall'Era MA, Sridhar SS, McGrath JS, Aning J, **Shariat SF**, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Grivas P, Garcia JA, Stephenson AJ, Shah JB, Daneshmand S, Spiess PE, van Rhijn BWG, Mertens L, Black P, Wright JL. Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort. *J Urol*. 2023 Feb 16: PMID: 36795962
79. Tappero S, Sorce G, Panunzio A, Hohenhorst L, Garcia CC, Piccinelli ML, Tian Z, Parodi S, Chun FKH, Graefen M, Antonelli A, De Cobelli O, Saad F, **Shariat SF**, Montorsi F, Suardi NR, Borghesi M, Terrone C, Karakiewicz PI. Efficacy of chemotherapy on overall survival in metastatic sarcomatoid bladder cancer patients. *Cent European J Urol*. 2022;75(4):352-356. PMID: 36794025
80. von Deimling M, Schuettfort VM, D'Andrea D, Pradere B, Grossmann NC, Kawada T, Yanagisawa T, Majdoub M, Laukhtina E, Rajwa P, Quhal F, Mostafaei H, Fajkovic H, Teoh JY, Moschini M, Karakiewicz PI, Fisch M, Rink M, **Shariat SF**. Predictive and Prognostic Role of the Neutrophil-to-Lymphocyte Ratio in Muscle Invasive Bladder Cancer Treated With Neoadjuvant Chemotherapy and Radical Cystectomy. *Clin Genitourin Cancer*. 2023 Jan 26:S1558-7673(23)00031-9. PMID: 36781346
81. Yanagisawa T, Schmidinger M, Kawada T, Bekku K, Kimura T, **Shariat SF**. Radical Nephrectomy After Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma. *Eur Urol Focus*. 2023 Feb 10:S2405-4569(23)00036-6. PMID: 36775716

82. Kawada T, Yanagisawa T, Mostafaei H, Sari Motlagh R, Quhal F, Rajwa P, Laukhtina E, von Deimling M, Bianchi A, Majdoub M, Pallauf M, Pradere B, Teoh JY, Karakiewicz PI, Araki M, **Shariat SF**. Impact of Performance Status on Oncologic Outcomes in Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitor: A Systematic Review and Meta-analysis. *Eur Urol Focus*. 2023 Feb 9:S2405-4569(23)00037-8. PMID: 36774273
83. Cano Garcia C, Barletta F, Incesu RB, Piccinelli ML, Tappero S, Panunzio A, Tian Z, Saad F, **Shariat SF**, Antonelli A, Terrone C, De Cobelli O, Graefen M, Tilki D, Briganti A, Wenzel M, Banek S, Kluth LA, Chun FKH, Karakiewicz PI. Survival of Testicular Pure Teratoma vs. Mixed Germ Cell Tumor Patients in Primary Tumor Specimens across All Stages. *Cancers (Basel)*. 2023 Jan 23;15(3):694. PMID: 36765653
84. Claps F, van de Kamp MW, Mayr R, Bostrom PJ, **Shariat SF**, Hippe K, Bertz S, Neuzillet Y, Sanders J, Otto W, van der Heijden MS, Jewett MAS, Stöhr R, Zlotta AR, Trombetta C, Eckstein M, Mertens LS, Burger M, Soorojebally Y, Wullich B, Bartoletti R, Radvanyi F, Pavan N, Sirab N, Mir MC, Pouessel D, van der Kwast TH, Hartmann A, Lotan Y, Bussani R, Allory Y, van Rhijn BWG. Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy. *BJU Int*. 2023 Feb 6. PMID: 36748180
85. Flammia RS, Hoeh B, Chierigo F, Hohenhorst L, Sorce G, Tian Z, Leonardo C, Graefen M, Terrone C, Saad F, **Shariat SF**, Briganti A, Montorsi F, Chun FKH, Gallucci M, Karakiewicz PI. Differences in rates of pelvic lymph node dissection in National Comprehensive Cancer Network favorable, unfavorable intermediate- and high-risk prostate cancer across United States SEER registries. *Curr Urol*. 2022 Dec;16(4):191-196. PMID: 36714227
86. Tonin E, **Shariat SF**, Schiavina R, Brunocilla E, D'Andrea D. En-bloc resection of non-muscle invasive bladder cancer: does it really make a difference? *Curr Opin Urol*. 2023 Mar 1;33(2):147-151. PMID: 36710595
87. Rajwa P, Zattoni F, Maggi M, Marra G, Kroyer P, **Shariat SF**, Briganti A, Montorsi F, Heidegger I, Gandaglia G; EAU-Young Academic Urologists (YAU) Prostate Cancer Working Party. Cytoreductive Radical Prostatectomy for Metastatic Hormone-sensitive Prostate Cancer-Evidence from Recent Prospective Reports. *Eur Urol Focus*. 2023 Jan 23:S2405-4569(23)00024-X. PMID: 36697321 Review.
88. Yanagisawa T, Kawada T, Rajwa P, Kimura T, **Shariat SF**. Emerging systemic treatment for metastatic castration-resistant prostate cancer: a review of recent randomized controlled trials. *Curr Opin Urol*. 2023 Jan 25. PMID: 36692012
89. Callaris G, Marra G, Benfant N, Rajwa P, Ahmed M, Abreu A, Cacciamani G, Ghoreifi A, Ribeiro L, Westhofen T, Tourinho-Barbosa R, Raskin Y, Veerman H, Albisinni S, Smith JA, Rouprêt M, Oderda M, Massari E, Persad R, Van Der Poel H, Joniau S, Sanchez-Salas R, Kretschmer A, Cathcart P, Gill I, Karnes RJ, Tilki D, **Shariat SF**, Touijer K, Gontero P. Salvage Radical Prostatectomy for Recurrent Prostate Cancer Following First-line Nonsurgical Treatment: Validation of the European Association of Urology Criteria in a Large, Multicenter, Contemporary Cohort. *Eur Urol Focus*. 2023 Jan 20:S2405-4569(23)00006-8. PMID: 36682962
90. Beijert IJ, Hentschel AE, Bründl J, Compérat EM, Plass K, Rodríguez O, Subiela Henríquez JD, Hernández V, de la Peña E, Alemany I, Turturica D, Pisano F, Soria F, Čapoun O, Bauerová L, Pešl M, Bruins HM, Runneboom W, Herdegen S, Breyer J, Brisuda A, Calatrava A, Rubio-Briones J, Seles M, Mannweiler S, Bosschieter J, Kusuma VRM, Ashabere D, Huebner N, Cotte J, Mertens LS, Claps F, Masson-Lecomte A, Liedberg F, Cohen D, Lunelli L, Cussenot O, El Sheikh S, Volanis D, Côté JF, Rouprêt M, Haitel A, **Shariat SF**, Mostafid AH, Nieuwenhuijzen JA, Zigeuner R, Dominguez-Escrig JL, Hacek J, Zlotta AR, Burger M, Evert M, Hulsbergen-van de Kaa CA, van

- der Heijden AG, Kiemeney LALM, Soukup V, Molinaro L, Gontero P, Llorente C, Algaba F, Palou J, N'Dow J, Ribal MJ, van der Kwast TH, Babjuk M, Sylvester RJ, van Rhijn BWG. Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non-muscle-invasive Spectrum. *Eur Urol Oncol*. 2023 Jan 18:S2588-9311(23)00004-4.PMID: 36670042.
91. Yanagisawa T, Hata K, Narita S, Hatakeyama S, Mori K, Yata Y, Sano T, Otsuka T, Hara S, Miyajima K, Enei Y, Fukuokaya W, Nakazono M, Matsukawa A, Miki J, Habuchi T, Ohyama C, **Shariat SF**, Kimura T. Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy. *Prostate*. 2023 Jan 20. doi: 10.1002/pros.24488. PMID: 36661102
 92. Al Jalali V, Wasinger G, Rasul S, Grubmueller B, Wulkersdorfer B, Balber T, Mitterhauser M, Simon J, Hacker M, **Shariat S**, Egger G, Zeitlinger M. Consecutive PSMA and AR PET imaging shows positive correlation to AR and PSMA protein expression in primary hormone naïve prostate cancer. *J Nucl Med*. 2023 Jan 19:jnumed.122.264981. PMID: 36657982
 93. Garcia CC, Nimer N, Piccinelli ML, Tappero S, Panunzio A, Barletta F, Incesu RB, Tian Z, Saad F, Kapoor A, Briganti A, Terrone C, **Shariat SF**, Tilki D, Antonelli A, De Cobelli O, Kluth LA, Becker A, Chun FKH, Karakiewicz PI. Differences in overall survival between clear cell metastatic renal cell carcinoma patients versus population-based controls according to race/ethnicity in the United States. *Ann Epidemiol*. 2023 PMID: 36640918
 94. Wu J, Jin S, Gu C, Wei Y, Zhu Y, Necchi A, **Shariat SF**, Pan J, Gan H, Dai B, Zhang H, Shi G, Zhu Y, Shen Y, Zhu Y, Ye D. Inherited mutations in Chinese patients with upper tract urothelial carcinoma. *Cell Rep Med*. 2023 Jan 17;4(1):100883. PMID: 36630951
 95. Rajwa P, Maggi M, Puche-Sanz I, Rempega G, **Shariat SF**, Zattoni F; EAU-Young Academic Urologists (YAU) Prostate Cancer Working Party. Comment on: "Molecular biomarkers in the context of focal therapy for prostate cancer: recommendations of a Delphi Consensus from the Focal Therapy Society". *Minerva Urol Nephrol*. 2022 Dec;74(6):816-818. PMID: 36629815
 96. Ertl IE, Brettner R, Kronabitter H, Mohr T, Derdak S, Jeitler M, Bilban M, Garstka N, **Shariat SF**. The SMARCD Family of SWI/SNF Accessory Proteins Is Involved in the Transcriptional Regulation of Androgen Receptor-Driven Genes and Plays a Role in Various Essential Processes of Prostate Cancer. *Cells*. 2022 Dec 28;12(1):124. PMID: 36611918
 97. Rajwa P, Quhal F, Pradere B, Gandaglia G, Ploussard G, Leapman MS, Gore JL, Paradysz A, Tilki D, Merseburger AS, Morgan TM, Briganti A, Palapattu GS, **Shariat SF**. Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations. *Nat Rev Urol*. 2023 Jan 4. PMID: 36600087
 98. Lemberger U, Pjevac P, Hausmann B, Berry D, Moser D, Jahrreis V, Özsoy M, **Shariat SF**, Veser J. The microbiome of kidney stones and urine of patients with nephrolithiasis. *Urolithiasis*. 2023 Jan 4;51(1):27.PMID: 36596939
 99. Lotan Y, Raman JD, Konety B, Daneshmand S, Schroeck F, **Shariat SF**, Black P, de Lange M, Asroff S, Goldfischer E, Efros M, Chong KT, Huang E, Chua HL, Wu QH, Yeow S, Lau W, Yong J, Eng M. Urinary Analysis of *FGFR3* and *TERT* Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification. *J Urol*. 2022 Dec 30 PMID: 36583640
 100. Bravi CA, Heidenreich A, Fossati N, Gandaglia G, Suardi N, Mazzone E, Stabile A, Cucchiara V, Osmonov D, Juenemann KP, Karnes RJ, Kretschmer A, Buchner A, Stief C, Hiester A, Albers P, Devos G, Joniau S, Van Poppel H, Grubmüller B, **Shariat S**, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, Briganti A, Pfister D. Combining PSA and PET features to select

- candidates for salvage lymph node dissection in recurrent prostate cancer. *BJUI Compass*. 2022 Aug 4;4(1):123-129. PMID: 36569505
101. Rajwa P, Pfister D, Rieger C, Heidenreich J, Drzezga A, Persigehl T, **Shariat SF**, Heidenreich A. Importance of magnetic resonance imaging and prostate-specific membrane antigen PET-CT in patients treated with salvage radical prostatectomy for radiorecurrent prostate cancer. *Prostate*. 2022 Dec 23. PMID: 36564936
 102. Nocera L, Stolzenbach LF, Collà Ruvolo C, Wenzel M, Wurnschimmel C, Tian Z, Gandaglia G, Fossati N, Mirone V, Chun FKH, **Shariat SF**, Graefen M, Saad F, Montorsi F, Briganti A, Karakiewicz PI. Predicting the probability of pT3 or higher pathological stage at radical prostatectomy: COVID19-specific considerations. *Front Oncol*. 2022 Dec 6;12:990851. PMID: 36561531
 103. Yanagisawa T, Quhal F, Kawada T, Mostafaei H, Motlagh RS, Laukhtina E, Rajwa P, Deimling MV, Bianchi A, Pallauf M, Majdoub M, Pradere B, Moschini M, Karakiewicz PI, Teoh JY, Miki J, Kimura T, **Shariat SF**. A Systematic Review and Meta-analysis of Chemoablation for Non-muscle-invasive Bladder Cancer. *Eur Urol Focus*. 2022 Dec 12:S2405-4569(22)00287-5. PMID: 36517409
 104. Tully KH, Berg S, Paciotti M, Janisch F, Reese SW, Noldus J, **Shariat SF**, Choueiri T, Müller G, McGregor B, Chang SL, Trinh QD, Mossanen M. The Natural History of Renal-Cell Carcinoma with Sarcomatoid Differentiation, a Stage-by-Stage Analysis. *Clin Genitourin Cancer*. 2022 Nov 24:S1558-7673(22)00250-6. PMID: 36517393
 105. Kardoust Parizi M, Margulis V, Lotan Y, Aydh A, **Shariat SF**. A Systematic Review and Meta-Analysis of Clinicopathologic Factors Predicting Upper Urinary Tract Recurrence After Radical Cystectomy for Urothelial Bladder Cancer. *Clin Genitourin Cancer*. 2022 Nov 13:S1558-7673(22)00236-1. PMID: 36513557 .
 106. Abufaraj M, Li R, Meeks J, **Shariat SF**. Cytoreductive Surgery in Patients with Urothelial Bladder Cancer. *Eur Urol Focus*. 2022 Dec 9:S2405-4569(22)00283-8. PMID: 36509654
 107. von Deimling M, Laukhtina E, Pradere B, Pallauf M, Klemm J, Fisch M, **Shariat SF**, Rink M. Radical cystectomy and urinary diversion in women: techniques, outcomes, and challenges-a narrative review. *Transl Androl Urol*. 2022 Nov;11(11):1598-1610. PMID: 36507477
 108. Barletta F, Tappero S, Panunzio A, Incesu RB, Cano Garcia C, Piccinelli ML, Tian Z, Gandaglia G, Moschini M, Terrone C, Antonelli A, Tilki D, Chun FKH, de Cobelli O, Saad F, **Shariat SF**, Montorsi F, Briganti A, Karakiewicz PI. Differences in Cancer-Specific Mortality after Trimodal Therapy for T2N0M0 Bladder Cancer according to Histological Subtype. *Cancers (Basel)*. 2022 Nov 23;14(23):5766. PMID: 36497246
 109. Kawada T, Yanagisawa T, Araki M, Pradere B, **Shariat SF**. Sequential intravesical gemcitabine and docetaxel therapy in patients with nonmuscle invasive bladder cancer: a systematic review and meta-analysis. *Curr Opin Urol*. 2022 Dec 12. PMID: 36482766
 110. Rahman SN, Lokeshwar SD, Syed JS, Javier-Desloges JF, Press BH, Choksi AU, Rajwa P, Pradere B, Ploussard G, Kim JW, Monaghan TF, Renzulli JR, **Shariat SF**, Leapman MS. Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladder. *Urol Oncol*. 2022. PMID: 36481253
 111. Yanagisawa T, Quhal F, Kawada T, Mostafaei H, Sari Motlagh R, Laukhtina E, Rajwa P, von Deimling M, Bianchi A, Pallauf M, Majdoub M, Pradere B, Abufaraj M, Moschini M, Karakiewicz PI, Iwatani K, Miki J, Kimura T, **Shariat SF**. Oncologic Impact of Cystoscopic Findings in Non-

- Muscle Invasive Bladder Cancer: A Meta-analysis. *BJU Int.* 2022 Dec 7. PMID: 36479820 Review.
112. Pallauf M, D'Andrea D, König F, Laukhtina E, Yanagisawa T, Rouprêt M, Daneshmand S, Djaladat H, Ghoreifi A, Soria F, Fujita K, Boorjian SA, Potretzke AM, Mari A, Roumiguié M, Antonelli A, Bianchi A, Khene ZE, Sfakianos JP, Jamil M, Boormans JL, Raman JD, Grossmann NC, Breda A, Heidenreich A, Del Giudice F, Singla N, **Shariat SF**, Pradere B. Diagnostic Accuracy of Clinical Lymph Node Staging for Upper Tract Urothelial Cancer Patients - A Multicenter, Retrospective, Observational Study. *J Urol.* 2022. PMID: 36475808
 113. Tappero S, Sorce G, Hoeh B, Hohenhorst L, Panunzio A, Garcia CC, Piccinelli M, Tian Z, Parodi S, Montorsi F, Chun FKH, Graefen M, Antonelli A, Saad F, **Shariat SF**, De Cobelli O, Suardi NR, Borghesi M, Terrone C, Karakiewicz PI. The effect of chemotherapy in sarcomatoid bladder cancer patients treated with radical cystectomy. *Can Urol Assoc J.* 2022 Oct 25. PMID: 36473471
 114. Kawada T, Laukhtina E, Quhal F, Yanagisawa T, Rajwa P, Pallauf M, von Deimling M, Bianchi A, Pradere B, Fajkovic H, Enikeev D, Gontero P, Rouprêt M, Seisen T, Araki M, **Shariat SF**. Oncologic and Safety Outcomes for Endoscopic Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An Updated Systematic Review and Meta-analysis. *Eur Urol Focus.* 2022 Nov 30:S2405-4569(22)00275-9. PMID: 36463089
 115. Panunzio A, Tappero S, Hohenhorst L, Cano Garcia C, Piccinelli M, Barletta F, Tian Z, Tafuri A, Briganti A, De Cobelli O, Chun FKH, Tilki D, Terrone C, Kapoor A, Saad F, **Shariat SF**, Cerruto MA, Antonelli A, Karakiewicz PI. Collecting duct carcinoma: Epidemiology, clinical characteristics and survival. *Urol Oncol.* 2022 Nov 28:S1078-1439(22)00446-X. PMID: 36456452
 116. Sorce G, Hoeh B, Hohenhorst L, Panunzio A, Tappero S, Tian Z, Kokorovic A, Larcher A, Capitanio U, Tilki D, Terrone C, Chun FKH, Antonelli A, Saad F, **Shariat SF**, Montorsi F, Briganti A, Karakiewicz PI. Cancer-specific Mortality After Cryoablation vs Heat-based Thermal Ablation in T1a Renal Cell Carcinoma. *J Urol.* 2023 Jan;209(1):81-88. PMID: 36440817
 117. Bianchi A, von Deimling M, Pallauf M, Yanagisawa T, Kawada T, Mostafaei H, Quhal F, Laukhtina E, Rajwa P, Majdoub M, Motlagh RS, Pradere B, Karakiewicz PI, Cerruto MA, Antonelli A, **Shariat SF**. Perspectives on the future of urothelial carcinoma therapy: chemotherapy and beyond. *Expert Opin Pharmacother.* 2022 Nov 29:1-19. PMID: 36440477
 118. Panunzio A, Barletta F, Tappero S, Cano Garcia C, Piccinelli M, Incesu RB, Law KW, Tian Z, Tafuri A, Tilki D, De Cobelli O, Chun FKH, Terrone C, Briganti A, Saad F, **Shariat SF**, Bourdeau I, Cerruto MA, Antonelli A, Karakiewicz PI. Contemporary conditional cancer-specific survival rates in surgically treated adrenocortical carcinoma patients: A stage-specific analysis. *J Surg Oncol.* 2022 Nov 26. doi: 10.1002/jso.27161. PMID: 36434748
 119. Laukhtina E, Kawada T, Quhal F, Yanagisawa T, Rajwa P, von Deimling M, Pallauf M, Bianchi A, Majdoub M, Enikeev D, Fajkovic H, Teoh JY, Rouprêt M, Gontero P, **Shariat SF**. Oncologic and Safety Outcomes for Retrograde and Antegrade Endoscopic Surgeries for Upper Tract Urothelial Carcinoma: A Systematic Review and Meta-analysis. *Eur Urol Focus.* 2022 Nov 22:S2405-4569(22)00264-4. PMID: 36428210
 120. Barletta F, Tappero S, Panunzio A, Incesu RB, Cano Garcia C, Piccinelli ML, Tian Z, Gandaglia G, Moschini M, Terrone C, Antonelli A, Tilki D, Chun FKH, De Cobelli O, Saad F, **Shariat SF**, Montorsi F, Briganti A, Karakiewicz PI. Conditional survival after radical cystectomy for non-metastatic muscle-invasive squamous cell carcinoma of the urinary bladder: A population-based analysis. *Urol Oncol.* 2022 Nov 22:S1078-1439(22)00428-8. PMID: 36428165

121. Panunzio A, Sorce G, Tappero S, Hohenhorst L, Garcia CC, Piccinelli M, Tian Z, Tafuri A, De Cobelli O, Chun FKH, Tilki D, Terrone C, Briganti A, Kapoor A, Saad F, **Shariat SF**, Cerruto MA, Antonelli A, Karakiewicz PI. Cancer specific mortality in patients with collecting duct vs. clear cell renal carcinoma. *Cancer Epidemiol.* 2022 Nov 16;82:102297. PMID: 36401949
122. Flammia RS, Chierigo F, Würnschimmel C, Wenzel M, Horlemann B, Tian Z, Borghesi M, Leonardo C, Tilki D, **Shariat SF**, Anceschi U, Chun FKH, Terrone C, Saad F, Gallucci M, Karakiewicz PI. Sex-related differences in non-urothelial variant histology, non-muscle invasive bladder cancer. *Cent European J Urol.* 2022;75(3):240-247. PMID: 36381153
123. Rajwa P, Yanagisawa T, Gruber M, Heidenreich A, Joniau S, Briganti A, **Shariat SF**, Marra G, Gandaglia G. Surgical Metastasectomy for Visceral and Bone Prostate Cancer Metastases: A Mini-Review. *Eur Urol Focus.* 2022 Nov 9:S2405-4569(22)00241-3. PMID: 36371377
124. Vartolomei L, Schmidinger M, Vartolomei MD, **Shariat SF**. Psychological Distress in Patients Treated for Renal Cell Carcinoma: A Systematic Literature Review. *J Clin Med.* 2022 Oct 28;11(21):6383. PMID: 36362610
125. Katayama S, Pradere B, Grossman NC, Potretzke AM, Boorjian SA, Ghoreifi A, Daneshmand S, Djaladat H, Sfakianos JP, Mari A, Khene ZE, D'Andrea D, Hayakawa N, Breda A, Fontana M, Fujita K, Antonelli A, van Doeveren T, Steinbach C, Mori K, Laukhtina E, Rouprêt M, Margulis V, Karakiewicz PI, Araki M, Compérat E, Nasu Y, **Shariat SF**. Biological and prognostic implications of biopsy upgrading for high-grade upper tract urothelial carcinoma at nephroureterectomy. *Int J Urol.* 2022 PMID: 36349904
126. Compérat E, Oszwald A, Wasinger G, **Shariat S**, Amin M. Update on Flat and Papillary Urothelial Lesions: Genitourinary Pathology Society Consensus Recommendations. *Surg Pathol Clin.* 2022 Dec;15(4):629-640. PMID: 36344180
127. Panunzio A, Sorce G, Hoeh B, Hohenhorst L, Tappero S, Nimer N, Rajwa P, Tian Z, Terrone C, Chun FKH, Briganti A, Saad F, **Shariat SF**, Cerruto MA, Antonelli A, Karakiewicz PI. Effect of positive surgical margins at radical prostatectomy on cancer-specific mortality in high/very high-risk prostate cancer patients with Gleason Grade Group 4-5. *Prostate.* 2022 Nov 6. PMID: 36336728
128. Hoeh B, Flammia RS, Hohenhorst L, Sorce G, Panunzio A, Tappero S, Tian Z, Saad F, Gallucci M, Briganti A, Terrone C, **Shariat SF**, Graefen M, Tilki D, Antonelli A, Kosiba M, Kluth LA, Becker A, Chun FKH, Karakiewicz PI. IO-IO vs IO-TKI efficacy in metastatic kidney cancer patients: A structured systematic review over time. *Semin Oncol.* 2022 Oct;49(5):394-399. PMID: 36333148
129. Vartolomei MD, Remzi M, Fajkovic H, **Shariat SF**. Robot-Assisted Partial Nephrectomy Mid-Term Oncologic Outcomes: A Systematic Review. *J Clin Med.* 2022 Oct 19;11(20):6165. PMID: 36294486
130. Panunzio A, Tappero S, Garcia CC, Piccinelli M, Barletta F, Incesu RB, Tian Z, Tafuri A, Tilki D, Briganti A, DE Cobelli O, Chun FKH, Terrone C, Saad F, **Shariat SF**, Bourdeau I, Cerruto MA, Antonelli A, Karakiewicz PI. Hispanic vs. Caucasian Race/Ethnicity in Adrenocortical Carcinoma Patients. *Anticancer Res.* 2022 Nov;42(11):5579-5585. PMID: 36288855
131. Rajwa P, Yanagisawa T, Heidegger I, Zattoni F, Marra G, Soeterik TFW, van den Bergh RCN, Valerio M, Ceci F, Kesch CV, Kasivisvanathan V, Laukhtina E, Kawada T, Nyiriadi P, Trinh QD, Chlosta P, Karakiewicz PI, Ploussard G, Briganti A, Montorsi F, **Shariat SF**, Gandaglia G; EAU-YAU Prostate Cancer Working Party. Association between age and efficacy of combination systemic therapies in patients with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. *Prostate Cancer Prostatic Dis.* 2022 Oct 25. PMID: 36284192

132. Claps F, Mir MC, van Rhijn BWG, Mazzon G, Soria F, D'Andrea D, Marra G, Boltri M, Traunero F, Massanova M, Liguori G, Dominguez-Escrig JL, Celia A, Gontero P, **Shariat SF**, Trombetta C, Pavan N. Impact of the controlling nutritional status (CONUT) score on perioperative morbidity and oncological outcomes in patients with bladder cancer treated with radical cystectomy. *Urol Oncol.* 2023 Jan;41(1):49.e13-49.e22. PMID: 36274030
133. Leow JJ, Tan WS, Tan WP, Tan TW, Chan VW, Tikkinen KAO, Kamat A, Sengupta S, Meng MV, **Shariat S**, Roupret M, Decaestecker K, Vasdev N, Chong YL, Enikeev D, Giannarini G, Ficarra V, Teoh JY; UroSoMe Collaborators. A systematic review and meta-analysis on delaying surgery for urothelial carcinoma of bladder and upper tract urothelial carcinoma: Implications for the COVID19 pandemic and beyond. *Front Surg.* 2022 Oct 4;9:879774. PMID: 36268209
134. Del Giudice F, D'Andrea D, Pradere B, Berndl F, Pallauf M, Flammia RS, Philipp D, Moschini M, Mari A, Albisinni S, Krajewski W, Laukhtina E, Gallioli A, Mertens LS, Marcq G, Cimadamore A, Afferi L, Gontero P, **Shariat SF**, Chung BI, Soria F. Surgical checklist adherence across urology expertise levels impacts transurethral resection of bladder tumour quality indicators. *BJU Int.* 2022 Oct 17. PMID: 36251366
135. Tappero S, Piccinelli M, Barletta F, Panunzio A, Cano Garcia C, Incesu RB, Tian Z, Parodi S, Dell'Oglio P, De Cobelli O, Briganti A, Antonelli A, Chun FKH, Graefen M, Saad F, **Shariat SF**, Suardi NR, Borghesi M, Terrone C, Karakiewicz PI. Effect of inguinal lymph node dissection in lymph node negative patients with squamous cell carcinoma of the penis. *World J Urol.* 2022 Oct 14. PMID: 36239810
136. Sorce G, Hoeh B, Hohenhorst L, Panunzio A, Tappero S, Nimer N, Tian Z, Larcher A, Capitanio U, Tilki D, Terrone C, Chun FKH, Antonelli A, Saad F, **Shariat SF**, Montorsi F, Briganti A, Karakiewicz PI. Contemporary vs historical survival rates in metastatic clear cell renal carcinoma according to race/ethnicity. *World J Urol.* 2022 Dec;40(12):2971-2978. PMID: 36222885
137. von Deimling M, Rajwa P, Tilki D, Heidenreich A, Pallauf M, Bianchi A, Yanagisawa T, Kawada T, Karakiewicz PI, Gontero P, Pradere B, Ploussard G, Rink M, **Shariat SF**. The current role of precision surgery in oligometastatic prostate cancer. *ESMO Open.* 2022 Oct 5;7(6):100597. PMID: 36208497
138. Tafuri A, Marchioni M, Cerrato C, Mari A, Tellini R, Odorizzi K, Veccia A, Amparore D, Shakir A, Carbonara U, Panunzio A, Trovato F, Catellani M, Janello LMI, Bianchi L, Novara G, Dal Moro F, Schiavina R, De Lorenzis E, Parma P, Cimino S, De Cobelli O, Maiorino F, Bove P, Crocero F, Cantello F, D'Andrea D, Di Cosmo F, Porpiglia F, Ditunno P, Montanari E, Soria F, Gontero P, Liguori G, Trombetta C, Mantica G, Borghesi M, Terrone C, Del Giudice F, Sciarra A, Galosi A, Moschini M, **Shariat SF**, Di Nicola M, Minervini A, Ferro M, Cerruto MA, Schips L, Pagliarulo V, Antonelli A. Changes in renal function after nephroureterectomy for upper urinary tract carcinoma: analysis of a large multicenter cohort (Radical Nephroureterectomy Outcomes (RaNeO) Research Consortium). *World J Urol.* 2022 Nov;40(11):2771-2779. PMID: 36203101
139. Baard J, **Shariat SF**, Roupret M, Yoshida T, Saita A, Saltirov I, Burgos JR, Celik O, de la Rosette J, Laguna P. Adherence to guideline recommendations in the management of upper tract urothelial carcinoma: an analysis of the CROES-UTUC registry. *World J Urol.* 2022 Nov;40(11):2755-2763. PMID: 36197507
140. Yanagisawa T, Mori K, Quhal F, Kawada T, Mostafaei H, Laukhtina E, Rajwa P, Sari Motlagh R, Aydh A, König F, Pallauf M, Pradere B, Miki J, Kimura T, Egawa S, **Shariat SF**. Iatrogenic ureteric injury during abdominal or pelvic surgery: a meta-analysis. *BJU Int.* 2022 Oct 5. PMID: 36196670

141. Tappero S, Panunzio A, Hohenhorst L, Cano Garcia C, Barletta F, Piccinelli M, Tian Z, Parodi S, Antonelli A, Graefen M, Chun FKH, Briganti A, De Cobelli O, Saad F, **Shariat SF**, Suardi N, Borghesi M, Terrone C, Karakiewicz PI. Radical cystectomy in non-metastatic sarcomatoid bladder cancer: A direct comparison vs urothelial bladder cancer. *Eur J Surg Oncol*. 2022 Sep 24:S0748-7983(22)00683-7. PMID: 36192262
142. Hoeh B, Flammia RS, Hohenhorst L, Sorce G, Panunzio A, Tappero S, Tian Z, Saad F, Gallucci M, Briganti A, Terrone C, **Shariat SF**, Graefen M, Tilki D, Antonelli A, Kosiba M, Mandel P, Kluth LA, Becker A, Chun FKH, Karakiewicz PI. Effect of Inferior Vena Cava Tumor Thrombus on Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated with Cytoreductive Nephrectomy. *Eur Urol Open Sci*. 2022 Aug 30;44:94-101.PMID: 36185586
143. Einerhand SMH, Black AJ, Zargar H, Fairey AS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobson NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Kassouf W, Dall'Era MA, Sridhar SS, McGrath JS, Aning J, **Shariat SF**, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Garcia JA, Stephenson AJ, Shah JB, Daneshmand S, Zargar-Shoshtari K, Spiess PE, van Rhijn BWG, Black PC, Mertens LS. Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancer. *World J Urol*. 2022 Nov;40(11):2707-2715. PMID: 36169695
144. Laukhtina E, Moschini M, Krajewski W, Teoh JY, Ploussard G, Soria F, Roghmann F, Muenker MA, Roumiguie M, Alvarez-Maestro M, Misrai V, Antonelli A, Tafuri A, Simone G, Mastroianni R, Zhao H, Rahoma RG, D'Andrea D, Mori K, Albinini S, Karakiewicz PI, Fajkovic H, Enikeev D, Montorsi F, **Shariat SF**, Pradere B. Oncological and safety profiles in patients undergoing simultaneous transurethral resection (TUR) of bladder tumour and TUR of the prostate. *BJU Int*. 2022 Sep 22. PMID: 36134575
145. Zisser L, Yu J, Oszwald A, Wollenweber T, Kretschmer-Chott E, Grubmüller B, Kramer G, **Shariat SF**, Mitterhauser M, Vranka C, Hacker M, Haug AR, Rasul S. Response to [177 Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases. *Nucl Med Commun*. 2022 Nov 1;43(11):1113-1120. PMID: 36120814
146. Panunzio A, Sorce G, Tappero S, Hohenhorst L, Cano Garcia C, Piccinelli M, Tian Z, Tafuri A, De Cobelli O, Chun FKH, Tilki D, Terrone C, Briganti A, Kapoor A, Saad F, **Shariat SF**, Cerruto MA, Antonelli A, Karakiewicz PI. Mortality According to Treatment in Metastatic Collecting Duct Renal Cell Carcinoma. *Clin Genitourin Cancer*. 2022 Aug 26:S1558-7673(22)00178-1.PMID: 36117092
147. Wasinger G, Oszwald A, **Shariat SF**, Compérat E. Histological patterns, subtypes and aspects of prostate cancer: different aspects, different outcomes. *Curr Opin Urol*. 2022 Sep 9. PMID: 36081403
148. Rajwa P, Hopen P, Wojnarowicz J, Kaletka J, Paszkiewicz I, Lach-Wojnarowicz O, Mostafaei H, Krajewski W, D'Andrea D, Małkiewicz B, Paradysz A, Ploussard G, Moschini M, Breyer BN, Pradere B, **Shariat SF**, Leapman MS. Online Crowdfunding for Urologic Cancer Care. *Cancers (Basel)*. 2022 Aug 25;14(17):4104. PMID: 36077641
149. Wenzel M, Würnschimmel C, Nocera L, Colla Ruvolo C, Hoeh B, Tian Z, **Shariat SF**, Saad F, Briganti A, Graefen M, Preisser F, Becker A, Mandel P, Chun FKH, Karakiewicz PI. The effect of race/ethnicity on cancer-specific mortality after salvage radical prostatectomy. *Front Oncol*. 2022 Aug 19;12:874945.PMID: 36059656

150. Yanagisawa T, Rajwa P, Thibault C, Gandaglia G, Mori K, Kawada T, Fukuokaya W, Shim SR, Mostafaei H, Motlagh RS, Quhal F, Laukhtina E, Pallauf M, Pradere B, Kimura T, Egawa S, **Shariat SF**. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis. *Eur Urol*. 2022 Aug 19:S0302-2838(22)02551-9. PMID: 35995644
151. Yanagisawa T, Kawada T, Rajwa P, Mostafaei H, Motlagh RS, Quhal F, Laukhtina E, König F, Pallauf M, Pradere B, Karakiewicz PI, Nyirady P, Kimura T, Egawa S, **Shariat SF**. Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis. *Urol Oncol*. 2022 Aug 12:S1078-1439(22)00238-1. PMID: 35970698
152. Mori K, Yanagisawa T, Katayama S, Laukhtina E, Pradere B, Mostafaei H, Quhal F, Rajwa P, Moschini M, Soria F, D'andrea D, Abufaraj M, Albisinni S, Krajewski W, Fukuokaya W, Miki J, Kimura T, Egawa S, Teoh JY, **Shariat SF**; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU). Impact of sex on outcomes after surgery for non-muscle-invasive and muscle-invasive bladder urothelial carcinoma: a systematic review and meta-analysis. *World J Urol*. 2022 Aug 13. PMID: 35963957
153. Goujon A, Khene ZE, Thenault R, Vigneau C, Peyronnet B, Belabbas D, Guérin S, Chemouny J, Gasmi A, Verhoest G, **Shariat S**, Bensalah K, Mathieu R. Contrast-enhanced CT texture analysis for the prediction of delayed graft function following kidney transplantation from cadaveric donors. *Prog Urol*. 2022 Aug 6:S1166-7087(22)00340-2. PMID: 35945114
154. Moll FH, Halling T, **Shariat SF**. [Granting of *venia legendi* as an indicator of specialization : Victor von Ivánchich de Margita (1812-1892) "Lecturer for surgery of the urogenital organs" in Vienna in 1851]. *Urologie*. 2022 Sep;61(9):996-1010. doi: 10.1007/s00120-022-01904-6. Epub 2022 Aug 9. PMID: 35943546
155. Pallauf M, Steinkohl F, Zimmermann G, Horetzky M, Rajwa P, Pradere B, Lindner AK, Pichler R, Kunit T, **Shariat SF**, Lusuardi L, Drerup M. External validation of two mpMRI-risk calculators predicting risk of prostate cancer before biopsy. *World J Urol*. 2022 PMID: 35941246
156. Sorce G, Hoeh B, Hohenhorst L, Panunzio A, Tappero S, Tian Z, Kokorovic A, Larcher A, Capitanio U, Tilki D, Terrone C, Chun FKH, Antonelli A, Saad F, **Shariat SF**, Montorsi F, Briganti A, Karakiewicz PI. Cancer-specific Mortality in T1a Renal Cell Carcinoma Treated with Local Tumor Destruction Versus Partial Nephrectomy. *Eur Urol Focus*. 2022 Jul 30:S2405-4569(22)00167-5. PMID: 35918270
157. Compérat E, Oszwald A, Wasinger G, Kläger J, Hassler MR, **Shariat SF**. Molecular uropathology and cancer genetics for the urologist: key findings for classification and diagnosis. *Curr Opin Urol*. 2022 Sep 1;32(5):451-455. PMID: 35916009
158. Soria F, Pradere B, Hurle R, D'Andrea D, Albisinni S, Diamand R, Laukhtina E, Di Trapani E, Aziz A, Krajewski W, Teoh JY, Mari A, Moschini M, Chiancone F, Autorino R, Porreca A, Marchioni M, Liguori G, Lucarelli G, Busetto GM, Foschi N, Antonelli A, Bove P, Russo GI, Crisan N, Borghesi M, Boeri L, Veccia A, Greco F, Longo N, De Cobelli O, **Shariat SF**, Gontero P, Ferro M; European Association of Urology—Young Academic Urologists EAU-YAU: Urothelial Carcinoma Working Group. Radical Nephroureterectomy Tetrafecta: A Proposal Reporting Surgical Strategy Quality at Surgery. *Eur Urol Open Sci*. 2022 Jun 13;42:1-8. PMID: 35911084
159. Sorce G, Hoeh B, Hohenhorst L, Panunzio A, Tappero S, Tian Z, Larcher A, Capitanio U, Tilki D, Terrone C, Chun FKH, Antonelli A, Saad F, **Shariat SF**, Montorsi F, Briganti A, Karakiewicz PI.

- Other-cause mortality and access to care in metastatic renal cell carcinoma according to race/ethnicity. *Urol Oncol*. 2022 PMID: 35907705
160. Trimmel B, Oszwald A, Diemand C, Ertl IE, Lemberger U, Bruchbacher A, Brettner R, Korn S, Resch I, Comperat E, **Shariat SF**, Hassler MR. Evaluation of APOBEC3 expression as prognostic marker in squamous cell carcinoma of the penis. *Sci Rep*. 2022 Jul 28;12(1):12911.PMID: 35902635
161. Collà Ruvolo C, Deuker M, Wenzel M, Nocera L, Würnschimmel C, Califano G, Tian Z, Saad F, Briganti A, Xylinas E, Verze P, Musi G, **Shariat SF**, Mirone V, Karakiewicz PI. Impact of the primary tumor location on secondary sites and overall mortality in patients with metastatic upper tract urothelial carcinoma. *Urol Oncol*. 2022 Sep;40(9):411.e1-411.e8. 25.PMID: 35902301
162. Nowak Ł, Krajewski W, Łaszkiewicz J, Małkiewicz B, Chorbińska J, Del Giudice F, Mori K, Moschini M, Kaliszewski K, Rajwa P, Laukhtina E, **Shariat SF**, Szydelko T, On Behalf Of European Association Of Urology Eau-Young Academic Urologists Yau Urothelial Cancer Working PartyThe Impact of Surgical Waiting Time on Oncological Outcomes in Patients with Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy: A Systematic Review. *J Clin Med*. 2022 Jul 11;11(14):4007. doi: 10.3390/jcm11144007.PMID: 35887771
163. von Deimling M, Pallauf M, Bianchi A, Laukhtina E, Karakiewicz PI, Rink M, **Shariat SF**, Pradere B. Active surveillance for non-muscle-invasive bladder cancer: fallacy or opportunity? *Curr Opin Urol*. 2022 Sep 1;32(5):567-574. doi: 10.1097PMID: 35869738
164. Krajewski W, Aumatell J, Subiela JD, Nowak Ł, Tukiendorf A, Moschini M, Basile G, Poletajew S, Małkiewicz B, Del Giudice F, Maggi M, Chung BI, Cimadamore A, Galosi AB, Fave RFD, D'Andrea D, **Shariat SF**, Hornak J, Babjuk M, Chorbińska J, Teoh JY, Muilwijk T, Joniau S, Tafuri A, Antonelli A, Panunzio A, Alvarez-Maestro M, Simone G, Mastroianni R, Łaszkiewicz J, Lonati C, Zamboni S, Simeone C, Niedziela Ł, Candela L, Macek P, Contieri R, Hidalgo BG, Rivas JG, Sosnowski R, Mori K, Mir C, Soria F, González-Padilla DA, Faba ÖR, Palou J, Ploussard G, Rajwa P, Hałoń A, Laukhtina E, Pradere B, Tully K, Burgos FJ, Cidre MÁJ, Szydelko T; European Association of Urology- Young Academic Urologists (EAU-YAU): Urothelial carcinoma working group. Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer. *Urol Oncol*. 2022 Jul 15:S1078-1439(22)00227-7. doi: 10.1016/j.urolonc.2022.06.008. Online ahead of print.
165. Laukhtina E, Pradere B, Lemberger U, Karakiewicz PI, Fajkovic H, **Shariat SF**. Molecular biomarkers to help select neoadjuvant systemic therapy for urothelial carcinoma of the bladder. *Curr Opin Urol*. 2022 Sep 1;32(5):561-566. Epub 2022 Jul 15.PMID: 35849719
166. Compérat E, Wasinger G, Oszwald A, **Shariat SF**. Brief update of the new WHO classification for urothelial carcinoma.*Curr Opin Urol*. 2022 Sep 1;32(5):511-516. PMID: 35849698
167. Pallauf M, König F, D'Andrea D, Laukhtina E, Mostafaei H, Motlagh RS, Quhal F, Aydh A, Yanagisawa T, Kawada T, Rajwa P, Lusuardi L, Soria F, Karakiewicz PI, Rouprêt M, Rink M, Lotan Y, Margulis V, Singla N, Xylinas E, **Shariat SF**, Pradere B. A Systematic Review and Meta-Analysis of Prognostic Nomograms After UTUC Surgery. *Front Oncol*. 2022 PMID: 35847838
168. Flammia RS, Hoeh B, Hohenhorst L, Sorce G, Chierigo F, Panunzio A, Tian Z, Saad F, Leonardo C, Briganti A, Antonelli A, Terrone C, **Shariat SF**, Anceschi U, Graefen M, Chun FKH, Montorsi F, Gallucci M, Karakiewicz PI. Adverse upgrading and/or upstaging in contemporary low-risk prostate cancer patients. *Int Urol Nephrol*. 2022 Oct;54(10):2521-2528. doi: 10.1007/s11255-022-03250-0. Epub 2022 Jul 15.PMID: 35838831

169. Hoeh B, Flammia RS, Hohenhorst L, Sorce G, Chierigo F, Tian Z, Saad F, Gallucci M, Briganti A, Terrone C, **Shariat SF**, Graefen M, Tilki D, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Treatment patterns and rates of upgrading and upstaging in prostate cancer patients with single GGG1 positive biopsy core. *Urol Oncol*. 2022 Sep;40(9):407.e9-407.e19. doi: 10.1016/j.urolonc.2022.06.003. Epub 2022 Jul 9. PMID: 35817649
170. D'Andrea D, **Shariat SF**, Soria F, Mari A, Mertens LS, Di Trapani E, Carrion DM, Pradere B, Pichler R, Filippot R, Grisay G, Del Giudice F, Laukhtina E, Paulnsteiner D, Krajewski W, Vallet S, Maggi M, De Berardinis E, Álvarez-Maestro M, Brönimann S, Di Maida F, van Rhijn BWG, Hendricksen K, Moschini M; European Association of Urology Young Academic Urologists Urothelial Carcinoma Working Group. The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy. *Eur Urol Open Sci*. 2022 May 28;41:74-80. doi: 10.1016/j.euros.2022.05.001. eCollection 2022 Jul. PMID: 35813257
171. Pötsch N, Rainer E, Clauser P, Vatteroni G, Hübner N, Korn S, **Shariat SF**, Helbich TH, Baltzer PAT. Impact of PI-QUAL on PI-RADS and cancer yield in an MRI-TRUS fusion biopsy population. *Eur J Radiol*. 2022 Sep;154:110431. doi: 10.1016/j.ejrad.2022.110431. Epub 2022 Jul 4. PMID: 35803101
172. Stangl-Kremser J, Lambertini L, Di Maida F, Martinez-Fundichely A, Ferro M, Pradere B, Soria F, Albisinni S, Wu Z, Del Giudice F, Cacciamani GE, Valerio M, Briganti A, Rouprêt M, **Shariat SF**, Lee C, Minervini A, Moschini M, Mari A: Enhancing Recovery After Major Bladder Cancer Surgery: Comprehensive Review and Assessment of Application of the Enhanced Recovery After Surgery Guidelines. European Association of Urology-Young Academic Urologists Urothelial Carcinoma Working Group. *Eur Urol Focus*. 2022. PMID: 35773181
173. Yanagisawa T, Kimura T, Hata K, Narita S, Hatakeyama S, Enei Y, Atsuta M, Mori K, Obayashi K, Yoshihara K, Kondo Y, Oguchi T, Sadakane I, Habuchi T, Ohyama C, **Shariat SF**, Egawa S. Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer. *Prostate*. 2022 PMID: 35767376
174. Rebhan K, Wasinger G, Hassler MR, **Shariat SF**, Compérat EM. Basal cell carcinoma of the prostate: a case report responding to the FGFR inhibitor pemigatinib and literature review. *Curr Opin Urol*. 2022 Jul 1;32(4):358-363. PMID: 35749783.
175. Compérat E, Wasinger G, Oszwald A, Pradere B, **Shariat S**. Nonmuscle-invasive bladder cancer, old problems, new insights. *Curr Opin Urol*. 2022 Jul 1;32(4):352-357. PMID: 35749782.
176. Vartolomei MD, Ferro M, Roth B, Teoh JY, Gontero P, **Shariat SF**. Device-assisted intravesical chemotherapy treatment for nonmuscle invasive bladder cancer: 2022 update. *Curr Opin Urol*. 2022 Jun 27. PMID: 35749398
177. Tan WS, Steinberg G, Witjes JA, Li R, **Shariat SF**, Roupret M, Babjuk M, Bivalacqua TJ, Psutka SP, Williams SB, Cookson MS, Palou J, Kamat AM. Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. *Eur Urol Oncol*. 2022 PMID: 35718695.
178. Kawada T, Yanagisawa T, Rajwa P, Sari Motlagh R, Mostafaei H, Quhal F, Laukhtina E, Aydh A, König F, Pallauf M, Pradere B, Ceci F, Baltzer PAT, Hacker M, Rasul S, Karakiewicz PI, Araki M, Nasu Y, **Shariat SF**. Diagnostic Performance of Prostate-specific Membrane Antigen Positron Emission Tomography-targeted biopsy for Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis. *Eur Urol Oncol*. 2022 PMID: 35715320
179. Afferi L, Lonati C, Montorsi F, Briganti A, Necchi A, Mari A, Minervini A, Tellini R, Campi R, Schulz GB, Black PC, di Trapani E, de Cobelli O, Karnes RJ, Ahmed M, Mir MC, Algarra MA,

- Rink M, Zamboni S, Mondini F, Simeone C, Antonelli A, Tafuri A, Krajewski W, Małkiewicz B, Xylinas E, Soria F, Sanchez Salas R, Arora A, Cathelineau X, Hendricksen K, Ammiwala M, Borghesi M, Chierigo F, Teoh JY, Mattei A, Albisinni S, Roghmann F, Roumiguié M, Bajet AS, Maier E, Aziz A, Hurle R, Contieri R, Pradere B, Carando R, Poyet C, Alvarez-Maestro M, D'Andrea D, **Shariat SF**, Moschini M; Selecting the Best Candidates for Cisplatin-based Adjuvant Chemotherapy After Radical Cystectomy Among Patients with pN+ Bladder Cancer. European Association of Urology Young Academic Urologists Urothelial Carcinoma Working Group. *Eur Urol Oncol*. 2022 PMID: 35715319
180. Hoeh B, Flammia RS, Hohenhorst L, Sorce G, Chierigo F, Panunzio A, Tian Z, Saad F, Gallucci M, Briganti A, Terrone C, **Shariat SF**, Graefen M, Tilki D, Antonelli A, Kluth LA, Becker A, Chun FKH, Karakiewicz PI. Outcomes of robotic-assisted versus open radical cystectomy in a large-scale, contemporary cohort of bladder cancer patients. *J Surg Oncol*. 2022 PMID: 35661361
181. Sorce G, Hoeh B, Flammia RS, Chierigo F, Hohenhorst L, Panunzio A, Nimer N, Tian Z, Gandaglia G, Tilki D, Terrone C, Gallucci M, Chun FKH, Antonelli A, Saad F, **Shariat SF**, Montorsi F, Briganti A, Karakiewicz PI. Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk level. *Prostate*. 2022 PMID: 35652586
182. Huebner N, Rasul S, Baltzer P, Clauser P, Hermann Grubmüller K, Mitterhauser M, Hacker M, Heidenreich A, Rajwa P, Fajkovic H, **Shariat SF**, Grubmüller B. Feasibility and Optimal Time Point of [68Ga]Gallium-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography Imaging in Patients Undergoing Cytoreductive Surgery After Systemic Therapy for Primary Oligometastatic Prostate Cancer: Implications for Patient Selection and Extent of Surgery. *Eur Urol Open Sci*. 2022 May 5;40:117-124. PMID: 35638090.
183. Baboudjian M, Moser D, Yanagisawa T, Gondran-Tellier B, Compérat EM, Ambrosetti D, Daniel L, Bastide C, **Shariat SF**, Lechevallier E, Diana P, Breda A, Pradere B, Boissier R. Benefit and Harm of Active Surveillance for Biopsy-proven Renal Oncocytoma: A Systematic Review and Pooled Analysis. *Eur Urol Open Sci*. 2022 May 19;41:8-15. PMID: 3563383
184. Chierigo F, Borghesi M, Würnschimmel C, Flammia RS, Sorce G, Hoeh B, Hohenhorst L, Tian Z, Saad F, Tilki D, Gallucci M, Briganti A, Montorsi F, Chun FKH, **Shariat SF**, Mantica G, Suardi N, Terrone C, Karakiewicz PI. Contemporary Pathological Stage Distribution After Radical Prostatectomy in North American High-Risk Prostate Cancer Patients. *Clin Genitourin Cancer*. 2022 Apr 21:S1558-7673(22)00080-5. PMID: 35618597
185. Flammia RS, Hoeh B, Hohenhorst L, Sorce G, Chierigo F, Panunzio A, Tian Z, Saad F, Leonardo C, Briganti A, Antonelli A, Terrone C, **Shariat SF**, Graefen M, Chun FKH, Montorsi F, Gallucci M, Karakiewicz PI. Cancer-specific mortality in patients with non-metastatic renal cell carcinoma who have undergone a nephrectomy and are eligible for adjuvant pembrolizumab. *Semin Oncol*. 2022 Apr 29:S0093-7754(22)00027-6. PMID: 35610060
186. Hoeh B, Flammia RS, Hohenhorst L, Sorce G, Panunzio A, Chierigo F, Nimer N, Tian Z, Saad F, Gallucci M, Briganti A, **Shariat SF**, Graefen M, Tilki D, Antonelli A, Terrone C, Kluth LA, Becker A, Chun FKH, Karakiewicz PI. Metastatic stage vs complications at radical nephrectomy with inferior vena cava thrombectomy. *Surg Oncol*. 2022 May 16;42:101783. PMID: 35605557
187. Yanagisawa T, Kimura T, Hata K, Narita S, Hatakeyama S, Mori K, Sano T, Otsuka T, Iwamoto Y, Enei Y, Nakazono M, Sakanaka K, Iwatani K, Matsukawa A, Atsuta M, Nishikawa H, Tsuzuki S, Miki J, Habuchi T, Ohyama C, **Shariat SF**, Egawa S. Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis. *World J Urol*. 2022 May 21. PMID: 35596809

188. Laukhtina E, Boehm A, Peyronnet B, Bravi CA, Batista Da Costa J, Soria F, D'Andrea D, Rajwa P, Quhal F, Yanagisawa T, König F, Mostafaei H, Enikeev D, Ingels A, Verhoest G, D'Hondt F, Mottrie A, Joniau S, Van Poppel H, de la Taille A, Bensalah K, Bruyère F, **Shariat SF**, Pradere B. Urethrectomy at the time of radical cystectomy for non-metastatic urothelial carcinoma of the bladder: a collaborative multicenter study. *World J Urol.* 2022 May 20. PMID: 35596017
189. Hensley PJ, Panebianco V, Pietzak E, Kutikov A, Vikram R, Galsky MD, **Shariat S**, Roupert M, Kamat AM. Contemporary Staging for Muscle-Invasive Bladder Cancer: Accuracy and Limitations. *Eur Urol Oncol.* 2022 May 14:S2588-9311(22)00066-9. PMID: 35581143.
190. Beijert IJ, Hentschel AE, Bründl J, Compérat EM, Plass K, Rodríguez O, Subiela Henríquez JD, Hernández V, de la Peña E, Alemany I, Turturica D, Pisano F, Soria F, Čapoun O, Bauerová L, Pešl M, Maxim Bruins H, Runneboom W, Herdegen S, Breyer J, Brisuda A, Calatrava A, Rubio-Briones J, Seles M, Mannweiler S, Bosschieter J, Kusuma VRM, Ashabere D, Huebner N, Cotte J, Mertens LS, Masson-Lecomte A, Liedberg F, Cohen D, Lunelli L, Cussenot O, El Sheikh S, Volanis D, Côté JF, Rouprêt M, Haitel A, **Shariat SF**, Mostafid AH, Nieuwenhuijzen JA, Zigeuner R, Dominguez-Escrig JL, Hacek J, Zlotta AR, Burger M, Evert M, Hulsbergen-van de Kaa CA, van der Heijden AG, A L M Kiemeney L, Soukup V, Molinaro L, Gontero P, Llorente C, Algaba F, Palou J, N'Dow J, Ribal MJ, van der Kwast TH, Babjuk M, Sylvester RJ, van Rhijn BWG. T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non-muscle-invasive Bladder Cancer Spectrum. *Eur Urol Focus.* 2022 May 13:S2405-4569(22)00110-9. PMID: 35577750
191. König F, Pradere B, Grossmann NC, Quhal F, Rajwa P, Laukhtina E, Mori K, Katayama S, Yanagisawa T, Mostafai H, Motlagh RS, Aydh A, Dahlem R, **Shariat SF**, Rink M. Quality indicators for the management of muscle-invasive bladder cancer in the perioperative setting of radical cystectomy: a narrative review. *Transl Cancer Res.* 2022 Apr;11(4):908-917. PMID: 35571640.
192. Yanagisawa T, Mori K, Kawada T, Motlagh RS, Mostafaei H, Quhal F, Laukhtina E, Rajwa P, Aydh A, König F, Pallauf M, Pradere B, Miki J, Kimura T, Egawa S, **Shariat SF**. Differential efficacy of ablation therapy versus partial nephrectomy between clinical T1a and T1b renal tumors: A systematic review and meta-analysis. *Urol Oncol.* 2022 May 10:S1078-1439(22)00112-0. PMID: 35562311
193. Laukhtina E, Hassler MR, Pradere B, Yanagisawa T, Quhal F, Rajwa P, Sari Motlagh R, König F, Pallauf M, Kawada T, Mostafaei H, D'Andrea D, Enikeev D, **Shariat SF**. Circulating Tumour DNA Is a Strong Predictor of Outcomes in Patients Treated with Systemic Therapy for Urothelial Carcinoma. *Eur Urol Focus.* 2022 May 10:S2405-4569(22)00112-2. PMID: 35562252
194. Mori K, Schuettfort VM, Katayama S, Laukhtina E, Pradere B, Quhal F, Sari Motlagh R, Mostafaei H, Grossmann NC, Rajwa P, Teoh JYC, Resch I, Fajkovic H, Moschini M, D'andrea D, Abufaraj M, Karakiewicz PI, Lotan Y, Scherr D, Egawa S, Compérat E, **Shariat SF**. ASO Visual Abstract: Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. *Ann Surg Oncol.* 2022 May 9. PMID: 35532830.
195. Aydh A, Motlagh RS, Abufaraj M, Mori K, Katayama S, Grossmann N, Rajawa P, Mostafai H, Laukhtina E, Pradere B, Quhal F, Schuettfort VM, Briganti A, Karakiewicz PI, Fajkovic H, **Shariat SF**. Radiation therapy compared to radical prostatectomy as first-line definitive therapy for patients with high-risk localised prostate cancer: An updated systematic review and meta-analysis. *Arab J Urol.* 2022 Mar 30;20(2):71-80. PMID: 35530569

196. Grossmann NC, Rajwa P, Quhal F, König F, Mostafaei H, Laukhtina E, Mori K, Katayama S, Motlagh RS, Fankhauser CD, Mattei A, Moschini M, Chlosta P, van Rhijn BWG, Teoh JYC, Compérat E, Babjuk M, Abufaraj M, Karakiewicz PI, **Shariat SF**, Pradere B. Comparative Outcomes of Primary Versus Recurrent High-risk Non-muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study. *Eur Urol Open Sci.* 2022 Apr 1;39:14-21. PMID: 35528782
197. Chierigo F, Borghesi M, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Hoeh B, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Montorsi F, Chun FKH, **Shariat SF**, Mantica G, Suardi N, Terrone C, Karakiewicz PI. Life expectancy in metastatic urothelial bladder cancer patients according to race/ethnicity. *Int Urol Nephrol.* 2022 May 4. PMID: 35508792
198. Martini A, Lonati C, Nocera L, Fallara G, Raggi D, Herout R, Zamboni S, Ploussard G, Predere B, Mattei A, Simeone C, Krajewski W, Simone G, Soria F, Gontero P, Roupret M, Montorsi F, Briganti A, **Shariat SF**, Necchi A, Moschini M. Oncologic Surveillance After Radical Nephroureterectomy for High-risk Upper Tract Urothelial Carcinoma. *Eur Urol Oncol.* 2022.PMID: 35504834
199. Yanagisawa T, Sato S, Hayashida Y, Okada Y, Iwatani K, Matsukawa A, Kimura T, Takahashi H, Egawa S, **Shariat SF**, Miki J. Do we need repeat TUR after en bloc resection for pT1 bladder cancer? *BJU Int.* 2022 Apr 29. PMID: 35488409
200. Mertens LS, Claps F, Mayr R, Hodgson A, **Shariat SF**, Hippe K, Neuzillet Y, Sanders J, Burger M, Pouessel D, Otto W, van der Kwast TH, Lotan Y, Allory Y, Downes MR, van Rhijn BWG. The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory Analysis. *Int J Surg Pathol.* 2022 PMID: 35466737
201. Rajwa P, Pradere B, Gandaglia G, van den Bergh RCN, Tsaour I, Shim SR, Yanagisawa T, Laukhtina E, Mori K, Mostafaei H, Quhal F, Bryniarski P, Compérat E, Roubaud G, Massard C, Merseburger AS, Leapman MS, Spratt DE, Saad F, Joniau S, D'Amico AV, Briganti A, **Shariat SF**, Ploussard G; European Association of Urology Young Academic Urologists Prostate Cancer Working Party. Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis. *Eur Urol.* 2022 Apr 21:S0302-2838(22)01802-4. PMID: 35465985 Review.
202. Yanagisawa T, Mori K, Katayama S, Mostafaei H, Quhal F, Laukhtina E, Rajwa P, Motlagh RS, Aydh A, König F, Grossmann NC, Pradere B, Miki J, Schmidinger M, Egawa S, **Shariat SF**. Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis. *Immunotherapy.* 2022 PMID: 35465726
203. Sorce G, Chierigo F, Flammia RS, Hoeh B, Hohenhorst L, Tian Z, Goyal JA, Graefen M, Terrone C, Gallucci M, Chun FKH, Saad F, **Shariat SF**, Montorsi F, Briganti A, Karakiewicz PI. Survival trends in chemotherapy exposed metastatic bladder cancer patients and chemotherapy effect across different age, sex, and race/ethnicity. *Urol Oncol.* 2022 Apr 14:S1078-1439(22)00105-3. PMID: 35431135
204. Sari Motlagh R, Yanagisawa T, Kawada T, Laukhtina E, Rajwa P, Aydh A, König F, Pallauf M, Huebner NA, Baltzer PA, Karakiewicz PI, Heidenreich A, **Shariat SF**. Accuracy of SelectMDx compared to mpMRI in the diagnosis of prostate cancer: a systematic review and diagnostic meta-analysis. *Prostate Cancer Prostatic Dis.* 2022 Apr 12.PMID: 35414118
205. Mori K, Schuettfort VM, Egawa S, Compérat E, **Shariat SF**. ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder? *Ann Surg Oncol.* 2022 Apr 12. PMID: 35412203

206. König F, Grossmann NC, Soria F, D'Andrea D, Juvet T, Potretzke A, Djaladat H, Ghoreifi A, Kikuchi E, Hayakawa N, Mari A, Khene ZE, Fujita K, Raman JD, Breda A, Fontana M, Sfakianos JP, Pfail JL, Laukhtina E, Rajwa P, Pallauf M, Cacciamani GE, van Doeveren T, Boormans JL, Antonelli A, Jamil M, Abdollah F, Budzyn J, Ploussard G, Heidenreich A, Daneshmand S, Boorjian SA, Rouprêt M, Rink M, **Shariat SF**, Pradere B. Pentafecta for Radical Nephroureterectomy in Patients with High-Risk Upper Tract Urothelial Carcinoma: A Proposal for Standardization of Quality Care Metrics. *Cancers (Basel)*. 2022 Mar 31;14(7):1781 PMID: 35406553
207. Flammia RS, Hoeh B, Sorce G, Chierigo F, Hohenhorst L, Tian Z, Goyal JA, Leonardo C, Briganti A, Graefen M, Terrone C, Saad F, **Shariat SF**, Montorsi F, Chun FKH, Gallucci M, Karakiewicz PI. Contemporary seminal vesicle invasion rates in NCCN high-risk prostate cancer patients. *Prostate*. 2022 Apr 11 PMID: 35403734
208. Ertl IE, Lemberger U, Iijazi D, Hassler MR, Bruchbacher A, Brettner R, Kronabitter H, Gutmann M, Vician P, Zeitler G, Koren A, Lardeau CH, Mohr T, Haitel A, Compérat E, Oszwald A, Wasinger G, Clozel T, Elemento O, Kubicek S, Berger W, **Shariat SF**. Molecular and Pharmacological Bladder Cancer Therapy Screening: Discovery of Clofarabine as a Highly Active Compound. *Eur Urol*. 2022 Apr 4:S0302-2838(22)01678-5. PMID: 35393162
209. Martini A, Lonati C, Necchi A, Galsky MD, Ploussard G, Fallara G, Pellegrino A, Simeone C, Suardi N, Zamboni S, Krajewski W, Simone G, Briganti A, Montorsi F, Mattei A, **Shariat SF**, Moschini M; European Association of Urology - Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Metastasis Within Three Years from Radical Nephroureterectomy as a Potential Surrogate for Overall Survival. *Clin Genitourin Cancer*. 2022 PMID: 35383003
210. Sari Motlagh R, Schuettfort VM, Mori K, Katayama S, Rajwa P, Aydh A, Grossmann NC, Laukhtina E, Pradere B, Mostafai H, Quhal F, Abufaraj M, Lee R, Karakiewicz PI, Lotan Y, Comprate E, Moschini M, Gontero P, **Shariat SF**. Prognostic impact of insulin-like growth factor-I and its binding proteins, insulin-like growth factor-I binding protein-2 and -3, on adverse histopathological features and survival outcomes after radical cystectomy. *Int J Urol*. 2022 Apr 2. PMID: 35368130
211. Nyame YA, Cooperberg MR, Cumberbatch MG, Eggener SE, Etzioni R, Gomez SL, Haiman C, Huang F, Lee CT, Litwin MS, Lyratzopoulos G, Mohler JL, Murphy AB, Pettaway C, Powell JJ, Sasieni P, Schaeffer EM, **Shariat SF**, Gore JL. Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. *Eur Urol*. 2022 Mar 30:S0302-2838(22)01677-3. doi: 10.1016/j.eururo.2022.03.007. PMID: 35367082 Review.
212. Sorce G, Flammia RS, Hoeh B, Chierigo F, Hohenhorst L, Panunzio A, Stabile A, Gandaglia G, Tian Z, Tilki D, Terrone C, Gallucci M, Chun FKH, Antonelli A, Saad F, **Shariat SF**, Montorsi F, Briganti A, Karakiewicz PI. Grade and stage misclassification in intermediate unfavorable-risk prostate cancer radiotherapy candidates. *Prostate*. 2022 Apr 1. PMID: 35365851
213. Teoh JY, Kamat AM, Black PC, Grivas P, **Shariat SF**, Babjuk M. Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective. *Nat Rev Urol*. 2022 Mar 31. PMID: 35361927
214. Mori K, Schuettfort VM, Katayama S, Laukhtina E, Pradere B, Quhal F, Sari Motlagh R, Mostafaei H, Grossmann NC, Rajwa P, Teoh JY, Resch I, Fajkovic H, Moschini M, D'andrea D, Abufaraj M, Karakiewicz PI, Lotan Y, Scherr D, Egawa S, Compérat E, **Shariat SF**. Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. *Ann Surg Oncol*. 2022 Mar 26. PMID: 35347517

215. Piccinelli ML, Luzzago S, Marvaso G, Laukhtina E, Miura N, Schuettfort VM, Mori K, Colombo A, Ferro M, Mistretta FA, Fusco N, Petralia G, Jereczek-Fossa BA, **Shariat SF**, Karakiewicz PI, de Cobelli O, Musi G. Association between previous negative biopsies and lower rates of progression during active surveillance for prostate cancer. *World J Urol.* 2022 Mar 26 PMID: 35347414
216. Mori K, Quhal F, Yanagisawa T, Katayama S, Pradere B, Laukhtina E, Rajwa P, Mostafaei H, Sari Motlagh R, Kimura T, Egawa S, Bensalah K, Karakiewicz PI, Schmidinger M, **Shariat SF**. The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: A systematic review and meta-analysis. *Int Immunopharmacol.* 2022 Mar 24; PMID: 35339843
217. Laukhtina E, Moschini M, Soria F, Andrea DD, Teoh JY, Mori K, Albisinni S, Mari A, Krajewski W, Cimadamore A, Abufaraj M, Enikeev D, Neuzillet Y, Giannarini G, Xylinas E, Kamat AM, Roupret M, Babjuk M, Witjes JA, **Shariat SF**, Pradere B; European Association of Urology; Young Academic Urologists EAU-YAU: Urothelial Carcinoma Working Group; European Association of Urology Section of Oncological Urology ESOU. Follow-up of the Urethra and Management of Urethral Recurrence After Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma Working Group. *Eur Urol Focus.* 2022 PMID: 35337773
218. Alimohammadi A, Fajkovic H, Remzi M, **Shariat S**, Schmidinger M. Recent pharmacological approaches for the treatment of renal cell carcinoma. *Expert Rev Clin Pharmacol.* 2022 Mar 14. doi: 10.1080/17512433.2022.2053521. Online ahead of print. PMID: 35285369
219. Moll M, D'Andrea D, Zaharie A, Grubmüller B, Paschen C, Zehetmayer S, **Shariat SF**, Widder J, Goldner G. Comparative effectiveness of moderate hypofractionation with volumetric modulated arc therapy versus conventional 3D-radiotherapy after radical prostatectomy. *Strahlenther Onkol.* 2022. PMID: 35284951
220. Mori K, Schuettfort VM, Yanagisawa T, Katayama S, Pradere B, Laukhtina E, Rajwa P, Mostafaei H, Sari Motlagh R, Quhal F, Moschini M, Soria F, Teoh JYC, D'Andrea D, Abufaraj M, Albisinni S, Krajewski W, Egawa S, Karakiewicz PI, Rink M, **Shariat SF**; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU). Reassessment of the Efficacy of Carboplatin for Metastatic Urothelial Carcinoma in the Era of Immunotherapy: A Systematic Review and Meta-analysis. *Eur Urol Focus.* 2022 Mar 9;9:S2405-4569(22)00052-9. doi: 10.1016/j.euf.2022.02.007. PMID: 35279408 Review.
221. Hoeh B, Flammia RS, Hohenhorst L, Sorce G, Chierigo F, Panunzio A, Tian Z, Saad F, Gallucci M, Briganti A, Terrone C, **Shariat SF**, Graefen M, Tilki D, Antonelli A, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Effect of Neoadjuvant Chemotherapy on Complications, in-Hospital Mortality, Length of Stay and Total Hospital Costs in Bladder Cancer Patients Undergoing Radical Cystectomy. *Cancers (Basel).* 2022 Feb 26;14(5):1222.. PMID: 35267529
222. Hoeh B, Flammia R, Hohenhorst L, Sorce G, Chierigo F, Tian Z, Saad F, Gallucci M, Briganti A, Terrone C, **Shariat SF**, Graefen M, Tilki D, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer. *Prostate Int.* 2022 PMID: 35261911
223. Stangl-Kremser J, Muto G, Grosso AA, Briganti A, Comperat E, Maida FD, Montironi R, Remzi M, Pradere B, Soria F, Albisinni S, Roupret M, **Shariat SF**, Minervini A, Teoh JY, Moschini M, Cimadamore A, Mari A; European Association of Urology-Young Academic Urologists (EAU-YAU): Urothelial carcinoma working group. The impact of lymphovascular invasion in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma: An extensive updated systematic review and meta-analysis. *Urol Oncol.* 2022 Feb 28: 35241364.

224. Lonati C, Mordasini L, Afferi L, De Cobelli O, Di Trapani E, Necchi A, Colombo R, Briganti A, Montorsi F, Simeone C, Zamboni S, Simone G, Karnes RJ, Marra G, Soria F, Gontero P, **Shariat SF**, Pradere B, Hendricksen K, Ammiwala M, Rink M, Poyet C, Krajewski W, Baumeister P, Mattei A, Moschini M, Carando R; European Association of Urology - Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Diagnostic accuracy of preoperative lymph node staging of bladder cancer according to different lymph node locations: A multicenter cohort from the European Association of Urology - Young Academic Urologists. *Urol Oncol.* 2022 Feb 27:S1078-1439(22)00003-5.PMID: 35236621
225. Würnschimmel C, Wenzel M, Chierigo F, Flammia RS, Horlemann B, Tian Z, Saad F, Briganti A, **Shariat SF**, Gallucci M, Suardi N, Chun FKH, Tilki D, Graefen M, Karakiewicz PI. Radiation therapy after radical prostatectomy is associated with higher other-cause mortality. *Cancer Causes Control.* 2022 Mar 1. PMID: 35230576
226. Chierigo F, Borghesi M, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Hoeh B, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Montorsi F, Chun FKH, **Shariat SF**, Mantica G, Suardi N, Terrone C, Karakiewicz PI. Survival after radical prostatectomy versus radiation therapy in clinical node-positive prostate cancer. *Prostate.* 2022 Feb 28. PMID: 35226380
227. Würnschimmel C, Chandrasekar T, Hahn L, Esen T, **Shariat SF**, Tilki D. MRI as a screening tool for prostate cancer: current evidence and future challenges. *World J Urol.* 2022 Feb 28. PMID: 35226140
228. Lonati C, Afferi L, Mari A, Minervini A, Krajewski W, Borghesi M, Schulz GB, Rink M, Montorsi F, Briganti A, Colombo R, Martini A, Necchi A, Contieri R, Hurle R, Umari P, Zamboni S, Simeone C, Soria F, Marra G, Gontero P, Teoh JY, Klatte T, Bajet AS, Roumiguié M, Rouprêt M, Masson-Lecomte A, Laukhtina E, Valiquette AS, Mir MC, Antonelli A, Einerhand SMH, Hendricksen K, Carando R, Fankhauser CD, Baumeister P, Mattei A, **Shariat SF**, Moschini M; European Association of Urology—Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration. *World J Urol.* 2022 Feb 26. PMID: 35218372
229. Cimadamore A, Lonati C, Di Trapani E, De Cobelli O, Rink M, Zamboni S, Simeone C, Soria F, Briganti A, Montorsi F, Afferi L, Mattei A, Carando R, Ornaghi PI, Tafuri A, Antonelli A, Karnes RJ, Colomer A, Sanchez-Salas R, Contieri R, Hurle R, Poyet C, Simone G, D'Andrea D, **Shariat SF**, Galfano A, Umari P, Francavilla S, Roumiguie M, Terrone C, Hendricksen K, Krajewski W, Buisan O, Laukhtina E, Xylinas E, Alvarez-Maestro M, Rouprêt M, Montironi R, Moschini M; European Association of Urology - Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy? *Urol Oncol.* 2022 Feb 22:S1078-1439(22)00026-6. PMID: 35216892
230. Califano G, Ouzaid I, Laine-Caroff P, Peyrottes A, Collà Ruvolo C, Pradère B, Elalouf V, Misrai V, Hermieu JF, **Shariat SF**, Xylinas E. Current Advances in Immune Checkpoint Inhibition and Clinical Genomics in Upper Tract Urothelial Carcinoma: State of the Art. *Curr Oncol.* 2022 Jan 29;29(2):687-697. PMID: 35200559
231. Hoeh B, Flammia RS, Hohenhorst L, Sorce G, Chierigo F, Tian Z, Saad F, Gallucci M, Briganti A, Terrone C, **Shariat SF**, Graefen M, Tilki D, Kluth LA, Mandel P, Becker A, Chun FKH, Karakiewicz PI. Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients. *Prostate.* 2022 Feb 21. PMID: 35188982
232. Hoeh B, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Terrone C, **Shariat SF**, Tilki D, Kluth LA, Mandel P, Chun

- FKH, Karakiewicz PI. Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups. *Prostate*. 2022 Feb 21..PMID: 35188981
233. Würnschimmel C, Nocera L, Wenzel M, Ruvolo CC, Tian Z, Saad F, Briganti A, **Shariat SF**, Mirone V, Chun FKH, Tilki D, Graefen M, Karakiewicz PI. Race/Ethnicity may be an Important Predictor of Life Expectancy in Localized Prostate Cancer Patients: Novel Analyses Using Social Security Administration Life Tables. *Racial Ethn Health Disparities*. 2022 Feb 18. PMID: 35182370
234. Vartolomei L, Cotruş A, Tătaru SO, Vartolomei MD, Man A, Ferro M, Stanciu C, Sin AI, **Shariat SF**. Lower urinary tract symptoms are associated with clinically relevant depression, anxiety, and stress symptoms. *Aging Male*. 2022 Dec;25(1):62-66. PMID: 35179090
235. Afferi L, Lonati C, Montorsi F, Briganti A, Necchi A, Mari A, Minervini A, Campi R, di Trapani E, de Cobelli O, Karnes RJ, Ahmed M, Mir MC, Algarra MA, Rink M, Zamboni S, Simeone C, Krajewski W, Xylinas E, Soria F, Hendricksen K, Einerhand S, Mattei A, Carando R, Roumiguié M, Bajeot AS, Black PC, **Shariat SF**, Moschini M; European Association of Urology-Young Academic Urologists (EAU-YAU), Urothelial carcinoma working group. Carboplatin-based adjuvant chemotherapy versus observation after radical cystectomy in patients with pN1-3 urothelial bladder cancer. *World J Urol*. 2022 Feb 10. PMID: 35142865
236. Katayama S, Mori K, Pradere B, Mostafaei H, Schuettfort VM, Quhal F, Motlagh RS, Laukhtina E, Grossmann NC, Rajwa P, Aydh A, König F, Mathieu R, Nyirady P, Karakiewicz PI, Nasu Y, **Shariat SF**. Comparison of short-term and long-term neoadjuvant hormone therapy prior to radical prostatectomy: a systematic review and meta-analysis. *Scand J Urol*. 2022 Feb 10:1-9. PMID: 35142251
237. Grossmann NC, Pradere B, D'Andrea D, Schuettfort VM, Mori K, Rajwa P, Quhal F, Laukhtina E, Katayama S, Fankhauser CD, Xylinas E, Margulis V, Moschini M, Abufaraj M, Bandini M, Lonati C, Nyirady P, Karakiewicz PI, Fajkovic H, **Shariat SF**. Neoadjuvant Chemotherapy in Elderly Patients With Upper Tract Urothelial Cancer: Oncologic Outcomes From a Multicenter Study. *Clin Genitourin Cancer*. 2022 Jan 11: PMID: 35125303
238. Enikeev D, Taratkin M, Morozov A, Petov V, Korolev D, Shpikina A, Spivak L, Kharlamova S, Shchedrina I, Mestnikov O, Fiev D, Ganzha T, Geladze M, Mambetova A, Kogan E, Zharkov N, Demyashkin G, **Shariat SF**, Glybochko P. Prospective two-arm study of testicular function in patients with COVID-19. *Andrology*. 2022 Feb 6. PMID: 35124885
239. Martini A, Lonati C, Montorsi F, Briganti A, Colombo R, Necchi A, Simeone C, Zamboni S, Afferi L, Mattei A, Carando R, Ploussard G, Soria F, Marra G, Rouprêt M, Xylinas E, Pradere B, Abufaraj M, D'Andrea D, **Shariat SF**, Moschini M. The Role of Prior Bladder Cancer on Recurrence in Patients Treated with Radical Nephroureterectomy. *Clin Genitourin Cancer*. 2021 Dec 11: PMID: 35105509
240. Sorce G, Flammia RS, Hoeh B, Chierigo F, Horlemann B, Würnschimmel C, Tian Z, Graefen M, Terrone C, Gallucci M, Chun FKH, Saad F, **Shariat SF**, Montorsi F, Briganti A, Karakiewicz PI. Plasmacytoid variant urothelial carcinoma of the bladder: effect of radical cystectomy and chemotherapy in non-metastatic and metastatic patients. *World J Urol*. 2022 Jan 27. PMID: 35084543
241. Aydh A, Motlagh RS, Alshyarba M, Mori K, Katayama S, Grossmann N, Rajwa P, Mostafai H, Laukhtina E, Pradere B, Quhal F, König F, Nyirady P, Karakiewicz PI, Haydter M, **Shariat SF**. Association of statins use and mortality outcomes in prostate cancer patients who received androgen deprivation therapy: a systematic review and meta-analysis. *Cent European J Urol*. 2021;74(4):484-490. PMID: 35083066

242. Brönimann S, Talhammer F, Springer A, Tonnhof U, **Shariat SF**, D'Andrea D. Ischemic priapism in a 12-year old patient associated with coronavirus disease 2019 (COVID-19): a case report. *Urology*. 2022 Jan 23: PMID: 35081397
243. Yanagisawa T, Mori K, Motlagh RS, Kawada T, Mostafaei H, Quhal F, Laukhtina E, Rajwa P, Aydh A, König F, Pallauf M, Pradere B, D'Andrea D, Compérat E, Miki J, Kimura T, Egawa S, **Shariat SF**. En bloc Resection for Bladder Tumors: An Updated Systematic Review and Meta-Analysis of Its Differential Effect on Its Safety, Recurrence, and Histopathology. *J Urol*. 2022 PMID: 35060770
244. Arnoldner MA, Polanec SH, Lazar M, Kadhjavi S, Clauser P, Pötsch N, Schwarz-Nemec U, Korn S, Hübner N, **Shariat SF**, Helbich TH, Baltzer PAT. Rectal preparation significantly improves prostate imaging quality: Assessment of the PI-QUAL score with visual grading characteristics. *Eur J Radiol*. 2022.PMID: 35007983
245. Katayama S, Schuettfort VM, Pradere B, Mori K, Mostafaei H, Quhal F, Sari Motlagh R, Laukhtina E, Grossmann NC, Aydh A, Rajwa P, König F, Karakiewicz PI, Haydter M, Moschini M, Abufaraj M, Lotan Y, Lee RK, Trinh QD, Compérat E, Teoh J, Nasu Y, **Shariat SF**. Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer. *J Cancer Res Clin Oncol*. 2022 Jan 8. PMID: 34997350
246. Laukhtina E, Quhal F, Mori K, Sari Motlagh R, Rajwa P, Yanagisawa T, Mostafaei H, König F, Aydh A, Pradere B, Enikeev D, Karakiewicz PI, Schmidinger M, **Shariat SF**. Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy. *Eur Urol Oncol*. 2022 Jan 3:S2588-9311(21)00223-6. PMID: 34992006
247. Dillinger T, Sheibani-Tezerji R, Pulverer W, Stelzer I, Hassler MR, Scheibelreiter J, Pérez Malla CU, Kuroll M, Domazet S, Redl E, Ely S, Brezina S, Tiefenbacher A, Rebhan K, Hübner N, Grubmüller B, Mitterhauser M, Hacker M, Weinhaeusel A, Simon J, Zeitlinger M, Gsur A, Kramer G, **Shariat SF**, Kenner L, Egger G. Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies. *Mol Cancer*. 2022 Jan 3;21(1):7 .PMID: 34980142
248. Katayama S, Mori K, Pradere B, Yanagisawa T, Mostafaei H, Quhal F, Motlagh RS, Laukhtina E, Grossmann NC, Rajwa P, Aydh A, König F, Karakiewicz PI, Araki M, Nasu Y, **Shariat SF**. Influence of steep Trendelenburg position on postoperative complications: a systematic review and meta-analysis. *J Robot Surg*. 2021 Dec 31. PMID: 34972981
249. Keresztes D, Csizmarik A, Nagy N, Módos O, Fazekas T, Bracht T, Sitek B, Witzke K, Pühr M, Sevcenco S, Kramer G, **Shariat S**, Küronya Z, Takács L, Tornyi I, Lázár J, Hadaschik B, Lászik A, Szűcs M, Nyirády P, Szarvas T. Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration-resistant prostate cancer. *J Cell Mol Med*. 2021 Dec 30. PMID: 34970839
250. Enikeev D, Babjuk M, Shpikina A, **Shariat S**, Glybochko P. En bloc resection for nonmuscle-invasive bladder cancer: selecting a proper laser. *Curr Opin Urol*. 2021 Dec 24. PMID: 34954702
251. Mostafaei H, Jilch S, Carlin GL, Mori K, Quhal F, Pradere B, Laukhtina E, Schuettfort VM, Aydh A, Sari Motlagh R, Roehrborn CG, **Shariat SF**, Hajebrahimi S. The placebo and nocebo effects in functional urology. *Nat Rev Urol*. 2021 Dec 23. PMID: 34949831
252. Kosiba M, Stolzenbach LF, Collà Ruvolo C, Nocera L, Mansour M, Tian Z, Roos FC, Becker A, Kluth LA, Tilki D, **Shariat SF**, Saad F, Chun FKH, Karakiewicz PI. Contemporary Trends and

- Efficacy of Pelvic Lymph Node Dissection at Radical Cystectomy for Urothelial and Variant Histology Carcinoma of the Urinary Bladder. *Clin Genitourin Cancer*. 2021.PMID: 34906434
253. Mertens LS, Claps F, Mayr R, Bostrom PJ, **Shariat SF**, Zwarthoff EC, Boormans JL, Abas C, van Leenders GJLH, Götz S, Hippe K, Bertz S, Neuzillet Y, Sanders J, Broeks A, Peters D, van der Heijden MS, Jewett MAS, Stöhr R, Zlotta AR, Eckstein M, Soorjebally Y, van der Schoot DKE, Wullich B, Burger M, Otto W, Radvanyi F, Sirab N, Pouessel D, van der Kwast TH, Hartmann A, Lotan Y, Allory Y, Zuiverloon TCM, van Rhijn BWG. Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients. *Urol Oncol*. 2021.PMID: 34906411
254. Laukhtina E, Sari Motlagh R, Mori K, Katayama S, Rajwa P, Yanagisawa T, Quhal F, Mostafaei H, Grossmann NC, König F, Aydh A, Pradere B, Resch I, Merseburger AS, Enikeev D, **Shariat SF**. Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes. *Crit Rev Oncol Hematol*. 2021 PMID: 34902554 Review.
255. Lonati C, Necchi A, Gómez Rivas J, Afferi L, Laukhtina E, Martini A, Ventimiglia E, Colombo R, Gandaglia G, Salonia A, Briganti A, Montorsi F, Mattei A, Simeone C, Carlo MI, **Shariat SF**, Spiess PE, Moschini M; European Association of Urology Young Academic Urologists EAU-YAU: Urothelial Carcinoma Working Group, the Global Society of Rare Genitourinary Tumors GSRGT. Upper Tract Urothelial Carcinoma in the Lynch Syndrome Tumour Spectrum: A Comprehensive Overview from the European Association of Urology - Young Academic Urologists and the Global Society of Rare Genitourinary Tumors. *Eur Urol Oncol*. 2021.PMID: 34896051 Review.
256. Zhao H, Chan VW, Castellani D, Chan EO, Ong WLK, Peng Q, Moschini M, Krajewski W, Pradere B, Ng CF, Enikeev D, Vasdev N, Ekin G, Sousa A, Leon J, Guerrero-Ramos F, Tan WS, Kelly J, **Shariat SF**, Witjes JA, Teoh JY. Intravesical Chemohyperthermia vs. Bacillus Calmette-Guerin Instillation for Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. *Front Surg*. 2021 Nov 23;8:775527. PMID: 34888347 Free PMC article.
257. Hoeh B, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Terrone C, **Shariat SF**, Tilki D, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients. *Front Oncol*. 2021.PMID: 34888250
258. Janisch F, Kienapfel C, Fühner C, Klotzbücher T, Marks P, Hillemacher T, Meyer CP, Iwata T, Parizi MK, Sauter G, Fisch M, **Shariat SF**, Dahlem R, Rink M. Treatment and Outcome of Metastatic Renal Cell Carcinoma With Sarcomatoid Differentiation: A Single-Center, Real-World Analysis of Retrospective Data. *Front Surg*. 2021 Nov 18;8:763271. PMID: 34869564
259. Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, Necchi A, Valderrama BP, Ravaud A, **Shariat SF**, Szabados B, van der Heijden MS, Gillessen S; ESMO Guidelines Committee. Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. *Ann Oncol*. 2021 Nov 27:S0923-7534(21)04827-4. PMID: 34861372
260. Rajwa P, Huebner NA, Hostermann DI, Grossmann NC, Schuettfort VM, Korn S, Quhal F, König F, Mostafaei H, Laukhtina E, Mori K, Motlagh RS, Yanagisawa T, Aydh A, Bryniarski P, Pradere B, Paradysz A, Baltzer PA, Grubmüller B, **Shariat SF**. Evaluation of the predictive role of blood-based biomarkers in the context of suspicious prostate mri in patients undergoing prostate biopsy. *J Pers Med*. 2021 Nov 19;11(11):1231. PMID: 34834583

261. Laukhtina E, Lemberger U, Bruchbacher A, Ilijazi D, Korn S, Berndl F, D'Andrea D, Susani M, Enikeev D, Compérat E, **Shariat SF**, Hassler MR. Expression analysis and mutational status of histone methyltransferase KMT2D at different upper tract urothelial carcinoma locations. *J Pers Med*. 2021 Nov 4;11(11):1147. PMID: 34834500
262. Chierigo F, Wenzel M, Würnschimmel C, Flammia RS, Horlemann B, Tian Z, Saad F, Chun FKH, Tilki D, **Shariat SF**, Gallucci M, Borghesi M, Suardi N, Terrone C, Karakiewicz PI. Immunotherapy in metastatic bladder cancer: a systematic review and network meta-analysis. *Crit Rev Oncol Hematol*. 2021 Nov 22:103534. doi: 10.1016/j.critrevonc.2021.103534. PMID: 34823022
263. Grossmann NC, Schuettfort VM, Pradere B, Rajwa P, Quhal F, Mostafaei H, Laukhtina E, Mori K, Motlagh RS, Aydh A, Katayama S, Moschini M, Fankhauser CD, Hermanns T, Abufaraj M, Mun DH, Zimmermann K, Fajkovic H, Haydter M, **Shariat SF**. Impact of preoperative systemic immune-inflammation Index on oncologic outcomes in bladder cancer patients treated with radical cystectomy. *Urol Oncol*. 2021 PMID: 34810077
264. Gust KM, Resch I, D'Andrea D, **Shariat SF**. Update on systemic treatment of upper tract urothelial carcinoma: a narrative review of the literature. *Transl Androl Urol*. 2021 PMID: 34804847
265. Chierigo F, Borghesi M, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Höh B, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Montorsi F, Chun FKH, **Shariat SF**, Mantica G, Suardi N, Terrone C, Karakiewicz PI. Survival after radical prostatectomy vs. radiation therapy in ductal carcinoma of the prostate. *Int Urol Nephrol*. 2021 Nov 19. PMID: 34797483
266. Würnschimmel C, Wenzel M, Chierigo F, Simone Flammia R, Tian Z, Saad F, Briganti A, **Shariat SF**, Suardi N, Terrone C, Gallucci M, Chun FK, Tilki D, Graefen M, Karakiewicz PI. Response to Re: External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients. *Int J Urol*. 2021 Nov 17. PMID: 34788899
267. Hoeh B, Hohenhorst JL, Flammia R, Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Terrone C, **Shariat SF**, Kluth LA, Becker A, Chun FKH, Karakiewicz PI. Cancer-specific mortality after radical prostatectomy vs external beam radiotherapy in high-risk Hispanic/Latino prostate cancer patients. *Int Urol Nephrol*. 2021 Nov 16. PMID: 34783982
268. Tulchiner G, Staudacher N, Fritz J, Hackl M, Pichler M, Seles M, **Shariat SF**, D'Andrea D, Gust K, Albrecht W, Grubmüller K, Madersbacher S, Graf S, Lusuuardi L, Augustin H, Berger A, Loidl W, Horninger W, Pichler R. Seasonal Variations in the Diagnosis of Testicular Germ Cell Tumors: A National Cancer Registry Study in Austria. *Cancers (Basel)*. 2021 Oct 27;13(21):5377. PMID: 34771540
269. Mori K, Katayama S, Laukhtina E, Schuettfort VM, Pradere B, Quhal F, Sari Motlagh R, Mostafaei H, Grossmann NC, Rajwa P, Zimmermann K, Karakiewicz PI, Abufaraj M, Fajkovic H, Rouprêt M, Margulis V, Enikeev DV, Egawa S, **Shariat SF**. Discordance Between Clinical and Pathological Staging and Grading in Upper Tract Urothelial Carcinoma. *Clin Genitourin Cancer*. 2021 Oct 10:S1558-7673(21)00192-0. PMID: 34764007
270. Yanagisawa T, Mori K, Katayama S, Mostafaei H, Quhal F, Laukhtina E, Rajwa P, Motlagh RS, Aydh A, König F, Grossmann NC, Pradere B, Miki J, Kimura T, Egawa S, **Shariat SF**. Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis. *Int J Clin Oncol*. 2021 Nov 10. PMID: 34757531
271. Laukhtina E, Shim SR, Mori K, D'Andrea D, Soria F, Rajwa P, Mostafaei H, Compérat E, Cimadamore A, Moschini M, Teoh JY, Enikeev D, Xylinas E, Lotan Y, Palou J, Gontero P, Babjuk

- M, Witjes JA, Kamat AM, Roupert M, **Shariat SF**, Pradere B; European Association of Urology–Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. *Eur Urol Oncol.* 2021 Nov 6:S2588-9311(21)00183-8. PMID: 34753702
272. Laukhtina E, Mori K, Mostafaei H, Merseburger AS, Nyirady P, Moschini M, Quhal F, Pradere B, Motlagh RS, Enikeev D, **Shariat SF**. Adverse events of different chemotherapy regimens in the first-line treatment of patients with advanced or metastatic urothelial cancer: A systematic review and network meta-analysis of randomized controlled trials. *Semin Oncol.* 2021 Jun;48(3):181-192. PMID: 34749886
273. Winkler D, Grohmann R, Friedrich ME, Toto S, Bleich S, Seifert J, Konstantinidis A, **Shariat SF**, Kasper S, Pjrek E. Urological adverse drug reactions of psychotropic medication in psychiatric inpatients - A drug surveillance report from German-speaking countries. *J Psychiatr Res.* 2021 Oct 27;144:412-420. PMID: 34741839
274. Quhal F, Mori K, Fajkovic H, Remzi M, **Shariat SF**, Schmidinger M. Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysis. *Curr Opin Urol.* 2021 Oct 29. PMID: 34720102
275. Sari Motlagh R, Rajwa P, Mori K, Laukhtina E, Aydh A, Katayama S, Yanagisawa T, König F, Grossmann NC, Pradere B, Mostafai H, Quhal F, Karakiewicz PI, Babjuk M, **Shariat SF**. Comparison of Clinicopathologic and Oncological Outcomes Between Transurethral En Bloc Resection and Conventional Transurethral Resection of Bladder Tumor: A Systematic Review, Meta-Analysis and Network Meta-Analysis with Focus on Different Energy Sources. *J Endourol.* 2021 Nov 16. PMID: 34693740
276. Luzzago S, Piccinelli ML, Marvaso G, Laukhtina E, Miura N, Schuettfort VM, Mori K, Aydh A, Ferro M, Mistretta FA, Fusco N, Petralia G, Jerezek-Fossa BA, **Shariat SF**, Karakiewicz PI, de Cobelli O, Musi G. Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies. *World J Urol.* 2021 Oct 23. doi: 10.1007/s00345-021-03864-6. Online ahead of print. PMID: 34687344
277. Flammia RS, Chierigo F, Würnschimmel C, Horlemann B, Hoeh B, Sorce G, Tian Z, Leonardo C, Tilki D, Terrone C, Saad F, **Shariat SF**, Montorsi F, Chun FK, Gallucci M, Karakiewicz PI. Survival benefit of chemotherapy in a contemporary cohort of metastatic urachal carcinoma. *Urol Oncol.* 2021 Oct 19:S1078-1439(21)00432-4. PMID: 34686429
278. Laukhtina E, Schuettfort VM, D'Andrea D, Pradere B, Quhal F, Mori K, Sari Motlagh R, Mostafaei H, Katayama S, Grossmann NC, Rajwa P, Karakiewicz PI, Schmidinger M, Fajkovic H, Enikeev D, **Shariat SF**. Selection and evaluation of preoperative systemic inflammatory response biomarkers model prior to cytoreductive nephrectomy using a machine-learning approach. *World J Urol.* 2021 Oct 20. doi: 10.1007/s00345-021-03844-w. Online ahead of print. PMID: 34671856
279. Hoeh B, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Terrone C, **Shariat SF**, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Cancer-specific survival after radical prostatectomy versus external beam radiotherapy in high-risk and very high-risk African American prostate cancer patients. *Prostate.* 2021 Oct 18. PMID: 34662443
280. Cacciamani GE, Matulewicz RS, Kumar R, Teoh JY, Mari A, Pradere B, Gomez Rivas J, Necchi A, Kumar Pal S, Ribal MJ, **Shariat S**, Rink M; SMART (Stop sMoking for Advance Rehabilitation Treatments) Urology Working Group. Fighting the 'tobacco epidemic' - A call to action to identify

- Targeted Intervention Points (TIPs) for better counseling patients with urothelial cancer. *Urol Oncol.* 2021 Oct 7:S1078-1439(21)00407-5. PMID: 34629283
281. Horlemann B, Würnschimmel C, Hoeh B, Sorce G, Chierigo F, Flammia RS, Tian Z, Saad F, Briganti A, **Shariat SF**, Galucci M, Chun FKH, Graefen M, Karakiewicz PI. Radical Cystectomy vs. Radiotherapy in Urothelial Bladder Cancer in Elderly and Very Elderly Patients. *Clin Genitourin Cancer.* 2021 Sep 1:S1558-7673(21)00160-9. PMID: 34620567
 282. Wollenweber T, Zisser L, Kretschmer-Chott E, Weber M, Grubmüller B, Kramer G, **Shariat SF**, Mitterhauser M, Schmitl S, Vranka C, Haug AR, Hacker M, Hartenbach M, Rasul S. Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer. *Curr Oncol.* 2021 Sep 23;28(5):3692-3704. PMID: 34590608
 283. Laukhtina E, Schuettfort VM, D Andrea D, Pradere B, Mori K, Quhal F, Sari Motlagh R, Mostafaei H, Katayama S, Grossmann NC, Rajwa P, Zeinler F, Abufaraj M, Moschini M, Zimmermann K, Karakiewicz PI, Fajkovic H, Scherr D, Compérat E, Nyirady P, Rink M, Enikeev D, **Shariat SF**. Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder. *Mol Carcinog.* 2021 Sep 29. PMID: 34587660
 284. Reichl F, Muhr D, Rebhan K, Kramer G, **Shariat SF**, Singer CF, Tan YY. Cancer Spectrum, Family History of Cancer and Overall Survival in Men with Germline *BRCA1* or *BRCA2* Mutations. *J Pers Med.* 2021 Sep 15;11(9):917 .PMID: 34575694
 285. Mostafaei H, Salehi-Pourmehr H, Jilch S, Carlin GL, Mori K, Quhal F, Pradere B, Grossmann NC, Laukhtina E, Schuettfort VM, Aydh A, Sari Motlagh R, König F, Roehrborn CG, Katayama S, Rajwa P, Hajebrahimi S, **Shariat SF**. Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis. *Eur Urol Focus.* 2021 Sep 22:S2405-4569(21)00226-1. PMID: 34563481
 286. Chierigo F, Wenzel M, Würnschimmel C, Flammia RS, Horlemann B, Tian Z, Saad F, Chun FKH, Graefen M, Gallucci M, **Shariat SF**, Mantica G, Borghesi M, Suardi N, Terrone C, Karakiewicz PI. Survival after Radical Prostatectomy vs. Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer. *Urol.* 2021 Sep 24. PMID: 34555930
 287. Würnschimmel C, Wenzel M, Chierigo F, Flammia RS, Tian Z, Saad F, Briganti A, **Shariat SF**, Suardi N, Terrone C, Gallucci M, Chun FK, Tilki D, Graefen M, Karakiewicz PI. External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients. *Int J Urol.* 2021 Sep 22. PMID: 34553428
 288. Nocera L, Karakiewicz PI, Wenzel M, Tian Z, **Shariat SF**, Saad F, Chun FKH, Briganti A, Kapoor A, Lalani AK. Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis. *J Urol.* 2021. PMID: 34546767
 289. Hoeh B, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Terrone C, **Shariat SF**, Tilki D, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients. *Prostate.* 2021 Sep 15. PMID: 34523162
 290. Wenzel M, Würnschimmel C, Chierigo F, Tian Z, **Shariat SF**, Terrone C, Saad F, Tilki D, Graefen M, Banek S, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Increased risk of postoperative in-hospital complications after radical prostatectomy in patients with prior organ transplant. *Prostate.* 2021 Sep 13. PMID: 34516668

291. Babjuk M, Burger M, Capoun O, Cohen D, Comp erat EM, Dominguez Escrig JL, Gontero P, Liedberg F, Masson-Lecomte A, Mostafid AH, Palou J, van Rhijn BWG, Roup r t M, **Shariat SF**, Seisen T, Soukup V, Sylvester RJ. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). *Eur Urol*. 2021 Sep 9:S0302-2838(21)01978-3. PMID: 34511303.
292. Coll  Ruvolo C, W rnshimmel C, Nocera L, Wenzel M, Tian Z, **Shariat SF**, Saad F, Verze P, Imbimbo C, Briganti A, Mirone V, Karakiewicz PI. Stage and cancer-specific mortality differ within specific Asian ethnic groups for upper tract urothelial carcinoma: North American population-based study. *Int J Urol*. 2021 Sep 3. PMID: 34480378
293. Sari Motlagh R, Abufaraj M, Karakiewicz PI, Rajwa P, Mori K, Mun DH, **Shariat SF**. Association between SARS-CoV-2 infection and disease severity among prostate cancer patients on androgen deprivation therapy: a systematic review and meta-analysis. *World J Urol*. 2021 Sep 3:1-8. doi: 10.1007/s00345-021-03810-6. PMID: 34477955 .
294. Wenzel M, Siron N, Coll  Ruvolo C, Nocera L, W rnshimmel C, Tian Z, **Shariat SF**, Saad F, Briganti A, Tilki D, Banek S, Kluth LA, Roos FC, Chun FKH, Karakiewicz PI. Temporal trends, tumor characteristics and stage-specific survival in penile non-squamous cell carcinoma vs. squamous cell carcinoma. *Cancer Causes Control*. 2021 Sep 2 PMID: 34476653
295. Mori K, Schuettfort VM, Katayama S, Laukhtina E, Pradere B, Quhal F, Sari Motlagh R, Mostafaei H, Grossmann NC, Rajwa P, K nig F, Aydh A, Soria F, Moschini M, Karakiewicz PI, Lotan Y, Scherr D, Haydter M, Nyirady P, Teoh JYC, Egawa S, Comp erat E, **Shariat SF**. The Value of Preoperative Plasma VEGF Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. *Eur Urol Focus*. 2021 Aug 25:S2405-4569(21)00221-2. PMID: 34454852
296. D'Andrea D, Black PC, Zargar H, Dinney CP, Soria F, Cookson MS, Montgomery JS, Kassouf W, Dall'Era MA, Sridhar SS, McGrath JS, Wright JL, Thorpe AC, Holzbeierlein JM, Carri n DM, Di Trapani E, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, van Rhijn BW, Daneshmand S, Spiess PE, **Shariat SF**, Zargar-Shoshtar K, Mertens LS, Fairey AS, Mir MC, Krabbe LM, Jacobsen NE, Vasdev N, Yu EY, Xylinas E, Pradere B, Pichler R, Campaign NJ, Seah JA, Ercole CE, Horenblas S, Aning J, Morgan TM, Shah JB, Moschini M. Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle-Invasive Bladder Cancer. *J Urol*. 2021 Aug 27. PMID: 34445891
297. Nocera L, Wenzel M, Coll  Ruvolo C, W rnshimmel C, Tian Z, Gandaglia G, Fossati N, Chun FKH, Mirone V, Graefen M, Saad F, **Shariat SF**, Montorsi F, Briganti A, Karakiewicz PI. The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy. *World J Urol*. 2021 Aug 26. PMID: 34436637
298. Grubm ller B, Jahrreiss V, Br nimann S, Quhal F, Mori K, Heidenreich A, Briganti A, Tilki D, **Shariat SF**. Salvage Radical Prostatectomy for Radio-Recurrent Prostate Cancer: An Updated Systematic Review of Oncologic, Histopathologic and Functional Outcomes and Predictors of Good Response. *Curr Oncol*. 2021 Jul 29;28(4):2881-2892. PMID: 34436018
299. Lonati C, Baumeister P, Afferi L, Mari A, Minervini A, Krajewski W, Azizi S, Hendricksen K, Martini A, Necchi A, Montorsi F, Briganti A, Colombo R, Tafuri A, Antonelli A, Cerruto MA, Roup r t M, Masson-Lecomte A, Laukhtina E, D'Andrea D, **Shariat SF**, Soria F, Marra G, Gontero P, Contieri R, Hurler R, Valiquette AS, Mir MC, Zamboni S, Simeone C, Klatte T, Teoh JY, Yoshida S, Fujii Y, Carando R, Schulz GB, Mordasini L, Mattei A, Moschini M; European Association of Urology Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Survival Outcomes After Immediate Radical Cystectomy Versus Conservative

- Management with Bacillus Calmette-Guérin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration. *Eur Urol Focus*. 2021.PMID: 34419381
300. Laukhtina E, Quhal F, Mori K, Sari Motlagh R, Pradere B, Schuettfort VM, Mostafaei H, Katayama S, Grossmann NC, Rajwa P, Resch I, Enikeev D, Karakiewicz PI, **Shariat SF**, Schmidinger M. Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis. *Urol Oncol*. 2021 Aug 14:S1078-1439(21)00340-9. PMID: 34400065
301. Enikeev D, Misrai V, **Shariat S**. Lower urinary tract symptoms, benign prostate hyperplasia and beyond. *Curr Opin Urol*. 2021 Sep 1;31(5):437. PMID: 34397504
302. Wenzel M, Deuker M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, **Shariat SF**, Saad F, Briganti A, Tilki D, Graefen M, Kluth LA, Becker A, Roos FC, Chun FKH, Karakiewicz PI. Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis. *Eur J Cancer*. 2021 Aug 12;155:245-255. PMID: 34392067.
303. D'Andrea D, Black PC, Zargar H, Zargar-Shoshtari K, Soria F, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, **Shariat SF**. Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. *World J Urol*. 2021 Aug 9.PMID: 34370078
304. Wenzel M, Collà Ruvolo C, Nocera L, Würnschimmel C, Tian Z, **Shariat SF**, Saad F, Briganti A, Graefen M, Becker A, Mandel P, Chun FKH, Karakiewicz PI. Regional differences in patient age and prostate cancer characteristics and rates of treatment modalities in favorable and unfavorable intermediate risk prostate cancer across United States SEER registries. *Cancer Epidemiol*. 2021 Aug 5;74:101994. PMID: 34364187
305. Khene ZE, Kokorian R, Mathieu R, Gasmi A, Nathalie RL, Solène-Florence KJ, **Shariat S**, de Crevoisier R, Laguerre B, Bensalah K. Metastatic clear cell renal cell carcinoma: computed tomography texture analysis as predictive biomarkers of survival in patients treated with nivolumab. *Int J Clin Oncol*. 2021 Aug 2. PMID: 34338919
306. Stangl-Kremser J, Rasul S, Tosoian JJ, Salami SS, Zaslavsky A, Udager A, Mazal P, Kain R, Comperat E, Hacker M, Haug A, Mitterhauser M, Pozo-Salido C, Steinbach C, Hassler MR, Kramer G, **Shariat SF**, Palapattu GS. Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [177Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer. *Eur Urol Open Sci*. 2021 Jun 30;30:63-66. PMID: 34337549
307. Wenzel M, Würnschimmel C, Chierigo F, Flammia RS, Tian Z, **Shariat SF**, Gallucci M, Terrone C, Saad F, Tilki D, Graefen M, Becker A, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Nomogram Predicting Downgrading in National Comprehensive Cancer Network High-risk Prostate Cancer Patients Treated with Radical Prostatectomy. *Eur Urol Focus*. 2021 Jul 29:S2405-4569(21)00188-7. PMID: 34334344
308. Collà Ruvolo C, Wenzel M, Nocera L, Würnschimmel C, Tian Z, **Shariat SF**, Saad F, Longo N, Imbimbo C, Briganti A, Mirone V, Karakiewicz PI. The effect of race on stage at presentation and survival in upper tract urothelial carcinoma. *Urol Oncol*. 2021 Jul 27:S1078-1439(21)00303-3. PMID: 34330651

309. Wenzel M, Würnschimmel C, Chierigo F, Tian Z, **Shariat SF**, Terrone C, Saad F, Tilki D, Graefen M, Roos FC, A Kluth L, Mandel P, Chun FKH, Karakiewicz PI. Assessment of the optimal number of positive biopsy cores to discriminate between cancer-specific mortality in high-risk versus very high-risk prostate cancer patients. *Prostate*. 2021 Oct;81(14):1055-1063. PMID: 34312910
310. Mori K, Quhal F, Katayama S, Mostafaei H, Laukhtina E, Schuetfort VM, Sari Motlagh R, Grossmann NC, Rajwa P, Ploussard G, Briganti A, Kimura T, Egawa S, Papalia R, Carrion DM, Fiori C, **Shariat SF**, Esperto F, Pradere B. Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile: an updated systematic review and meta-analysis. *Minerva Urol Nephrol*. 2021 Jul 26. doi: 10.23736/S2724-6051.21.04431-1. PMID: 34308608
311. Sari Motlagh R, Abufaraj M, Mori K, Aydh A, Rajwa P, Katayama S, Grossmann NC, Laukhtina E, Mostafai H, Pradere B, Quhal F, Karakiewicz PI, Enikeev DV, **Shariat SF**. The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials. *Eur Urol Oncol*. 2021 Jul 20:S2588-9311(21)00122-X. PMID: 34301529.
312. Laukhtina E, Mori K, D Andrea D, Moschini M, Abufaraj M, Soria F, Mari A, Krajewski W, Albisinni S, Teoh JY, Quhal F, Sari Motlagh R, Mostafaei H, Katayama S, Grossmann NC, Rajwa P, Enikeev D, Zimmermann K, Fajkovic H, Glybochko P, **Shariat SF**, Pradere B; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU). Incidence, risk factors and outcomes of urethral recurrence after radical cystectomy for bladder cancer: A systematic review and meta-analysis. *Urol Oncol*. 2021 PMID: 34266740
313. Gmeiner J, Garstka N, Helbich TH, **Shariat SF**, Baltzer PA. Vesical Imaging Reporting and Data System (VI-RADS): Are the individual MRI sequences equivalent in diagnostic performance of high grade NMIBC and MIBC? *Eur J Radiol*. 2021 PMID: 34252867
314. Resch I, Bruchbacher A, Franke J, Fajkovic H, Remzi M, **Shariat SF**, Schmidinger M. Outcome of immune checkpoint inhibitors in metastatic renal cell carcinoma across different treatment lines. *ESMO Open*. 2021 Jul 1;6(4):100122. PMID: 34217917
315. Chan VW, Tan WS, Asif A, Ng A, Gbolahan O, Dinneen E, To W, Kadhim H, Premchand M, Burton O, Koe JS, Wang N, Leow JJ, Giannarini G, Vasdev N, **Shariat SF**, Enikeev D, Ng CF, Teoh JY. Effects of Delayed Radical Prostatectomy and Active Surveillance on Localised Prostate Cancer-A Systematic Review and Meta-Analysis. *Cancers (Basel)*. 2021 Jun 30;13(13):3274. PMID: 34208888
316. Mun DH, Yang L, **Shariat SF**, Reitter-Pfoertner S, Gredinger G, Waldhoer T. Difference in Incontinence Pad Use between Patients after Radical Prostatectomy and Cancer-Free Population with Subgroup Analysis for Open vs. Minimally Invasive Radical Prostatectomy: A Descriptive Analysis of Insurance Claims-Based Data. *Int J Environ Res Public Health*. 2021 PMID: 34199008
317. Claps F, van de Kamp MW, Mayr R, Bostrom PJ, Boormans JL, Eckstein M, Mertens LS, Boevé ER, Neuzillet Y, Burger M, Pouessel D, Trombetta C, Wullich B, van der Kwast TH, Hartmann A, Allory Y, Lotan Y, **Shariat SF**, Zuiverloon TCM, Mir MC, van Rhijn BWG. Risk factors associated with positive surgical margins' location at radical cystectomy and their impact on bladder cancer survival. *World J Urol*. 2021 Jul 1. PMID: 34196758
318. Aydh A, Mori K, D'Andrea D, Motlagh RS, Abufaraj M, Pradere B, Mostafaei H, Laukhtina E, Quhal F, Karakiewicz PI, Luzzago S, Briganti A, Trinh QD, Parizi MK, Tilki D, Enikeev DV, **Shariat SF**. Prognostic value of the pre-operative serum albumin to globulin ratio in patients with non-metastatic prostate cancer undergoing radical prostatectomy. *Int J Clin Oncol*. 2021 Jun 28. PMID: 34184136

319. Schuettfort VM, Pradere B, D'Andrea D, Grossmann NC, Quhal F, Mostafaei H, Laukhtina E, Mori K, Rink M, Karakiewicz PI, Motlagh RS, Katayama S, Lotan Y, Scherr D, Abufaraj M, Fajkovic H, Comp erat E, Enikeev D, **Shariat SF**. Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes After Radical Cystectomy. *J Urol*. 2021 Online ahead of print.PMID: 34181469
320. Bravi CA, Droghetti M, Fossati N, Gandaglia G, Suardi N, Mazzone E, Cucchiara V, Scuderi S, Barletta F, Schiavina R, Osmonov D, Juenemann KP, Boeri L, Karnes RJ, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, Grubm uller B, **Shariat SF**, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Motttrie A, Karakiewicz PI, Montorsi F, Briganti A. Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy. *Eur Urol Oncol*. 2021 Jun.PMID: 34176768
321. Mori K, Mostafaei H, Sari Motlagh R, Pradere B, Quhal F, Laukhtina E, Schuettfort VM, Kramer G, Abufaraj M, Karakiewicz PI, Kimura T, Egawa S, **Shariat SF**. Systemic Therapies for Metastatic Hormone-Sensitive Prostate Cancer: Network Meta-Analysis. *BJU Int*. 2021 Jun 25.
322. Mori K, Pradere B, Quhal F, Katayama S, Mostafaei H, Laukhtina E, Schuettfort VM, D'Andrea D, Egawa S, Bensalah K, Schmidinger M, Powles T, **Shariat SF**. Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis. *Cancer Treat Rev*. 2021 Jun 12;99:102242. PMID: 34153830
323. Mori K, Sharma V, Egawa S, Tilki D, Boorjian SA, **Shariat SF**.ASO Author Reflections: Is There Any Difference Among Various Gleason Scores Classified as Grade Group 4 Prostate Cancer? *Ann Surg Oncol*. 2021 Jun 21. PMID: 34152524
324. Pisano F, Gontero P, Sylvester R, Joniau S, Serretta V, Larr e S, Di Stasi S, van Rhijn B, Witjes A, Grotenhuis A, Colombo R, Briganti A, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha E, Ardelt P, Varkarakis J, Bartoletti R, Dalbagni G, **Shariat SF**, Xylinas E, Karnes RJ, Palou J. Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients. *Actas Urol Esp (Engl Ed)*. 2021 Jun 16:S2173-5786(21)00071-8. PMID: 34147426
325. Katayama S, Mori K, Pradere B, Mostafaei H, Schuettfort VM, Quhal F, Motlagh RS, Laukhtina E, Moschini M, Grossmann NC, Nasu Y, **Shariat SF**, Fajkovic H. Intracorporeal versus extracorporeal urinary diversion in robot-assisted radical cystectomy: a systematic review and meta-analysis. *Int J Clin Oncol*. 2021 Jun 19. PMID: 34146185 Review.
326. Katayama S, Mori K, Pradere B, Laukhtina E, Schuettfort VM, Quhal F, Motlagh RS, Mostafaei H, Grossmann NC, Rajwa P, Moschini M, Mathieu R, Abufaraj M, D'Andrea D, Comp erat E, Haydter M, Egawa S, Nasu Y, **Shariat SF**; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU). Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer. *World J Urol*. 2021 Jun 18. doi: 10.1007/s00345-021-03740-3. Online ahead of print.PMID: 34143284
327. Comp erat E, Amin MB, Epstein JI, Hansel DE, Paner G, Al-Ahmadie H, True L, Bayder D, Bivalacqua T, Brimo F, Cheng L, Chevill e J, Dalbagni G, Falzarano S, Gordetsky J, Guo C, Gupta S, Hes O, Iyer G, Kaushal S, Kunju L, Magi-Galluzzi C, Matoso A, McKenney J, Netto GJ, Osunkoya AO, Pan CC, Pivovarcikova K, Raspollini MR, Reis H, Rosenberg J, Roupret M, Shah RB, **Shariat SF**, Trpkov K, Weyerer V, Zhou M, Reuter V. The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and

- Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. *Adv Anat Pathol.* 2021 Jul 1;28(4):196-208. PMID: 34128484
328. Amin MB, Comperat E, Epstein JI, True LD, Hansel D, Paner GP, Al-Ahmadie H, Baydar D, Bivalacqua T, Brimo F, Cheng L, Cheville J, Dalbagni G, Falzarano S, Gordetsky J, Guo CC, Gupta S, Hes O, Iyer G, Kaushal S, Kunju L, Magi-Galluzzi C, Matoso A, Netto G, Osunkoya AO, Pan CC, Pivovarcikova K, Raspollini MR, Reis H, Rosenberg J, Roupert M, Shah RB, **Shariat SF**, Trpkov K, Weyerer V, Zhou M, McKenney J, Reuter VE. The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia. *Adv Anat Pathol.* 2021 Jul 1;28(4):179-195. PMID: 34128483
329. Laukhtina E, Rajwa P, Mori K, Moschini M, D'Andrea D, Abufaraj M, Soria F, Mari A, Krajewski W, Albisinni S, Teoh JY, Quhal F, Sari Motlagh R, Mostafaei H, Katayama S, Grossmann NC, Enikeev D, Zimmermann K, Fajkovic H, Glybochko P, **Shariat SF**, Pradere B; European Association of Urology Young Academic Urologists Urothelial Carcinoma Working Group (EAU YAU). Accuracy of Frozen Section Analysis of Urethral and Ureteral Margins During Radical Cystectomy for Bladder Cancer: A Systematic Review and Diagnostic Meta-Analysis. *Eur Urol Focus.* 2021 Jun 11:S2405-4569(21)00162-0. PMID: 34127436 Review.
330. Mori K, Sharma V, Comperat EM, Sato S, Laukhtina E, Schuettfort VM, Pradere B, Sari Motlagh R, Mostafaei H, Quhal F, Kardoust Parizi M, Abufaraj M, Karakiewicz PI, Egawa S, Tilki D, Boorjian SA, **Shariat SF**. Prognostic Impact of Different Gleason Patterns on Biopsy Within Grade Group 4 Prostate Cancer. *Ann Surg Oncol.* 2021 Jun 11. PMID: 34117577
331. Rajwa P, Schuettfort VM, D'Andrea D, Quhal F, Mori K, Katayama S, Laukhtina E, Pradere B, Motlagh RS, Mostafaei H, Grossmann NC, Huebner N, Aulitzky A, Mun DH, Briganti A, Karakiewicz PI, Fajkovic H, **Shariat SF**. Impact of systemic Immune-inflammation Index on oncologic outcomes in patients treated with radical prostatectomy for clinically nonmetastatic prostate cancer. *Urol Oncol.* 2021 Jun 8:S1078-1439(21)00208-8. PMID: 34116934
332. Schuettfort VM, Gust K, D'Andrea D, Quhal F, Mostafaei H, Laukhtina E, Mori K, Rink M, Abufaraj M, Karakiewicz PI, Luzzago S, Rouprêt M, Enikeev D, Zimmermann K, Deuker M, Moschini M, Sari Motlagh R, Grossmann NC, Katayama S, Pradere B, **Shariat SF**. Impact of the preoperative modified glasgow prognostic score on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. *Minerva Urol Nephrol.* 2021 Jun 11. PMID: 34114784
333. Kozikowski M, Suarez-Ibarrola R, Osiecki R, Bilski K, Gratzke C, **Shariat SF**, Miernik A, Dobruch J. Role of Radiomics in the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. *Eur Urol Focus.* 2021 Jun 4:S2405-4569(21)00157-7. PMID: 34099417
334. Jobczyk M, Stawiski K, Kaszkowiak M, Rajwa P, Róžański W, Soria F, **Shariat SF**, Fendler W. Deep Learning-based Recalibration of the CUETO and EORTC Prediction Tools for Recurrence and Progression of Non-muscle-invasive Bladder Cancer. *Eur Urol Oncol.* 2021 Jun 3:S2588-9311(21)00112-7. PMID: 34092528
335. Ruvolo CC, Nocera L, Stolzenbach FL, Wenzel M, Würnschimmel C, Fusco F, Palmieri A, Tian Z, **Shariat SF**, Saad F, Briganti A, Imbimbo C, Mirone V, Karakiewicz PI. Contemporary analysis of the effect of marital status on survival in upper tract urothelial carcinoma patients treated with radical nephroureterectomy: A population-based study. *Urol Oncol.* 2021 Jun 4:S1078-1439(21)00197-6. PMID: 34092481
336. Collà Ruvolo C, Würnschimmel C, Wenzel M, Nocera L, Celentano G, Mangiapia F, Tian Z, **Shariat SF**, Saad F, Chun FHC, Briganti A, Longo N, Mirone V, Karakiewicz PI. Comparison

- between 1973 and 2004/2016 World Health Organization grading in upper tract urothelial carcinoma treated with radical nephroureterectomy. *Int J Clin Oncol*. 2021 Jun 6. PMID: 34091795
337. Laukhtina E, Mori K, Mostafaei H, Merseburger AS, Nyirady P, Moschini M, Quhal F, Schuettfort VM, Pradere B, Motlagh RS, Enikeev D, **Shariat SF**, Of Urology-Young Academic Urologists Eau-Yau Urothelial Carcinoma Working Group EA. Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysis. *Immunotherapy*. 2021 Jun 3. PMID: 34078134
338. Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, Bamias A, Le Bret T, **Shariat SF**, Park SH, Ye D, Agerbaek M, Enting D, McDermott R, Gajate P, Peer A, Milowsky MI, Nosov A, Neif Antonio J Jr, Tupikowski K, Toms L, Fischer BS, Qureshi A, Collette S, Unsal-Kacmaz K, Broughton E, Zardavas D, Koon HB, Galsky MD. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. *N Engl J Med*. 2021 Jun 3;384(22):2102-2114. PMID: 34077643
339. Pones M, D'Andrea D, Mori K, Abufraj M, Moschini M, Comperat E, **Shariat SF**. Differential Prognosis and Response of De novo vs. Secondary Muscle-Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis. *Cancers (Basel)*. 2021 May 20;13(10):2496. PMID: 34065365
340. Rasul S, Wollenweber T, Zisser L, Kretschmer-Chott E, Grubmüller B, Kramer G, **Shariat SF**, Eidherr H, Mitterhauser M, Vranka C, Langsteger W, Hacker M, Haug AR. Response and Toxicity to the Second Course of 3 Cycles of 177Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer. *Cancers (Basel)*. 2021 May 20;13(10):2489. PMID: 34065303
341. Quhal F, Rajwa P, Mori K, Laukhtina E, Grossmann NC, Schuettfort VM, König F, Aydh A, Motlagh RS, Katayama S, Mostafai H, Pradere B, Marra G, Gontero P, Mathieu R, Karakiewicz PI, Briganti A, **Shariat SF**, Heidenreich A. The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer. *Prostate*. 2021 May 31. PMID: 34057227
342. Würnschimmel C, Wenzel M, Chierigo F, Flammia RS, Mori K, Tian Z, **Shariat SF**, Saad F, Briganti A, Suardi N, Terrone C, Gallucci M, Chun FKH, Tilki D, Graefen M, Karakiewicz PI. Presence of biopsy Gleason pattern 5 + 3 is associated with higher mortality after radical prostatectomy but not after external beam radiotherapy compared to other Gleason Grade Group IV patterns. *Prostate*. 2021 May 31. PMID: 34057220
343. Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, **Shariat SF**, Saad F, Tilki D, Graefen M, Kluth LA, Briganti A, Mandel P, Montorsi F, Chun FKH, Karakiewicz PI. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. *Prostate Cancer Prostatic Dis*. 2021 May 30. PMID: 34054128.
344. Katayama S, Mori K, Schuettfort VM, Pradere B, Mostafaei H, Quhal F, Rajwa P, Motlagh RS, Laukhtina E, Moschini M, Grossmann NC, Araki M, Teoh JY, Rouprêt M, Margulis V, Enikeev D, Karakiewicz PI, Abufaraj M, Compérat E, Nasu Y, **Shariat SF**. Accuracy and Clinical Utility of a Tumor Grade- and Stage-based Predictive Model in Localized Upper Tract Urothelial Carcinoma. *Eur Urol Focus*. 2021 May 27:S2405-4569(21)00154-1. PMID: 34053904 .
345. Laukhtina E, Sari Motlagh R, Mori K, Quhal F, Schuettfort VM, Mostafaei H, Katayama S, Grossmann NC, Ploussard G, Karakiewicz PI, Briganti A, Abufaraj M, Enikeev D, Pradere B, **Shariat SF**. Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review. *World J Urol*. 2021 May 28;1-15PMID: 34047825

346. Martini A, Afferi L, Zamboni S, Schultz JG, Lonati C, Mattei A, Karnes RJ, Soligo M, Stabile A, Di Trapani E, De Cobelli O, Simone G, Simeone C, Alvarez-Maestro M, Gandaglia G, Gallina A, Colombo R, Briganti A, Montorsi F, Xylinas E, Shariat SF, Moschini M: Oncologic Surveillance for Variant Histology Bladder Cancer after Radical Cystectomy. *J Urol*. 2021 PMID: 34032498
347. Stangl-Kremser J, Mari A, Lai LY, Lee CT, Vince R, Zaslavsky A, Salami SS, Fajkovic H, **Shariat SF**, Palapattu GS. Sarcopenic Obesity and Its Prognostic Impact on Urologic Cancers: A Systematic Review. *J Urol*. 2021 May 25; PMID: 34032495
348. Schuettfort VM, Pradere B, Trinh QD, D'Andrea D, Quhal F, Mostafaei H, Laukhtina E, Mori K, Sari Motlagh R, Rink M, Karakiewicz PI, Chlosta P, Yuen-Chun Teoh J, Lotan Y, Scherr D, Abufaraj M, Moschini M, **Shariat SF**. Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer. *Cancer Immunol Immunother*. 2021 May 23. PMID: 34023914
349. Foerster B, Abufaraj M, Matin SF, Azizi M, Gupta M, Li WM, Seisen T, Clinton T, Xylinas E, Mir MC, Schweitzer D, Mari A, Kimura S, Bandini M, Mathieu R, Ku JH, Marcq G, Guruli G, Grabbert M, Czech AK, Muilwijk T, Pycha A, D'Andrea D, Petros FG, Spiess PE, Bivalacqua T, Wu WJ, Roupriet M, Krabbe LM, Hendricksen K, Egawa S, Briganti A, Moschini M, Graffelle V, Kassouf W, Autorino R, Heidenreich A, Chlosta P, Joniau S, Soria F, Pierorazio PM, **Shariat SF**. Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study. *Eur Urol*. 2021 May 19;S0302-2838(21)00328-6. PMID: 34023164
350. Rajwa P, Pradere B, Quhal F, Mori K, Laukhtina E, Huebner NA, D'Andrea D, Krzywon A, Shim SR, Baltzer PA, Renard-Penna R, Leapman MS, **Shariat SF**, Ploussard G. Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis. *Eur Urol*. 2021 May 18;S0302-2838(21)00325-0. PMID: 34020828
351. Wenzel M, Würnschimmel C, Chierigo F, Tian Z, **Shariat SF**, Terrone C, Saad F, Tilki D, Graefen M, Mandel P, Kluth LA, Chun FKH, Karakiewicz PI. Non-cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy. *Prostate*. 2021 May 19. PMID: 34010465
352. Baard J, Cormio L, Cavadas V, Alcaraz A, **Shariat SF**, de la Rosette J, Laguna MP. Contemporary patterns of presentation, diagnostics and management of upper tract urothelial cancer in 101 centres: the Clinical Research Office of the Endourological Society Global upper tract urothelial carcinoma registry. *Curr Opin Urol*. 2021 Jul 1;31(4):354-362. PMID: 34009177
353. Rajwa P, Schuettfort VM, Quhal F, Mori K, Katayama S, Laukhtina E, Pradere B, Motlagh RS, Mostafaei H, Grossmann NC, Aulitzky A, Paradysz A, Karakiewicz PI, Fajkovic H, Zimmermann K, Heidenreich A, Gontero P, **Shariat SF**. Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy. *World J Urol*. 2021 May 17. PMID: 33997919
354. Würnschimmel C, Wenzel M, Collà Ruvolo C, Nocera L, Tian Z, Saad F, Briganti A, **Shariat SF**, Mirone V, Chun FK, Tilki D, Graefen M, Karakiewicz PI. Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups. *Int J Urol*. 2021 May 15. PMID: 33993551
355. Nocera L, Wenzel M, Collà Ruvolo C, Würnschimmel C, Tian Z, Gandaglia G, Fossati N, Chun FKH, Mirone V, Graefen M, **Shariat SF**, Saad F, Montorsi F, Briganti A, Karakiewicz PI. The effect of race/ethnicity on active treatment rates among septuagenarian or older low risk prostate cancer patients. *Urol Oncol*. 2021 May 12;S1078-1439(21)00161-7. PMID: 33992522

356. Pisano F, Gontero P, Sylvester R, Joniau S, Serretta V, Larré S, Di Stasi S, van Rhijn B, Witjes A, Grotenhuis A, Colombo R, Briganti A, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha E, Ardelt P, Varkarakis J, Bartoletti R, Dalbagni G, **Shariat SF**, Xylinas E, Karnes RJ, Palou J. Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients. *Actas Urol Esp*. 2021 May 12;S0210-4806(21)00012-7. PMID: 33992448 .
357. Enikeev D, Taratkin M, Efetov S, Shlomina A, Boldyreva M, Galkina I, Spivak L, Gitel E, Kuchieva A, Mikhailov V, Teoh JY, Herrmann TRW, Kikic Ž, Fomin V, **Shariat SF**, Glybochko P. Acute kidney injury in COVID-19: are kidneys the target or just collateral damage? A comprehensive assessment of viral RNA and AKI rate in patients with COVID-19. *Curr Opin Urol*. 2021 May 14 PMID: 33989230
358. Würnschimmel C, Wenzel M, Collà Ruvolo C, Nocera L, Tian Z, Saad F, Briganti A, **Shariat SF**, Mandel P, Chun FKH, Tilki D, Graefen M, Karakiewicz PI. Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities. *World J Urol*. 2021 May 12. PMID: 33978812
359. König F, **Shariat SF**, Karakiewicz PI, Mun DH, Rink M, Pradere B. Quality indicators for the management of high-risk upper tract urothelial carcinoma requiring radical nephroureterectomy. *Curr Opin Urol*. 2021 PMID: 33973537
360. Zimmermann K, Mostafaei H, Heidenreich A, Schmelz HU, **Shariat SF**, Mori K. Health-related quality of life in bladder cancer patients: bladder cancer-specific instruments and domains. Part 2. *Curr Opin Urol*. 2021 PMID: 33973536
361. Schuettfort VM, Pradere B, Compérat E, Abufaraj M, Shariat SF. Novel transurethral resection technologies and training modalities in the management of nonmuscle invasive bladder cancer: a comprehensive review. *Curr Opin Urol*. 2021 PMID: 33973535
362. Deuker M, Krimphove MJ, Stolzenbach LF, Collà Ruvolo C, Nocera L, Mansour M, Tian Z, Roos FC, Becker A, Kluth LA, **Shariat SF**, Black PC, Kassouf W, Tilki D, Saad F, Chun FKH, Karakiewicz PI. Radical Cystectomy vs. Multimodality Treatment in T2N0M0 Bladder Cancer: A Population-based, Age-matched Analysis. *Clin Genitourin Cancer*. 2021 PMID: 33972185
363. Jahrreiss V, Laukhtina E, D'Andrea D, **Shariat SF**. The prognostic value of sarcopenia in patients with prostate cancer: a systematic review. *Curr Opin Urol*. 2021 May 6. PMID: 33965982
364. Mun DH, Pradere B, **Shariat SF**, Yurdakul O, Remzi M. COVID-19 crisis and minimally invasive surgery: a narrative review on intraoperative aerosol viral transmission and their impact on guidelines and clinical practice in Austria. *Curr Opin Urol*. 2021 PMID: 33965981
365. Zimmermann K, Mostafaei H, Heidenreich A, Schmelz HU, **Shariat SF**, Mori K. Part I. Health-related quality of life in bladder cancer patients: general and cancer-specific instruments. *Curr Opin Urol*. 2021 May 6 PMID: 33965980
366. Laukhtina E, Mori K, Pradere B, **Shariat SF**. Association between male infertility and prostate cancer: a systematic review and meta-analysis. *Curr Opin Urol*. 2021 May 6. PMID: 33965979
367. Quhal F, Mori K, Remzi M, Fajkovic H, **Shariat SF**, Schmidinger M. Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma: systematic review and network meta-analysis. *Curr Opin Urol*. 2021 PMID: 33965978
368. Oszwald A, Wasinger G, Pradere B, **Shariat SF**, Compérat EM. Artificial intelligence in prostate histopathology: where are we in 2021? *Curr Opin Urol*. 2021 PMID: 33965977
369. Mori K, Pradere B, Moschini M, Mostafaei H, Laukhtina E, Schuettfort VM, Sari Motlagh R, Soria F, Teoh JYC, Egawa S, Powles T, **Shariat SF**; European Association of Urology–Young

- Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU). First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis. *Eur J Cancer*. 2021 May 4;151:35-48. PMID: 33962359 Review.
370. Rosiello G, Palumbo C, Deuker M, Stolzenbach LF, Martin T, Tian Z, Larcher A, Capitanio U, Montorsi F, **Shariat SF**, Kapoor A, Saad F, Briganti A, Karakiewicz PI. Partial nephrectomy in frail patients: Benefits of robot-assisted surgery *Surg Oncol*. 2021 Apr 22;38:101588. PMID: 33945961
371. Wenzel M, Würnschimmel C, Chierigo F, Mori K, Tian Z, Terrone C, **Shariat SF**, Saad F, Tilki D, Graefen M, Mandel P, Roos FC, Chun FKH, Karakiewicz PI. Pattern of Biopsy Gleason Grade Group 5 (4 + 5 vs 5 + 4 vs 5 + 5) Predicts Survival After Radical Prostatectomy or External Beam Radiation Therapy. *Eur Urol Focus*. 2021 Apr 28:S2405-4569(21)00117-6. PMID: 33933420
372. Mori K, Sasaki H, Tsutsumi Y, Sato S, Takiguchi Y, Saito S, Nishi E, Ishii G, Yamamoto T, Koike Y, Miki J, Shimomura T, Kimura T, Miki K, **Shariat SF**, Takahashi H, Aoki M, Egawa S. Trimodal therapy with high-dose-rate brachytherapy and hypofractionated external beam radiation combined with long-term androgen deprivation for unfavorable-risk prostate cancer. *Strahlenther Onkol*. 2021 Apr 28. PMID: 33909100
373. Rajwa P, Mori K, Huebner NA, Martin DT, Sprenkle PC, Weinreb JC, Ploussard G, Pradere B, **Shariat SF**, Leapman MS. The Prognostic Association of Prostate MRI PI-RADS v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-analysis. *J Urol*. 2021 PMID: 33904755
374. Laukhtina E, Pradere B, Mori K, Schuettfort VM, Quhal F, Mostafaei H, Sari Motlagh R, Aydh A, Moschini M, Enikeev D, Karakiewicz PI, Abufaraj M, **Shariat SF**; European Association of Urology-Young Academic Urologists (EAU-YAU): Urothelial carcinoma working group. Prognostic blood-based biomarkers in patients treated with neoadjuvant chemotherapy for urothelial carcinoma of the bladder: A systematic review. *Urol Oncol*. 2021 Apr 19:S1078-1439(21)00115-0. PMID: 33888424
375. Wenzel M, Würnschimmel C, Nocera L, Collà Ruvolo C, Tian Z, **Shariat SF**, Saad F, Briganti A, Tilki D, Graefen M, Kluth LA, Roos FC, Mandel P, Chun FKH, Karakiewicz PI. Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis. *Eur Urol Focus*. 2021 Apr 11:S2405-4569(21)00109-7. PMID: 33853754
376. Wenzel M, Würnschimmel C, Nocera L, Collà Ruvolo C, Tian Z, **Shariat SF**, Saad F, Briganti A, Graefen M, Becker A, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Salvage Radical Prostatectomy: Baseline Prostate Cancer Characteristics and Survival Across SEER Registries. *Clin Genitourin Cancer*. 2021 Mar 19:S1558-7673(21)00078-1. PMID: 33849813
377. Glukhov A, Potoldykova N, Taratkin M, Gordeev S, Polyakovsky K, Laukhtina E, Moschini M, Abufaraj M, **Shariat SF**, Sekacheva M, Enikeev D, Glybochko P. Detection of Urothelial Bladder Cancer Based on Urine and Tissue Telomerase Activity Measured by Novel RT-TRAP-2PCR Method. *J Clin Med*. 2021 Mar 4;10(5):1055. PMID: 33806392
378. Marcq G, Foerster B, Abufaraj M, Matin SF, Azizi M, Gupta M, Li WM, Seisen T, Clinton T, Xylinas E, Mir MC, Schweitzer D, Mari A, Kimura S, Bandini M, Mathieu R, Ku JH, Guruli G, Grabbert M, Czech AK, Muilwijk T, Pycha A, D'Andrea D, Petros FG, Spiess PE, Bivalacqua T, Wu WJ, Roupêt M, Krabbe LM, Hendricksen K, Egawa S, Briganti A, Moschini M, Graffelle V, Autorino R, John P, Heidenreich A, Chlosta P, Joniau S, Soria F, Pierorazio PM, **Shariat SF**, Kassouf W. Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify

- Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study. *Eur Urol Focus*. 2021 Mar 24:S2405-4569(21)00097-3. PMID: 33773965
379. Laukhtina E, Pradere B, D'Andrea D, Rosiello G, Luzzago S, Pecoraro A, Palumbo C, Knipper S, Karakiewicz PI, Margulis V, Quhal F, Sari Motlagh R, Mostafaei H, Mori K, Schuettfort VM, Enikeev D, **Shariat SF**. Prognostic effect of preoperative systemic immune-inflammation index in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. *Minerva Urol Nephrol*. 2021 Mar 26. PMID: 33769012
380. Awamlh BAHA, Shoag JE, Basourakos SP, Lewicki PJ, Posada L, Ma X, Raman JD, **Shariat SF**, Scherr D. The consequences of inadvertent radical nephrectomy in the treatment of upper tract urothelial carcinoma. *Urology*. 2021 Mar 22:S0090-4295(21)00255-7. doi:
381. Aydh A, Abufaraj M, Mori K, Quhal F, Pradere B, Motlagh RS, Mostafaei H, Karakiewicz PI, **Shariat SF**. Performance of fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography imaging for lymph node staging in bladder and upper tract urothelial carcinoma: a systematic review. *Arab J Urol*. 2020 Dec 10;19(1):59-66. PMID: 33763249
382. Moschini M, Zamboni S, Afferi L, Pradere B, Abufaraj M, Soria F, D'Andrea D, Roupret M, De la Taille A, Simeone C, Mattei A, Mathieu R, Bensalah K, Wirth MP, Montorsi F, Briganti A, Gallina A, Simone G, Gallucci M, Di Bona C, Marra G, Mari A, Di Trapani E, Alvarez Maestro M, Krajewski W, **Shariat SF**, Xylinas E, Baumeister P. Comparing oncological outcomes of laparoscopic vs open radical nephroureterectomy for the treatment of upper tract urothelial carcinoma: A propensity score-matched analysis. *rab J Urol*. 2020 Sep 4;19(1):31-36. PMID: 33763246
383. Laukhtina E, Abufaraj M, Al-Ani A, Ali MR, Mori K, Moschini M, Quhal F, Sari Motlagh R, Pradere B, Schuettfort VM, Mostafaei H, Katayama S, Grossmann NC, Fajkovic H, Soria F, Enikeev D, **Shariat SF**; European Association of Urology-Young Academic Urologists (EAU-YAU): Urothelial carcinoma working group. Intravesical Therapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis of Disease Recurrence. *Eur Urol Focus*. 2021 Mar 21:S2405-4569(21)00095-X. PMID: 33762203
384. Quhal F, Mori K, Bruchbacher A, Resch I, Mostafaei H, Pradere B, Schuettfort VM, Laukhtina E, Egawa S, Fajkovic H, Remzi M, **Shariat SF**, Schmidinger M. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. *Eur Urol Oncol*. 2021 Mar 20:S2588-9311(21)00045-6. PMID: 33757737
385. Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, **Shariat SF**, Saad F, Briganti A, Tilki D, Mandel P, Becker A, Kluth LA, Chun FKH, Karakiewicz PI. Incidence rates and contemporary trends in primary urethral cancer. *Cancer Causes Control*. 2021 Mar 22. PMID: 33751293
386. Schmidinger M, Resch I, Fajkovic H, Remzi M, **Shariat SF**, Bedke J. Dual immune check point blockade or immune check point-tyrosine kinase inhibitor combination: as a first-line treatment in metastatic renal cell carcinoma? *Curr Opin Urol*. 2021 May 1;31(3):270-275. PMID: 33742987
387. Mori K, Schmidinger M, Quhal F, Egawa S, **Shariat SF**, Grünwald V. What is next in second- and later-line treatment of metastatic renal cell carcinoma? review of the recent literature. *Curr Opin Urol*. 2021 May 1;31(3):276-284. PMID: 33742984
388. Abufaraj M, Al-Ani A, AlQudah A, **Shariat SF**. Surgical intervention in patients with urothelial carcinoma of the bladder and lymph node metastasis. *Curr Opin Urol*. 2021 May 1;31(3):220-225. PMID: 33742983

389. Collà Ruvolo C, Nocera L, Stolzenbach LF, Wenzel M, Califano G, Tian Z, Verze P, **Shariat SF**, Saad F, Briganti A, Mirone V, Karakiewicz PI. Tumor Size Predicts Muscle-invasive and Non-organ-confined Disease in Upper Tract Urothelial Carcinoma at Radical Nephroureterectomy. *Eur Urol Focus*. 2021 Mar 15:S2405-4569(21)00060-2. PMID: 33737024
390. Abufaraj M, Siyam A, Xu T, Imm K, Cao C, Waldoer T, Schernhammer E, **Shariat SF**, Yang L. Association Between Body Fat Mass and Kidney Stones in US Adults: Analysis of the National Health and Nutrition Examination Survey 2011-2018. *Eur Urol Focus*. 2021 Mar 15:S2405-4569(21)00067-5. PMID: 33737023
391. Abufaraj M, Xu T, Cao C, Siyam A, Isleem U, Massad A, Soria F, **Shariat SF**, Sutcliffe S, Yang L. Prevalence and trends in urinary incontinence among women in the United States 2005-2018. *Am J Obstet Gynecol*. 2021 Mar 13:S0002-9378(21)00168-X. PMID: 33727114
392. Laukhtina E, Pradere B, D'Andrea D, Rosiello G, Luzzago S, Pecoraro A, Palumbo C, Knipper S, Karakiewicz PI, Margulis V, Quhal F, Motlagh RS, Mostafaei H, Mori K, Schuettfort VM, Enikeev D, **Shariat SF**. Prognostic effect of preoperative serum albumin to globulin ratio in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. *Transl Androl Urol*. 2021 Feb;10(2):609-619. PMID: 33718063
393. D'Andrea D, Soria F, Grotenhuis AJ, Cha EK, Malats N, Di Stasi S, Joniau S, Cai T, van Rhijn BWG, Irani J, Karnes J, Varkarakis J, Baniel J, Palou J, Babjuk M, Spahn M, Ardelt P, Colombo R, Serretta V, Dalbagni G, Gontero P, Bartoletti R, Larré S, Malmstrom PU, Sylvester R, **Shariat SF**. Association of patients' sex with treatment outcomes after intravesical bacillus Calmette-Guérin immunotherapy for T1G3/HG bladder cancer. *World J Urol*. 2021 Mar 13. PMID: 33713162
394. Collà Ruvolo C, Stolzenbach LF, Nocera L, Deuker M, Wenzel M, Tian Z, La Rocca R, Creta M, Capece M, Saad F, **Shariat SF**, Tilki D, Briganti A, Mirone V, Karakiewicz PI. Higher Cancer Mortality in Rural Upper Urinary Tract Urothelial Carcinoma Patients. *Urol Int*. 2021 Mar 12:1-7. PMID: 33709970
395. Rajwa P, Pradere B, Mori K, Ploussard G, Leapman MS, **Shariat SF**. Association of Negative Follow-Up Biopsy and Reclassification during Active Surveillance of Prostate Cancer: A Systematic Review and meta-Analysis. *J Urol*. 2021 PMID: 33683937
396. Wenzel M, Nocera L, Ruvolo CC, Würnschimmel C, Tian Z, **Shariat SF**, Saad F, Briganti A, Tilki D, Graefen M, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Racial/Ethnic Disparities in Tumor Characteristics and Treatments in Favorable and Unfavorable Intermediate Risk Prostate Cancer. *J Urol*. 2021 PMID: 33683934
397. Sari Motlagh R, Mori K, Laukhtina E, Aydh A, Katayama S, Grossmann NC, Mostafai H, Pradere B, Quhal F, Schuettfort VM, Roshandel MR, Karakiewicz PI, Teoh J, **Shariat SF**, Fajkovic H. Impact of enhanced optical techniques at time of TURBT with or without single immediate intravesical chemotherapy on recurrence rate of NMIBC, a systematic review and network meta-analysis of randomized trials. *BJU Int*. 2021 Mar 8. PMID: 33683778
398. Mostafaei H, Janisch F, Mori K, Quhal F, Pradere B, Hajebrahimi S, Roehrborn CG, **Shariat SF**. Placebo Response in Patients with Oral Therapy for Overactive Bladder: A Systematic Review and Meta-analysis. *Eur Urol Focus*. 2021 Mar 2:S2405-4569(21)00048-1. PMID: 33674256
399. Miura N, Mori K, Laukhtina E, Schuettfort VM, Abufaraj M, Teoh JYC, Luzzago S, Stolzenbach F, Deuker M, Karakiewicz PI, Briganti A, Enikeev DV, Rouprêt M, Margulis V, Chlosta P, Nyirady P, Babjuk M, Egawa S, Saika T, **Shariat SF**. Prognostic value of the preoperative albumin-globulin ratio in patients with upper urinary tract urothelial carcinoma treated with radical

- nephroureterectomy: results from a large multicenter international collaboration. *Jpn J Clin Oncol*. 2021 Feb 27. PMID: 33667307
400. Wenzel M, Würnschimmel C, Nocera L, Collà Ruvolo C, Tian Z, **Shariat SF**, Saad F, Briganti A, Graefen M, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. The effect of lymph node dissection on cancer-specific survival in salvage radical prostatectomy patients. *Prostate*. 2021 Mar 5. PMID: 33666271
 401. Nocera L, Collà Ruvolo C, Stolzenbach LF, Wenzel M, Tian Z, Larcher A, Capitanio U, Mirone V, Tilki D, Chun FKH, Kapoor A, **Shariat SF**, Saad F, Montorsi F, Briganti A, Karakiewicz PI. Tumor stage and substage predict cancer-specific mortality after nephrectomy for nonmetastatic renal cancer: histological subtype-specific validation. *Eur Urol Focus*. 2021 Feb 27:S2405-4569(21)00052-3. PMID: 33653677
 402. Schuettfort VM, Andrea DD, Quhal F, Mostafaei H, Laukhtina E, Mori K, König F, Rink M, Abufaraj M, Karakiewicz PI, Luzzago S, Rouprêt M, Enikeev D, Zimmermann K, Deuker M, Moschini M, Sari Motlagh R, Grossmann NC, Katayama S, Pradere B, **Shariat SF**. A Panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma. *BJU Int*. 2021 Mar 1. PMID: 33650265
 403. Janisch F, Klotzbücher T, Marks P, Kienapfel C, Meyer CP, Yu H, Fühner C, Hillemacher T, Mori K, Mostafaei H, **Shariat SF**, Fisch M, Dahlem R, Rink M. Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors. *World J Urol*. 2021 Mar 1. PMID: 33649869
 404. Kardoust Parizi M, Margulis V, Lotan Y, Mori K, **Shariat SF**. Fibroblast growth factor receptor: A systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma. *Urol Oncol*. 2021 Feb 25:S1078-1439(21)00048-X. PMID: 33642228.
 405. Collà Ruvolo C, Würnschimmel C, Wenzel M, Nocera L, Califano G, Tian Z, **Shariat SF**, Saad F, Chun FKH, Briganti A, Verze P, Imbimbo C, Mirone V, Karakiewicz PI. Comparison between 1973 and 2004/2016 WHO grading systems in patients with Ta urothelial carcinoma of urinary bladder. *J Clin Pathol*. 2021 Feb 23. PMID: 33622681
 406. Würnschimmel C, Ruvolo CC, Nocera L, Wenzel M, Tian Z, Saad F, Briganti A, **Shariat SF**, Mirone V, Chun FKH, Tilki D, Graefen M, Karakiewicz PI. Race/Ethnicity Determines Life Expectancy in Surgically Treated T1aN0M0 Renal Cell Carcinoma Patients. *Eur Urol Focus*. 2021. PMID: 33610487
 407. Pecoraro A, Deuker M, Rosiello G, Stolzenbach F, Luzzago S, Tian Z, **Shariat SF**, Saad F, Briganti A, Kapoor A, Fiori C, Porpiglia F, Karakiewicz PI. Comparison between small renal masses 0-2 cm vs. 2.1-4 cm in size: A population-based study. *Urol Oncol*. 2021 Apr;39(4):239. PMID: 33602621
 408. Wenzel M, Deuker M, Nocera L, Collà Ruvolo C, Tian Z, **Shariat SF**, Saad F, Briganti A, Becker A, Kluth LA, Chun FKH, Karakiewicz PI. Comparison between urothelial and non-urothelial urethral cancer. *Front Oncol*. 2021 Jan 29;10:629692. PMID: 33585257
 409. Mori K, Resch I, Miura N, Laukhtina E, Schuettfort VM, Pradere B, Katayama S, D'Andrea D, Kardoust Parizi M, Abufaraj M, Fukuokaya W, Collà Ruvolo C, Luzzago S, Knipper S, Palumbo C, Karakiewicz PI, Briganti A, Enikeev DV, Rouprêt M, Margulis V, Egawa S, **Shariat SF**. Prognostic role of the systemic immune-inflammation index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration. *Cancer Immunol Immunother*. 2021 Feb 16. PMID: 33591412

410. Zhao C, Bjurlin MA, Roberts T, Rink M, **Shariat SF**, Matulewicz RS. A Systematic Review and Scoping Analysis of Smoking Cessation after a Urological Cancer Diagnosis. *J Urol*. 2021 Feb 12. PMID: 33577364
411. Deuker M, Rosiello G, Stolzenbach LF, Martin T, Collà Ruvolo C, Nocera L, Tian Z, Roos FC, Becker A, Kluth LA, Tilki D, **Shariat SF**, Saad F, Chun FKH, Karakiewicz PI. Sex- and age-related differences in the distribution of metastases in patients with upper urinary tract urothelial carcinoma. *J Natl Compr Canc Netw*. 2021 Feb 11:1-7. PMID: 33571954
412. Krajewski W, Nowak Ł, Moschini M, Poletajew S, Chorbińska J, Necchi A, Montorsi F, Briganti A, Sanchez-Salas R, **Shariat SF**, Palou J, Babjuk M, Teoh JY, Soria F, Pradere B, Ornaghi PI, Pawlak A, Dembowski J, Zdrojowy R. Impact of adjuvant chemotherapy on survival of patients with advanced residual disease at radical cystectomy following neoadjuvant chemotherapy: systematic review and meta-analysis. *J Clin Med*. 2021 Feb 8;10(4):651. PMID: 33567656
413. Rosiello G, Palumbo C, Deuker M, Stolzenbach LF, Martin T, Tian Z, Gallina A, Montorsi F, Black P, Kassouf W, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Sex- and age-related differences in the distribution of bladder cancer metastases. *Jpn J Clin Oncol*. 2021. PMID: 33558890
414. Rosiello G, Palumbo C, Deuker M, Stolzenbach LF, Martin T, Tian Z, Gallina A, Montorsi F, Black P, Kassouf W, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Racial differences in the distribution of bladder cancer metastases: a population-based analysis. *Cent European J Urol*. 2020;73(4):407-415. PMID: 33552564
415. Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, **Shariat SF**, Saad F, Briganti A, Tilki D, Mandel P, Kluth LA, Chun FKH, Karakiewicz PI. Sex-Related Differences Include Stage, Histology, and Survival in Urethral Cancer Patients. *Clin Genitourin Cancer*. 2021 PMID: 33526327
416. Rosiello G, Pecoraro A, Deuker M, Stolzenbach LF, Martin T, Tian Z, Larcher A, Capitanio U, Montorsi F, **Shariat SF**, Kapoor A, Saad F, Briganti A, Karakiewicz PI. The impact of sex and age on distribution of metastases in patients with renal cell carcinoma. *Int J Clin Oncol*. 2021 Jan 30. PMID: 33515351
417. Khene ZE, Dosin G, Peyronnet B, Gasmi A, Doumerc N, Ouzaid I, Pradere B, Brassier M, Roumiguié M, Mathieu R, Rioux-Leclercq N, Raman JD, **Shariat S**, Bensalah K. Adherent perinephric fat affects perioperative outcomes after partial nephrectomy: a systematic review and meta-analysis. *Int J Clin Oncol*. 2021 Jan 27. PMID: 33502646
418. Quhal F, Pradere B, Laukhtina E, Sari Motlagh R, Mostafaei H, Mori K, Schuettfort VM, Karakiewicz PI, Rouprêt M, Enikeev D, Rink M, Abufaraj M, **Shariat SF**. Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer. *World J Urol*. 2021 Jan 26. PMID: 33496841
419. Grossmann NC, Schuettfort VM, Pradere B, Moschini M, Quhal F, Mostafaei H, Soria F, Katayama S, Laukhtina E, Mori K, Sari Motlagh R, Poyet C, Abufaraj M, Karakiewicz PI, **Shariat SF**, D'Andrea D. Further understanding of urokinase plasminogen activator overexpression in urothelial bladder cancer progression, clinical outcomes and potential therapeutic targets. *Onco Targets Ther*. 2021 Jan 13;14:315-324. PMID: 33488094
420. Lemberger U, Quhal F, Bruchbacher A, **Shariat SF**, Hiess M. The microbiome in urinary tract infections in children - an update. *Eur Urol*. 2021 Jan 21:S0302-2838(21)00017-8. PMID: 33487477
Curr Opin Urol. 2021 Mar 1;31(2):147-154. PMID: 33449574

421. Motlagh RS, Abufaraj M, Yang L, Mori K, Pradere B, Laukhtina E, Mostafaei H, Schuettfort V, Quhal F, Montorsi F, Amjadi M, Gratzke C, **Shariat SF**. Penile Rehabilitation Strategy after Nerve Sparing Radical Prostatectomy: A Systematic Review and Network Meta-Analysis of Randomized Trials. *J Urol*. 2021 Jan 14;. PMID: 33443457
422. Abufaraj M, Siyam A, Ali MR, Suarez-Ibarrola R, Yang L, Foerster B, **Shariat SF**. Functional Outcomes after Local Salvage Therapies for Radiation-Recurrent Prostate Cancer Patients: A Systematic Review. *Cancers (Basel)*. 2021 Jan 11;13(2):244. PMID: 33440752
423. Afferi L, Abufaraj M, Soria F, D'Andrea D, Xylinas E, Seisen T, Roupert M, Lonati C, De la Taille A, Peyronnet B, Laukhtina E, Pradere B, Mari A, Krajewski W, Alvarez-Maestro M, Kikuchi E, Shigeta K, Chlosta P, Montorsi F, Briganti A, Simone G, Ornaghi PI, Cerruto MA, Antonelli A, Matsumoto K, Karakiewicz PI, Mordasini L, Mattei A, **Shariat SF**, Moschini M. A comparison of perioperative outcomes of laparoscopic versus open nephroureterectomy for upper tract urothelial carcinoma: a propensity score matching analysis. *Minerva Urol Nefrol*. 2021 Jan 13. PMID: 33439575
424. Luzzago S, Palumbo C, Rosiello G, Pecoraro A, Deuker M, Stolzenbach F, Mistretta FA, Tian Z, Musi G, Montanari E, **Shariat SF**, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. Metabolic syndrome predicts worse perioperative outcomes in patients treated with radical prostatectomy for non-metastatic prostate cancer. *Surg Oncol*. 2021 Jan 3;37:101519. PMID: 33429324
425. van Rhijn BWG, Hentschel AE, Bründl J, Compérat EM, Hernández V, Čapoun O, Bruins HM, Cohen D, Roupert M, **Shariat SF**, Mostafid AH, Zigeuner R, Dominguez-Escrig JL, Burger M, Soukup V, Gontero P, Palou J, van der Kwast TH, Babjuk M, Sylvester RJ; Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. *Eur Urol Oncol*. 2021 Jan 8:S2588-9311(20)30210-8. PMID: 33423944
426. Laukhtina E, Pradere B, Mori K, Schuettfort VM, Quhal F, Mostafaei H, Sari Motlagh R, Katayama S, Grossmann NC, Moschini M, Enikeev D, **Shariat SF**. Catalog of prognostic tissue-based biomarkers in patients treated with neoadjuvant systemic therapy for urothelial carcinoma of the bladder: a systematic review. *Urol Oncol*. 2021 Jan 7:S1078-1439(20)30647-5. PMID: 33423937.
427. Schmidinger M, **Shariat SF**, Fajkovic H. Dual immune checkpoint inhibition in metastatic renal cell carcinoma: Editorial re.: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced RCC: extended 4-year follow-up of the phase III CheckMate 214 trial. *ESMO Open*. 2021 Jan 6;6(1):100035. PMID: 33421736
428. Sylvester RJ, Rodríguez O, Hernández V, Turturica D, Bauerová L, Bruins HM, Bründl J, van der Kwast TH, Brisuda A, Rubio-Briones J, Seles M, Hentschel AE, Kusuma VRM, Huebner N, Cotte J, Mertens LS, Volanis D, Cussenot O, Subiela Henríquez JD, de la Peña E, Pisano F, Pešl M, van der Heijden AG, Herdegen S, Zlotta AR, Hacek J, Calatrava A, Mannweiler S, Bosschieter J, Ashabere D, Haitel A, Côté JF, El Sheikh S, Lunelli L, Algaba F, Alemany I, Soria F, Runneboom W, Breyer J, Nieuwenhuijzen JA, Llorente C, Molinaro L, Hulsbergen-van de Kaa CA, Evert M, Kiemeny LALM, N'Dow J, Plass K, Čapoun O, Soukup V, Dominguez-Escrig JL, Cohen D, Palou J, Gontero P, Burger M, Zigeuner R, Mostafid AH, **Shariat SF**, Roupert M, Compérat EM, Babjuk M, van Rhijn BWG. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. *Eur Urol*. 2021 Jan 6:S0302-2838(20)31019-8. PMID: 33419683

429. Luzzago S, Rosiello G, Pecoraro A, Deuker M, Stolzenbach F, Mistretta FA, Tian Z, Musi G, Montanari E, **Shariat SF**, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. Contemporary rates and predictors of open conversion during minimally invasive partial nephrectomy for kidney cancer. *Surg Oncol.* 2021 Mar;36:131-137. PMID: 33401103
430. Sfakianos JP, Gul Z, **Shariat SF**, Matin SF, Daneshmand S, Plimack E, Lerner S, Roupret M, Pal S. Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy. *Eur Urol Oncol.* 2020 Dec 30:S2588-9311(20)30215-7. PMID: 33386276
431. Mori K, Sharma V, Comperat EM, Sato S, Laukhtina E, Schuettfort VM, Pradere B, Parizi MK, Karakiewicz PI, Egawa S, Tilki D, Boorjian SA, **Shariat SF**. Differential prognostic impact of different Gleason patterns in grade group 4 in radical prostatectomy specimens. *Eur J Surg Oncol.* 2020 Dec 24:S0748-7983(20)31235-X. PMID: 33371950
432. Deuker M, Stolzenbach LF, Collà Ruvolo C, Nocera L, Tian Z, Roos FC, Becker A, Kluth LA, Tilki D, **Shariat SF**, Saad F, Chun FKH, Karakiewicz PI. Upper Urinary Tract Tumors: Variant Histology Versus Urothelial Carcinoma. *Clin Genitourin Cancer.* 2020 Dec 2:S1558-7673(20)30265-2. PMID: 33358490
433. Woldu SL, Ng CK, Loo RK, Slezak JM, Jacobsen SJ, Tan WS, Kelly JD, Lough T, Darling D, van Kessel KEM, de Jong JJ, van Criekinge W, **Shariat SF**, Hiar A, Brown S, Boorjian SA, Barocas DA, Svatek RS, Lotan Y. Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria. *J Urol.* 2020 Dec 24: PMID: 33356483
434. Papp L, Spielvogel CP, Grubmüller B, Grahovac M, Krajnc D, Ecsedi B, Saresghi RAM, Mohamad D, Hamboeck M, Rausch I, Mitterhauser M, Wadsak W, Haug AR, Kenner L, Mazal P, Susani M, Hartenbach S, Baltzer P, Helbich TH, Kramer G, **Shariat SF**, Beyer T, Hartenbach M, Hacker M. Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [68Ga]Ga-PSMA-11 PET/MRI. *Eur J Nucl Med Mol Imaging.* 2020 Dec 19. PMID: 33341915
435. Wenzel M, Deuker M, Stolzenbach F, Nocera L, Collà Ruvolo C, Tian Z, **Shariat SF**, Saad F, Briganti A, Kluth LA, Chun FKH, Karakiewicz PI. The effect of race/ethnicity on histological subtype distribution, stage at presentation and cancer specific survival in urethral cancer. *Urol Oncol.* 2020 Dec 10:S1078-1439(20)30618-9. PMID: 33309509
436. Ziouziou I, **Shariat SF**, Ajdi F, Khabbal Y.: Association of Processed Meats and Alcohol Consumption with Renal Cell Carcinoma: A Worldwide Population-Based Study. *Nutr Cancer.* 2020. PMID: 33283531
437. Huebner NA, Korn S, Resch I, Grubmüller B, Gross T, Gale R, Kramer G, Poetsch N, Clauser P, Haitel A, Fajkovic H, **Shariat SF**, Baltzer PA.: Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)-do we still need contrast media? *Eur Radiol.* 2020. PMID: 33263793
438. Mostafaei H, Mori K, Hajebrahimi S, Abufaraj M, Karakiewicz PI, **Shariat SF**.: Association of erectile dysfunction and cardiovascular diseases: an umbrella review of systematic reviews and meta-analyses. *BJU Int.* 2020. PMID: 33260254.
439. Huebner NA, **Shariat SF**.: Clinical Impact and Statistical Significance of Multiparametric Magnetic Resonance Imaging for Local Staging of Prostate Cancer. *Eur Urol.* 2020. PMID: 33246667.
440. Deuker M, Stolzenbach LF, Collà Ruvolo C, Nocera L, Tian Z, Roos FC, Becker A, Kluth LA, Tilki D, **Shariat SF**, Saad F, Chun FKH, Karakiewicz PI.: Bladder cancer stage and mortality: urban vs. rural residency. *Cancer Causes Control.* 2020. PMID: 33230694

441. Schuettfort VM, D Andrea D, Quhal F, Mostafaei H, Laukhtina E, Mori K, Sari Motlagh R, Rink M, Abufaraj M, Karakiewicz PI, Luzzago S, Rouprêt M, Chlosta P, Babjuk M, Deuker M, Moschini M, **Shariat SF**, Pradere B. Impact of Preoperative Serum Albumin-Globulin Ratio on Disease Outcome After Radical Cystectomy for Urothelial Carcinoma of the Bladder. *Urol Oncol*. 2020.PMID: 33189530
442. Mori K, Abufaraj M, Mostafaei H, Quhal F, Fajkovic H, Remzi M, Karakiewicz PI, Egawa S, Schmidinger M, **Shariat SF**, Gust KM. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis.*Eur Urol*. 2020 Nov 7:S0302-2838(20)30783-1. PMID: 33172722
443. Rosiello G, Pecoraro A, Luzzago S, Deuker M, Stolzenbach LF, Tian Z, Larcher A, Capitanio U, Montorsi F, **Shariat SF**, Kapoor A, Saad F, Briganti A, Karakiewicz PI. Prognostic factors in patients with small renal masses: a comparison between <2 vs. 2.1-4 cm renal cell carcinomas. *Cancer Causes Control*. 2020 Nov 9. PMID: 33169306
444. Nocera L, Stolzenbach LF, Ruvolo CC, Wenzel M, Tian Z, Rosiello G, Bravi CA, Candela L, Basile G, Larcher A, **Shariat SF**, Bertini R, Capitanio U, Salonia A, Montorsi F, Briganti A, Karakiewicz PI. Predicting the risk of pT3a stage in cT1 clear cell renal cell carcinoma. *Eur J Surg Oncol*. 2020 Nov 5:S0748-7983(20)30877-5. PMID: 33168336
445. Tellini R, Mari A, Muto G, Cacciamani GE, Ferro M, Stangl-Kremser J, Campi R, Soria F, Rink M, Xylinas E, Minervini A, Briganti A, Montorsi F, Roupert M, **Shariat SF**, Moschini M; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU). Impact of Smoking Habit on Perioperative Morbidity in Patients Treated with Radical Cystectomy for Urothelial Bladder Cancer: A Systematic Review and Meta-analysis. *Eur Urol Oncol*. 2020 Nov 4:S2588-9311(20)30171-1. PMID: 33160975
446. Roumiguie M, Brisuda A, Burger M, Escrig J, Hammerer P, Mccracken S, Mostafid H, Muto G, Redorta J, de Reijke T, **Shariat S**, Ströck V, Malavaud B. Un patient sur quatre ressent un inconfort significatif lors des cystoscopies de surveillance (TVNIM) dans une étude observationnelle européenne.*Prog Urol*. 2020 Nov;30(13):830-831. PMID: 33157794
447. Khene Z, Brassier M, Kokorian R, Mathieu R, Peyronnet B, Gasmi A, Rioux-Leclercq N, Kammerer-Jacquet S, **Shariat S**, Pradere B, Laguerre B, Bensalah K. Carcinome à cellules claire métastatique : la radiomique comme biomarqueur prédictif de la survie des patients traités par nivolumab. *Prog Urol*. 2020 Nov;30(13):818. PMID: 33157774
448. Khene Z, Brassier M, Mathieu R, Kokorian R, Gasmi A, Peyronnet B, Khene F, Rioux-Leclercq N, **Shariat S**, Laguerre B, Bensalah K. L'apprentissage machine peut prédire la réponse tumorale chez les patients traités par nivolumab pour un carcinome rénal métastatique – Un concept d'intelligence artificielle. *Prog Urol*. 2020 Nov;30(13):787-788. PMID: 33157724
449. Mazouin C, Khene Z, Peyronnet B, Gasmi A, Dosin G, Brassier M, Thi Dang V, Ouzaid I, Larcher A, Roumiguie M, Verhoest G, Pradère B, **Shariat S**, Mathieu R, Bigot P, Doumerc N, Bensalah K. Prédire la morbidité de la néphrectomie partielle : retour à la simplicité. *Prog Urol*. 2020 Nov;30(13):748-749. PMID: 33157662
450. Mostafaei H, Mori K, Quhal F, Miura N, Motlagh RS, Pradere B, Laukhtina E, Lysenko I, Ghaffari S, Hajebrahimi S, **Shariat SF**. Nocebo Response in the Pharmacological Management of Overactive Bladder: A Systematic Review and Meta-analysis. *Eur Urol Focus*. 2020 Nov 2:S2405-4569(20)30294-7. PMID: 33153953

451. Stolzenbach LF, Rosiello G, Pecoraro A, Palumbo C, Luzzago S, Deuker M, Tian Z, Knipper AS, Pompe R, Zorn KC, **Shariat SF**, Chun FKH, Graefen M, Saad F, Karakiewicz PI. Prostate Cancer Grade and Stage Misclassification in Active Surveillance Candidates: Black Versus White Patients. *J Natl Compr Canc Netw*. 2020 Nov 2;18(11):1492-1499. PMID: 33152695
452. Soria F, Black PC, Fairey AS, Cookson MS, Yu EY, Kassouf W, Dall'Era MA, Sridhar SS, McGrath JS, Wright JL, Thorpe AC, Morgan TM, Daneshmand S, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Spiess PE, **Shariat SF**, Gontero P. Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis. *BJU Int*. 2020 Nov 5. PMID: 33152179
453. Ziouziou I, Touzani AM, Lahlou L, **Shariat SF**, Sanguedolce F, Neuzillet Y, Ajdi F, Khabbal Y. Association of Prostate Cancer with Nuts, Seeds, Alcohol and Processed Meats: A Worldwide Population-Based Study. *Nutr Cancer*. 2020 Nov 5:1-8. PMID: 33148052
454. Rasul S, Hartenbach M, Wollenweber T, Kretschmer-Chott E, Grubmüller B, Kramer G, **Shariat S**, Wadsak W, Mitterhauser M, Pichler V, Vranka C, Hacker M, Haug AR. Prediction of response and survival after standardized treatment with 7400 MBq ¹⁷⁷Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer. *Eur J Nucl Med Mol Imaging*. 2020 Oct 30. PMID: 33128131
455. Kardoust Parizi M, **Shariat SF**, Margulis V, Mori K, Lotan Y. Value of tumour-infiltrating immune cells in predicting response to intravesical BCG in patients with non-muscle-invasive bladder cancer: a systematic review and meta-analysis. *BJU Int*. 2020 Oct 18. PMID: 33073457.
456. Schuettfort VM, Pradere B, Quhal F, Mostafaei H, Laukhtina E, Mori K, Motlagh RS, Rink M, D'Andrea D, Abufaraj M, Karakiewicz PI, **Shariat SF**. Diagnostic challenges and treatment strategies in the management of upper-tract urothelial carcinoma. *Turk J Urol*. 2020 Oct 9. PMID: 33052841
457. Foerster B, Abufaraj M, Mari A, Seisen T, Bandini M, Schweitzer D, Czech AK, Moschini M, D'Andrea D, Bianchi M, Hendricksen K, Rouprêt M, Briganti A, van Rhijn BWG, Chłosta P, Colin P, John H, **Shariat SF**. The Performance of Tumor Size as Risk Stratification Parameter in Upper Tract Urothelial Carcinoma (UTUC). *Clin Genitourin Cancer*. 2020 Sep 18:S1558-7673(20)30218-4. PMID: 33046411
458. Szarvas T, Csizmarik A, Váradi M, Fazekas T, Hüttl A, Nyirády P, Hadaschik B, Grünwald V, Tschirdewahn S, **Shariat SF**, Sevcenco S, Maj-Hes A, Kramer G. The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy. *Urol Oncol*. 2020 Oct 9:S1078-1439(20)30436-1. PMID: 33046366
459. Rosiello G, Palumbo C, Pecoraro A, Luzzago S, Deuker M, Stolzenbach LF, Tian Z, Gallina A, Gandaglia G, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. The effect of sex on disease stage and survival after radical cystectomy: a population-based analysis. *Urol Oncol*. 2020 Oct 6:S1078-1439(20)30435-X. PMID: 33036900
460. Aksoy O, Pencik J, Hartenbach M, Moazzami AA, Schleder M, Balber T, Varady A, Philippe C, Baltzer PA, Mazumder B, Whitchurch JB, Roberts CJ, Haitel A, Herac M, Susani M, Mitterhauser M, Marculescu R, Stangl-Kremser J, Hassler MR, Kramer G, **Shariat SF**, Turner SD, Tichy B, Oppelt J, Pospisilova S, Hartenbach S, Tangermann S, Egger G, Neubauer HA, Moriggl R, Culig Z, Greiner G, Hoermann G, Hacker M, Heery DM, Merkel O, Kenner L. Thyroid and androgen receptor signaling are antagonized by μ -Crystallin in prostate cancer. *Int J Cancer*. 2020 Oct 9. PMID: 33034050

461. Pecoraro A, Rosiello G, Luzzago S, Deuker M, Stolzenbach F, Tian Z, **Shariat SF**, Saad F, Briganti A, Kapoor A, Fiori C, Porpiglia F, Karakiewicz PI. Small Renal Masses With Tumor Size 0 to 2 cm: A SEER-Based Study and Validation of NCCN Guidelines. *J Natl Compr Canc Netw*. 2020 Oct 1;18(10):1340-1347. PMID: 33022641
462. Moschini M, Afferi L, Gandaglia G, D'Andrea D, Zamboni S, Di Bona C, Mordasini L, Mattei A, Baumeister P, Martini A, Burgio G, **Shariat SF**, Sanchez-Salas R, Cathelineau X, Stabile A, Zaffuto E, Salonia A, Colombo R, Necchi A, Montorsi F, Briganti A, Gallina A. Prediction of the Need for an Extended Lymphadenectomy at the Time of Radical Cystectomy in Patients with Bladder Cancer. *Eur Urol Focus*. 2020 Oct 2:S2405-4569(20)30268-6. PMID: 33020030
463. Schuettfort VM, Pradere B, Quhal F, Mostafaei H, Laukhtina E, Mori K, Sari Motlagh R, Fisch M, D'Andrea D, Rink M, Gontero P, Soria F, **Shariat SF**. Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis. *World J Urol*. 2020 Sep 29. PMID: 32995918
464. Palumbo C, Mazzone E, Mistretta FA, Knipper S, Tian Z, Perrotte P, Montorsi F, **Shariat SF**, Saad F, Simeone C, Briganti A, Antonelli A, Karakiewicz PI. Primary lymphomas of the genitourinary tract: A population-based study. *Asian J Urol*. 2020 Oct;7(4):332-339. PMID: 32995277
465. Grubmüller B, Jahrreiss V, Huebner N, Mitterhauser M, Stangl-Kremser J, Grubmüller KH, Baltzer P, Hacker M, Goldner G, **Shariat SF**, Rasul S. Differential impact of radiation therapy after radical prostatectomy on recurrence patterns: an assessment using [68Ga]Ga-PSMA ligand PET/CT(MRI). *Prostate Cancer Prostatic Dis*. 2020 Sep 29. PMID: 32994534
466. Quhal F, Pradere B, Sari Motlagh R, Mori K, Laukhtina E, Aydh A, Mostafaei H, Lysenko I, Schuettfort VM, Stolzenbach F, Palumbo C, Heidenreich A, Briganti A, Karakiewicz PI, Chlosta P, **Shariat SF**. Prognostic value of preoperative albumin to globulin ratio in patients treated with salvage radical prostatectomy for radiation recurrent prostate cancer. *Minerva Urol Nefrol*. 2020 Sep 29. doi: 10.23736/S0393-2249.20.03938-7. PMID: 32993278
467. D'Andrea D, Pradere B, **Shariat SF**. Re: Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial. *Eur Urol*. 2020 Sep 24:S0302-2838(20)30632-1. PMID: 32981804.
468. D'Andrea D, Matin S, Black PC, Petros FG, Zargar H, Dinney CP, Cookson MS, Kassouf W, Dall'Era MA, McGrath JS, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, Sridhar SS, North S, Barocas DA, Lotan Y, Stephenson AJ, van Rhijn BW, Spiess PE, Daneshmand S, **Shariat SF**. Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. *BJU Int*. 2020 Sep 27. PMID: 32981193
469. Luzzago S, Knipper S, Palumbo C, Rosiello G, Pecoraro A, Deuker M, Mistretta FA, Tian Z, Musi G, Montanari E, **Shariat SF**, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. Effect of Age on Cancer-specific Mortality in Patients With Urothelial Carcinoma of the Urinary Bladder: A Population-based Competing-risks Analysis Across Disease Stages. *Am J Clin Oncol*. 2020 Sep 23. PMID: 32976177
470. Teoh JY, Huang J, Ko WY, Lok V, Choi P, Ng CF, Sengupta S, Mostafid H, Kamat AM, Black PC, **Shariat S**, Babjuk M, Wong MC. Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita. *Eur Urol*. 2020 Sep 21:S0302-2838(20)30697-7. PMID: 32972792.
471. Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U, Bögemann M, Bamias A, Eigl BJ, Gurney H, Mukherjee SD, Fradet Y, Skoneczna I, Tsiatas M, Novikov A, Suárez C, Fay AP, Duran I, Necchi A, Wildsmith S, He P,

- Angra N, Gupta AK, Levin W, Bellmunt J; DANUBE study investigators. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. *Lancet Oncol*. 2020 Sep 21:S1470-2045(20)30541-6. PMID: 32971005.
472. Deuker M, Stolzenbach LF, Collà Ruvolo C, Nocera L, Mansour M, Tian Z, Roos FC, Becker A, Kluth LA, Tilki D, **Shariat SF**, Saad F, Chun FKH, Karakiewicz PI. Micropapillary Versus Urothelial Carcinoma of the Urinary Bladder: Stage at Presentation and Efficacy of Chemotherapy Across All Stages-A SEER-based Study. *Eur Urol Focus*. 2020 Sep 19:S2405-4569(20)30223-6. PMID: 32962961.
473. Laukhtina E, Pradere B, D Andrea D, Rosiello G, Luzzago S, Pecoraro A, Palumbo C, Knipper S, Karakiewicz PI, Margulis V, Quhal F, Sari Motlagh R, Mostafaei H, Mori K, Kimura S, Enikeev D, **Shariat SF**. Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. *Urol Oncol*. 2020 Sep 19:S1078-1439(20)30380-X. PMID: 32962909.
474. Benamran D, Seisen T, Naoum E, Vaessen C, Parra J, Mozer P, **Shariat SF**, Rouprêt M. Risk stratification for upper tract urinary carcinoma. *Transl Androl Urol*. 2020 Aug;9(4):1799-1808. PMID: 32944543; PMCID: PMC7475669.
475. Kocher NJ, Canes D, Bensalah K, Roupert M, Lallas C, Margulis V, **Shariat S**, Colin P, Matin S, Tracy C, Xylinas E, Wagner A, Roumiguie M, Kassouf W, Klatter T, Raman JD. Incidence and preoperative predictors for major complications following radical nephroureterectomy. *Transl Androl Urol*. 2020 Aug;9(4):1786-1793. PMID: 32944541
476. Mun DH, Pradere B, **Shariat SF**, Remzi M. Intraoperative aerosol viral transmission in minimally invasive surgery: A scoping review and impact on clinical guidelines and practice during the onset of the COVID-19 pandemic. *BJU Int*. 2020 Sep 16. PMID: 32937006.
477. Baboudjian M, Ploussard G, **Shariat SF**, Ost P, Briganti A, Roupert M, Pradere B. How to deal with steroids use in the management of metastatic prostate cancer during pandemic. *Transl Androl Urol*. 2020 Aug;9(4):1546-1549. PMID: 32944516; PMCID: PMC7475678.
478. Enikeev D, Traxer O, Taratkin M, Okhunov Z, **Shariat S**. A review of thulium-fiber laser in stone lithotripsy and soft tissue surgery. *Curr Opin Urol*. 2020 Sep 10. PMID: 32925311.
479. Mori K, Mostafaei H, Pradere B, Motlagh RS, Quhal F, Laukhtina E, Schuetthfort VM, Abufaraj M, Karakiewicz PI, Kimura T, Egawa S, **Shariat SF**. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. *Int J Clin Oncol*. 2020 Sep 14. PMID: 32924096.
480. Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. *N Engl J Med*. 2020 Sep 10;383(11):1040-1049. PMID: 32905676.
481. Abufaraj M, Xu T, Cao C, Waldhoer T, Seitz C, D'andrea D, Siyam A, Tarawneh R, Fajkovic H, Schernhammer E, Yang L, **Shariat SF**. Prevalence and trends in kidney stone among adults in the usa: analyses of national health and nutrition examination survey 2007-2018 Data. *Eur Urol Focus*. 2020 Sep 5:S2405-4569(20)30224-8. PMID: 32900675.
482. Kardoust Parizi M, Margulis V, Compe Rat E, **Shariat SF**. The value and limitations of urothelial bladder carcinoma molecular classifications to predict oncological outcomes and cancer treatment

- response: A systematic review and meta-analysis. *Urol Oncol*. 2020 Sep 5:S1078-1439(20)30389-6. PMID: 32900624.
483. Gild P, Vetterlein MW, Seiler R, Necchi A, Hendricksen K, Mertens LS, Roghmann F, Landenberg NV, Gontero P, Cumberbatch M, Dobruch J, Seisen T, Grande P, D'Andrea D, Anract J, Comploj E, Pycha A, Saba K, Poyet C, van Rhijn BW, Noon AP, Roupret M, **Shariat SF**, Fisch M, Xylinas E, Rink M. The association of cigarette smoking and pathological response to neoadjuvant platinum-based chemotherapy in patients undergoing treatment for urinary bladder cancer – A prospective European multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial carcinoma working group. *Surg Oncol*. 2020 Sep;34:312-317. PMID: 32891350.
484. Schuettfort VM, Pradere B, Rink M, Comperat E, **Shariat SF**. Pathomics in urology. *Curr Opin Urol*. 2020 Sep 15. PMID: 32881725.
485. Sari Motlagh R, Quhal F, Mori K, Miura N, Aydh A, Laukhtina E, Pradere B, Karakiewicz PI, Enikeev DV, Deuker M, **Shariat SF**. The risk of new onset dementia and/or alzheimer's disease among prostate cancer patients treated with androgen deprivation therapy: a systematic review and meta-analysis. *J Urol*. 2020 Aug 28; PMID: 32856962.
486. Pecoraro A, Knipper S, Palumbo C, Rosiello G, Luzzago S, Tian Z, **Shariat SF**, Saad F, Briganti A, Fiori C, Porpiglia F, Karakiewicz PI. Assessment of other-cause mortality in localized renal cell carcinoma patients within 15 years: A population-based analysis. *J Surg Oncol*. 2020 Aug 18. PMID: 32812284.
487. Laukhtina E, Mostafaei H, D'Andrea D, Pradere B, Quhal F, Mori K, Miura N, Schuettfort VM, Sari Motlagh R, Aydh A, Abufaraj M, Karakiewicz PI, Enikeev D, Kimura S, **Shariat SF**. Association of De Ritis ratio with oncological outcomes in patients with non-muscle invasive bladder cancer (NMIBC). *World J Urol*. 2020 Aug 17. PMID: 32808107.
488. Palumbo C, Mistretta FA, Knipper S, Pecoraro A, Tian Z, Dzyuba-Negrean C, **Shariat SF**, Saad F, Simeone C, Berruti A, Briganti A, Kapoor A, Antonelli A, Karakiewicz PI. Contemporary cytoreductive nephrectomy provides survival benefit in clear-cell metastatic renal cell carcinoma. *Clin Genitourin Cancer*. 2020 May 20:S1558-7673(20)30117-8. PMID: 32800473.
489. Deuker M, Martin T, Stolzenbach F, Rosiello G, Collà Ruvolo C, Nocera L, Tian Z, Becker A, Kluth L, Roos FC, Tilki D, **Shariat SF**, Black PC, Kassouf W, Saad F, Chun F, Karakiewicz PI. Bladder Cancer: A comparison between non-urothelial variant histology and urothelial carcinoma across all stages and treatment modalities. *Clin Genitourin Cancer*. 2020 Jul 18:S1558-7673(20)30171-3. PMID: 32782133.
490. Quhal F, D'Andrea D, Soria F, Moschini M, Abufaraj M, Rouprêt M, Karakiewicz PI, Yang L, Mostafaei H, Laukhtina E, Mori K, Sari Motlagh R, Rink M, **Shariat SF**. Primary Ta high grade bladder tumors: Determination of the risk of progression. *Urol Oncol*. 2020 Aug 6:S1078-1439(20)30339-2. PMID: 32773232.
491. Mir MC, Marchioni M, Zargar H, Zargar-Shoshtari K, Fairey AS, Mertens LS, Dinney CP, Krabbe LM, Cookson MS, Jacobsen NE, Griffin J, Montgomery JS, Vasdev N, Yu EY, Xylinas E, McGrath JS, Kassouf W, Dall'Era MA, Sridhar SS, Aning J, **Shariat SF**, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Spiess PE, Daneshmand D, Black PC. Nomogram predicting bladder cancer-specific mortality after neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: results of an international consortium. *Eur Urol Focus*. 2020 Aug 5:S2405-4569(20)30208-X. PMID: 32771446.

492. Ilijazi D, Pulverer W, Ertl IE, Lemberger U, Kimura S, Abufaraj M, D'Andrea D, Pradere B, Bruchbacher A, Graf A, Soria F, Susani M, Haitel A, Molinaro L, Pycha A, Comploj E, Pabinger S, Weinhäusel A, Egger G, **Shariat SF**, Hassler MR. Discovery of Molecular DNA Methylation-Based Biomarkers through Genome-Wide Analysis of Response Patterns to BCG for Bladder Cancer. *Cells*. 2020 Aug 5;9(8):1839. PMID: PMC7464079.
493. Mori K, Mostafaei H, Miura N, Karakiewicz PI, Luzzago S, Schmidinger M, Bruchbacher A, Pradere B, Egawa S, **Shariat SF**. Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis. *Cancer Immunol Immunother*. 2020 Aug 5. PMID: 32757054.
494. Quhal F, Pradere B, Mori K, **Shariat SF**. Volume outcome relationship in penile cancer: a systematic review. *Curr Opin Urol*. 2020 Sep;30(5):696-700. PMID: 32740139.
495. Tully KH, Moschini M, von Rundstedt FE, Aziz A, Kluth LA, Necchi A, Rink M, Hendricksen K, Sargos P, Vetterlein MW, Seiler R, Poyet C, Krajewski W, Fajkovic H, **Shariat SF**, Xylinas E, Roghmann F. Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer - examining the utility of classifying Ta bladder cancer based on size. *Urol Oncol*. 2020 Jul 29;S1078-1439(20)30321-5. PMID: 32739227.
496. Sari Motlagh R, Mori K, Aydh A, Karakiewicz PI, Trinh QD, **Shariat SF**. Impact of hospital and surgeon volumes on short-term and long-term outcomes of radical cystectomy. *Curr Opin Urol*. 2020 Sep;30(5):701-710. PMID: 32732625.
497. Mori K, Abufaraj M, Mostafaei H, Quhal F, Karakiewicz PI, Briganti A, Kimura S, Egawa S, **Shariat SF**. A Systematic Review and Meta-Analysis of Variant Histology in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. *J Urol*. 2020 Jul 275. PMID: 32716694.
498. Zamboni S, Afferi L, Soria F, Aziz A, Abufaraj M, Poyet C, Necchi A, D'Andrea D, Simone G, Ferriero M, Di Trapani E, Simeone C, Antonelli A, Gallina A, Montorsi F, Briganti A, Colombo R, Gandaglia G, Mattei A, Baumeister P, Mordasini L, Hendricksen K, Voskuilen CS, Rink M, **Shariat SF**, Xylinas E, Moschini M. Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy with curative intent. *World J Urol*. 2020 Jul 25. PMID: 32712850.
499. Brönimann S, Rebhan K, Lemberger U, Misrai V, **Shariat SF**, Pradere B. Secretion of severe acute respiratory syndrome coronavirus 2 in urine. *Curr Opin Urol*. 2020 Sep;30(5):735-739. PMID: 32701726; PMID: PMC7386676.
500. Brönimann S, Pradere B, Karakiewicz P, Huebner NA, Briganti A, **Shariat SF**. An up-to-date catalogue of urinary markers for the management of prostate cancer. *Curr Opin Urol*. 2020 Sep;30(5):684-688. PMID: 32701725.
501. Rebhan K, Ertl IE, **Shariat SF**, Grollman AP, Rosenquist T. Aristolochic acid and its effect on different cancers in uro-oncology. *Curr Opin Urol*. 2020 Sep;30(5):689-695. PMID: 32701724.
502. Mori K, Mostafaei H, Abufaraj M, Yang L, Egawa S, **Shariat SF**. Smoking and bladder cancer: review of the recent literature. *Curr Opin Urol*. 2020 Sep;30(5):720-725. PMID: 32701723.
503. Miura N, Mori K, Mostafaei H, Quhal F, Motlagh RS, Pradere B, Laukhtina E, D'Andrea D, Saika T, **Shariat SF**. The Prognostic Impact of Intraductal Carcinoma of the Prostate: A Systematic Review and Meta-Analysis. *J Urol*. 2020 Jul 23; PMID: 32698712.
504. Deuker M, Stolzenbach LF, Collà Ruvolo C, Nocera L, Mansour M, Tian Z, Roos FC, Becker A, Kluth LA, Tilki D, **Shariat SF**, Saad F, Chun FKH, Karakiewicz PI. Obesity is associated with

- adverse short-term perioperative outcomes in patients treated with open and robot-assisted radical cystectomy for bladder cancer. *Urol Oncol*. 2020 Jul 16:S1078-1439(20)30291-X. doi: 10.1016/j.urolonc.2020.06.020. PMID: 32684511.
505. Miura N, Mori K, Mostafaei H, Quhal F, Sari Motlagh R, Abufaraj M, Pradere B, Aydh A, Laukhtina E, D'Andrea D, Saika T, **Shariat SF**. Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis. *Int J Clin Oncol*. 2020 Jul 17. PMID: 32681382.
506. Cao C, Yang L, Xu T, Cavazos-Rehg PA, Liu Q, McDermott D, Veronese N, Waldhoer T, Ilie PC, **Shariat SF**, Smith L. Trends in Sexual Activity and Associations With All-Cause and Cause-Specific Mortality Among US Adults. *J Sex Med*. 2020 Jul 11: PMID: 32665214.
507. Mori K, Miura N, Babjuk M, Karakiewicz PI, Mostafaei H, Laukhtina E, Quhal F, Motlagh RS, Pradere B, Kimura S, Egawa S, **Shariat SF**. Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: A systematic review. *Urol Oncol*. 2020 Jul 9:S1078-1439(20)30281-7. PMID: 32654948.
508. Palumbo C, Pecoraro A, Rosiello G, Luzzago S, Deuker M, Stolzenbach F, Tian Z, **Shariat SF**, Simeone C, Briganti A, Saad F, Berruti A, Antonelli A, Karakiewicz PI. Bladder cancer incidence rates and trends in young adults aged 20-39 years. *Urol Oncol*. 2020 Jul 8:S1078-1439(20)30280-5. PMID: 32653412.
509. Khene ZE, Mathieu R, Peyronnet B, Kokorian R, Gasmi A, Khene F, Rioux- Leclercq N, Kammerer-Jacquet SF, **Shariat S**, Laguerre B, Bensalah K. Radiomics can predict tumour response in patients treated with Nivolumab for a metastatic renal cell carcinoma: an artificial intelligence concept. *World J Urol*. 2020 Jul 6. PMID: 32632555.
510. Bravi CA, Fossati N, Gandaglia G, Suardi N, Mazzone E, Robesti D, Osmonov D, Juenemann KP, Boeri L, Jeffrey Karnes R, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, **Shariat SF**, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, Briganti A. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. *Eur Urol*. 2020 Jul 2:S0302-2838(20)30472-3. PMID: 32624288.
511. Bravi CA, Fossati N, Gandaglia G, Suardi N, Mazzone E, Robesti D, Osmonov D, Juenemann KP, Boeri L, Jeffrey Karnes R, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, **Shariat SF**, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, Briganti A. Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series. *Eur Urol*. 2020 Jul 2:S0302-2838(20)30507-8. PMID: 32624281.
512. Abufaraj M, Iwata T, Kimura S, Haddad A, Al-Ani H, Abusubaih L, Moschini M, Briganti A, Karakiewicz PI, **Shariat SF**. Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials. *Eur Urol*. 2020 Jun 27:S0302-2838(20)30429-2. PMID: 32605859.
513. Rouprêt M, Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Cowan NC, Dominguez-Escrig JL, Gontero P, Hugh Mostafid A, Palou J, Peyronnet B, Seisen T, Soukup V, Sylvester RJ, Rhijn BWGV, Zigeuner R, **Shariat SF**. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *Eur Urol*. 2020 Jun 24:S0302-2838(20)30427-9. PMID: 32593530.

514. Palumbo C, Pecoraro A, Rosiello G, Luzzago S, Deuker M, Stolzenbach F, Tian Z, **Shariat SF**, Simeone C, Briganti A, Saad F, Berruti A, Antonelli A, Karakiewicz PI. Renal cell carcinoma incidence rates and trends in young adults aged 20-39 years. *Cancer Epidemiol.* 2020 Jun 22;67:101762. PMID: 32585430.
515. Janisch F, Hillemacher T, Fuehner C, D'Andrea D, Meyer CP, Klotzbücher T, Kienapfel C, Vetterlein MW, Kimura S, Abufaraj M, Dahlem R, **Shariat SF**, Fisch M, Rink M. The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort. *Urol Oncol.* 2020 Jun 21:S1078-1439(20)30192-7. PMID: 32576526.
516. Hassler MR, Bray F, Catto JWF, Grollman AP, Hartmann A, Margulis V, Matin SF, Roupert M, Sfakianos JP, **Shariat SF**, Faltas BM. Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature. *Eur Urol.* 2020 Jun 20:S0302-2838(20)30417-6. PMID: 32571725.
517. Sari Motlagh R, Mori K, Miura N, Quhal F, Aydh A, Laukhtina E, Pradere B, Karakiewicz PI, Enikeev DV, Deuker M, **Shariat SF** The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumor and benign prostatic hyperplasia; a systematic review and meta-analysis. *BJU Int.* 2020 Jun 21. PMID: 32564458
518. Brönimann S, Pradere B, Karakiewicz P, Abufaraj M, Briganti A, **Shariat SF**. An overview of current and emerging diagnostic, staging and prognostic markers for prostate cancer. *Expert Rev Mol Diagn.* 2020 Jun 18. PMID: 32552088
519. Miura N, Pradere B, Mori K, Mostafaei H, Quhal F, Misrai V, D'andrea D, Albisinni S, Papalia R, Saika T, Scarpa RM, **Shariat SF**, Esperto F. Metastasis-directed therapy and prostate-targeted therapy in oligometastatic prostate cancer: a systematic review. *Minerva Urol Nefrol.* 2020 Jun 16. PMID: 32550632.
520. Soria F, D'Andrea D, Abufaraj M, Moschini M, Giordano A, Gust KM, Karakiewicz PI, Babjuk M, Gontero P, **Shariat SF**. Stratification of Intermediate-risk Non-muscle-invasive Bladder Cancer Patients: Implications for Adjuvant Therapies. *Eur Urol Focus.* 2020 Jun 9:S2405-4569(20)30115-2. PMID: 32532704.
521. Gontero P, Marra G, Teber D, **Shariat S**, Albayrak S, Coelho R, Tanguay S, Konety B. Making a case "against" focal therapy for intermediate-risk prostate cancer. *World J Urol.* 2020 Jun 11. PMID: 32529451.
522. Mostafaei H, **Shariat SF**, Salehi-Pourmehr H, Janisch F, Mori K, Quhal F, Hajebrahimi S. The clinical pharmacology of the medical treatment for overactive bladder in adults. *Expert Rev Clin Pharmacol.* 2020 Jun 16:1-13. PMID: 32500759.
523. Palumbo C, Mazzone E, Mistretta FA, Knipper S, Perrotte P, **Shariat SF**, Saad F, Kapoor A, Lattouf JB, Simeone C, Briganti A, Antonelli A, Karakiewicz PI. A plea for optimizing selection in current adjuvant immunotherapy trials for high-risk nonmetastatic renal cell carcinoma according to expected cancer-specific mortality. *Clin Genitourin Cancer.* 2019 Dec 5:S1558-7673(19)30361-1. PMID: 32482565.
524. Luzzago S, Palumbo C, Rosiello G, Pecoraro A, Deuker M, Mistretta FA, Tian Z, Musi G, Montanari E, **Shariat SF**, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. The Effect of systemic chemotherapy on survival in patients with localized, regional, or metastatic adenocarcinoma of the urinary bladder. *Am J Clin Oncol.* 2020 May 27. PMID: 32467527.
525. Deuker M, Franziska Stolzenbach L, Rosiello G, Luzzago S, Martin T, Tian Z, Tilki D, **Shariat SF**, Saad F, Kassouf W, Black PC, Chun FKH, Karakiewicz PI. Radical cystectomy improves

- survival in patients with stage T1 squamous cell carcinoma and neuroendocrine carcinoma of the urinary bladder. *Eur J Surg Oncol*. 2020 May 12:S0748-7983(20)30459-5. PMID: 32457017.
526. Palumbo C, Pecoraro A, Knipper S, Rosiello G, Luzzago S, Deuker M, Tian Z, **Shariat SF**, Simeone C, Briganti A, Saad F, Berruti A, Antonelli A, Karakiewicz PI. Contemporary Age-adjusted Incidence and Mortality Rates of Renal Cell Carcinoma: Analysis According to Gender, Race, Stage, Grade, and Histology. *Eur Urol Focus*. 2020 May 23:S2405-4569(20)30114-0. PMID: 32456993.
527. Huebner NA, **Shariat SF**, Resch I, Gust K, Kramer G. The role of taxane-based chemotherapy in the treatment of prostate cancer. *Curr Opin Urol*. 2020 Jul;30(4):527-533. PMID: 32453003.
528. Gust KM, Rebhan K, Resch I, **Shariat SF**, Necchi A. Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancer. *Curr Opin Urol*. 2020 Jul;30(4):547-556. PMID: 32453001.
529. Ertl IE, **Shariat SF**, Mostafaei H, Ilijazi D, Lorient Y. Fibroblast growth factor receptors across urothelial carcinoma landscape. *Curr Opin Urol*. 2020 Jul;30(4):557-565. PMID: 32452999.
530. Mori K, Miura N, Mostafaei H, Quhal F, Motlagh RS, Lysenko I, Kimura S, Egawa S, Karakiewicz PI, **Shariat SF**. Prognostic value of preoperative hematologic biomarkers in urothelial carcinoma of the bladder treated with radical cystectomy: a systematic review and meta-analysis. *Int J Clin Oncol*. 2020 May 26. PMID: 32451768.
531. Pradere B, **Shariat SF**. Exploring the molecular basis of sexual dimorphism in bladder cancer. *Nat Rev Urol*. 2020 May 22. PMID: 32444779.
532. Luzzago S, Palumbo C, Rosiello G, Knipper S, Pecoraro A, Mistretta FA, Tian Z, Musi G, Montanari E, Soulières D, **Shariat SF**, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. Association Between Systemic Therapy and/or Cytoreductive Nephrectomy and Survival in Contemporary Metastatic Non-clear Cell Renal Cell Carcinoma Patients. *Eur Urol Focus*. 2020 May 19:S2405-4569(20)30108-5. PMID: 32444303.
533. Mori K, Miura N, Comperat E, Nikles S, Pang KH, Misrai V, Gomez Rivas J, Papalia R, **Shariat SF**, Esperto F, Pradere B. A systematic review and meta-analysis of prognostic impact of different Gleason patterns in ISUP grade group 4. *Minerva Urol Nefrol*. 2020 May 20. PMID: 32432435.
534. Soria F, Giordano A, **Shariat SF**, Gontero P. Bladder sparing landscape for bacillus Calmette-Guérin unresponsive bladder cancer. *Curr Opin Urol*. 2020 May 13. PMID: 32427633.
535. Hughes T, Ho HC, **Shariat SF**, Somani BK. Where do urologists stand in the era of novel coronavirus-2019 disease. *Curr Opin Urol*. 2020 May 13. PMID: 32427632.
536. Brönimann S, Lemberger U, Bruchbacher A, **Shariat SF**, Hassler MR. Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancer. *Curr Opin Urol*. 2020 May 13. PMID: 32427631.
537. Rosiello G, Pecoraro A, Palumbo C, Knipper S, Luzzago S, Deuker M, Tian Z, Gandaglia G, Fossati N, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Radical cystectomy plus chemotherapy in patients with pure squamous cell bladder carcinoma: a population-based study. *World J Urol*. 2020 May 18. PMID: 32424515.
538. Abufaraj M, Kimura S, Haitel A, Iwata T, Isleem U, D'Andrea D, Soria F, Mori K, Rink M, Bensalah K, Rouprêt M, Margulis V, Briganti A, Karakiewicz PI, **Shariat SF**. The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy. *Urol Oncol*. 2020 May 4:S1078-1439(20)30136-8. PMID: 32381392.

539. Cao C, Liu Q, Abufaraj M, Han Y, Xu T, Waldhoer T, **Shariat SF**, Li S, Yang L, Smith L. Regular Coffee Consumption Is Associated with Lower Regional Adiposity Measured by DXA among US Women. *J Nutr*. 2020 May 3:nxaa121. PMID: 32361729.
540. Afferi L, Zamboni S, Karnes RJ, Roghmann F, Sargos P, Montorsi F, Briganti A, Gallina A, Mattei A, Schulz GB, Hendricksen K, Voskuilen CS, Rink M, Poyet C, De Cobelli O, di Trapani E, Simeone C, Soligo M, Simone G, Tuderti G, Alvarez- Maestro M, Martínez-Piñeiro L, Aziz A, **Shariat SF**, Abufaraj M, Xylinas E, Moschini M; European Association of Urology-Young Academic Urologists (EAU-YAU), Urothelial Carcinoma Working Group. The impact of treatment modality on survival in patients with clinical node-positive bladder cancer: results from a multicenter collaboration. *World J Urol*. 2020 Apr 30. PMID: 32356226.
541. Teoh JYC, Roupret M, **Shariat SF**, Herrmann T. Intravesical therapy for bladder cancer in the pandemic of Covid-19. *World J Urol*. 2020 Apr 30:1–2. PMID: 32356225; PMCID: PMC7191133.
542. Szarvas T, Csizmarik A, Fazekas T, Hüttl A, Nyirády P, Hadaschik B, Grünwald V, Püllen L, Jurányi Z, Kocsis ZS, **Shariat SF**, Sevcenco S, Maj-Hes A, Kramer G. Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer. *BJU Int*. 2020 Apr 20. PMID: 32314509
543. Sari Motlagh R, Pradere B, Mori K, Miura N, Abufaraj M, **Shariat SF**. Bladder-preserving strategies for Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer; where are we and what will be expected? *Curr Opin Urol*. 2020 Apr 16. PMID: 32304379
544. Schuettfort V, **Shariat SF**, Rink M. Surgery only? Multimodal treatment for urothelial carcinoma of the bladder. *Aktuelle Urol*. 2020 Apr 14. PMID: 32289833
545. Rosiello G, Palumbo C, Knipper S, Pecoraro A, Luzzago S, St-Hilaire PA, Tian Z, Capitanio U, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Comparison of survival outcomes in patients with metastatic papillary vs. clear-cell renal cell carcinoma: a propensity-score analysis. *World J Urol*. 2020 Apr 6. PMID: 32253579
546. Deuker M, Stolzenbach F, Rosiello G, Palumbo C, Martin T, Tian Z, Chun FK, Saad F, **Shariat SF**, Kapoor A, Karakiewicz PI. Renal Cell Carcinoma: Comparison Between Variant Histology and Clear Cell Carcinoma Across all Stages and Treatment Modalities. *J Urol*. 2020 Apr 6:PMID: 32250728
547. Rosiello G, Knipper S, Palumbo C, Pecoraro A, Luzzago S, Deuker M, Stolzenbach LF, Tian Z, Gallina A, Gandaglia G, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Rates of other-cause mortality after radical cystectomy are decreasing over time-A population-based analysis over two decades. *J Surg Oncol*. 2020 Apr 4. PMID: 32246846
548. Enikeev D, **Shariat SF**. Novel technologies that change the diagnostic and treatment paradigm in urology: En-bloc as the new treatment standard. *Curr Opin Urol*. 2020 May;30(3):475-476. PMID: 32235286
549. Rebhan K, Laukhtina E, **Shariat SF**, Gust KM. Frontiers in combining immune checkpoint inhibitors for advanced urothelial cancer management. *Curr Opin Urol*. 2020 May;30(3):457-466. PMID: 32235284
550. Jahrreiss V, Pradere B, Laukhtina E, Mori K, **Shariat SF**. Catalog of exogenous risk factors for bladder carcinogenesis. *Curr Opin Urol*. 2020 May;30(3):449-456. PMID: 32235283
551. Carando R, **Shariat SF**, Moschini M, D'Andrea D. Ureteral and urethral recurrence after radical cystectomy: a systematic review. *Curr Opin Urol*. 2020 May;30(3):441-448. PMID: 32235282

552. Lysenko I, Mori K, Mostafaei H, Enikeev DV, Karakiewicz PI, Briganti A, Quhal F, Janisch F, **Shariat SF**. Prognostic Value of Gleason Score at Positive Surgical Margin in Prostate Cancer: A Systematic Review and Meta-analysis. *Clin Genitourin Cancer*. 2020 Mar 4. PMID: 32229268
553. Palumbo C, Knipper S, Pecoraro A, Rosiello G, Luzzago S, Deuker M, Tian Z, **Shariat SF**, Simeone C, Briganti A, Saad F, Berruti A, Antonelli A, Karakiewicz PI. Differences in short-term outcomes between open versus robot-assisted radical cystectomy in frail malnourished patients. *Eur J Surg Oncol*. 2020 Mar 14. PMID: 32220544
554. Jilch S, Sel R, **Shariat SF**. Medical practice and placebo response: an inseparable bond? *Wien Klin Wochenschr*. 2020 Mar 24. PMID: 32211987
555. Misrai V, Taille A, Zorn KC, Marraud L, Pon D, **Shariat SF**, Rouprêt M. A Plea for the Evaluation of the Carbon Footprint of New Mini-invasive Surgical Technologies in Urology. *Eur Urol*. 2020 Mar 21. PMID: 32209285
556. Mori K, Egawa S, **Shariat SF**. Re: Cabazitaxel Versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. *Eur Urol*. 2020 Mar 21. PMID: 32209284
557. Janisch F, D'Andrea D, Iwata T, Kimura S, Abufaraj M, Enikeev D, Glybochko PV, Karakiewicz PI, Nyirady P, Fajkovic H, Haitel A, Seebacher V, Rink M, **Shariat SF**. The prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer patients treated with radical cystectomy. *Urol Oncol*. 2020 Mar 21. PMID: 32209281
558. Quhal F, Mori K, Sari Motlagh R, Laukhtina E, Pradere B, Rouprêt M, Necchi A, Moschini M, **Shariat SF**. Efficacy of neoadjuvant and adjuvant chemotherapy for localized and locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis. *Int J Clin Oncol*. 2020 Mar 23. PMID: 32206939
559. Rosiello G, Palumbo C, Knipper S, Deuker M, Stolzenbach LF, Tian Z, Gandaglia G, Fossati N, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Preoperative frailty predicts adverse short-term postoperative outcomes in patients treated with radical prostatectomy. *Prostate Cancer Prostatic Dis*. 2020 Mar 18. PMID: 32203071
560. Mostafid H, Babjuk M, Bochner B, Lerner SP, Witjes F, Palou J, Roupert M, **Shariat S**, Gontero P, van Rhijn B, Zigeuner R, Sylvester R, Comperat E, Burger M, Malavaud B, Soloway M, Williams S, Black P, Daneshmand S, Steinberg G, Brausi M, Catto J, Kamat AM. Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer. *Eur Urol*. 2020 Mar 16. PMID: 32192815
561. Luzzago S, Rosiello G, Pecoraro A, Deuker M, Stolzenbach F, Mistretta FA, Tian Z, Musi G, Montanari E, **Shariat SF**, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. Contemporary Rates and Predictors of Open Conversion During Minimally Invasive Radical Prostatectomy for Nonmetastatic Prostate Cancer. *J Endourol*. 2020 Apr 14. PMID: 32178532
562. Pecoraro A, Palumbo C, Knipper S, Rosiello G, Luzzago S, Tian Z, **Shariat SF**, Saad F, Lavallée L, Briganti A, Kapoor A, Fiori C, Porpiglia F, Karakiewicz PI. Histologic Subtype, Tumor Grade, Tumor Size, and Race Can Accurately Predict the Probability of Synchronous Metastases in T2 Renal Cell Carcinoma. *Clin Genitourin Cancer*. 2020 Feb 8. PMID: 32173357
563. Mistretta FA, Negrean-Dzyuba C, Palumbo C, Pecoraro A, Knipper S, Tian Z, Musi G, Montanari E, Perrotte P, Briganti A, **Shariat SF**, Saad F, de Cobelli O, Karakiewicz PI. Adherence to guideline recommendations for multimodality treatment of patients with pT2-3 M0 non-urothelial carcinoma of the urinary bladder: Temporal trends and survival outcomes. *Int J Urol*. 2020 Mar 14. PMID: 32172530

564. Pecoraro A, Palumbo C, Knipper S, Mistretta FA, Rosiello G, Tian Z, St-Hilaire PA, **Shariat SF**, Saad F, Lavallée L, Briganti A, Kapoor A, Fiori C, Porpiglia F, Karakiewicz PI. Synchronous Metastasis Rates in T1 Renal Cell Carcinoma: A Surveillance, Epidemiology, and End Results Database-based Study. *Eur Urol Focus*. 2020 Mar 10. PMID: 32169361
565. Kamat AM, Shore N, Hahn N, Alanee S, Nishiyama H, **Shariat S**, Nam K, Kapadia E, Frenkl T, Steinberg G. KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC. *Future Oncol*. 2020 Apr;16(10):507-516. PMID: 32162533
566. Mori K, Miura N, Mostafaei H, Quhal F, Sari Motlagh R, Pradere B, Kimura S, Kimura T, Egawa S, Briganti A, Karakiewicz PI, **Shariat SF**. Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis. *Prostate Cancer Prostatic Dis*. 2020 Mar 9. PMID: 32152435
567. Luzzago S, Palumbo C, Rosiello G, Pecoraro A, Deuker M, Stolzenbach F, Mistretta FA, Tian Z, Musi G, Montanari E, **Shariat SF**, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. Metabolic syndrome predicts worse perioperative outcomes in patients treated with partial nephrectomy for renal cell carcinoma. *Urology*. 2020 Mar 6. PMID: 32151650
568. Luzzago S, Palumbo C, Rosiello G, Knipper S, Pecoraro A, Nazzani S, Tian Z, Musi G, Montanari E, **Shariat SF**, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. survival of contemporary patients with non-metastatic small-cell carcinoma of urinary bladder, according to alternative treatment modalities. *Clin Genitourin Cancer*. 2019 Dec 13. PMID: 32146153
569. Luzzago S, Palumbo C, Rosiello G, Knipper S, Pecoraro A, Mistretta FA, Tian Z, Musi G, Montanari E, **Shariat SF**, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. Effect of stage and grade migration on cancer specific mortality in renal cell carcinoma patients, according to clear cell vs. non-clear cell histology: A contemporary population-based analysis. *Urol Oncol*. 2020 Mar 2. PMID: 32139292
570. Mori K, Janisch F, Mostafaei H, Kimura S, Lysenko I, Karakiewicz PI, Briganti A, Enikeev DV, Rouprêt M, Margulis V, Chlostka P, Nyirady P, Babjuk M, Egawa S, **Shariat SF**. Prognostic role of preoperative De Ritis ratio in upper tract urothelial carcinoma treated with nephroureterectomy. *Urol Oncol*. 2020 Feb 29. PMID: 32127252
571. Rosiello G, Palumbo C, Knipper S, Pecoraro A, Luzzago S, Tian Z, Larcher A, Capitano U, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Histotype predicts the rate of lymph node invasion at nephrectomy in patients with nonmetastatic renal cell carcinoma. *Urol Oncol*. 2020 Feb 28. PMID: 32122729
572. Hupe MC, Offermann A, Tharun L, Fürschke A, Frydrychowicz A, Garstka N, **Shariat SF**, Barkhausen J, Merseburger AS, Kramer MW, Perner S. Histomorphological analysis of false positive PI-RADS 4 and 5 lesions. *Urol Oncol*. 2020 Feb 27. PMID: 32113858
573. Rosiello G, Palumbo C, Knipper S, Pecoraro A, Luzzago S, Deuker M, Mistretta FA, Tian Z, Fossati N, Gallina A, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Contemporary conditional cancer-specific survival after radical nephroureterectomy in patients with nonmetastatic urothelial carcinoma of upper urinary tract. *J Surg Oncol*. 2020 Feb 27. PMID: 32107785
574. Cacciamani GE, Ghodoussipour S, Mari A, Gill KS, Desai M, Artibani W, Gill PS, **Shariat SF**, Gill IS, Djaladat H. Association Between Smoking Exposure, Neoadjuvant Chemotherapy Response and Survival Outcomes Following Radical Cystectomy: Systematic Review and Meta-Analysis. *J Urol*. 2020 Feb 27. PMID: 32105187

575. Stangl-Kremser J, Lemberger U, Hassler MR, Garstka N, Grubmüller B, Haitel A, Enikeev DV, Glybochko PV, Kramer G, Susani M, **Shariat SF**. The prognostic impact of tumour NSD2 expression in advanced prostate cancer. *Biomarkers*. 2020 Mar 2;1-6. PMID: 32091270
576. Mori K, Janisch F, Mostafaei H, Lysenko I, Kimura S, Egawa S, **Shariat SF**. Prognostic value of preoperative blood-based biomarkers in upper tract urothelial carcinoma treated with nephroureterectomy: A systematic review and meta-analysis. *Urol Oncol*. 2020 Feb 19. PMID: 32088103
577. Fossati N, Scarcella S, Gandaglia G, Suardi N, Robesti D, Boeri L, Karnes RJ, Heidenreich A, Pfister D, Kretschmer A, Buchner A, Stief C, Battaglia A, Joniau S, Van Poppel H, Osmonov D, Juenemann KP, **Shariat SF**, Hiester A, Nini A, Albers P, Tilki D, Graefen M, Gill IS, Mottrie A, Galosi AB, Montorsi F, Briganti A. Underestimation of PET/CT Scan in Assessing Tumour Burden of Men With Nodal Recurrence From Prostate Cancer: Head-to-Head Comparison OF 68Ga-PSMA and 11C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections. *J Urol*. 2020 Feb 18. PMID: 32068488
578. Mottet N, Ribal MJ, Boyle H, De Santis M, Caillet P, Choudhury A, Garg T, Nielsen M, Wüthrich P, Gust KM, **Shariat SF**, Gakis G. Management of bladder cancer in older patients: Position paper of a SIOG Task Force. *J Geriatr Oncol*. 2020 Feb 10. PMID: 32057720
579. D'Andrea D, Black PC, Zargar H, Zargar-Shoshtari K, Zehetmayer S, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, **Shariat SF**. Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. *Urol Oncol*. 2020 Feb 11. PMID: 32057595
580. Soria F, Giordano A, D'Andrea D, Moschini M, Rouprêt M, Margulis V, Karakiewicz PI, Briganti A, Bensalah K, Mathieu R, Chlosta P, Babjuk M, Glybochko PV, Enikeev DV, Remzi M, Gust K, Gontero P, **Shariat SF**. Prognostic value of the systemic inflammation modified Glasgow prognostic score in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy: Results from a large multicenter international collaboration. *Urol Oncol*. 2020 Feb 6. PMID: 32037197
581. Luzzago S, Palumbo C, Rosiello G, Knipper S, Pecoraro A, Deuker M, Mistretta FA, Tian Z, Musi G, Montanari E, **Shariat SF**, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. Survival After Partial Cystectomy for Variant Histology Bladder Cancer Compared With Urothelial Carcinoma: A Population-based Study. *Clin Genitourin Cancer*. 2019 Oct 16. pii: S1558-7673(19)30320-9. PMID: 32035800
582. Baard J, Celebi M, de la Rosette J, Alcaraz A, **Shariat SF**, Cormio L, Cavadas V, Laguna MP. Evaluation of Patterns of Presentation, Practice, and Outcomes of Upper Tract Urothelial Cancer: Protocol for an Observational, International, Multicenter, Cohort Study by the Clinical Research Office of the Endourology Society. *JMIR Res Protoc*. 2020 Jan 24;9(1):e15363. PMID:32012106
583. Janisch F, Rink M, **Shariat SF**. The promise and challenges of neoadjuvant immunotherapy in the management of non-metastatic muscle-invasive bladder cancer. *BJU Int*. 2020 Feb 3. PMID: 32011069
584. Mori K, Janisch F, Mostafaei H, Lysenko I, Karakiewicz PI, Enikeev DV, Briganti A, Kimura S, Egawa S, **Shariat SF**. Prognostic Value of Hemoglobin in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis. *Clin Genitourin Cancer*. 2019 Dec 13. PMID: 32007439

585. Mistretta FA, Cyr SJ, Luzzago S, Mazzone E, Knipper S, Palumbo C, Tian Z, Nazzani S, Saad F, Montanari E, Tilki D, Briganti A, **Shariat SF**, de Cobelli O, Karakiewicz PI. Partial Cystectomy With Pelvic Lymph Node Dissection for Patients With Nonmetastatic Stage pT2-T3 Urothelial Carcinoma of Urinary Bladder: Temporal Trends and Survival Outcomes. *Clin Genitourin Cancer*. 2019 Sep 26. PMID: 32001182
586. Mori K, Mostafaei H, Enikeev DV, Lysenko I, Qahal F, Kimura S, Karakiewicz PI, Egawa S, **Shariat SF**. Differential Effect of Sex on Outcomes After Radical Surgery for Upper Tract and Bladder Urothelial Carcinoma: A Systematic Review and Meta-Analysis. *J Urol*. 2020 Jan 29; PMID: 31995432
587. Luzzago S, Palumbo C, Rosiello G, Knipper S, Pecoraro A, Nazzani S, Tian Z, Musi G, Montanari E, **Shariat SF**, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. Racial and ethnic differences in survival in contemporary metastatic renal cell carcinoma patients, according to alternative treatment modalities. *Cancer Causes Control*. 2020 Mar;31(3):263-272. PMID: 31993859
588. D'Andrea D, Soria F, Zehetmayer S, Stangl-Kremser J, Grubmüller B, Abufaraj M, Gust K, Kimura S, Babjuk M, Goldner GM, **Shariat SF**. Comparative effectiveness of radical cystectomy and radiotherapy without chemotherapy in frail patients with bladder cancer. *Scand J Urol*. 2020 Jan 24:1-6. PMID: 31975654
589. Resch I, Abufaraj M, Hübner NA, **Shariat SF**. An update on systemic therapy for penile cancer. *Curr Opin Urol*. 2020 Mar;30(2):229-233. PMID: 31972637
590. Ilijazi D, **Shariat SF**, Hassler MR, Lemberger U, Ertl IE. Epigenetic alterations of testicular germ cell tumours. *Curr Opin Urol*. 2020 Mar;30(2):264-270. PMID: 31905176
591. Rasul S, Hacker M, Kretschmer-Chott E, Leisser A, Grubmüller B, Kramer G, **Shariat S**, Wadsak W, Mitterhauser M, Hartenbach M, Haug AR. Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks. *Eur J Nucl Med Mol Imaging*. 2020 Mar;47(3):713-720. PMID: 31781834
592. Palumbo C, Knipper S, Pecoraro A, Rosiello G, Luzzago S, Deuker M, Tian Z, **Shariat SF**, Simeone C, Briganti A, Saad F, Berruti A, Antonelli A, Karakiewicz PI. Patient frailty predicts worse perioperative outcomes and higher cost after radical cystectomy. *Surg Oncol*. 2020 Mar;32:8-13. PMID: 31683158
593. Knipper S, Pecoraro A, Palumbo C, Rosiello G, Luzzago S, Deuker M, Tian Z, **Shariat SF**, Saad F, Tilki D, Graefen M, Karakiewicz PI. The effect of age on cancer-specific mortality in patients with prostate cancer: a population-based study across all stages. *Cancer Causes Control*. 2020 Feb 7. PMID: 32034540
594. Janisch F, Rink M, **Shariat SF**. The promise and challenges of neoadjuvant immunotherapy in the management of non-metastatic muscle-invasive bladder cancer. *BJU Int*. 2020 Feb 3. PMID: 32011069
595. D'Andrea D, Soria F, Abufaraj M, Pones M, Gontero P, Machado AT, Waksman R, Enikeev DV, Glybochko PV, Adonias SP, Nahas WC, **Shariat SF**, Chade DC. Comparative Effectiveness of Intravesical BCG-Tice and BCG-Moreau in Patients With Non-muscle-invasive Bladder Cancer. *Clin Genitourin Cancer*. 2020 Feb;18(1):20-25. PMID: 31786120
596. Rosiello G, Knipper S, Palumbo C, Pecoraro A, Luzzago S, Deuker M, Tian Z, Gandaglia G, Gallina A, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Increasing Rates of Perioperative Chemotherapy are Associated With Improved Survival in Men With Urothelial Bladder Cancer With Prostatic Stromal Invasion. *Clin Genitourin Cancer*. 2020 Feb;18(1):35-44. PMID: 31711842

597. Polanec SH, Bickel H, Wengert GJ, Arnoldner M, Clauser P, Susani M, **Shariat SF**, Pinker K, Helbich TH, Baltzer PAT. Can the addition of clinical information improve the accuracy of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer in positive MRI? *Clin Radiol*. 2020 Feb;75(2):157.e1-157.e7. PMID: 31690449
598. Vartolomei MD, Kimura S, Vartolomei L, **Shariat SF**. Systematic Review of the Impact of Testosterone Replacement Therapy on Depression in Patients with Late-onset Testosterone Deficiency. *Eur Urol Focus*. 2020 Jan 15;6(1):170-177. PMID: 30017901
599. Stangl-Kremser J, Mari A, Suarez-Ibarrola R, D'Andrea D, Korn SM, Pones M, Kramer G, Karakiewicz P, Enikeev DV, Glybochko PV, Briganti A, **Shariat SF**. Development of a prognostic model for survival time prediction in castration-resistant prostate cancer patients. *Urol Oncol*. 2020 Jan 14. PMID: 31953003
600. Rosiello G, Palumbo C, Deuker M, Stolzenbach LF, Tian Z, Larcher A, Capitanio U, Montorsi F, **Shariat SF**, Kapoor A, Saad F, Briganti A, Karakiewicz PI. Preoperative frailty predicts adverse short-term postoperative outcomes in patients treated with radical nephroureterectomy. *J Surg Oncol*. 2020 Jan 12. PMID: 31930511
601. Ilijazi D, **Shariat SF**, Hassler MR, Lemberger U, Ertl IE. Epigenetic alterations of testicular germ cell tumours. *Curr Opin Urol*. 2020 Jan 3. PMID: 31905176
602. Foerster B, Abufaraj M, Petros F, Azizi M, Gupta M, Schweitzer D, Margulis V, Iwata T, Kimura S, Shabsigh A, Briganti A, Ku JH, Muilwijk T, Kassouf W, Matin SF, Spiess PE, Pierorazio PM, Hendricksen K, **Shariat SF**; UTUC collaboration. Efficacy of Preoperative Chemotherapy in High-Risk Upper Tract Urothelial Carcinoma (UTUC). *J Urol*. 2020 PMID: 31898919
603. Mori K, D'Andrea D, Enikeev DV, Egawa S, Shariat SF. En bloc resection for nonmuscle invasive bladder cancer: review of the recent literature. *Curr Opin Urol*. 2020 Jan;30(1):41-47. PMID: 31724997
604. Moschini M, **Shariat SF**, Black P, Kamat AM, Stabile A, Cathelineau X, Kassouf W, Bochner BH, Xylinas E, Roupert M, Boorjian SA, Catto JW, Sanchez-Salas R. Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails. *Eur Urol*. 2020 Jan;77(1):1-2. PMID: 31506227
605. Palumbo C, Mistretta FA, Knipper S, Pecoraro A, Tian Z, **Shariat SF**, Saad F, Simeone C, Briganti A, Antonelli A, Karakiewicz PI. Conditional Survival of Patients With Nonmetastatic Renal Cell Carcinoma: How Cancer-Specific Mortality Changes After Nephrectomy. *J Natl Compr Canc Netw*. 2020 Jan;18(1):44-51. PMID: 31910387
606. Grubmüller B, Rasul S, Baltzer P, Fajkovic H, D'Andrea D, Berndl F, Maj-Hes A, Grubmüller KH, Mitterhauser M, Wadsak W, Pfaff S, **Shariat SF**, Hacker M, Kramer G, Hartenbach M. Response assessment using [68 Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer. *Prostate*. 2020 Jan;80(1):74-82. PMID: 31614001
607. Black AJ, Zargar H, Zargar-Shoshtari K, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Griffin J, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campaign NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, McGrath JS, Aning J, **Shariat SF**, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Spiess PE, Daneshmand S, Sridhar SS, Black PC. The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. *Urol Oncol*. 2020 Jan;38(1):3.e17-3.e27. PMID: 31676278

608. D'Andrea D, Abufaraj M, Soria F, Gust K, Haitel A, Krakiewicz PI, **Shariat SF**. Association of super-extended lymphadenectomy at radical cystectomy with perioperative complications and re-hospitalization. *World J Urol*. 2020 Jan;38(1):121-128. PMID: 31006052
609. Ferro M, Di Lorenzo G, Vartolomei MD, Bruzzese D, Cantiello F, Lucarelli G, Musi G, Di Stasi S, Hurle R, Guazzoni G, Busetto GM, Gabriele A, Del Giudice F, Damiano R, Perri F, Perdona S, Verze P, Borghesi M, Schiavina R, Almeida GL, Bove P, Lima E, Autorino R, Crisan N, Farhan ARA, Battaglia M, Russo GI, Ieluzzi V, Morgia G, De Placido P, Terracciano D, Cimmino A, Scafuri L, Mirone V, De Cobelli O, **Shariat S**, Sonpavde G, Buonerba C. Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. *World J Urol*. 2020 Jan;38(1):143-150. PMID: 30993426
610. Beer L, Polanec SH, Baltzer PAT, Schatzl G, Georg D, Schestak C, Dutschke A, Herrmann H, Mazal P, Brendel AK, **Shariat SF**, Ringl H, Helbich TH, Apfaltrer P. 4D perfusion CT of prostate cancer for image-guided radiotherapy planning: A proof of concept study. *PLoS One*. 2019 Dec 19;14(12):e0225673. PMID: 31856177
611. Yeh HC, Margulis V, Singla N, Hernandez E, Panwar V, Woldu SL, Karam JA, Wood CG, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Li CC, Ke HL, Li WM, Lee HY, Rapoport LM, Lotan Y, Kapur P, **Shariat SF**, Hsieh JT, Wu WJ. PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy. *Urol Oncol*. 2019 Dec 17. pii: S1078-1439(19)30483-1. PMID: 31862213
612. Vartolomei L, Vartolomei MD, **Shariat SF**. Bladder Cancer: Depression, Anxiety, and Suicidality Among the Highest-risk Oncology Patients. *Eur Urol Focus*. 2019 Dec 10. PMID: 31836463
613. Kimura S, Iwata T, Abufaraj M, Janisch F, D'Andrea D, Moschini M, Al-Rawashdeh B, Fajkovic H, Seebacher V, Egawa S, **Shariat SF**. Impact of Gender on Chemotherapeutic Response and Oncologic Outcomes in Patients Treated With Radical Cystectomy and Perioperative Chemotherapy for Bladder Cancer: A Systematic Review and Meta-Analysis. *Clin Genitourin Cancer*. 2019 Dec 5. PMID: 31889669
614. Kimura S, D'Andrea D, Iwata T, Foerster B, Janisch F, Parizi MK, Moschini M, Briganti A, Babjuk M, Chlosta P, Karakiewicz PI, Enikeev D, Rapoport LM, Seebacher V, Egawa S, Abufaraj M, **Shariat SF**. Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer. *World J Urol*. 2019 Dec 4. PMID: 31797075
615. Mazzone E, Mistretta FA, Knipper S, Tian Z, Palumbo C, Gandaglia G, Soulieres D, Tilki D, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Contemporary Assessment of Long-Term Survival Rates in Patients With Stage I Nonseminoma Germ-Cell Tumor of the Testis: Population-Based Comparison Between Surveillance and Active Treatment After Initial Orchiectomy. *Clin Genitourin Cancer*. 2019 Dec;17(6):e1153-e1162. PMID: 31515197
616. Rasul S, Hacker M, Kretschmer-Chott E, Leisser A, Grubmüller B, Kramer G, **Shariat SF**, Wadsak W, Mitterhauser M, Hartenbach M, Haug AR. Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks. *Eur J Nucl Med Mol Imaging*. 2019 Nov 28. PMID: 31781834
617. Mori K, Janisch F, Parizi MK, Mostafaei H, Lysenko I, Enikeev DV, Kimura S, Egawa S, **Shariat SF**. Prognostic value of alkaline phosphatase in hormone-sensitive prostate cancer: a systematic review and meta-analysis. *Int J Clin Oncol*. 2019 Nov 25. PMID: 31768692

618. Rosiello G, Palumbo C, Knipper S, Pecoraro A, Dzyuba-Negrean C, Luzzago S, Tian Z, Gallina A, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Unmarried men have worse oncologic outcomes after radical cystectomy for nonmetastatic urothelial bladder cancer. *Urol Oncol*. 2019 Nov 21. PMID: 31761614
619. Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, **Shariat SF**, Der Kwast TV, Xylinas E, EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees. *Eur Urol*. 2019 Nov 16. pii: S0302-2838(19)30763-8. doi: 10.1016/j.eururo.2019.09.035. PMID: 31753752
620. Lebentrau S, Wolff I, Hempel MC, Haccius M, Kluth LA, Pycha A, Brookman-May S, Schneider TR, Hermanns T, Distler FA, Boegemann M, Kübler H, **Shariat SF**, Burger M, May M. Knowledge of German-speaking urologists regarding the association between penile cancer and human papilloma virus: results of a survey of the European PROspective Penile Cancer Study (E-PROPS). *Aktuelle Urol*. 2019 Nov 19. PMID: 31745963
621. Stangl-Kremser J, Suarez-Ibarrola R, Andrea D, Korn SM, Pones M, Kramer G, Marhold M, Krainer M, Enikeev DV, Glybochko PV, Tamandl D, **Shariat SF**, Baltzer P. Assessment of body composition in the advanced stage of castration-resistant prostate cancer: special focus on sarcopenia. *Prostate Cancer Prostatic Dis*. 2019 Nov 19. PMID: 31745255
622. Horwich A, Babjuk M, Bellmunt J, Bruins HM, Reijke TM, Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, **Shariat SF**, Kwast TV, Xylinas E. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†. *Ann Oncol*. 2019 Nov 19. PMID: 31740927
623. Enikeev D, **Shariat SF**, Taratkin M, Glybochko P. The changing role of lasers in urologic surgery. *Curr Opin Urol*. 2019 Nov 12. PMID: 31724998
624. Rosiello G, Knipper S, Palumbo C, Pecoraro A, Luzzago S, Deuker M, Tian Z, Gandaglia G, Gallina A, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Increasing Rates of Perioperative Chemotherapy are Associated With Improved Survival in Men With Urothelial Bladder Cancer With Prostatic Stromal Invasion. *Clin Genitourin Cancer*. 2019 Oct 17. PMID: 31711842
625. Mistretta FA, Cyr SJ, Palumbo C, Mazzone E, Knipper S, Tian Z, Nazzani S, Montanari E, Tilki D, Briganti A, **Shariat SF**, Perrotte P, Saad F, de Cobelli O, Karakiewicz PI. Adherence to Guideline Recommendations for Perioperative Chemotherapy in Patients with pN2-3 M0 Squamous Cell Carcinoma of the Penis: Temporal Trends and Survival Outcomes. *Clin Oncol (R Coll Radiol)*. 2019 Nov 6. PMID: 31706712
626. Hentschel AE, van Rhijn BWG, Bründl J, Compérat EM, Plass K, Rodríguez O, Henríquez JDS, Hernández V, de la Peña E, Alemany I, Turturica D, Pisano F, Soria F, Čapoun O, Bauerová L, Pešl M, Bruins HM, Runneboom W, Herdegen S, Breyer J, Brisuda A, Scavarda-Lamberti A, Calatrava A, Rubio-Briones J, Seles M, Mannweiler S, Bosschieter J, Kusuma VRM, Ashabere D, Huebner N, Cotte J, Mertens LS, Cohen D, Lunelli L, Cussenot O, Sheikh SE, Volanis D, Coté JF, Rouprêt M, Haitel A, **Shariat SF**, Mostafid AH, Nieuwenhuijzen JA, Zigeuner R, Dominguez-Escrig JL, Hacek J, Zlotta AR, Burger M, Evert M, Hulsbergen-van de Kaa CA, van der Heijden AG, Kiemeny LALM, Soukup V, Molinaro L, Gontero P, Llorente C, Algaba F, Palou J, N'Dow J, Babjuk M, van der Kwast TH, Sylvester RJ. Papillary urothelial neoplasm of low malignant

- potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019? *Urol Oncol.* 2019 Nov 5. PMID: 31704141
627. Mazzone E, Knipper S, Mistretta FA, Palumbo C, Tian Z, Gallina A, Tilki D, **Shariat SF**, Montorsi F, Saad F, Briganti A, Karakiewicz PI. Trends and social barriers for inpatient palliative care in patients with metastatic bladder cancer receiving critical care therapies. *J Natl Compr Canc Netw.* 2019 Nov 1;17(11):1344-1352. PMID: 31693981
628. Gontero P, Pisano F, Palou J, Joniau S, Albersen M, Colombo R, Briganti A, Pellucchi F, Faba OR, van Rhijn BW, van de Putte EF, Babjuk M, Fritsche HM, Mayr R, Albers P, Niegisch G, Anract J, Masson-Lecomte A, De la Taille A, Roupret M, Peyronnet B, Cai T, Witjes AJ, Bruins M, Baniel J, Mano R, Lapini A, Sessa F, Irani J, Brausi M, Stenzl A, Karnes JR, Scherr D, O'Malley P, Taylor B, **Shariat SF**, Black P, Abdi H, Matveev VB, Samuseva O, Parekh D, Gonzalgo M, Vetterlein MW, Aziz A, Fisch M, Catto J, Pang KH, Xylinas E, Rink M; Young Academic Urologists Urothelial Carcinoma Group of the European Association of Urology. Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases. *World J Urol.* 2019 Nov 6. PMID: 31691084
629. Polanec SH, Bickel H, Wengert GJ, Arnoldner M, Clauser P, Susani M, **Shariat SF**, Pinker K, Helbich TH, Baltzer PAT. Can the addition of clinical information improve the accuracy of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer in positive MRI? *Clin Radiol.* 2019 Nov 2. PMID: 31690449
630. Mazzone E, Mistretta FA, Knipper S, Tian Z, Palumbo C, Gandaglia G, Fossati N, **Shariat SF**, Saad F, Montorsi F, Graefen M, Briganti A, Karakiewicz PI. Temporal trends and social barriers for inpatient palliative care delivery in metastatic prostate cancer patients receiving critical care therapies. *Prostate Cancer Prostatic Dis.* 2019 Nov 4. PMID: 31685982
631. Palumbo C, Knipper S, Pecoraro A, Rosiello G, Luzzago S, Deuker M, Tian Z, **Shariat SF**, Simeone C, Briganti A, Saad F, Berruti A, Antonelli A, Karakiewicz PI. Patient frailty predicts worse perioperative outcomes and higher cost after radical cystectomy. *Surg Oncol.* 2019 Oct 25;32:8-13. PMID: 31683158
632. Black AJ, Zargar H, Zargar-Shoshtari K, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Griffin J, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, McGrath JS, Aning J, **Shariat SF**, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Spiess PE, Daneshmand S, Sridhar SS, Black PC. The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. *Urol Oncol.* 2019 Oct 29. PMID: 31676278
633. Hassler MR, Abufaraj M, Kimura S, Stangl-Kremser J, Gust K, Glybochko PV, Schmidinger M, Karakiewicz PI, **Shariat SF**. Impact of Patients' Gender on Efficacy of Immunotherapy in Patients With Metastatic Kidney Cancer: A Systematic Review and Meta-analysis. *Clin Genitourin Cancer.* 2019 Sep 27. PMID: 31668768
634. Stangl-Kremser J, Kramer G, **Shariat SF**. Association of Hyponatremia With Survival in Patients With Castration-resistant Prostate Cancer: A Clinical Commentary. *Clin Genitourin Cancer.* 2019 Aug 20. PMID:31623929
635. Grubmüller B, Rasul S, Baltzer P, Fajkovic H, D'Andrea D, Berndl F, Maj-Hes A, Grubmüller KH, Mitterhauser M, Wadsak W, Pfaff S, **Shariat SF**, Hacker M, Kramer G, Hartenbach M. Response assessment using [68 Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer. *Prostate.* 2019 Oct 15. PMID: 31614001

636. Veskimäe E, Espinos EL, Bruins HM, Yuan Y, Sylvester R, Kamat AM, **Shariat SF**, Witjes JA, Compérat EM. What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic Review. *Eur Urol Oncol*. 2019 Oct 7. PMID: 31601522
637. Bandini M, Marchioni M, Preisser F, Nazzani S, Tian Z, Graefen M, Montorsi F, Saad F, **Shariat SF**, Schips L, Briganti A, Karakiewicz PI. Comprehensive analysis of in-hospital delirium after major surgical oncology procedures. *Can Urol Assoc J*. 2019 Sep 27. PMID: 31599720
638. Voskuilen CS, Schweitzer D, Jensen JB, Nielsen AM, Joniau S, Muilwijk T, Necchi A, Azizi M, Spiess PE, Briganti A, Bandini M, Goffin K, Bouchelouche K, van Werkhoven E, **Shariat SF**, Xylinas E, Azawi NH, Ku JH, Foerster B, van Rhijn BWG, Vegt E, Hendricksen K. Diagnostic Value of 18F-fluorodeoxyglucose Positron Emission Tomography with Computed Tomography for Lymph Node Staging in Patients with Upper Tract Urothelial Carcinoma. *Eur Urol Oncol*. 2019 Oct 4. PMID: 31591037
639. Leow JJ, Catto JWF, Efstathiou JA, Gore JL, Hussein AA, **Shariat SF**, Smith AB, Weizer AZ, Wirth M, Witjes JA, Trinh QD. Quality Indicators for Bladder Cancer Services: A Collaborative Review. *Eur Urol*. 2019 Sep 25. PMID: 31563501
640. Luzzago S, Palumbo C, Rosiello G, Pecoraro A, Deuker M, Tian Z, **Shariat SF**, Saad F, de Cobelli O, Karakiewicz PI. The effect of radical cystectomy on survival in patients with metastatic urothelial carcinoma of the urinary bladder. *J Surg Oncol*. 2019 Sep 28. PMID: 31562831
641. Mori K, Kimura S, Parizi MK, Enikeev DV, Glybochko PV, Seebacher V, Fajkovic H, Mostafaei H, Lysenko I, Janisch F, Egawa S, **Shariat SF**. Prognostic Value of Lactate Dehydrogenase in Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. *Clin Genitourin Cancer*. 2019 Jul 19. PMID: 31558410
642. Janisch F, Yu H, Vetterlein MW, Dahlem R, Engel O, Fisch M, **Shariat SF**, Soave A, Rink M. Do Younger Patients with Muscle-Invasive Bladder Cancer have Better Outcomes? *J Clin Med*. 2019 Sep 13;8(9). PMID: 31540247
643. Lobo N, **Shariat SF**, Guo CC, Fernandez MA, Kassouf W, Choudhury A, Gao J, Williams SB, Galsky MD, Taylor JA 3rd, Roupret M, Kamat AM. What Is the Significance of Variant Histology in Urothelial Carcinoma? *Eur Urol Focus*. 2019 Sep 14. PMID: 31530497
644. Soria F, D'Andrea D, Moschini M, Giordano A, Mazzoli S, Pizzuto G, Hurle R, Colombo R, Briganti A, Altieri V, **Shariat SF**, Gontero P. Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients? *Urol Oncol*. 2019 Sep 14. PMID: 31526650
645. Heide J, Ribback S, Klatte T, **Shariat S**, Burchardt M, Dombrowski F, Belldegrun AS, Drakaki A, Pantuck AJ, Kroeger N. Evaluation of the prognostic role of co-morbidities on disease outcome in renal cell carcinoma patients. *World J Urol*. 2019 Sep 13. PMID: 31520111
646. Mazzone E, Mistretta FA, Knipper S, Tian Z, Palumbo C, Gandaglia G, Soulieres D, Tilki D, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Contemporary Assessment of Long-Term Survival Rates in Patients With Stage I Nonseminoma Germ-Cell Tumor of the Testis: Population-Based Comparison Between Surveillance and Active Treatment After Initial Orchiectomy. *Clin Genitourin Cancer*. 2019 Aug 21. PMID: 31515197
647. Moschini M, **Shariat SF**, Black P, Kamat AM, Stabile A, Cathelineau X, Kassouf W, Bochner BH, Xylinas E, Roupret M, Boorjian SA, Catto JW, Sanchez-Salas R. Do Not Learn a Technique, Learn

- the Biology Underlying the Disease: Techniques Evolve, Biology Prevails. *Eur Urol*. 2019 Sep 7. PMID: 31506227
648. Kardoust Parizi M, Enikeev D, Glybochko PV, Seebacher V, Janisch F, Fajkovic H, Chłosta PL, **Shariat SF**. Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis. *World J Urol*. 2019 Sep 6. PMID: 31493109
649. Palumbo C, Mistretta FA, Knipper S, Mazzone E, Pecoraro A, Tian Z, Perrotte P, Antonelli A, Montorsi F, **Shariat SF**, Saad F, Simeone C, Briganti A, Lavallee LT, Karakiewicz PI. Assessment of local tumor ablation and non-interventional management versus partial nephrectomy in T1a renal cell carcinoma. *Minerva Urol Nefrol*. 2019 Sep 4. PMID: 31487976
650. **Shariat S**, Gontero P, Catto JWF. How to Treat a Patient with T1 High-grade Disease and No Tumour on Repeat Transurethral Resection of the Bladder? *Eur Urol Oncol*. 2019 Aug 31. pii: S2588-9311(19)30109-9. PMID: 31481345
651. Mori K, Janisch F, Parizi MK, Mostafaei H, Lysenko I, Kimura S, Enikeev DV, Egawa S, **Shariat SF**. Prognostic Value of Variant Histology in Upper Tract Urothelial Carcinoma Treated with Nephroureterectomy: A Systematic Review and Meta-Analysis. *J Urol*. 2019 PMID:31479406
652. Rosiello G, Knipper S, Palumbo C, Dzyuba-Negrean C, Pecoraro A, Mazzone E, Mistretta FA, Tian Z, Capitanio U, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Unmarried status is a barrier for access to treatment in patients with metastatic renal cell carcinoma. *Int Urol Nephrol*. 2019 Aug 29. PMID: 1468289
653. Mazzone E, Knipper S, Mistretta FA, Tian Z, Palumbo C, Soulieres D, De Cobelli O, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Contemporary North-American population-based validation of the International Germ Cell Consensus Classification for metastatic germ cell tumors of the testis. *World J Urol*. 2019 Aug 28. PMID:31463562
654. Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J, van Rhijn BWG, Rouprêt M, **Shariat SF**, Sylvester R, Zigeuner R, Capoun O, Cohen D, Escrig JLD, Hernández V, Peyronnet B, Seisen T, Soukup V. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. *Eur Urol*. 2019 Aug 20. PMID: 31443960
655. Mazzone E, Preisser F, Nazzani S, Tian Z, Bandini M, Gandaglia G, Fossati N, Montorsi F, Graefen M, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative Outcomes. *Eur Urol Oncol*. 2019 Sep;2(5):541-548. PMID: 31411992
656. Moschini M, Zamboni S, Soria F, Mathieu R, Xylinas E, Tan WS, Kelly JD, Simone G, Meraney A, Krishna S, Konety B, Mattei A, Baumeister P, Mordasini L, Montorsi F, Briganti A, Gallina A, Stabile A, Sanchez-Salas R, Cathelineau X, Rink M, Necchi A, Karakiewicz PI, Rouprêt M, Koupparis A, Kassouf W, Scherr DS, Ploussard G, Boorjian SA, Lotan Y, Sooriakumaran P, **Shariat SF**. Open Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes. *J Clin Med*. 2019 Aug 9;8(8). PMID: 31395826
657. **Shariat SF**, Enikeev DV, Mostafaei H. Six essential conditions for bladder-sparing strategies in bacillus Calmette-Guérin unresponsive bladder cancer. *Immunotherapy*. 2019 Sep;11(13):1083-1086. doi: 10.2217/imt-2019-0083. Epub 2019 Aug 6. No abstract available. MID: 31385744
658. Sevcenco S, Grubmüller B, Sonneck-Koenne C, Ahmadi Y, Knoll P, Floth A, Pokieser W, Zandieh S, Christoph Klingler H, **Shariat S**, Mirzaei S. Bone Scintigraphy in Staging of Newly Diagnosed

- Prostate Cancer in Regard of Different Risk Groups. *Asia Ocean J Nucl Med Biol.* 2019 Spring;7(2):149-152 PMID: 31380454
659. Palumbo C, Mistretta FA, Mazzone E, Knipper S, Tian Z, Perrotte P, Antonelli A, Montorsi F, **Shariat SF**, Saad F, Simeone C, Briganti A, Lattouf JB, Karakiewicz PI. Contemporary Incidence and Mortality Rates in Patients With Testicular Germ Cell Tumors. *Clin Genitourin Cancer.* 2019 Jun 13. pii: PMID: 31378580
660. Preisser F, Nazzani S, Mazzone E, Marchioni M, Bandini M, Tian Z, Haese A, Saad F, Zorn K, Montorsi F, **Shariat SF**, Graefen M, Tilki D, Karakiewicz PI. Comparison of Open Versus Robotically Assisted Cytoreductive Radical Prostatectomy for Metastatic Prostate Cancer. *Clin Genitourin Cancer.* 2019 May 27. PMID: 31375352
661. Palumbo C, Pecoraro A, Knipper S, Rosiello G, Tian Z, **Shariat SF**, Simeone C, Briganti A, Saad F, Berruti A, Antonelli A, Karakiewicz PI. Survival and Complication Rates of Metastectomy in Patients With Metastatic Renal Cell Carcinoma Treated Exclusively With Targeted Therapy: A Combined Population-based Analysis. *Anticancer Res.* 2019 Aug;39(8):4357-4361. PMID: 31366530
662. Pecoraro A, Palumbo C, Knipper S, Mistretta FA, Tian Z, **Shariat SF**, Saad F, Briganti A, Fiori C, Porpiglia F, Karakiewicz PI. In Patients with Nonmetastatic pT1b Kidney Cancer Cryoablation Predisposes to Higher Cancer Specific Mortality Relative to Partial Nephrectomy. *J Urol.* 2019 Jul 26; PMID: 31347950
663. Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Torre P, O'Hagan A, Avadhani A, Siefker-Radtke AO; BLC2001 Study Group. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. *N Engl J Med* 2019 Jul 25;381(4):338-348. PMID:31340094
664. Stangl-Kremser J, Lemberger U, Hassler MR, Bruchbacher A, Ilijazi D, Garstka N, Kramer G, Haitel A, Abufaraj M, **Shariat SF**. Prevalence and Prognostic Value of the Polymorphic Variant 1245A>C of HSD3B1 in Castration-resistant Prostate Cancer. *Clin Genitourin Cancer.* 2019 Jun 26. PMID 31331867
665. Janisch F, **Shariat SF**, Baltzer P, Fajkovic H, Kimura S, Iwata T, Korn P, Yang L, Glybochko PV, Rink M, Abufaraj M. Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis. *World J Urol.* 2019 Jul 18. PMID: 31321509
666. Janisch F, Abufaraj M, Fajkovic H, Kimura S, Iwata T, Nyirady P, Rink M, **Shariat SF**. Current Disease Management of Primary Urethral Carcinoma. *Eur Urol Focus.* 2019 Jul 12. PMID:31307949
667. Mistretta FA, Palumbo C, Knipper S, Mazzone E, Pecoraro A, Tian Z, Musi G, Perrotte P, Montanari E, **Shariat SF**, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. Conditional survival of patients with stage I-III squamous cell carcinoma of the penis: temporal changes in cancer-specific mortality. *World J Urol.* 2019 Jul 11. PMID: 31297629
668. Palumbo C, Mistretta FA, Knipper S, Pecoraro A, Tian Z, **Shariat SF**, Saad F, Simeone C, Briganti A, Antonelli A, Karakiewicz PI. How cancer-specific mortality changes over time after radical cystectomy: Conditional survival of patients with nonmetastatic urothelial carcinoma of the urinary bladder. *Urol Oncol.* 2019 Jul 8. PMID: 31296422
669. Kardoust Parizi M, Abufaraj M, Fajkovic H, Kimura S, Iwata T, D'Andrea D, Karakiewicz PI, **Shariat SF**. Oncological safety of testosterone replacement therapy in prostate cancer survivors

- after definitive local therapy: A systematic literature review and meta-analysis. *Urol Oncol.* 2019 Jul 8. PMID: 31296421
670. Mistretta FA, Mazzone E, Palumbo C, Knipper S, Tian Z, Nazzani S, Tilki D, Musi G, Perrotte P, Montanari E, **Shariat SF**, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. Adherence to guideline recommendations for lymph node dissection in squamous cell carcinoma of the penis: Effect on survival and complication rates. *Urol Oncol.* 2019 Jul 8. PMID: 31296420
671. Lucca I, Hofbauer SL, Haitel A, Susani M, **Shariat SF**, Klatte T, De Martino M. Urinary expression of genes involved in DNA methylation and histone modification for diagnosis of bladder cancer in patients with asymptomatic microscopic haematuria. *Oncol Lett.* 2019 Jul;18(1):57-62. PMID: 31289472
672. Robinson BD, Vlachostergios PJ, Bhinder B, Liu W, Li K, Moss TJ, Bareja R, Park K, Tavassoli P, Cyra J, Tagawa ST, Nanus DM, Beltran H, Molina AM, Khani F, Miguel Mosquera J, Xylinas E, **Shariat SF**, Scherr DS, Rubin MA, Lerner SP, Matin SF, Elemento O, Faltas BM. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. *Nat Commun.* 2019 Jul 5;10(1):2977. PMID: 31278255
673. Pignot G, Loriot Y, Kamat AM, **Shariat SF**, Plimack ER. Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies. *Eur Urol Oncol.* 2019 Jul;2(4):355-364. PMID: 31277773
674. Palumbo C, Knipper S, Dzyuba-Negrean C, Pecoraro A, Rosiello G, Tian Z, **Shariat SF**, Simeone C, Briganti A, Saad F, Berruti A, Antonelli A, Karakiewicz PI. Complication rates, failure to rescue and in-hospital mortality after cytoreductive nephrectomy in the older patients. *J Geriatr Oncol.* 2019 Jun 27. PMID: 31257163
675. Iwata T, Kimura S, Abufaraj M, Janisch F, Parizi MK, Haitel A, Rink M, Rouprêt M, Fajkovic H, Seebacher V, Nyirady P, Karakiewicz PI, Enikeev D, Rapoport LM, Nasu Y, **Shariat SF**. Prognostic role of the urokinase plasminogen activator (uPA) system in patients with nonmuscle invasive bladder cancer. *Urol Oncol.* 2019 Jun 26. PMID: 31255543
676. Iwata T, Kimura S, Abufaraj M, Janisch F, Karakiewicz PI, Seebacher V, Rouprêt M, Nasu Y, **Shariat SF**. The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: A systematic review. *Urol Oncol.* 2019 Jun 26. PMID: 31255542
677. Abufaraj M, Grubmüller B, Zeitlinger M, Kramer G, Seitz C, Haitel A, Baltzer P, Hacker M, Wadsak W, Pfaff S, Wiatr T, Mitterhauser M, **Shariat SF**, Hartenbach M. Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy. *Eur J Nucl Med Mol Imaging.* 2019 Jun 29. PMID: 31254037
678. Krimphove MJ, Szymaniak J, Marchese M, Tully KH, D'Andrea D, Mossanen M, Lipsitz SR, Kilbridge K, Kibel AS, Kluth LA, **Shariat SF**, Trinh QD. Sex-specific Differences in the Quality of Treatment of Muscle-invasive Bladder Cancer Do Not Explain the Overall Survival Discrepancy. *Eur Urol Focus.* 2019 Jun 18. PMID: 31227463
679. Khene ZE, Peyronnet B, Bernhard JC, Kocher NJ, Vaessen C, Doumerc N, Pradere B, Seisen T, Beauval JB, Verhoest G, Roumiguié M, De la Taille A, Bruyere F, Rouporet M, Mejean A, Mathieu R, **Shariat S**, Raman JD, Bensalah K; members of the French Committee of Urologic Oncology (CCAFU). A preoperative nomogram to predict major complications after robot assisted partial nephrectomy (UroCCR-57 study). *Urol Oncol.* 2019 Jun 8. PMID: 31186143
680. Mistretta FA, Mazzone E, Palumbo C, Knipper S, Tian Z, Nazzani S, Lattouf JB, Musi G, Perrotte P, Montanari E, **Shariat SF**, Montorsi F, Saad F, de Cobelli O, Karakiewicz PI. Contemporary

- Assessment of Survival Rates in Stage I Testicular Seminoma: A Population-Based Comparison Between Surveillance and Active Treatment After Orchiectomy. *Clin Genitourin Cancer*. 2019 Apr 30. PMID: 31182339
681. Vartolomei MD, Iwata T, Roth B, Kimura S, Mathieu R, Ferro M, **Shariat SF**, Seitz C. Impact of alcohol consumption on the risk of developing bladder cancer: a systematic review and meta-analysis. *World J Urol*. 2019 Jun 6. PMID: 31172281
682. Cantiello F, Russo GI, Vartolomei MD, Farhan ARA, Terracciano D, Musi G, Lucarelli G, Di Stasi SM, Hurle R, Serretta V, Busetto GM, Scafuro C, Perdonà S, Borghesi M, Schiavina R, Cioffi A, De Berardinis E, Almeida GL, Bove P, Lima E, Ucciero G, Matei DV, Crisan N, Verze P, Battaglia M, Guazzoni G, Autorino R, Morgia G, Damiano R, de Cobelli O, Mirone V, **Shariat SF**, Ferro M. Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer. *Eur Urol Oncol*. 2018 Oct;1(5):403-410. PMID: 31158079
683. González J, Gaynor JJ, Martínez-Salamanca JI, Capitanio U, Tilki D, Carballido JA, Chantada V, Daneshmand S, Evans CP, Gasch C, Gontero P, Haferkamp A, Huang WC, Espinós EL, Master VA, McKiernan JM, Montorsi F, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, **Shariat SF**, Spahn M, Terrone C, Vera-Donoso C, Zigeuner R, Hohenfellner M, Libertino JA, Ciancio G. Association of an organ transplant-based approach with a dramatic reduction in postoperative complications following radical nephrectomy and tumor thrombectomy in renal cell carcinoma. *Eur J Surg Oncol*. 2019 May 15. PMID: 31155470
684. Kimura S, Abufaraj M, Janisch F, Iwata T, Parizi MK, Foerster B, Fossati N, Briganti A, Egawa S, Hartenbach M, **Shariat SF**. Performance of [68Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection: a systematic review and meta-analysis. *Prostate Cancer Prostatic Dis*. 2019 May 30. PMID: 31147628
685. Mazzone E, Mistretta FA, Knipper S, Palumbo C, Tian Z, Pecoraro A, Preisser F, Gallina A, Shariat SF, Saad F, Graefen M, Montorsi F, Briganti A, Karakiewicz PI. Long-Term Incidence of Secondary Bladder, Rectal Cancer in Patients Treated with Brachytherapy for Localized Prostate Cancer: A Large-Scale Population-Based Analysis. *BJU Int*. 2019 May 30. PMID: 31144770
686. Kardoust Parizi M, Glybochko PV, Enikeev D, Rouprêt M, Fajkovic H, Seebacher V, **Shariat SF**. Risk stratification of upper tract urothelial carcinoma: A Review of the Current Literature. *Expert Rev Anticancer Ther*. 2019 Jun;19(6):503-513. PMID: 31131643
687. Knipper S, Preisser F, Mazzone E, Mistretta FA, Palumbo C, Tian Z, Briganti A, **Shariat SF**, Saad F, Tilki D, Graefen M, Karakiewicz PI. Contemporary analysis of the effect of marital status on survival of prostate cancer patients across all stages: A population-based study. *Urol Oncol*. 2019 May 15. PMID: 31103337
688. Bandini M, Preisser F, Nazzani S, Marchioni M, Tian Z, Mazzone E, Graefen M, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients. *Eur Urol Oncol*. 2018 Aug;1(3):215-222. PMID: 31102624
689. Nazzani S, Preisser F, Bandini M, Marchioni M, Tian Z, Soulières D, Montanari E, Ratti D, Acquati P, Briganti A, **Shariat SF**, Abdollah F, Carmignani L, Karakiewicz PI. Surgically Treated Retroperitoneal Sarcoma: A Population-based Competing Risks Analysis. *Eur Urol Oncol*. 2018 Sep;1(4):346-351. PMID: 31100257
690. Bandini M, Mazzone E, Preisser F, Nazzani S, Zaffuto E, Marchioni M, Tian Z, Pompe RS, Tilki D, Graefen M, **Shariat SF**, Montorsi F, Saad F, Briganti A, Karakiewicz P. Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the

- Surveillance, Epidemiology and End Results Database. *Eur Urol Oncol*. 2018 Sep;1(4):314-320. PMID: 31100253
691. Vartolomei L, **Shariat SF**, Vartolomei MD. Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature. *Eur Urol Oncol*. 2018 Sep;1(4):283-291. PMID: 31100249
692. Zaffuto E, Bandini M, Moschini M, Leyh-Bannurah SR, Gazdovich S, Dell'Oglio P, Gallina A, **Shariat SF**, Briganti A, Montorsi F, Saad F, Karakiewicz PI. Location of Metastatic Bladder Cancer as a Determinant of In-hospital Mortality After Radical Cystectomy. *Eur Urol Oncol*. 2018 Jun;1(2):169-175. PMID: 31100242
693. Heidenreich A, Fossati N, Pfister D, Suardi N, Montorsi F, **Shariat S**, Grubmüller B, Gandaglia G, Briganti A, Karnes RJ. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases. *Eur Urol Oncol*. 2018 May ;1(1):46-53. PMID: 31100228
694. Kimura S, Iwata T, Foerster B, Fossati N, Briganti A, Nasu Y, Egawa S, Abufaraj M, **Shariat SF**. Comparison of perioperative complications and health-related quality of life between robot-assisted and open radical cystectomy: A systematic review and meta-analysis. *Int J Urol*. 2019 May 13. PMID: 31083783
695. Zamboni S, Soria F, Mathieu R, Xylinas E, Abufaraj M, D'Andrea D, Tan WS, Kelly JD, Simone G, Gallucci M, Meraney A, Krishna S, Konety BR, Antonelli A, Simeone C, Baumeister P, Mattei A, Briganti A, Gallina A, Montorsi F, Rink M, Aziz A, Karakiewicz PI, Rouprêt M, Koupparis A, Scherr DS, Ploussard G, Sooriakumaran P, **Shariat SF**, Moschini M: Differences in utilization-trend and time changes of peri-operative outcomes of robotic and open radical cystectomy between American and European selected centers: an international multicenter collaboration. *BJU Int*. 2019 May 4. PMID: 31055865
696. Mazzone E, Preisser F, Nazzani S, Tian Z, Zaffuto E, Gallina A, Tilki D, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. The effect of age and comorbidities on early postoperative complications after radical cystectomy: A contemporary population-based analysis. *J Geriatr Oncol*. 2019 Apr 19. PMID: 31010691
697. Abufaraj M, Tabung FK, **Shariat SF**, Moschini M, Devore E, Papantoniou K, Yang L, Strohmaier S, Rohrer F, Markt SC, Zhang X, Giovannucci E, Schernhammer E. Association between inflammatory potential of diet and bladder cancer risk: Results from three US prospective cohort studies. *J Urol*. 2019 Apr 22:PMID: 31009297
698. D'Andrea D, Abufaraj M, Soria F, Gust K, Haitel A, Krakiewicz PI, **Shariat SF**. Association of super-extended lymphadenectomy at radical cystectomy with perioperative complications and re-hospitalization. *World J Urol*. 2019 Apr 20. PMID: 31006052
699. Nazzani S, Preisser F, Mazzone E, Marchioni M, Bandini M, Tian Z, Mistretta FA, **Shariat SF**, Soulières D, Saad F, Montanari E, Luzzago S, Briganti A, Carmignani L, Karakiewicz PI. Survival effect of nephroureterectomy in metastatic upper urinary tract urothelial carcinoma. *Clin Genitourin Cancer*. 2019 Mar 29. PMID: 31005472
700. Ferro M, Di Lorenzo G, Vartolomei MD, Bruzzese D, Cantiello F, Lucarelli G, Musi G, Di Stasi S, Hurler R, Guazzoni G, Busetto GM, Gabriele A, Del Giudice F, Damiano R, Perri F, Perdona S, Verze P, Borghesi M, Schiavina R, Almeida GL, Bove P, Lima E, Autorino R, Crisan N, Farhan ARA, Battaglia M, Russo GI, Ieluzzi V, Morgia G, De Placido P, Terracciano D, Cimmino A, Scafuri L, Mirone V, De Cobelli O, **Shariat S**, Sonpavde G, Buonerba C. Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving

- bacillus Calmette-Guérin after transurethral resection of the bladder tumor. *World J Urol.* 2019 Apr 16. PMID: 30993426
701. Palumbo C, Cyr SJ, Mazzone E, Mistretta FA, Knipper S, Pecoraro A, Tian Z, **Shariat SF**, Saad F, Simeone C, Briganti A, Kapoor A, Antonelli A, Karakiewicz PI. Impact of tumor size on cancer specific mortality after local tumor ablation in T1a renal cell carcinoma. *J Endourol.* 2019 Apr 16. PMID: 30990074
702. Iwata T, Kimura S, Foerster B, Fossati N, Briganti A, Karakiewicz PI, Gust KM, Egawa S, Nasu Y, Abufaraj M, **Shariat SF**. Oncologic outcomes after robot-assisted versus open radical cystectomy: a systematic review and meta-analysis. *World J Urol.* 2019 Apr 11. PMID: 30976902
703. D'Andrea D, Gontero P, **Shariat SF**, Soria F. Intravesical bacillus Calmette-Guérin for bladder cancer: are all the strains equal? *Transl Androl Urol.* 2019 Feb;8(1):85-93. PMID: 30976572
704. Soria F, Marra G, D'Andrea D, Gontero P, **Shariat SF**. The rational and benefits of the second look transurethral resection of the bladder for T1 high grade bladder cancer. *Transl Androl Urol.* 2019 Feb;8(1):46-53. PMID: 30976568
705. Pozo C, **Shariat SF**, D'Andrea D, Fajkovic H, Abufaraj M. Enhanced Recovery after Radical Cystectomy. *Curr Opin Urol.* 2019 May;29(3):227-238. PMID: 30950886
706. Azizi M, Cheriyan SK, Peyton CC, Foerster B, **Shariat SF**, Spiess PE. Optimal Management of Upper Tract Urothelial Carcinoma: an Unmet Need. *Curr Treat Options Oncol.* 2019 Apr 1;20(5):40. PMID: 30937554
707. Mazzone E, Mistretta FA, Knipper S, Tian Z, Larcher A, Widmer H, Zorn KC, Capitanio U, Graefen M, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Contemporary North-American Assessment of Robot-assisted Surgery Rates and Total Hospital Charges for Major Surgical Uro-oncological Procedures. *J Endourol.* 2019 Mar 30. PMID: 30931607
708. Zamboni S, Foerster B, Abufaraj M, Seisen T, Roupert M, Colin P, De la Taille A, Di Bona C, Peyronnet B, Bensalah K, Herout R, Wirth MP, Novotny V, Soria F, Chlosta P, Antonelli A, Simeone C, Baumeister P, Mattei A, Montorsi F, Simone G, Gallucci M, Matsumoto K, Karakiewicz PI, Briganti A, Xylinas E, **Shariat SF**, Moschini M. Incidence and survival outcomes of upper urinary tract urothelial carcinoma (UTUC) patients diagnosed with variant histology treated with nephroureterectomy. *BJU Int.* 2019 Mar 25. PMID: 30908835
709. Kardoust Parizi M, Iwata T, Kimura S, Janisch F, Abufaraj M, Karakiewicz PI, Enikeev D, Rapoport LM, Hutterer G, **Shariat SF**. Focal Neuroendocrine Differentiation of Conventional Prostate Adenocarcinoma as a Prognostic Factor after Radical Prostatectomy: A Systematic Review and Meta-Analysis. *Int J Mol Sci.* 2019 Mar 19;20(6). PMID: 30893781
710. Janisch F, **Shariat SF**, Schernhammer E, Rink M, Fajkovic H. The interaction of gender and smoking on bladder cancer risks. *Curr Opin Urol.* 2019 May;29(3):249-255. PMID: 30888973
711. Mun DH, Kimura S, **Shariat SF**, Abufaraj M. The impact of gender on oncologic outcomes of bladder cancer. *Curr Opin Urol.* 2019 Mar 6. PMID: 30855378
712. Marks P, Gild P, Soave A, Janisch F, Minner S, Engel O, Vetterlein MW, **Shariat SF**, Sauter G, Dahlem R, Fisch M, Rink M. The impact of variant histological differentiation on extranodal extension and survival in node positive bladder cancer treated with radical cystectomy. *Surg Oncol.* 2019 Mar;28:208-213. PMID: 30851902
713. Nazzani S, Bandini M, Preisser F, Mazzone E, Marchioni M, Tian Z, Stubinski R, Clementi MC, Saad F, **Shariat SF**, Montanari E, Briganti A, Carmignani L, Karakiewicz PI. Postoperative

- paralytic ileus after major oncological procedures in the enhanced recovery after surgery era: A population based analysis. *Surg Oncol.* 2019 Mar;28:201-207. PMID: 30851901
714. Moschini M, Martini A, Zamboni S, Mattei A, Baumeister P, Di Bona C, Dell'Oglio P, Zaffuto E, Burgio G, **Shariat SF**, Sanchez-Salas R, Cathelineau X, Salonia A, Montorsi F, Briganti A, Gallina A, Colombo R. Evaluation of Cause of Death After Radical Cystectomy for Patients With Bladder Cancer: The Impact of Age at the Time of Surgery. *Clin Genitourin Cancer.* 2019 Feb 13. PMID: 30850337
715. Foerster B, D'Andrea D, Abufaraj M, Broenimann S, Karakiewicz PI, Rouprêt M, Gontero P, Lerner SP, **Shariat SF**, Soria F. Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature. *Urol Oncol.* 2019 Mar 4. PMID: 30846387
716. Fossati N, Robesti D, Karnes RJ, Soligo M, Boorjian SA, Bossi A, Coraggio G, Di Muzio N, Cozzarini C, Noris Chiorda B, Gandaglia G, Scarcella S, Bartkowiak D, Böhmer D, **Shariat S**, Goldner G, Battaglia A, Joniau S, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Wiegel T, Briganti A. Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study. *Eur Urol.* 2019 Feb 21. PMID: 3079918
717. Mistretta FA, Mazzone E, Knipper S, Palumbo C, Tian Z, Nazzani S, Saad F, Montanari E, Tilki D, Briganti A, **Shariat SF**, de Cobelli O, Karakiewicz PI. Contemporary trends of pelvic lymph node dissection at radical cystectomy for urothelial carcinoma of urinary bladder and associated cancer specific mortality and complications: comparison between octogenarian versus younger patients. *Cancer Epidemiol.* 2019 Feb 13;59:135-142. PMID: 30771698
718. Hassler MR, **Shariat SF**, Soria F. Salvage therapeutic strategies for bacillus Calmette-Guerin failure. *Curr Opin Urol.* 2019 Feb 11. PMID: 30762670
719. Aydin AM, Singla N, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Westerman ME, Sagalowsky AI, **Shariat SF**, Lotan Y, Bagrodia A, Kapur P, Margulis V, Krabbe LM. Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. *World J Urol.* 2019 Feb 13. PMID: 30759271
720. Nazzani S, Bazinet A, Preisser F, Mazzone E, Tian Z, Mistretta FA, **Shariat SF**, Saad F, Zorn KC, Montanari E, Briganti A, Carmignani L, Karakiewicz PI. Comparison of perioperative outcomes between open and minimally invasive nephroureterectomy: A population-based analysis. *Int J Urol.* 2019 Feb 12. PMID: 30756440
721. Mazzone E, Nazzani S, Knipper S, Tian Z, Preisser F, Gallina A, Soulières D, Tilki D, Montorsi F, **Shariat SF**, Saad F, Briganti A, Wisnivesky J, Karakiewicz PI. Contemporary use and survival after perioperative systemic chemotherapy in patients with locally advanced non-metastatic urothelial carcinoma of the bladder treated with radical cystectomy. *Eur J Surg Oncol.* 2019 Feb 3. PMID: 30755341
722. Iwata T, Kimura S, Foerster B, Abufaraj M, Karakiewicz PI, Preisser F, Nasu Y, **Shariat SF**: Perioperative blood transfusion affects oncologic outcomes after nephrectomy for renal cell carcinoma: A systematic review and meta-analysis. *Urol Oncol.* 2019 Feb 5. PMID: 30737159
723. Moschini M, Zamboni S, Mattei A, Baumeister P, Di Bona C, Cornelius J, **Shariat SF**, Freschi M, Zaffuto E, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A: Radical Cystectomy in Pathological T4a and T4b Bladder Cancer Patients: Is There Any Space for Sub Stratification? *Urol Int.* 2019 Jan 29:1-8. PMID: 30695782

724. Soria F, **Shariat SF**. Biomarkers for the prediction of oncologic outcomes in non-muscle invasive bladder cancer: state of affairs and new frontiers. *Transl Androl Urol*. 2018 Dec;7(Suppl 6):S753-S755. PMID: 30687617
725. D'Andrea D, Soria F, Zehetmayer S, Gust KM, Korn S, Witjes JA, **Shariat SF**. Diagnostic accuracy, clinical utility and influence on decision making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer. *BJU Int*. 2019 Jan 17. PMID: 30653818
726. Korn SM, Hübner NA, Seitz C, **Shariat SF**, Fajkovic H. Role of lasers in urology. *Photochem Photobiol Sci*. 2019 Jan 14. PMID: 30640321
727. Berg S, D'Andrea D, Vetterlein MW, Cole AP, Fletcher SA, Krimphove MJ, Marchese M, Lipsitz SR, Sonpavde G, Noldus J, **Shariat SF**, Kibel AS, Trinh QD, Mossanen M. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter? *Cancer*. 2019 Jan 8. PMID: 30620387
728. Foerster B, **Shariat SF**, Klein JT, Bolenz C. Biopsy techniques in the upper urinary tract for the diagnosis of urothelial carcinoma: systematic review. *Urologe A*. 2019 Jan 7. PMID: 30617531
729. Preisser F, Mazzone E, Nazzani S, Knipper S, Tian Z, Mandel P, Pompe R, Saad F, Montorsi F, **Shariat SF**, Huland H, Graefen M, Tilki D, Karakiewicz PI. Impact of age on perioperative outcomes at radical prostatectomy: a population-based study. *Eur Urol Focus*. 2018 Dec 26. PMID: 30594487
730. Kimura S, D' Andrea D, Soria F, Foerster B, Abufaraj M, Vartolomei MD, Iwata T, Karakiewicz PI, Rink M, Gust KM, Egawa S, **Shariat SF**. Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer. *Urol Oncol*. 2018 Dec 20. PMID: 30580906
731. Stangl-Kremser J, D'Andrea D, Vartolomei M, Abufaraj M, Goldner G, Baltzer P, **Shariat SF**, Tamandl D. Prognostic value of nutritional indices and body composition parameters including sarcopenia in patients treated with radiotherapy for urothelial carcinoma of the bladder. *Urol Oncol*. 2018 Dec 18. PMID: 30578161
732. Grubmüller B, Senn D, Kramer G, Baltzer P, D'Andrea D, Grubmüller KH, Mitterhauser M, Eidherr H, Haug AR, Wadsak W, Pfaff S, **Shariat SF**, Hacker M, Hartenbach M. Response assessment using ⁶⁸Ga-PSMA ligand PET in patients undergoing ¹⁷⁷Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. *Eur J Nucl Med Mol Imaging*. 2018 Dec 19. PMID: 30569186
733. Nazzani S, Mazzone E, Preisser F, Tian Z, Mistretta FA, **Shariat SF**, Montanari E, Acquati P, Briganti A, Saad F, Carmignani L, Karakiewicz PI. Rates of lymph node invasion and their impact on cancer specific mortality in upper urinary tract urothelial carcinoma. *Eur J Surg Oncol*. 2018 Dec 11. PMID: 30563773
734. Abufaraj M, Foerster B, Schernhammer E, Moschini M, Kimura S, Hassler MR, Preston MA, Karakiewicz PI, Remzi M, **Shariat SF**. Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes. *Eur Urol*. 2018 Dec 12. PMID: 30553613
735. Vartolomei MD, D'Andrea D, Chade DC, Soria F, Kimura S, Foerster B, Abufaraj M, Mathieu R, Moschini M, Rouprêt M, Briganti A, Karakiewicz PI, **Shariat SF**. Role of serum cholinesterase in patients treated with salvage radical prostatectomy. *Urol Oncol*. 2018 Dec 3. PMID: 30522902
736. Mazzone E, Knipper S, Mistretta FA, Tian Z, Preisser F, Gallina A, Soulieres D, Tilki D, Montorsi F, **Shariat SF**, Saad F, Briganti A, Wisnivesky J, Karakiewicz PI. Is neoadjuvant chemotherapy for

- pT2 bladder cancer associated with a survival benefit in a population-based analysis? *Cancer Epidemiol.* 2018 Dec 5;58:83-88. PMID: 30528834
737. Mazzone E, Preisser F, Nazzani S, Tian Z, Fossati N, Gandaglia G, Gallina A, Soulieres D, Tilki D, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. More Extensive Lymph Node Dissection Improves Survival Benefit of Radical Cystectomy in Metastatic Urothelial Carcinoma of the Bladder. *Clin Genitourin Cancer.* 2018 Nov 17. PMID: 30527745
738. Soukup V, Čapoun O, Cohen D, Hernández V, Burger M, Compérat E, Gontero P, Lam T, Mostafid AH, Palou J, van Rhijn BWG, Rouprêt M, **Shariat SF**, Sylvester R, Yuan Y, Zigeuner R, Babjuk M. Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel. *Eur Urol Focus.* 2018 Nov 20. PMID: 30470647
739. Soria F, Moschini M, D'andrea D, Abufaraj M, Foerster B, Mathiéu R, Gust KM, Gontero P, Simone G, Meraney A, Krishna S, Konety B, Rouprêt M, Perry M, Rowe E, Ploussard G, Boorjian SA, Wiklund P, Sooriakumaran P, **Shariat SF**. Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. *Eur Urol Focus.* 2018 Nov 16. PMID: 30455153
740. D'Andrea D, Soria F, Abufaraj M, Gust K, Foerster B, Vartolomei MD, Kimura S, Mari A, Briganti A, Remzi M, Seitz CK, Mathieu R, Karakiewicz PI, **Shariat SF**. Clinical value of cholinesterase in the prediction of biochemical recurrence after radical prostatectomy. *Urol Oncol.* 2018 Nov 13. PMID: 30446461
741. Moschini M, Soria F, Mathieu R, Xylinas E, D'Andrea D, Tan WS, Kelly JD, Simone G, Tuderti G, Meraney A, Krishna S, Konety B, Zamboni S, Baumeister P, Mattei A, Briganti A, Montorsi F, Galucci M, Rink M, Karakiewicz PI, Rouprêt M, Aziz A, Perry M, Rowe E, Koupparis A, Kassouf W, Scherr DS, Ploussard G, Boorjian SA, Sooriakumaran P, **Shariat SF**: Propensity-score-matched comparison of soft tissue surgical margins status between open and robotic-assisted radical cystectomy. *Urol Oncol.* 2018 Nov 13. PMID: 30446442
742. Khene ZE, Peyronnet B, Freton L, Graffaille V, Pradere B, Robert C, Kammerer-Jacquet SF, Verhoest G, Rioux-Leclercq N, **Shariat S**, Mathieu R, Bensalah K. What Is Better for Predicting Morbidity of Robotic Partial Nephrectomy-A Score or Your Clinical Judgement? *Eur Urol Focus.* 2018 Nov 12. PMID: 30442584
743. Preisser F, Mazzone E, Nazzani S, Marchioni M, Bandini M, Tian Z, Saad F, Soulières D, **Shariat SF**, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI. North American population-based validation of the National Comprehensive Cancer Network Practice Guideline Recommendations for locoregional lymph node and bone imaging in prostate cancer patients. *Br J Cancer.* 2018 Nov 14. PMID: 30425350
744. Rieken M, Boorjian SA, Kluth LA, Capitanio U, Briganti A, Thompson RH, Leibovich BC, Krabbe LM, Margulis V, Raman JD, Regelman M, Karakiewicz PI, Rouprêt M, Abufaraj M, Foerster B, Gönen M, **Shariat SF**. Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma. *World J Urol.* 2018 Nov 7. PMID: 30406477
745. Salami SS, Hovelson DH, Kaplan JB, Mathieu R, Udager AM, Curci NE, Lee M, Plouffe KR, de la Vega LL, Susani M, Rioux-Leclercq N, Spratt DE, Morgan TM, Davenport MS, Chinnaiyan AM, Cyrta J, Rubin MA, **Shariat SF**, Tomlins SA, Palapattu GS. Transcriptomic heterogeneity in multifocal prostate cancer. *JCI Insight.* 2018 Nov 2;3(21). PMID: 30385730

746. Preisser F, Mazzone E, Knipper S, Nazzani S, Bandini M, **Shariat SF**, Tian Z, Saad F, Montorsi F, Zorn KC, Graefen M, Tilki D, Karakiewicz PI. Rates of Positive Surgical Margins and Their Effect on Cancer-specific Mortality at Radical Prostatectomy for Patients With Clinically Localized Prostate Cancer. *Clin Genitourin Cancer*. 2018 Oct 4. PMID: 30366880
747. Williams SB, Kamat AM, Chamie K, Froehner M, Wirth MP, Wiklund PN, Black PC, Steinberg GD, Boorjian SA, Daneshmand S, Goebell PJ, Pohar KS, **Shariat SF**, Thalmann GN. Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients. *Eur Urol Oncol*. 2018 Jun;1(2):91-100. PMID: 30345422
748. Bandini M, Nazzani S, Marchioni M, Preisser F, Tian Z, Moschini M, Abdollah F, Suardi N, Graefen M, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Increasing Rate of Noninterventional Treatment Management in Localized Prostate Cancer Candidates for Active Surveillance: A North American Population-Based Study. *Clin Genitourin Cancer*. 2018 Sep 22. PMID: 30342845
749. Nazzani S, Preisser F, Mazzone E, Marchioni M, Bandini M, Tian Z, Mistretta FA, **Shariat SF**, Soulières D, Montanari E, Acquati P, Briganti A, Carmignani L, Karakiewicz PI. Survival Effect of Chemotherapy in Metastatic Upper Urinary Tract Urothelial Carcinoma. *Clin Genitourin Cancer*. 2018 Sep 27. PMID: 30337106
750. Mazzone E, Bandini M, Preisser F, Nazzani S, Tian Z, Abdollah F, Soulieres D, Graefen M, Montorsi F, **Shariat S**, Saad F, Briganti A, Karakiewicz P. The effect of race on survival after local therapy in metastatic prostate cancer patients. *Can Urol Assoc J*. 2018 Oct 15. PMID: 30332592
751. Hofbauer SL, de Martino M, Lucca I, Haitel A, Susani M, **Shariat SF**, Klatte T. A urinary microRNA (miR) signature for diagnosis of bladder cancer. *Urol Oncol*. 2018 Oct 12. PMID: 30322728
752. Preisser F, Nazzani S, Mazzone E, Knipper S, Bandini M, Tian Z, Haese A, Saad F, Zorn KC, Montorsi F, **Shariat SF**, Graefen M, Tilki D, Karakiewicz PI. Regional differences in total hospital charges between open and robotically assisted radical prostatectomy in the United States. *World J Urol*. 2018 Oct 12. PMID: 30315358
753. Fossati N, Suardi N, Gandaglia G, Bravi CA, Soligo M, Karnes RJ, **Shariat S**, Battaglia A, Everaerts W, Joniau S, Van Poppel H, Rajarubendra N, Gill IS, Larcher A, Mottrie A, Schmautz M, Heidenreich A, Kalz A, Osmonov D, Juenemann KP, Herlemann A, Gratzke C, Stief C, Montorsi F, Briganti A. Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis. *Eur Urol*. 2018 Oct 6. PMID: 30301694
754. Nazzani S, Preisser F, Mazzone E, Tian Z, Mistretta FA, **Shariat SF**, Soulières D, Saad F, Montanari E, Luzzago S, Briganti A, Carmignani L, Karakiewicz PI. Survival effect of perioperative systemic chemotherapy on overall mortality in locally advanced and/or positive regional lymph node non-metastatic urothelial carcinoma of the upper urinary tract. *World J Urol*. 2018 Oct 8. PMID: 30298285
755. Moschini M, Zaffuto E, Karakiewicz PI, Andrea DD, Foerster B, Abufaraj M, Soria F, Mattei A, Montorsi F, Briganti A, **Shariat SF**. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. *Eur Urol*. 2018 Oct 4. PMID: 30293908
756. Moschini M, Zaffuto E, Karakiewicz P, Mattei A, Gandaglia G, Fossati N, Montorsi F, Briganti A, **Shariat SF**. The effect of androgen deprivation treatment on subsequent risk of bladder cancer diagnosis in male patients treated for prostate cancer. *World J Urol*. 2018 Oct 1. PMID: 30276543

757. Nazzani S, Preisser F, Mazzone E, Tian Z, Mistretta FA, Soulières D, Montanari E, Acquati P, Briganti A, **Shariat SF**, Abdollah F, Carmignani L, Karakiewicz PI. Nephroureterectomy with or without Bladder Cuff Excision for Localized Urothelial Carcinoma of the Renal Pelvis. *Eur Urol Focus*. 2018 Sep 25. PMID: 30266210
758. Soria F, Krabbe LM, Todenhöfer T, Dobruch J, Mitra AP, Inman BA, Gust KM, Lotan Y, **Shariat SF**. Molecular markers in bladder cancer. *World J Urol*. 2018 Sep 26. PMID: 30259123
759. Suarez-Ibarrola R, Soria F, Abufaraj M, D'Andrea D, Preto M, Gust KM, Briganti A, **Shariat SF**, Gontero P. Surgical checklist impact on recurrence-free survival of non-muscle invasive bladder cancer patients undergoing transurethral resection of bladder tumor. *BJU Int*. 2018 PMID: 30248235
760. Hübner N, **Shariat SF**, Remzi M. Focal therapy of prostate cancer. *Curr Opin Urol*. 2018 Nov;28(6):550-554. PMID: 30239415
761. Bruchbacher A, Soria F, Hassler M, **Shariat SF**, D'Andrea D. Tissue biomarkers in nonmuscle-invasive bladder cancer: any role in clinical practice? *Curr Opin Urol*. 2018 Nov;28(6):584-590. PMID: 30188332
762. Hübner N, **Shariat SF**. Palliative surgery for metastatic urothelial cancer. *Aktuelle Urol*. 2018 Sep;49(5):412-416. PMID: 30184599
763. Gächter A, Halling T, **Shariat SF**, Moll FH: Transfer of Knowledge in Urology: A Case Study of Jacob Eduard Polak (1818-1891) and the Introduction of Contemporary Techniques of Lithotomy and Lithotripsy from Vienna to Persia in the Mid-19th Century: A New Analysis of Scientific Papers from the 19th Century. *Urol Int*. 2018 Sep 3:1-12. PMID: 30176666
764. Mazzone E, Nazzani S, Preisser F, Tian Z, Marchioni M, Bandini M, Capitanio U, Kapoor A, Tilki D, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz P. Partial nephrectomy seems to confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma. *Cancer Epidemiol*. 2018 Aug 30;56:118-125. PMID: 30173050
765. Soria F, Pisano F, Gontero P, Palou J, Joniau S, Serretta V, Larré S, Di Stasi S, van Rhijn B, Witjes JA, Grotenhuis A, Colombo R, Briganti A, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha E, Ardelt P, Varkarakis J, Bartoletti R, Dalbagni G, **Shariat SF**, Xylinas E, Karnes RJ, Sylvester R. Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy. *World J Urol*. 2018 Aug 31. PMID: 30171454
766. Soria F, D'Andrea D, Pohar K, **Shariat SF**, Lotan Y. Diagnostic, prognostic and surveillance urinary markers in nonmuscle invasive bladder cancer: any role in clinical practice? *Curr Opin Urol*. 2018 Aug 27. PMID: 30157039
767. Preisser F, Nazzani S, Bandini M, Marchioni M, Tian Z, Saad F, Chun FK, **Shariat SF**, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI. Racial disparities in lymph node dissection at radical prostatectomy: A Surveillance, Epidemiology and End Results database analysis. *Int J Urol*. 2018 Aug 26. PMID: 30146729
768. Grubmüller B, Baltzer PA, Hartenbach S, D'Andrea D, Helbich TH, Haug A, Goldner G, Wadsak W, Pfaff S, Mitterhauser M, Balber T, Berroterán-Infante N, Grahovac M, Babich JW, Seitz C, Kramer G, Susani M, Mazal P, Kenner L, **Shariat SF**, Hacker M, Hartenbach M. PSMA ligand PET/MRI for primary prostate cancer: Staging performance and clinical impact. *Clin Cancer Res*. 2018 Aug 23. PMID: 30139879
769. Abufaraj M, Mostafid H, **Shariat SF**, Babjuk M. What to do during Bacillus Calmette-Guérin shortage? Valid strategies based on evidence. *Curr Opin Urol*. 2018 Aug 21. PMID: 30138122

770. Vartolomei L, Ferro M, Mirone V, **Shariat SF**, Vartolomei MD. Systematic Review: Depression and Anxiety Prevalence in Bladder Cancer Patients. *Bladder Cancer*. 2018 Jul 30;4(3):319-326. PMID: 30112443
771. Stangl-Kremser, Mari A, D'Andrea D, Kimura S, Resch I, **Shariat SF**, Klatte T. Sarcopenia as a Predictive Factor for Response to Upfront Cisplatin-Based Chemotherapy in Patients with Muscle-Invasive Urothelial Bladder Cancer. *Urol Int*. 2018;101(2):197-200. PMID: 30089304
772. Kimura S, Mari A, Foerster B, Abufaraj M, Vartolomei MD, Stangl-Kremser J, Karakiewicz PI, Egawa S, **Shariat SF**. Prognostic value of concomitant carcinoma in situ in the radical cystectomy specimen: A systematic review and meta-analysis. *J Urol*. 2018 Aug 2. PMID: 30077559
773. Vartolomei MD, Ferro M, Cantiello F, Lucarelli G, Di Stasi S, Hurle R, Guazzoni G, Busetto GM, De Berardinis E, Damiano R, Perdonà S, Verze P, La Rocca R, Borghesi M, Schiavina R, Brunocilla E, Almeida GL, Bove P, Lima E, Grimaldi G, Autorino R, Crisan N, Abu Farhan AR, Battaglia M, Serretta V, Russo GI, Morgia G, Terracciano D, Musi G, de Cobelli O, Mirone V, **Shariat SF**. Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer. *Clin Genitourin Cancer*. 2018 Jul 6. PMID: 30077463
774. Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid HA, Palou J, van Rhijn BWG, Rouprêt M, **Shariat SF**, Sylvester R, Zigeuner R, Capoun O, Cohen D, Dominguez-Escrig JL, Hernández V, Peyronnet B, Seisen T, Soukup V; European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer. Indication for a Single Postoperative Instillation of Chemotherapy in Non-muscle-invasive Bladder Cancer: What Factors Should Be Considered? *Eur Urol Focus*. 2018 Jul 27. PMID: 30061076
775. Kimura S, Soria F, D'Andrea D, Foerster B, Abufaraj M, Vartolomei MD, Karakiewicz PI, Mathieu R, Moschini M, Rink M, Egawa S, **Shariat SF**, Gust KM. Prognostic Value of Serum Cholinesterase in Non-muscle-invasive Bladder Cancer. *Clin Genitourin Cancer*. 2018 Jul 6. PMID: 30061034
776. Suarez-Ibarrola R, Abufaraj M, **Shariat SF**. Intermediate and long-term complications associated with adjuvant chemotherapy for stage I germ cell tumor patients. *Curr Opin Urol*. 2018 Sep;28(5):485-490. PMID: 30044319
777. Preisser F, Mazzone E, Nazzani S, Bandini M, Tian Z, Marchioni M, Steuber T, Saad F, Montorsi F, **Shariat SF**, Huland H, Graefen M, Tilki D, Karakiewicz PI. Comparison of Perioperative Outcomes Between Cytoreductive Radical Prostatectomy and Radical Prostatectomy for Nonmetastatic Prostate Cancer. *Eur Urol*. 2018 Jul 20. PMID: 30037529
778. Vartolomei MD, Kimura S, Vartolomei L, **Shariat SF**. Systematic Review of the Impact of Testosterone Replacement Therapy on Depression in Patients with Late-onset Testosterone Deficiency. *Eur Urol Focus*. 2018 Jul 14. PMID: 30017901
779. Ferro M, Vartolomei MD, Russo GI, Cantiello F, Farhan ARA, Terracciano D, Cimmino A, Di Stasi S, Musi G, Hurle R, Serretta V, Busetto GM, De Berardinis E, Cioffi A, Perdonà S, Borghesi M, Schiavina R, Cozzi G, Almeida GL, Bove P, Lima E, Grimaldi G, Matei DV, Crisan N, Muto M, Verze P, Battaglia M, Guazzoni G, Autorino R, Morgia G, Damiano R, de Cobelli O, **Shariat S**, Mirone V, Lucarelli G. An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. *World J Urol*. 2018 Jul 10. PMID: 29992381
780. Polanec SH, Helbich TH, Bickel H, Wengert GJ, Pinker K, Spick C, Clauser P, Susani M, **Shariat S**, Baltzer PAT. Quantitative Apparent Diffusion Coefficient Derived From Diffusion-Weighted

- Imaging Has the Potential to Avoid Unnecessary MRI-Guided Biopsies of mpMRI-Detected PI-RADS 4 and 5 Lesions. *Invest Radiol.* 2018 Jul 6. PMID: 29985792
781. Mathieu R, Castelli C, Fardoun T, Peyronnet B, **Shariat SF**, Bensalah K, Vincendeau S. Cost analysis of prostate cancer detection including the prostate health index (phi). *World J Urol.* 2018 Jul 6. PMID: 29980838
782. Ferro M, Vartolomei MD, Cantiello F, Lucarelli G, Di Stasi SM, Hurle R, Guazzoni G, Busetto GM, De Berardinis E, Damiano R, Perdonà S, Borghesi M, Schiavina R, Almeida GL, Bove P, Lima E, Grimaldi G, Autorino R, Crisan N, Abu Farhan AR, Verze P, Battaglia M, Serretta V, Russo GI, Morgia G, Musi G, de Cobelli O, Mirone V, **Shariat SF**. High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study. *Urol Int.* 2018;101(1):7-15. PMID: 29975950
783. Mazzone E, Preisser F, Nazzani S, Tian Z, Bandini M, Gandaglia G, Fossati N, Soulières D, Graefen M, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Location of Metastases in Contemporary Prostate Cancer Patients Affects Cancer-Specific Mortality. *Clin Genitourin Cancer.* 2018 Jun 5. PMID: 29954690
784. Darr C, Krafft U, Hadaschik B, Tschirdewahn S, Sevcenco S, Csizmarik A, Nyirady P, Küronya Z, Reis H, Maj-Hes A, **Shariat SF**, Kramer G, Szarvas T. The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer. *Urol Int.* 2018;101(1):65-73. PMID: 29949801
785. Krabbe LM, Margulis V, Schrader AJ, **Shariat SF**, Gust KM, Boegemann M. Molecularly-driven precision medicine for advanced bladder cancer. *World J Urol.* 2018 Jun 8. PMID: 29948043
786. Soria F, Droller MJ, Lotan Y, Gontero P, D'Andrea D, Gust KM, Rouprêt M, Babjuk M, Palou J, **Shariat SF**. An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer. *World J Urol.* 2018 Jun 21. PMID: 29931526
787. Vartolomei MD, Porav-Hodade D, Ferro M, Mathieu R, Abufaraj M, Foerster B, Kimura S, **Shariat SF**. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis. *Urol Oncol.* 2018 Jun 5. PMID: 29884342
788. Vasdev N, Zargar H, Noël JP, Veeratterapillay R, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, **Shariat SF**, Wright JL, Morgan TM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Holzbeierlein JM, Thorpe A, Black PC. Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy. *World J Urol.* 2018 Jun 7. PMID: 29882105
789. Garstka N, **Shariat SF**, Remzi M. The evolving role of percutaneous biopsy in renal masses. *Curr Opin Urol.* 2018 Jul;28(4):364-368. PMID: 29847524
790. Hübner N, **Shariat S**, Remzi M. Prostate biopsy: guidelines and evidence. *Curr Opin Urol.* 2018 Jul;28(4):354-359. PMID: 29847523
791. Nazzani S, Mazzone E, Preisser F, Bandini M, Tian Z, Marchioni M, Ratti D, Motta G, Zorn KC, Briganti A, **Shariat SF**, Montanari E, Carmignani L, Karakiewicz PI. Comparison of Perioperative Outcomes Between Open and Robotic Radical Cystectomy: A Population-Based Analysis. *J Endourol.* 2018 Aug;32(8):701-709. PMID: 29845866

792. Mari A, Kimura S, Foerster B, Abufaraj M, D'Andrea D, Hassler M, Minervini A, Rouprêt M, Babjuk M, **Shariat SF**. A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens. *BJU Int*. 2018 May 28. doi: 10.1111/bju.14417. PMID: 29807387
793. Szarvas T, Sevcenco S, Módos O, Keresztes D, Nyirády P, Csizmarik A, Ristl R, Pühr M, Hoffmann MJ, Niedworok C, Hadaschik B, Maj-Hes A, **Shariat SF**, Kramer G. Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer. *BJU Int*. 2018 May 26. PMID: 29802777
794. Preisser F, Bandini M, Mazzone E, Nazzani S, Marchioni M, Tian Z, Saad F, Pompe RS, **Shariat SF**, Heinzer H, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI. Validation of the Social Security Administration Life Tables (2004-2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results database. *Eur Urol Focus*. 2018 May 22. PMID: 29802052
795. Foerster B, Pozo C, Abufaraj M, Mari A, Kimura S, D'Andrea D, John H, **Shariat SF**. Association of Smoking Status With Recurrence, Metastasis, and Mortality Among Patients With Localized Prostate Cancer Undergoing Prostatectomy or Radiotherapy: A Systematic Review and Meta-analysis. *JAMA Oncol*. 2018 Jul 1;4(7):953-961. PMID: 29800115
796. Nazzani S, Preisser F, Mazzone E, Tian Z, Mistretta FA, **Shariat SF**, Saad F, Graefen M, Tilki D, Montanari E, Luzzago S, Briganti A, Carmignani L, Karakiewicz PI. In-hospital length of stay after major surgical oncological procedures. *Eur J Surg Oncol*. 2018 Jul;44(7):969-974. PMID: 29784507
797. Singla N, Krabbe LM, Aydin AM, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, **Shariat SF**, Lotan Y, Bagrodia A, Kapur P, Margulis V. Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. *Urol Oncol*. 2018 Jul;36(7):343.e1-343.e8. PMID: 29748098
798. Marchioni M, Nazzani S, Preisser F, Bandini M, Tian Z, Kapoor A, Cindolo L, Primiceri G, Carmignani L, Briganti A, Montorsi F, **Shariat SF**, Schips L, Karakiewicz PI. The Effect of Institution Teaching Status on Perioperative Outcomes After Robotic Partial or Radical Nephrectomy. *J Endourol*. 2018 Jul;32(7):621-629. PMID: 29739253
799. D'Andrea D, Hassler MR, Abufaraj M, Soria F, Ertl IE, Ilijazi D, Mari A, Foerster B, Egger G, **Shariat SF**. Progressive tissue biomarker profiling in non-muscle-invasive bladder cancer. *Expert Rev Anticancer Ther*. 2018 Jul;18(7):695-703. PMID: 29737231
800. Palou J, Pisano F, Sylvester R, Joniau S, Serretta V, Larré S, Di Stasi S, van Rhijn B, Witjes AJ, Grotenhuis A, Colombo R, Briganti A, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Varkarakis J, Bartoletti R, Dalbagni G, **Shariat SF**, Xylinas E, Karnes RJ, Gontero P. Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought. *World J Urol*. 2018 May 2. PMID: 29721611
801. Bandini M, Marchioni M, Preisser F, Zaffuto E, Tian Z, Tilki D, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer. *World J Urol*. 2018 Sep;36(9):1399-1407. PMID: 29717358
802. Marchioni M, Harmouch SS, Nazzani S, Bandini M, Preisser F, Tian Z, Kapoor A, Cindolo L, Briganti A, **Shariat SF**, Schips L, Karakiewicz PI. Effect of African-American race on cancer

- specific mortality differs according to clear cell vs. non-clear cell histologic subtype in metastatic renal cell carcinoma. *Cancer Epidemiol.* 2018 Jun;54:112-118. PMID: 29715680
803. Vartolomei MD, Kimura S, Ferro M, Foerster B, Abufaraj M, Briganti A, Karakiewicz PI, **Shariat SF**. The impact of moderate wine consumption on the risk of developing prostate cancer. *Clin Epidemiol.* 2018 Apr 17;10:431-444. PMID: 29713200
804. Ferro M, Vartolomei MD, Russo GI, Cantiello F, Farhan ARA, Terracciano D, Cimmino A, Di Stasi S, Musi G, Hurle R, Serretta V, Busetto GM, De Berardinis E, Cioffi A, Perdonà S, Borghesi M, Schiavina R, Cozzi G, Almeida GL, Bove P, Lima E, Grimaldi G, Matei DV, Crisan N, Muto M, Verze P, Battaglia M, Guazzoni G, Autorino R, Morgia G, Damiano R, de Cobelli O, **Shariat S**, Mirone V, Lucarelli G. An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. *World J Urol.* 2018 Jul 10. PMID: 29992381
805. Polanec SH, Helbich TH, Bickel H, Wengert GJ, Pinker K, Spick C, Clauser P, Susani M, **Shariat S**, Baltzer PAT. Quantitative apparent diffusion coefficient derived from diffusion-weighted imaging has the potential to avoid unnecessary mri-guided biopsies of mpMRI-detected PI-RADS 4 and 5 lesions. *Invest Radiol.* 2018 Jul 6. PMID: 29985792
806. Mathieu R, Castelli C, Fardoun T, Peyronnet B, **Shariat SF**, Bensalah K, Vincendeau S. Cost analysis of prostate cancer detection including the prostate health index (phi). *World J Urol.* 2018 Jul 6. PMID: 29980838
807. Ferro M, Vartolomei MD, Cantiello F, Lucarelli G, Di Stasi SM, Hurle R, Guazzoni G, Busetto GM, De Berardinis E, Damiano R, Perdonà S, Borghesi M, Schiavina R, Almeida GL, Bove P, Lima E, Grimaldi G, Autorino R, Crisan N, Abu Farhan AR, Verze P, Battaglia M, Serretta V, Russo GI, Morgia G, Musi G, de Cobelli O, Mirone V, **Shariat SF**. High-Grade T1 on re-transurethral resection after initial high-grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study. *Urol Int.* 2018 Jul 4;101(1):1-9. PMID: 29975950
808. Mazzone E, Preisser F, Nazzani S, Tian Z, Bandini M, Gandaglia G, Fossati N, Soulières D, Graefen M, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Location of Metastases in Contemporary Prostate Cancer Patients Affects Cancer-Specific Mortality. *Clin Genitourin Cancer.* 2018 Jun 5. PMID: 29954690
809. Darr C, Krafft U, Hadaschik B, Tschirdewahn S, Sevcenco S, Csizmarik A, Nyirady P, Küronya Z, Reis H, Maj-Hes A, **Shariat SF**, Kramer G, Szarvas T. The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer. *Urol Int.* 2018 Jun 27;1-9. PMID: 29949801
810. Krabbe LM, Margulis V, Schrader AJ, **Shariat SF**, Gust KM, Boegemann M. Molecularly-driven precision medicine for advanced bladder cancer. *World J Urol.* 2018 Jun 8. PMID: 29948043
811. Soria F, Droller MJ, Lotan Y, Gontero P, D'Andrea D, Gust KM, Rouprêt M, Babjuk M, Palou J, **Shariat SF**. An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer. *World J Urol.* 2018 Jun 21. PMID: 29931526
812. Vartolomei MD, Porav-Hodade D, Ferro M, Mathieu R, Abufaraj M, Foerster B, Kimura S, **Shariat SF**. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis. *Urol Oncol.* 2018 Jun 5. PMID: 29884342
813. Vasdev N, Zargar H, Noël JP, Veeratterapillay R, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath

- JS, Aning J, **Shariat SF**, Wright JL, Morgan TM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Holzbeierlein JM, Thorpe A, Black PC. Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy. *World J Urol.* 2018 Jun 7. PMID: 29882105
814. Garstka N, **Shariat SF**, Remzi M. The evolving role of percutaneous biopsy in renal masses. *Curr Opin Urol.* 2018 Jul;28(4):364-368. PMID: 29847524
815. Hübner N, **Shariat S**, Remzi M. Prostate biopsy: guidelines and evidence. *Curr Opin Urol.* 2018 Jul;28(4):354-359. PMID: 29847523
816. Nazzani S, Mazzone E, Preisser F, Bandini M, Tian Z, Marchioni M, Ratti D, Motta G, Zorn KC, Briganti A, **Shariat SF**, Montanari E, Carmignani L, Karakiewicz PI. Comparison of perioperative outcomes between open and robotic radical cystectomy: a population based analysis. *J Endourol.* 2018 May 30. PMID: 29845866
817. Mari A, Kimura S, Foerster B, Abufaraj M, D'Andrea D, Hassler M, Minervini A, Rouprêt M, Babjuk M, **Shariat SF**. A Systematic Review and Meta-Analysis of the impact of Lymphovascular Invasion in Bladder Cancer Transurethral Resection Specimens. *BJU Int.* 2018 May 28. PMID: 29807387
818. Szarvas T, Sevcenco S, Módos O, Keresztes D, Nyirády P, Csizmarik A, Ristl R, Pühr M, Hoffmann MJ, Niedworok C, Hadaschik B, Maj-Hes A, **Shariat SF**, Kramer G. MMP-7, sFas and FasL serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer. *BJU Int.* 2018 May 26. PMID: 29802777
819. Preisser F, Bandini M, Mazzone E, Nazzani S, Marchioni M, Tian Z, Saad F, Pompe RS, **Shariat SF**, Heinzer H, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI. Validation of the Social Security Administration Life Tables (2004-2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results database. *Eur Urol Focus.* 2018 May 22. PMID: 29802052
820. Foerster B, Pozo C, Abufaraj M, Mari A, Kimura S, D'Andrea D, John H, **Shariat SF**. Association of Smoking Status With Recurrence, Metastasis, and Mortality Among Patients With Localized Prostate Cancer Undergoing Prostatectomy or Radiotherapy: A Systematic Review and Meta-analysis. *JAMA Oncol.* 2018 May 24. PMID: 29800115
821. Nazzani S, Preisser F, Mazzone E, Tian Z, Mistretta FA, **Shariat SF**, Saad F, Graefen M, Tilki D, Montanari E, Luzzago S, Briganti A, Carmignani L, Karakiewicz PI. In-hospital length of stay after major surgical oncological procedures. *Eur J Surg Oncol.* 2018 May 9. PMID: 29784507
822. Singla N, Krabbe LM, Aydin AM, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, **Shariat SF**, Lotan Y, Bagrodia A, Kapur P, Margulis V. Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. *Urol Oncol.* 2018 May 7. PMID: 29748098
823. Marchioni M, Nazzani S, Preisser F, Bandini M, Tian Z, Kapoor A, Cindolo L, Primiceri G, Carmignani L, Briganti A, Montorsi F, **Shariat SF**, Schips L, Karakiewicz PI. The effect of institution teaching status on perioperative outcomes after robotic partial or radical nephrectomy. *J Endourol.* 2018 May 9. PMID: 29739253
824. D'Andrea D, Hassler MR, Abufaraj M, Soria F, Ertl IE, Ilijazi D, Mari A, Foerster B, Egger G, **Shariat SF**. Progressive tissue biomarker profiling in non-muscle-invasive bladder cancer. *Expert Rev Anticancer Ther.* 2018 May 9:1-9. PMID: 29737231

825. Palou J, Pisano F, Sylvester R, Joniau S, Serretta V, Larré S, Di Stasi S, van Rhijn B, Witjes AJ, Grotenhuis A, Colombo R, Briganti A, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Varkarakis J, Bartoletti R, Dalbagni G, **Shariat SF**, Xylinas E, Karnes RJ, Gontero P. Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought. *World J Urol.* 2018 May 2. PMID: 29721611
826. Bandini M, Marchioni M, Preisser F, Zaffuto E, Tian Z, Tilki D, Montorsi F, **Shariat SF**, Saad F, Briganti A, Karakiewicz PI. Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer. *World J Urol.* 2018 May 2. PMID: 29717358
827. Marchioni M, Harmouch SS, Nazzani S, Bandini M, Preisser F, Tian Z, Kapoor A, Cindolo L, Briganti A, **Shariat SF**, Schips L, Karakiewicz PI. Effect of African-American race on cancer specific mortality differs according to clear cell vs. non-clear cell histologic subtype in metastatic renal cell carcinoma. *Cancer Epidemiol.* 2018 Apr 28;54:112-118. PMID: 29715680
828. Vartolomei MD, Kimura S, Ferro M, Foerster B, Abufaraj M, Briganti A, Karakiewicz PI, **Shariat SF**. The impact of moderate wine consumption on the risk of developing prostate cancer. *Clin Epidemiol.* 2018 Apr 17;10:431-444. PMID: 29713200
829. Zaffuto E, Bandini M, Gazdovich S, Valiquette AS, Leyh-Bannurah SR, Tian Z, Dell'Oglio P, Graefen M, Moschini M, Necchi A, **Shariat SF**, Briganti A, Montorsi F, Karakiewicz PI. Contemporary rates of adherence to international guidelines for pelvic lymph node dissection in radical cystectomy: a population-based study. *World J Urol.* 2018 Apr 27. PMID: 29704059
830. Mari A, Kimura S, Foerster B, Abufaraj M, D'Andrea D, Gust KM, **Shariat SF**. A systematic review and meta-analysis of lymphovascular invasion in patients treated with radical cystectomy for bladder cancer. *Urol Oncol.* 2018 Apr 20. PubMed PMID: 29685374.
831. Khene ZE, Bensalah K, Largent A, **Shariat S**, Verhoest G, Peyronnet B, Acosta O, DeCrevoisier R, Mathieu R. Role of quantitative computed tomography texture analysis in the prediction of adherent perinephric fat. *World J Urol.* 2018 Apr 19. PMID: 29675631.
832. Pompe RS, Tilki D, Preisser F, Leyh-Bannurah SR, Bandini M, Marchioni M, Gild P, Tian Z, Fossati N, Cindolo L, **Shariat SF**, Huland H, Graefen M, Briganti A, Karakiewicz PI. Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages. *Prostate.* 2018 Apr 16. PMID: 29663462.
833. Leisser A, Nejabat M, Hartenbach M, Agha Mohammadi Sareshgi R, **Shariat S**, Kramer G, Krainer M, Hacker M, Haug AR. Analysis of hematological parameters as prognostic markers for toxicity and survival of (223)Radium treatment. *Oncotarget.* 2018 Mar 5;9(22):16197-16204. PMID: 29662636;
834. Rieken M, Kluth LA, Fajkovic H, Capitanio U, Briganti A, Krabbe LM, Margulis V, Abufaraj M, Mari A, Foerster B, Raman JD, Regelman M, Brookman-May S, Sjoberg DD, Karakiewicz PI, **Shariat SF**. Predictors of Cancer-specific Survival After Disease Recurrence in Patients With Renal Cell Carcinoma: The Effect of Time to Recurrence. *Clin Genitourin Cancer.* 2018 Mar 24. PMID: 29653814.
835. Nazzani S, Bandini M, Marchioni M, Preisser F, Tian Z, Soulières D, Montanari E, Motta G, Acquati P, Briganti A, **Shariat SF**, Abdollah F, Carmignani L, Karakiewicz PI. A contemporary analysis of radiotherapy effect in surgically treated retroperitoneal sarcoma. *Radiother Oncol.* 2018 Apr 6. PMID: 29631934.

836. Szarvas T, Sevcenco S, Módos O, Keresztes D, Nyirády P, Kubik A, Romics M, Kovalszky I, Reis H, Hadaschik B, **Shariat SF**, Kramer G. Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer. *Urol Oncol*. 2018 Apr 5. PMID: 29628317.
837. Resch I, **Shariat SF**, Gust KM. PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients: Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer. *Memo*. 2018;11(1):43-46. PMID: 29606979;
838. Bandini M, Marchioni M, Pompe RS, Tian Z, Martel T, Chun FK, Cindolo L, Kapoor A, Montorsi F, **Shariat SF**, Briganti A, Karakiewicz PI. The effect of age on cancer specific mortality in patients with small renal masses: A population-based analysis. *Can Urol Assoc J*. 2018 Mar 19. PMID: 29603918.
839. Dell'oglio P, Valiquette AS, Leyh-Bannurah SR, Tian Z, Trudeau V, Larcher A, **Shariat SF**, Capitanio U, Briganti A, Graefen M, Montorsi F, Karakiewicz PI. Treatment trends and Medicare reimbursements for localized prostate cancer in elderly patients. *Can Urol Assoc J*. 2018 Mar 19. PMID: 29603911.
840. Tilki D, Preisser F, Karakiewicz P, **Shariat SF**, Graefen M, Huland H, Chun FK, Pompe RS. The impact of time to catheter removal on short-, intermediate- and long-term urinary continence after radical prostatectomy. *World J Urol*. 2018 Mar 26. PubMed PMID: 29582100.
841. Moschini M, Arbelaez E, Cornelius J, Mattei A, **Shariat SF**, Dell'Oglio P, Zaffuto E, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A. Pattern of node metastases in patients treated with radical cystectomy and extended or superextended pelvic lymph node dissection due to bladder cancer. *Urol Oncol*. 2018 Mar 27. PubMed PMID: 29602638.
842. Soria F, Beleni AI, D'Andrea D, Resch I, Gust KM, Gontero P, **Shariat SF**. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer. *World J Urol*. 2018 Mar 16. PMID: 29549485
843. Fossati N, Parker WP, Karnes RJ, Colicchia M, Bossi A, Seisen T, Di Muzio N, Cozzarini C, Chiorda BN, Fiorino C, Gandaglia G, Bartkowiak D, Wiegel T, **Shariat S**, Goldner G, Battaglia A, Joniau S, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Briganti A, Boorjian SA. More extensive lymph node dissection at radical prostatectomy is associated with improved outcomes with salvage radiotherapy for rising prostate-specific antigen after surgery: a long-term, multi-institutional Analysis. *Eur Urol*. 2018 Mar 12 PMID:29544737
844. Ilijazi D, Abufaraj M, Hassler MR, Ertl IE, D'Andrea D, **Shariat SF**. Waiting in the wings: the emerging role of molecular biomarkers in bladder cancer. *Expert Rev Mol Diagn*. 2018 Mar 15. PMID:29542328
845. Vince R, Hampton LJ, Vartolomei MD, **Shariat SF**, Porpiglia F, Autorino R. Robotic assisted simple prostatectomy: recent advances. *Curr Opin Urol*. 2018 Mar 9 PMID: 29528970
846. Cumberbatch MGK, Foerster B, Catto JWF, Kamat AM, Kassouf W, Jubber I, **Shariat SF**, Sylvester RJ, Gontero P. Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review. *Eur Urol*. 2018 Mar 6 PMID:29523366
847. D Andrea D, Abufaraj M, Susani M, Ristl R, Foerster B, Kimura S, Mari A, Soria F, Briganti A, Karakiewicz PI, Gust KM, Rouprêt M, **Shariat SF**. Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: A clinical decision-making tool. *Urol Oncol*. 2018 Mar 2. PMID: 29506941

848. von Landenberg N, Aziz A, von Rundstedt FC, Dobruch J, Kluth LA, Necchi A, Noon A, Rink M, Hendricksen K, Decaestecker KPJ, Seiler R, Poyet C, Fajkovic H, **Shariat SF**, Xylinas E, Roghmann F; Young Academic Urologists' Working Group on Urothelial Cancer of the European Association of Urology. Conditional analyses of recurrence and progression in patients with TaG1 non-muscle-invasive bladder cancer. *Urol Oncol*. 2018 Mar 2. PMID: 29506940
849. Pompe RS, Bandini M, Preisser F, Marchioni M, Zaffuto E, Tian Z, Salomon G, Schlomm T, Huland H, Graefen M, Tilki D, **Shariat SF**, Karakiewicz PI. Contemporary approach to predict early biochemical recurrence after radical prostatectomy: update of the Walz nomogram. *Prostate Cancer Prostatic Dis*. 2018 Feb 27. PMID: 29487397
850. Vartolomei MD, Kimura S, Ferro M, Vartolomei L, Foerster B, Abufaraj M, **Shariat SF**. Is neutrophil-to-lymphocytes ratio a clinical relevant preoperative biomarker in upper tract urothelial carcinoma? A meta-analysis of 4385 patients. *World J Urol*. 2018 Feb 21. PMID: 29468284
851. Preisser F, Bandini M, Marchioni M, Nazzani S, Tian Z, Pompe RS, Fossati N, Briganti A, Saad F, **Shariat SF**, Heinzer H, Huland H, Graefen M, Tilki D, Karakiewicz PI. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. *Prostate*. 2018 May;78(6):469-475. PMID: 9460290
852. Bandini M, Smith A, Marchioni M, Pompe RS, Martel TF, Cindolo L, Montorsi F, **Shariat SF**, Briganti A, Kapoor A, Capitanio U, Karakiewicz PI. Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature. *Clin Genitourin Cancer*. 2018 Feb 2. PMID: 29449091
853. Westhoff E, Witjes JA, Fleshner NE, Lerner SP, **Shariat SF**, Steineck G, Kampman E, Kiemeny LA, Vrieling A. Body Mass Index, Diet-Related Factors, and Bladder Cancer Prognosis: A Systematic Review and Meta-Analysis. *Bladder Cancer*. 2018 PMID:29430510
854. Marchioni M, Preisser F, Bandini M, Nazzani S, Tian Z, Kapoor A, Cindolo L, Abdollah F, Tilki D, Briganti A, Montorsi F, **Shariat SF**, Schips L, Karakiewicz PI. Comparison of Partial Versus Radical Nephrectomy Effect on Other-cause Mortality, Cancer-specific Mortality, and 30-day Mortality in Patients Older Than 75 Years. *Eur Urol Focus*. 2018 Feb PMID: 29398456
855. Territo A, Foerster B, **Shariat SF**, Rouprêt M, Gaya JM, Palou J, Breda A. Diagnosis and kidney-sparing treatments for upper tract urothelial carcinoma: state of the art. *Minerva Urol Nefrol*. 2018 Feb 1. PMID: 29392926
856. Moschini M, Mattei A, Cornelius J, **Shariat SF**, Dell'Oglio P, Zaffuto E, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A. Surgical treatment for clinical node-positive bladder cancer patients treated with radical cystectomy without neoadjuvant chemotherapy. *World J Urol*. 2018 Jan 24. PMID: 29368231
857. Bandini M, Preisser F, Nazzani S, Marchioni M, Tian Z, Fossati N, Gandaglia G, Gallina A, Abdollah F, **Shariat SF**, Montorsi F, Saad F, Tilki D, Briganti A, Karakiewicz PI. Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients. *Eur Urol Focus*. 2018 Jan 20. PMID:29366856
858. Compérat EM, Burger M, Gontero P, Mostafid AH, Palou J, Rouprêt M, van Rhijn BWG, **Shariat SF**, Sylvester RJ, Zigeuner R, Babjuk M. Grading of Urothelial Carcinoma and The New "World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016, *Eur Urol Focus*. 2018 Jan 20. PMID: 29366854
859. Bandini M, Fossati N, Gandaglia G, Preisser F, Dell'Oglio P, Zaffuto E, Stabile A, Gallina A, Suardi N, **Shariat SF**, Montorsi F, Karakiewicz PI, Briganti A. Neoadjuvant and adjuvant

- treatment in high-risk prostate cancer. *Expert Rev Clin Pharmacol*. 2018 Apr;11(4):425-438. PMID:29355037
860. Mari A, D'Andrea D, Abufaraj M, Foerster B, Kimura S, **Shariat SF**. Genetic determinants for chemo- and radiotherapy resistance in bladder cancer. *Transl Androl Urol*. 2017 Dec;6(6):1081-1089. PMID:29354495
861. Vetterlein MW, Roschinski J, Gild P, Marks P, Soave A, Doh O, Isbarn H, Höppner W, Wagner W, **Shariat SF**, Brausi M, Büscheck F, Sauter G, Fisch M, Rink M. Impact of the Ki-67 labeling index and p53 expression status on disease-free survival in pT1 urothelial carcinoma of the bladder. *Transl Androl Urol*. 2017 Dec;6(6):1018-1026. PMID: 29354488
862. Pompe RS, Smith A, Bandini M, Marchioni M, Martel T, Preisser F, Leyh-Bannurah SR, Schiffmann J, Saad F, Huland H, Graefen M, **Shariat SF**, Tilki D, Karakiewicz PI. Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged ≤ 50 years: a population-based study. *Prostate Cancer Prostatic Dis*. 2018 Jan 16. PMID: 29339806
863. Leisser A, Nejabat M, Hartenbach M, Duan H, **Shariat SF**, Kramer G, Krainer M, Hacker M, Haug AR. Hematopoiesis is prognostic for toxicity and survival of ²²³Radium treatment in patients with metastatic castration-resistant prostate cancer. *Hell J Nucl Med*. 2017 Sep-Dec;20 Suppl:157. PMID: 29324927
864. Özsoy M, D'Andrea D, Moschini M, Foerster B, Abufaraj M, Mathieu R, Briganti A, Karakiewicz PI, Roupret M, Seitz C, Czech AK, Susani M, **Shariat SF**. Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer. *Urol Oncol*. 2017 Dec 26. PMID: 29288003
865. Foerster B, Kimura S, Vartolomei MD, Abufaraj M, Gust K, Fajkovic H, **Shariat SF**, Seitz C. Robot-assisted partial nephrectomy: systematic review of functional results. *Curr Opin Urol*. 2017 Dec 22. PMID: 29278584
866. Vartolomei MD, Foerster B, Kimura S, Autorino R, **Shariat SF**, Seitz C. Oncologic outcomes after minimally invasive surgery for cT1 renal masses: a comprehensive review. *Curr Opin Urol*. 2017 Dec 22. PMID: 29278581
867. Bandini M, Marchioni M, Preisser F, Nazzani S, Tian Z, Fossati N, Gandaglia G, **Shariat SF**, Montorsi F, Saad F, Briganti A, Tilki D, Karakiewicz PI. A Head-to-head Comparison of Four Prognostic Models for Prediction of Lymph Node Invasion in African American and Caucasian Individuals. *Eur Urol Focus*. 2017 Dec 14. PMID: 29249688
868. Leyh-Bannurah SR, Budäus L, Zaffuto E, Pompe RS, Bandini M, Briganti A, Montorsi F, Schiffmann J, **Shariat SF**, Fisch M, Chun F, Huland H, Graefen M, Karakiewicz PI. Adherence to pelvic lymph node dissection recommendations according to the National Comprehensive Cancer Network pelvic lymph node dissection guideline and the D'Amico lymph node invasion risk stratification. *Urol Oncol*. 2017 Dec 13. PMID: 29248430
869. Mari A, Abufaraj M, Foerster B, Özsoy M, Briganti A, Rouprêt M, Karakiewicz PI, Mathieu R, D'Andrea D, Chade DC, **Shariat SF**. Oncologic effect of cumulative smoking exposure in patients treated with salvage radical prostatectomy for radiation-recurrent prostate cancer. *Clin Genitourin Cancer*. 2017 Nov 10. PMID: 29239845
870. Özsoy M, Moschini M, Fajkovic H, Soria F, Seitz C, Klatt T, Gust K, Briganti A, Karakiewicz PI, Roupret M, Kramer G, **Shariat SF**. Elevated preoperative neutrophil-lymphocyte ratio predicts upgrading at radical prostatectomy. *Prostate Cancer Prostatic Dis*. 2017 Dec 11. PMID: 29230007

871. Marchioni M, Bandini M, Preisser F, Tian Z, Kapoor A, Cindolo L, Primiceri G, Berardinelli F, Briganti A, **Shariat SF**, Schips L, Karakiewicz PI. Survival after cytoreductive nephrectomy in metastatic non-clear cell renal cell carcinoma patients: a population-based study. *Eur Urol Focus*. 2017 Dec 8. PMID: 29229582
872. Gandaglia G, Fossati N, Karnes RJ, Boorjian SA, Colicchia M, Bossi A, Seisen T, Cozzarini C, Di Muzio N, Noris Chiorda B, Zaffuto E, Wiegel T, **Shariat SF**, Goldner G, Joniau S, Battaglia A, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Briganti A. Use of concomitant androgen deprivation therapy in patients treated with early salvage radiotherapy for biochemical recurrence after radical prostatectomy: long-term results from a large, multi-institutional series. *Eur Urol*. 2017 Dec 8. PMID: 29229176
873. Xylinas E, Kent M, Dabi Y, Rieken M, Kluth LA, Al Awamlh BAH, Ouzaid I, Pycha A, Comploj E, Svatek RS, Lotan Y, Karakiewicz PI, Holmang S, **Shariat SF**. Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C. *Urol Oncol*. 2017 Dec 5. PMID: 29221642
874. Dominguez-Escrig JL, Peyronnet B, Seisen T, Bruins HM, Yuan CY, Babjuk M, Böhle A, Burger M, Compérat EM, Gontero P, Lam T, MacLennan S, Mostafid H, Palou J, van Rhijn BWG, Sylvester RJ, Zigeuner R, **Shariat SF**, Roupriet M. Potential benefit of lymph node dissection during radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the european association of urology guidelines panel on non-muscle-invasive bladder cancer. *Eur Urol Focus*. 2017 Nov 17. PMID: 29158169
875. Moschini M, **Shariat SF**, Roupriet M, De Santis M, Bellmunt J, Sternberg CN, Tombal B, Collette L. Impact of primary tumor location on survival from EORTC advanced urothelial cancer studies. *J Urol*. 2017 Nov 17. PMID: 29158104
876. Peyronnet B, Seisen T, Dominguez-Escrig JL, Bruins HM, Yuan CY, Lam T, MacLennan S, N'dow J, Babjuk M, Comperat E, Zigeuner R, Sylvester RJ, Burger M, Mostafid H, van Rhijn BWG, Gontero P, Palou J, **Shariat SF**, Roupriet M. Oncological outcomes of laparoscopic nephroureterectomy versus open radical nephroureterectomy for upper tract urothelial carcinoma: an european association of urology guidelines systematic review. *Eur Urol Focus*. 2017 Nov 15. PMID: 29154042
877. Mari A, Campi R, Tellini R, Gandaglia G, Albisinni S, Abufaraj M, Hatzichristodoulou G, Montorsi F, van Velthoven R, Carini M, Minervini A, **Shariat SF**. Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature. *World J Urol*. 2017 Nov 16. PMID: 29147759
878. Polanec SH, Lazar M, Wengert GJ, Bickel H, Spick C, Susani M, **Shariat SF**, Clauser P, Baltzer PAT. 3D T2-weighted imaging to shorten multiparametric prostate MRI protocols. *Eur Radiol*. 2017 Nov 13. PMID: 29134351
879. Tilki D, Chandrasekar T, Capitanio U, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Linares Espinós E, Lorentz A, Martinez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, **Shariat SF**, Spahn M, Terrone C, Vera-Donoso C, Zigeuner R, Libertino JA, Evans CP. Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: Results from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). *Urol Oncol*. 2017 Nov 9. PMID: 29129353
880. Abufaraj M, **Shariat SF**, Foerster B, Pozo C, Moschini M, D'Andrea D, Mathieu R, Susani M, Czech AK, Karakiewicz PI, Seebacher V. Accuracy and prognostic value of variant histology and

- lymphovascular invasion at transurethral resection of bladder. *World J Urol.* 2017 Nov 11. PMID: 29127452
881. Bandini M, Marchioni M, Pompe RS, Tian Z, Gandaglia G, Fossati N, Abdollah F, Graefen M, Montorsi F, Saad F, **Shariat SF**, Briganti A, Karakiewicz PI. First North American validation and head-to-head comparison of four preoperative nomograms for prediction of lymph node invasion before radical prostatectomy. *BJU Int.* 2017 Nov 10. PMID: 29124911
882. Abufaraj M, Dalbagni G, Daneshmand S, Horenblas S, Kamat AM, Kanzaki R, Zlotta AR, **Shariat SF**. The role of surgery in metastatic bladder cancer: a systematic review. *Eur Urol.* 2017 Nov 6. PMID: 29122377
883. Grubmüller B, Baltzer P, D'Andrea D, Korn S, Haug AR, Hacker M, Grubmüller KH, Goldner GM, Wadsak W, Pfaff S, Babich J, Seitz C, Fajkovic H, Susani M, Mazal P, Kramer G, **Shariat SF**, Hartenbach M. 68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy - diagnostic performance and impact on therapeutic decision-making. *Eur J Nucl Med Mol Imaging.* 2017 Oct 26. PMID: 29075832
884. Hendricksen K, Aziz A, Bes P, Chun FK, Dobruch J, Kluth LA, Gontero P, Necchi A, Noon AP, van Rhijn BWG, Rink M, Roghmann F, Rouprêt M, Seiler R, **Shariat SF**, Qvick B, Babjuk M, Xylinas E; Young Academic Urologists Urothelial Carcinoma Group of the European Association of Urology. Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non-muscle-invasive Bladder Cancer: Results of a European Survey. *Eur Urol Focus.* 2017 Oct 23. PMID: 29074050
885. Bandini M, Pompe RS, Marchioni M, Tian Z, Gandaglia G, Fossati N, Tilki D, Graefen M, Montorsi F, **Shariat SF**, Briganti A, Saad F, Karakiewicz PI. Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis. *World J Urol.* 2017 Oct 23. PMID: 29063268
886. Mari A, Abufaraj M, Gust KM, **Shariat SF**. Novel endoscopic visualization techniques for bladder cancer detection: a review of the contemporary literature. *Curr Opin Urol.* 2017 PMID: 29045251
887. Bandini M, Smith A, Zaffuto E, Pompe RS, Marchioni M, Capitanio U, Chun FK, Kapoor AB, **Shariat SF**, Montorsi F, Briganti A, Karakiewicz PI. Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy. *World J Urol.* 2017 PMID: 29022072
888. D'Andrea D, Moschini M, Soria F, Gust KM, Briganti A, Karakiewicz PI, Rouprêt M, **Shariat SF**. ABO Blood Group and Rhesus Factor Are Not Associated with Outcomes After Radical Cystectomy for Non-metastatic Urothelial Carcinoma of the Bladder. *Anticancer Res.* 2017 Oct;37(10):5747-5753. PMID: 28982896
889. Rieken M, **Shariat SF**, Kluth L, Crivelli JJ, Abufaraj M, Foerster B, Mari A, Ilijazi D, Karakiewicz PI, Babjuk M, Gönen M, Xylinas E. Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer. *Urol Oncol.* 2017 PMID: 28947304
890. Marchioni M, Bandini M, Pompe RS, Martel T, Tian Z, **Shariat SF**, Kapoor A, Cindolo L, Briganti A, Schips L, Capitanio U, Karakiewicz PI. The impact of lymph node dissection and positive lymph nodes on cancer specific mortality in contemporary pT2-3 non-metastatic renal cell carcinoma treated with radical nephrectomy. *BJU Int.* 2017 PMID: 28940649
891. Necchi A, Lo Vullo S, Mariani L, Moschini M, Hendricksen K, Rink M, Sosnowski R, Dobruch J, Raman JD, Wood CG, Margulis V, Roupret M, Briganti A, Montorsi F, Xylinas E, **Shariat SF**; European Association of Urology - Young Academic Urologists (EAU-YAU) Urothelial Cancer

- Group the Upper Tract Urothelial Carcinoma Collaboration group. Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study of the EAU-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration. *BJU Int.* 2017 PMID: 28940605
892. Marchioni M, Bandini M, Pompe RS, Tian Z, Martel T, Kapoor A, Cindolo L, Berardinelli F, Briganti A, **Shariat SF**, Schips L, Karakiewicz PI. Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era. *Int Urol Nephrol.* 2017 PMID: 28932952
893. Malte R, Kluth LA, Kaushik D, Boorjian SA, Abufaraj M, Foerster B, Rink M, Gust K, Roghmann F, Noldus J, Vordos D, Hagiwara M, Kikuchi E, Ikeda M, Matsumoto K, Karakiewicz PI, Rouprêt M, Briganti A, Scherr DS, **Shariat SF**, Seebacher V. Frequency and prognostic significance of incidental prostate cancer at radical cystectomy: Results from an international retrospective study. *Eur J Surg Oncol.* 2017 PMID: 28928012
894. Rieken M, Kluth LA, Seitz C, Abufaraj M, Foerster B, Mathieu R, Karakiewicz PI, Bachmann A, Briganti A, Rouprêt M, Gönen M, **Shariat SF**, Seebacher V. External Validation of the Pathologic Nodal Staging Score for Prostate Cancer: A Population -based Study. *Clin Genitourin Cancer.* 2017 PMID: 28916272
895. Moschini M, D'Andrea D, Korn S, Irmak Y, Soria F, Compérat E, **Shariat SF**. Characteristics and clinical significance of histological variants of bladder cancer. *Nat Rev Urol.* 2017 PMID: 28895563
896. Rink M, Engel O, Gakis G, Fritsche HM, Vetterlein MW, Soave A, Peine S, Aziz A, Dahlem R, Stenzl A, Burger M, **Shariat SF**, Fisch M, Gild P. The effect of ABO and Rhesus blood grouping systems on oncological outcome in patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma. *Urol Oncol.* 2017 PMID: 28889922
897. Moschini M, **Shariat SF**, Abufaraj M, Foerster B, D Andrea D, Soria F, Dell'Oglio P, Mattei A, Montorsi F, Colombo R, Briganti A, Gallina A. Predicting local failure after radical cystectomy in patients with bladder cancer: Implications for the selection of candidates at adjuvant radiation therapy. *Urol Oncol.* 2017 PMID: 28887096
898. Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester RJ, Burger M, Cowan NC, Gontero P, Van Rhijn BWG, Mostafid AH, Palou J, **Shariat SF**. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. *Eur Urol.* 2017 PMID: 28867446
899. Dell'Oglio P, Stabile A, Gandaglia G, Zaffuto E, Fossati N, Bandini M, Suardi N, Karakiewicz PI, **Shariat SF**, Montorsi F, Briganti A. New surgical approaches for clinically high-risk or metastatic prostate cancer. *Expert Rev Anticancer Ther.* 2017 Sep 1. PMID: 28862047
900. Abufaraj M, Haitel A, Moschini M, Gust K, Foerster B, Özsoy M, D'Andrea D, Karakiewicz PI, Rouprêt M, Briganti A, **Shariat SF**. Prognostic Role of N-cadherin Expression in Patients With Invasive Bladder Cancer. *Clin Genitourin Cancer.* 2017 Aug 15. PMID: 28851591
901. Marchioni M, Martel T, Bandini M, Pompe RS, Tian Z, Kapoor A, Cindolo L, Autorino R, Briganti A, **Shariat SF**, Schips L, Karakiewicz PI. Marital status and gender affect stage, tumor grade, treatment type and cancer specific mortality in T1-2 N0 M0 renal cell carcinoma. *World J Urol.* 2017 Aug 28. PMID: 28849260
902. Borgmann H, Musquera M, Haferkamp A, Vilaseca A, Klatte T, **Shariat SF**, Scavuzzo A, Jimenez Rios MA, Wolff I, Capitanio U, Dell'Oglio P, Krabbe LM, Herrmann E, Ecke T, Vergho D, Huck N, Wagener N, Pahernik S, Zastrow S, Wirth M, Surcel C, Mirvald C, Prochazkova K, Hutterer G, Zigeuner R, Cindolo L, Hora M, Stief CG, May M, Brookman-May SD. Prognostic significance of

- Fuhrman grade and age for cancer-specific and overall survival in patients with papillary renal cell carcinoma: results of an international multi-institutional study on 2189 patients. *World J Urol.* 2017 Aug 23. PMID: 28836063
903. Moschini M, Soria F, Susani M, Korn S, Briganti A, Roupret M, Seitz C, Gust K, Haitel A, Montorsi F, Wirth G, Robinson BD, Karakiewicz PI, Özsoy M, Rink M, **Shariat SF**. Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy. *Bladder Cancer.* 2017 Jul 27;3(3):161-169. PMID: 28824943
904. Bedke J, Heide J, Ribback S, Rausch S, de Martino M, Scharpf M, Haitel A, Zimmermann U, Pechoel M, Alkhayat H, **Shariat SF**, Dombrowski F, Stenzl A, Burchardt M, Klatter T, Kroeger N. Microvascular and lymphovascular tumor invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: A validation study in clinical practice. *BJU Int.* 2017 PMID: 28803448
905. Wolff I, Scavuzzo A, Capitanio U, Klatter T, **Shariat SF**, Wagener N, Zastrow S, Borgmann H, Krabbe LM, Hutterer G, May M, Brookman-May SD. Organ Preservation is Less Frequently Performed in Women Surgically Treated for Papillary Renal Cell Carcinoma - Results of a Comprehensive Multicenter Study. *Urology.* 2017 PMID: 28802570
906. Fossati N, Karnes RJ, Colicchia M, Boorjian SA, Bossi A, Seisen T, Di Muzio N, Cozzarini C, Noris Chiorda B, Fiorino C, Gandaglia G, Dell'Oglio P, **Shariat SF**, Goldner G, Joniau S, Battaglia A, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Wiegel T, Montorsi F, Briganti A. Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. *Eur Urol.* 2017 Aug 2. PMID: 28779974
907. Zaffuto E, Pompe R, Bondarenko HD, Moschini M, Dell'Oglio P, Gandaglia G, Fossati N, **Shariat SF**, Montorsi F, Briganti A, Karakiewicz PI. Hospitalization before surgery and subsequent risk of infective complications after radical cystectomy: A population-based analysis. *Urol Oncol.* 2017 Jul 26. PMID: 28755960
908. Aumayr K, Klatter T, Neudert B, Birner P, **Shariat S**, Schmidinger M, Susani M, Haitel A. HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial Carcinomas. *Pathol Oncol Res.* 2017 PMID: 28755093
909. D'Andrea D, Moschini M, Foerster B, Abufaraj M, Margulis V, Karam J, Lotan Y, Raman J, Mathieu R, Roupret M, Karakiewicz PI, Briganti A, Haitel A, **Shariat SF**. Caveolin-1 Expression in Upper Tract Urothelial Carcinoma. *Eur Urol Focus.* 2017 Jul 1. PMID: 28753840
910. Vetterlein MW, Seisen T, May M, Nuhn P, Gierth M, Mayr R, Fritsche HM, Burger M, Novotny V, Froehner M, Wirth MP, Protzel C, Hakenberg OW, Roghmann F, Palisaar RJ, Noldus J, Pycha A, Bastian PJ, Trinh QD, Xylinas E, **Shariat SF**, Rink M, Chun FK, Dahlem R, Fisch M, Aziz A; PROMETRICS 2011 Study Group. Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis. *Eur Urol Focus.* 2016 Jul 18. PMID: 28753775
911. de Martino M, Leitner CV, Hofbauer SL, Lucca I, Haitel A, **Shariat SF**, Klatter T. Serum Adiponectin Predicts Cancer-specific Survival of Patients with Renal Cell Carcinoma. *Eur Urol Focus.* 2016 Jun;2(2):197-203. PMID: 28723535
912. Rieken M, **Shariat SF**, Karam JA, Foerster B, Khani F, Gust K, Abufaraj M, Wood CG, Weizer AZ, Raman JD, Guo CC, Rioux-Leclercq N, Haitel A, Bensalah K, Lotan Y, Bachmann A, De Marzo AM, Robinson BD, Margulis V. Frequency and prognostic value of PTEN loss in patients

- with upper tract urothelial carcinoma treated with radical nephroureterectomy. *J Urol*. 2017 Jul 11. PMID: 28709887
913. Foerster B, Moschini M, Abufaraj M, Soria F, Gust KM, Rouprêt M, Karakiewicz PI, Briganti A, Rink M, Kluth L, Mathieu R, Margulis V, Lotan Y, Aziz A, John H, **Shariat SF**; UTUC Collaboration. Predictive and Prognostic Value of Preoperative Thrombocytosis in Upper Tract Urothelial Carcinoma. *Clin Genitourin Cancer*. 2017 Jun 19. PMID: 28694147
914. Krabbe LM, Heitzplatz B, Preuss S, Hutchinson RC, Woldu SL, Singla N, Boegemann M, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Rapoport LM, Glybochko PV, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, **Shariat SF**, Lotan Y, Xylinas E, Margulis V. Prognostic Value of PD-1 and PD-L1 Expression in Patients with High-Grade Upper Tract Urothelial Carcinoma. *J Urol*. 2017 Jun 28 PMID: 28668287
915. Gschliesser T, Eredics K, Berger I, Szelinger M, Klingler HC, Colombo T, Ponholzer A, Plas E, Grubmüller K, Dunzinger M, Jeschke K, Würnschimmel E, Krause FS, **Shariat S**, Leeb K, Pelzer A, Riedl C, Rauchenwald M, Hübner W, Brössner C, Madersbacher S; Cystectomy Registry of the Austrian Society of Urology. The Impact of Gender on Tumour Stage in In-House Complications and Choice of Urinary Diversion: Results of the Austrian Cystectomy Registry. *Urol Int*. 2017 Jun 23. PMID: 28641294
916. Marchioni M, Primiceri G, Cindolo L, Hampton LJ, Grob MB, Guruli G, Schips L, **Shariat SF**, Autorino R. Impact of diagnostic ureteroscopy on intravesical recurrence in patients undergoing radical nephroureterectomy for upper tract urothelial cancer: a systematic review and meta-analysis. *BJU Int*. 2017 Jun 16. PMID: 28621055
917. Soria F, Moschini M, Wirth GJ, Gust KM, Klätte T, Briganti A, Gontero P, Abufaraj M, Özsoy M, Karakiewicz PI, **Shariat SF**. Characterization of Late Recurrence after Radical Cystectomy in a Large Multicenter Cohort of Bladder Cancer Patients. *Urology*. 2017 May 12. PMID: 28506860
918. Maj-Hes AB, Mathieu R, Özsoy M, Soria F, Moschini M, Abufaraj M, Briganti A, Roupert M, Karakiewicz PI, Klätte T, **Shariat SF**. Obesity is associated with biochemical recurrence after radical prostatectomy: A multi-institutional extended validation study. *Urol Oncol*. 2017 PMID: 28460801
919. Soukup V, Čapoun O, Cohen D, Hernández V, Babjuk M, Burger M, Compérat E, Gontero P, Lam T, MacLennan S, Mostafid AH, Palou J, van Rhijn BWG, Rouprêt M, **Shariat SF**, Sylvester R, Yuan Y, Zigeuner R. Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. *Eur Urol*. 2017 PMID: 28457661
920. Moschini M, **Shariat SF**, Freschi M, Soria F, D'Andrea D, Abufaraj M, Foerster B, Dell'Oglio P, Zaffuto E, Mattei A, Salonia A, Montorsi F, Briganti A, Gallina A, Colombo R. Is transurethral resection alone enough for the diagnosis of histological variants? A single-center study. *Urol Oncol*. 2017 PMID: 28433471
921. D'Andrea D, Moschini M, Gust K, Abufaraj M, Özsoy M, Mathieu R, Soria F, Briganti A, Rouprêt M, Karakiewicz PI, **Shariat SF**. Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Primary Non-muscle-invasive Bladder Cancer. *Clin Genitourin Cancer*. 2017 PMID: 28420564
922. May M, Surcel C, Capitanio U, Dell'Oglio P, Klätte T, **Shariat S**, Ecke T, Wolff I, Vergho D, Wagener N, Huck N, Pahernik S, Zastrow S, Wirth M, Borgmann H, Haferkamp A, Musquera M, Krabbe LM, Herrmann E, Scavuzzo A, Mirvald C, Hutterer G, Zigeuner R, Stief CG, Waidelich R, Cindolo L, Kalusova K, Brookman-May SD Prognostic and discriminative power of the 7th TNM

- classification for patients with surgically treated papillary renal cell carcinoma: results of a multi-institutional validation study (CORONA subtype project). *Scand J Urol*. 2017 Apr 12:1-8. PMID: 28399699
923. Leyh-Bannurah SR, Gazdovich S, Budäus L, Zaffuto E, Briganti A, Abdollah F, Montorsi F, Schiffmann J, Menon M, **Shariat SF**, Fisch M, Chun F, Steuber T, Huland H, Graefen M, Karakiewicz PI. Local Therapy Improves Survival in Metastatic Prostate Cancer. *Eur Urol*. 2017 PMID: 28385454
924. Lotan Y, O'Sullivan P, Raman JD, **Shariat SF**, Kavalieris L, Frampton C, Guilford P, Luxmanan C, Suttie J, Crist H, Scherr D, Asroff S, Goldfischer E, Thill J, Darling D. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. *Urol Oncol*. 2017 Mar 30. PMID: 28366272
925. Soria F, Lucca I, Moschini M, Mathieu R, Rouprêt M, Karakiewicz PI, Briganti A, Rink M, Gust KM, Hassler MR, Foerster B, Abufarraj M, Haitel A, Klatter T, **Shariat SF**. Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer. *Urol Oncol*. 2017 Mar 22. PMID: 28342660
926. Dell'Oglio P, Zaffuto E, Boehm K, Trudeau V, Larcher A, Tian Z, Moschini M, **Shariat SF**, Graefen M, Saad F, Capitanio U, Briganti A, Montorsi F, Karakiewicz PI. Long-term survival of patients aged 80 years or older treated with radical prostatectomy for prostate cancer. *Eur J Surg Oncol*. 2017 Mar 10. PMID: 28330822
927. Moschini M, Foerster B, Abufarraj M, Soria F, Seisen T, Roupret M, Colin P, De la Taille A, Peyronnet B, Bensalah K, Herout R, Wirth MP, Novotny V, Chłosta P, Bandini M, Montorsi F, Simone G, Gallucci M, Romeo G, Matsumoto K, Karakiewicz P, Briganti A, **Shariat SF**. Trends of lymphadenectomy in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy. *World J Urol*. 2017 Feb 28. PMID: 28247066
928. Abufarraj M, **Shariat SF**, Haitel A, Moschini M, Foerster B, Chłosta P, Gust K, Babjuk M, Briganti A, Karakiewicz PI, Albrecht W. Prognostic role of N-cadherin expression in patients with non-muscle-invasive bladder cancer. *Urol Oncol*. 2017 Feb 14. PMID: 28214283
929. Moschini M, Soria F, Abufarraj M, Foerster B, D'Andrea D, Damiano R, Klatter T, Montorsi F, Briganti A, Colombo R, Gallina A, **Shariat SF**. Impact of intra- and postoperative blood transfusion on the incidence, timing, and pattern of disease recurrence after radical cystectomy. *Clin Genitourin Cancer*. 2017 Jan 11. PMID: 28162943
930. Pompe RS, Davis-Bondarenko H, Zaffuto E, Tian Z, **Shariat SF**, Leyh-Bannurah SR, Schiffmann J, Saad F, Huland H, Graefen M, Tilki D, Karakiewicz PI. Population-based validation of the 2014 ISUP Gleason grade groups in patients treated with radical prostatectomy, brachytherapy, external beam radiation or no local treatment. *Prostate*. 2017 Feb 3. PMID: 28156003
931. Moschini M, **Shariat SF**, Freschi M, Soria F, Abufarraj M, Gandaglia G, Dell'Oglio P, Mattei A, Damiano R, Salonia A, Montorsi F, Briganti A, Gallina A, Colombo R. Impact of Prostate Involvement on Outcomes in Patients Treated with Radical Cystoprostatectomy for Bladder Cancer. *Urol Int*. 2017 Feb 1. PMID: 28142141
932. Sosnowski R, Bjurlin MA, Verze P, De Nunzio C, **Shariat SF**, Brausi M, Donin NM. Role of cigarette smoking in urological malignancies and clinical interventions for smoking cessation. *Cent European J Urol*. 2016;69(4):366-369. PMID: 28127452
933. D'Andrea D, Moschini M, Gust KM, Abufarraj M, Özsoy M, Mathieu R, Soria F, Briganti A, Rouprêt M, Karakiewicz PI, **Shariat SF**. Lymphocyte-to-monocyte ratio and neutrophil-to-

- lymphocyte ratio as biomarkers for predicting lymph node metastasis and survival in patients treated with radical cystectomy. *J Surg Oncol*. 2017 Jan 20. PMID: 28105663
934. Leyh-Bannurah SR, Budäus L, Pompe R, Zaffuto E, Briganti A, Abdollah F, Montorsi F, Schiffmann J, Menon M, **Shariat SF**, Fisch M, Chun F, Huland H, Graefen M, Karakiewicz PI. North American population-based validation of the national comprehensive cancer network practice guideline recommendation of pelvic lymphadenectomy in contemporary prostate cancer. *Prostate*. 2017 Jan 17. PMID: 28093788
935. Soria F, de Martino M, Leitner CV, Moschini M, **Shariat SF**, Klatte T. Perioperative allogenic blood transfusion in renal cell carcinoma: risk factors and effect on long-term outcomes. *Clin Genitourin Cancer*. 2016 Dec 29. PMID: 28089722
936. Moschini M, Dell'Oglio P, Luciano' R, Gandaglia G, Soria F, Mattei A, Klatte T, Damiano R, **Shariat SF**, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A. Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy. *Urol Oncol*. 2017 Jan 10. PMID: 28087131
937. Rink M, **Shariat SF**, Soave A. Liquid biopsies in bladder cancer-did we find the Holy Grail for biomarker analyses? *Transl Androl Urol*. 2016 Dec;5(6):980-983. PMID: 28078238
938. Aziz A, Dobruch J, Hendricksen K, Kluth LA, Necchi A, Noon A, Rink M, Roghmann F, Seiler R, Gontero P, Kassouf W, **Shariat SF**, Xylinas E; Young Academic Urologists Urothelial Carcinoma Group of the European Association of Urology. Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review. *World J Urol*. 2017 Jan 10. doi: 10.1007/s00345-016-1995-z. PMID: 28074261
939. Mathieu R, Moschini M, Beyer B, Gust KM, Seisen T, Briganti A, Karakiewicz P, Seitz C, Salomon L, de la Taille A, Rouprêt M, Graefen M, **Shariat SF**. Prognostic value of the new Grade Groups in Prostate Cancer: a multi-institutional European validation study. *Prostate Cancer Prostatic Dis*. 2017 Jan 10. PMID: 28071673
940. Moschini M, **Shariat SF**, Lucianò R, D'Andrea D, Foerster B, Abufaraj M, Bandini M, Dell'Oglio P, Damiano R, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A. Pure but not mixed histologic variants are associated with poor survival at radical cystectomy in bladder cancer patients. *Clin Genitourin Cancer*. 2016 Dec 14. PMID: 28040422
941. Kavalieris L, O'Sullivan P, Frampton C, Guilford P, Darling D, Jacobson E, Suttie J, Raman JD, **Shariat SF**, Lotan Y. Performance characteristics of a multigene urine biomarker test for monitoring for recurrent urothelial carcinoma in a multicenter study. *J Urol*. 2016 Dec 13. PMID: 27986532
942. Anract J, Barry Delongchamps N, Gontero P, Dobruch J, Necchi A, Seisen T, Rouprêt M, **Shariat S**, Aziz A, Rink M, Xylinas E. L'impact de l'intoxication tabagique sur l'agressivité tumorale au moment de la cystectomie totale. *Prog Urol*. 2016 Nov;26(13):764-765. PMID: 27969287
943. Aziz A, Bes P, Masson-Lecomte A, Barry-Delongchamps N, Rouprêt M, **Shariat S**, Qvick B, Xylinas E. Discordance entre les recommandations et la pratique quotidienne dans la prise en charge des tumeurs de vessie n'infiltrant pas le muscle. *Prog Urol*. 2016 Nov;26(13):704-705. PMID: 27969169
944. Duquesne I, Barry Delongchamps N, Barry Delongchamps N, Pisano F, Aziz A, Masson-Lecomte A, **Shariat S**, Gontero P, Xylinas E. Évaluation de la morbidité de la cystectomie totale après radiothérapie abdomino-pelvienne. *Prog Urol*. 2016 Nov;26(13):673-674. PMID: 27969107

945. Babjuk M, Burger M, Compérat E, Palou J, Rouprêt M, van Rhijn B, **Shariat S**, Sylvester R, Zigeuner R, Gontero P, Mostafid H. Reply to Harry Herr's Letter to the Editor re: Marko Babjuk, Andreas Böhle, Maximilian Burger, et al. EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. *Eur Urol*. 2016 Dec 7. pii: S0302-2838(16)30881-8. PMID: 27939074
946. Moschini M, **Shariat SF**, Abufaraj M, Soria F, Klatte T, Croce G, Mattei A, Damiano R, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A. The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: Implications for follow-up schemes. *Urol Oncol*. 2016 Dec 5. PMID: 27932269
947. Soria F, Moschini M, Abufaraj M, Wirth GJ, Foerster B, Gust KM, Özsoy M, Briganti A, Gontero P, Mathieu R, Rouprêt M, Karakiewicz PI, **Shariat SF**. Preoperative anemia is associated with disease recurrence and progression in patients with non-muscle-invasive bladder cancer. *Urol Oncol*. 2016 Nov 28. PMID: 27908681
948. May M, Protzel C, Vetterlein MW, Gierth M, Noldus J, Karl A, Grimm T, Wullich B, Grimm MO, Nuhn P, Bastian PJ, Roigas J, Hadaschik B, Gilfrich C, Burger M, Fisch M, Brookman-May S, Aziz A, **Shariat S.**, Hakenberg OW; PROMETRICS 2011 Research Group.. Is there evidence for a close connection between side of intravesical tumor location and ipsilateral lymphatic spread in lymph node-positive bladder cancer patients at radical cystectomy? Results of the PROMETRICS 2011 database. *Int Urol Nephrol*. 2016 Nov 28. PMID: 27896578
949. Schiffmann J, Larcher A, Sun M, Tian Z, Berdugo J, Leva I, Widmer H, Lattouf JB, Zorn KC, **Shariat SF**, Montorsi F, Graefen M, Saad F, Karakiewicz PI. Suboptimal use of pelvic lymph node dissection: Differences in guideline adherence between robot-assisted and open radical prostatectomy. *Can Urol Assoc J*. 2016 Aug;10(7-8):269-276. PMID: 27878050
950. Zaffuto E, Gazdovich S, Leyh-Bannurah SR, Huland H, Abdollah F, **Shariat SF**, Menon M, Briganti A, Montorsi F, Karakiewicz PI. Contemporary rates of pathological features and mortality for adenocarcinoma of the urinary bladder in the USA. *Int J Urol*. 2016 Nov 22. PMID: 27875858
951. Abufaraj M, Moschini M, Soria F, Gust K, Özsoy M, Mathieu R, Rouprêt M, Margulis V, Karam JA, Wood CG, Briganti A, Bensalah K, Haitel A, **Shariat SF**. Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma: a multi-institutional study. *World J Urol*. 2016 Nov 9. PMID: 27830374
952. Xylinas E, Kluth L, Rieken M, Rouprêt M, Al Awamlh BA, Clozel T, Sun M, Karakiewicz PI, Gonen M, **Shariat SF**. External validation of the pathological nodal staging score in upper tract urothelial carcinoma: A population-based study. *Urol Oncol*. 2016 Nov 2. PMID: 27816402
953. Peyronnet B, Seisen T, Oger E, Vaessen C, Grassano Y, Benoit T, Carrouget J, Pradère B, Khene Z, Giwerc A, Mathieu R, Beauval JB, Nouhaud FX, Bigot P, Doumerc N, Bernhard JC, Mejean A, Patard JJ, **Shariat S**, Roupret M, Bensalah K; French Committee of Urologic Oncology (CCAFU). Comparison of 1800 Robotic and Open Partial Nephrectomies for Renal Tumors. *Ann Surg Oncol*. 2016 Dec;23(13):4277-4283. PMID: 27411552
954. Krabbe LM, Woldu SL, **Shariat SF**, Lotan Y. Improving diagnostic molecular tests to monitor urothelial carcinoma recurrence. *Expert Rev Mol Diagn*. 2016 Nov;16(11):1189-1199. PMID: 27696932
955. Mager R, Daneshmand S, Evans CP, Palou J, Martínez-Salamanca JI, Master VA, McKiernan JM, Libertino JA, Haferkamp A; International Renal Cell Carcinoma-Venous Thrombus Consortium., Haferkamp A, Capitanio U, Carballido JA, Chantada V, Chromecki T, Ciancio G, Daneshmand S, Evans CP, Gontero P, González J, Hohenfellner M, Huang WC, Koppie TM, Libertino JA, Espinós

- EL, Lorentz A, Martínez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, O'Malley P, Pahernik S, Palou J, Moreno JL, Pruthi RS, Faba OR, Russo P, Scherr DS, **Shariat SF**, Spahn M, Terrone C, Tilki D, Vázquez-Martul D, Donoso CV, Vergho D, Wallen EM, Zigeuner R. Renal cell carcinoma with inferior vena cava involvement: Prognostic effect of tumor thrombus consistency on cancer specific survival. *J Surg Oncol*. 2016 Nov;114(6):764-768. PMID: 27562252
956. Bianchi L, Gandaglia G, Fossati N, Suardi N, Moschini M, Cucchiara V, Bianchi M, Damiano R, Schiavina R, **Shariat SF**, Montorsi F, Briganti A. Pelvic lymph node dissection in prostate cancer: indications, extent and tailored approaches. *Urologia*. 2015 Dec 16:0. doi: 10.5301/uro.5000139. PMID: 26689534
957. Mathieu R, **Shariat SF**. Building bridges in urothelial carcinoma to face common challenges. *Transl Androl Urol*. 2016 Oct;5(5):745-748. PMID: 27785431
958. Abufaraj M, Gust K, Moschini M, Foerster B, Soria F, Mathieu R, **Shariat SF**. Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery. *Transl Androl Urol*. 2016 Oct;5(5):735-744. PMID: 27785430
959. Mbeutcha A, Mathieu R, Rouprêt M, Gust KM, Briganti A, Karakiewicz PI, **Shariat SF**. Predictive models and prognostic factors for upper tract urothelial carcinoma: a comprehensive review of the literature. *Transl Androl Urol*. 2016 Oct;5(5):720-734. PMID: 27785429
960. Khene ZE, Mathieu R, Kammerer-Jacquet SF, Seisen T, Roupret M, **Shariat SF**, Peyronnet B, Bensalah K. Risk stratification for kidney sparing procedure in upper tract urothelial carcinoma. *Transl Androl Urol*. 2016 Oct;5(5):711-719. PMID: 27785428
961. Sargos P, Baumann BC, Eapen LJ, Bahl A, Murthy V, Roubaud G, Orré M, Efstathiou JA, **Shariat S**, Larré S, Richaud P, Christodouleas JP. Adjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: time to reconsider? *Transl Androl Urol*. 2016 Oct;5(5):702-710. PMID: 27785427
962. Soria F, Moschini M, Korn S, **Shariat SF**. How to optimally manage elderly bladder cancer patients? *Transl Androl Urol*. 2016 Oct;5(5):683-691. PMID: 27785425
963. Marks P, Soave A, **Shariat SF**, Fajkovic H, Fisch M, Rink M. Female with bladder cancer: what and why is there a difference? *Transl Androl Urol*. 2016 Oct;5(5):668-682. PMID: 27785424
964. Colin P, Seisen T, Mathieu R, **Shariat SF**, Rouprêt M. Lynch syndrome and exposure to aristolochic acid in upper-tract urothelial carcinoma: its clinical impact? *Transl Androl Urol*. 2016 Oct;5(5):648-654. PMID: 27785421
965. **Shariat SF**, Mathieu R. Contemporary concepts and controversies in the diagnosis and management of urothelial carcinoma. *Transl Androl Urol*. 2016 Oct;5(5):633-635. PMID: 27785419
966. Moschini M, Soria F, Briganti A, **Shariat SF**. The impact of local treatment of the primary tumor site in node positive and metastatic prostate cancer patients. *Prostate Cancer Prostatic Dis*. 2016 Oct 25. PMID: 27779202
967. Módos O, Reis H, Niedworok C, Rübber H, Szendrői A, Szász MA, Tímár J, Baghy K, Kovalszky I, Golabek T, Chlostá P, Okon K, Peyronnet B, Mathieu R, **Shariat SF**, Hollósi P, Nyirády P, Szarvas T. Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurrence and prognostic significance. *Oncotarget*. 2016 Jun 28;7(26):39293-39301. PMID: 27283768

968. Munbauhal G, Seisen T, Gomez FD, Peyronnet B, Cussenot O, **Shariat SF**, Rouprêt M. Current perspectives of sentinel lymph node dissection at the time of radical surgery for prostate cancer. *Cancer Treat Rev*. 2016 Oct 6;50:228-239. PMID: 27768918
969. Bianchi L, Gandaglia G, Fossati N, Suardi N, Moschini M, Cucchiara V, Bianchi M, Damiano R, Schiavina R, **Shariat SF**, Montorsi F, Briganti A. Pelvic lymph node dissection in prostate cancer: indications, extent and tailored approaches. *Urologia*. 2015 Dec 16:0. PMID: 26689534
970. Sevcenco S, Spick C, Helbich TH, Heinz G, **Shariat SF**, Klingler HC, Rauchenwald M, Baltzer PA. Malignancy rates and diagnostic performance of the Bosniak classification for the diagnosis of cystic renal lesions in computed tomography - a systematic review and meta-analysis. *Eur Radiol*. 2016 Oct 19.
971. Schiffmann J, Sun M, Gandaglia G, Tian Z, Popa I, Larcher A, Briganti A, McCormack M, **Shariat SF**, Montorsi F, Graefen M, Saad F, Karakiewicz PI. Use of adjuvant chemotherapy in radical cystectomy patients aged >65 years: a population-based study from the surveillance epidemiology and end results (SEER)- medicare database. *Minerva Urol Nefrol*. 2016 Oct 12. PMID: 27733752
972. Wirth GJ, Haitel A, Moschini M, Soria F, Klatt T, Hassler MR, Bensalah K, Briganti A, Karam JA, Lotan Y, Margulis V, Raman JD, Remzi M, Rioux-Leclercq N, Robinson BD, Rouprêt M, Wood CG, **Shariat SF**. Androgen receptor expression is associated with adverse pathological features in ureteral but not in pelvicalyceal urothelial carcinomas of the upper urinary tract. *World J Urol*. 2016 Oct 11. PMID: 27730305
973. Moschini M, Luzzago S, Zaffuto E, Dell'Oglio P, Gandaglia G, Mattei A, Damiano R, Soria F, Klatt T, **Shariat SF**, Salonia A, Montorsi F, Briganti A, Gallina A, Colombo R. The surgical management of patients with clinical stage T4 bladder cancer: A single institution experience. *Eur J Surg Oncol*. 2016 Sep 28. PMID: 27720312
974. Grubmüller B, Baum RP, Capasso E, Singh A, Ahmadi Y, Knoll P, Floth A, Righi S, Zandieh S, Meleddu C, **Shariat SF**, Klingler HC, Mirzaei S. ⁶⁴Cu-PSMA-617 PET/CT Imaging of Prostate Adenocarcinoma: First In-Human Studies. *Cancer Biother Radiopharm*. 2016 Oct 7. PMID: 27715146
975. Krabbe LM, Woldu SL, **Shariat SF**, Lotan Y. Improving diagnostic molecular tests to monitor urothelial carcinoma recurrence. *Expert Rev Mol Diagn*. 2016 Oct 4. PMID: 27696932
976. Leyh-Bannurah SR, Gazdovich S, Budäus L, Zaffuto E, Dell'Oglio P, Briganti A, Abdollah F, Montorsi F, Schiffmann J, Menon M, **Shariat SF**, Fisch M, Chun F, Graefen M, Karakiewicz PI. Population-based external validation of the updated 2012 Partin tables in contemporary North American prostate cancer patients. *Prostate*. 2016 Sep 29. PMID: 27683103
977. Rieken M, Bachmann A, **Shariat SF**. Long-term results after prostate vaporisation: GreenLight™ laser vaporisation of the prostate and electrovaporisation. *Urologe A*. 2016 Sep 28. PMID: 27680971
978. Krabbe LM, Eminaga O, **Shariat SF**, Hutchinson RC, Lotan Y, Sagalowsky AI, Raman JD, Wood CG, Weizer AZ, Roscigno M, Montorsi F, Bolenz C, Novara G, Kikuchi E, Fajkovic H, Rapoport LM, Glybochko PV, Zigeuner R, Remzi M, Bensalah K, Kassouf W, Margulis V. Post-operative nomogram for relapse-free survival in patients with high-grade upper tract urothelial carcinoma. *J Urol*. 2016 Sep 23. PMID: 27670916
979. Zaffuto E, Gandaglia G, Fossati N, Dell'Oglio P, Moschini M, Cucchiara V, Suardi N, Mirone V, Bandini M, **Shariat SF**, Karakiewicz PI, Montorsi F, Briganti A. Early post-operative radiotherapy

- is associated with worse functional outcomes in prostate cancer patients. *J Urol*. 2016 Sep 23. PMID: 27670915
980. Soria F, Moschini M, Haitel A, Wirth GJ, Gust KM, Briganti A, Roupêt M, Klatter T, Hassler MR, Karakiewicz PI, **Shariat SF**. The effect of HER2 status on oncological outcomes of patients with invasive bladder cancer. *Urol Oncol*. 2016 Sep 21. PMID: 27665356
981. Redrow GP, Guo CC, Brausi MA, Coleman JA, Fernandez MI, Kassouf W, Keeley FX Jr, Margulis V, Raman JD, Roupret M, **Shariat SF**, Spiess PE, Thalmann GN, Matin SF. Upper urinary tract carcinoma in situ: current knowledge, future direction. *J Urol*. 2016 Sep 21. PMID: 27664578
982. Mbeutcha A, **Shariat SF**, Rieken M, Rink M, Xylinas E, Seitz C, Lucca I, Mathieu R, Roupêt M, Briganti A, Karakiewicz PI, Klatter T. Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer. *Urol Oncol*. 2016 Sep 16. PMID: 27646875
983. Schmitz-Dräger BJ, Kuckuck EC, Zuiverloon TC, Zwarthoff EC, Saltzman A, Srivastava A, Hudson MA, Seiler R, Todenhöfer T, Vlahou A, Grossman HB, Schoenberg MP, Sanchez-Carbayo M, Brünn LA, van Rhijn BW, Goebell PJ, Kamat AM, Roupret M, **Shariat SF**, Kiemeny LA. Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelines. *Urol Oncol*. 2016 Oct;34(10):437-51. PMID: 27641313
984. Witjes JA, Dalbagni G, Karnes RJ, **Shariat S**, Joniau S, Palou J, Serretta V, Larré S, di Stasi S, Colombo R, Babjuk M, Malmström PU, Malats N, Irani J, Baniel J, Cai T, Cha E, Ardel T, Varkarakis J, Bartoletti R, Spahn M, Pisano F, Gontero P, Sylvester R. The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. *Urol Oncol*. 2016 Sep 14. PMID: 27639776
985. Passoni N, Gayed B, Kapur P, Sagalowsky AI, **Shariat SF**, Lotan Y. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer. *Urol Oncol*. 2016 Sep 13. PMID: 27637323
986. Soria F, **Shariat SF**, Lerner SP, Fritsche HM, Rink M, Kassouf W, Spiess PE, Lotan Y, Ye D, Fernández MI, Kikuchi E, Chade DC, Babjuk M, Grollman AP, Thalmann GN. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). *World J Urol*. 2016 Sep 7. PMID: 27604375
987. Xylinas E, Hassler MR, Zhuang D, Krzywinski M, Erdem Z, Robinson BD, Elemento O, Clozel T, **Shariat SF**. An epigenomic approach to improving response to neoadjuvant cisplatin chemotherapy in bladder cancer. *Biomolecules*. 2016 Sep 2;6(3). PMID: 27598218
988. Moschini M, Luzzago S, Cazzaniga W, Cucchiara V, Bandini M, Damiano R, Soria F, Klatter T, **Shariat SF**, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A. Effect of stage migration on bladder cancer: a slow but steady improvement in long-term survival rates after radical cystectomy in previous 25 years. *Clin Genitourin Cancer*. 2016 Aug 8. PMID: 27589904
989. Heidenreich A, Moul JW, **Shariat S**, Karnes RJ. Role of salvage lymph node dissection in prostate cancer. *Curr Opin Urol*. 2016 Aug 31. PMID: 27584024
990. Mager R, Daneshmand S, Evans CP, Palou J, Martínez-Salamanca JI, Master VA, McKiernan JM, Libertino JA, Haferkamp A; International Renal Cell Carcinoma-Venous Thrombus Consortium, Haferkamp A, Capitanio U, Carballido JA, Chantada V, Chromecki T, Ciancio G, Daneshmand S, Evans CP, Gontero P, González J, Hohenfellner M, Huang WC, Koppie TM, Libertino JA, Espinós EL, Lorentz A, Martínez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G,

- O'Malley P, Pahernik S, Palou J, Moreno JL, Pruthi RS, Faba OR, Russo P, Scherr DS, **Shariat SF**, Spahn M, Terrone C, Tilki D, Vázquez-Martul D, Donoso CV, Vergo D, Wallen EM, Zigeuner R. Renal cell carcinoma with inferior vena cava involvement: Prognostic effect of tumor thrombus consistency on cancer specific survival. *J Surg Oncol*. 2016 Aug 26. PMID: 27562252
991. Moschini M, Soria F, Klatter T, Wirth GJ, Özsoy M, Gust K, Briganti A, Roupret M, Susani M, Haitel A, **Shariat SF**. Validation of preoperative risk grouping of the selection of patients most likely to benefit from neoadjuvant chemotherapy before radical cystectomy. *Clin Genitourin Cancer*. 2016 Jul 22. PMID: 27530435
992. Mathieu R, Korn SM, Bensalah K, Kramer G, **Shariat SF**. Cytoreductive radical prostatectomy in metastatic prostate cancer: Does it really make sense? *World J Urol*. 2016 Aug 8. PMID: 27502935
993. Fiorino C, Broggi S, Fossati N, Cozzarini C, Goldner G, Wiegel T, Hinkelbein W, Karnes RJ, Boorjian SA, Haustermans K, Joniau S, Palorini F, **Shariat S**, Montorsi F, Van Poppel H, Di Muzio N, Calandrino R, Briganti A. Predicting the 5-Year risk of biochemical relapse after postprostatectomy radiation therapy in $\geq pT2$, $pN0$ patients with a comprehensive tumor control probability Model. *Int J Radiat Oncol Biol Phys*. 2016 Jun 18. PMID: 27497691
994. Schiffmann J, Larcher A, Sun M, Tian Z, Berdugo J, Leva I, Widmer H, Lattouf JB, Zorn K, Haese A, **Shariat SF**, Saad F, Montorsi F, Graefen M, Karakiewicz PI. Differences in patient characteristics among men choosing open or robot-assisted radical prostatectomy in contemporary practice - analysis of Surveillance, Epidemiology, and End Results database. *Urol Int*. 2016 Aug 4. PMID: 27486887
995. Fossati N, Karnes RJ, Boorjian SA, Moschini M, Morlacco A, Bossi A, Seisen T, Cozzarini C, Fiorino C, Chiorda BN, Gandaglia G, Dell'Oglio P, Joniau S, Tosco L, **Shariat S**, Goldner G, Hinkelbein W, Bartkowiak D, Haustermans K, Tombal B, Montorsi F, Van Poppel H, Wiegel T, Briganti A. Long-term impact of adjuvant versus early salvage radiation therapy in $pT3N0$ prostate cancer patients treated with radical prostatectomy: results from a multi-institutional series. *Eur Urol*. 2016 Jul 30. PMID: 27484843
996. Dell'Oglio P, Boehm K, Trudeau V, Tian Z, Larcher A, Leyh-Bannurah SR, Moschini M, Capitanio U, **Shariat SF**, Briganti A, Montorsi F, Saad F, Karakiewicz PI. Survival after conservative management versus external beam radiation therapy in elderly patients with localized prostate cancer. *Int J Radiat Oncol Biol Phys*. 2016 May 10. PMID: 27478167
997. Seisen T, Peyronnet B, Dominguez-Escrig JL, Bruins HM, Yuan CY, Babjuk M, Böhle A, Burger M, Compérat EM, Cowan NC, Kaasinen E, Palou J, van Rhijn BW, Sylvester RJ, Zigeuner R, **Shariat SF**, Rouprêt M. Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the eau non-muscle invasive bladder cancer guidelines panel. *Eur Urol*. 2016 Jul 28. PMID: 27477528
998. Moschini M, Gandaglia G, Fossati N, Dell'Oglio P, Cucchiara V, Luzzago S, Zaffuto E, Suardi N, Damiano R, **Shariat SF**, Montorsi F, Briganti A. Incidence and predictors of 30-day readmission after robot-assisted radical prostatectomy. *Clin Genitourin Cancer*. 2016 Jun 29. PMID: 27452733
999. Mathieu R, Lucca I, Rouprêt M, Briganti A, **Shariat SF**. The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. *Nat Rev Urol*. 2016 Jul 19. PMID: 27431340
1000. Peyronnet B, Seisen T, Oger E, Vaessen C, Grassano Y, Benoit T, Carrouget J, Pradère B, Khene Z, Giwerc A, Mathieu R, Beauval JB, Nouhaud FX, Bigot P, Doumerc N, Bernhard JC, Mejean A, Patard JJ, **Shariat SF**, Roupret M, Bensalah K; French Committee of Urologic Oncology (CCAFU). Comparison of 1800 robotic and open partial nephrectomies for renal tumors. *Ann Surg Oncol*. 2016 Jul 13. PMID: 27411552

1001. Passoni NM, **Shariat SF**, Bagrodia A, Francis F, Rachakonda V, Xylinas E, Kapur P, Sagalowsky AI, Lotan Y. Concordance in biomarker status between bladder tumors at time of transurethral resection and subsequent radical cystectomy: results of a 5-year prospective study. *Bl Cancer*. 2016 Jan 7;2(1):91-99. PMID: 27376130
1002. Schiffmann J, Sun M, Gandaglia G, Tian Z, Popa I, Larcher A, Meskawi M, Briganti A, McCormack M, **Shariat SF**, Montorsi F, Graefen M, Saad F, Karakiewicz PI. Suboptimal use of neoadjuvant chemotherapy in radical cystectomy patients: a population-based study. *Can Urol Assoc J*. 2016 Mar-Apr;10(3-4):E82-6. PMID: 27330584
1003. Seisen T, Rouprêt M, Gomez F, Malouf GG, **Shariat SF**, Peyronnet B, Spano JP, Cancel-Tassin G, Cussenot O. A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer. *Cancer Treat Rev*. 2016 Jun 15;48:25-33. PMID: 27327958
1004. Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M, van Rhijn BW, **Shariat SF**, Soukup V, Sylvester RJ, Zigeuner R. eau guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. *Eur Urol*. 2016 Jun 17. PMID: 27324428
1005. Raman JD, Lin YK, **Shariat SF**, Krabbe LM, Margulis V, Arnouk A, Lallas CD, Trabulsi EJ, Drouin SJ, Rouprêt M, Bozzini G, Colin P, Peyronnet B, Bensalah K, Bailey K, Canes D, Klatte T. Preoperative nomogram to predict likelihood of complications following radical nephroureterectomy. *BJU Int*. 2016 Jun 20. PMID: 27322735
1006. Lucca I, Hofbauer SL, Leitner CV, de Martino M, Özsoy M, Susani M, **Shariat SF**, Klatte T. Development of a preoperative nomogram incorporating biomarkers of systemic inflammatory response to predict non-organ-confined urothelial carcinoma of the bladder at radical cystectomy. *Urology*. 2016 Jun 14. PMID: 27316373
1007. May M, Fritsche HM, Vetterlein MW, Bastian PJ, Gierth M, Nuhn P, Aziz A, Fisch M, Stief CG, Hohenfellner M, Wirth MP, Novotny V, Hakenberg OW, Noldus J, Gilfrich C, Bolenz C, Burger M, Brookman-May SD; **Shariat SF**; PROMETRICS 2011 Research Group. Impact of photodynamic diagnosis-assisted transurethral resection of bladder tumors on the prognostic outcome after radical cystectomy: results from PROMETRICS 2011. *World J Urol*. 2016 Jun 14. PMID: 27300339
1008. Leyh-Bannurah SR, Dell'Oglio P, Tian Z, Schiffmann J, **Shariat SF**, Suardi N, Francesco M, Alberto B, Heinzer H, Huland H, Graefen M, Budäus L, Karakiewicz PI. A proposal of a new nomogram for predicting upstaging in contemporary D'Amico low-risk prostate cancer patients. *World J Urol*. 2016 Jun 11. PMID: 27289238
1009. Módos O, Reis H, Niedworok C, Rübber H, Szendrői A, Szász MA, Tímár J, Baghy K, Kovalszky I, Golabek T, Chlosta P, Okon K, Peyronnet B, Mathieu R, **Shariat SF**, Hollósi P, Nyirády P, Szarvas T. Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma - occurrence and prognostic significance. *Oncotarget*. 2016 Jun 5. PMID: 27283768
1010. Soria F, Moschini M, Haitel A, Wirth GJ, Karam JA, Wood CG, Rouprêt M, Margulis V, Karakiewicz PI, Briganti A, Raman JD, Kammerer-Jacquet SF, Mathieu R, Bensalah K, Lotan Y, Özsoy M, Remzi M, Gust KM, **Shariat SF**. HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). *World J Urol*. 2016 Jun 7. PMID: 27272502
1011. Trudeau V, Karakiewicz PI, Boehm K, Dell'Oglio P, Tian Z, Briganti A, **Shariat SF**, Valiquette L, Bhojani N. The effect of obesity on perioperative outcomes following percutaneous nephrolithotomy. *J Endourol*. 2016 Jun 2. PMID: 27257037

1012. Raman JD, Warrick JI, Caruso C, Yang Z, Shuman L, Bruggeman RD, **Shariat S**, Karam JA, Wood C, Weizer AZ, Remzi M, Haitel A, Bensalah K, Rioux-Leclercq N, Bolenz C, Roscigno M, Krabbe LM, Kapur P, Lotan Y, Margulis V, DeGraff DJ. Altered expression of the transcription factor forkhead box a1 (foxa1) is associated with poor prognosis in urothelial carcinoma of the upper urinary tract. *Urology*. 2016 May 20. PMID: 27215483
1013. D'Andrea D, **Shariat SF**, Klatte T. Update on ablative therapies of renal tumors. *Curr Opin Urol*. 2016 May 20. PMID: 27214581
1014. Vartolomei MD, Mathieu R, Margulis V, Karam JA, Rouprêt M, Lucca I, Mbeutcha A, Seitz C, Karakiewicz PI, Fajkovic H, Wood CG, Weizer AZ, Raman JD, Rioux-Leclercq N, Haitel A, Bensalah K, Rink M, Briganti A, Xylinas E, **Shariat SF**. Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. *World J Urol*. 2016 May 21. PMID: 27209168
1015. Polanec S, Helbich TH, Bickel H, Pinker-Domenig K, Georg D, **Shariat SF**, Aulitzky W, Susani M, Baltzer PA. Head-to-head comparison of PI-RADS v2 and PI-RADS v1. *Eur J Radiol*. 2016 Jun;85(6):1125-31. PMID: 27161062
1016. Favaretto RL, Bahadori A, Mathieu R, Haitel A, Grubmüller B, Margulis V, Karam JA, Rouprêt M, Seitz C, Karakiewicz PI, Cunha IW, Zequi SC, Wood CG, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Jacquet-Kammerer S, Bensalah K, Lotan Y, Bachmann A, Rink M, Briganti A, **Shariat SF**. Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. *World J Urol*. 2016 Apr 29. PMID: 27129576
1017. Mathieu R, Vartolomei MD, Mbeutcha A, Karakiewicz PI, Briganti A, Rouprêt M, **Shariat SF**. Urothelial cancer of the upper urinary tract: emerging biomarkers and integrative models for risk stratification. *Minerva Urol Nefrol*. 2016 Apr 28. PMID: 27124417
1018. Mbeutcha A, Rouprêt M, Kamat AM, Karakiewicz PI, Lawrentschuk N, Novara G, Raman JD, Seitz C, Xylinas E, **Shariat SF**. Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. *World J Urol*. 2016 Apr 21. PMID: 27101100
1019. Pouessel D, Neuzillet Y, Mertens LS, van der Heijden MS, de Jong J, Sanders J, Peters D, Leroy K, Manceau A, Maille P, Soyeux P, Moktefi A, Semprez F, Vordos D, de la Taille A, Hurst CD, Tomlinson DC, Harnden P, Bostrom PJ, Mirtti T, Horenblas S, Loriot Y, Houédé N, Chevreau C, Beuzeboc P, **Shariat SF**, Sagalowsky AI, Ashfaq R, Burger M, Jewett MA, Zlotta AR, Broeks A, Bapat B, Knowles MA, Lotan Y, van der Kwast TH, Culine S, Allory Y, van Rhijn BW. Tumor Heterogeneity of Fibroblast Growth Factor Receptor 3 (FGFR3) Mutations in Invasive Bladder Cancer: Implications for Peri-Operative anti-FGFR3 Treatment. *Ann Oncol*. 2016 Apr 18. PMID: 27091807
1020. Gakis G, Schubert T, Alemozaffar M, Bellmunt J, Bochner BH, Boorjian SA, Daneshmand S, Huang WC, Kondo T, Konety BR, Laguna MP, Matin SF, Siefker-Radtke AO, **Shariat SF**, Stenzl A. Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease. *World J Urol*. 2016 Apr 4. PMID: 27043218
1021. Bishr M, Boehm K, Trudeau V, Tian Z, Dell'Oglio P, Schiffmann J, Jeldres C, Sun M, **Shariat SF**, **Graefen M**, Saad F, Karakiewicz PI. Medical management of benign prostatic hyperplasia: Results from a population-based study. *Can Urol Assoc J*. 2016 Jan-Feb;10(1-2):55-9. PMID: 26977208
1022. Fajkovic H, Mathieu R, Lucca I, Hiess M, Hübner N, Al Awamlh BA, Lee R, Briganti A, Karakiewicz P, Lotan Y, Roupert M, Rink M, Kluth L, Loidl W, Seitz C, Klatte T, Kramer G, Susani M, **Shariat SF**. Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy. *Urol Oncol*. 2016 Mar 10. PMID: 26973136

1023. Dell'Oglio P, Abou-Haidar H, Leyh-Bannurah SR, Tian Z, Larcher A, Gandaglia G, Fossati N, **Shariat SF**, Capitanio U, Briganti A, Montorsi F, Graefen M, Saad F, Karakiewicz PI. Assessment of the rate of adherence to international guidelines for androgen deprivation therapy with external-beam radiation therapy: a population-based study. *Eur Urol*. 2016 Mar 4. PMID: 26951945
1024. Mathieu R, Lucca I, Vartolomei MD, MBeutcha A, Klatter T, Seitz C, Karakiewicz PI, Fajkovic H, Sun M, Lotan Y, Montorsi F, Briganti A, Rouprêt M, Margulis V, Rink M, Rieken M, Kenner L, Susani M, Wolfgang L, **Shariat SF**. Role of Survivin expression in predicting biochemical recurrence after radical prostatectomy: a multi-institutional study. *BJU Int*. 2016 Mar 4. PMID: 26940243
1025. Moschini M, Karnes RJ, Sharma V, Gandaglia G, Fossati N, Dell'Oglio P, Cucchiara V, Capogrosso P, **Shariat SF**, Damiano R, Salonia A, Montorsi F, Briganti A, Gallina A, Colombo R. Patterns and prognostic significance of clinical recurrences after radical cystectomy for bladder cancer: A 20-year single center experience. *Eur J Surg Oncol*. 2016 Feb 18. PMID: 26927300
1026. Trudeau V, Larcher A, Sun M, Boehm K, Dell'Oglio P, Sosa J, Tian Z, Fossati N, Briganti A, **Shariat SF**, Karakiewicz PI. Comparison of oncologic outcomes between sarcomatoid and clear cell renal cell carcinoma. *World J Urol*. 2016 Feb 22. PubMed PMID: 26902877.
1027. Wolff I, May M, Hoschke B, Zigeuner R, Cindolo L, Hutterer G, Schips L, De Cobelli O, Rocco B, De Nunzio C, Tubaro A, Coman I, Feciche B, Truss M, Dalpiaz O, Figenschau RS, Madison K, Sánchez-Chapado M, Santiago Martin MD, Salzano L, Lotrecchiano G, **Shariat SF**, Hohenfellner M, Waidelich R, Stief C, Miller K, Pahernik S, Brookman-May S; Members of the CORONA Project and the European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Group. Do we need new high-risk criteria for surgically treated renal cancer patients to improve the outcome of future clinical trials in the adjuvant setting? Results of a comprehensive analysis based on the multicenter CORONA database. *Eur J Surg Oncol*. 2016 Jan 22. PubMed PMID: 26899942.
1028. Fajkovic H, **Shariat SF**, Klatter T, Vartolomei MD, Lucca I, Mbeutcha A, Rouprêt M, Briganti A, Karakiewicz PI, Margulis V, Rink M, Remzi M, Seitz C, Bensalah K, Mathieu R. Impact of smoking status on survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. *World J Urol*. 2016 Feb 15. PubMed PMID: 26879416.
1029. Gandaglia G, Lista G, Fossati N, Suardi N, Gallina A, Moschini M, Bianchi L, Rossi MS, Schiavina R, **Shariat SF**, Salonia A, Montorsi F, Briganti A. Non-surgically related causes of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. *Prostate Cancer Prostatic Dis*. 2016 Feb 9. PubMed PMID: 26857023.
1030. Moschini M, Bianchi M, Rossi MS, Dell'Oglio P, Gandaglia G, Fossati N, Mattei A, Damiano R, **Shariat SF**, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A. Timing of blood transfusion and not ABO blood type is associated with survival in patients treated with radical cystectomy for nonmetastatic bladder cancer: Results from a single high-volume institution. *Urol Oncol*. 2016 Feb 2. PubMed PMID: 26850780.
1031. Leitner CV, Ederer IA, de Martino M, Hofbauer SL, Lucca I, Mbeutcha A, Mathieu R, Haitel A, Susani M, **Shariat SF**, Klatter T. Dynamic prognostication using conditional recurrence and progression estimates for patients with non-muscle invasive bladder cancer. *J Urol*. 2016 Jan 30. PubMed PMID: 26835832.
1032. Mathieu R, Bensalah K, Lucca I, Mbeutcha A, Rouprêt M, **Shariat SF**. Upper urinary tract disease: what we know today and unmet needs. *Transl Androl Urol*. 2015 Jun;4(3):261-72. PubMed Central PMCID: PMC4708228.

1033. Gandaglia G, Suardi N, Cucchiara V, Bianchi M, **Shariat SF**, Roupret M, Salonia A, Montorsi F, Briganti A. Penile rehabilitation after radical prostatectomy: does it work? *Transl Androl Urol*. 2015 Apr;4(2):110-23. PubMed PMID: 26816818; PubMed Central PMCID: PMC4708129.
1034. Sevcenco S, Mathieu R, Baltzer P, Klatte T, Fajkovic H, Seitz C, Karakiewicz PI, Rouprêt M, Rink M, Kluth L, Trinh QD, Loidl W, Briganti A, Scherr DS, **Shariat SF**. The prognostic role of preoperative serum C-reactive protein in predicting the biochemical recurrence in patients treated with radical prostatectomy. *Prostate Cancer Prostatic Dis*. 2016 Jan 26. PubMed PMID: 26810014.
1035. Seisen T, **Shariat SF**, Cussenot O, Peyronnet B, Renard-Penna R, Colin P, Rouprêt M. Contemporary role of lymph node dissection at the time of radical nephroureterectomy for upper tract urothelial carcinoma. *World J Urol*. 2016 Jan 25. PubMed PMID: 26809456.
1036. Moschini M, Gandaglia G, Dell'Oglio P, Fossati N, Cucchiara V, Burgio G, Mattei A, Damiano R, **Shariat SF**, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A. Incidence and Predictors of 30-Day Readmission in Patients Treated With Radical Cystectomy: A Single Center European Experience. *Clin Genitourin Cancer*. 2015 Dec 23. PubMed PMID: 26797584.
1037. Grubmueller B, Seitz C, **Shariat SF**. The treatment of muscle-invasive bladder cancer in geriatric patients. *Curr Opin Urol*. 2016 Mar;26(2):160-4. PubMed PMID: 26765044.
1038. Bianchi L, Gandaglia G, Fossati N, Suardi N, Moschini M, Cucchiara V, Bianchi M, Damiano R, Schiavina R, **Shariat SF**, Montorsi F, Briganti A. Pelvic lymph node dissection in prostate cancer: indications, extent and tailored approaches. *Urologia*. 2015 Dec 16:0. PubMed PMID: 26689534.
1039. Moschini M, Karnes RJ, Gandaglia G, Luzzago S, Dell'Oglio P, Rossi MS, di Trapani E, La Croce G, Damiano R, Salonia A, **Shariat SF**, Montorsi F, Briganti A, Gallina A, Colombo R. Preoperative Favorable Characteristics in Bladder Cancer Patients Cannot Substitute the Necessity of Extended Lymphadenectomy During Radical Cystectomy: A Sensitivity Curve Analysis. *Urology*. 2015 Dec 9. PubMed PMID: 26683751.
1040. Seisen T, Nison L, Remzi M, Klatte T, Mathieu R, Lucca I, Bozzini G, Capitanio U, Novara G, Cussenot O, Compérat E, Renard-Penna R, Peyronnet B, Merseburger AS, Fritsche HM, Hora M, **Shariat SF**, Colin P, Rouprêt M. Oncologic Outcomes of Kidney Sparing Surgery versus Radical Nephroureterectomy for the Elective Treatment of Clinically Organ Confined Upper Tract Urothelial Carcinoma of the Distal Ureter. *J Urol*. 2015 Nov 21. PubMed PMID: 26612196.
1041. Mbeutcha A, Lucca I, Mathieu R, Lotan Y, **Shariat SF**. Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer. *Urol Clin North Am*. 2016 Feb;43(1):47-62. PubMed PMID: 26614028.
1042. Mbeutcha A, Lucca I, Margulis V, Karam JA, Wood CG, de Martino M, Mathieu R, Haitel A, Xylinas E, Kluth L, Rouprêt M, Karakiewicz PI, Briganti A, Rink M, Rieken M, Weizer AZ, Raman JD, Rioux-Leclecq N, Bolenz C, Bensalah K, Lotan Y, Seitz C, Remzi M, **Shariat SF**, Klatte T. Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. *World J Urol*. 2015 Dec 11. PubMed PMID: 26658888.
1043. Lotan Y, Karam JA, **Shariat SF**, Gupta A, Roupret M, Bensalah K, Margulis V. Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial. *Urol Oncol*. 2015 Nov 18. PubMed PMID: 26602092.
1044. Hofbauer SL, **Shariat SF**, Chade DC, Sarkis AS, Ribeiro-Filho LA, Nahas WC, Klatte T. The Moreau Strain of Bacillus Calmette-Guerin (BCG) for High-Risk Non-Muscle Invasive Bladder Cancer: An Alternative during Worldwide BCG Shortage? *Urol Int*. 2015 Nov 11. PMID: 265557

1045. Rieken M, Bachmann A, **Shariat SF**. Long-term follow-up data more than 5 years after surgical management of benign prostate obstruction: who stands the test of time? *Curr Opin Urol*. 2015 Nov 9. PMID: 2655569
1046. Moschini M, Fossati N, Abdollah F, Gandaglia G, Cucchiara V, Dell'Oglio P, Luzzago S, **Shariat SF**, Dehò F, Salonia A, Montorsi F, Briganti A. Determinants of long-term survival of patients with locally advanced prostate cancer: the role of extensive pelvic lymph node dissection. *Prostate Cancer Prostatic Dis*. 2015 Nov 10. PMID: 26553644
1047. Nison L, Colin P, Remzi M, **Shariat S**, Klatter T, Yakoubi R, Bozzini G, Capitanio U, Babjuk M, Merseburger A, Cha E, Fritsche H, Novara G, Montorsi F, Hora M, Roupret M. Résultats oncologiques du traitement des TVES \leq pT2 de l'uretère pelvien par néphro-urétérectomie, résection segmentaire et chirurgie endoscopique : résultats d'une étude multicentrique européenne. *Prog Urol*. 2015 Nov;25(13):807. PMID: 26544377
1048. Seisen T, Granger B, Colin P, Léon P, Utard G, Renard Penna R, Compérat E, Mozer P, Cussenot O, **Shariat S**, Rouprêt M. Revue systématique de la littérature et méta-analyse des facteurs de risque de récurrence vésicale après néphro-urétérectomie totale pour le traitement d'une tumeur de la voie excrétrice urinaire supérieure. *Prog Urol*. 2015 Nov;25(13):805. PMID: 26544373
1049. Riccio R, Aziz A, Rink M, Peyromaure M, **Shariat S**, May M, Xylinas E. Optimisation de la transcription des résultats de la cystectomie totale : vers la définition d'un Trifecta et d'un Pentafecta. *Prog Urol*. 2015 Nov;25(13):770. PMID: 26544307
1050. Xylinas E, Huillard O, Peyromaure M, Black P, **Shariat SF**. L'intervalle entre le diagnostic et la cystectomie totale n'a pas d'impact sur le devenir oncologique des patients traités par chimiothérapie néoadjuvante. *Prog Urol*. 2015 Nov;25(13):767. PMID: 26544301
1051. Mbeutcha A, Lucca I, De Martino M, Mathieu R, Rieken M, Xylinas E, Kluth L, Crivelli J, Lotan Y, **Shariat S**, Klatter T, Karakiewicz P. Le rapport neutrophiles/lymphocytes est un facteur prédictif indépendant de récurrence et de progression dans les tumeurs de vessie non infiltrantes. *Prog Urol*. 2015 Nov;25(13):759-60. PMID: 26544285
1052. Mathieu R, Lucca I, Mbeutcha A, Seitz C, Karakiewicz P, Sun M, Montorsi F, Briganti A, Rouprêt M, Robinson B, Xylinas E, **Shariat S**. Valeur pronostique de Caveolin-1 dans le cancer de prostate : une étude multicentrique internationale. *Prog Urol*. 2015 Nov;25(13):741-2. PMID: 26544248
1053. Mathieu R, Mbeutcha A, Lucca I, Briganti A, Karakiewicz P, Rouprêt M, Seitz C, Klatter T, **Shariat SF**. L'obésité est associée à la récurrence biologique après prostatectomie radicale : une étude multicentrique internationale. *Prog Urol*. 2015 Nov;25(13):740. PMID: 26544245
1054. Trudeau V, Larcher A, Boehm K, Dell'Oglio P, Sun M, Tian Z, Briganti A, **Shariat SF**, Jeldres C, Karakiewicz PI. Comparison of Postoperative Complications and Mortality Between Laparoscopic and Percutaneous Local Tumor Ablation for T1a Renal Cell Carcinoma: a Population-Based Study. *Urology*. 2015 Oct 26. PMID: 26514977
1055. Rink M, Soave A, Dahlem R, Aziz A, Al-Sayed F, Peine S, Engel O, Kluth LA, Stenzl A, Burger M, **Shariat SF**, Fisch M, Fritsche HM, Gakis G. Impact of Perioperative Allogenic Blood Transfusion on Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. *Clin Genitourin Cancer*. 2015 Oct 20. PMID: 26506908
1056. Fossati N, Karnes RJ, Cozzarini C, Fiorino C, Gandaglia G, Joniau S, Boorjian SA, Goldner G, Hinkelbein W, Haustermans K, Tombal B, **Shariat SF**, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T, Briganti A. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. *Eur Urol*. 2015 Oct 20. PMID: 26497924

1057. Lucca I, Klatter T, Fajkovic H, de Martino M, **Shariat SF**. Gender differences in incidence and outcomes of urothelial and kidney cancer. *Nat Rev Urol*. 2015 Oct 20. PMID: 2648157
1058. Gontero P, Sylvester R, Pisano F, Joniau S, Oderda M, Serretta V, Larre S, Stasi SD, Van Rhijn B, Witjes AJ, Grotenhuis AJ, Colombo R, Briganti A, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Vakarakis J, Bartoletti R, Dalbagni G, **Shariat SF**, Xylinas E, Karnes RJ, Palou J. The impact of re-TUR on clinical outcomes in a large multi-centre cohort of T1-HG/G3 patients treated with BCG. *BJU Int*. 2015 Oct 15. PMID: 26469362
1059. Xylinas E, Rieken M, **Shariat S**. Comparaison des tables de l'EORTC et de la nouvelle classification simplifiée EAU pour la prédiction de la récurrence tumorale et de la progression des TVNIM. *Prog Urol*. 2014 Nov;24(13):846-7. PMID: 26461666
1060. Seisen T, Colin P, Hupertan V, Léon P, Bozzini G, Nison L, Phé V, Rozet F, **Shariat S**, Cussenot O, Rouprêt M. Validation externe du nomogramme prédictif de la récurrence vésicale après néphro-urétérectomie totale pour le traitement des tumeurs de la voie excrétrice urinaire supérieure. *Prog Urol*. 2014 Nov;24(13):845-6. PMID: 26461665
1061. Xylinas E, Rink M, Rouprêt M, **Shariat SF**. Impact de la consommation tabagique sur la récurrence vésicale après néphro-urétérectomie totale pour tumeur de la voie excrétrice supérieure. *Prog Urol*. 2014 Nov;24(13):845. PMID: 26461663
1062. Neuzillet Y, Mertens L, **Shariat S**, Bostrom P, Mirtti T, Sagalowsky A, Ashfaq R, Broeks A, Van der Heijden M, Peters D, Curial C, De Jong J, Horenblas S, Hurst C, Tomlinson D, Knowles M, Bapat B, Jewett M, Zlotta A, Sanders J, Lotan Y, Van der Kwast T, Van Rhijn B. Le Fibroblast Growth Factor Receptor 3 (FGFR3), cible thérapeutique pour le traitement personnalisé du cancer de la vessie : validation anatomo-pathologique du concept. *Prog Urol*. 2014 Nov;24(13):806-7. PMID: 26461579
1063. Vom Dorp F, Tschirdewahn S, Niedworok C, Reis H, Krause H, Kempkensteffen C, Busch J, Kramer G, **Shariat SF**, Nyirady P, Rübber H, Szarvas T. Circulating and tissue expression levels of YKL-40 in renal cell cancer. *J Urol*. 2015 Oct 7. PMID: 26454102
1064. Lucca I, Klatter T, Fajkovic H, de Martino M, **Shariat SF**. Gender differences in incidence and outcomes of urothelial and kidney cancer. *Nat Rev Urol*. 2015 Oct 5;12(10):585-92. PMID: 26436686
1065. Suardi N, Dell'Oglio P, Gallina A, Gandaglia G, Buffi N, Moschini M, Fossati N, Lughezzani G, Karakiewicz PI, Freschi M, Lucianò R, **Shariat SF**, Guazzoni G, Gaboardi F, Montorsi F, Briganti A. Evaluation of positive surgical margins in patients undergoing robot-assisted and open radical prostatectomy according to preoperative risk groups. *Urol Oncol*. 2015 Sep 28. PMID: 26427694
1066. Polanec SH, Pinker-Domenig K, Brader P, Georg D, **Shariat SF**, Spick C, Susani M, Helbich TH, Baltzer PA. Multiparametric MRI of the prostate at 3 T: limited value of 3D 1H-MR spectroscopy as a fourth parameter. *World J Urol*. 2015 Sep 25. PMID: 26407583
1067. Larcher A, Trudeau V, Sun M, Boehm K, Meskawi M, Tian Z, Fossati N, Dell'Oglio P, Capitano U, Briganti A, **Shariat SF**, Montorsi F, Karakiewicz PI. Population-based assessment of cancer specific mortality after local tumour ablation or observation for kidney cancer: a competing risks analysis. *BJU Int*. 2015 Sep 19. PMID: 26384713
1068. Castells X, Karanović S, Ardin M, Tomić K, Xylinas E, Durand G, Villar S, Forey N, Le Calvez-Kelm F, Voegelé C, Karlović K, Mišić M, Dittrich D, Dolgalev I, McKay JD, **Shariat SF**, Sidorenko VS, Fernandes A, Heguy A, Dickman KG, Olivier M, Grollman AP, Jelaković B, Zavadil J. Low-coverage exome sequencing screen in formalin-fixed paraffin-embedded tumors

- reveals evidence of exposure to carcinogenic aristolochic acid. *Cancer Epidemiol Biomarkers Prev.* 2015 Sep 17. PMID: 26383547
1069. Grubmueller B, Rouprêt M, Briganti A, **Shariat SF**. The use of biomarkers for bladder cancer diagnosis and surveillance. *Mini Rev Med Chem.* 2015 Sep 9. PMID: 26349498
1070. Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, **Shariat SF**, Zlotta AR, Boorjian SA. Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. *Eur Urol.* 2015 Sep 4. PMID: 26346676
1071. Brooks M, Godoy G, Sun M, **Shariat SF**, Amiel GE, Lerner SP. External Validation of Bladder Cancer Predictive Nomograms for Recurrence, Cancer-Free Survival, and Overall Survival Following Radical Cystectomy. *J Urol.* 2015 Sep 4. PMID: 26343350
1072. de Martino M, Taus C, Lucca I, Hofbauer SL, Haitel A, **Shariat SF**, Klatter T. Association of human telomerase reverse transcriptase gene polymorphisms, serum levels, and telomere length with renal cell carcinoma risk and pathology. *Mol Carcinog.* 2015 Aug 21. PMID: 26294352
1073. Leisser A, Pruscha K, Ubl P, Wadsak W, Mayerhöfer M, Mitterhauser M, Hacker M, Kramer G, **Shariat S**, Karanikas G, Hartenbach M, Haug AR. Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [11 C] acetate PET as a prognostic marker. *Prostate.* 2015 Aug 18. PMID: 26282590
1074. Veneziano D, Minervini A, Beatty J, Fornara P, Gozen A, Greco F, Langenhuijsen JF, Lunelli L, Overgaauw D, Rassweiler J, Rocco B, Salas RS, **Shariat S**, Sweet RM, Simone G, Springer C, Tuccio A, Van Cleynebreugel B, Weibl P, Cozzupoli P. Construct, content and face validity of the camera handling trainer (CHT): a new E-BLUS training task for 30° laparoscope navigation skills. *World J Urol.* 2015 Aug 6. PMID: 26245746
1075. Mathieu R, Klatter T, Margulis V, Karam JA, Rouprêt M, Seitz C, Karakiewicz PI, Fajkovic H, Wood CG, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Bensalah K, Lotan Y, Rink M, Kluth LA, Scherr DS, Robinson BD, **Shariat SF**. Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: A multi-institutional study. *Urol Oncol.* 2015 Jul 27. PMID: 26228160
1076. Mathieu R, Klatter T, Lucca I, Beutcha AM, Seitz C, Karakiewicz PI, Fajkovic H, Sun M, Lotan Y, Scherr DS, Montorsi F, Briganti A, Rouprêt M, Margulis V, Rink M, Kluth LA, Rieken M, Kenner L, Susani M, Robinson BD, Xylinas E, Loidl W, **Shariat SF**. Prognostic value of Caveolin-1 in patients treated with radical prostatectomy: a multicentric validation study. *BJU Int.* 2015 Jul 18. PMID: 26189876
1077. Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester RJ, Burger M, Cowan NC, Böhle A, Van Rhijn BW, Kaasinen E, Palou J, **Shariat SF**. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. *Eur Urol.* 2015 Jul 15. PMID: 26188393
1078. Klatter T, Seitz C, Rink M, Rouprêt M, Xylinas E, Karakiewicz P, Susani M, **Shariat SF**. ERCC1 as a prognostic and predictive biomarker for urothelial carcinoma of the bladder following radical cystectomy. *J Urol.* 2015 Jul 7. PMID: 26162296
1079. de Martino M, Lucca I, Mbeutcha A, Wiener HG, Haitel A, Susani M, **Shariat SF**, Klatter T. Carbonic anhydrase IX as a diagnostic urinary marker for urothelial bladder cancer. *Eur Urol.* 2015 Oct;68(4):552-4. PMID: 26138037
1080. Mathieu R, Lucca I, Klatter T, Babjuk M, **Shariat SF**. Trimodal therapy for invasive bladder cancer: is it really equal to radical cystectomy? *Curr Opin Urol.* 2015 Jun 29. PMID: 26125510

1081. Rieken M, **Shariat SF**, Kluth LA, Fajkovic H, Rink M, Karakiewicz PI, Seitz C, Briganti A, Rouprêt M, Loidl W, Trinh QD, Bachmann A, Pourmand G. Association of cigarette smoking and smoking cessation with biochemical recurrence of prostate cancer in patients treated with radical prostatectomy. *Eur Urol*. 2015 Jun 3. PMID: 26050111
1082. Krabbe LM, Bagrodia A, Westerman ME, Gayed BA, Haddad AQ, Sagalowsky AI, **Shariat SF**, Kapur P, Lotan Y, Margulis V. Molecular profile of urothelial carcinoma of the upper urinary tract: are pelvicalyceal and ureteral tumors different? *World J Urol*. 2015 May 20. PMID: 25991599
1083. Ghoneim TP, Sjoberg DD, Lowrance W, **Shariat SF**, Savage C, Bernstein M, Russo P. Partial nephrectomy for renal tumors in solitary kidneys: postoperative renal function dynamics. *World J Urol*. 2015 May 13. PMID: 25966661
1084. Youssef RF, Krabbe LM, **Shariat SF**, Lotan Y, Sagalowsky AI, Raman J, Wood CG, Weizer A, Roscigno M, Montorsi F, Bolenz C, Remzi M, Bensalah K, Kassouf W, Margulis V.: TALL score for prediction of oncological outcomes after radical nephroureterectomy for high-grade upper tract urothelial carcinoma. *World J Urol*. 2015 May 10. PMID: 25957592
1085. Aziz A, Gierth M, Rink M, Schmid M, Chun FK, Dahlem R, Roghmann F, Palisaar RJ, Noldus J, Ellinger J, Müller SC, Pycha A, Martini T, Bolenz C, Moritz R, Herrmann E, Keck B, Wullich B, Mayr R, Fritsche HM, Burger M, Bastian PJ, Seitz C, Brookman-May S, Xylinas E, **Shariat SF**, Fisch M, May M; PROMETRICS 2011 Research Group. Optimizing outcome reporting after radical cystectomy for organ-confined urothelial carcinoma of the bladder using oncological trifecta and pentafecta. *World J Urol*. 2015 May 7. PMID: 25947885
1086. Weibl P, **Shariat SF**, Klatte T. Partial nephrectomy driven by cavitron ultrasonic surgical aspirator under zero ischemia: a pilot study. *World J Urol*. 2015 May 3. PMID: 25935329
1087. Lucca I, de Martino M, Hofbauer SL, Zamani N, **Shariat SF**, Klatte T. Comparison of the prognostic value of pretreatment measurements of systemic inflammatory response in patients undergoing curative resection of clear cell renal cell carcinoma. *World J Urol*. 2015 Apr 17. PMID: 25894368
1088. Lucca I, de Martino M, Klatte T, **Shariat SF**. Novel biomarkers to predict response and prognosis in localized bladder cancer. *Urol Clin North Am*. 2015 May;42(2):225-233. PMID: 25882564
1089. Ederer IA, Lucca I, Hofbauer SL, Haidinger M, Haitel A, Susani M, **Shariat SF**, Klatte T. Histopathology and prognosis of de novo bladder tumors following solid organ transplantation. *World J Urol*. 2015 Apr 10. PMID: 25860378
1090. Lucca I, Leow JJ, **Shariat SF**, Chang SL. Diagnosis and Management of Upper Tract Urothelial Carcinoma. *Hematol Oncol Clin North Am*. 2015 Apr;29(2):271-288. PMID: 25836934
1091. Nguyen HG, Tilki D, Dall'Era MA, Durbin-Johnson B, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Linares Espinós E, Mandel P, Martinez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, **Shariat SF**, Spahn M, Terrone C, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. Cardiopulmonary bypass (CPB) has no significant impact on survival in patients undergoing nephrectomy and level III-IV inferior vena cava thrombectomy; a multi-institutional analysis. *J Urol*. 2015 Mar 19. PMID: 25797392
1092. Moschini M, Gandaglia G, Suardi N, Fossati N, Cucchiara V, Damiano R, Cantiello F, **Shariat SF**, Montorsi F, Briganti A. Importance of prostate volume in the stratification of patients with intermediate-risk prostate cancer. *Int J Urol*. 2015 Mar 17. PMID: 25783998

1093. Engel O, Soave A, Peine S, Kluth LA, Schmid M, **Shariat SF**, Dahlem R, Fisch M, Rink M. The impact of the ABO and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy. *World J Urol.* 2015 Mar 18. PMID: 25782867
1094. Mork M, Hubosky SG, Roupert M, Margulis V, Raman J, Lotan Y, O'Brien T, You N, **Shariat SF**, Matin SF. Lynch Syndrome: A Primer for Urologists and Panel Recommendations. *J Urol.* 2015 Feb 21. PMID: 25711197
1095. Kluth LA, Black PC, Bochner BH, Catto J, Lerner SP, Stenzl A, Sylvester R, Vickers AJ, Xylinas E, **Shariat SF**. Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. *Eur Urol.* 2015 Feb 20. PMID: 25709027
1096. Brookman-May SD, May M, Wolff I, Zigeuner R, Hutterer GC, Cindolo L, Schips L, De Cobelli O, Rocco B, De Nunzio C, Tubaro A, Coman I, Truss M, Dalpiaz O, Feciche B, Figenshau RS, Madison K, Sánchez-Chapado M, Del Carmen Santiago Martin M, Salzano L, Lotrecchiano G, Zastrow S, Wirth M, Sountoulides P, **Shariat S**, Waidelich R, Stief C, Gunia S; members of the CORONA Project and the European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Group. Evaluation of the Prognostic Significance of Perirenal Fat Invasion and Tumor Size in Patients with pT1-pT3a Localized Renal Cell Carcinoma in a Comprehensive Multicenter Study of the CORONA project. Can We Improve Prognostic Discrimination for Patients with Stage pT3a tumors? *Eur Urol.* 2015 Feb 12. PMID: 25684695
1097. Hwang IC, Park SM, Shin D, Ahn HY, Rieken M, **Shariat SF**. Metformin Association with Lower Prostate Cancer Recurrence in Type 2 Diabetes: a Systematic Review and Meta-analysis. *Asian Pac J Cancer Prev.* 2015;16(2):595-600. PMID: 25684493
1098. Al Hussein Al Awamlh B, Lee DJ, Nguyen DP, Green DA, **Shariat SF**, Scherr DS. Assessment of the Quality-of-life and Functional Outcomes in Patients Undergoing Cystectomy and Urinary Diversion for the Management of Radiation-induced Refractory Benign Disease. *Urology.* 2015 Feb;85(2):394-401. PMID: 25623700
1099. Soave A, Engel O, von Amsberg G, Becker A, Dahlem R, **Shariat SF**, Fisch M, Rink M. The management of advanced bladder cancer in the era of targeted therapies. *Minerva Urol Nefrol.* 2015 Jan 21. PMID: 25604695
1100. Lucca I, Klätte T, Rouprêt M, **Shariat SF**. Kidney-sparing surgery for upper tract urothelial cancer. *Curr Opin Urol.* 2015 Mar;25(2):100-4. PMID: 25581542
1101. Otto BJ, Osterberg EC, Salgado S, Scherr DS, **Shariat SF**. Prostate Cancer Risk Estimation Tool Usage Among Members of the American Urological Association (AUA): A Survey-Based Study. *J Urol.* 2015 Jan 3. PMID: 25562444
1102. Gandaglia G, Sun M, Popa I, Schiffmann J, Trudeau V, **Shariat SF**, Trinh QD, Graefen M, Widmer H, Saad F, Briganti A, Montorsi F, Karakiewicz PI. Cardiovascular Mortality in Patients With Metastatic Prostate Cancer Exposed to Androgen Deprivation Therapy: A Population-Based Study. *Clin Genitourin Cancer.* 2014 Dec 9. PMID: 25547676
1103. Seisen T, Granger B, Colin P, Léon P, Utard G, Renard-Penna R, Compérat E, Mozer P, Cussenot O, **Shariat SF**, Rouprêt M. A Systematic Review and Meta-analysis of Clinicopathologic Factors Linked to Intravesical Recurrence After Radical Nephroureterectomy to Treat Upper Tract Urothelial Carcinoma. *Eur Urol.* 2014 Dec 5. PMID: 2548868
1104. Schmitz-Dräger BJ, Droller M, Lokeshwar VB, Lotan Y, Hudson MA, van Rhijn BW, Marberger MJ, Fradet Y, Hemstreet GP, Malmstrom PU, Ogawa O, Karakiewicz PI, **Shariat SF**. Molecular Markers for Bladder Cancer Screening, Early Diagnosis, and Surveillance: The WHO/ICUD Consensus. *Urol Int.* 2014 Dec 10. PMID: 25501325

1105. Larcher A, Sun M, Schiffmann J, Tian Z, **Shariat SF**, McCormack M, Saad F, Fossati N, Abdollah F, Briganti A, Buffi N, Graefen M, Guazzoni G, Montorsi F, Karakiewicz PI. Differential effect on survival of pelvic lymph node dissection at radical cystectomy for muscle invasive bladder cancer. *Eur J Surg Oncol*. 2014 Nov 21. PMID: 25477269
1106. Casey RG, Catto JW, Cheng L, Cookson MS, Herr H, **Shariat S**, Witjes JA, Black PC. Diagnosis and Management of Urothelial Carcinoma In Situ of the Lower Urinary Tract: A Systematic Review. *Eur Urol*. 2014 Nov 14. PMID: 25466937
1107. Soave A, Schmidt S, Dahlem R, Minner S, Engel O, Kluth LA, John LM, Hansen J, Schmid M, Sauter G, **Shariat SF**, Fisch M, Rink M. Does the extent of variant histology affect oncological outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy? *Urol Oncol*. 2014 Nov 24. PMID: 25465301
1108. Schiffmann J, Gandaglia G, Larcher A, Sun M, Tian Z, **Shariat SF**, McCormack M, Valiquette L, Montorsi F, Graefen M, Saad F, Karakiewicz PI. Contemporary 90-day mortality rates after radical cystectomy in the elderly. *Eur J Surg Oncol*. 2014 Oct 15. PMID: 25454826
1109. Krabbe LM, Bagrodia A, Haddad AQ, Kapur P, Khalil D, Hynan LS, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, **Shariat SF**, Lotan Y, Margulis V. Multi-Institutional Validation of the Predictive Value of KI-67 in Patients with High-Grade Urothelial Carcinoma of the Upper Urinary Tract. *J Urol*. 2014 Nov 11. PMID 25451830
1110. Weibl P, Klatte T, Laurinc P, Tomaškin R, **Shariat SF**, Helbich M, Fackovcova D, Bujdák P. Patient's behavior and attitudes toward the management of benign prostatic hyperplasia among patients with the risk of disease progression: prospective study by "Prostate and Expectations of Treatment Epidemiology Research (PETER) study group". *Wien Klin Wochenschr*. 2014 Dec 2. PMID: 25447967
1111. Bagrodia A, Krabbe LM, Gayed BA, Kapur P, Bernstein I, Xie XJ, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, **Shariat SF**, Lotan Y, Margulis V. Evaluation of the prognostic significance of altered Mammalian target of rapamycin pathway biomarkers in upper tract urothelial carcinoma. *Urology*. 2014 Nov;84(5):1134-40. PMID: 25443916
1112. Lucca I, **Shariat SF**, Briganti A, Lotan Y, Roehrborn CG, Montorsi F, Remzi M, Seitz C, Fajkovic H, Klingler C, Karakiewicz PI, Sun M, Rouprêt M, Loidl W, Pummer K, Klatte T. Validation of tertiary Gleason pattern 5 in Gleason score 7 prostate cancer as an independent predictor of biochemical recurrence and development of a prognostic model. *Urol Oncol*. 2014 Oct 23. PMID: 25443275
1113. de Martino M, Taus C, Wessely IS, Lucca I, Hofbauer SL, Haitel A, **Shariat SF**, Klatte T. The T309G Murine Double Minute 2 Gene Polymorphism Is an Independent Prognostic Factor for Patients with Renal Cell Carcinoma. *DNA Cell Biol*. 2014 Nov 21. PMID: 25415135
1114. Trudeau V, Gandaglia G, Schiffmann J, Popa I, **Shariat SF**, Montorsi F, Perrotte P, Trinh QD, Karakiewicz PI, Sun M Robot-assisted versus laparoscopic nephroureterectomy for upper-tract urothelial cancer: A population-based assessment of costs and perioperative outcomes. *Can Urol Assoc J*. 2014 Sep;8(9-10):E695-E701. PMID: 25408809
1115. Aziz A, **Shariat SF**, Roghmann F, Brookman-May S, Stief CG, Rink M, Chun FK, Fisch M, Novotny V, Froehner M, Wirth MP, Schnabel MJ, Fritsche HM, Burger M, Pycha A, Brisuda A, Babjuk M, Vallo S, Haferkamp A, Roigas J, Noldus J, Stredele R, Volkmer B, Bastian PJ, Xylinas E, May M. Prediction of cancer-specific survival after radical cystectomy in pT4a urothelial

- carcinoma of the bladder - development of a tool for clinical decision-making. *BJU Int.* 2014 Nov 10. PMID: 25381844
1116. Mathieu R, **Shariat SF**, Seitz C, Karakiewicz PI, Fajkovic H, Sun M, Lotan Y, Scherr DS, Tewari A, Montorsi F, Briganti A, Rouprêt M, Lucca I, Margulis V, Rink M, Kluth LA, Rieken M, Bachman A, Xylinas E, Robinson BD, Bensalah K, Margreiter M. Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomy. *World J Urol.* 2014 Oct 26. PMID: 25344896
1117. Colin P, Irani J, Drouin SJ, **Shariat SF**, Rouprêt M. Prognostic factors of upper tract urothelial carcinomas and impact on survival: A systematic review for the yearly scientific report of the French National Association of Urology. *J Prog Urol.* 2014 PMID: 25199726
1118. Haddad AQ, Kapur P, Singla N, Raman JD, Then MT, Nuhn P, Buchner A, Bastian P, Seitz C, **Shariat SF**, Bensalah K, Rioux-Leclercq N, Sagalowsky A, Lotan Y, Margulis V. Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma. *Cancer.* 2014 Sep 3. PMID: 25186283
1119. Zargar H, Espiritu PN, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Vasdev N, Yu EY, Youssef D, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, **Shariat SF**, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Garcia JA, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black PC. Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. *Eur Urol.* 2014 Sep 22. PMID: 25257030
1120. Hofbauer SL, Pantuck AJ, de Martino M, Lucca I, Haitel A, **Shariat SF**, Belldgrun AS, Klatte T. The preoperative prognostic nutritional index is an independent predictor of survival in patients with renal cell carcinoma. *Urol Oncol.* 2014 Sep 15. PMID: 25240758
1121. van Rhijn BW, Catto JW, Goebell PJ, Knüchel R, **Shariat SF**, van der Poel HG, Sanchez-Carbayo M, Thalmann GN, Schmitz-Dräger BJ, Kiemeny LA. Molecular markers for urothelial bladder cancer prognosis: Toward implementation in clinical practice. *Urol Oncol.* 2014 Sep 9. PMID: 25217465
1122. Sevcenco S, Haitel A, Ponhold L, Susani M, Fajkovic H, **Shariat SF**, Hiess M, Spick C, Szarvas T, Baltzer PA. Quantitative apparent diffusion coefficient measurements obtained by 3-tesla MRI are correlated with biomarkers of bladder cancer proliferative activity. *PLoS One.* 2014 Sep 9;9(9):e106866. PMID: 25202965
1123. Colin P, Irani J, Drouin SJ, **Shariat SF**, Rouprêt M. Prognostic factors of upper tract urothelial carcinomas and impact on survival: A systematic review for the yearly scientific report of the French National Association of Urology. *J Prog Urol.* 2014 Sep 5. pii: S1166-7087(14)00204-8. PMID: 25199726
1124. Haddad AQ, Kapur P, Singla N, Raman JD, Then MT, Nuhn P, Buchner A, Bastian P, Seitz C, **Shariat SF**, Bensalah K, Rioux-Leclercq N, Sagalowsky A, Lotan Y, Margulis V. Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma. *Cancer.* 2014 Sep 3. PMID: 25186283
1125. Gupta A, Atoria CL, Ehdai B, **Shariat SF**, Rabbani F, Herr HW, Bochner BH, Elkin EB. Risk of Fracture After Radical Cystectomy and Urinary Diversion for Bladder Cancer. *J Clin Oncol.* 2014 Sep 2. PMID: 25185104

1126. Al Hussein Al Awamlh B, Wang LC, Nguyen DP, Rieken M, Lee RK, Lee DJ, Flynn T, Chrystal J, **Shariat SF**, Scherr DS. Is continent cutaneous urinary diversion a suitable alternative to orthotopic bladder substitute and ileal conduit after cystectomy? *BJU Int*. 2014 Aug 28. PMID: 25168771
1127. Tilki D, Hu B, Nguyen HG, Dall'Era MA, Bertini R, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Linares E, Lorentz CA, Mandel P, Martinez-Salamanca JI, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Faba OR, Russo P, **Shariat SF**, Spahn M, Terrone C, Thieu W, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. Impact of synchronous metastasis distribution on cancer-specific survival in renal cell carcinoma after radical nephrectomy with tumor thrombectomy. *J Urol*. 2014 Jul 22. PMID: 25063493
1128. Neuzillet Y, Colin P, Phé V, **Shariat SF**, Rouprêt M. Surgical treatment of upper tract urothelial carcinomas by nephroureterectomy: State of the art for the yearly scientific report of the French National Association of Urology. *Prog Urol*. 2014 Aug 26. PMID: 25158323
1129. Ploussard G, Xylinas E, Lotan Y, Novara G, Margulis V, Rouprêt M, Matsumoto K, Karakiewicz PI, Montorsi F, Remzi M, Seitz C, Scherr DS, Kapoor A, Fairey AS, Rendon R, Izawa J, Black PC, Lacombe L, **Shariat SF**, Kassouf W. Conditional Survival After Radical Nephroureterectomy for Upper Tract Carcinoma. *Eur Urol*. 2014 Aug 18. PMID: 25145551
1130. Hofbauer SL, de Martino M, Seemann C, Zamani N, Lucca I, Haitel A, **Shariat SF**, Klatter T. Associations between presenting symptoms, clinicopathological parameters, and prognosis in a contemporary series of patients with renal cell carcinoma. *Korean J Urol*. 2014 Aug;55(8):505-10. Epub 2014 Aug 8. PMID:25132943
1131. Hofbauer SL, Stangl KI, de Martino M, Lucca I, Haitel A, **Shariat SF**, Klatter T. Pretherapeutic gamma-glutamyltransferase is an independent prognostic factor for patients with renal cell carcinoma. *Br J Cancer*. 2014 Aug 12. PMID: 25117808
1132. Yakoubi R, Colin P, Seisen T, Léon P, Nison L, Bozzini G, **Shariat SF**, Rouprêt M. Radical nephroureterectomy versus endoscopic procedures for the treatment of localised upper tract urothelial carcinoma: A meta-analysis and a systematic review of current evidence from comparative studies. *Eur J Surg Oncol*. 2014 Jul 25. Review. PMID: 25108813
1133. Nuhn P, Novara G, Seitz C, Gupta A, Matsumoto K, Kassouf W, Walton TJ, Fritsche HM, Tritschler S, Martínez-Salamanca JI, Ficarra V, Karakiewicz PI, Mazzoleni G, **Shariat SF**, Bastian PJ. Prognostic value of prior history of urothelial carcinoma of the bladder in patients with upper urinary tract urothelial carcinoma: results from a retrospective multicenter study. *World J Urol*. 2014 Jul 22. PMID: 25048439
1134. Krabbe LM, Svatek RS, **Shariat SF**, Messing E, Lotan Y. Bladder cancer risk: Use of the PLCO and NLST to identify a suitable screening cohort. *Urol Oncol*. 2014 Jul 16. PMID: 25044253
1135. Gontero P, Sylvester R, Pisano F, Joniau S, Vander Eeckt K, Serretta V, Larré S, Di Stasi S, Van Rhijn B, Witjes AJ, Grotenhuis AJ, Kiemeny LA, Colombo R, Briganti A, Babjuk M, Malmström PU, Oderda M, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Varkarakis J, Bartoletti R, Spahn M, Johansson R, Frea B, Soukup V, Xylinas E, Dalbagni G, Karnes RJ, **Shariat SF**, Palou J. Prognostic Factors and Risk Groups in T1G3 Non-Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guérin: Results of a Retrospective Multicenter Study of 2451 Patients. *Eur Urol*. 2014 Jul 16. PMID: 25043942
1136. Kluth LA, Abdollah F, Xylinas E, Rieken M, Fajkovic H, Seitz C, Sun M, Karakiewicz PI, Schramek P, Herman MP, Becker A, Hansen J, Ehdaie B, Loidl W, Pummer K, Lee RK, Lotan Y,

- Scherr DS, Seiler D, Ahyai SA, Chun FK, Graefen M, Tewari A, Nonis A, Bachmann A, Montorsi F, Gönen M, Briganti A, **Shariat SF**. Clinical nodal staging scores for prostate cancer: a proposal for preoperative risk assessment. *Br J Cancer*. 2014 Jul 15;111(2):213-9. PMID: 25003663
1137. de Martino M, Zhuang D, Klätte T, Rieken M, Rouprêt M, Xylinas E, Clozel T, Krzywinski M, Elemento O, **Shariat SF**. Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib. *Cancer Biol Ther*. 2014 Jun 27;15(9). PMID: 24971884
1138. Comploj E, West J, Mian M, Kluth LA, Karl A, Dechet C, **Shariat SF**, Stief CG, Trenti E, Palermo S, Lodde M, Horninger W, Madersbacher S, Pycha A. Comparison of Complications from Radical Cystectomy between Old-Old versus Oldest-Old Patients. *Urol Int*. 2014 Jun 24. PMID: 24969739
1139. Sevcenco S, Ponhold L, Heinz-Peer G, Fajkovic H, Haitel A, Susani M, **Shariat SF**, Szarvas T, Baltzer PA. Prospective evaluation of diffusion-weighted MRI of the bladder as a biomarker for prediction of bladder cancer aggressiveness. *Urol Oncol*. 2014 Jun 21. PMID: 24962659
1140. Becker A, Ravi P, Roghmann F, Trinh QD, Tian Z, Larouche A, Kim S, **Shariat SF**, Kluth L, Dahlem R, Fisch M, Graefen M, Eichelberg C, Karakiewicz PI, Sun M. Laparoscopic radical nephrectomy vs laparoscopic or open partial nephrectomy for T1 renal cell carcinoma: comparison of complication rates in elderly patients during the initial phase of adoption. *Urology*. 2014 Jun;83(6):1285-93. PubMed PMID: 24862392.
1141. Abdollah F, Gandaglia G, Suardi N, Capitanio U, Salonia A, Nini A, Moschini M, Sun M, Karakiewicz PI, **Shariat SF**, Montorsi F, Briganti A. More Extensive Pelvic Lymph Node Dissection Improves Survival in Patients with Node-positive Prostate Cancer. *Eur Urol*. 2014 May 29. PMID: 24882672.
1142. Lucca I, **Shariat SF**, Hofbauer SL, Klätte T. Outcomes of minimally invasive simple prostatectomy for benign prostatic hyperplasia: a systematic review and meta-analysis. *World J Urol*. 2014 May 31. PubMed PMID: 24879405.
1143. Rieken M, Djajadiningrat RS, Kluth LA, Favaretto RL, Xylinas E, Guimaraes GC, Soares FA, Kent M, Sjoberg DD, Horenblas S, **Shariat SF**. Predictors of Cancer-specific Mortality After Disease Recurrence in Patients with Squamous Cell Carcinoma of the Penis. *Eur Urol*. 2014 Jun 9. PMID: 24924553.
1144. Lucca I, Rouprêt M, Kluth L, Rink M, Tilki D, Fajkovic H, Kassouf W, Hofbauer SL, de Martino M, Karakiewicz PI, Briganti A, Trinh QD, Seitz C, Fritsche HM, Burger M, Lotan Y, Kramer G, **Shariat SF**, Klätte T. Adjuvant cisplatin-based combination chemotherapy for lymph node-positive urothelial carcinoma of the bladder following radical cystectomy: a retrospective international study of more than 1500 patients. *BJU Int*. 2014 Jun 6. PubMed PMID: 24905084.
1145. Simonis K, **Shariat SF**, Rink M. Smoking and smoking cessation effects on oncological outcomes in nonmuscle invasive bladder cancer. *Curr Opin Urol*. 2014 May 30. PubMed PMID: 24887046.
1146. Lotan Y, Svatek RS, Krabbe LM, Xylinas E, Klätte T, **Shariat SF**. Prospective External Validation of Model for Bladder Cancer Detection. *J Urol*. 2014 May 21. PubMed PMID: 24859442.
1147. Aziz A, Fritsche HM, Gakis G, Kluth LA, Al-Sayed Hassan F, Engel O, Dahlem R, Otto W, Gierrh M, Denzinger S, Schwentner C, Stenzl A, **Shariat SF**, Fisch M, Burger M, Rink M. Comparative analysis of comorbidity and performance indices for prediction of oncological outcomes in patients with upper tract urothelial carcinoma who were treated with radical nephroureterectomy. *Urol Oncol*. 2014 May 22. PubMed PMID: 24856977.
1148. Lucca I, Kassouf W, Kapoor A, Fairey A, Rendon RA, Izawa JI, Black PC, Fajkovic H, Seitz C, Remzi M, Nyirády P, Rouprêt M, Margulis V, Lotan Y, de Martino M, Hofbauer SL, Karakiewicz

- PI, Briganti A, Novara G, **Shariat SF**, Klatter T. The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study. *BJU Int.* 2014 May 13. PubMed PMID: 24825476.
1149. Tschirdewahn S, Reis H, Niedworok C, Nyirady P, Szendrői A, Schmid KW, **Shariat SF**, Kramer G, Vom Dorp F, Rübber H, Szarvas T. Prognostic effect of serum and tissue YKL-40 levels in bladder cancer. *Urol Oncol.* 2014 May 7. PubMed PMID: 24814404.
1150. Ehdaie B, **Shariat SF**, Savage C, Coleman J, Dalbagni G. Postoperative nomogram for disease recurrence and cancer-specific death for upper tract urothelial carcinoma: comparison to american joint committee on cancer staging classification. *Urol J.* 2014 May 6;11(2):1435-41. PubMed PMID: 24807756.
1151. Margreiter M, Heinisch BB, Schwarzer R, Klatter T, **Shariat SF**, Ferlitsch A. Lower urinary tract symptoms in patients with liver cirrhosis. *World J Urol.* 2014 May 6. PubMed PMID: 24798455.
1152. Rieken M, Schubert T, Xylinas E, Kluth L, Rouprêt M, Trinh QD, Lee RK, Al Hussein Al Awamlh B, Fajkovic H, Novara G, Margulis V, Lotan Y, Martinez-Salamanca JI, Matsumoto K, Seitz C, Remzi M, Karakiewicz PI, Scherr DS, Briganti A, Bachmann A, **Shariat SF**; for the UTUC Collaboration. Association of perioperative blood transfusion with oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. *Eur J Surg Oncol.* 2014 Apr 13. pii: S0748-7983(14)00380-1. PubMed PMID: 24780094.
1153. Schmid M, **Shariat SF**, Soave A, Engel O, Fisch M, Rink M. Contemporary gender-specific outcomes in Germany after radical cystectomy for bladder cancer. *Curr Urol Rep.* 2014 Jun;15(6):409. PubMed PMID: 24756451.
1154. Weibl P, Hora M, Kollarik B, **Shariat SF**, Klatter T. Management, pathology and outcomes of Bosniak category IIF and III cystic renal lesions. *World J Urol.* 2014 Apr 18. PubMed PMID: 24744224.
1155. Sevcenco S, Heinz-Peer G, Ponhold L, Javor D, Kuehhas FE, Klingler HC, Remzi M, Weibl P, **Shariat SF**, Baltzer PA. Utility and limitations of 3-Tesla diffusion-weighted magnetic resonance imaging for differentiation of renal tumors. *Eur J Radiol.* 2014 Jun;83(6):909-13. doi: 10.1016/j.ejrad.2014.02.026. Epub 2014 Mar 24. PubMed PMID: 24709332.
1156. Gacci M, Ficarra V, Sebastianelli A, Corona G, Serni S, **Shariat SF**, Maggi M, IZattoni F, Carini M, Novara G. Impact of Medical Treatments for Male Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia on Ejaculatory Function: A Systematic Review and Meta-Analysis. *J Sex Med.* 2014 Apr 7. PubMed PMID: 24708055.
1157. de Martino M, Leitner CV, Seemann C, Hofbauer SL, Lucca I, Haitel A, **Shariat SF**, Klatter T. Preoperative serum cholesterol is an independent prognostic factor for patients with renal cell carcinoma. *BJU Int.* 2014 Apr 4. PubMed PMID: 24698164.
1158. Martínez-Salamanca JI, Linares E, González J, Bertini R, Carballido JA, Chromecki T, Ciancio G, Daneshmand S, Evans CP, Gontero P, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Nguyen HG, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Faba OR, Russo P, **Shariat SF**, Spahn M, Terrone C, Tilki D, Verghe D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA. Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). *Curr Urol Rep.* 2014 May;15(5):404. PubMed PMID: 24682884.
1159. **Shariat SF**. Incorporating biomarker research in a real-world setting: challenges of a prophecy. *Urol Oncol.* 2014 Apr;32(3):219-21. PubMed PMID: 24679461.

1160. Soave A, Dahlem R, Hansen J, Weisbach L, Minner S, Engel O, Kluth LA, Chun FK, **Shariat SF**, Fisch M, Rink M. Gender-specific outcomes of bladder cancer patients: A stage-specific analysis in a contemporary, homogenous radical cystectomy cohort. *Eur J Surg Oncol*. 2014 Mar 13. pii: S0748-7983(14)00348-5. PubMed PMID: 24674298.
1161. Ravi P, Trinh VQ, Sun M, Sammon J, Sukumar S, Gervais MK, **Shariat SF**, Kim SP, Kowalczyk KJ, Hu JC, Menon M, Karakiewicz PI, Trinh QD. Is there any evidence of a "July effect" in patients undergoing major cancer surgery? *Can J Surg*. 2014 Apr;57(2):82-8. PubMed PMID: 24666444; PubMed Central PMCID: PMC3968195.
1162. Gandaglia G, Suardi N, Gallina A, Zaffuto E, Cucchiara V, Vizziello D, **Shariat S**, Cantiello F, Damiano R, Guazzoni G, Montorsi F, Briganti A. How to Optimize Patient Selection for Robot-Assisted Radical Prostatectomy: Functional Outcome Analyses from a Tertiary Referral Center. *J Endourol*. 2014 Mar 24. PubMed PMID: 24660774.
1163. Szarvas T, Reis H, Kramer G, **Shariat SF**, Vom Dorp F, Tschirdewahn S, Schmid KW, Kovalszky I, Rübben H. Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer. *Hum Pathol*. 2014 Apr;45(4):674-82. PubMed PMID: 24656090.
1164. **Shariat SF**, Klatte T. Optimal results come from optimal surgery and optimal (neoadjuvant) systemic therapy. *BJU Int*. 2014 Apr;113(4):516-7 PubMed PMID: 24629083.
1165. Szarvas T, Tschirdewahn S, Niedworok C, Kramer G, Sevcenco S, Reis H, **Shariat SF**, Rübben H, Dorp FV. Prognostic value of tissue and circulating levels of IMP3 in prostate cancer. *Int J Cancer*. 2014 Feb 24. doi: 10.1002/ijc.28808. PubMed PMID: 24615121.
1166. Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, Rödel CM, **Shariat SF**, Shipley WU, Sternberg CN, Thalmann GN, Kassouf W. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. *Eur Urol*. 2014 Feb 26. pii: S0302-2838(14)00167-5. PubMed PMID: 24613684.
1167. Sevcenco S, Krssak M, Javor D, Ponhold L, Kuehhas FE, Fajkovic H, Haitel A, **Shariat SF**, Baltzer PA. Diagnosis of renal tumors by in vivo proton magnetic resonance spectroscopy. *World J Urol*. 2014 Mar 9. PubMed PMID: 24609220.
1168. de Martino M, **Shariat SF**, Hofbauer SL, Lucca I, Taus C, Wiener HG, Haitel A, Susani M, Klatte T. Aurora A Kinase as a diagnostic urinary marker for urothelial bladder cancer. *World J Urol*. 2014 Feb 23. PubMed PMID: 24562316.
1169. Schoenthaler M, Avcil T, Sevcenco S, Nagele U, Hermann TE, Kuehhas FE, **Shariat SF**, Frankenschmidt A, Wetterauer U, Miernik A. Single-Incision Transumbilical Surgery (SITUS) versus Single-Port Laparoscopic Surgery and conventional laparoscopic surgery: a prospective randomized comparative study of performance with novices in a dry laboratory. *World J Urol*. 2014 Feb 23. [Epubahead of print] PubMed PMID: 24562315.
1170. Hansen J, Gandaglia G, Bianchi M, Sun M, Rink M, Tian Z, Meskawi M, Trinh QD, **Shariat SF**, Perrotte P, Chun FK, Graefen M, Karakiewicz PI. Re-assessment of 30-, 60- and 90-day mortality rates in non-metastatic prostate cancer patients treated either with radical prostatectomy or radiation therapy. *Can Urol Assoc J*. 2014 Jan-Feb;8(1-2):E75-80. doi: 10.5489/auaj.749. PubMed PMID: 24554978; PubMed Central PMCID: PMC3926930.
1171. Becker A, Bianchi M, Hansen J, Tian Z, **Shariat SF**, Popa I, Perrotte P, Trinh QD, Karakiewicz PI, Sun M. Benefit in regionalization of care for patients treated with nephrectomy: a Nationwide Inpatient Sample. *World J Urol*. 2014 Feb 11. PubMed PMID: 24515596.

1172. Gandaglia G, Sun M, Hu JC, Novara G, Choueiri TK, Nguyen PL, Schiffmann J, Graefen M, **Shariat SF**, Abdollah F, Briganti A, Montorsi F, Trinh QD, Karakiewicz PI. Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer. *Eur Urol*. 2014 Jan 28. pii: S0302-2838(14)00095-5. doi: 10.1016/j.eururo.2014.01.026. PubMed PMID: 24495466.
1173. Klatte T, Xylinas E, Rieken M, Rouprêt M, Fajkovic H, Seitz C, Karakiewicz PI, Lotan Y, Babjuk M, de Martino M, **Shariat SF**. Effect of ABO blood type on mortality in patients with urothelial carcinoma of the bladder treated with radical cystectomy. *Urol Oncol*. 2014 Feb 1. PubMed PMID: 24495451.
1174. Gandaglia G, Popa I, Abdollah F, Schiffmann J, **Shariat SF**, Briganti A, Montorsi F, Trinh QD, Karakiewicz PI, Sun M. The Effect of Neoadjuvant Chemotherapy on Perioperative Outcomes in Patients Who Have Bladder Cancer Treated with Radical Cystectomy: A Population-based Study. *Eur Urol*. 2014 Jan 24. PubMed PMID: 24486024.
1175. Messer JC, **Shariat SF**, Dinney CP, Novara G, Fradet Y, Kassouf W, Karakiewicz PI, Fritsche HM, Izawa JI, Lotan Y, Skinner EC, Tilki D, Ficarra V, Volkmer BG, Isbarn H, Wei C, Lerner SP, Curiel TJ, Kamat AM, Svatek RS. Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. *Urology*. 2014 Apr;83(4):863-7. PubMed PMID: 24485993.
1176. Seisen T, Colin P, Hupertan V, Yates DR, Xylinas E, Nison L, Cussenot O, Neuzillet Y, Bensalah K, Novara G, Montorsi F, Zigeuner R, Remzi M, **Shariat SF**, Rouprêt M. Post-operative nomogram to predict cancer-specific survival after radical nephroureterectomy in patients with localized and/or locally advanced upper tract urothelial carcinoma without metastasis. *BJU Int*. 2014 Jan 21. PubMed PMID: 24447471.
1177. Wang LC, Xylinas E, Kent MT, Kluth LA, Rink M, Jamzadeh A, Rieken M, Al Awamlh BA, Trinh QD, Sun M, Karakiewicz PI, Novara G, Chrystal J, Zerbib M, Scherr DS, Lotan Y, Vickers A, **Shariat SF**. Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder. *Urol Oncol*. 2014 May;32(4):433-40. PubMed PMID: 24433754.
1178. Lee DJ, Xylinas E, Rieken M, Khani F, Klatte T, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Guo CC, Rioux-Leclercq N, Haitel A, Bolenz C, Bensalah K, Sagalowsky AI, Montorsi F, Lotan Y, **Shariat SF**, Robinson BD, Margulis V. Insulin-like Growth Factor Messenger RNA-binding Protein 3 Expression Helps Prognostication in Patients with Upper Tract Urothelial Carcinoma. *Eur Urol*. 2013 Dec 25. PMID: 24388440.
1179. Aziz A, May M, Burger M, Palisaar RJ, Trinh QD, Fritsche HM, Rink M, Chun F, Martini T, Bolenz C, Mayr R, Pycha A, Nuhn P, Stief C, Novotny V, Wirth M, Seitz C, Noldus J, Gilfrich C, **Shariat SF**, Brookman-May S, Bastian PJ, Denzinger S, Gierth M, Roghmann F; PROMETRICS 2011 research group. Prediction of 90-day Mortality After Radical Cystectomy for Bladder Cancer in a Prospective European Multicenter Cohort. *Eur Urol*. 2013 Dec 27. PubMed PMID: 24388438.
1180. Rink M, Sharifi N, Fritsche HM, Aziz A, Miller F, Kluth LA, Ngamsri T, Dahlem R, Chun FK, **Shariat SF**, Stenzl A, Fisch M, Gakis G. Impact of preoperative anemia on oncologic outcomes of upper tract urothelial carcinoma treated with radical nephroureterectomy. *J Urol*. 2014 Feb;191(2):316-22. vPMID:24036235
1181. Sevcenco S, Heinz-Peer G, Ponhold L, Javor D, Kuehhas FE, Klingler HC, Remzi M, Weibl P, **Shariat SF**, Baltzer PA. Utility and limitations of 3-Tesla diffusion-weighted magnetic resonance imaging for differentiation of renal tumors. *Eur J Radiol*. 2014 Mar 24. PMID: 24709332

1182. Gacci M, Ficarra V, Sebastianelli A, Corona G, Serni S, **Shariat SF**, Maggi M, Zattoni F, Carini M, Novara G. Impact of Medical Treatments for Male Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia on Ejaculatory Function: A Systematic Review and Meta-Analysis. *J Sex Med.* 2014 Apr 7. PMID: 24708055
1183. de Martino M, Leitner CV, Seemann C, Hofbauer SL, Lucca I, Haitel A, **Shariat SF**, Klatter T. Preoperative serum cholesterol is an independent prognostic factor for patients with renal cell carcinoma. *BJU Int.* 2014 Apr 4. PMID:24698164
1184. Martínez-Salamanca JI, Linares E, González J, Bertini R, Carballido JA, Chromecki T, Ciancio G, Daneshmand S, Evans CP, Gontero P, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Nguyen HG, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Faba OR, Russo P, **Shariat SF**, Spahn M, Terrone C, Tilki D, Vergo D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA. Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). *Curr Urol Rep.* 2014 May;15(5):404. PMID: 24682884
1185. Soave A, Dahlem R, Hansen J, Weisbach L, Minner S, Engel O, Kluth LA, Chun FK, **Shariat SF**, Fisch M, Rink M. Gender-specific outcomes of bladder cancer patients: A stage-specific analysis in a contemporary, homogenous radical cystectomy cohort. *Eur J Surg Oncol.* 2014 Mar 13. PMID:24674298
1186. Ravi P, Trinh VQ, Sun M, Sammon J, Sukumar S, Gervais MK, **Shariat SF**, Kim SP, Kowalczyk KJ, Hu JC, Menon M, Karakiewicz PI, Trinh QD. Is there any evidence of a "July effect" in patients undergoing major cancer surgery? *Can J Surg.* 2014 Apr;57(2):82-8. PMID: 24666444
1187. Gandaglia G, Suardi N, Gallina A, Zaffuto E, Cucchiara V, Vizziello D, **Shariat S**, Cantiello F, Damiano R, Guazzoni G, Montorsi F, Briganti A. How to Optimize Patient Selection for Robot-Assisted Radical Prostatectomy: Functional Outcome Analyses from a Tertiary Referral Center. *J Endourol.* 2014 Mar 24. PMID :24660774
1188. **Shariat SF**. Incorporating biomarker research in a real-world setting: Challenges of a prophecy. *Urol Oncol.* 2014 Apr;32(3):219-221. doi: 10.1016/j.urolonc.2014.01.006. Review. PMID: 24679461
1189. Szarvas T, Reis H, Kramer G, **Shariat SF**, Vom Dorp F, Tschirdewahn S, Schmid KW, Kovalszky I, Rübber H. Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer. *Hum Pathol.* 2014 Apr;45(4):674-82. PMID: 24656090
1190. Szarvas T, Tschirdewahn S, Niedworok C, Kramer G, Sevcenco S, Reis H, **Shariat SF**, Rübber H, Dorp FV. Prognostic value of tissue and circulating levels of IMP3 in prostate cancer. *Int J Cancer.* 2014 Feb 24. PMID: 24615121
1191. Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, Rödel CM, **Shariat SF**, Shipley WU, Sternberg CN, Thalmann GN, Kassouf W. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. *Eur Urol.* 2014 Feb 26. pii: S0302-2838(14)00167-5. PMID: 24613684
1192. Sevcenco S, Krssak M, Javor D, Ponhold L, Kuehhas FE, Fajkovic H, Haitel A, **Shariat SF**, Baltzer PA. Diagnosis of renal tumors by in vivo proton magnetic resonance spectroscopy. *World J Urol.* 2014 Mar 9. PMID: 24609220
1193. Xylinas E, Green DA, Otto B, Jamzadeh A, Kluth L, Lee RK, Robinson BD, **Shariat SF**, Scherr DS. Robotic-assisted radical cystectomy with extracorporeal urinary diversion for urothelial carcinoma of the bladder: analysis of complications and oncologic outcomes in 175 patients with a median follow-up of 3 years. *Urology.* 2013 Dec;82(6):1323-9. PMID: 24295248

1194. Gandaglia G, Sun M, Hu JC, Novara G, Choueiri TK, Nguyen PL, Schiffmann J, Graefen M, **Shariat SF**, Abdollah F, Briganti A, Montorsi F, Trinh QD, Karakiewicz PI. Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer. *Eur Urol*. 2014 Jan 28. PMID: 24495466
1195. Becker A, Bianchi M, Hansen J, Tian Z, **Shariat SF**, Popa I, Perrotte P, Trinh QD, Karakiewicz PI, Sun M. Benefit in regionalization of care for patients treated with nephrectomy: a Nationwide Inpatient Sample. *World J Urol*. 2014 Feb 11. PMID: 24515596
1196. Klatte T, Xylinas E, Rieken M, Rouprêt M, Fajkovic H, Seitz C, Karakiewicz PI, Lotan Y, Babjuk M, de Martino M, **Shariat SF**. Effect of ABO blood type on mortality in patients with urothelial carcinoma of the bladder treated with radical cystectomy. *Urol Oncol*. 2014 Feb 1. PMID: 24495451
1197. Gandaglia G, Popa I, Abdollah F, Schiffmann J, **Shariat SF**, Briganti A, Montorsi F, Trinh QD, Karakiewicz PI, Sun M. The Effect of Neoadjuvant Chemotherapy on Perioperative Outcomes in Patients Who Have Bladder Cancer Treated with Radical Cystectomy: A Population-based Study. *Eur Urol*. 2014 Jan 24. PMID: 24486024
1198. Messer JC, **Shariat SF**, Dinney CP, Novara G, Fradet Y, Kassouf W, Karakiewicz PI, Fritsche HM, Izawa JI, Lotan Y, Skinner EC, Tilki D, Ficarra V, Volkmer BG, Isbarn H, Wei C, Lerner SP, Curiel TJ, Kamat AM, Svatek RS. Female Gender Is Associated With a Worse Survival After Radical Cystectomy for Urothelial Carcinoma of the Bladder: A Competing Risk Analysis. *Urology*. 2014 Jan 30. PMID: 24485993
1199. Seisen T, Colin P, Hupertan V, Yates DR, Xylinas E, Nison L, Cussenot O, Neuzillet Y, Bensalah K, Novara G, Montorsi F, Zigeuner R, Remzi M, **Shariat SF**, Rouprêt M. Post-operative nomogram to predict cancer-specific survival after radical nephroureterectomy in patients with localized and/or locally advanced upper tract urothelial carcinoma without metastasis. *BJU Int*. 2014 Jan 21. PMID: 24447471
1200. Wang LC, Xylinas E, Kent MT, Kluth LA, Rink M, Jamzadeh A, Rieken M, Al Awamlh BA, Trinh QD, Sun M, Karakiewicz PI, Novara G, Chrystal J, Zerbib M, Scherr DS, Lotan Y, Vickers A, **Shariat SF**. Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder. *Urol Oncol*. 2014 Jan 13. PMID: 24433754
1201. Matin SF, **Shariat SF**, Milowsky MI, Hansel DE, Kassouf W, Koppie T, Bajorin D, Grollman AP. Highlights from the first symposium on upper tract urothelial carcinoma. *Urol Oncol*. 2014 Jan 4. pii: S1078-1439(13)00340-2. PMID: 24397995
1202. Lee DJ, Xylinas E, Rieken M, Khani F, Klatte T, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Guo CC, Rioux-Leclercq N, Haitel A, Bolenz C, Bensalah K, Sagalowsky AI, Montorsi F, Lotan Y, **Shariat SF**, Robinson BD, Margulis V. Insulin-like growth factor messenger rna-binding protein 3 expression helps prognostication in patients with upper tract urothelial carcinoma. *Eur Urol*. 2013 Dec 25. PMID: 2438844
1203. Aziz A, May M, Burger M, Palisaar RJ, Trinh QD, Fritsche HM, Rink M, Chun F, Martini T, Bolenz C, Mayr R, Pycha A, Nuhn P, Stief C, Novotny V, Wirth M, Seitz C, Noldus J, Gilfrich C, **Shariat SF**, Brookman-May S, Bastian PJ, Denzinger S, Gierth M, Roghmann F; PROMETRICS 2011 research group. Prediction of 90-day mortality after radical cystectomy for bladder cancer in a prospective European multicenter cohort. *Eur Urol*. 2013 Dec 27. PMID: 24388438
1204. Xylinas E, **Shariat SF**. BCG maintenance treatment: an optimal scheme? *Prog Urol*. 2014 Jan;24(1):1-2. doi: 10.1016/j.purol.2013.08.319. Epub 2013 Sep 21. PubMed PMID: 24365621.

1205. Krabbe LM, Westerman ME, Bagrodia A, Gayed BA, Khalil D, Kapur P, **Shariat SF**, Raj GV, Sagalowsky AI, Cadeddu JA, Lotan Y, Margulis V. Surgical management of the distal ureter during radical nephroureterectomy is an independent predictor of oncological outcomes: Results of a current series and a review of the literature. *Urol Oncol*. 2014 Jan;32(1):54.e19-26. PubMed PMID: 24360665.
1206. Trudeau V, Becker A, Roghmann F, **Shariat SF**, Kluth LA, Hanna N, Abdo A, Gandaglia G, Tian Z, Perrotte P, Trinh QD, Karakiewicz PI, Sun M. Local tumor destruction in renal cell carcinoma- An inpatient population-based study. *Urol Oncol*. 2014 Jan;32(1):54.e1-7. PMID:24360664.
1207. Briganti A, Joniau S, Gandaglia G, Cozzarini C, Sun M, Tombal B, Haustermans K, Hinkelbein W, **Shariat SF**, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T. Patterns and Predictors of Early Biochemical Recurrence After Radical Prostatectomy and Adjuvant Radiation Therapy in Men With pT3N0 Prostate Cancer: Implications for Multimodal Therapies. *Int J Radiat Oncol Biol Phys*. 2013 Dec 1;87(5):960-7. Epub 2013 Oct 23. PMID: 24351411
1208. Briganti A, Karnes RJ, Joniau S, Boorjian SA, Cozzarini C, Gandaglia G, Hinkelbein W, Haustermans K, Tombal B, **Shariat S**, Sun M, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T. Prediction of Outcome Following Early Salvage Radiotherapy Among Patients with Biochemical Recurrence After Radical Prostatectomy. *Eur Urol*. 2013 Dec 12. PMID: 24345725
1209. Klatte T, Xylinas E, Rieken M, Kluth LA, Rouprêt M, Pycha A, Fajkovic H, Seitz C, Karakiewicz PI, Lotan Y, Babjuk M, de Martino M, Scherr DS, **Shariat SF**. Impact of ABO blood type on outcomes of patients with primary non-muscle-invasive bladder cancer. *J Urol*. 2013 Dec 10. PMID: 24333243
1210. Xylinas E, Kluth LA, Lotan Y, Daneshmand S, Rieken M, Karakiewicz PI, **Shariat SF**. Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder. *Urol Oncol*. 2013 Dec 11. PMID: 24332648
1211. Kluth LA, Rieken M, Xylinas E, Kent M, Rink M, Rouprêt M, Sharifi N, Jamzadeh A, Kassouf W, Kaushik D, Boorjian SA, Roghmann F, Noldus J, Masson-Lecomte A, Vordos D, Ikeda M, Matsumoto K, Hagiwara M, Kikuchi E, Fradet Y, Izawa J, Rendon R, Fairey A, Lotan Y, Bachmann A, Zerbib M, Fisch M, Scherr DS, Vickers A, **Shariat SF**. Gender-specific Differences in Clinicopathologic Outcomes Following Radical Cystectomy: An International Multi-institutional Study of More Than 8000 Patients. *Eur Urol*. 2013 Dec 5. PMID: 24331151
1212. Lee RK, Abol-Enein H, Artibani W, Bochner B, Dalbagni G, Daneshmand S, Fradet Y, Hautmann RE, Lee CT, Lerner SP, Pycha A, Sievert KD, Stenzl A, Thalmann G, **Shariat SF**. Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. *BJU Int*. 2014 Jan;113(1):11-23. PMID: 24330062
1213. Kaag M, Trost L, Thompson RH, Favaretto R, Elliott V, **Shariat SF**, Maschino A, Vertosick E, Raman JD, Dalbagni G. Pre-operative predictors of renal function decline following radical nephroureterectomy for upper tract urothelial carcinoma. *BJU Int*. 2013 Dec 9. PMID: 24314050
1214. Xylinas E, Green DA, Otto B, Jamzadeh A, Kluth L, Lee RK, Robinson BD, **Shariat SF**, Scherr DS. Robotic-assisted Radical cystectomy with extracorporeal urinary diversion for urothelial carcinoma of the bladder: analysis of complications and oncologic outcomes in 175 patients with a median follow-up of 3 years. *Urology*. 2013 Dec;82(6):1323-9. PMID: 24295248
1215. Sooriakumaran P, Srivastava A, **Shariat SF**, Stricker PD, Ahlering T, Eden CG, Wiklund PN, Sanchez-Salas R, Mottrie A, Lee D, Neal DE, Ghavamian R, Nyirady P, Nilsson A, Carlsson S, Xylinas E, Loidl W, Seitz C, Schramek P, Roehrborn C, Cathelineau X, Skarecky D, Shaw G, Warren A, Delprado WJ, Haynes AM, Steyerberg E, Roobol MJ, Tewari AKA Multinational,

- Multi-institutional Study Comparing Positive Surgical Margin Rates Among 22393 Open, Laparoscopic, and Robot-assisted Radical Prostatectomy Patients. *Eur Urol*. 2013 Nov 24. PMID: 24290695
1216. Youssef RF, Lotan Y, Sagalowsky AI, **Shariat SF**, Wood CG, Raman JD, Langner C, Zigeuner R, Roscigno M, Montorsi F, Bolenz C, Kassouf W, Margulis V. Radical nephroureterectomy for pathologic T4 upper tract urothelial cancer: can oncologic outcomes be improved with multimodality therapy? *Int Braz J Urol*. 2013 Sep-Oct;39(5):614-21. doi: 10.1590/S1677-5538.IBJU.2013.05.02. PMID: 24267122
1217. Klatte T, **Shariat SF**, Remzi M. Systematic review and meta-analysis of perioperative and oncological outcomes of laparoscopic cryoablation versus laparoscopic partial nephrectomy for the treatment of small renal tumors. *J Urol*. 2013 Nov 11. PMID: 24231845
1218. Xylinas E, Rouprêt M, **Shariat SF**. Segmental ureterectomy for upper tract urothelial carcinoma: Two procedures with different indications. *Urol Oncol*. 2013 Nov;31(8):1841-3. PMID: 24210083
1219. Trinh VQ, Karakiewicz PI, Sammon J, Sun M, Sukumar S, Gervais MK, **Shariat SF**, Tian Z, Kim SP, Kowalczyk KJ, Hu JC, Menon M, Trinh QD. Venous Thromboembolism After Major Cancer Surgery: Temporal Trends and Patterns of Care. *JAMA Surg*. 2013 Nov 6. PMID: 24197279
1220. Dell'oglio P, Abdollah F, Suardi N, Gallina A, Cucchiara V, Vizziello D, Zaffuto E, Cantiello F, Damiano R, **Shariat SF**, Montorsi F, Briganti A. External validation of the european association of urology recommendations for pelvic lymph node dissection in patients treated with robotic-assisted radical prostatectomy. *J Endourol*. 2013 Nov 4. PMID: 24188052
1221. Raman JD, Lin YK, Kaag M, Atkinson T, Crispen P, Wille M, Smith N, Hockenberry M, Guzzo T, Peyronnet B, Bensalah K, Simhan J, Kutikov A, Cha E, Herman M, Scherr D, **Shariat SF**, Boorjian SA. High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy. *Urol Oncol*. 2013 Oct 17. PMID: 24140248
1222. Rieken M, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Faison T, Lotan Y, Karakiewicz PI, Sun M, Fajkovic H, Babjuk M, Bachmann A, Scherr DS, **Shariat SF**. Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. *Urol Oncol*. 2013 Oct 17. PMID: 24140245
1223. Xylinas E, Robinson BD, Kluth LA, Volkmer BG, Hautmann R, Küfer R, Zerbib M, Kwon E, Thompson RH, Boorjian SA, **Shariat SF**. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. *Eur J Surg Oncol*. 2013 Sep 18. PMID:24140000
1224. Ploussard G, **Shariat SF**, Dragomir A, Kluth LA, Xylinas E, Masson-Lecomte A, Rieken M, Rink M, Matsumoto K, Kikuchi E, Klatte T, Boorjian SA, Lotan Y, Roghmann F, Fairey AS, Fradet Y, Black PC, Rendon R, Izawa J, Kassouf W. Conditional Survival After Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time. *Eur Urol*. 2013 Oct 9. PMID:24139235
1225. Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, **Shariat SF**, Kim SP, Perrotte P, Montorsi F, Briganti A, Trinh QD, Karakiewicz PI, Sun M. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis.*Prostate*. 2013 Oct 16. PMID: 24132735
1226. Solomon DA, Kim JS, Bondaruk J, **Shariat SF**, Wang ZF, Elkahloun AG, Ozawa T, Gerard J, Zhuang D, Zhang S, Navai N, Siefker-Radtke A, Phillips JJ, Robinson BD, Rubin MA, Volkmer B, Hautmann R, Küfer R, Hogendoorn PC, Netto G, Theodorescu D, James CD, Czerniak B, Miettinen M, Waldman T. Frequent truncating mutations of STAG2 in bladder cancer.*Nat Genet*. 2013 Dec;45(12):1428-30. PMID:24121789

1227. Rieken M, Xylinas E, Kluth L, Trinh QD, Lee RK, Fajkovic H, Novara G, Margulis V, Lotan Y, Martinez-Salamanca JI, Matsumoto K, Seitz C, Remzi M, Karakiewicz PI, Scherr DS, Briganti A, Kautzky-Willer A, Bachmann A, **Shariat SF**. Diabetes mellitus without metformin intake is associated with worse oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. *Eur J Surg Oncol*. 2013 Sep 20. PMID:24113620
1228. Babjuk M., Burger M., Zigeuner R., **Shariat S.**, VanRhijn B., Comperat E., Sylvester R., Kaasinen E., Boehe A., Palou J., Roupert M.: Recommendations on the treatment of non-muscle invasive bladder cancer. *Egyptian Journal of Urology* 19 (2): 58-62, 2013
1229. Pummer K, Rieken M, Augustin H, Gutsch T, **Shariat SF**. Innovations in diagnostic imaging of localized prostate cancer. *World J Urol*. 2013 Sep 28. PMID: 24078105
1230. Kapur P, Christie A, Raman JD, Then MT, Nuhn P, Buchner A, Bastian P, Seitz C, **Shariat SF**, Bensalah K, Rioux-Leclercq N, Xie XJ, Lotan Y, Margulis V, Brugarolas J. BAP1 immunohistochemistry in a multi-institutional cohort predicts outcomes in patients with clear cell renal cell carcinoma. *J Urol*. 2013 Sep 24. PMID: 24076305
1231. Misraï V, Faron M, Guillotreau J, Bruguière E, Bordier B, **Shariat SF**, Rouprêt M. Assessment of the learning curves for photoselective vaporization of the prostate using GreenLight™ 180-Watt-XPS laser therapy: defining the intra-operative parameters within a prospective cohort. *World J Urol*. 2013 Sep 26. PMID: 24072009
1232. Xylinas E, Kluth L, Passoni N, Trinh QD, Rieken M, Lee RK, Fajkovic H, Novara G, Margulis V, Raman JD, Lotan Y, Rouprêt M, Aziz A, Fritsche HM, Weizer A, Martinez-Salamanca JI, Matsumoto K, Seitz C, Remzi M, Walton T, Karakiewicz PI, Montorsi F, Zerbib M, Scherr DS, **Shariat SF**. Prediction of Intravesical Recurrence After Radical Nephroureterectomy: Development of a Clinical Decision-making Tool. *Eur Urol*. 2013 Sep 19. PMID: 24070577
1233. Roghmann F, Becker A, Trinh QD, Djahagirian O, Tian Z, Meskawi M, **Shariat SF**, Graefen M, Karakiewicz P, Noldus J, Sun M. Updated assessment of neobladder utilization and morbidity according to urinary diversion after radical cystectomy: A contemporary US-population-based cohort. *Can Urol Assoc J*. 2013 Sep;7(9-10):E552-60. PMID:24069095
1234. Rieken M, Kluth LA, Xylinas E, Fajkovic H, Becker A, Karakiewicz PI, Herman M, Lotan Y, Seitz C, Schramek P, Remzi M, Loidl W, Pummer K, Lee RK, Faison T, Scherr DS, Kautzky-Willer A, Bachmann A, Tewari A, **Shariat SF**. Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer. *World J Urol*. 2013 Sep 24. PMID:24062093
1235. Krabbe LM, Lotan Y, Bagrodia A, Gayed BA, Darwish OM, Youssef RF, Bolenz C, Sagalowsky AI, Raj GV, **Shariat SF**, Kapur P, Margulis V. Prospective comparison of molecular signatures in urothelial cancer of the bladder and the upper urinary tract: is there evidence for discordant biology? *J Urol*. 2013 Sep 20. PMID: 24060642
1236. Kluth LA, Xylinas E, Rieken M, Chun FK, Fajkovic H, Becker A, Karakiewicz PI, Passoni N, Herman M, Lotan Y, Seitz C, Schramek P, Remzi M, Loidl W, Guillonneau B, Rouprêt M, Briganti A, Scherr DS, Graefen M, Tewari AK, **Shariat SF**. Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy? *Urol Oncol*. 2013 Sep 18. PMID: 24055425
1237. Xylinas E, Kluth LA, Rieken M, Karakiewicz PI, Lotan Y, **Shariat SF**. Urine markers for detection and surveillance of bladder cancer. *Urol Oncol*. 2013 Sep 17 PMID: 24054865
1238. Rieken M, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Faison T, Lotan Y, Karakiewicz PI, Fajkovic H, Babjuk M, Kautzky-Willer A, Bachmann A, Scherr DS, **Shariat SF**. Association of Diabetes

- Mellitus and Metformin Use with Oncological Outcomes of Patients with non-muscle invasive Bladder Cancer. *BJU Int.* 2013 Sep 5. PMID: 24053906
1239. Kluth LA, Xylinas E, Kent M, Hagiwara M, Kikuchi E, Matsumoto K, Ikeda M, Dalpiaz O, Zigeuner R, Aziz A, Fritsche HM, Deliere A, Raman JD, Bensalah K, Al-Matar B, Gakis G, Novara G, Klatte T, Remzi M, Comploj E, Pycha A, Rouprêt M, Tagawa ST, Chun FK, Scherr DS, Vickers A, **Shariat SF**. Predictors of survival in patients with disease recurrence following radical nephroureterectomy. *BJU Int.* 2013 Jul 19. PMID: 24053651
1240. Kluth LA, Xylinas E, Rieken M, Ghouayel ME, Sun M, Karakiewicz PI, Lotan Y, Chun FK, Boorjian SA, Lee RK, Briganti A, Rouprêt M, Fisch M, Scherr DS, **Shariat SF**. Impact of perioperative blood transfusion on the outcome of patients undergoing radical cystectomy for urothelial carcinoma of the bladder. *BJU Int.* 2013 Sep 5. PMID: 24053618
1241. Rom M, Waldert M, Schatzl G, Swietek N, **Shariat SF**, Klatte T. Bladder outlet obstruction in men with castration-resistant prostate cancer. *BJU Int.* 2013 PMID: 24053594
1242. **Shariat SF**, Passoni N, Bagrodia A, Rachakonda V, Xylinas E, Robinson B, Kapur P, Sagalowsky AI, Lotan Y. Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy. *BJU Int.* 2013 Jul 2. PMID: 24053584
1243. Passoni NM, Fajkovic H, Xylinas E, Kluth L, Seitz C, Robinson BD, Rouprêt M, Chun FK, Lotan Y, Roehrborn CG, Crivelli JJ, Karakiewicz PI, Scherr DS, Rink M, Graefen M, Schramek P, Briganti A, Montorsi F, Tewari A, **Shariat SF**. Prognosis of patients with pelvic lymph node metastasis following radical prostatectomy: value of extranodal extension and size of the largest lymph node metastasis. *BJU Int.* 2013 Jul 2. PMID: 24053552
1244. de Martino M, Waldert M, Haitel A, Schatzl G, **Shariat SF**, Klatte T. Evaluation of ABO blood group as a prognostic marker in renal cell carcinoma. *BJU Int.* 2013 Sep 5. PMID: 24053513
1245. Xylinas E, Kluth LA, Rieken M, Lee RK, Elghouayel M, Ficarra V, Margulis V, Lotan Y, Rouprêt M, Martinez-Salamanca JI, Matsumoto K, Seitz C, Karakiewicz PI, Zerbib M, Scherr DS, **Shariat SF**. Impact of smoking status and cumulative exposure on intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy. *BJU Int.* 2013 Aug 12. PMID: 24053463
1246. Hansen J, Bianchi M, Sun M, Rink M, Castiglione F, Abdollah F, Steuber T, Ahyai SA, Steurer S, Göbel C, Freschi M, Montorsi F, **Shariat SF**, Fisch M, Graefen M, Karakiewicz PI, Briganti A, Chun FK. Percentage of High-Grade Tumor Volume does not Meaningfully Improve Prediction of Early Biochemical Recurrence after Radical Prostatectomy Compared to Gleason Score. *BJU Int.* 2013 Aug 23. PMID: 24053339
1247. Rink M, Sharifi N, Fritsche HM, Aziz A, Miller F, Kluth LA, Ngamsri T, Dahlem R, Chun FK, **Shariat SF**, Stenzl A, Fisch M, Gakis G. Impact of Preoperative Anemia on Oncological Outcomes of Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. *J Urol.* 2013 Sep 11. PMID:24036235
1248. Gandaglia G, Bianchi M, Trinh QD, Becker A, Larouche A, Abdollah F, Rognmann F, Tian Z, **Shariat SF**, Briganti A, Montorsi F, Karakiewicz PI, Sun M. Survival after nephroureterectomy for upper tract urothelial carcinoma: A population-based competing-risks analysis. *Int J Urol.* 2013 Aug 29. PMID: 24033809
1249. Ravi P, Bianchi M, Hansen J, Trinh QD, Tian Z, Meskawi M, Abdollah F, Briganti A, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI, Sun M. Benefit in regionalisation of care for patients treated with radical cystectomy: a nationwide inpatient sample analysis. *BJU Int.* 2013 Jun 13. PMID: 24007240

1250. Kluth LA, **Shariat SF**, Kratzik C, Tagawa S, Sonpavde G, Rieken M, Scherr DS, Pummer K. The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy. *World J Urol.* 2013 Sep 3. PMID: 23999854
1251. Rieken M, Kluth LA, Xylinas E, Seitz C, Fajkovic H, Karakiewicz PI, Lotan Y, Briganti A, Loidl W, Faison T, Crivelli JJ, Scherr DS, Bachmann A, Tewari AK, Kautzky-Willer A, Pummer K, **Shariat SF**. Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy. *Prostate Cancer Prostatic Dis.* 2013 PMID: 23999669
1252. Rieken M, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Faison T, Lotan Y, Karakiewicz PI, Holmäng S, Babjuk M, Fajkovic H, Seitz C, Klatter T, Pycha A, Bachmann A, Scherr DS, **Shariat SF**. Long-term Cancer-specific Outcomes of TaG1 Urothelial Carcinoma of the Bladder. *Eur Urol.* 2013 Aug 27. PMID: 23998688
1253. Xylinas E, Cha EK, Khani F, Kluth LA, Rieken M, Volkmer BG, Hautmann R, Küfer R, Chen YT, Zerbib M, Rubin MA, Scherr DS, **Shariat SF**, Robinson BD. Association of oncofetal protein expression with clinical outcomes in patients with urothelial carcinoma of the bladder. *J Urol.* 2013 Aug 28. PMID: 23994370
1254. Xylinas E, Kent M, Kluth L, Pycha A, Comploj E, Svatek RS, Lotan Y, Trinh QD, Karakiewicz PI, Holmang S, Scherr DS, Zerbib M, Vickers AJ, **Shariat SF**. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. *Br J Cancer.* 2013 Sep 17;109(6):1460-6. PMID:23982601
1255. Rink M, Babjuk M, Catto JW, Jichlinski P, **Shariat SF**, Stenzl A, Stepp H, Zaak D, Witjes JA. Hexyl Aminolevulinic-Acid-Guided Fluorescence Cystoscopy in the Diagnosis and Follow-up of Patients with Non-Muscle-invasive Bladder Cancer: A Critical Review of the Current Literature. *Eur Urol.* 2013 Jul 19. PMID: 23906669
1256. Brookman-May SD, May M, **Shariat SF**, Novara G, Zigeuner R, Cindolo L, De Cobelli O, De Nunzio C, Pahernik S, Wirth MP, Longo N, Simonato A, Serni S, Siracusano S, Volpe A, Morgia G, Bertini R, Dalpiaz O, Stief C, Ficarra V; Members of the CORONA-Project, the SATURN-Project, and the Young Academic Urologists Renal Cancer Group. Time to recurrence is a significant predictor of cancer-specific survival after recurrence in patients with recurrent renal cell carcinoma - results from a comprehensive multi-centre database (CORONA/SATURN-Project). *BJU Int.* 2013 May 23. PMID: 23890378
1257. Weisbach L, Dahlem R, Simone G, Hansen J, Soave A, Engel O, Chun FK, **Shariat SF**, Fisch M, Rink M. Lymph node dissection during radical cystectomy for bladder cancer treatment: considerations on relevance and extent. *Int Urol Nephrol.* 2013 Jul 25. PMID: 23884728
1258. Audenet F, Audouin M, Drouin SJ, Comperat E, Mozer P, Chartier-Kastler E, Méjean A, Cussenot O, **Shariat SF**, Rouprêt M. Charlson score as a single pertinent criterion to select candidates for active surveillance among patients with small renal masses. *World J Urol.* 2013 Jul 20. PMID: 23873357
1259. Krabbe LM, Bagrodia A, Lotan Y, Gayed BA, Darwish OM, Youssef RF, John G, Harrow B, Jacobs C, Gaitonde M, Sagalowsky AI, **Shariat SF**, Kapur P, Margulis V. Ki-67 is an independent predictor of oncological outcomes in patients with high-grade upper tract urothelial carcinoma: results of a prospective analysis and a review of the literature. *J Urol.* 2013 Jul 16. PMID: 23871758
1260. Tilki D, Nguyen HG, Dall'era MA, Bertini R, Carballido JA, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Lorentz CA, Mandel P, Martinez-Salamanca JI, Master VA, Matloob R, McKiernan JM,

- Mlynarczyk CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Rodriguez Faba O, Russo P, **Shariat SF**, Spahn M, Terrone C, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. Impact of Histologic Subtype on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus. *Eur Urol*. 2013 Jul 10. PMID: 23871402
1261. Kluth LA, Abdollah F, Xylinas E, Rieken M, Fajkovic H, Sun M, Karakiewicz PI, Seitz C, Schramek P, Herman MP, Becker A, Loidl W, Pummer K, Nonis A, Lee RK, Lotan Y, Scherr DS, Seiler D, Chun FK, Graefen M, Tewari A, Gönen M, Montorsi F, **Shariat SF**, Briganti A. Pathologic Nodal Staging Scores in Patients Treated with Radical Prostatectomy: A Postoperative Decision Tool. *Eur Urol*. 2013 Jul 2. PMID: 23850255
1262. Sammon JD, Karakiewicz PI, Sun M, Ravi P, Ghani KR, Jeong W, Bianchi M, Hansen J, Perrotte P, Peabody JO, Rogers CG, **Shariat SF**, Menon M, Trinh QD. Robot-assisted vs. Laparoscopic Partial Nephrectomy: utilization rates and perioperative outcomes. *Int Braz J Urol*. 2013 May-Jun;39(3):377-86. PMID: 23849569
1263. de Martino M, Pantuck AJ, Hofbauer S, Waldert M, **Shariat SF**, Belldegrun AS, Klatte T. Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized non-clear cell renal cell carcinoma. *J Urol*. 2013 Jul 2. PMID: 23831313
1264. Babjuk M, Burger M, Zigeuner R, **Shariat SF**, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A, Palou Redorta J, Roupêt M. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013. *Eur Urol*. 2013 Jun 12. PMID: 23827737
1265. Brookman-May S, May M, **Shariat SF**, Zigeuner R, Chromecki T, Cindolo L, Schips L, De Cobelli O, Rocco B, De Nunzio C, Tubaro A, Feciche B, Coman I, Truss M, Pahernik S, Wirth MP, Zastrow S, Dalpiaz O, Fenske F, Waidelich R, Stief C, Gunia S; Members of the CORONA Project. Prognostic Effect of Sarcomatoid Dedifferentiation in Patients With Surgically Treated Renal Cell Carcinoma: A Matched-Pair Analysis. *Clin Genitourin Cancer*. 2013 Jun 29. doi:pii: S1558-7673(13)00087-6. 10.1016/j.clgc.2013.04.026. PMID: 23820063
1266. Crivelli JJ, Xylinas E, Kluth LA, Rieken M, Rink M, **Shariat SF**. Effect of Smoking on Outcomes of Urothelial Carcinoma: A Systematic Review of the Literature. *Eur Urol*. 2013 Jun 19. doi:pii: S0302-2838(13)00608-8. 10.1016/j.eururo.2013.06.010. PMID: 23810104
1267. Crivelli JJ, Xylinas E, Kluth LA, da Silva RD, Chrystal J, Novara G, Karakiewicz PI, David SG, Scherr DS, Lotan Y, **Shariat SF**. Effect of statin use on outcomes of non-muscle-invasive bladder cancer. *BJU Int*. 2013 Jul;112(2):E4-E12. doi: 10.1111/bju.12150. PMID: 23795797
1268. Trinh VQ, Trinh QD, Tian Z, Hu JC, **Shariat SF**, Perrotte P, Karakiewicz PI, Sun M. In-hospital mortality and failure-to-rescue rates after radical cystectomy. *BJU Int*. 2013 Jul;112(2):E20-7. doi: 10.1111/bju.12214. PMID: 23795794
1269. Merseburger AS, Herrmann TR, **Shariat SF**, Kyriazis I, Nagele U, Traxer O, Liatsikos EN. EAU Guidelines on Robotic and Single-site Surgery in Urology. *Eur Urol*. 2013 Aug;64(2):277-91. doi: 10.1016/j.eururo.2013.05.034. Epub 2013 May 25. PMID: 23764016
1270. Gakis G, Boorjian SA, Briganti A, Joniau S, Karazanashvili G, Karnes RJ, Mattei A, **Shariat SF**, Stenzl A, Wirth M, Stief CG. The Role of Radical Prostatectomy and Lymph Node Dissection in Lymph Node-Positive Prostate Cancer: A Systematic Review of the Literature. *Eur Urol*. 2013 May 22. doi:pii: S0302-2838(13)00500-9. 10.1016/j.eururo.2013.05.033. PMID: 23735200
1271. Drouin SJ, Comperat E, Varinot J, Vaessen C, Bitker MO, Chartier-Kastler E, Mozer P, **Shariat SF**, Cussenot O, Roupêt M. The surgical approach can be determined from the pathological

- specimen obtained after open or robot-assisted laparoscopic radical prostatectomy. *World J Urol.* 2013 May 31. PMID: 23723015
1272. Bianchi M, Becker A, Hansen J, Trinh QD, Tian Z, Abdollah F, Briganti A, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI, Sun M. Conditional survival after nephrectomy for renal cell carcinoma (RCC): changes in future survival probability over time. *BJU Int.* 2013 Jun;111(8):E283-9. PMID: 23714646
1273. Becker A, Roghmann F, Trinh QD, Hansen J, Tian Z, **Shariat SF**, Noldus J, Perrotte P, Graefen M, Karakiewicz PI, Sun M. Sociodemographic disparities in the treatment of small renal masses. *BJU Int.* 2013 Jun;111(8):E274-82. doi: 10.1111/bju.12111. PMID: 23714645
1274. Kluth LA, Rink M, Ahyai SA, Fisch M, **Shariat SF**, Dahm P. [Randomized controlled trials terminated prematurely : Beneficial therapy effects.] *Urologe A.* 2013 May 29. German. PMID: 23712423
1275. Kluth LA, Rink M, Chun FK, Fisch M, **Shariat SF**, Dahm P. [The likelihood ratio : Estimation of the impact of a diagnostic test on treatment decision]. *Urologe A.* 2013 Jul;52(7):982-5. doi: 10.1007/s00120-013-3145-1. German. PMID: 23708004
1276. Rink M, Kluth LA, **Shariat SF**, Fisch M, Dahlem R, Dahm P. [Kaplan-Meier analysis in urological practice]. *Urologe A.* 2013 Jun;52(6):838-41. doi: 10.1007/s00120-013-3150-4. German. PMID: 23703691
1277. Trinh QD, Bjartell A, Freedland SJ, Hollenbeck BK, Hu JC, **Shariat SF**, Sun M, Vickers AJ. A Systematic Review of the Volume-Outcome Relationship for Radical Prostatectomy. *Eur Urol.* 2013 Apr 19. doi:pii: S0302-2838(13)00375-8. 10.1016/j.eururo.2013.04.012. PMID 23664423
1278. Bianchi M, Becker A, Trinh QD, Abdollah F, Tian Z, **Shariat SF**, Montorsi F, Perrotte P, Graefen M, Karakiewicz PI, Sun M. An analysis of patients with T2 renal cell carcinoma (RCC) according to tumour size: a population-based analysis. *BJU Int.* 2013 Apr 12. PMID: 23651446
1279. Tilki D, Brausi M, Colombo R, Evans CP, Fradet Y, Fritsche HM, Lerner SP, Sagalowsky A, **Shariat SF**, Bochner BH. lymphadenectomy for bladder cancer at the time of radical cystectomy. *Eur Urol.* 2013 Apr 29. PMID: 23648149
1280. Lotan Y, Bagrodia A, Passoni N, Rachakonda V, Kapur P, Arriaga Y, Bolenz C, Margulis V, Raj GV, Sagalowsky AI, **Shariat SF**. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy. *Eur Urol.* 2013 Apr 3. PMID: 23571005
1281. Sun M, **Shariat SF**, Trinh QD, Meskawi M, Bianchi M, Hansen J, Abdollah F, Perrotte P, Karakiewicz PI. An evidence-based guide to the selection of sequential therapies in metastatic renal cell carcinoma. *Ther Adv Urol.* 2013 Apr;5(2):121-8. PMID: 23554847
1282. Gontero P, Oderda M, Mehnert A, Gurioli A, Marson F, Lucca I, Rink M, Schmid M, Kluth LA, Pappagallo G, Sogni F, Sanguedolce F, Schiavina R, Martorana G, **Shariat SF**, Chun F. The impact of intravesical Gemcitabine and 1/3 dose Bacillus Calmette Guerin instillation therapy on the quality of life in non-muscle-invasive bladder cancer patients: results of a prospective, randomised phase II trial. *J Urol.* 2013 Mar 29. PMID: 23545101
1283. Xylinas E, Kluth LA, Crivelli JJ, Rieken M, Margulis V, Seitz C, **Shariat SF**. Impact of statin use on oncologic outcomes of patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. *Eur Urol.* 2013 Jun;63(6):1134-5. PMID: 23540954

1284. Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester R, Burger M, Cowan N, Böhle A, Van Rhijn BW, Kaasinen E, Palou J, **Shariat SF**. European guidelines on upper tract urothelial carcinomas: 2013 update. *Eur Urol*. 2013 Jun;63(6):1059-71. PMID: 23540953
1285. Kluth LA, Rink M, **Shariat SF**, Chun FK, Fisch M, Dahm P. Use and interpretation of the number needed to treat in urological practice. *Urologe A*. 2013 May;52(5):682-5. PMID: 23532201
1286. Bagrodia A, Kuehhas FE, Gayed BA, Wood CG, Raman JD, Kapur P, Derweesh IH, Bensalah K, Sagalowsky AI, **Shariat SF**, Lotan Y, Margulis V. Comparative analysis of oncologic outcomes of partial ureterectomy vs radical nephroureterectomy in upper tract urothelial carcinoma. *Urology*. 2013 May;81(5):972-8. PMID: 23523292
1287. Sammon J, Trinh VQ, Ravi P, Sukumar S, Gervais MK, **Shariat SF**, Larouche A, Tian Z, Kim SP, Kowalczyk KJ, Hu JC, Menon M, Karakiewicz PI, Trinh QD, Sun M. Health care-associated infections after major cancer surgery: Temporal trends, patterns of care, and effect on mortality. *Cancer*. 2013 Mar 19. PMID: 23512473
1288. Dariane C, Le Cossec C, Drouin SJ, Wolff B, Granger B, Mozer P, Bitker MO, **Shariat SF**, Cussenot O, Rouprêt M. Comparison of oncologic outcomes after radical prostatectomy in men diagnosed with prostate cancer with PSA levels below and above 4 ng/mL. *World J Urol*. 2013 Apr 26. PMID: 23619479
1289. Rink M, Kluth LA, **Shariat SF**, Dahlem R, Fisch M, Dahm P. [Confidence intervals and p-values in urology: Interpretation and misinterpretation.] *Urologe A*. 2013 Mar 21. German. PMID: 2351185
1290. Rink M, Kluth LA, **Shariat SF**, Chun FK, Fisch M, Dahm P. [Use of PubMed to improve evidence-based medicine in routine urological practice]. *Urologe A*. 2013 Mar;52(3):367-72. German. PMID: 23503794
1291. Sun M, Trinh QD, Bianchi M, Hansen J, Abdollah F, Tian Z, **Shariat SF**, Montorsi F, Perrotte P, Karakiewicz PI. Extent of lymphadenectomy does not improve the survival of patients with renal cell carcinoma and nodal metastases: biases associated with the handling of missing data. *BJU Int*. 2013 Mar 12. PMID: 23490031
1292. Abdollah F, Gandaglia G, Thuret R, Schmitges J, Tian Z, Jeldres C, Passoni NM, Briganti A, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI, Sun M. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: A trend analysis. *Cancer Epidemiol*. 2013 Feb 25. PMID: 2348548
1293. Cindolo L, Chiodini P, Brookman-May S, De Cobelli O, May M, Squillacciotti S, De Nunzio C, Tubaro A, Coman I, Feciche B, Truss M, Wirth MP, Dalpiaz O, Chromecki TF, **Shariat SF**, Sanchez-Chapado M, Del Carmen Santiago Martin M, Rocco B, Salzano L, Lotrecchiano G, Berardinelli F, Schips L. Assessing the accuracy and generalizability of the preoperative and postoperative Karakiewicz nomograms for renal cell carcinoma: results from a multicentre European and US study. *BJU Int*. 2013 Mar 7 PMID: 23470199
1294. Xylinas E, Rink M, Robinson BD, Lotan Y, Babjuk M, Brisuda A, Green DA, Kluth LA, Pycha A, Fradet Y, Faison T, Lee RK, Karakiewicz PI, Zerbib M, Scherr DS, **Shariat SF**. Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. *Eur J Cancer*. 2013 Mar 2. PMID: 23466126
1295. Rink M, Xylinas E, Trinh QD, Lotan Y, Margulis V, Raman JD, Fisch M, Lee RK, Chun FK, Abdennabi J, Seitz C, Pycha A, Zlotta AR, Karakiewicz PI, Babjuk M, Scherr DS, **Shariat SF**: Gender-specific effect of smoking on upper tract urothelial carcinoma outcomes. *BJU Int*. 2013 Mar 6. PMID: 23465088

1296. Xylinas E, Rink M, Margulis V, Clozel T, Lee RK, Comploj E, Novara G, Raman JD, Lotan Y, Weizer A, Roupret M, Pycha A, Scherr DS, Seitz C, Ficarra V, Trinh QD, Karakiewicz PI, Montorsi F, Zerbib M, **Shariat SF**: Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. *BJU Int*. 2013 Mar 6. PMID: 23464979
1297. Trinh QD, Sun M, Kim SP, Sammon J, Kowalczyk KJ, Friedman AA, Sukumar S, Ravi P, Muhletaler F, Agarwal PK, **Shariat SF**, Hu JC, Menon M, Karakiewicz PI. The impact of hospital volume, residency, and fellowship training on perioperative outcomes after radical prostatectomy. *Urol Oncol*. 2013 Feb 28. PMID: 23453659
1298. May M, Ficarra V, **Shariat SF**, Zigeuner R, Chromecki T, Cindolo L, Burger M, Gunia S, Feciche B, Wenzl V, Aziz A, Chun F, Becker A, Pahernik S, Simeone C, Longo N, Zucchi A, Antonelli A, Mirone V, Stief C, Novara G, Brookman-May S; Members of the CORONA- and the SATURN projects, and the Young Academic Urologists Renal Cancer Group. Impact of clinical and histopathological parameters on disease-specific survival in patients with collecting duct renal cell carcinoma - Development of a disease-specific risk-model. *J Urol*. 2013 Feb 19. PMID: 23434943
1299. Bianchi M, Becker A, Abdollah F, Trinh QD, Hansen J, Tian Z, **Shariat SF**, Perrotte P, Karakiewicz PI, Sun M. Rates of open versus laparoscopic and partial versus radical nephrectomy for T1a renal cell carcinoma: A population-based evaluation. *Int J Urol*. 2013 Feb 19. PMID: 23418921
1300. Sun M, Ravi P, Karakiewicz PI, Sukumar S, Sammon J, Bianchi M, **Shariat SF**, Jeong W, Ghani KR, Hansen J, Friedman A, Perrotte P, Peabody JO, Menon M, Trinh QD. Is there a relationship between leapfrog volume thresholds and perioperative outcomes after radical cystectomy? *Urol Oncol*. 2013 Feb 9. PMID: 23403162
1301. da Silva RD, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Chade D, Guglielmetti GB, Pycha A, Lotan Y, Karakiewicz PI, Sun M, Fajkovic H, Zerbib M, Scherr DS, **Shariat SF**: Impact of Statin Use on Oncological Outcomes of Patients with Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. *J Urol*. 2013 Feb 7. PMID: 23395802
1302. Kluth LA, Xylinas E, Crivelli JJ, Passoni N, Comploj E, Pycha A, Chrystal J, Sun M, Karakiewicz PI, Gontero P, Lotan Y, Chun FK, Fisch M, Scherr DS, **Shariat SF**. Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder. *J Urol*. 2013 Jan 31. PMID: 23376707
1303. Larré S, Catto JW, Cookson MS, Messing EM, **Shariat SF**, Soloway MS, Svatek RS, Lotan Y, Zlotta AR, Grossman HB. Screening for bladder cancer: rationale, limitations, whom to target, and perspectives. *Eur Urol*. 2013 PMID: 23313034
1304. Hansen J, Rink M, Graefen M, **Shariat S**, Chun FK: Assays for Prostate Cancer: Changing the Screening Paradigm? *Mol Diagn Ther*. 2013 Jan 25. PMID:23355098
1305. Margulis V, **Shariat SF**, Rapoport Y, Rink M, Sjoberg DD, Tannir NM, Abel EJ, Culp SH, Tamboli P, Wood CG. Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. *Eur Urol*. 2012 PMID: 23273681
1306. Xylinas E, Rink M, Margulis V, Faison T, Comploj E, Novara G, Raman JD, Lotan Y, Guillonneau B, Weizer A, Pycha A, Scherr DS, Seitz C, Sun M, Trinh QD, Karakiewicz PI, Montorsi F, Zerbib M, Gönen M, **Shariat SF**. Prediction of true nodal status in patients with pathological lymph node negative upper tract urothelial carcinoma at radical nephroureterectomy. *J Urol*. 2012 Dec 14. PMID: 23253960

1307. Trinh QD, Sukumar S, Schmitges J, Bianchi M, Sun M, **Shariat SF**, Sammon JD, Jeldres C, Zorn KC, Perrotte P, Graefen M, Rogers CG, Peabody JO, Menon M, Karakiewicz PI: Effect of nodal metastases on cancer-specific mortality after cytoreductive nephrectomy. *Ann Surg Oncol*. 2012 Dec 23. PMID: 23263779
1308. Rink M, Zabor EC, Furberg H, Xylinas E, Ehdaie B, Novara G, Babjuk M, Pycha A, Lotan Y, Trinh QD, Chun FK, Lee RK, Karakiewicz PI, Fisch M, Robinson BD, Scherr DS, **Shariat SF**. Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy. *Eur Urol*. 2012 Nov 27 PMID: 23206854 the
1309. Najari BB, Rink M, Li PS, Karakiewicz PI, Scherr DS, Shabsigh R, Meryn S, Schlegel PN, **Shariat SF**. Sex disparities in cancer mortality: risks of being a man in the U.S. *J Urol*. 2012 Nov 30. PMID: 23206422
1310. Kluth LA, Fajkovic H, Xylinas E, Crivelli JJ, Passoni N, Rouprêt M, Becker A, Comploj E, Pycha A, Holmang S, Gupta A, Lotan Y, Karakiewicz PI, Gontero P, Chun FK, Fisch M, Scherr DS, **Shariat SF**. Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder. *World J Urol*. 2012 Nov 30. PMID: 23196773
1311. Tilki D, **Shariat SF**, Lotan Y, Rink M, Karakiewicz PI, Schoenberg MP, Lerner SP, Sonpavde G, Sagalowsky AI, Gupta A. Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. *BJU Int*. 2012 Nov 26. PMID: 23181623
1312. Xylinas E, Cha EK, Sun M, Rink M, Trinh QD, Novara G, Green DA, Pycha A, Fradet Y, Daneshmand S, Svatek RS, Fritsche HM, Kassouf W, Scherr DS, Faison T, Crivelli JJ, Tagawa ST, Zerbib M, Karakiewicz PI, **Shariat SF**. Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling. *Br J Cancer*. 2012 Nov 20;107(11):1826-32. PMID: 23169335
1313. Green DA, Osterberg EC, Xylinas E, Rink M, Karakiewicz PI, Scherr DS, **Shariat SF**. Predictive tools for prostate cancer staging, treatment response and outcomes. *Arch Esp Urol*. 2012 Nov;65(9):787-807. English, Spanish. PMID:23154603
1314. Cha EK, Tirsar LA, Schwentner C, Hennenlotter J, Christos PJ, Stenzl A, Mian C, Martini T, Pycha A, Schmitz-Dräger BJ **Shariat SF**. Accurate risk assessment of patients with asymptomatic hematuria for the presence of bladder cancer. *World J Urol*. 2012 Nov 5. PMID: 23124847
1315. Thuret R, Sun M, Budaus L, Abdollah F, Liberman D, **Shariat SF**, Iborra F, Guiter J, Patard JJ, Perrotte P, Karakiewicz PI. A population-based analysis of the effect of marital status on overall and cancer-specific mortality in patients with squamous cell carcinoma of the penis. *Cancer Causes Control*. 2012 Oct 30. PMID: 23109172
1316. Rouprêt M, Hupertan V, Seisen T, Colin P, Xylinas E, Yates DR, Fajkovic H, Lotan Y, Raman JD, Zigeuner R, Remzi M, Bolenz C, Novara G, Kassouf W, Ouzzane A, Rozet F, Cussenot O, Martinez-Salamanca JI, Fritsche HM, Walton TJ, Wood CG, Bensalah K, Karakiewicz PI, Montorsi F, Margulis V, **Shariat SF**. Prediction of cancer-specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized post-operative nomogram using decision curve analysis. *J Urol*. 2012 Oct 23. PMID: 23103802
1317. Xylinas E, Rink M, Novara G, Green DA, Clozel T, Fritsche HM, Guillonnet B, Lotan Y, Kassouf W, Tilki D, Babjuk M, Karakiewicz PI, Montorsi F, Abdennabi J, Trinh QD, Svatek RS, Scherr DS, Zerbib M, **Shariat SF**. Predictors of Survival in Patients With Soft Tissue Surgical Margin Involvement at Radical Cystectomy. *Ann Surg Oncol*. 2012 Oct 26. PMID: 23099729

1318. Bianchi M, Trinh QD, Sun M, Meskawi M, Schmitges J, **Shariat SF**, Briganti A, Tian Z, Jeldres C, Sukumar S, Peabody JO, Graefen M, Perrotte P, Menon M, Montorsi F, Karakiewicz PI. Impact of academic affiliation on radical cystectomy outcomes in North America: A population-based study. *Can Urol Assoc J*. 2012 Aug;6(4):245-50. PMID: 23093532
1319. Carlsson SV, Tafe LJ, Chade DC, Sjoberg DD, Passoni N, **Shariat SF**, Eastham J, Scardino PT, Fine SW, Touijer KA. Pathological features of lymph node metastases in predicting biochemical recurrence after radical prostatectomy for prostate cancer. *J Urol*. 2012 Oct 18. PMID: 23085057
1320. Sammon JD, Karakiewicz PI, Sun M, Sukumar S, Ravi P, Ghani KR, Bianchi M, Peabody JO, **Shariat SF**, Perrotte P, Hu JC, Menon M, Trinh QD. Robot-assisted vs. Open radical prostatectomy: The differential effect of regionalization, procedure volume and operative approach. *J Urol*. 2012 Oct 18. PMID: 23085052
1321. Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N, **Shariat SF**, Xylinas E, Schmitz-Dräger BJ, Lotan Y, Jenkins LC, Droller M, van Rhijn BW, Karakiewicz PI. ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, Diagnosis, and Molecular Markers. *Eur Urol*. 2012 Oct 4. PMID: 23083902
1322. Rink M, Xylinas E, Babjuk M, Hansen J, Pycha A, Comploj E, Lotan Y, Sun M, Karakiewicz PI, Abdennabi J, Fajkovic H, Loidl W, Chun FK, Fisch M, Scherr DS, **Shariat SF**. Impact of Smoking on Outcomes of Patients with a History of Recurrent Nonmuscle Invasive Bladder Cancer. *J Urol*. 2012 Oct 17. PMID: 23083868
1323. Thuret R, Sun M, Abdollah F, Budaus L, **Shariat SF**, Iborra F, Guiter J, Patard JJ, Karakiewicz PI. Competing-risks analysis in patients with T1 squamous cell carcinoma of the penis. *BJU Int*. 2012 Oct 12. PMID: 23057865
1324. Rouprêt M, Xylinas E, Colin P, Kluth L, Karakiewicz P, **Shariat SF**. Oncologic Outcomes and Survival in pT0 Tumors After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: Results from of a Large Multicenter International Collaborative Study. *Eur Urol*. 2012 Sep 23. PMID: 23040206
1325. Abdollah F, Abdo A, Sun M, Schmitges J, Tian Z, Briganti A, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI. Pelvic lymph node dissection for prostate cancer: Adherence and accuracy of the recent guidelines. *Int J Urol*. 2012 Oct 8. PMID: 23039245
1326. Sun M, Bianchi M, Hansen J, Abdollah F, Trinh QD, Lughezzani G, **Shariat SF**, Montorsi F, Perrotte P, Karakiewicz PI. Nodal involvement at nephrectomy is associated with worse survival: A stage-for-stage and grade-for-grade analysis. *Int J Urol*. 2012 Oct 8. PMID: 23039208
1327. Catto JW, **Shariat SF**. The Changing Face of Renal Cell Carcinoma: The Impact of Systematic Genetic Sequencing on Our Understanding of This Tumor's Biology. *Eur Urol*. 2012 Sep 26. PMID: 23026395
1328. Green DA, Rink M, Xylinas E, Matin SF, Stenzl A, Roupret M, Karakiewicz PI, Scherr DS, **Shariat SF**. Urothelial Carcinoma of the Bladder and the Upper Tract: Disparate Twins. *J Urol*. 2012 Sep 27. PMID: 23023150
1329. Fajkovic H, Cha EK, Xylinas E, Rink M, Pycha A, Seitz C, Bolenz C, Dunning A, Novara G, Trinh QD, Karakiewicz PI, Margulis V, Raman JD, Walton TJ, Baba S, Carballido J, Otto W, Montorsi F, Lotan Y, Kassouf W, Fritsche HM, Bensalah K, Zigeuner R, Scherr DS, Sonpavde G, Roupret M, **Shariat SF**. Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma. *World J Urol*. 2012 Sep 26. PMID: 23011256

1330. Xylinas E, Kluth L, Mangal S, Roupret M, Karakiewicz PI, **Shariat SF**. Predictive tools for clinical decision-making and counseling of patients with upper tract urothelial carcinoma. *World J Urol*. 2012 Sep 18. PMID: 22986907
1331. Trinh QD, Bianchi M, Hansen J, Tian Z, Abdollah F, **Shariat SF**, Montorsi F, Perrotte P, Karakiewicz PI, Sun M. In-hospital Mortality and Failure to Rescue After Cytoreductive Nephrectomy. *Eur Urol*. 2012 Sep 7. pii: S0302-2838(12)01022-6. PMID: 22981674
1332. Rink M, Xylinas E, Babjuk M, Pycha A, Karakiewicz PI, Novara G, Dahlem R, **Shariat SF**. Smoking Reduces the Efficacy of Intravesical Bacillus Calmette-Guérin Immunotherapy in Non-muscle-invasive Bladder Cancer. *Eur Urol*. 2012 Sep 5. . PMID: 22980442
1333. Yates DR, Brausi MA, Catto JW, Dalbagni G, Rouprêt M, **Shariat SF**, Sylvester RJ, Witjes JA, Zlotta AR, Palou-Redorta J. Treatment Options Available for Bacillus Calmette-Guérin Failure in Non-muscle-invasive Bladder Cancer. *Eur Urol*. 2012 Sep 3. PMID: 22959049
1334. Green DA, Rink M, Cha EK, Xylinas E, Chughtai B, Scherr DS, **Shariat SF**, Lee RK. Cost-effective treatment of low-risk carcinoma not invading bladder muscle. *BJU Int*. 2012 Sep 7. PMID: 22958598
1335. Rink M, Park K, Volkmer BG, Xylinas E, Hansen J, Cha EK, Robinson BD, Hautmann R, Küfer R, Engel O, Chun FK, Dahlem R, Rubin MA, **Shariat SF**, Mosquera JM. Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy. *Urol Oncol*. 2012 Sep 1. pii: S1078-1439(12)00237-2. PMID: 22944196
1336. Rink M, Lee DJ, Kent M, Xylinas E, Fritsche HM, Babjuk M, Brisuda A, Hansen J, Green DA, Aziz A, Cha EK, Novara G, Chun FK, Lotan Y, Bastian PJ, Tilki D, Gontero P, Pycha A, Baniel J, Mano R, Ficarra V, Trinh QD, Tagawa ST, Karakiewicz PI, Scherr DS, Sjoberg DD, **Shariat SF**; for the Bladder Cancer Research Consortium. Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. *BJU Int*. 2012 Sep 3. PMID: 22938654
1337. Bachir BG, **Shariat SF**, Zlotta A, Svatek R, Black PC, Shah JB, Kassouf W; on behalf of the Bladder Cancer Think Tank (Bladder Cancer Advocacy Network) and Canadian Bladder Cancer Network (Bladder Cancer Canada). Demographic analysis of randomized controlled trials in bladder cancer. *BJU Int*. 2012 Aug 29. doi: 10.1111/j.1464-410X.2012.11401.x. PMID: 22928764
1338. Rink M, Furberg H, Zabor EC, Xylinas E, Babjuk M, Pycha A, Lotan Y, Karakiewicz PI, Novara G, Robinson BD, Montorsi F, Chun FK, Scherr DS, **Shariat SF**. Impact of Smoking and Smoking Cessation on Oncologic Outcomes in Primary Non-muscle-invasive Bladder Cancer. *Eur Urol*. 2012 Aug 21. PMID: 22925575
1339. Xylinas E, Rouprêt M, Kluth L, Scherr DS, **Shariat SF**; for the Upper Tract Urothelial Carcinoma Collaboration (UTUCC). Collaborative Research Networks as a Platform for Virtual Multidisciplinary, International Approach to Managing Difficult Clinical Cases: An Example from the Upper Tract Urothelial Carcinoma Collaboration. *Eur Urol*. 2012 Aug 20. PMID: 22921717
1340. Reifsnnyder JE, Ramasamy R, Ng CK, Dipietro J, Shin B, **Shariat SF**, Del Pizzo JJ, Scherr DS. Laparoscopic and open partial nephrectomy: complication comparison using the Clavien system. *JLS*. 2012 Jan-Mar;16(1):38-44. PMID: 22906328
1341. Sammon J, Trinh QD, Sun M, Bianchi M, Schmitges J, **Shariat SF**, Ghani KR, Sukumar S, Jeldres C, Briganti A, Perrotte P, Rogers CG, Peabody JO, Montorsi F, Menon M, Karakiewicz PI. The effect of gender on nephrectomy perioperative outcomes: a national survey. *Can J Urol*. 2012 Aug;19(4):6337-44. PMID: 22892256

1342. Skeldon SC, Semotiuk K, Aronson M, Holter S, Gallinger S, Pollett A, Kuk C, van Rhijn B, Bostrom P, Cohen Z, Fleshner NE, Jewett MA, Hanna S, **Shariat SF**, Van Der Kwast TH, Evans A, Catto J, Bapat B, Zlotta AR. Patients with Lynch Syndrome Mismatch Repair Gene Mutations Are at Higher Risk for Not Only Upper Tract Urothelial Cancer but Also Bladder Cancer. *Eur Urol*. 2012 Aug 2. PMID: 22883484
1343. Adibi M, Youssef R, **Shariat SF**, Lotan Y, Wood CG, Sagalowsky AI, Zigeuner R, Montorsi F, Bolenz C, Margulis V. Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: Comparison over the three decades. *Int J Urol*. 2012 Aug 12. PMID: 22882743
1344. Fajkovic H, Cha EK, Jeldres C, Robinson BD, Rink M, Xylinas E, Chromecki TF, Breinl E, Svatek RS, Donner G, Tagawa ST, Tilki D, Bastian PJ, Karakiewicz PI, Volkmer BG, Novara G, Joul A, Faison T, Sonpavde G, Daneshmand S, Lotan Y, Scherr DS, **Shariat SF**. Extranodal Extension Is a Powerful Prognostic Factor in Bladder Cancer Patients with Lymph Node Metastasis. *Eur Urol*. 2012 Jul 20. PMID: 22877503
1345. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeny LA, La Vecchia C, **Shariat SF**, Lotan Y. Epidemiology and Risk Factors of Urothelial Bladder Cancer. *Eur Urol*. 2012 Jul 25. PMID: 22877502
1346. Hansen J, Auprich M, Ahyai SA, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Fisch M, Abbou CC, Schalken JA, Fradet Y, Marks LS, Ellis W, Partin AW, Pummer K, Graefen M, Haese A, Walz J, Briganti A, **Shariat SF**, Chun FK. Initial Prostate Biopsy: Development and Internal Validation of a Biopsy-specific Nomogram Based on the Prostate Cancer Antigen 3 Assay. *Eur Urol*. 2012 Jul 20. PMID: 22854248
1347. Xylinas E, **Shariat SF**, Zerbib M. Uptake of Laparoscopic Radical Nephroureterectomy in France: A 2003-2011 National Practice Report. *Eur Urol*. 2012 Jul 21. PMID: 22840352
1348. Rink M, **Shariat SF**, Xylinas E, Fitzgerald JP, Hansen J, Green DA, Kamat AM, Novara G, Daneshmand S, Fradet Y, Tagawa ST, Bastian PJ, Kassouf W, Trinh QD, Karakiewicz PI, Fritsche HM, Tilki D, Chun FK, Volkmer BG, Babjuk M, Merseburger AS, Scherr DS, Lotan Y, Svatek RS. Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy? *World J Urol*. 2012 Jul 26. PMID: 22832587
1349. Hansen J, Rink M, Bianchi M, Kluth LA, Tian Z, Ahyai SA, **Shariat SF**, Briganti A, Steuber T, Fisch M, Graefen M, Karakiewicz PI, Chun FK. External validation of the updated briganti nomogram to predict lymph node invasion in prostate cancer patients undergoing extended lymph node dissection. *Prostate*. 2012 Jul 20. doi: 10.1002/pros.22559. PMID: 22821742
1350. Sukumar S, Sun M, Karakiewicz PI, Friedman AA, Chun FK, Sammon J, Ghani KR, Ravi P, Bianchi M, Jeong W, **Shariat SF**, Hansen J, Peabody JO, Elder JS, Menon M, Trinh QD. National trends and disparities in the use of minimally invasive adult pyeloplasty. *J Urol*. 2012 Sep;188(3):913-8. Epub 2012 Jul 20. PMID: 22819404
1351. Rink M, Hansen J, Cha EK, Green DA, Babjuk M, Svatek RS, Xylinas E, Tagawa ST, Faison T, Novara G, Karakiewicz PI, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Pycha A, Comploj E, Tilki D, Bastian PJ, Chun FK, Dahlem R, Scherr DS, **Shariat SF**: Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy. *BJU Int*. 2012 Jul 19. PMID: 22809039
1352. Rink M, Sjoberg D, Comploj E, Margulis V, Xylinas E, Lee RK, Hansen J, Cha EK, Raman JD, Remzi M, Bensalah K, Novara G, Matin SF, Chun FK, Kikuchi E, Kassouf W, Martinez-Salamanca JI, Lotan Y, Seitz C, Pycha A, Zigeuner R, Karakiewicz PI, Scherr DS, Vickers AJ,

- Shariat SF.** Risk of Cancer-specific Mortality following Recurrence After Radical Nephroureterectomy. *Ann Surg Oncol.* 2012 Jul 18. PMID: 22805867
1353. Green DA, Rink M, Hansen J, Cha EK, Robinson B, Tian Z, Chun FK, Tagawa S, Karakiewicz PI, Fisch M, Scherr DS, **Shariat SF:** Accurate preoperative prediction of non-organ-confined bladder urothelial carcinoma at cystectomy. *BJU Int.* 2012 Jul 13. PMID: 22805163
1354. Novara G, Ficarra V, Rosen RC, Artibani W, Costello A, Eastham JA, Graefen M, Guazzoni G, **Shariat SF,** Stolzenburg JU, Van Poppel H, Zattoni F, Montorsi F, Mottrie A, Wilson TG. Systematic Review and Meta-analysis of Perioperative Outcomes and Complications After Robot-assisted Radical Prostatectomy. *Eur Urol.* 2012 Jun 2. PMID: 22749853
1355. Novara G, Ficarra V, Mocellin S, Ahlering TE, Carroll PR, Graefen M, Guazzoni G, Menon M, Patel VR, **Shariat SF,** Tewari AK, Van Poppel H, Zattoni F, Montorsi F, Mottrie A, Rosen RC, Wilson TG. Systematic Review and Meta-analysis of Studies Reporting Oncologic Outcome After Robot-assisted Radical Prostatectomy. *Eur Urol.* 2012 Jun 2. PMID: 22749851
1356. Brookman-May S, May M, **Shariat SF,** Xylinas E, Stief C, Zigeuner R, Chromecki T, Burger M, Wieland WF, Cindolo L, Schips L, De Cobelli O, Rocco B, De Nunzio C, Feciche B, Truss M, Gilfrich C, Pahernik S, Hohenfellner M, Zastrow S, Wirth MP, Novara G, Carini M, Minervini A, Simeone C, Antonelli A, Mirone V, Longo N, Simonato A, Carmignani G, Ficarra V; members of the CORONA project and the SATURN project. Features Associated with Recurrence beyond 5 Years after Nephrectomy and Nephron-Sparing Surgery for Renal Cell Carcinoma: Development and Internal Validation of a Risk Model (PRELANE score) to Predict Late Recurrence Based on a Large Multicenter Database (CORONA/SATURN Project). *Eur Urol.* 2012 Jun 22. PMID: 22748912
1357. Rink M, Xylinas E, Margulis V, Cha EK, Ehdaie B, Raman JD, Chun FK, Matsumoto K, Lotan Y, Furberg H, Babjuk M, Pycha A, Wood CG, Karakiewicz PI, Fisch M, Scherr DS, **Shariat SF;** for the Upper Tract Urothelial Carcinoma Collaboration. Impact of Smoking on Oncologic Outcomes of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. *Eur Urol.* 2012 Jun 22. PMID: 22743166
1358. Chromecki TF, Cha EK, Fajkovic H, Rink M, Ehdaie B, Svatek RS, Karakiewicz PI, Lotan Y, Tilki D, Bastian PJ, Daneshmand S, Kassouf W, Durand M, Novara G, Fritsche HM, Burger M, Izawa JI, Brisuda A, Babjuk M, Pummer K, **Shariat SF:** Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy. *BJU Int.* 2012 Jun 21. PMID: 22727036
1359. **Shariat SF,** Rink M, Ehdaie B, Xylinas E, Babjuk M, Merseburger AS, Svatek RS, Cha EK, Tagawa ST, Fajkovic H, Novara G, Karakiewicz PI, Trinh QD, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Chun FK, Sonpavde G, Joul A, Scherr DS, Gonen M. Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy. *Eur Urol.* 2012 Jun 16. PMID: 22727174
1360. Rink M, Adam M, Hansen J, Chun FK, Ahyai SA, Remzi M, Schlomm T, Engel O, Heuer R, Eichelberg C, Fisch M, Dahlem R, **Shariat SF:** Upper tract urothelial carcinoma : An update on clinical and pathological prognostic factors. *Urologe A.* 2012 Jun 16. PMID: 22699513
1361. Rink M, Robinson BD, Green DA, Cha EK, Hansen J, Comploj E, Margulis V, Raman JD, Ng CK, Remzi M, Bensalah K, Kabbani W, Haitel A, Rioux-Leclercq N, Guo CC, Chun FK, Kikuchi E, Kassouf W, Sircar K, Sun M, Sonpavde G, Lotan Y, Pycha A, Karakiewicz PI, Scherr DS, **Shariat SF.** Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma. *J Urol.* 2012 Jun 12. PMID: 22698626

1362. Hansen J, Sun M, Bianchi M, Rink M, Tian Z, Hanna N, Meskawi M, Schmitges J, **Shariat SF**, Chun FK, Perrotte P, Graefen M, Karakiewicz PI. Assessment of cancer control outcomes in patients with high-risk renal cell carcinoma treated with partial nephrectomy. *Urology*. 2012 Jun 12. PMID: 22698478
1363. Sun M, Abdollah F, Hansen J, Trinh QD, Bianchi M, Tian Z, Briganti A, **Shariat SF**, Montorsi F, Perrotte P, Karakiewicz PI. Is a treatment delay in radical prostatectomy safe in individuals with low-risk prostate cancer? *J Sex Med*. 2012 Jun 6. PMID: 22672479
1364. Ehdaie B, Furberg H, Zabor EC, Ostroff JS, **Shariat SF**, Bochner BH, Coleman JA, Dalbagni G. Impact of smoking status at diagnosis on disease recurrence and death in upper tract urothelial carcinoma. *BJU Int*. 2012 May 29. PMID: 22642265
1365. Sun M, Bianchi M, Trinh QD, Hansen J, Abdollah F, Hanna N, Tian Z, **Shariat SF**, Montorsi F, Perrotte P, Karakiewicz PI. Comparison of partial vs radical nephrectomy with regard to other-cause mortality in T1 renal cell carcinoma among patients aged ≥ 75 years with multiple comorbidities. *BJU Int*. 2012 May 22. PMID: 22612472
1366. Degraff DJ, Clark PE, Cates JM, Yamashita H, Robinson VL, Yu X, Smolkin ME, Chang SS, Cookson MS, Herrick MK, **Shariat SF**, Steinberg GD, Frierson HF, Wu XR, Theodorescu D, Matusik RJ. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. *PLoS One*. 2012;7(5):e36669. Epub 2012 May 10. PMID: 22590586
1367. Xylinas E, Rink M, Cha EK, Clozel T, Lee RK, Fajkovic H, Comploj E, Novara G, Margulis V, Raman JD, Lotan Y, Kassouf W, Fritsche HM, Weizer A, Martinez-Salamanca JI, Matsumoto K, Zigeuner R, Pycha A, Scherr DS, Seitz C, Walton T, Trinh QD, Karakiewicz PI, Matin S, Montorsi F, Zerbib M, **Shariat SF**. Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma. *Eur Urol*. 2012 May 4. PMID: 22579047
1368. Abdollah F, Sun M, Schmitges J, Thuret R, Bianchi M, **Shariat SF**, Briganti A, Jeldres C, Perrotte P, Montorsi F, Karakiewicz PI. Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics. *J Urol*. 2012 May 12. PMID: 22578732
1369. Meskawi M, Sun M, Trinh QD, Bianchi M, Hansen J, Tian Z, Rink M, Ismail S, **Shariat SF**, Montorsi F, Perrotte P, Karakiewicz PI. A Review of Integrated Staging Systems for Renal Cell Carcinoma. *Eur Urol*. 2012 May 3. PMID: 22575911
1370. Abdollah F, Schmitges J, Sun M, Jeldres C, Tian Z, Briganti A, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI. Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: A population-based analysis. *Int J Urol*. 2012 May 10. PMID: 22574746
1371. Bagrodia A, Youssef RF, Kapur P, Darwish OM, Cannon C, Belsante MJ, Gerecci D, Sagalowsky AI, **Shariat SF**, Lotan Y, Margulis V. Prospective Evaluation of Molecular Markers for the Staging and Prognosis of Upper Tract Urothelial Carcinoma. *Eur Urol*. 2012 Apr 17. PMID: 22552216
1372. Xylinas E, Rink M, Margulis V, Karakiewicz PI, Bensalah K, **Shariat SF**. Histologic Variants of Upper Tract Urothelial Carcinoma Do Not Affect Response to Adjuvant Chemotherapy After Radical Nephroureterectomy. *Eur Urol*. 2012 Apr 17. No abstract available. PMID: 22537797

1373. Green DA, Durand M, Gumpeni N, Rink M, Cha EK, Karakiewicz PI, Scherr DS, **Shariat SF**. Role of magnetic resonance imaging in bladder cancer: current status and emerging techniques. *BJU Int*. 2012 PMID: 22500557
1374. Abdollah F, Sun M, Thuret R, Jeldres C, Tian Z, Briganti A, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI. Lymph node count threshold for optimal pelvic lymph node staging in prostate cancer. *Int J Urol*. 2012 Mar 14. PubMed PMID: 22416788.
1375. Sammon JD, Morgan M, Djahangirian O, Trinh QD, Sun M, Ghani KR, Jeong W, Jhaveri J, Ehlert M, Schmitges J, Bianchi M, **Shariat SF**, Perrotte P, Rogers CG, Peabody JO, Menon M, Karakiewicz PI. Marital status: a gender-independent risk factor for poorer survival after radical cystectomy. *BJU Int*. 2012 Mar 27. PubMed PMID: 22449122.
1376. Schmitges J, Trinh QD, Sun M, Abdollah F, Bianchi M, Budäus L, Hansen J, Eichelberg C, Perrotte P, **Shariat SF**, Menon M, Montorsi F, Graefen M, Karakiewicz PI. Annual prostatectomy volume is related to rectal laceration rate after radical prostatectomy. *Urology*. 2012 Apr;79(4):796-803. PubMed PMID: 22469573.
1377. Sun M, Bianchi M, Hansen J, Trinh QD, Abdollah F, Tian Z, Sammon J, **Shariat SF**, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Chronic kidney disease after nephrectomy in patients with small renal masses: a retrospective observational analysis. *Eur Urol*. 2012 Mar 31. PubMed PMID: 22483407.
1378. Lotan Y, Goodman PJ, Youssef RF, Svatek RS, **Shariat SF**, Tangen CM, Thompson IM Jr, Klein EA. Evaluation of vitamin E and Selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. *J Urol*. 2012 Apr 11. PubMed PMID: 22498220.
1379. Green DA, Durand M, Gumpeni N, Rink M, Cha EK, Karakiewicz PI, Scherr DS, **Shariat SF**. Role of magnetic resonance imaging in bladder cancer: current status and emerging techniques. *BJU Int*. 2012 Apr 13. PubMed PMID: 22500557.
1380. Xylinas E, Rink M, Margulis V, Karakiewicz PI, Bensalah K, **Shariat SF**. Histologic variants of upper tract urothelial carcinoma do not affect response to adjuvant chemotherapy after radical nephroureterectomy. *Eur Urol*. 2012 Apr 17. PubMed PMID: 22537797.
1381. Bagrodia A, Youssef RF, Kapur P, Darwish OM, Cannon C, Belsante MJ, Gerecci D, Sagalowsky AI, **Shariat SF**, Lotan Y, Margulis V. Prospective evaluation of molecular markers for the staging and prognosis of upper tract urothelial carcinoma. *Eur Urol*. 2012 Apr 17. PubMed PMID: 22552216.
1382. Xylinas E, Rink M, Margulis V, Karakiewicz P, Novara G, **Shariat SF**: Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence. *Eur Urol*. 2012 Feb 25. PMID: 22402109
1383. Trinh QD, Sun M, Sammon J, Tian Z, Bianchi M, **Shariat SF**, Jeong W, Ghani KR, Jeldres C, Perrotte P, Agarwal PK, Rogers CG, Peabody JO, Menon M, Karakiewicz PI: Leapfrog volume thresholds and perioperative complications after radical prostatectomy. *Cancer*. 2012 Mar 5. doi: 10.1002/cncr.27486. PMID: 22392599
1384. Lughezzani G, Burger M, Margulis V, Matin SF, Novara G, Roupert M, **Shariat SF**, Wood CG, Zigeuner R. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. *Eur Urol*. 2012 Feb 23. PMID 22381168
1385. Youssef R, Kapur P, **Shariat SF**, Arendt T, Kabbani W, Mosbah A, Abol-Enein H, Ghoneim M, Lotan Y. Prognostic value of apoptotic markers in squamous cell carcinoma of the urinary bladder. *BJU Int*. 2012 Feb 28. PMID: 22372762

1386. Marberger M, Barentsz J, Emberton M, Hugosson J, Loeb S, Klotz L, Koch M, **Shariat SF**, Vickers A. Novel approaches to improve prostate cancer diagnosis and management in early-stage disease. *BJU Int.* 2012 Mar;109 Suppl 2:1-7. PMID: 22257098
1387. Rink M, Cha EK, Green D, Hansen J, Robinson BD, Lotan Y, Sagalowsky AI, Chun FK, Karakiewicz PI, Fisch M, Scherr DS, **Shariat SF**. Biomolecular predictors of urothelial cancer behavior and treatment outcomes. *Curr Urol Rep.* 2012 Feb 23. PMID: 22354565
1388. Bianchi M, Trinh QD, Sun M, Sammon J, Schmitges J, **Shariat SF**, Sukumar S, Ghani KR, Jeldres C, Perrotte P, Rogers CG, Briganti A, Peabody JO, Montorsi F, Menon M, Karakiewicz PI: Discharge patterns after radical cystectomy: contemporary trends in the United States. *J Urol.* 2012 Feb 13. PMID: 22335867
1389. Rink M, Ehdäie B, Cha EK, Green DA, Karakiewicz PI, Babjuk M, Margulis V, Raman JD, Svatek RS, Fajkovic H, Lee RK, Novara G, Hansen J, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Pycha A, Fisch M, Scherr DS, **Shariat SF**: Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. *Eur Urol.* 2012 Feb 15. PMID: 22349570
1390. Roscigno M, Cha EK, Rink M, Seitz C, Novara G, Chromecki TF, Fritsche HM, Matsumoto K, Walton TJ, Carballido J, Filippo Da Pozzo L, Bertini R, Ficarra V, Otto W, Karakiewicz PI, Pycha A, Fajkovic H, Naspro R, Scherr DS, Montorsi F, **Shariat SF**. International validation of the prognostic value of subclassification for AJCC stage pT3 upper tract urothelial carcinoma of the renal pelvis. *BJU Int.* 2012 Feb 20. PMID: 22348322
1391. Abdollah F, Sun M, Schmitges J, Thuret R, Tian Z, **Shariat SF**, Briganti A, Jeldres C, Perrotte P, Montorsi F, Karakiewicz PI: Competing-risks Mortality After Radiotherapy vs. Observation for Localized Prostate Cancer: A Population-based Study. *Int J Radiat Oncol Biol Phys.* 2012 Feb 11. PMID: 22330991
1392. Sun M, Abdollah F, Bianchi M, Trinh QD, Jeldres C, Thuret R, Tian Z, **Shariat SF**, Montorsi F, Perrotte P, Karakiewicz PI. Treatment Management of Small Renal Masses in the 21st Century: A Paradigm Shift. *Ann Surg Oncol.* 2012 Feb 10. PMID: 2232295
1393. Schmitges J, Trinh QD, Sun M, Hansen J, Bianchi M, Jeldres C, Perrotte P, Dahlem R, **Shariat SF**, Chun FK, Montorsi F, Menon M, Fisch M, Graefen M, Karakiewicz PI. Higher perioperative morbidity and in-hospital mortality in patients with end-stage renal disease undergoing nephrectomy for non-metastatic kidney cancer: a population-based analysis. *BJU Int.* 2012 Feb 9. PMID: 22321256
1394. Schmitges J, Trinh QD, Sun M, Abdollah F, Bianchi M, Budäus L, Salomon G, Schlomm T, Perrotte P, **Shariat SF**, Montorsi F, Menon M, Graefen M, Karakiewicz PI. Venous thromboembolism after radical prostatectomy: the effect of surgical caseload. *BJU Int.* 2012 Feb 7. PMID: 22313499
1395. Trinh QD, Sun M, Sammon J, Bianchi M, Sukumar S, Ghani KR, Jeong W, Dabaja A, **Shariat SF**, Perrotte P, Agarwal PK, Rogers CG, Peabody JO, Menon M, Karakiewicz PI. Disparities in access to care at high-volume institutions for uro-oncologic procedures. *Cancer.* 2012 Feb 1. PMID:22298310
1396. Rink M, Chun FK, Chromecki TF, Fajkovic H, Dahlem R, Fisch M, **Shariat SF**. [Advanced bladder cancer in elderly patients : Prognostic outcomes and therapeutic strategies.] *Urologe A.* 2012 Jan 28. German. PMID: 22282102
1397. Cha EK, **Shariat SF**, Kormaksson M, Novara G, Chromecki TF, Scherr DS, Lotan Y, Raman JD, Kassouf W, Zigeuner R, Remzi M, Bensalah K, Weizer A, Kikuchi E, Bolenz C, Roscigno M,

- Koppie TM, Ng CK, Fritsche HM, Matsumoto K, Walton TJ, Ehdaie B, Tritschler S, Fajkovic H, Martínez-Salamanca JI, Pycha A, Langner C, Ficarra V, Patard JJ, Montorsi F, Wood CG, Karakiewicz PI, Margulis V. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. *Eur Urol.* 2012 Jan 23. PMID: 22284969
1398. **Shariat SF**, Zigeuner R, Rink M, Margulis V, Hansen J, Kikuchi E, Kassouf W, Raman JD, Remzi M, Koppie TM, Bensalah K, Guo CC, Mikami S, Sircar K, Ng CK, Haitel A, Kabbani W, Chun FK, Wood CG, Scherr DS, Karakiewicz PI, Langner C. Subclassification of pT3 urothelial carcinoma of the renal pelvicalyceal system is associated with recurrence-free and cancer-specific survival: proposal for a revision of the current tmn classification. *Eur Urol.* 2012 Jan 24. PMID: 22285763
1399. Chade DC, Eastham J, Graefen M, Hu JC, Karnes RJ, Klotz L, Montorsi F, van Poppel H, Scardino PT, **Shariat SF**. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. *Eur Urol.* 2012 Jan 23. PMID: 22280856
1400. Rink M, Chun FK, Dahlem R, Soave A, Minner S, Hansen J, Stoupiec M, Coith C, Kluth LA, Ahyai SA, Friedrich MG, **Shariat SF**, Fisch M, Pantel K, Riethdorf S. Prognostic Role and HER2 Expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. *Eur Urol.* 2012 Jan 20. PMID: 22277196
1401. Fajkovic H, Cha EK, Jeldres C, Donner G, Chromecki TF, Margulis V, Novara G, Lotan Y, Raman JD, Kassouf W, Seitz C, Bensalah K, Weizer A, Kikuchi E, Roscigno M, Remzi M, Matsumoto K, Breinl E, Pycha A, Ficarra V, Montorsi F, Karakiewicz PI, Scherr DS, **Shariat SF**. Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma. *J Urol.* 2012 Jan 14. PMID:22248522
1402. Rink M, Fajkovic H, Cha EK, Gupta A, Karakiewicz PI, Chun FK, Lotan Y, **Shariat SF**: Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. *Eur Urol.* 2012 Jan 5. PMID: 22226583
1403. Hanna N, Sun M, Trinh QD, Hansen J, Bianchi M, Montorsi F, **Shariat SF**, Graefen M, Perrotte P, Karakiewicz PI. Propensity-Score-Matched Comparison of Perioperative Outcomes Between Open and Laparoscopic Nephroureterectomy: A National Series. *Eur Urol.* 2011 Dec 22. PMID: 22209172
1404. Trinh QD, Sammon J, Sun M, Ravi P, Ghani KR, Bianchi M, Jeong W, **Shariat SF**, Hansen J, Schmitges J, Jeldres C, Rogers CG, Peabody JO, Montorsi F, Menon M, Karakiewicz PI. Perioperative Outcomes of Robot-Assisted Radical Prostatectomy Compared With Open Radical Prostatectomy: Results From the Nationwide Inpatient Sample. *Eur Urol.* 2011 Dec 22. PMID: 22206800
1405. Sun M, Abdollah F, Bianchi M, Trinh QD, **Shariat SF**, Jeldres C, Tian Z, Hansen J, Briganti A, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Conditional survival of patients with urothelial carcinoma of the urinary bladder treated with radical cystectomy. *Eur J Cancer.* 2011 Dec 21. PMID: 22196034
1406. Clements T, Messer JC, Terrell JD, Herman MP, Ng C, Scherr D, Scoll B, Boorjian SA, Uzzo RG, Wille M, Eggener SE, Lucas SM, Lotan Y, **Shariat SF**, Raman JD: High grade ureteroscopic biopsy is associated with advanced pathology of upper tract urothelial carcinoma tumors at definitive surgical resection. *J Endourol.* 2011 Dec 22. PMID: 22192113
1407. Yafi FA, Novara G, **Shariat SF**, Gupta A, Matsumoto K, Walton TJ, Fritsche HM, El-Hakim A, Trischler S, Martínez-Salamanca JI, Seitz C, Ficarra V, Zattoni F, Karakiewicz PI, Kassouf W.

- Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy. *BJU Int.* 2011 Dec 16. PMID: 22177329
1408. Kroeger N, Rampersaud EN, Patard JJ, Klatte T, Birkhäuser FD, **Shariat SF**, Lang H, Rioux-Leclercq N, Remzi M, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ Prognostic value of microvascular invasion in predicting the cancer specific survival and risk of metastatic disease in renal cell carcinoma: a multicenter investigation. *J Urol.* 2012 Feb;187(2):418-23. Epub 2011 Dec 15. PMID: 22177164
1409. Schmitges J, Trinh QD, Bianchi M, Sun M, Abdollah F, Ahyai SA, Jeldres C, Steuber T, Perrotte P, **Shariat SF**, Menon M, Montorsi F, Graefen M, Karakiewicz PI: The effect of annual surgical caseload on the rates of in-hospital pneumonia and other in-hospital outcomes after radical prostatectomy. *Int Urol Nephrol.* 2011 Dec 13. PMID: 22160759
1410. Sun M, Trinh QD, Bianchi M, Hansen J, Hanna N, Abdollah F, **Shariat SF**, Briganti A, Montorsi F, Perrotte P, Karakiewicz PI. A Non-Cancer-Related Survival Benefit Is Associated With Partial Nephrectomy. *Eur Urol.* 2011 Dec 3. PMID: 22172373
1411. **Shariat SF**, Chromecki TF, Cha EK, Karakiewicz PI, Sun M, Fradet Y, Isbarn H, Scherr DS, Bastian PJ, Pummer K, Fajkovic H, Sagalowsky AI, Ashfaq R, Doblinger M, Cote RJ, Lotan Y. Risk Stratification of Organ Confined Bladder Cancer After Radical Cystectomy Using Cell Cycle Related Biomarkers. *J Urol.* 2011 Dec 14. PMID: 22177145
1412. Sun M, Bianchi M, Trinh QD, Abdollah F, Schmitges J, Jeldres C, **Shariat SF**, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Hospital Volume is a Determinant of Postoperative Complications, Blood Transfusion and Length of Stay After Radical or Partial Nephrectomy. *J Urol.* 2011 Dec 14. PMID: 22177151
1413. Abdollah F, Schmitges J, Sun M, Thuret R, Djahangirian O, Tian Z, **Shariat SF**, Briganti A, Perrotte P, Montorsi F, Karakiewicz PI. Head-to-head comparison of three commonly used preoperative tools for prediction of lymph node invasion at radical prostatectomy. *Urology.* 2011 Dec;78(6):1363-7. PMID:22137704
1414. Trinh QD, Bianchi M, Sun M, Sammon J, Schmitges J, **Shariat SF**, Sukumar S, Jeldres C, Zorn K, Perrotte P, Rogers CG, Peabody JO, Montorsi F, Menon M, Karakiewicz PI. Discharge patterns after radical prostatectomy in the United States of America. *Urol Oncol.* 2011 Nov 17. PMID: 22100070
1415. Ehdai B, Maschino A, **Shariat SF**, Rioja J, Hamilton RJ, Lowrance WT, Poon SA, Al-Ahmadie HA, Herr HW. Comparative Outcomes of Pure Squamous Cell Carcinoma and Urothelial Carcinoma With Squamous Differentiation in Patients Treated With Radical Cystectomy. *J Urol.* 2011 Nov 14. PMID: 22088332
1416. Chromecki TF, Cha EK, Pummer K, Scherr DS, Tewari AK, Sun M, Fajkovic H, Roehrborn CG, Ashfaq R, Karakiewicz PI, **Shariat SF**. Prognostic value of insulin-like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy. *BJU Int.* 2011 Nov 11. PMID: 22077633
1417. Lotan Y, Amiel G, Boorjian SA, Clark PE, Droller M, Gingrich JR, Guzzo TJ, Inman BA, Kamat AM, Karsh L, Nielsen ME, Smith ND, **Shariat SF**, Svatek RS, Taylor JM; on Behalf of the Bladder Cancer Think Tank, and Bladder Cancer Advocacy Network: Comprehensive handbook for developing a bladder cancer cystectomy database. *Urol Oncol.* 2011 Nov 4. PMID: 22056403
1418. Trinh QD, Schmitges J, Bianchi M, Sun M, **Shariat SF**, Sammon J, Jeldres C, Zorn K, Sukumar S, Perrotte P, Graefen M, Rogers CG, Peabody JO, Menon M, Karakiewicz PI. Node-positive renal

- cell carcinoma in the absence of distant metastases: predictors of cancer-specific mortality in a population-based cohort. *BJU Int.* 2011 Nov 1. PMID: 22044638
1419. Lee DJ, Cha EK, Dubin JM, Beltran H, Chromecki TF, Fajkovic H, Scherr DS, Tagawa ST, **Shariat SF**. Novel therapeutics for the management of castration-resistant prostate cancer (CRPC). *BJU Int.* 2011 Oct 28. PMID: 22035221
1420. **Shariat SF**, Ehdaie B, Rink M, Cha EK, Svatek RS, Chromecki TF, Fajkovic H, Novara G, David SG, Daneshmand S, Fradet Y, Lotan Y, Sagalowsky AI, Clozel T, Bastian PJ, Kassouf W, Fritsche HM, Burger M, Izawa JI, Tilki D, Abdollah F, Chun FK, Sonpavde G, Karakiewicz PI, Scherr DS, Gonen M. Clinical Nodal Staging Scores for Bladder Cancer: A Proposal for Preoperative Risk Assessment. *Eur Urol.* 2011 Oct 21. PMID: 22033174
1421. Najari BB, Rink M, Graefen M, **Shariat SF**, Chun FK. Does low-risk prostate cancer detection change with repeat biopsies? *Eur Urol.* 2012 Jan;61(1):230-1. Epub 2011 Oct 18. PMID: 22024602
1422. Brookman-May S, May M, Zigeuner R, **Shariat SF**, Scherr DS, Chromecki T, Moch H, Wild PJ, Mohamad-Al-Ali B, Cindolo L, Wieland WF, Schips L, De Cobelli O, Rocco B, Santoro L, De Nunzio C, Tubaro A, Coman I, Feciche B, Truss M, Dalpiaz O, Hohenfellner M, Gilfrich C, Wirth MP, Burger M, Pahernik S; Members of the CORONA Project (Collaborative Research on Renal Neoplasms Association). Collecting System Invasion and Fuhrman Grade But Not Tumor Size Facilitate Prognostic Stratification of Patients With pT2 Renal Cell Carcinoma. *J Urol.* 2011 Dec;186(6):2175-81. Epub 2011 Oct 19. PMID: 22014800
1423. **Shariat S.**, Scherr D., Gupta A. , Bianco F., Karakiewicz P., Zeltser I., Samadi D., Akhavan A.: Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis. *Arch. Esp. Urol.* 2011; 64 (8): 681-694. way. PMID:22052751
1424. Trinh QD, Schmitges J, Sun M, Sammon J, **Shariat SF**, Zorn K, Sukumar S, Bianchi M, Perrotte P, Graefen M, Rogers CG, Peabody JO, Menon M, Karakiewicz PI: Morbidity and mortality of radical prostatectomy differs by insurance status. *Cancer.* 2011 Aug 25. PMID: 22009603
1425. Chromecki TF, Mauermann J, Cha EK, Svatek RS, Fajkovic H, Karakiewicz PI, Lotan Y, Tilki D, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Novara G, Fritsche HM, Ficarra V, Stief CG, Dinney CP, Skinner E, Pummer K, Fradet Y, **Shariat SF**: Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy. *World J Urol.* 2011 Oct 19. PMID: 22009117
1426. Rink M, Chun FK, Robinson B, Sun M, Karakiewicz PI, Bensalah K, Fisch M, Scherr DS, Lee RK, Margulis V, **Shariat SF**: Tissue-based molecular markers for renal cell carcinoma. *Minerva Urol Nefrol.* 2011 Dec;63(4):293-308. PMID: 21996985
1427. Sun M, Abdollah F, **Shariat SF**, Schmitges J, Trinh QD, Tian Z, Jeldres C, Abdo A, Bianchi M, Briganti A, Montorsi F, Perrotte P, Karakiewicz PI : Propensity-score matched comparison of complications, blood transfusions, length of stay, and in-hospital mortality between open and laparoscopic partial nephrectomy: A national series. *Eur J Surg Oncol.* 2011 Oct 11. PMID: 21996370
1428. Putluri N, Shojaie A, Vasu VT, Vareed SK, Nalluri S, Putluri V, Thangjam GS, Panzitt K, Tallman CT, Butler C, Sana TR, Fischer SM, Sica G, Brat DJ, Shi H, Palapattu GS, Lotan Y, Weizer AZ, Terris MK, **Shariat SF**, Michailidis G, Sreekumar A: Metabolomic Profiling Reveals Potential Markers and Bioprocesses Altered in Bladder Cancer Progression. *Cancer Res.* 2011 Oct 11. PMID: 21990318
1429. Alkhateeb SS, Neill M, Bar-Moshe S, Rhijn BV, Kakiashvili DM, Fleshner N, Jewett M, Petein M, Schulman C, Hanna S, Bostrom PJ, Roumequere T, **Shariat SF**, Rorive S, Zlotta AR: Long-term

- prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin. *Urol Ann.* 2011 Sep;3(3):119-26. PMID:21976923
1430. Chromecki TF, Cha EK, Fajkovic H, Margulis V, Novara G, Scherr DS, Lotan Y, Raman JD, Kassouf W, Bensalah K, Weizer A, Kikuchi E, Roscigno M, Remzi M, Matsumoto K, Walton TJ, Pycha A, Ficarra V, Karakiewicz PI, Zigeuner R, Pummer K, **Shariat SF**: The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. *Eur Urol.* 2011 Sep 28. PMID: 21975249
1431. Abdollah F, Sun M, Schmitges J, Tian Z, Jeldres C, Briganti A, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI: Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large north american population-based cohort. *Eur Urol.* 2011 Nov;60(5):920-30. Epub 2011 Jun 29. PMID: 21741762
1432. Youssef RF, **Shariat SF**, Lotan Y, Wood CG, Sagalowsky AI, Zigeuner R, Kikuchi E, Weizer A, Raman JD, Remzi M, Kabbani W, Langner C, Guo CC, Roscigno M, Montorsi F, Bolenz C, Kassouf W, Margulis V. Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration. *BJU Int.* 2011 Oct;108(8):1286-1291. Epub 2011 Feb 18. PMID: 21332905
1433. Sun M, Abdollah F, Schmitges J, Bianchi M, Tian Z, **Shariat SF**, Zorn K, Pharand D, Widmer H, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI: Cytoreductive nephrectomy in the elderly: a population-based cohort from the USA. *BJU Int.* 2011 Sep 27. PMID: 21951647
1434. **Shariat SF**, Chromecki TF, Hofer J, Barbieri CE, Scherr DS, Karakiewicz PI, Roehrborn CG, Montorsi F, Culig Z, Cavarretta IT: Soluble gp130 regulates prostate cancer invasion and progression in an interleukin-6 dependent and independent manner. *J Urol.* 2011 Sep 22. PMID: 21944124
1435. Trinh QD, Schmitges J, Sun M, **Shariat SF**, Sukumar S, Bianchi M, Tian Z, Jeldres C, Sammon J, Perrotte P, Graefen M, Peabody JO, Menon M, Karakiewicz PI: Radical prostatectomy at academic versus nonacademic institutions: a population based analysis. *J Urol.* 2011 Sep 22. PMID: 21944081
1436. Auprich M, Augustin H, Budäus L, Kluth L, Mannweiler S, **Shariat SF**, Fisch M, Graefen M, Pummer K, Chun FK: A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. *BJU Int.* 2011 Sep 21. PMID: 21939492
1437. Cha EK, Tirsar LA, Schwentner C, Christos PJ, Mian C, Hennenlotter J, Martini T, Stenzl A, Pycha A, **Shariat SF**, Schmitz-Dräger BJ: Immunocytology is a strong predictor of bladder cancer presence in patients with painless hematuria: a multicentre study. *Eur Urol.* 2011 Sep 9. PMID: 21924544
1438. Lee R, Chughtai B, Herman M, **Shariat SF**, Scherr DS: Cost-analysis comparison of robot-assisted laparoscopic radical cystectomy (RC) vs open RC. *BJU Int.* 2011 Sep;108(6):976-83. PMID: 21917100
1439. Messer JC, Terrell JD, Herman MP, Ng CK, Scherr DS, Scoll B, Boorjian SA, Uzzo RG, Wille M, Eggener SE, Lucas SM, Lotan Y, **Shariat SF**, Raman JD: Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma. *Urol Oncol.* 2011 Sep 7. PMID: 21906967
1440. Trinh QD, Schmitges J, Sun M, Sammon J, **Shariat SF**, Sukumar S, Zorn K, Bianchi M, Jeldres C,

- Perrotte P, Graefen M, Rogers CG, Peabody JO, Menon M, Karakiewicz PI: Does partial nephrectomy at an academic institution result in better outcomes? *World J Urol.* 2011 Sep 9. PMID: 21904920
1441. Trinh QD, Schmitges J, Sun M, Sukumar S, Sammon J, **Shariat SF**, Jeldres C, Bianchi M, Tian Z, Perrotte P, Rogers CG, Graefen M, Peabody JO, Menon M, Karakiewicz PI: Improvement of racial disparities with respect to the utilization of minimally invasive radical prostatectomy in the United States. *Cancer.* 2011 Sep 6. doi: 10.1002/cncr.26527. PMID: 21898379
1442. Trinh QD, Schmitges J, Sun M, **Shariat SF**, Sukumar S, Tian Z, Bianchi M, Sammon J, Perrotte P, Rogers CG, Graefen M, Peabody JO, Menon M, Karakiewicz PI: Open radical prostatectomy in the elderly: a case for concern? *BJU Int.* 2011 Sep 6. PMID:21895940
1443. Abdo A, Trinh QD, Sun M, Schmitges J, Bianchi M, Sammon J, **Shariat SF**, Sukumar S, Zorn K, Jeldres C, Perrotte P, Rogers CG, Peabody JO, Menon M, Karakiewicz PI: The effect of insurance status on outcomes after partial nephrectomy. *Int Urol Nephrol.* 2011 Sep 6. PMID: 21894468
1444. Bianchi M, Sun M, Jeldres C, **Shariat SF**, Trinh QD, Briganti A, Tian Z, Schmitges J, Graefen M, Perrotte P, Menon M, Montorsi F, Karakiewicz PI: Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. *Ann Oncol.* 2011 Sep 2. PMID: 21890909
1445. Martinez-Salamanca JI, **Shariat SF**, Rodriguez JC, Chromecki TF, Ficarra V, Fritsche HM, Kassouf W, Matsumoto K, Cabello LO, Seitz C, Tritschler S, Walton TJ, Zattoni F, Novara G: Prognostic role of ECOG performance status in patients with urothelial carcinoma of the upper urinary tract: an international study. *BJU Int.* 2011 Aug 24. PMID: 21883847
1446. Abdollah F, Schmitges J, Sun M, **Shariat SF**, Briganti A, Abdo A, Tian Z, Perrotte P, Montorsi F, Karakiewicz PI: A population-based assessment of the National Comprehensive Cancer Network practice guideline indications for pelvic lymph node dissection at radical prostatectomy. *BJU Int.* 2011 Aug 22. PMID: 21880105
1447. Sun M, Abdollah F, Schmitges J, Jeldres C, **Shariat SF**, Perrotte P, Karakiewicz PI: Clinical experience and critical evaluation of the role of everolimus in advanced renal cell carcinoma. *Open Access Journal of Urology* April 2011 Volume 2011:3 Pages 43 - 48
1448. Sun M, Abdollah F, Bianchi M, Trinh QD, Jeldres C, Tian Z, **Shariat SF**, Widmer H, Zorn K, Menon M, Montorsi F, Perrotte P, Karakiewicz PI: A stage-for-stage and grade-for-grade analysis of cancer-specific mortality rates in renal cell carcinoma according to age: a competing-risks regression analysis. *Eur Urol.* 2011 Aug 5. PMID: 21868147
1449. Barbieri CE, Cha EK, Chromecki TF, Dunning A, Lotan Y, Svatek RS, Scherr DS, Karakiewicz PI, Sun M, Mazumdar M, **Shariat SF**: Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial. *BJU Int.* 2011. PMID: 21851550
1450. Abdollah F, Sun M, Schmitges J, Djahangirian O, Tian Z, Jeldres C, Perrotte P, **Shariat SF**, Montorsi F, Karakiewicz PI: Stage-specific impact of pelvic lymph node dissection on survival in patients with non-metastatic bladder cancer treated with radical cystectomy. *BJU Int.* 2011 Aug 24. PMID: 21883849
1451. Remzi M, **Shariat S**, Huebner W, Fajkovic H, Seitz C.: Upper urinary tract urothelial carcinoma: what have we learned in the last 4 years? *Ther Adv Urol.* 2011 Apr;3(2):69-80. PMID: 21869907
1452. Abdollah F, Sun M, Jeldres C, Schmitges J, Thuret R, Djahangirian O, Tian Z, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI: Survival after radical cystectomy of non-bilharzial squamous cell carcinoma vs urothelial carcinoma: a competing-risks analysis. *BJU Int.* 2011 Aug 2. PMID:

21810161

1453. Roscigno M, Brausi M, Heidenreich A, Lotan Y, Margulis V, **Shariat SF**, Van Poppel H, Zigeuner R: Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. *Eur Urol.* 2011 Jul 14. PMID: 21798659
1454. Abdollah F, Schmitges J, Sun M, Thuret R, Djahangirian O, Jeldres C, **Shariat SF**, Graefen M, Perrotte P, Montorsi F, Karakiewicz PI: Hospital and surgical caseload are predictors of comprehensive surgical treatment for bladder cancer: a population based study. *J Urol.* 2011 Jul 23. PMID:21788051
1455. Matsushita K, Cha EK, Matsumoto K, Baba S, Chromecki TF, Fajkovic H, Sun M, Karakiewicz PI, Scherr DS, **Shariat SF**: Immunohistochemical biomarkers for bladder cancer prognosis. *Int J Urol.* 2011 Jul 20. PMID: 21771101
1456. Sun M, **Shariat SF**, Cheng C, Ficarra V, Murai M, Oudard S, Pantuck AJ, Zigeuner R, Karakiewicz PI: Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. *Eur Urol.* 2011 Jun 30. PMID: 21741163
1457. **Shariat SF**, Patschan O, Chade DC, Karakiewicz PI, Ashfaq R, Lotan Y, Hotakainen K, Stenman UH, Bjartell A.: Association of tumor-associated trypsin inhibitor (TATI) expression with molecular markers, pathologic features and clinical outcomes of urothelial carcinoma of the urinary bladder. *World J Urol.* 2011 Jul 8. PMID: 21739120
1458. Chromecki TF, Bensalah K, Remzi M, Verhoest G, Cha EK, Scherr DS, Novara G, Karakiewicz PI, **Shariat SF**: Prognostic factors for upper urinary tract urothelial carcinoma. *Nat Rev Urol.* 2011 PMID: 21727942
1459. Jerónimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, Clark SJ, Henrique R, Nelson WG, **Shariat SF**: Epigenetics in prostate cancer: biologic and clinical relevance. *Eur Urol.* 2011 Jun 22. PMID: 21719191
1460. Youssef RF, **Shariat SF**, Lotan Y, Cost N, Wood CG, Sagalowsky AI, Zigeuner R, Langner C, Chromecki TF, Montorsi F, Bolenz C, Margulis V: Urothelial carcinoma at the uretero-enteric junction: Multi-center evaluation of oncologic outcomes after radical nephroureterectomy. *Urol Oncol.* 2011 Jun 23. PMID: 21704538
1461. Abdollah F, Sun M, Schmitges J, Thuret R, Djahangirian O, Jeldres C, Tian Z, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI: Development and validation of a reference table for prediction of postoperative mortality rate in patients treated with radical cystectomy: a population-based study. *Ann Surg Oncol.* 2011 Jun 24. PMID: 21701925
1462. **Shariat SF**, Savage C, Chromecki TF, Sun M, Scherr DS, Lee RK, Lughezzani G, Remzi M, Marberger MJ, Karakiewicz PI, Vickers AJ: Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with non muscle-invasive bladder cancer and negative cytology: A decision-curve analysis. *Cancer.* 2011 Jul 1;117(13):2892-7. PMID: 21692050
1463. Tilki D, Burger M, Dalbagni G, Grossman HB, Hakenberg OW, Palou J, Reich O, Rouprêt M, **Shariat SF**, Zlotta AR: Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. *Eur Urol.* 2011 Jun 12. PMID: 21684071
1464. Verhoest G, **Shariat SF**, Chromecki TF, Raman JD, Margulis V, Novara G, Seitz C, Remzi M, Rouprêt M, Scherr DS, Bensalah K: Predictive factors of recurrence and survival of upper tract urothelial carcinomas. *World J Urol.* 2011 Jun 17. PMID: 21681525
1465. Chromecki TF, Cha EK, **Shariat SF**: Stage pT0 after radical cystectomy: are all patients equal? *Eur Urol.* 2011 Jun 7. PMID: 21665358

1466. Nuhn P, Bastian PJ, Novara G, Svatek RS, Karakiewicz PI, Skinner E, Fradet Y, Izawa JI, Kassouf W, Montorsi F, Müller SC, Fritsche HM, Sonpavde G, Tilki D, Isbarn H, Ficarra V, Dinney CP, **Shariat SF**: Concomitant carcinoma in situ in cystectomy specimens is not associated with clinical outcomes after surgery. *Urol Int*. 2011 Jun 9. PMID: 21659717
1467. Fajkovic H, Halpern JA, Cha EK, Bahadori A, Chromecki TF, Karakiewicz PI, Breinl E, Merseburger AS, **Shariat SF**: Impact of gender on bladder cancer incidence, staging, and prognosis. *World J Urol*. 2011 Jun 9. PMID: 21656173
1468. Abdollah F, Sun M, Thuret R, Abdo A, Morgan M, Jeldres C, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI.: The effect of marital status on stage and survival of prostate cancer patients treated with radical prostatectomy: a population-based study. *Cancer Causes Control*. 2011 Jun 5. PMID: 21643929
1469. Cha EK, Ng CK, Jeun B, Dunning A, Reifsnnyder JE, Dipietro JR, Mazumdar M, Shih G, Auh YH, Del Pizzo JJ, **Shariat SF**, Scherr DS.: Preoperative radiographic parameters predict long-term renal impairment following partial nephrectomy. *World J Urol*. 2011 May 21. PMID: 21604019
1470. Favaretto RL, **Shariat SF**, Savage C, Godoy G, Chade DC, Kaag M, Bochner BH, Coleman J, Dalbagni G.: Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma. *BJU Int*. 2011 Jun 1. PMID:21631698
1471. **Shariat SF**, Semjonow A, Lilja H, Savage C, Vickers AJ, Bjartell A.: Tumor markers in prostate cancer I: blood-based markers. *Acta Oncol*. 2011 Jun;50 Suppl 1:61-75. PMID: 21604943
1472. Burger M, **Shariat SF**, Fritsche HM, Martinez-Salamanca JI, Matsumoto K, Chromecki TF, Ficarra V, Kassouf W, Seitz C, Pycha A, Tritschler S, Walton TJ, Novara G: No overt influence of lymphadenectomy on cancer-specific survival in organ-confined versus locally advanced upper urinary tract urothelial carcinoma undergoing radical nephroureterectomy: a retrospective international, multi-institutional study. *World J Urol*. 2011 Jun 1. PMID: 21630120
1473. Ehdaie B, Chromecki TF, Lee RK, Lotan Y, Margulis V, Karakiewicz PI, Novara G, Raman JD, Ng C, Lowrance WT, Scherr DS, **Shariat SF**: Obesity adversely impacts disease specific outcomes in patients with upper tract urothelial carcinoma. *J Urol*. 2011 May 13. PMID: 21571333
1474. Sun M, Abdollah F, Budaüs L, Liberman D, Tian Z, Morgan M, Johal R, Schmitges J, **Shariat SF**, Montorsi F, Greafe M, Perrotte P, Karakiewicz PI: Trends of retroperitoneal lymphadenectomy use in patients with nonseminomatous germ cell tumor of the testis: a population-based study. *Ann Surg Oncol*. 2011 Apr 21. PMID: 21509630
1475. Lee R, Ng CK, **Shariat SF**, Borkina A, Guimento R, Brumit KF, Scherr DS.: The economics of robotic cystectomy: cost comparison of open versus robotic cystectomy. *BJU Int*. 2011 Apr 18. PMID: 21501370
1476. Matsumoto K, Novara G, Gupta A, Margulis V, Walton TJ, Roscigno M, Ng C, Kikuchi E, Zigeuner R, Kassouf W, Fritsche HM, Ficarra V, Martignoni G, Tritschler S, Rodriguez JC, Seitz C, Weizer A, Remzi M, Raman JD, Bolenz C, Bensalah K, Koppie TM, Karakiewicz PI, Wood CG, Montorsi F, Iwamura M, **Shariat SF**: Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study. *BJU Int*. 2011 Apr 20. PMID: 21507184
1477. Abdollah F, Sun M, Briganti A, Thuret R, Schmitges J, Gallina A, Suardi N, Capitanio U, Salonia A, **Shariat SF**, Perrotte P, Rigatti P, Montorsi F, Karakiewicz PI.: Critical assessment of the European Association of Urology guideline indications for pelvic lymph node dissection at radical prostatectomy. *BJU Int*. 2011 Apr 20. PMID:21507189

1478. Chromecki TF, Ehdaie B, Novara G, Pummer K, Zigeuner R, Seitz C, Pycha A, Lee RK, Cha EK, Karakiewicz PI, Ng C, Raman JD, Chun FK, Fritsche HM, Matsumoto K, Kassouf W, Walton TJ, Bastian PJ, Martínez-Salamanca JI, Scherr DS, **Shariat SF**: Chronological age is not an independent predictor of clinical outcomes after radical nephroureterectomy. *World J Urol.* 2011 Apr 17.
1479. Abdollah F, Sun M, Thuret R, Schmitges J, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI: Mortality and morbidity after cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based study. *Ann Surg Oncol.* 2011 Apr 16.
1480. Abdollah F, Sun M, **Shariat SF**, Schmitges J, Djahangirian O, Tian Z, Jeldres C, Perrotte P, Montorsi F, Karakiewicz PI: The importance of pelvic lymph node dissection in the elderly population: implications for interpreting the 2010 National Comprehensive Cancer Network practice guidelines for bladder cancer treatment. *J Urol.* 2011 Apr 13.
1481. Abdollah F, Schmitges J, Sun M, Tian Z, Briganti A, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI: A critical assessment of the value of lymph node dissection at radical prostatectomy: A population-based study. *Prostate.* 2011 Apr 7. doi: 10.1002/pros.21376.
1482. Kassouf W, Svatek RS, **Shariat SF**, Novara G, Lerner SP, Fradet Y, Bastian PJ, Aprikian A, Karakiewicz PI, Fritsche HM, Dinney CP, Tilki D, Kamat AM, Izawa JI, Ficarra V, Lotan Y, Sagalowsky AI, Schoenberg MP, Skinner EC. Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. *Urol Oncol.* 2011 Apr 7. [Epub ahead of print]
1483. Zlotta AR, Roumeguere T, Kuk C, Alkhateeb S, Rorive S, Lemy A, van der Kwast TH, Fleshner NE, Jewett MA, Finelli A, Schulman C, Lotan Y, **Shariat SF**, Nortier J: Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer. *Eur Urol.* 2011 Mar 30. PMID: 21458152
1484. Chade DC, **Shariat SF**, Cronin AM, Savage CJ, Karnes RJ, Blute ML, Briganti A, Montorsi F, van der Poel HG, Van Poppel H, Joniau S, Godoy G, Hurtado-Coll A, Gleave ME, Dall'oglio M, Srougi M, Scardino PT, Eastham JA.: Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. *Eur Urol.* 2011 Mar 17. PMID: 21420229
1485. Gurbuz C, Youssef RF, **Shariat SF**, Lotan Y, Wood CG, Sagalowsky AI, Zigeuner R, Kikuchi E, Weizer A, Raman JD, Remzi M, Roscigno M, Montorsi F, Bolenz C, Kassouf W, Margulis V.: The impact of previous ureteroscopic tumor ablation on oncologic outcomes after radical nephroureterectomy for upper urinary tract urothelial carcinoma. *J Endourol.* 2011 Mar 9. PMID: 21388245
1486. Sun M, Abdollah F, Liberman D, Abdo A, Thuret R, Tian Z, **Shariat SF**, Montorsi F, Perrotte P, Karakiewicz PI.: Racial disparities and socioeconomic status in men diagnosed with testicular germ cell tumors: A survival analysis. *Cancer.* 2011 Mar 8. doi: 10.1002/cncr.25969. PMID: 21387261
1487. Thuret R, Sun M, Abdollah F, Schmitges J, **Shariat SF**, Iborra F, Guiter J, Patard JJ, Perrotte P, Karakiewicz PI.: Conditional survival predictions after surgery for patients with penile carcinoma. *Cancer.* 2011 Feb 24. PMID: 21360525
1488. Abdollah F, Sun M, Schmitges J, Thuret R, Djahangirian O, Jeldres C, Tian Z, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI. Surgical caseload is an important determinant of continent urinary diversion rate at radical cystectomy: a population-based study. *Ann Surg Oncol.* 2011 Feb 23. PMID: 21347778
1489. Sonpavde G, Khan MM, Svatek RS, Lee R, Novara G, Tilki D, Lerner SP, Amiel GE, Skinner E, Karakiewicz PI, Bastian PJ, Kassouf W, Fritsche HM, Izawa JI, Scherr DS, Ficarra V, Dinney CP,

- Lotan Y, Fradet Y, **Shariat SF**: Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. *J Urol*. 2011 Apr;185(4):1216-21. Epub 2011 Feb 22. PMID: 21334687
1490. Messer J, **Shariat SF**, Brien JC, Herman MP, Ng CK, Scherr DS, Scoll B, Uzzo RG, Wille M, Eggener SE, Steinberg G, Terrell JD, Lucas SM, Lotan Y, Boorjian SA, Raman JD. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. *BJU Int*. 2011 Feb 14. PMID: 21320275.
1491. Youssef R, **Shariat S**, Kapur P, Kabbani W, Mosbah A, Abol-Enein H, Ghoniem M, Lotan Y: Prognostic value of cyclooxygenase-2 expression in squamous cell carcinoma of the bladder. *J Urol*. 2011 Jan 20. PMID: 21255800.
1492. Liberman D, Lughezzani G, Sun M, Alasker A, Thuret R, Abdollah F, Budaus L, Widmer H, Graefen M, Montorsi F, **Shariat SF**, Perrotte P, Karakiewicz PI: Perioperative mortality is significantly greater in septuagenarian and octogenarian patients treated with radical cystectomy for urothelial carcinoma of the bladder. *Urology*. 2011 Jan 20. PMID: 21256568.
1493. Otto W, **Shariat SF**, Fritsche HM, Gupta A, Matsumoto K, Kassouf W, Martignoni G, Walton TJ, Tritschler S, Baba S, Bastian PJ, Martínez-Salamanca JI, Seitz C, Pycha A, Burger M, Karakiewicz PI, Ficarra V, Novara G: Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial carcinoma: a multicenter analysis of 772 patients. *World J Urol*. 2011 Jan 20. PMID: 21249372.
1494. Svatek RS, **Shariat SF**, Novara G, Skinner EC, Fradet Y, Bastian PJ, Kamat AM, Kassouf W, Karakiewicz PI, Fritsche HM, Izawa JI, Tilki D, Ficarra V, Volkmer BG, Isbarn H, Dinney CP: Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. *BJU Int*. 2011 Jan 18. PMID: 21244604.
1495. Mazzola CR, Ghoneim T, **Shariat SF**: [Emerging biomarkers for the diagnosis, staging and prognosis of prostate cancer]. *Prog Urol*. 2011 Jan;21(1):1-10. Epub 2010 Aug 14. French. PMID: 21193139
1496. Youssef RF, **Shariat SF**, Lotan Y, Wood CG, Sagalowsky AI, Zigeuner R, Langner C, Montorsi F, Bolenz C, Margulis V.: Prognostic Effect of Urinary Bladder Carcinoma In Situ on Clinical Outcome of Subsequent Upper Tract Urothelial Carcinoma. *Urology*. 2010 Dec 15. PMID: 21167566
1497. Sonpavde G, Khan MM, Lerner SP, Svatek RS, Novara G, Karakiewicz PI, Skinner E, Tilki D, Kassouf W, Fradet Y, Dinney CP, Fritsche HM, Izawa JI, Bastian PJ, Ficarra V, Schoenberg M, Sagalowsky AI, Lotan Y, **Shariat SF**.: Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. *J Urol*. 2010 Dec 16. PMID: 21167527
1498. Thuret R, Sun M, Abdollah F, Budaus L, Lughezzani G, Liberman D, Morgan M, Johal R, Jeldres C, Latour M, **Shariat SF**, Iborra F, Guiter J, Patard JJ, Perrotte P, Karakiewicz PI.: Tumor grade improves the prognostic ability of American Joint Committee on cancer stage in patients with penile carcinoma. *J Urol*. 2010 Dec 16. PMID: 21167526
1499. Ahallal Y, **Shariat SF**, Chade DC, Mazzola C, Reuter VE, Sandhu JS, Laudone VP, Touijer KA, Guillonneau BD.: Pilot study of salvage laparoscopic prostatectomy for the treatment of recurrent prostate cancer. *BJU Int*. 2010 Dec 16. PMID: 21166755
1500. Budäus L, Abdollah F, Sun M, Johal R, Morgan M, Thuret R, Zorn KC, Lughezzani G, Isbarn H, Haese A, **Shariat SF**, Montorsi F, Perrotte P, Graefen M, Karakiewicz PI.: The impact of surgical

- experience on total hospital charges for minimally invasive prostatectomy: a population-based study. *BJU Int.* 2010 Dec 13. PMID: 21156018
1501. Sfakianos J, **Shariat SF**, Favaretto RL, Rioja J, Herr HW: Impact of smoking on outcomes after intravesical Bacillus Calmette-Guérin therapy for urothelial carcinoma not invading muscle of the bladder. *BJU Int.* 2010 Nov 29. PMID: 2111461
1502. Youssef RF, **Shariat SF**, Kapur P, Kabbani W, Ghoneim T, King E, Cockburn A, Mosbah A, Abol-Enein H, Ghoneim M, Lotan Y. Expression of cell cycle-related molecular markers in patients treated with radical cystectomy for squamous cell carcinoma of the bladder. *Hum Pathol.* 2010 Nov 25. PMID: 2111452.
1503. Sun M, Abdo A, Abdollah F, Schmitges J, Thuret R, Jeldres C, **Shariat SF**, Perrotte P, Karakiewicz PI. Management of upper urinary tract urothelial carcinoma. *Expert Rev Anticancer Ther.* 2010 Dec; PMID: 21110761.
1504. Youssef R, Kapur P, Kabbani W, **Shariat SF**, Mosbah A, Abol-Enein H, Ghoniem M, Lotan Y. Bilharzial vs non-bilharzial related bladder cancer: pathological characteristics and value of cyclooxygenase-2 expression. *BJU Int.* 2010 Nov 24. PMID: 21105986.
1505. Lowrance WT, Tarin TV, **Shariat SF**. Evidence-based comparison of robotic and open radical prostatectomy. *Scientific World Journal.* 2010 Nov 16; PMID: 21103791.
1506. Sonpavde G, Khan MM, Svatek RS, Lee R, Novara G, Tilki D, Lerner SP, Amiel GE, Skinner E, Karakiewicz PI, Bastian PJ, Kassouf W, Fritsche HM, Izawa JI, Ficarra V, Dinney CP, Lotan Y, Fradet Y, **Shariat SF**. Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. *BJU Int.* 2010 Nov 19. PMID: 21087453.
1507. Walton TJ, Novara G, Matsumoto K, Kassouf W, Fritsche HM, Artibani W, Bastian PJ, Martínez-Salamanca JI, Seitz C, Thomas SA, Ficarra V, Burger M, Tritschler S, Karakiewicz PI, **Shariat SF**. Oncological outcomes after laparoscopic and open radical nephroureterectomy: results from an international cohort. *BJU Int.* 2010 Nov 15. PMID: 21078048.
1508. Mir C, **Shariat SF**, Van Der Kwast TH, Ashfaq R, Lotan Y, Evans A, Skeldon S, Hanna S, Vajpeyi R, Kuk C, Alkhateeb S, Morote J, Van Rhijn BW, Bostrom P, Yao J, Miyamoto H, Jewett M, Fleshner N, Messing E, Zlotta AR. Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. *BJU Int.* 2010 Nov 10. PMID: 21070579.
1509. Yee DS, **Shariat SF**, Lowrance WT, Maschino AC, Savage CJ, Cronin AM, Scardino PT, Eastham JA. Prognostic significance of lymphovascular invasion in radical prostatectomy specimens. *BJU Int.* 2010 Nov 2. PMID: 21050364.
1510. Sun M, Thuret R, Abdollah F, Lughezzani G, Schmitges J, Tian Z, **Shariat SF**, Montorsi F, Patard JJ, Perrotte P, Karakiewicz PI. Age-Adjusted Incidence, Mortality, and Survival Rates of Stage-Specific Renal Cell Carcinoma in North America: A Trend Analysis. *Eur Urol.* 2010 Oct 27. PMID: 21035250.
1511. Abdollah F, Sun M, Thuret R, Jeldres C, Tian Z, Briganti A, **Shariat SF**, Perrotte P, Rigatti P, Montorsi F, Karakiewicz PI. A Competing-Risks Analysis of Survival After Alternative Treatment Modalities for Prostate Cancer Patients: 1988-2006. *Eur Urol.* 2010 Oct 14. PMID: 20965646.
1512. Budäus L, Sun M, Abdollah F, Zorn KC, Morgan M, Johal R, Liberman D, Thuret R, Isbarn H, Salomon G, Haese A, Montorsi F, **Shariat SF**, Perrotte P, Graefen M, Karakiewicz PI. Impact of Surgical Experience on In-Hospital Complication Rates in Patients Undergoing Minimally Invasive Prostatectomy: A Population-Based Study. *Ann Surg Oncol.* 2010 Oct 16. PMID: 20953720.

1513. Budäus L, Abdollah F, Sun M, Morgan M, Johal R, Thuret R, Zorn KC, Isbarn H, **Shariat SF**, Montorsi F, Perrotte P, Graefen M, Karakiewicz PI. Annual surgical caseload and open radical prostatectomy outcomes: improving temporal trends. *J Urol*. 2010 Dec; Epub 2010 Oct 16. PMID: 20952010.
1514. Barbieri CE, Lotan Y, Lee RK, Sonpavde G, Karakiewicz PI, Robinson B, Scherr DS, **Shariat SF**. Tissue-based molecular markers for bladder cancer. *Minerva Urol Nefrol*. 2010 Sep; PMID: 20940694.
1515. Fritsche HM, Novara G, Burger M, Gupta A, Matsumoto K, Kassouf W, Sircar K, Zattoni F, Walton T, Tritschler S, Baba S, Bastian PJ, Martínez-Salamanca JI, Seitz C, Otto W, Wieland WF, Karakiewicz PI, Ficarra V, Hartmann A, **Shariat SF**. Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma. *Urol Oncol*. 2010 Oct 6. PMID: 20933445.
1516. Crépel M, Jeldres C, Sun M, Lughezzani G, Isbarn H, Alasker A, Capitanio U, **Shariat SF**, Arjane P, Widmer H, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. A population-based comparison of cancer-control rates between radical and partial nephrectomy for T1A renal cell carcinoma. *Urology*. 2010 Oct; PMID: 20932408.
1517. **Shariat SF**, Favaretto RL, Gupta A, Fritsche HM, Matsumoto K, Kassouf W, Walton TJ, Tritschler S, Baba S, Matsushita K, Bastian PJ, Martínez-Salamanca JI, Seitz C, Pycha A, Otto W, Karakiewicz PI, Ficarra V, Novara G. Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. *World J Urol*. 2010 Oct 1. PMID: 20886219.
1518. Chun FK, Epstein JI, Ficarra V, Freedland SJ, Montironi R, Montorsi F, **Shariat SF**, Schröder FH, Scattoni V. Optimizing Performance and Interpretation of Prostate Biopsy: A Critical Analysis of the Literature. *Eur Urol*. 2010 Sep 4. PMID: 20884114.
1519. Liberman D, Alasker A, Sun M, Ismail S, Lughezzani G, Jeldres C, Budaus L, Thuret R, **Shariat SF**, Widmer H, Perrotte P, Graefen M, Montorsi F, Karakiewicz PI. Radical cystectomy for patients with pT4 urothelial carcinoma in a large population-based study. *BJU Int*. 2010 Sep 22. PMID: 20860649.
1520. Seitz C, Gupta A, **Shariat SF**, Matsumoto K, Kassouf W, Walton TJ, Fritsche HM, Otto W, Tritschler S, Bastian PJ, Carballido J, Ficarra V, Karakiewicz PI, Artibani W, Mazzoleni G, Novara G. Association of tumor necrosis with pathological features and clinical outcome in 754 patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma: an international validation study. *J Urol*. 2010 Nov; Epub 2010 Sep 17. PMID: 20846680.
1521. Thuret R, Sun M, Lughezzani G, Budaus L, Liberman D, Abdollah F, Morgan M, Johal R, Jeldres C, Latour M, **Shariat SF**, Iborra F, Guiter J, Patard JJ, Perrotte P, Karakiewicz PI. A Contemporary Population-Based Assessment of the Rate of Lymph Node Dissection for Penile Carcinoma. *Ann Surg Oncol*. 2010 Sep 14. PMID: 20839061.
1522. Lughezzani G, Sun M, **Shariat SF**, Budäus L, Thuret R, Jeldres C, Liberman D, Montorsi F, Perrotte P, Karakiewicz PI. A population-based competing-risks analysis of the survival of patients treated with radical cystectomy for bladder cancer. *Cancer*. 2010 Aug 27. PMID: 20803606.
1523. Lughezzani G, Briganti A, Karakiewicz PI, Kattan MW, Montorsi F, **Shariat SF**, Vickers AJ. Predictive and Prognostic Models in Radical Prostatectomy Candidates: A Critical Analysis of the Literature. *Eur Urol*. 2010 Aug 6. PMID: 20727668.
1524. Favaretto RL, **Shariat SF**, Chade DC, Godoy G, Kaag M, Cronin AM, Bochner BH, Coleman J, Dalbagni G. Comparison between laparoscopic and open radical nephroureterectomy in a

- contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique? *Eur Urol.* 2010 Aug 11. PMID: 20724065.
1525. Svatek RS, **Shariat SF**, Lasky RE, Skinner EC, Novara G, Lerner SP, Fradet Y, Bastian PJ, Kassouf W, Karakiewicz PI, Fritsche HM, Müller SC, Izawa JI, Ficarra V, Sagalowsky AI, Schoenberg MP, Siefker-Radtke AO, Millikan RE, Dinney CP. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. *Clin Cancer Res.* 2010 Sep 1;16(17):4461-7. Epub 2010 Jul 22. PMID: 20651056.
1526. Tilki D, Svatek RS, Novara G, Seitz M, Godoy G, Karakiewicz PI, Kassouf W, Fradet Y, Fritsche HM, Sonpavde G, Izawa JI, Ficarra V, Lerner SP, Schoenberg M, Stief CG, Dinney CP, Skinner E, Lotan Y, Sagalowsky AI, Reich O, **Shariat SF**. Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients. *J Urol.* 2010 Sep; Erratum in: *J Urol.* 2010 Nov; PMID: 20643448.
1527. Favaretto RL, **Shariat SF**, Chade DC, Godoy G, Adamy A, Kaag M, Bochner BH, Coleman J, Dalbagni G. The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. *Eur Urol.* 2010 Oct; Epub 2010 Jul 9. PMID: 20637540.
1528. **Shariat SF**, Chade DC, Karakiewicz PI, Scherr DS, Dalbagni G. Update on intravesical agents for non-muscle-invasive bladder cancer. *Immunotherapy.* 2010 May; Review. PMID: 20635902.
1529. Tilki D, Svatek RS, Karakiewicz PI, Novara G, Seitz M, Sonpavde G, Gupta A, Kassouf W, Fradet Y, Ficarra V, Skinner E, Lotan Y, Sagalowsky AI, Stief CG, Reich O, **Shariat SF**. pT3 Substaging is a prognostic indicator for lymph node negative urothelial carcinoma of the bladder. *J Urol.* 2010 Aug; Epub 2010 Jun 17. PMID: 20620401.
1530. Chade DC, **Shariat SF**, Adamy A, Bochner BH, Donat SM, Herr HW, Dalbagni G. Clinical outcome of primary versus secondary bladder carcinoma in situ. *J Urol.* 2010 Aug; Epub 2010 Jun 17. PMID: 20620399.
1531. Margulis V, Youssef RF, Karakiewicz PI, Lotan Y, Wood CG, Zigeuner R, Kikuchi E, Weizer A, Raman JD, Remzi M, Roscigno M, Montorsi F, Bolenz C, Kassouf W, **Shariat SF**; Upper Tract Urothelial Carcinoma Collaborative Group. Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. *J Urol.* 2010 Aug; Epub 2010 Jun 17. PMID: 20620397.
1532. Lotan Y, **Shariat SF**, Schmitz-Dräger BJ, Sanchez-Carbayo M, Jankevicius F, Racioppi M, Minner SJ, Stöhr B, Bassi PF, Grossman HB. Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. *Urol Oncol.* 2010 Jul-Aug; PMID: 20610281.
1533. **Shariat SF**, Lotan Y, Vickers A, Karakiewicz PI, Schmitz-Dräger BJ, Goebell PJ, Malats N. Statistical consideration for clinical biomarker research in bladder cancer. *Urol Oncol.* 2010 Jul-Aug; Review. PMID: 20610277.
1534. Sun M, **Shariat SF**, Karakiewicz PI. Factors affecting outcome in renal cell carcinoma. *Curr Opin Urol.* 2010 Sep; Review. PMID: 20592610.
1535. Jeldres C, Sun M, Lughezzani G, Isbarn H, **Shariat SF**, Widmer H, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Highly predictive survival nomogram after upper urinary tract urothelial carcinoma. *Cancer.* 2010 Aug 5; PMID: 20564085.
1536. Chade DC, **Shariat SF**, Godoy G, Savage CJ, Cronin AM, Bochner BH, Donat SM, Herr HW, Dalbagni G. Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. *J Urol.* 2010 Jul; PMID: 20546806.

1537. Brien JC, **Shariat SF**, Herman MP, Ng CK, Scherr DS, Scoll B, Uzzo RG, Wille M, Eggener SE, Terrell JD, Lucas SM, Lotan Y, Boorjian SA, Raman JD. Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. *J Urol*. 2010 Jul; Epub 2010 May 15. PMID: 20478585.
1538. Bigot P, Bernhard JC, Crepel M, Bensalah K, Azzouzi AR, de la Taille A, Salomon L, Tostain J, Ficarra V, Pantuck AJ, Beldegrun AS, Méjean A, Ferrière JM, Pfister C, Albouy B, Colombel M, Zini L, Villers A, Montorsi F, **Shariat S**, Rioux-Leclercq N, Patard JJ. [How radical nephrectomy compares to partial nephrectomy for the treatment of pT1a papillary renal cell carcinomas?]. *Prog Urol*. 2010 May; Epub 2010 Mar 29. French. PMID: 20471579.
1539. Wheat JC, Weizer AZ, Wolf JS Jr, Lotan Y, Remzi M, Margulis V, Wood CG, Montorsi F, Roscigno M, Kikuchi E, Zigeuner R, Langner C, Bolenz C, Koppie TM, Raman JD, Fernández M, Karakiewicz P, Capitanio U, Bensalah K, Patard JJ, **Shariat SF**. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy. *Urol Oncol*. 2010 May 5. PMID: 20451416.
1540. Novara G, Svatek RS, Karakiewicz PI, Skinner E, Ficarra V, Fradet Y, Lotan Y, Isbarn H, Capitanio U, Bastian PJ, Kassouf W, Fritsche HM, Izawa JI, Tilki D, Dinney CP, Lerner SP, Schoenberg M, Volkmer BG, Sagalowsky AI, **Shariat SF**. Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. *J Urol*. 2010 Jun; PMID: 20399473.
1541. **Shariat SF**, Tilki D. Bladder cancer: Nomogram aids clinical decision making after radical cystectomy. *Nat Rev Urol*. 2010 Apr; PMID: 20383183.
1542. Tilki D, Reich O, Svatek RS, Karakiewicz PI, Kassouf W, Novara G, Ficarra V, Chade DC, Fritsche HM, Gerwens N, Izawa JI, Lerner SP, Schoenberg M, Stief CG, Skinner E, Lotan Y, Sagalowsky AI, **Shariat SF**. Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients. *J Urol*. 2010 May; Epub 2010 Mar 17. PMID: 20299059.
1543. **Shariat SF**, Youssef RF, Gupta A, Chade DC, Karakiewicz PI, Isbarn H, Jeldres C, Sagalowsky AI, Ashfaq R, Lotan Y. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. *J Urol*. 2010 May; Epub 2010 Mar 17. PMID: 20299037.
1544. Yee DS, **Shariat SF**, Lowrance WT, Sterbis JR, Vora KC, Bochner BH, Donat SM, Herr HW, Dalbagni G, Sandhu JS. Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer. *J Urol*. 2010 May; Epub 2010 Mar 17. PMID: 20299035.
1545. Lughezzani G, Sun M, Budäus L, Thuret R, **Shariat SF**, Perrotte P, Karakiewicz PI. Effect of the number of biopsy cores on prostate cancer detection and staging. *Future Oncol*. 2010 Mar; Review. PMID: 20222795.
1546. Jeldres C, Lughezzani G, Sun M, Isbarn H, **Shariat SF**, Budaus L, Lattouf JB, Widmer H, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Segmental ureterectomy can safely be performed in patients with transitional cell carcinoma of the ureter. *J Urol*. 2010 Apr; Epub 2010 Feb 19. PMID: 20171666.
1547. **Shariat SF**, Svatek RS, Tilki D, Skinner E, Karakiewicz PI, Capitanio U, Bastian PJ, Volkmer BG, Kassouf W, Novara G, Fritsche HM, Izawa JI, Ficarra V, Lerner SP, Sagalowsky AI, Schoenberg MP, Kamat AM, Dinney CP, Lotan Y, Marberger MJ, Fradet Y. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. *BJU Int*. 2010 May; Epub 2010 Feb 2. PMID: 20132195.

1548. Bhojani N, Capitanio U, Suardi N, Jeldres C, Isbarn H, **Shariat SF**, Graefen M, Arjane P, Duclos A, Lattouf JB, Saad F, Valiquette L, Montorsi F, Perrotte P, Karakiewicz PI. The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients. *Int J Radiat Oncol Biol Phys*. 2010 Feb 1; PMID: 20117287.
1549. Tilki D, Reich O, Karakiewicz PI, Novara G, Kassouf W, Ergün S, Fradet Y, Ficarra V, Sonpavde G, Stief CG, Skinner E, Svatek RS, Lotan Y, Sagalowsky AI, **Shariat SF**. Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome. *Eur Urol*. 2010 Jul; Epub 2010 Jan 20. PMID: 20097469.
1550. Bolenz C, **Shariat SF**, Karakiewicz PI, Ashfaq R, Ho R, Sagalowsky AI, Lotan Y. Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. *BJU Int*. 2010 Jan 19. PMID: 20089105.
1551. Baillargeon-Gagné S, Jeldres C, Lughezzani G, Sun M, Isbarn H, Capitanio U, **Shariat SF**, Crépel M, Alasker A, Widmer H, Arjane P, Patard JJ, Perrotte P, Montorsi F, Graefen M, Karakiewicz PI. A comparative population-based analysis of the rate of partial vs radical nephrectomy for clinically localized renal cell carcinoma. *BJU Int*. 2010 Feb; PMID: 20089096.
1552. Sun M, Lughezzani G, Alasker A, Isbarn H, Jeldres C, **Shariat SF**, Budäus L, Lattouf JB, Valiquette L, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Comparative study of inguinal hernia repair after radical prostatectomy, prostate biopsy, transurethral resection of the prostate or pelvic lymph node dissection. *J Urol*. 2010 Mar; Epub 2010 Jan 18. PMID: 20083257.
1553. Novara G, Matsumoto K, Kassouf W, Walton TJ, Fritsche HM, Bastian PJ, Martínez-Salamanca JI, Seitz C, Lemberger RJ, Burger M, El-Hakim A, Baba S, Martignoni G, Gupta A, Karakiewicz PI, Ficarra V, **Shariat SF**. Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. *Eur Urol*. 2010 Jun; Epub 2010 Jan 6. PMID: 20071073.
1554. Raman JD, **Shariat SF**, Karakiewicz PI, Lotan Y, Sagalowsky AI, Roscigno M, Montorsi F, Bolenz C, Weizer AZ, Wheat JC, Ng CK, Scherr DS, Remzi M, Waldert M, Wood CG, Margulis V; for the Upper-Tract Urothelial Carcinoma Collaborative Group. Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy? *Urol Oncol*. 2010 Jan 5. PMID: 20056458.
1555. Lughezzani G, Sun M, Perrotte P, Jeldres C, Alasker A, Isbarn H, Budäus L, **Shariat SF**, Guazzoni G, Montorsi F, Karakiewicz PI. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. *Eur J Cancer*. 2010 Mar; Epub 2010 Jan 13. PMID: 20044246.
1556. Chade DC, **Shariat SF**, Dalbagni G. Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review. *Int Braz J Urol*. 2009 Nov-Dec; discussion 651. PMID: 20028569.
1557. Lughezzani G, Sun M, Jeldres C, Alasker A, Budäus L, **Shariat SF**, Latour M, Widmer H, Duclos A, Jolivet-Tremblay M, Montorsi F, Perrotte P, Karakiewicz PI. Adenocarcinoma versus urothelial carcinoma of the urinary bladder: comparison between pathologic stage at radical cystectomy and cancer-specific mortality. *Urology*. 2010 Feb; PMID: 20022091.
1558. Lughezzani G, Sun M, Perrotte P, **Shariat SF**, Jeldres C, Budaus L, Alasker A, Duclos A, Widmer H, Latour M, Guazzoni G, Montorsi F, Karakiewicz PI. Should bladder cuff excision remain the standard of care at nephroureterectomy in patients with urothelial carcinoma of the renal pelvis? A population-based study. *Eur Urol*. 2010 Jun; Epub 2009 Dec 10. PMID: 20018438.

1559. Zaak D, Burger M, Otto W, Bastian PJ, Denzinger S, Stief CG, Buchner H, Hartmann A, Wieland WF, **Shariat SF**, Fritsche HM. Predicting individual outcomes after radical cystectomy: an external validation of current nomograms. *BJU Int.* 2010 Aug; Epub 2009 Dec 11. PMID: 20002664.
1560. **Shariat SF**, Kattan MW, Vickers AJ, Karakiewicz PI, Scardino PT. Critical review of prostate cancer predictive tools. *Future Oncol.* 2009 Dec; Review. PMID: 20001796.
1561. Jeldres C, Sun M, Isbarn H, Lughezzani G, Budäus L, Alasker A, **Shariat SF**, Lattouf JB, Widmer H, Pharand D, Arjane P, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. A population-based assessment of perioperative mortality after nephroureterectomy for upper-tract urothelial carcinoma. *Urology.* 2010 Feb; Epub 2009 Dec 6. PMID: 19963237.
1562. Crépel M, Jeldres C, Perrotte P, Capitanio U, Isbarn H, **Shariat SF**, Liberman D, Sun M, Lughezzani G, Arjane P, Widmer H, Graefen M, Montorsi F, Patard JJ, Karakiewicz PI. Nephron-sparing surgery is equally effective to radical nephrectomy for T1bN0M0 renal cell carcinoma: a population-based assessment. *Urology.* 2010 Feb; Epub 2009 Dec 4. PMID: 19962740.
1563. Lughezzani G, Sun M, Perrotte P, **Shariat SF**, Jeldres C, Budäus L, Latour M, Widmer H, Duclos A, Bénard F, McCormack M, Montorsi F, Karakiewicz PI. Gender-related differences in patients with stage I to III upper tract urothelial carcinoma: results from the Surveillance, Epidemiology, and End Results database. *Urology.* 2010 Feb; Epub 2009 Dec 4. PMID: 19962727.
1564. Zigeuner R, **Shariat SF**, Margulis V, Karakiewicz PI, Roscigno M, Weizer A, Kikuchi E, Remzi M, Raman JD, Bolenz C, Bensalah K, Capitanio U, Koppie TM, Kassouf W, Sircar K, Patard JJ, Fernández MI, Wood CG, Montorsi F, Ströbel P, Wheat JC, Haitel A, Oya M, Guo CC, Ng C, Chade DC, Sagalowsky A, Langner C. Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. *Eur Urol.* 2010 Apr; Epub 2009 Nov 25. PMID: 19959276.
1565. Tilki D, Svatek RS, Karakiewicz PI, Isbarn H, Reich O, Kassouf W, Fradet Y, Novara G, Fritsche HM, Bastian PJ, Izawa JI, Stief CG, Ficarra V, Lerner SP, Schoenberg M, Dinney CP, Skinner E, Lotan Y, Sagalowsky AI, **Shariat SF**. Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. *J Urol.* 2010 Jan; Epub PubMed PMID: 19942232.
1566. **Shariat SF**, Chade DC, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Montorsi F, Lerner SP, Sagalowsky AI, Cote RJ, Lotan Y. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. *J Urol.* 2010 Jan; Epub. PMID: 19913255.
1567. **Shariat SF**, Godoy G, Lotan Y, Droller M, Karakiewicz PI, Raman JD, Isbarn H, Weizer A, Remzi M, Roscigno M, Kikuchi E, Bolenz C, Bensalah K, Koppie TM, Kassouf W, Wheat JC, Zigeuner R, Langner C, Wood CG, Margulis V. Advanced patient age is associated with inferior cancer-specific survival after radical nephroureterectomy. *BJU Int.* 2010 Jun; Epub 2009 Nov 13. PMID: 19912201.
1568. **Shariat SF**, Sfakianos JP, Droller MJ, Karakiewicz PI, Meryn S, Bochner BH. The effect of age and gender on bladder cancer: a critical review of the literature. *BJU Int.* 2010 Feb;105(3):300-8. Epub 2009 Nov 13. Review. PMID: 19912200.
1569. **Shariat SF**, Karakiewicz PI, Godoy G, Karam JA, Ashfaq R, Fradet Y, Isbarn H, Montorsi F, Jeldres C, Bastian PJ, Nielsen ME, Müller SC, Sagalowsky AI, Lotan Y. Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. *Clin Cancer Res.* 2009 Nov 15; Epub 2009 Nov 10. PMID: 19903782.

1570. Roscigno M, **Shariat SF**, Freschi M, Margulis V, Karakiewicz P, Suardi N, Remzi M, Zigeuner R, Bolenz C, Kikuchi E, Weizer A, Bensalah K, Sagalowsky A, Koppie TM, Raman J, Fernández M, Ströbel P, Kabbani W, Langner C, Wheat J, Guo CC, Kassouf W, Haitel A, Wood CG, Montorsi F. Assessment of the minimum number of lymph nodes needed to detect lymph node invasion at radical nephroureterectomy in patients with upper tract urothelial cancer. *Urology*. 2009 Nov; PMID: 19883824.
1571. **Shariat SF**, Milowsky M, Droller MJ. Bladder cancer in the elderly. *Urol Oncol*. 2009 Nov-Dec; Review. PMID: 19879476.
1572. Lughezzani G, Jeldres C, Isbarn H, **Shariat SF**, Sun M, Pharand D, Widmer H, Arjane P, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma. *Urology*. 2010 Jan; Epub 2009 Oct 28. PMID: 19864000.
1573. Karakiewicz PI, Suardi N, Capitanio U, Isbarn H, Jeldres C, Perrotte P, Sun M, Ficarra V, Zigeuner R, Tostain J, Mejean A, Cindolo L, Pantuck AJ, Belldegrun AS, Zini L, de la Taille A, Chautard D, Descotes JL, **Shariat SF**, Valeri A, Mulders PF, Lang H, Lechevallier E, Patard JJ. Conditional survival predictions after nephrectomy for renal cell carcinoma. *J Urol*. 2009 Dec; Epub 2009 Oct 17. PMID: 19836798.
1574. Jeldres C, Cardinal H, Duclos A, **Shariat SF**, Suardi N, Capitanio U, Hébert MJ, Karakiewicz PI. Prediction of delayed graft function after renal transplantation. *Can Urol Assoc J*. 2009 Oct; PMID: 19829730.
1575. Lughezzani G, Capitanio U, Jeldres C, Isbarn H, **Shariat SF**, Arjane P, Widmer H, Perrotte P, Montorsi F, Karakiewicz PI. Prognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma: a population-based perspective. *Cancer*. 2009 Dec 15; PMID: 19824083.
1576. Isbarn H, Patard JJ, Lughezzani G, Rioux-Leclercq N, Crépel M, Cindolo L, de la Taille A, Zini L, Villers A, **Shariat SF**, Bertini R, Karakiewicz PI. Limited prognostic value of tumor necrosis in patients with renal cell carcinoma. *Urology*. 2010 Jun; Epub 2009 Sep 25. PMID: 19781745.
1577. Fritsche HM, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G, Skinner E, Denzinger S, Fradet Y, Isbarn H, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Tilki D, Otto W, Capitanio U, Izawa JI, Ficarra V, Lerner S, Sagalowsky AI, Schoenberg M, Kamat A, Dinney CP, Lotan Y, **Shariat SF**. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. *Eur Urol*. 2010 Feb; Epub 2009 Sep 12. PMID: 19766384.
1578. Isbarn H, Jeldres C, **Shariat SF**, Liberman D, Sun M, Lughezzani G, Widmer H, Arjane P, Pharand D, Fisch M, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma. *J Urol*. 2009 Nov; Epub 2009 Sep 16. PMID: 19758662.
1579. **Shariat SF**, Zimmern PE, Hilton K, Gruchalla RS. Prospective questionnaire-based evaluation of the prevalence of urinary incontinence in women with chronic cough. *Urol Int*. 2009; Epub 2009 Sep 10. PMID: 19752614.
1580. Nuss GR, Morey AF, Jenkins AC, Pruitt JH, Dugi DD 3rd, Morse B, **Shariat SF**. Radiographic predictors of need for angiographic embolization after traumatic renal injury. *J Trauma*. 2009 Sep; discussion 582. PMID: 19741403.

1581. Waldert M, Karakiewicz PI, Raman JD, Remzi M, Isbarn H, Lotan Y, Capitanio U, Bensalah K, Marberger MJ, **Shariat SF**. A delay in radical nephroureterectomy can lead to upstaging. *BJU Int*. 2010 Mar; Epub 2009 Sep 3. PMID: 19732052.
1582. Lughezzani G, Jeldres C, Isbarn H, Sun M, **Shariat SF**, Widmer H, Arjane P, Graefen M, Perrotte P, Montorsi F, Karakiewicz PI. Temporal stage and grade migration in surgically treated patients with upper tract urothelial carcinoma. *BJU Int*. 2010 Mar; Epub 2009 Sep 2. PMID: 19725824.
1583. Lughezzani G, Jeldres C, Isbarn H, Perrotte P, **Shariat SF**, Sun M, Widmer H, Arjane P, Peloquin F, Pharand D, Patard JJ, Graefen M, Montorsi F, Karakiewicz PI. Tumor size is a determinant of the rate of stage T1 renal cell cancer synchronous metastasis. *J Urol*. 2009 Oct; Epub 2009 Aug 14. PMID: 19683281.
1584. **Shariat SF**, Bolenz C, Karakiewicz PI, Fradet Y, Ashfaq R, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Rigaud J, Müller SC, Lerner SP, Montorsi F, Sagalowsky AI, Cote RJ, Lotan Y. p53 expression in patients with advanced urothelial cancer of the urinary bladder. *BJU Int*. 2010 Feb; Epub 2009 Jul 31. PMID: 19659466.
1585. Crépel M, Isbarn H, Capitanio U, Liberman D, Jeldres C, Sun M, **Shariat SF**, Widmer H, Arjane P, Graefen M, Montorsi F, Patard JJ, Perrotte P, Karakiewicz PI. Does histologic subtype affect oncologic outcomes after nephron-sparing surgery? *Urology*. 2009 Oct; Epub 2009 Jul 22. PMID: 19628262.
1586. Capitanio U, Isbarn H, **Shariat SF**, Jeldres C, Zini L, Saad F, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Partial cystectomy does not undermine cancer control in appropriately selected patients with urothelial carcinoma of the bladder: a population-based matched analysis. *Urology*. 2009 Oct; Epub 2009 Jul 22. PMID: 19628260.
1587. Raman JD, Ng CK, Scherr DS, Margulis V, Lotan Y, Bensalah K, Patard JJ, Kikuchi E, Montorsi F, Zigeuner R, Weizer A, Bolenz C, Koppie TM, Isbarn H, Jeldres C, Kabbani W, Remzi M, Waldert M, Wood CG, Roscigno M, Oya M, Langner C, Wolf JS, Ströbel P, Fernández M, Karakiewicz P, **Shariat SF**. Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. *Eur Urol*. 2010 Jun; Epub 2009 Jul 15. PMID: 19619934.
1588. Jeldres C, Baillargeon-Gagne S, Liberman D, Isbarn H, Capitanio U, **Shariat SF**, Sun M, Lughezzani G, Perrotte P, Montorsi F, Graefen M, Karakiewicz PI. A population-based analysis of the rate of cytoreductive nephrectomy for metastatic renal cell carcinoma in the United States. *Urology*. 2009 Oct; Epub 2009 Jul 18. PMID: 19616828.
1589. **Shariat SF**, Lotan Y, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Montorsi F, Müller SC, Karam JA, Heukamp LC, Netto G, Lerner SP, Sagalowsky AI, Cote RJ. p53 predictive value for pT1-2 N0 disease at radical cystectomy. *J Urol*. 2009 Sep; Epub 2009 Jul 17. PMID: 19616250.
1590. Hellenthal NJ, **Shariat SF**, Margulis V, Karakiewicz PI, Roscigno M, Bolenz C, Remzi M, Weizer A, Zigeuner R, Bensalah K, Ng CK, Raman JD, Kikuchi E, Montorsi F, Oya M, Wood CG, Fernandez M, Evans CP, Koppie TM. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. *J Urol*. 2009 Sep; Epub 2009 Jul 17. PMID: 19616245.
1591. Lughezzani G, Jeldres C, Isbarn H, Sun M, **Shariat SF**, Alasker A, Pharand D, Widmer H, Arjane P, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients. *Eur J Cancer*. 2009 Dec; Epub 2009 Jul 15. PMID: 19615885.

1592. Bolenz C, Lotan Y, Ashfaq R, **Shariat SF**. Estrogen and progesterone hormonal receptor expression in urothelial carcinoma of the bladder. *Eur Urol*. 2009 Dec; Epub 2009 Jul 7. PMID: 19596509.
1593. Isbarn H, Jeldres C, Capitanio U, Zini L, **Shariat SF**, Lughezzani G, Sun M, Ahyai SA, Duclos A, Jolivet-Tremblay M, Lattouf JB, Valiquette L, Perrotte P, Montorsi F, Graefen M, Karakiewicz PI. Thirty-day mortality after transurethral resection of the prostate in patients treated with androgen deprivation therapy. *J Endourol*. 2009 Aug; PMID: 19591615.
1594. Sun M, Lughezzani G, Jeldres C, Isbarn H, **Shariat SF**, Arjane P, Widmer H, Pharand D, Latour M, Perrotte P, Patard JJ, Karakiewicz PI. A proposal for reclassification of the Fuhrman grading system in patients with clear cell renal cell carcinoma. *Eur Urol*. 2009 Nov; Epub 2009 Jun 21. PMID: 19573980.
1595. Roscigno M, **Shariat SF**, Margulis V, Karakiewicz P, Remzi M, Kikuchi E, Zigeuner R, Weizer A, Sagalowsky A, Bensalah K, Raman JD, Bolenz C, Kassou W, Koppie TM, Wood CG, Wheat J, Langner C, Ng CK, Capitanio U, Bertini R, Fernández MI, Mikami S, Isida M, Ströbel P, Montorsi F. The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed? *Eur Urol*. 2009 Sep; Epub 2009 Jun 18. PMID: 19559518.
1596. Jeldres C, Isbarn H, Capitanio U, Zini L, Bhojani N, **Shariat SF**, Cloutier V, Lattouf JB, Duclos A, Jolivet-Tremblay M, Valiquette L, Saad F, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Development and external validation of a highly accurate nomogram for the prediction of perioperative mortality after transurethral resection of the prostate for benign prostatic hyperplasia. *J Urol*. 2009 Aug; Epub 2009 Jun 17. PMID: 19535100.
1597. Isbarn H, Karakiewicz PI, **Shariat SF**, Capitanio U, Palapattu GS, Sagalowsky AI, Lotan Y, Schoenberg MP, Amiel GE, Lerner SP, Sonpavde G. Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer. *J Urol*. 2009 Aug; discussion 465. Epub 2009 Jun 13. PMID: 19524971.
1598. Capitanio U, Jeldres C, Perrotte P, Isbarn H, Crépel M, Cloutier V, Baillargeon-Gagne S, **Shariat SF**, Duclos A, Arjane P, Widmer H, Saad F, Montorsi F, Karakiewicz PI. Population-based study of perioperative mortality after retroperitoneal lymphadenectomy for nonseminomatous testicular germ cell tumors. *Urology*. 2009 Aug; Epub 2009 Jun 7. PMID: 19501893.
1599. Zini L, Capitanio U, Jeldres C, Lughezzani G, Sun M, **Shariat SF**, Isbarn H, Arjane P, Widmer H, Perrotte P, Graefen M, Montorsi F, Karakiewicz PI. External validation of a nomogram predicting mortality in patients with adrenocortical carcinoma. *BJU Int*. 2009 Dec; Epub 2009 Jun 2. PMID: 19493261.
1600. Tilki D, Singer BB, **Shariat SF**, Behrend A, Fernando M, Irmak S, Buchner A, Hooper AT, Stief CG, Reich O, Ergün S. CEACAM1: a novel urinary marker for bladder cancer detection. *Eur Urol*. 2010 Apr; Epub 2009 May 28. PMID: 19487071.
1601. Isbarn H, Jeldres C, Zini L, Perrotte P, Baillargeon-Gagne S, Capitanio U, **Shariat SF**, Arjane P, Saad F, McCormack M, Valiquette L, Peloquin F, Duclos A, Montorsi F, Graefen M, Karakiewicz PI. A population based assessment of perioperative mortality after cystectomy for bladder cancer. *J Urol*. 2009 Jul; Epub 2009 May 17. PMID: 19447427.
1602. **Shariat SF**, Bolenz C, Godoy G, Fradet Y, Ashfaq R, Karakiewicz PI, Isbarn H, Jeldres C, Rigaud J, Sagalowsky AI, Lotan Y. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. *J Urol*. 2009 Jul; discussion 84. Epub 2009 May 17. PMID: 19447418.

1603. Capitanio U, Perrotte P, Zini L, Jeldres C, **Shariat SF**, Isbarn H, Arjane P, Peloquin F, Pharand D, Montorsi F, Karakiewicz PI. Nephrectomy improves survival in patients with invasion of adjacent viscera and absence of nodal metastases (stage T4N0 renal cell carcinoma). *BJU Int*. 2009 Sep; Epub 2009 Apr 15. PMID: 19389018.
1604. Capitanio U, Perrotte P, Zini L, Suardi N, Antebi E, Cloutier V, Jeldres C, **Shariat SF**, Duclos A, Arjane P, Saad F, Montorsi F, Karakiewicz PI. Population-based analysis of normal total PSA and percentage of free/total PSA values: results from screening cohort. *Urology*. 2009 Jun; Epub 2009 Apr 18. PMID: 19376563.
1605. Roscigno M, **Shariat SF**, Margulis V, Karakiewicz P, Remzi M, Kikuchi E, Langner C, Lotan Y, Weizer A, Bensalah K, Raman JD, Bolenz C, Guo CC, Wood CG, Zigeuner R, Wheat J, Kabbani W, Koppie TM, Ng CK, Suardi N, Bertini R, Fernández MI, Mikami S, Isida M, Michel MS, Montorsi F. Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. *J Urol*. 2009 Jun; Epub 2009 Apr 16. PMID: 19371878.
1606. Capitanio U, **Shariat SF**, Isbarn H, Weizer A, Remzi M, Roscigno M, Kikuchi E, Raman JD, Bolenz C, Bensalah K, Koppie TM, Kassouf W, Fernández MI, Ströbel P, Wheat J, Zigeuner R, Langner C, Waldert M, Oya M, Guo CC, Ng C, Montorsi F, Wood CG, Margulis V, Karakiewicz PI. Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. *Eur Urol*. 2009 Jul; Epub 2009 Apr 3. PMID: 19361911.
1607. Lotan Y, Capitanio U, **Shariat SF**, Hutterer GC, Karakiewicz PI. Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection. *BJU Int*. 2009 May; Epub 2009 Mar 11. Erratum in: *BJU Int*. 2010 Apr; PMID: 19338566.
1608. Svatek RS, Jeldres C, Karakiewicz PI, Suardi N, Walz J, Roehrborn CG, Montorsi F, Slawin KM, **Shariat SF**. Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. *Prostate*. 2009 Jun 1; PMID: 19229851.
1609. Zini L, Perrotte P, Capitanio U, Jeldres C, **Shariat SF**, Antebi E, Saad F, Patard JJ, Montorsi F, Karakiewicz PI. Radical versus partial nephrectomy: effect on overall and noncancer mortality. *Cancer*. 2009 Apr 1; PMID: 19195042.
1610. Zini L, Cloutier V, Isbarn H, Perrotte P, Capitanio U, Jeldres C, **Shariat SF**, Saad F, Arjane P, Duclos A, Lattouf JB, Montorsi F, Karakiewicz PI. A simple and accurate model for prediction of cancer-specific mortality in patients treated with surgery for primary penile squamous cell carcinoma. *Clin Cancer Res*. 2009 Feb 1; PMID: 19188173.
1611. Margulis V, **Shariat SF**, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD, Wood CG; Upper Tract Urothelial Carcinoma Collaboration The Upper Tract Urothelial Carcinoma Collaboration. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. *Cancer*. 2009 Mar 15; PMID: 19156917.
1612. **Shariat SF**, Roehrborn CG. Using biopsy to detect prostate cancer. *Rev Urol*. 2008 Fall; PMID: 19145270.
1613. Margulis V, Lotan Y, Karakiewicz PI, Fradet Y, Ashfaq R, Capitanio U, Montorsi F, Bastian PJ, Nielsen ME, Müller SC, Rigaud J, Heukamp LC, Netto G, Lerner SP, Sagalowsky AI, **Shariat SF**. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. *J Natl Cancer Inst*. 2009 Jan 21; Epub 2009 Jan 13. PMID: 19141773.
1614. Ng CK, **Shariat SF**, Lucas SM, Bagrodia A, Lotan Y, Scherr DS, Raman JD. Does the presence of hydronephrosis on preoperative axial CT imaging predict worse outcomes for patients undergoing

- nephroureterectomy for upper-tract urothelial carcinoma? *Urol Oncol*. 2008 Dec 29. PMID: 19117771.
1615. Capitanio U, Cloutier V, Zini L, Isbarn H, Jeldres C, **Shariat SF**, Perrotte P, Antebi E, Patard JJ, Montorsi F, Karakiewicz PI. A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study. *BJU Int*. 2009 Jun; Epub 2008 Dec 8. PMID: 19076149.
1616. Capitanio U, Suardi N, **Shariat SF**, Lotan Y, Palapattu GS, Bastian PJ, Gupta A, Vazina A, Schoenberg M, Lerner SP, Sagalowsky AI, Karakiewicz PI. Assessing the minimum number of lymph nodes needed at radical cystectomy in patients with bladder cancer. *BJU Int*. 2009 May; Epub 2008 Dec 8. PMID: 19076140.
1617. Kikuchi E, Margulis V, Karakiewicz PI, Roscigno M, Mikami S, Lotan Y, Remzi M, Bolenz C, Langner C, Weizer A, Montorsi F, Bensalah K, Koppie TM, Fernández MI, Raman JD, Kassouf W, Wood CG, Suardi N, Oya M, **Shariat SF**. Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. *J Clin Oncol*. 2009 Feb 1; Epub 2008 Dec 15. PMID: 19075275.
1618. Cloutier V, Capitanio U, Zini L, Perrotte P, Jeldres C, **Shariat SF**, Arjane P, Patard JJ, Montorsi F, Karakiewicz PI. Thirty-day mortality after nephrectomy: clinical implications for informed consent. *Eur Urol*. 2009 Dec; Epub 2008 Nov 25. PMID: 19054604.
1619. Capitanio U, Perrotte P, Hutterer GC, Suardi N, Jeldres C, **Shariat SF**, Duclos A, Arjane P, Montorsi F, Karakiewicz PI. Effect of body mass index on prostate-specific antigen and percentage free prostate-specific antigen: results from a prostate cancer screening cohort of 1490 men. *Int J Urol*. 2009 Jan; Epub 2008 Nov 27. PMID: 19054167.
1620. **Shariat SF**, Scardino PT, Lilja H. Screening for prostate cancer: an update. *Can J Urol*. 2008 Dec; Review. PMID: 19046489.
1621. Zini L, Capitanio U, Perrotte P, Jeldres C, **Shariat SF**, Arjane P, Widmer H, Montorsi F, Patard JJ, Karakiewicz PI. Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. *Urology*. 2009 Feb; Epub 2008 Nov 28. PMID: 19041122.
1622. Salonia A, Briganti A, Gallina A, Karakiewicz P, **Shariat S**, Freschi M, Zanni G, Capitanio U, Bosi E, Rigatti P, Montorsi F. Sex hormone-binding globulin: a novel marker for nodal metastases prediction in prostate cancer patients undergoing extended pelvic lymph node dissection. *Urology*. 2009 Apr; Epub 2008 Nov 26. PMID: 19038425.
1623. Karam JA, **Shariat SF**, Hsieh JT, Knowles MA. Genomics: a preview of genomic medicine. *BJU Int*. 2008 Nov;102(9 Pt B):1221-7. PMID: 19035885.
1624. Gupta A, Karakiewicz PI, Roehrborn CG, Lotan Y, Zlotta AR, **Shariat SF**. Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer. *Clin Cancer Res*. 2008 Nov 15; PMID: 19010854.
1625. Bhojani N, Salomon L, Capitanio U, Suardi N, **Shariat SF**, Jeldres C, Zini L, Pharand D, Péloquin F, Arjane P, Abbou CC, De La Taille A, Montorsi F, Karakiewicz PI. External validation of the updated partin tables in a cohort of French and Italian men. *Int J Radiat Oncol Biol Phys*. 2009 Feb 1; Epub 2008 Nov 10. PMID: 19004573.
1626. Bolenz C, **Shariat SF**, Fernández MI, Margulis V, Lotan Y, Karakiewicz P, Remzi M, Kikuchi E, Zigeuner R, Weizer A, Montorsi F, Bensalah K, Wood CG, Roscigno M, Langner C, Koppie TM, Raman JD, Mikami S, Michel MS, Ströbel P. Risk stratification of patients with nodal involvement

- in upper tract urothelial carcinoma: value of lymph-node density. *BJU Int.* 2009 Feb; Epub 2008 Oct 16. PMID: 18990164.
1627. Remzi M, Haitel A, Margulis V, Karakiewicz P, Montorsi F, Kikuchi E, Zigeuner R, Weizer A, Bolenz C, Bensalah K, Suardi N, Raman JD, Lotan Y, Waldert M, Ng CK, Fernández M, Koppie TM, Ströbel P, Kabbani W, Murai M, Langner C, Roscigno M, Wheat J, Guo CC, Wood CG, **Shariat SF**. Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. *BJU Int.* 2009 Feb; Epub 2008 Oct 16. Erratum in: *BJU Int.* 2009 Aug; Karakiewicz, Pierre [corrected to Karakiewicz, Pierre]. PMID: 18990163.
1628. **Shariat SF**, Capitanio U, Jeldres C, Karakiewicz PI. Can nomograms be superior to other prediction tools? *BJU Int.* 2009 Feb; Epub 2008 Sep 18. PMID: 18990135.
1629. Zorn KC, Capitanio U, Jeldres C, Arjane P, Perrotte P, **Shariat SF**, Lee DI, Shalhav AL, Zagaja GP, Shikanov SA, Gofrit ON, Thong AE, Albala DM, Sun L, Karakiewicz PI. Multi-institutional external validation of seminal vesicle invasion nomograms: head-to-head comparison of Gallina nomogram versus 2007 Partin tables. *Int J Radiat Oncol Biol Phys.* 2009 Apr 1; Epub 2008 Oct 19. PMID: 18938046.
1630. Svatek RS, Lotan Y, Karakiewicz PI, **Shariat SF**. Screening for bladder cancer using urine-based tumor markers. *Minerva Urol Nefrol.* 2008 Dec; Review. PMID: 18923361.
1631. Herman MP, Svatek RS, Lotan Y, Karakiewicz PI, **Shariat SF**. Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer. *Minerva Urol Nefrol.* 2008 Dec; Review. PMID: 18923359.
1632. Fernández MI, **Shariat SF**, Margulis V, Bolenz C, Montorsi F, Suardi N, Remzi M, Wood CG, Roscigno M, Kikuchi E, Oya M, Zigeuner R, Langner C, Weizer A, Lotan Y, Koppie TM, Raman JD, Karakiewicz P, Bensalah K, Schultz M, Bernier P. Evidence-based sex-related outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: results of large multicenter study. *Urology.* 2009 Jan; Epub 2008 Oct 8. Erratum in: *Urology.* 2010 May; Karakiewicz, Pierre [corrected to Karakiewicz, Pierre]. PMID: 18845322.
1633. **Shariat SF**, Karakiewicz PI, Roehrborn CG, Kattan MW. An updated catalog of prostate cancer predictive tools. *Cancer.* 2008 Dec 1; Review. PMID: 18823041.
1634. Capitanio U, Zini L, Perrotte P, **Shariat SF**, Jeldres C, Arjane P, Pharand D, Widmer H, Péloquin F, Montorsi F, Patard JJ, Karakiewicz PI. Cyto-reductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study. *Urology.* 2008 Nov; Epub 2008 Sep 16. PMID: 18799207.
1635. Bhojani N, Ahyai S, Graefen M, Capitanio U, Suardi N, **Shariat SF**, Jeldres C, Erbersdobler A, Schlomm T, Haese A, Steuber T, Heinzer H, Montorsi F, Huland H, Karakiewicz PI. Partin Tables cannot accurately predict the pathological stage at radical prostatectomy. *Eur J Surg Oncol.* 2009 Feb; Epub 2008 Sep 10. PMID: 18786800.
1636. Raman JD, Ng CK, **Shariat SF**, Margulis V, Montorsi F, Karakiewicz P; Upper-Tract Urothelial Carcinoma Collaboration. Outcomes for patients with pT0 disease after radical nephroureterectomy for upper-tract urothelial carcinoma. *BJU Int.* 2009 Jan; Epub 2008 Aug 18. PMID: 18717670.
1637. Capitanio U, Briganti A, **Shariat SF**, Karakiewicz PI. The importance of the quantification of the extent of cancer in prostatic biopsies in prediction of biochemical recurrence: a global perspective. *Eur Urol.* 2008 Oct; Epub 2008 Jul 21. PMID: 18703272.

1638. Capitanio U, Ahyai S, Graefen M, Jeldres C, **Shariat SF**, Erbersdobler A, Schlomm T, Haese A, Steuber T, Heinzer H, Perrotte P, Pélouquin F, Pharand D, Arjane P, Huland H, Karakiewicz PI. Assessment of biochemical recurrence rate in patients with pathologically confirmed insignificant prostate cancer. *Urology*. 2008 Dec; Epub 2008 Aug 9. PMID: 18692880.
1639. **Shariat SF**, Karam JA, Lotan Y, Karakiewicz PI. Critical evaluation of urinary markers for bladder cancer detection and monitoring. *Rev Urol*. 2008 Spring; PMID: 18660854.
1640. Karakiewicz PI, Bhojani N, Capitanio U, Reuther AM, Suardi N, Jeldres C, Pharand D, Pélouquin F, Perrotte P, **Shariat SF**, Klein EA. External validation of the updated Partin tables in a cohort of North American men. *J Urol*. 2008 Sep; Epub 2008 Jul 17. PMID: 18635222.
1641. **Shariat SF**, Karakiewicz PI, Suardi N, Kattan MW. Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature. *Clin Cancer Res*. 2008 Jul 15; Review. PMID: 18628454.
1642. Gupta A, Lotan Y, Ashfaq R, Roehrborn CG, Raj GV, Aragaki CC, Montorsi F, **Shariat SF**. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. *Eur Urol*. 2009 May; Epub 2008 Jun 23. PMID: 18585843.
1643. **Shariat SF**, Karam JA, Walz J, Roehrborn CG, Montorsi F, Margulis V, Saad F, Slawin KM, Karakiewicz PI. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. *Clin Cancer Res*. 2008 Jun 15; PMID: 18559597.
1644. **Shariat SF**, Trinh QD, Morey AF, Stage KH, Roehrborn CG, Valiquette L, Karakiewicz PI. Development of a highly accurate nomogram for prediction of the need for exploration in patients with renal trauma. *J Trauma*. 2008 Jun; PMID: 18545108.
1645. Svatek RS, Karam JA, Roehrborn CG, Karakiewicz PI, Slawin KM, **Shariat SF**. Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy. *Clin Cancer Res*. 2008 Jun 1. PMID: 18519764.
1646. Capitanio U, Jeldres C, **Shariat SF**, Karakiewicz P. Clinicians are most familiar with nomograms and rate their clinical usefulness highest, look-up tables are second best. *Eur Urol*. 2008 Oct; Epub 2008 May 8. PMID: 18485579.
1647. Karam JA, Margulis V, Montorsi F, Karakiewicz PI, Lotan Y, Kikuchi E, Weizer A, Zigeuner R, Bolenz C, **Shariat SF**. Carcinoma in situ of the upper urinary tract treated with radical nephroureterectomy-results from a multicenter study. *Eur Urol*. 2008 Oct; Epub 2008 May 8. PMID: 18485573.
1648. Jeldres C, Suardi N, Capitanio U, Montorsi F, **Shariat SF**, Perrotte P, Pélouquin F, Pharand D, Graefen M, Karakiewicz PI. High surgical volume is associated with a lower rate of secondary therapy after radical prostatectomy for localized prostate cancer. *BJU Int*. 2008 Aug; Epub 2008 May 12. PMID: 18476966.
1649. Gallina A, Suardi N, Montorsi F, Capitanio U, Jeldres C, Saad F, Graefen M, **Shariat SF**, Widmer H, Arjane P, Pélouquin F, Perrotte P, Karakiewicz PI. Mortality at 120 days after prostatic biopsy: a population-based study of 22,175 men. *Int J Cancer*. 2008 Aug 1. PMID: 18470914.
1650. Walz J, **Shariat SF**, Suardi N, Perrotte P, Lotan Y, Palapattu GS, Gupta A, Bastian PJ, Rogers CG, Vazina A, Amiel GE, Sagalowsky AI, Schoenberg M, Lerner SP, Karakiewicz PI. Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study. *BJU Int*. 2008 Jun; PMID: 18454792.

1651. **Shariat SF**, Jenkins A, Roehrborn CG, Karam JA, Stage KH, Karakiewicz PI. Features and outcomes of patients with grade IV renal injury. *BJU Int.* 2008 Sep; Epub 2008 Apr 24. PMID: 18435808.
1652. Lotan Y, Bensalah K, Ruddell T, **Shariat SF**, Sagalowsky AI, Ashfaq R. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. *J Urol.* 2008 Jun; Epub 2008 Apr 18. PMID: 18423745.
1653. Gallina A, Chun FK, Suardi N, Eastham JA, Perrotte P, Graefen M, Hutterer G, Huland H, Klein EA, Reuther A, Montorsi F, Briganti A, **Shariat SF**, Roehrborn CG, de la Taille A, Salomon L, Karakiewicz PI. Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer. *BJU Int.* 2008 Jun; Epub 2008 Apr 16. PMID: 18422773.
1654. Walz J, Suardi N, **Shariat SF**, Jeldres C, Perrotte P, Graefen M, Widmer H, Arjane P, Valiquette L, Hutterer G, Saad F, Karakiewicz PI. Accuracy of life tables in predicting overall survival in patients after radical prostatectomy. *BJU Int.* 2008 Jul; Epub 2008 Apr 2. PMID: 18384631.
1655. **Shariat SF**, Karakiewicz PI, Margulis V, Kattan MW. Inventory of prostate cancer predictive tools. *Curr Opin Urol.* 2008 May; Review. PMID: 18382238.
1656. **Shariat SF**, Karam JA, Raman JD. Urine cytology and urine-based markers for bladder urothelial carcinoma detection and monitoring: developments and future prospects. *Biomark Med.* 2008 Apr; PMID: 20477438.
1657. Karakiewicz PI, Bhojani N, Neugut A, **Shariat SF**, Jeldres C, Graefen M, Perrotte P, Peloquin F, Kattan MW. The effect of comorbidity and socioeconomic status on sexual and urinary function and on general health-related quality of life in men treated with radical prostatectomy for localized prostate cancer. *J Sex Med.* 2008 Apr; PMID: 18371045.
1658. Bhojani N, Perrotte P, Hutterer G, Suardi N, Jeldres C, **Shariat SF**, Capitanio U, Arjane P, Widmer H, Benard F, Peloquin F, Montorsi F, Karakiewicz P. Body mass index and its association with genitourinary disorders in men undergoing prostate cancer screening. *J Sex Med.* 2008 Sep; Epub 2008 Mar 19. PMID: 18355173.
1659. **Shariat SF**, Walz J, Roehrborn CG, Zlotta AR, Perrotte P, Suardi N, Saad F, Karakiewicz PI. External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy. *J Clin Oncol.* 2008 Mar 20; PMID: 18349404.
1660. **Shariat SF**, Margulis V, Karakiewicz PI. Rebuttal from authors re: James W.F. Catto. More nomograms or better evidence of efficacy: what do we need in urologic oncology? *Eur Urol.* 2008 Jul; Epub 2008 Mar 4. PMID: 18329787.
1661. Margulis V, Lotan Y, Montorsi F, **Shariat SF**. Predicting survival after radical cystectomy for bladder cancer. *BJU Int.* 2008 Jul; Epub 2008 Mar 5. Review. PMID: 18325050.
1662. Walz J, Montorsi F, Jeldres C, Suardi N, **Shariat SF**, Perrotte P, Arjane P, Graefen M, Pharand D, Karakiewicz PI. The effect of surgical volume, age and comorbidities on 30-day mortality after radical prostatectomy: a population-based analysis of 9208 consecutive cases. *BJU Int.* 2008 Apr. PMID: 18321316.
1663. Karam JA, Svatek RS, Karakiewicz PI, Gallina A, Roehrborn CG, Slawin KM, **Shariat SF**. Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer. *Clin Cancer Res.* 2008 Mar 1; PMID: 18316564.

1664. Gupta A, Lotan Y, Bastian PJ, Palapattu GS, Karakiewicz PI, Raj GV, Schoenberg MP, Lerner SP, Sagalowsky AI, **Shariat SF**; Bladder Cancer Research Consortium. Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. *Urology*. 2008 Feb; PMID: 18308108.
1665. **Shariat SF**, Walz J, Roehrborn CG, Montorsi F, Jeldres C, Saad F, Karakiewicz PI. Early postoperative plasma transforming growth factor-beta1 is a strong predictor of biochemical progression after radical prostatectomy. *J Urol*. 2008 Apr; Epub 2008 Mar 4. PMID: 18295256.
1666. Lotan Y, **Shariat SF**; NMP22 Study Group. Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection. *BJU Int*. 2008 Jun; Epub 2008 Feb 18. PMID: 18284410.
1667. Karakiewicz PI, Capitanio U, **Shariat S**. Prostate growth and prevalence of prostate diseases in early onset spinal cord injuries. *Eur Urol*. 2009 Jul; Epub 2008 Feb 8. PMID: 18280634.
1668. Bensalah K, Traxer O, **Shariat SF**, Zimmern P. [What are the differences between American and French urologists?]. *Prog Urol*. 2007 Nov; French. PMID: 18271424.
1669. **Shariat SF**, Karakiewicz PI. Perspectives on prostate cancer biomarkers. *Eur Urol*. 2008 Jul; Epub 2008 Feb 4. PMID: 18262336.
1670. Hutterer GC, Karakiewicz PI, Zippe C, Lüdecke G, Boman H, Sanchez-Carbayo M, Casella R, Mian C, Friedrich MG, Eissa S, Akaza H, Serretta V, Hedelin H, Rupesh R, Miyanaga N, Sagalowsky AI, Perrotte P, Lotan Y, Marberger MJ, **Shariat SF**. Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma. *BJU Int*. 2008 Mar. PMID: 18257856.
1671. **Shariat SF**. Selecting patients for immediate cystectomy. *Rev Urol*. 2007 Fall. PMID: 18231621.
1672. **Shariat SF**, Lamb DJ, Iyengar RG, Roehrborn CG, Slawin KM. Herbal/hormonal dietary supplement possibly associated with prostate cancer progression. *Clin Cancer Res*. 2008 Jan 15. PMID: 18223237.
1673. Bhojani N, Perrotte P, Jeldres C, Suardi N, Hutterer G, **Shariat SF**, Karakiewicz PI. The effect of comorbidities and socioeconomic status on sexual and urinary function in men undergoing prostate cancer screening. *J Sex Med*. 2008 Mar; Epub 2008 Jan 21. PMID: 18221289.
1674. **Shariat SF**, Margulis V, Lotan Y, Montorsi F, Karakiewicz PI. Nomograms for bladder cancer. *Eur Urol*. 2008 Jul; Epub 2008 Jan 15. Review. PMID: 18207314.
1675. **Shariat SF**, Karam JA, Lerner SP. Molecular markers in bladder cancer. *Curr Opin Urol*. 2008 Jan; Review. PMID: 18090481.
1676. **Shariat SF**, Karakiewicz PI. Screening for prostate cancer in 2007: the PSA era and its challenges are not over. *Eur Urol*. 2008 Mar; Epub 2007 Dec 7. PMID: 18079050.
1677. Svatek RS, Karam J, Karakiewicz PI, Gallina A, Casella R, Roehrborn CG, **Shariat SF**. Role of urinary cathepsin B and L in the detection of bladder urothelial cell carcinoma. *J Urol*. 2008 Feb; PMID: 18076936.
1678. **Shariat SF**, Ashfaq R, Sagalowsky AI, Lotan Y. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. *Urol Oncol*. 2007 Nov-Dec; PMID: 18047954.
1679. **Shariat SF**, Karakiewicz PI, Ashfaq R, Lerner SP, Palapattu GS, Cote RJ, Sagalowsky AI, Lotan Y. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. *Cancer*. 2008 Jan 15; PMID: 18008359.

1680. Bensalah K, Lotan Y, Karam JA, **Shariat SF**. New circulating biomarkers for prostate cancer. *Prostate Cancer Prostatic Dis.* 2008; Epub 2007 Nov 13. Review. PMID: 17998918.
1681. Jeldres C, Suardi N, Saad F, Montorsi F, **Shariat SF**, Perrotte P, Bhojani N, Walz J, Hutterer GC, Graefen M, Valiquette L, Karakiewicz PI. High provider volume is associated with lower rate of secondary therapies after definitive radiotherapy for localized prostate cancer. *Eur Urol.* 2008 Jul; Epub 2007 Nov 6. PMID: 17997022.
1682. Briganti A, Chun FK, Suardi N, Gallina A, Walz J, Graefen M, **Shariat S**, Ebersdobler A, Rigatti P, Perrotte P, Saad F, Montorsi F, Huland H, Karakiewicz PI. Prostate volume and adverse prostate cancer features: fact not artifact. *Eur J Cancer.* 2007 Dec; Epub 2007 Nov 8. PMID: 17996442.
1683. Jeldres C, Suardi N, Walz J, Saad F, Hutterer GC, Bhojani N, **Shariat SF**, Perrotte P, Graefen M, Montorsi F, Karakiewicz PI. Poor overall survival in septa- and octogenarian patients after radical prostatectomy and radiotherapy for prostate cancer: a population-based study of 6183 men. *Eur Urol.* 2008 Jul; Epub 2007 Oct 30. PMID: 17996358.
1684. Walz J, Gallina A, Perrotte P, Jeldres C, Trinh QD, Hutterer GC, Traumann M, Ramirez A, **Shariat SF**, McCormack M, Perreault JP, Bénard F, Valiquette L, Saad F, Karakiewicz PI. Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. *BJU Int.* 2007 Dec; PMID: 17979925.
1685. Margulis V, Lotan Y, **Shariat SF**. Survivin: a promising biomarker for detection and prognosis of bladder cancer. *World J Urol.* 2008 Feb; Epub 2007 Oct 26. Review. PMID: 17962949.
1686. **Shariat SF**, Karam JA, Margulis V, Karakiewicz PI. New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer. *BJU Int.* 2008 Mar; Epub 2007 Oct 17. Review. PMID: 17941930.
1687. Bensalah K, Montorsi F, **Shariat SF**. Challenges of cancer biomarker profiling. *Eur Urol.* 2007 Dec; 2007 Oct 1. Review. PMID: 17919807.
1688. Karam JA, Lotan Y, Ashfaq R, Sagalowsky AI, **Shariat SF**. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. *Urology.* 2007 Sep; PMID: 17905101.
1689. **Shariat SF**, Bensalah K, Karam JA, Roehrborn CG, Gallina A, Lotan Y, Slawin KM, Karakiewicz PI. Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer. *Clin Cancer Res.* 2007 Sep 15; PMID: 17875766.
1690. **Shariat SF**, Svatek RS, Kabbani W, Walz J, Lotan Y, Karakiewicz PI, Roehrborn CG. Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy. *BJU Int.* 2008 Jan; Epub 2007 Sep 13. PMID: 17868422.
1691. Bastian PJ, Hutterer GC, **Shariat SF**, Rogers CG, Palapattu GS, Lotan Y, Vazina A, Amiel GE, Gupta A, Sagalowsky AI, Lerner SP, Schoenberg MP, Karakiewicz PI; Bladder Cancer Research Consortium. Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survival. *BJU Int.* 2008 Feb; Epub 2007 Sep 10. PMID: 17850359.
1692. Nielsen ME, Palapattu GS, Karakiewicz PI, Lotan Y, Bastian PJ, Lerner SP, Sagalowsky AI, Schoenberg MP, **Shariat SF**. A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome. *BJU Int.* 2007 Nov; Epub 2007 Sep 3. PMID: 17784888.

1693. Huang HY, **Shariat SF**, Sun TT, Lepor H, Shapiro E, Hsieh JT, Ashfaq R, Lotan Y, Wu XR. Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome. *Hum Pathol*. 2007 Nov; Epub 2007 Aug 17. PMID: 17707461.
1694. Walz J, Gallina A, Saad F, Montorsi F, Perrotte P, **Shariat SF**, Jeldres C, Graefen M, Bénard F, McCormack M, Valiquette L, Karakiewicz PI. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. *J Clin Oncol*. 2007 Aug 20. PMID: 17704404.
1695. **Shariat SF**, Park S, Trinh QD, Roehrborn CG, Slawin KM, Karakiewicz PI. Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms. *J Urol*. 2007 Oct; Epub 2007 Aug 14. PMID: 17698116.
1696. Karam JA, **Shariat SF**, Huang HY, Pong RC, Ashfaq R, Shapiro E, Lotan Y, Sagalowsky AI, Wu XR, Hsieh JT. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder. *Clin Cancer Res*. 2007 Aug 1. PMID: 17671122.
1697. **Shariat SF**, Karam JA, Roehrborn CG. Blood biomarkers for prostate cancer detection and prognosis. *Future Oncol*. 2007 Aug. PMID: 17661720.
1698. Malaeb BS, Rashid HH, Lotan Y, Khoddami SM, **Shariat SF**, Sagalowsky AI, McConnell JD, Roehrborn CG, Koeneman KS. Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts. *Urol Oncol*. 2007 Jul-Aug. PMID: 17628294.
1699. Briganti A, **Shariat SF**, Chun FK, Hutterer GC, Roehrborn CG, Gallina A, Rigatti P, Valiquette L, Montorsi F, Karakiewicz PI. Differences in the rate of lymph node invasion in men with clinically localized prostate cancer might be related to the continent of origin. *BJU Int*. 2007 Sep; Epub 2007 Jun 15. PMID: 17573893.
1700. Gallina A, Karakiewicz PI, Hutterer GC, Chun FK, Briganti A, Walz J, Antebi E, **Shariat SF**, Suardi N, Graefen M, Erbersdobler A, Salonia A, Rigatti P, Huland H, Montorsi F. Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men. *Int J Cancer*. 2007 Aug 15; PMID: 17455251.
1701. Walz J, Gallina A, Hutterer G, Perrotte P, **Shariat SF**, Graefen M, McCormack M, Bénard F, Valiquette L, Saad F, Karakiewicz PI. Accuracy of life tables in predicting overall survival in candidates for radiotherapy for prostate cancer. *Int J Radiat Oncol Biol Phys*. 2007 Sep 1; Epub 2007 Apr 18. PMID: 17446004.
1702. **Shariat SF**, Roehrborn CG, Karakiewicz PI, Dhimi G, Stage KH. Evidence-based validation of the predictive value of the American Association for the Surgery of Trauma kidney injury scale. *J Trauma*. 2007 Apr; PMID: 17426551.
1703. **Shariat SF**, Zlotta AR, Ashfaq R, Sagalowsky AI, Lotan Y. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. *Mod Pathol*. 2007 Apr; Epub 2007 Mar 2. PMID: 17384651.
1704. Chun FK, Briganti A, Gallina A, Hutterer GC, **Shariat SF**, Antebi E, Walz J, Roehrborn CG, Salonia A, Rigatti P, Saad F, Huland H, Montorsi F, Graefen M, Karakiewicz PI. Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium. *Eur Urol*. 2007 Oct; Epub 2007 Mar 20. PMID: 17383807.
1705. Briganti A, Chun FK, Hutterer GC, Gallina A, **Shariat SF**, Salonia A, Scattoni V, Valiquette L, Montorsi F, Rigatti P, Graefen M, Huland H, Karakiewicz PI. Systematic assessment of the ability

- of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy. *Eur Urol.* 2007 Sep; Epub 2007 Mar 6. PMID: 17350750.
1706. **Shariat SF**, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. *Cancer.* 2007 Mar 15; PMID: 17311310.
1707. Karam JA, Lotan Y, Roehrborn CG, Ashfaq R, Karakiewicz PI, **Shariat SF**. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. *Prostate.* 2007 May 1. PMID: 17299799.
1708. Margulis V, **Shariat SF**, Ashfaq R, Thompson M, Sagalowsky AI, Hsieh JT, Lotan Y. Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder. *J Urol.* 2007 Mar. PMID: 17296438.
1709. Karam JA, Lotan Y, Karakiewicz PI, Ashfaq R, Sagalowsky AI, Roehrborn CG, **Shariat SF**. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. *Lancet Oncol.* 2007 Feb. PMID: 17267327.
1710. Gallina A, Chun FK, Briganti A, **Shariat SF**, Montorsi F, Salonia A, Erbersdobler A, Rigatti P, Valiquette L, Huland H, Graefen M, Karakiewicz PI. Development and split-sample validation of a nomogram predicting the probability of seminal vesicle invasion at radical prostatectomy. *Eur Urol.* 2007 Jul; Epub 2007 Jan 22. PMID: 17267098.
1711. **Shariat SF**, Roehrborn CG, McConnell JD, Park S, Alam N, Wheeler TM, Slawin KM. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. *J Clin Oncol.* 2007 Feb 1. PMID: 17264329.
1712. **Shariat SF**, Ashfaq R, Sagalowsky AI, Lotan Y. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. *J Urol.* 2007 Feb. PMID: 17222615.
1713. Margulis V, **Shariat SF**, Ashfaq R, Sagalowsky AI, Lotan Y. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. *Clin Cancer Res.* 2006 Dec 15. PMID: 17189409.
1714. Gallina A, Jeldres C, Chun FK, **Shariat SF**, Briganti A, Walz J, Roehrborn CG, Saad F, Huland H, Graefen M, Montorsi F, Karakiewicz PI. Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL. *Eur Urol.* 2007 Nov; Epub 2006 Dec 11. PMID: 17174466.
1715. **Shariat SF**, Karakiewicz PI, Palapattu GS, Amiel GE, Lotan Y, Rogers CG, Vazina A, Bastian PJ, Gupta A, Sagalowsky AI, Schoenberg M, Lerner SP. Nomograms provide improved accuracy for predicting survival after radical cystectomy. *Clin Cancer Res.* 2006 Nov 15. PMID: 17121885.
1716. Nielsen ME, **Shariat SF**, Karakiewicz PI, Lotan Y, Rogers CG, Amiel GE, Bastian PJ, Vazina A, Gupta A, Lerner SP, Sagalowsky AI, Schoenberg MP, Palapattu GS; Bladder Cancer Research Consortium (BCRC). Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. *Eur Urol.* 2007 Mar; Epub 2006 Nov 13. PMID: 17113703.
1717. **Shariat SF**, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, Schoenberg MP, Lerner SP. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. *J Urol.* 2006 Dec. PMID: 17085118.
1718. **Shariat SF**, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ, Schoenberg MP, Lerner SP, Sagalowsky AI, Lotan Y. Concomitant carcinoma in situ is a feature of aggressive

- disease in patients with organ-confined TCC at radical cystectomy. *Eur Urol.* 2007 Jan; Epub 2006 Sep 11. PMID: 17011114.
1719. Slawin KM, **Shariat S**, Canto E. BPSA: A Novel Serum Marker for Benign Prostatic Hyperplasia. *Rev Urol.* 2005. PMID: 16985891.
1720. **Shariat SF**, Naderi AS, Miles B, Slawin KM. Anomalies of the wolffian duct derivatives encountered at radical prostatectomy. *Rev Urol.* 2005 Spring. PMID: 16985813.
1721. **Shariat SF**, Sadeghi F, Slawin KM. Vaccine-based immunotherapy for prostate cancer. *Rev Urol.* 2000 Fall. PMID: 16985756.
1722. **Shariat SF**, Slawin KM. Gene therapy for prostate cancer. *Rev Urol.* 2000 Spring. PMID: 16985740.
1723. **Shariat SF**, Haddad JL, Escudier S, Lerner SP. Metastatic transitional cell carcinoma of the urinary bladder to the shoulder girdle. *Rev Urol.* 2002 Spring. PMID: 16985663.
1724. Slawin KM, Canto EI, **Shariat SF**, Gore JL, Kim E, Kattan MW, Wheeler TM, Nath RK. Sural Nerve Interposition Grafting during Radical Prostatectomy. *Rev Urol.* 2002 Winter. PMID: 16985648.
1725. **Shariat SF**, Slawin KM. Peripheral blood rt-PCR assays for detection and prognosis of prostate cancer. *Rev Urol.* 2003 Winter. PMID: 16985619.
1726. **Shariat SF**, Canto EI, Kattan MW, Slawin KM. Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer. *Rev Urol.* 2004 Spring. PMID: 16985579.
1727. **Shariat SF**, Palapattu GS, Amiel GE, Karakiewicz PI, Rogers CG, Vazina A, Schoenberg MP, Lerner SP, Sagalowsky AI, Lotan Y. Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. *Urology.* 2006 Sep; Epub 2006 Sep 18. PMID: 16979748.
1728. Karakiewicz PI, **Shariat SF**, Palapattu GS, Gilad AE, Lotan Y, Rogers CG, Vazina A, Gupta A, Bastian PJ, Perrotte P, Sagalowsky AI, Schoenberg M, Lerner SP. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. *J Urol.* 2006 Oct. PMID: 16952631.
1729. **Shariat SF**, Ashfaq R, Sagalowsky AI, Lotan Y. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. *Hum Pathol.* 2006 Dec; Epub 2006 Aug 10. PMID: 16949911.
1730. **Shariat SF**, Marberger MJ, Lotan Y, Sanchez-Carbayo M, Zippe C, Lüdecke G, Boman H, Sawczuk I, Friedrich MG, Casella R, Mian C, Eissa S, Akaza H, Serretta V, Huland H, Hedelin H, Raina R, Miyanaga N, Sagalowsky AI, Roehrborn CG, Karakiewicz PI. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. *J Urol.* 2006 Sep. PMID: 16890655.
1731. Chun FK, Briganti A, **Shariat SF**, Graefen M, Montorsi F, Erbersdobler A, Steuber T, Salonia A, Currilin E, Scattoni V, Friedrich MG, Schlomm T, Haese A, Michl U, Colombo R, Heinzer H, Valiquette L, Rigatti P, Roehrborn CG, Huland H, Karakiewicz PI. Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation. *BJU Int.* 2006 Aug. PMID: 16879673.
1732. Karakiewicz PI, **Shariat SF**, Palapattu GS, Perrotte P, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, Schoenberg M, Lerner SP. Precystectomy nomogram for

- prediction of advanced bladder cancer stage. *Eur Urol.* 2006 Dec; Epub 2006 Jun 23. PMID: 16831511.
1733. Walsh LP, Zimmern PE, Pope N, **Shariat SF**; Urinary Incontinence Treatment Network. Comparison of the Q-tip test and voiding cystourethrogram to assess urethral hypermobility among women enrolled in a randomized clinical trial of surgery for stress urinary incontinence. *J Urol.* 2006 Aug. PMID: 16813912.
1734. **Shariat SF**, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ, Schoenberg MP, Lerner SP, Sagalowsky AI, Lotan Y. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. *Eur Urol.* 2007 Jan; Epub 2006 Jun 8. PMID: 16793197.
1735. Rogers CG, Palapattu GS, **Shariat SF**, Karakiewicz PI, Bastian PJ, Lotan Y, Gupta A, Vazina A, Gilad A, Sagalowsky AI, Lerner SP, Schoenberg MP. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. *J Urol.* 2006 Jun. PMID: 16697800.
1736. Palapattu GS, **Shariat SF**, Karakiewicz PI, Bastian PJ, Rogers CG, Amiel G, Lotan Y, Vazina A, Gupta A, Sagalowsky AI, Lerner SP, Schoenberg MP; Bladder Cancer Research Consortium. Cancer specific outcomes in patients with pT0 disease following radical cystectomy. *J Urol.* 2006 May. PMID: 16600721.
1737. Karakiewicz PI, Benayoun S, Zippe C, Lüdecke G, Boman H, Sanchez-Carbayo M, Casella R, Mian C, Friedrich MG, Eissa S, Akaza H, Huland H, Hedelin H, Rupesh R, Miyanaga N, Sagalowsky AI, Marberger MJ, **Shariat SF**. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. *BJU Int.* 2006 May; Epub 2006 Mar 17. PMID: 16542342.
1738. Svatek RS, Herman MP, Lotan Y, Casella R, Hsieh JT, Sagalowsky AI, **Shariat SF**. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer. *Cancer.* 2006 Apr 15. PMID: 16541433.
1739. **Shariat SF**, Abdel-Aziz KF, Roehrborn CG, Lotan Y. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml. *Eur Urol.* 2006 Feb; Epub 2005 Dec 20. PMID: 16387412.
1740. **Shariat SF**, Duchene D, Kabbani W, Mucher Z, Lotan Y. Gastrointestinal hemorrhage as first manifestation of metastatic testicular tumor. *Urology.* 2005 Dec. PMID: 16360470.
1741. **Shariat SF**, Ashfaq R, Roehrborn CG, Slawin KM, Lotan Y. Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia. *J Urol.* 2005 Nov. PMID: 16217391.
1742. Lotan Y, Gupta A, **Shariat SF**, Palapattu GS, Vazina A, Karakiewicz PI, Bastian PJ, Rogers CG, Amiel G, Perotte P, Schoenberg MP, Lerner SP, Sagalowsky AI. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. *J Clin Oncol.* 2005 Sep 20; Epub 2005 Aug 22. PMID: 16116151.
1743. Matsumoto K, **Shariat SF**, Ayala GE, Rauen KA, Lerner SP. Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer. *Urology.* 2005 Aug. PMID: 16040097.
1744. **Shariat SF**, Raptidis G, Masatoschi M, Bergamaschi F, Slawin KM. Pilot study of radiofrequency interstitial tumor ablation (RITA) for the treatment of radio-recurrent prostate cancer. *Prostate.* 2005 Nov 1. PMID: 16015591.

1745. **Shariat SF**, Matsumoto K, Casella R, Jian W, Lerner SP. Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder. *Eur Urol.* 2005 Jul; Epub 2005 Mar 8. PMID: 15967254.
1746. **Shariat SF**, Herman MP, Casella R, Lotan Y, Karam JA, Stenman UH. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder. *Eur Urol.* 2005 Sep. PMID: 15963628.
1747. **Shariat SF**, Zippe C, Lüdecke G, Boman H, Sanchez-Carbayo M, Casella R, Mian C, Friedrich MG, Eissa S, Akaza H, Sawczuk I, Serretta V, Huland H, Hedelin H, Rupesh R, Miyanaga N, Sagalowsky AI, Wians F Jr, Roehrborn CG, Lotan Y, Perrotte P, Benayoun S, Marberger MJ, Karakiewicz PI. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. *J Urol.* 2005 May. PMID: 15821471.
1748. Ramirez A, Perrotte P, Valiquette L, Benard F, McCormack M, Saad F, Fournier C, **Shariat S**, Karakiewicz PI. Exploration of health-related quality of life areas that may distinguish between continent diversion and ileal conduit patients. *Can J Urol.* 2005 Feb. PMID: 15777491.
1749. Karakiewicz P, **Shariat SF**, Naderi A, Kadmon D, Slawin KM. Reliability of remembered International Index of Erectile Function domain scores in men with localized prostate cancer. *Urology.* 2005 Jan. PMID: 15667878.
1750. Defreitas GA, Zimmern PE, Lemack GE, **Shariat SF**. Refining diagnosis of anatomic female bladder outlet obstruction: comparison of pressure-flow study parameters in clinically obstructed women with those of normal controls. *Urology.* 2004 Oct. PMID: 15491697.
1751. Canto EI, Singh H, **Shariat SF**, Kadmon D, Miles BJ, Wheeler TM, Slawin KM. Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection. *J Urol.* 2004 Sep. PMID: 15310993.
1752. Khoddami SM, **Shariat SF**, Lotan Y, Saboorian H, McConnell JD, Sagalowsky AI, Roehrborn CG, Koeneman KS. Predictive value of primary Gleason pattern 4 in patients with Gleason score 7 tumours treated with radical prostatectomy. *BJU Int.* 2004 Jul. PMID: 15217428.
1753. **Shariat SF**, Menesses-Diaz A, Kim IY, Muramoto M, Wheeler TM, Slawin KM. Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. *Urology.* 2004 Jun. PMID: 15183988.
1754. Singh H, Karakiewicz P, **Shariat SF**, Canto EI, Nath RK, Kattan MW, Slawin KM. Impact of unilateral interposition sural nerve grafting on recovery of urinary function after radical prostatectomy. *Urology.* 2004 Jun. PMID: 15183964.
1755. Canto EI, **Shariat SF**, Slawin KM. Molecular diagnosis of prostate cancer. *Curr Urol Rep.* 2004 Jun; Review. PMID: 15161569.
1756. Canto EI, Singh H, **Shariat SF**, Lamb DJ, Mikolajczyk SD, Linton HJ, Rittenhouse HG, Kadmon D, Miles BJ, Slawin KM. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. *Urology.* 2004 May. PMID: 15134977.
1757. Link RE, **Shariat SF**, Nguyen CV, Farr A, Weinberg AD, Morton RA, Richardson B, Bernard D, Slawin KM. Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening. *J Urol.* 2004 Jun. PMID: 15126793.
1758. Lotan Y, **Shariat SF**, Khoddami SM, Saboorian H, Koeneman KS, Cadeddu JA, Sagalowsky AI, McConnell JD, Roehrborn CG. The percent of biopsy cores positive for cancer is a predictor of

- advanced pathological stage and poor clinical outcomes in patients treated with radical prostatectomy. *J Urol*. 2004 Jun. PMID: 15126787.
1759. **Shariat SF**, Anwuri VA, Lamb DJ, Shah NV, Wheeler TM, Slawin KM. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. *J Clin Oncol*. 2004 May 1. PMID: 15117988.
1760. Singh H, Canto EI, **Shariat SF**, Kadmon D, Miles BJ, Wheeler TM, Slawin KM. Predictors of prostate cancer after initial negative systematic 12 core biopsy. *J Urol*. 2004 May. PMID: 15076292.
1761. Ohori M, Kattan MW, Koh H, Maru N, Slawin KM, **Shariat S**, Muramoto M, Reuter VE, Wheeler TM, Scardino PT. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. *J Urol*. 2004 May. PMID: 15076291.
1762. Vazina A, Dugi D, **Shariat SF**, Evans J, Link R, Lerner SP. Stage specific lymph node metastasis mapping in radical cystectomy specimens. *J Urol*. 2004 May. PMID: 15076287.
1763. **Shariat SF**, Kattan MW, Traxel E, Andrews B, Zhu K, Wheeler TM, Slawin KM. Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. *Clin Cancer Res*. 2004 Mar 15. PMID: 15041717.
1764. **Shariat SF**, Casella R, Wians FH Jr, Ashfaq R, Balko J, Sulser T, Gasser TC, Sagalowsky AI. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology. *Eur Urol*. 2004 Mar. PMID: 15036675.
1765. Stephenson AJ, **Shariat SF**, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, Klein EA, Kupelian PA, Roehrborn CG, Pistenmaa DA, Pacholke HD, Liauw SL, Katz MS, Leibel SA, Scardino PT, Slawin KM. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. *JAMA*. 2004 Mar 17. PMID: 15026399.
1766. **Shariat SF**, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, Lerner SP. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. *J Clin Oncol*. 2004 Mar 15; Epub 2004 Feb 23. PMID: 14981102.
1767. **Shariat SF**, Lotan Y, Saboorian H, Khoddami SM, Roehrborn CG, Slawin KM, Ashfaq R. Survivin expression is associated with features of biologically aggressive prostate carcinoma. *Cancer*. 2004 Feb 15. PMID: 14770431.
1768. **Shariat SF**, Khoddami SM, Saboorian H, Koeneman KS, Sagalowsky AI, Cadeddu JA, McConnell JD, Holmes MN, Roehrborn CG. Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy. *J Urol*. 2004 Mar. PMID: 14767284.
1769. Singh H, Canto EI, **Shariat SF**, Kadmon D, Miles BJ, Wheeler TM, Slawin KM. Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. *J Urol*. 2004 Mar. PMID: 14767277.
1770. **Shariat SF**, Casella R, Khoddami SM, Hernandez G, Sulser T, Gasser TC, Lerner SP. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. *J Urol*. 2004 Feb. PMID: 14713774.
1771. Singh H, Canto EI, **Shariat SF**, Kadmon D, Miles BJ, Wheeler TM, Slawin KM. Six additional systematic lateral cores enhance sextant biopsy prediction of pathological features at radical prostatectomy. *J Urol*. 2004 Jan. PMID: 14665877.

1772. Matsumoto K, **Shariat SF**, Casella R, Wheeler TM, Slawin KM, Lerner SP. Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. *J Urol*. 2003 Dec. PMID: 14634390.
1773. **Shariat SF**, Casella R, Monoski MA, Sulser T, Gasser TC, Lerner SP. The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer. *J Urol*. 2003 Dec. PMID: 14634389.
1774. Kattan MW, Eastham JA, Wheeler TM, Maru N, Scardino PT, Erbersdobler A, Graefen M, Huland H, Koh H, **Shariat SF**, Slawin KM, Ohori M. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. *J Urol*. 2003 Nov. PMID: 14532778.
1775. **Shariat SF**, Kattan MW, Song W, Bernard D, Gottenger E, Wheeler TM, Slawin KM. Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy. *Cancer Res*. 2003 Sep 15. PMID: 14522912.
1776. **Shariat SF**, Matsumoto K, Kim J, Ayala GE, Zhou JH, Jian W, Benedict WF, Lerner SP. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder. *J Urol*. 2003 Sep. PMID: 12913755.
1777. Kattan MW, **Shariat SF**, Andrews B, Zhu K, Canto E, Matsumoto K, Muramoto M, Scardino PT, Ohori M, Wheeler TM, Slawin KM. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. *J Clin Oncol*. 2003 Oct 1; Epub 2003 Aug 11. PMID: 12913106.
1778. **Shariat SF**, Roudier MP, Wilcox GE, Kattan MW, Scardino PT, Vessella RL, Erdamar S, Nguyen C, Wheeler TM, Slawin KM. Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. *Cancer Res*. 2003 Aug 1. PMID: 12907647.
1779. **Shariat SF**, Kim J, Raptidis G, Ayala GE, Lerner SP. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. *Urology*. 2003 Jun. PMID: 12809883.
1780. **Shariat SF**, Monoski MA, Andrews B, Wheeler TM, Lerner SP, Slawin KM. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. *Urology*. 2003 May. PMID: 12736046.
1781. Canto EI, **Shariat SF**, Slawin KM. Biochemical staging of prostate cancer. *Urol Clin North Am*. 2003 May; Review. PMID: 12735503.
1782. **Shariat SF**, Kattan MW, Erdamar S, Nguyen C, Scardino PT, Spencer DM, Wheeler TM, Slawin KM. Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein. *J Clin Oncol*. 2003 Apr 1. PMID: 12663708.
1783. **Shariat SF**, Kim J, Nguyen C, Wheeler TM, Lerner SP, Slawin KM. Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer. *Urology*. 2003 Feb. PMID: 12597948.

1784. **Shariat SF**, Kim JH, Ayala GE, Kho K, Wheeler TM, Lerner SP. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. *J Urol*. 2003 Mar. PMID: 12576817.
1785. Casella R, **Shariat SF**, Monoski MA, Lerner SP. Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma. *Cancer*. 2002 Dec 15. PMID: 12467062.
1786. **Shariat SF**, Gottenger E, Nguyen C, Song W, Kattan MW, Andenoro J, Wheeler TM, Spencer DM, Slawin KM. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. *Cancer Res*. 2002 Oct 15. PMID: 12384565.
1787. Andrews B, **Shariat SF**, Kim JH, Wheeler TM, Slawin KM, Lerner SP. Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. *J Urol*. 2002 Mar. PMID: 11832773.
1788. **Shariat SF**, Lamb DJ, Kattan MW, Nguyen C, Kim J, Beck J, Wheeler TM, Slawin KM. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. *J Clin Oncol*. 2002 Feb 1. PMID: 11821468.
1789. **Shariat SF**, Kim JH, Andrews B, Kattan MW, Wheeler TM, Kim IY, Lerner SP, Slawin KM. Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. *Cancer*. 2001 Dec 15. PMID: 11753975.
1790. Kim JH, **Shariat SF**, Kim IY, Menesses-Diaz A, Tokunaga H, Wheeler TM, Lerner SP. Predictive value of expression of transforming growth factor-beta(1) and its receptors in transitional cell carcinoma of the urinary bladder. *Cancer*. 2001 Sep 15. PMID: 11745225.
1791. **Shariat SF**, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. *Urology*. 2001 Dec. PMID: 11744478.
1792. Tokunaga H, **Shariat SF**, Green AE, Brown RM, Zhou JH, Benedict WF, Lerner SP. Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens. *Int J Radiat Oncol Biol Phys*. 2001 Sep 1. PMID: 11516846.
1793. **Shariat SF**, Shalev M, Menesses-Diaz A, Kim IY, Kattan MW, Wheeler TM, Slawin KM. Preoperative plasma levels of transforming growth factor beta(1)(TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. *J Clin Oncol*. 2001 Jun 1. PMID: 11387358.
1794. Gore JL, **Shariat SF**, Miles BJ, Kadmon D, Jiang N, Wheeler TM, Slawin KM. Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. *J Urol*. 2001 May. PMID: 11342916.
1795. Byrne RR, **Shariat SF**, Brown R, Kattan MW, Morton RA JR, Wheeler TM, Lerner SP. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. *J Urol*. 2001 May. PMID: 11342899.
1796. Leventis AK, **Shariat SF**, Slawin KM. Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. *Radiology*. 2001 May. PMID: 11323468.
1797. **Shariat SF**, Desai S, Song W, Khan T, Zhao J, Nguyen C, Foster BA, Greenberg N, Spencer DM, Slawin KM. Adenovirus-mediated transfer of inducible caspases: a novel "death switch" gene therapeutic approach to prostate cancer. *Cancer Res*. 2001 Mar 15. PMID: 11289132.

1798. Leventis AK, **Shariat SF**, Utsunomiya T, Slawin KM. Characteristics of normal prostate vascular anatomy as displayed by power Doppler. *Prostate*. 2001 Mar 1. PMID: 11241550.
1799. Leventis AK, **Shariat SF**, Kattan MW, Butler EB, Wheeler TM, Slawin KM. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. *J Clin Oncol*. 2001 Feb 15; Erratum in: *J Clin Oncol* 2001 Apr 1. PMID: 11181666.
1800. **Shariat SF**, Pahlavan S, Baseman AG, Brown RM, Green AE, Wheeler TM, Lerner SP. E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. *Urology*. 2001 Jan. PMID: 11164145.
1801. Slawin KM, **Shariat SF**, Nguyen C, Leventis AK, Song W, Kattan MW, Young CY, Tindall DJ, Wheeler TM. Detection of metastatic prostate cancer using a splice variant-specific reverse transcriptase-polymerase chain reaction assay for human glandular kallikrein. *Cancer Res*. 2000 Dec 15. PMID: 11156423.
1802. **Shariat SF**, Weizer AZ, Green A, Laucirica R, Frolov A, Wheeler TM, Lerner SP. Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. *Urology*. 2000 Nov 1. PMID: 11068290.
1803. **Shariat SF**, Bergamaschi F, Adler HL, Nguyen C, Kattan MW, Wheeler TM, Slawin KM. Correlation of preoperative plasma IGF-I levels with pathologic parameters and progression in patients undergoing radical prostatectomy. *Urology*. 2000 Sep 1. PMID: 10962307.
1804. Djavan B, **Shariat S**, Ghawidel K, Güven-Marberger K, Remzi M, Kovarik J, Hoerl WH, Marberger M. Impact of chronic dialysis on serum PSA, free PSA, and free/total PSA ratio: is prostate cancer detection compromised in patients receiving long-term dialysis? *Urology*. 1999 Jun. PMID: 10367847.
1805. Djavan B, Fakhari M, **Shariat S**, Ghawidel K, Marberger M. A novel intraurethral prostatic bridge catheter for prevention of temporary prostatic obstruction following high energy transurethral microwave thermotherapy in patients with benign prostatic hyperplasia. *J Urol*. 1999 Jan. PMID: 10037387.
1806. Djavan B, Roehrborn CG, **Shariat S**, Ghawidel K, Marberger M. Prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha-blocker treatment of patients with benign prostatic hyperplasia. *J Urol*. 1999 Jan. PMID: 10037386.
1807. Djavan B, **Shariat S**, Fakhari M, Ghawidel K, Seitz C, Partin AW, Roehrborn CG, Marberger M. Neoadjuvant and adjuvant alpha-blockade improves early results of high-energy transurethral microwave thermotherapy for lower urinary tract symptoms of benign prostatic hyperplasia: a randomized, prospective clinical trial. *Urology*. 1999 Feb. PMID: 9933035.
1808. Djavan B, Lin V, Kaplan EP, Richier JC, **Shariat S**, Marberger M, McConnell JD. Decreased elastin gene expression in noncompliant human bladder tissue: a competitive reverse transcriptase-polymerase chain reaction analysis. *J Urol*. 1998 Nov. PMID: 9783926.
1809. Djavan B, **Shariat S**, Schäfer B, Marberger M. Tolerability of high energy transurethral microwave thermotherapy with topical urethral anesthesia: results of a prospective, randomized, single-blinded clinical trial. *J Urol*. 1998 Sep. PMID: 9720545.
1810. Djavan B, Zlotta AR, Byttebier G, **Shariat S**, Omar M, Schulman CC, Marberger M. Prostate specific antigen density of the transition zone for early detection of prostate cancer. *J Urol*. 1998 Aug. PMID: 9679889.

1811. Djavan B, Susani M, **Shariat S**, Zlotta AR, Silverman DE, Schulman CC, Marberger M. Transperineal radiofrequency interstitial tumor ablation (RITA) of the prostate. *Tech Urol*. 1998 Jun. PMID: 9623628.
1812. Djavan B, Zlotta AR, Susani M, Heinz G, **Shariat S**, Silverman DE, Schulman CC, Marberger M. Transperineal radiofrequency interstitial tumor ablation of the prostate: correlation of magnetic resonance imaging with histopathologic examination. *Urology*. 1997 Dec. PMID: 9426739.

NON-PEER-REVIEWED PUBLICATIONS

1. Tatsushi Kawada, Ekaterina Laukhtina, Fahad Quhal, et al. Oncologic and Safety Outcomes for Endoscopic Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An Updated Systematic Review and Meta-analysis. Letter to the Editor re:*Eur Urol Focus* 2023;9:236-40.
2. Kawada T, Laukhtina E, Araki M, **Shariat SF**.*Eur Urol Focus*. 2023 Aug 8:S2405-4569(23)00180-3. doi: 10.1016/j.euf.2023.07.009. Online ahead of print.PMID: 37563005 No abstract available.
3. Laukhtina E, **Shariat SF**. Re: DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection with Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial. *Eur Urol*. 2023 Jun 1: PMID: 37270391
4. Hassler MR, **Shariat SF**. Re: Lymph Node Colonization Induces Tumor-immune Tolerance To Promote Distant Metastasis. *Eur Urol*. 2022.PMID: 35786326
5. Laukhtina E, **Shariat SF**. Re: Phase II Study of Gemcitabine and Split-dose Cisplatin plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer. *Eur Urol*. 2022 Apr 30:S0302-2838(22)01816-4. PMID: 35501200
6. **Shariat SF**. A commentary on: Comparative Cardiovascular Safety of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data. PracticeUpdate website. Available t: <https://www.practiceupdate.com/content/cardiovascular-safety-of-novel-hormonal-agents-in-mcrpc/132622/65/3/1>. Accessed March 17, 2022
7. Mori K, Schmidinger M, Egawa S, Gust KM, **Shariat SF**. Reply to Xiaoshuai Gao, Guo Chen, and Xin Wei's Letter to the Editor re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. *Eur Urol* 2021;79:783-92. *Eur Urol*. 2021 Sep 24:S0302-2838(21)02037-6. PMID: 34579998
8. Soria F, D'Andrea D, Gontero P, **Shariat SF**. Reply to Francesco Montorsi Letter to the Editor re: Francesco Soria, Marco Moschini, David D'Andrea, et al. Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. *Eur Urol Focus* 2020;6:1233-9. *Eur Urol Focus*. 2021 Apr 16:S2405-4569(21)00108-5. PMID: 33875390
9. Wenzel M, Nocera L, Ruvolo CC, Würnschimmel C, Tian Z, **Shariat SF**, Saad F, Briganti A, Tilki D, Graefen M, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI.*J Urol*. 2021 Apr PMID: 33820427
10. Mori K, Egawa S, **Shariat SF**. Re: Enzalutamide and Survival in Nonmetastatic Castration-Resistant Prostate Cancer. *Eur Urol*. 2020 Dec 20:S0302-2838(20)30935-0. PMID: 33357991

11. Huebner NA, **Shariat SF**. Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer. Eur Urol. 2019 Sep 19. PMID: 31542306
12. **Shariat S.**, Pones M. Urologische Medikamente und männliche Fertilität ClinCum Urologie CC Urologie 4/18, S. 18-19
13. **Shariat S.**: BCG Mythen Kommentar: Bladder cancer. ClinCum Urologie. CC Urologie 4/18, S. 22
14. **Shariat S.**, Hübner N.: Bedeutsame Risikofaktoren für Prostatakrebs. Rauchen stellt einen der vermeidbarsten Einflussfaktoren dar. Hausarzt 11/2018, S. 30-31
15. **Shariat S.**: Wettbewerb im Gesundheitswesen – Risiken in Lösungen umwandeln. klinik 1/2018, Gedanken, S. 12-13
16. **Shariat S.** Empathie – ein Schlüsselement zum Erfolg als Arzt und Führungskraft. klinik 2/2018, Gedanken, S. 8
17. Grubmüller B., **Shariat S.**, Remzi M.: Prostataembolisation zur Behandlung von LUTS – Ist der Hype evidenzbasiert? klinik 3/2018, S. 23-26
18. **Shariat S.**: Jahresrückblick 2017 Update zum Prostatakarzinom. krebs:hilfe! 1-2/2018, S. 16-17
19. **Shariat S.**: Editorial: Wir orientieren uns an der Klinik. krebs:hilfe! 8-9/2018
20. **Shariat S.**, Gust K. Panorama Perioperative Chemotherapie beim invasiven Urothelkarzinom des oberen Harntraktes. Adjuvant oder jetzt doch neoadjuvant? SO 4/2018, S. 106-108
21. Gust K., **Shariat S.**: „Cisplatin unfit“ – Wahl der Erstlinientherapie beim metastasierten Urothelkarzinom Personalisierte Medizin / Reihe „Molekulares Tumorboard“ SO 8/2018, S. 74-77
22. **Shariat S.**: Herausforderungen im Management der überaktiven Blase. Spectrum Urologie SU 4/2018, S. 38-39
23. D’Andrea, Gust K., **Shariat S.**: Drastische Verbesserung der Prognose nach jahrelanger unbefriedigender systemischer Therapie. 25 Jahre Jubiläum. Referat Metastasiertes Urothelkarzinom. Urologik 1/2018, S. 20-22
24. **Shariat S.**, Huebner N.: Prostatakrebs Vorbeugung. Diagnose. Therapie. Urologik 1/2018, S. 22
25. **Shariat S.**, Korn S.: Testosteronsupplementationstherapie und metabolisches Syndrom. Urologik 3/2018, S. 30
26. **Shariat S.**, Remzi M., Resch I.: Organerhaltende Therapie beim Urothelkarzinom des oberen Harntraktes (UTUC). J Urol Urogynäkol 2/2018, S. 72-74
27. **Shariat S.**, Huebner N.: Prostatakrebs Vorbeugung. Diagnose. Therapie. Urologik 1/2018, S. 22
28. **Shariat S.**: Prostatakrebs Therapie & Vorsorge. gesund & fit, 12.02.2018, S. 36
29. **Shariat S.**: Weintrinken und Prostatakrebs. gesund & fit, 30.04.2018, S. 23 / top-ärzte
30. **Shariat S.**: Aerzte-Tipp der Woche: Prostatakrebs Vorsorge. gesund & fit, 22.08.2018, S. 23
31. **Shariat S.**, Hübner N.: Wichtige Risikofaktoren für Prostatakrebs. gesund.at, 17.10.2018
32. **Shariat S.**: Leben Sprechstunde. Über Harninkontinenz beim Mann. active beauty Nr.4, Juni 2018, S.112
33. **Shariat S.**: Atezolizumab - Wirksamkeit beim Urothelkarzinom, Bewertung und Aussichten. ArzneimittelPROFIL 2018

34. **Shariat S.**, Rieken M.: <http://www.krebs-magazin.eu/prostatakrebs-jeder-10-mann-betroffen>
Krebsmagazin EU 2018
35. **S.F. Shariat**, M. Pones. Urologische Medikamente und männliche Fertilität. *CliniCum Urologie* 4/18, S. 18-19
36. **S.F. Shariat**: BCG Mythen Kommentar: Bladder cancer. *CliniCum Urologie* 4/18, S. 22
37. **S.F. Shariat**, N. Hübner Bedeutsame Risikofaktoren für Prostatakrebs: Rauchen stellt einen der vermeidbarsten Einflussfaktoren dar. *Hausarzt* 11/2018, S. 30-31
38. **S.F. Shariat** Wettbewerb im Gesundheitswesen – Risiken in Lösungen umwandeln. *Klinik* 1/2018, Gedanken, S. 12-13
39. **S.F. Shariat** Empathie – ein Schlüsselement zum Erfolg als Arzt und Führungskraft. *klinik* 2/2018, Gedanken, S. 8
40. B. Grubmüller, **S.F. Shariat**, M. Remzi: Prostataembolisation zur Behandlung von LUTS – Ist der Hype evidenzbasiert? *klinik* 3/2018 *klinik*, S. 23-26
41. **S.F. Shariat** Update zum Prostatakarzinom. *krebs:hilfe!* 1-2/2018, S. 16-17
42. **S.F. Shariat** Editorial: Wir orientieren uns an der Klinik. *krebs:hilfe!* 8-9/2018
43. **S.F. Shariat**, K Gust: Panorama. Perioperative Chemotherapie beim invasiven Urothelkarzinom des oberen Harntraktes. Adjuvant oder jetzt doch neoadjuvant? *Spectrum Onkologie* 4/2018, S. 106-108
44. K Gust, **S.F. Shariat**: Personalisierte Medizin / Reihe „Molekulares Tumorboard“. „Cisplatin unfit“ – Wahl der Erstlinientherapie beim metastasierten Urothelkarzinom. *Spectrum Onkologie* 8/2018, S. 74-77
45. **S.F. Shariat** Herausforderungen im Management der überaktiven Blase. *Spectrum Urologie* 4/2018, S. 38-39
46. D. D’Andrea, K.M. Gust, **S.F. Shariat** Drastische Verbesserung der Prognose nach jahrelanger unbefriedigender systemischer Therapie. 25 Jahre Jubiläum. *Urologik* 1/2018, S. 20-22
47. **S.F. Shariat**, S. Korn Testosteronsupplementationstherapie und metabolisches Syndrom *Urologik* 3/2018, S. 30
48. **S.F. Shariat**, M. Remzi, I. Resch Organerhaltende Therapie beim Urothelkarzinom des oberen Harntraktes (UTUC). *J Urol Urogynäkol* 2/2018, S. 72-74
49. **S.F. Shariat** Ein TCM-Kraut, das krank macht. *derStandard.at* Gesundheit, Therapie & Medikamente, 24.11.2018
50. **S.F. Shariat** Mann im Blickfeld: So wird Prostatakrebs behandelt. Heute 13.11.2018, S. 27
51. **S.F. Shariat** Prostatakrebs Autor: Ernst Mauritz *Kurier.at*
52. **S.F. Shariat** Lexikon #prostata. Experten-Talk: Prostatakrebs Therapie & Vorsorge *gesund & fit*, 12.02.2018, S. 36
53. **S.F. Shariat** Neuer Ratgeber: Wissen um Erkrankungen der Prostata *gesund & fit*, 03.04.2018, S. 25
54. **S.F. Shariat** Weintrinken und Prostatakrebs. *gesund & fit*, 30.04.2018, S. 23
55. **S.F. Shariat** Ärzte-Tipp der Woche: Prostatakrebs Vorsorge. *gesund & fit*, 22.08.2018, S. 23
56. **S.F. Shariat** Leben Sprechstunde Über Harninkontinenz beim Mann. *active beauty* Nr.4, Juni 2018, S.112

57. **S.F. Shariat**, N. Hübner Wichtige Risikofaktoren für Prostatakrebs. gesund.at 17.10.2018
58. **S.F. Shariat** Atezolizumab - Wirksamkeit beim Urothelkarzinom, Bewertung und Aussichten ArzneimittelPROFIL 12/2018
59. Gust KM, **Shariat SF**. Re: Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Carcinoma (PURE-01): An Open-label, Single-arm, Phase II Study. Eur Urol. 2019 Jan 7. PMID: 30630644
60. Moschini M, Zaffuto E, Mattei A, Karakiewicz PI, **Shariat SF**. Reply to Alba Fiorentino, Angelo Errico, and Marcello Scarcia's Letter to the Editor Radiation therapy versus radical prostatectomy: no way out without a randomized trial. Eur Urol. 2018 Nov 30. PMID: 30509762
61. D'Andrea D, **Shariat SF**, Soria F. Re: Docetaxel versus surveillance after radical prostatectomy for high-risk prostate cancer: results from the prospective randomised, open-label phase 3 scandinavian prostate cancer group 12 Trial. Eur Urol. 2018 Jul 30. PMID: 30072209
62. **Shariat S.**, Resch I.: DFP-Literaturstudium: Rauchen und Urologie. Clinicum Urologie. CC 1-2/17
63. **Shariat S.**: Manuela Schmidinger: Young Docs Urologie. Uro-Oncology Academy: Vorwort zur Fortbildungsveranstaltung. Clinicum Urologie.
Shariat S., Garstka N.: Uro-Oncology Academy: 10 Tipps für junge Assistenzärzte. Clinicum Urologie. CC 1-2/17
64. **Shariat S.**, Mun D.: Urothelkarzinom der Blase Therapie der Zukunft. Clinicum Urologie. CC 3/17
65. **Shariat S.**, Schmidinger M.: Uro-Oncology Academy: Vorwort zur Fortbildungsveranstaltung. Clinicum Urologie. CC 3/17
66. **Shariat S.**, Eschlböck J., Veser J.: Uro-Oncology Academy: Wie bereitet man eine hervorragende Journal Club Präsentation vor. Clinicum Urologie. CC 3/17
67. **Shariat S.**, Garstka N.: Active Surveillance bei kleinen Nierentumoren. Clinicum Urologie. CC 5/17
68. **Shariat S.**, Schmidinger M.: Uro-Oncology Academy: Vorwort zur Fortbildungsveranstaltung. Clinicum Urologie. CC 5/17
69. **Shariat S.**, Resch I.: DFP-Literaturstudium: Immuntherapien – ihr Stellenwert beim uro-onkologischen Patienten Clinicum Urologie. CC 5/17
70. **Shariat S.**: Mit RESPECT verständlicher kommunizieren. Management & Karriere. Clinicum Onkologie 11/2017
71. **Shariat S.**: Gelebte Komplexität im Gesundheitswesen. 3/2017 klinik, Seite 26.
72. Gust K., **Shariat S.**: Der große Jahresrückblick. Blasenkarzinom: Immuntherapie-Zulassungen werden erwartet. krebs:hilfe! 1-2/2017, Seite 23.
73. Resch I., **Shariat S.**: ASCO 2017: Die Take Home Messages. Zehn Highlights zum Urothelkarzinom. krebs:hilfe! 7/2017, Seiten 18-21.
74. **Shariat S.** ESMO 2017: Sechs Abstracts zum Urothelkarzinom. krebs:hilfe! 10/2017, Seite 47.
75. Grubmüller B., **Shariat S.**: Systemische Therapie, primäre lokale Therapie, Metastasektomie und darüber hinaus...Die Behandlung des oligometastasierten Prostatakarzinoms. SPECTRUM ONKOLOGIE 2/2017, Seiten 32-34.
76. **Shariat S.**, Garstka N.: Die Rolle der Ärzte bei der Unterstützung der Patienten im Entscheidungsprozess. SPECTRUM ONKOLOGIE 3/2017, Seiten 102-103.

77. **Shariat S.**, Mun D.: Die wachsende Bedeutung der aktiven Überwachung bei kleinen Nierentumoren. SPECTRUM ONKOLOGIE 4/2017, Seiten 82-85.
78. **Shariat S.**: Panorama: Männergesundheit 2017. Das nächste Ziel. SPECTRUM UROLOGIE 1/2017, Seite 32-33.
79. **Shariat S.**: Journal Club. Testosteron-Ersatztherapie bei älteren Männern. Julian Vesper
80. Resch I., **Shariat S.**, Gust K.: Focus: Neue Konzepte in der Urologie/Immunonkologie. Immun-Checkpoint-Inhibitoren in der Therapie des Harnblasenkarzinoms. SPECTRUM UROLOGIE 2/2017, Seite 16-17.
81. **Shariat S.**, Vesper J.: Effektives Mentoring - Goldene Regeln für Mentees. Urologik 1/2017, Seiten 34-35.
82. Irene Resch, **Shariat S.**: EAU 2017: Aktuelle Studien in der Uroonkologie: Neues zum Urothelkarzinom. Urologik 2/2017, Seiten 15-18.
83. Garstka N., **Shariat S.**: ProtecT-Studie für Prostatakrebs. Unsere Interpretation der ersten Ergebnisse. Urologik 2/2017, Seiten 18-20.
84. **Shariat S.**, Maary S.: Ein neuer Standard für das metastasierte Prostatakarzinom? Urologik 3/2017, Seiten 28-29.
85. **Shariat S.**, Remzi M., Resch I.: Organerhaltende Therapie beim Urothelkarzinom des oberen Harntraktes (UTUC) Springer Verlag - Journal für Urologie und Urogynäkologie
86. **Shariat S.**: Gesund-Guide für den Sommer. Die Blase schützen: Gesund&Fit, 29.07.2017
87. D'Andrea D., **Shariat S.**: Benigne Prostatahyperplasie (BPH). Der Hausarzt, 03.10.2017
88. **Shariat S.**: Ich bin 50 und...Gesund&Fit. 15.11.2017
89. **Shariat S.**: Blut im Harn – Was kann das sein? Gesund&Fit, 11.12.2017
90. D'Andrea D, **Shariat SF**. Re: Adjuvant chemotherapy vs observation for patients with adverse pathologic features at radical cystectomy previously treated with neoadjuvant chemotherapy. Eur Urol. 2017 Sep 27. PMID: 28964632
91. D'Andrea D, **Shariat SF**. Re: Radiation with or without antiandrogen therapy in recurrent prostate cancer. Eur Urol. 2017 Jun 20. PMID: 28645490
92. D'Andrea D, **Shariat SF**. Re: Comparative effectiveness of treatment strategies for bladder cancer with clinical evidence of regional lymph node involvement. Words of wisdom. Eur Urol. 2017 PMID: 28599913
93. **Shariat SF**. Electronic cigarettes: a wolf in sheep's clothing. Eur Urol. 2017 Jan 24. pii: S0302-2838(17)30021-0. PMID: 28129891
94. **Shariat SF**, Gust KM. Immune therapy meets precision medicine. Lancet Oncol. 2017 Mar;18(3):271-273. PMID: 28271858
95. **Shariat SF**. ICUD guidelines for upper tract urothelial carcinoma: a state-of-the-art evidence-based guidance for clinical decisions regarding diagnosis, management and treatment. World J Urol. 2017 Mar;35(3):325-326. PMID: 28197726
96. Moschini M, **Shariat SF**. Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE Trial. Words of wisdom. Eur Urol. 2016 Aug;70(2):398-9. PMID: 27353963

97. Lucca I, **Shariat SF**. Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. *Eur Urol*. 2016 Jul;70(1):205-6. PMID: 27302292
98. Mathieu R, **Shariat SF**. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. *Eur Urol*. 2016 Apr;69(4):755-6. PMID: 26972499
99. Rieken M, **Shariat SF**. Letter to the Editor. *Eur Urol*. 2015 Aug 24. PMID: 26314617
100. Mathieu R, **Shariat SF**. Nadir testosterone within first year of androgen-deprivation therapy (adt) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. *Eur Urol*. 2015 Sep;68(3):537-8. PMID: 26282354
101. **Shariat S.**, Klatter T.: Blasenkarzinom. *Österreichische Ärztezeitung* 10:28-36, 2015
102. Maj-Hes A., **Shariat S.**: Active Surveillance bei Prostatakrebs – Entscheidungshilfe. *Spectrum Urologie* 1:44-5, 2015
103. **Shariat S.**: Neue perioperative Konzepte- Verbesserung des outcomes nach radikale Zystektomie. *Spectrum Urologie* 1:53-4, 2015
104. **Shariat S.**: Urology Expert Forum 2014. *Spectrum Urologie* 1: 29, 2015
105. **Shariat S.**, Krainer M.: Vorwort zu Forschung beim Prostatakarzinom, *Spectrum Onkologie* 4:10-12, 2014
106. Maj-Hes A., Kramer G., **Shariat S.**: Androgendeprivationstherapie: *Spectrum Onkologie* 4:17-20, 2014
107. DeSantis M., **Shariat S.**: Das Urothelialkarzinom – Fokus auf einen Tumor, der selten im Fokus steht. *Spectrum Urologie* 3, 2013
108. **Shariat S.**, Loidl W., Dorfinger K.: Smoking kills. *CliniCum Urologie* 4: 12, 2014
109. Eschelboeck J., **Shariat S.**: Transurethrale Resektion des Blasen Tumors (TURBT): Room for improvement. *Spectrum Urologie* 3, 2014
110. **Shariat S.**, Hiess M.: Die prophylaktische Zirkumzision – weshalb ist die Zirkumzision in den USA so häufig? *Spectrum Urologie* 3, 2014
111. W. Horninger, K. Pummer, **S. Shariat**: Urologische Forschungslandschaft 2030 in Österreich. *NÖGU* 26-31, 2014
112. Hiess M., **Shariat S.**: Späte Morbidität bei Hodentumorpatienten. *Urologik* 5:68, 2014
113. **Shariat S.**, Maj-Hes A., Loidl W., Dorfinger K.: Was tun angesichts der BCG-Knappheit? *Spectrum Urologie* 3: 3-4, 2014
114. **Shariat S.**, Loidl W., Dorfinger K.: Schluss mit Rauchen. *Urologie* 4: 12, 2014
115. Grubmüller B., **Shariat S.**: Nicht muskulinvasives Blasenkarzinom: wie eine „zu späte“ radikale Zystektomie zu verhindern ist. *Spectrum Urologie* 2: 8-11, 2014
116. Maj-Hes A., **Shariat S.**: Gesundheit der Österreicher auf der Kippe. Urologen vereint gegen den Tabakkonsum. *Spectrum Urologie* 3: 10-3, 2014
117. **Shariat S.**: Was bedeutet Behinderung? Unsere Sprache beeinflusst unser Denken. *Klinik* 5: 16-7, 2014
118. Lucca I, Klatter T, **Shariat SF**. Radical prostatectomy or watchful waiting in early prostate cancer. *Eur Urol*. 2014 Aug;66(2):386-7. PMID: 25305785

119. Catto JW, Cooperberg MR, Cornu JN, Gratzke C, Novara G, **Shariat S**, Vickers A. European Urology: Serving Our Readership Through Systematic Peer Review, Use of Reporting Standards, and Encouragement of Postpublication Review. *Eur Urol.* 2014 Aug 27. PMID: 25175422
120. **Shariat S.**: Bladder cancer: the curious case of a not so rare disease. *Curr Opin Urol.* 2014 Sep;24(5):483-6. PMID: 24992244
121. **Rink M., Shariat S.**: Re: global effects of smoking, of quitting, and of taxing tobacco. *Eur Urol.* 2014 Jul;66(1):176-8. doi: 10.1016/j.eururo.2014.03.039.
122. **Shariat S.**, Swietek N.: Urologische Traumata. *Clinicum Urologie* 6-11, 1, 2014.
123. **Shariat SF**, Klatter T. Optimal results come from optimal surgery and optimal (neoadjuvant) systemic therapy. *BJU Int.* 2014 Apr;113(4):516-7. doi: 10.1111/bju.12611. PMID:24629083
124. Klatter T., **Shariat S.**: Impfungen & Immuntherapien: Prostatakarzinom-Impfung: Gegenwart und Zukunft. *medonline.at*
125. **Shariat S.**, Maddaluno D.: Alte und neue therapiestrategien beim Nichturothelkarzinom. *Urologik* 5/13: 14-20, 2013
126. **Shariat S.**, Maddaluno D.: Die zytoreduktive nephrektomie bei mRCC: die Frage ist nicht ob, sondern wann. *Haematologie & Onkologie* 5/13 p. 91-7.
127. Klatter T., **Shariat S.**: Novel Urinary Markers for Detection of Bladder Cancer-Are we Failing? *J Urol.* 2013 Oct 16. PMID:24139809
128. Xylinas E., Klatter T., Matin S., **Shariat S.**: Prognostic factors, markers and tools in upper tract urothelial carcinoma. *Urol List* 2013: 11(3):30-39
129. Schubert T., **Shariat S.**, Rieken M.: Alte und neue Marker in Diagnostik and Nachkontrolle. *Spectrum Urologie* 3:10-12, 2013
130. Mandel P., **Shariat S.**, Tilki D.: Lymphadenektomie bei klinisch nicht metastasietrten Harnblasenkarzinom. *Spectrum Urologie* 3:28-30, 2013
131. Klatter T., **Shariat S.**: Aktuelle und relevante Studien Juli/August/Spetember 2013 – ausgewaehlt vom Journal Club der urologischen Klinik am AKH Wien. *Spectrum Urologie* 3:42, 2013
132. **Shariat S.**: Meet the Expert – Prostata und Potenz. *Spectrum Urologie Sonderausgabe*: 1, 2013
133. Rieken M., **Shariat S.F.**: Biomarkers for screening and early detection of prostate cancer. *Hamdan Medical Journal*, 2013 Vol 6 Issue 2, p 121-9
134. Xylinas E, **Shariat SF**. Re: Prospective Randomized Phase II Trial of a Single Early Intravesical Instillation of Pirarubicin (THP) in the Prevention of Bladder Recurrence After Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma: The THP Monotherapy Study Group Trial. *Eur Urol.* 2013 Oct;64(4):683-4. PMID:23998501
135. Remzi M, **Shariat SF**. Bladder cancer: Is contrast-enhanced CT necessary for following up NMIBC? *Nat Rev Urol.* 2013 Sep;10(9):500-1. PMID: 23917120
136. Rieken M, **Shariat SF**: Renal Cancer Therapy: Going Forward by Going Backward? *Eur Urol.* 2013 Feb 16. PMID: 23433808
137. Xylinas E, Kluth L, **Shariat SF**: Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 Randomised Trial. *Eur Urol.* 2013 Jun;63(6):1132-3. PMID: 23608083

138. Kluth LA, Xylinas E, **Shariat SF**: Re: A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. *Eur Urol.* 2013 Feb;63(2):399-400. PMID: 23272731
139. **Shariat SF.**: Vorwort - Focus Prostatakarzinom. *Spectrum Urologie* 2:11-16, 2012
140. Rink M., **Shariat SF.**, Graefen M.: Aktive Ueberwachung: wer, wann und wie? *Spectrum Urologie* 2:18-21, 2012
141. Kluth L., **Shariat SF.**: Akenzeichen XY ungelöst: Chemopraevention. *Spectrum Urologie* 2:22-23, 2012
142. **Shariat SF**: 13 Tipps für eine erfolgreiche urologische Forschung. *Urologik* 5:22-23, 2012
143. Catto JW, **Shariat SF**. The changing face of renal cell carcinoma: the impact of systematic genetic sequencing on our understanding of this tumor's biology. *Eur Urol.* 2012 Sep 26. PMID: 23026395
144. **Shariat SF**, Xylinas E. Biomarkers in personalised treatment of renal-cell carcinoma. *Lancet Oncol.* 2012 Jun 29. . PMID: 22759479
145. Tagawa ST, **Shariat SF**: Is adjunctive systemic chemotherapy after cystectomy for T2N+ disease of therapeutic benefit? No. *J Urol.* 2012 Aug;188(2):359-60. No abstract available. PMID: 22966496
146. Ehdaie B, **Shariat SF**: Magnetic Resonance Imaging-Targeted Prostate Biopsy: Back to the Future. *Eur Urol.* 2012 Jul 4. No abstract available. PMID: 22790287
147. **Shariat SF**: Reply Letter to the Editor. *Eur Urol.* 2012 Jun 28. PMID: 22763080
148. Rink M, Fajkovic H, **Shariat SF**. Das Modell der „klinischen Stadien“: Was es ist und warum wir es benötigen. *SPECTRUM urologie* (1): 8-11. 2012
149. Galsky MD, Tagawa ST, **Shariat SF**: Is adjunctive systemic chemotherapy after cystectomy for t2n+ disease of therapeutic benefit? *J Urol.* 2012 Jun 13. PMID: 22704119
150. Rink M, Cha EK, **Shariat SF**. Recent research will improve outcomes of patients with upper tract urothelial carcinoma. *Eur Urol.* 2011 Nov 3. PMID:22071142
151. Fajkovic H, Chromecki T., Breinl E., Pummer K., Eisenmenger M., **Shariat SF**: Geschlechtsspezifische Charakteristika des Harnblasenkarzinoms: Inzidenz, Staging und Prognose. *Urologik* 4: 4-9, 2011
152. Fajkovic H, **Shariat SF**: Renal cell carcinoma in the era of targeted therapy: the role of cytoreductive nephrectomy. *Urologik* 3: 22-25, 2011
153. Cha EK, **Shariat SF**: Potential role of photodynamic techniques combined with new generation flexible ureterorenoscopes and molecular markers for the management of urothelial carcinoma of the upper urinary tract: adapting new technologies for the diagnosis and management of upper tract urothelial carcinoma. *BJU Int.* 2011 Oct 10. PMID: 21985330
154. Rink M, **Shariat SF**: Can We Apply Nomograms Derived in the United States to European Patients? Yes, We Can! *Eur Urol.* 2011 Aug 27. PMID: 21885183
155. Ramasamy R, **Shariat S**: Book review of Evidence-based Urology. *BJUI.* 2011; 1007:1844
156. Merseburger AS, **Shariat S**: Urothelial carcinoma. *World J Urol.* 2011 Aug;29(4):405-7. Epub 2011 Jul 21. No abstract available. PMID: 21779833

157. Dubin J, Chromecki T., Beltran H., Goldenberg S., Cha E., Karakiewicz P., Zeltser I., Scherr D., Tagawa S., **Shariat S.**: Management of Castration-Resistant Prostate Cancer in 2011. *Annals Of Urology*, 2011
158. Sun M., Abdollah F., Schmitges J., Jeldres C., **Shariat S.**, Perrotte P., Karakiewicz P.: Clinical experience and critical evaluation of the role of everolimus in advanced renal cell carcinoma. *Open Access Journal of Urology* 2011;3 43–48
159. Pierre I Karakiewicz, Cha EK, **Shariat S**: The use of 5 α -reductase inhibitors for the prevention and treatment of prostate cancer. *Eur Urol.* 2011 Jan 25. . PMID: 21277077.
160. Ahallal Y, **Shariat S**, Touijer KA: Les biomarqueurs émergents du cancer de la prostate: diagnostic, staging et pronostic. *Clinical Urology* 2010; 6:266-74.
161. **Shariat S**, Chromecki T: Highlights Bladder Cancer AUA 2010. *Debates on Bladder Cancer Yearbook* 2010, page 29-39. **Shariat S**, Tilki D: Bladder cancer: Nomogram aids clinical decision making after radical cystectomy. *Nat Rev Urol.* 2010 Apr;7(4):182-4.
163. **Shariat S**, Hammerich K: Words of wisdom. Re: Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. *J Urol* 2008;179:1830-7; discussion 1837. *Eur Urol.* 2009 Jan;55(1):245-6.
164. **Shariat S**, Karam JA, Karakiewicz PI. Words of wisdom. Re: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. *N Engl J Med* 2007;356:2271-81. *Eur Urol.* 2009 Jan;55(1):250-2. PMID: 20050019.
165. Godoy G, Chade DC, **Shariat SF**. Words of wisdom. Re: Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. *Polascik TJ, Mayes JM, Sun L, Madden JF, Moul JW, Mouraviev V. Eur Urol.* 2009 Sep; PMID: 19824127.
166. Karakiewicz PI, Suardi N, **Shariat SF**. The search for better prognostic factors for men treated for localized prostate cancer continues. *Eur Urol.* 2008 Apr; Epub 2007 Dec 17. PMID: 18093722.
167. **Shariat SF**, Hammerich KH. Words of wisdom. Re: Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. *Siddiqui SA, Boorjian SA, Inman B, Bagniewski S, Bergstralh EJ, Blute ML. J Urol* 2008; discussion 1837. *Eur Urol.* 2009 Jan; PMID: 20050015.
168. Sonpavde G, **Shariat SF**: Preoperative chemotherapy for bladder cancer: A standard waits to be optimally deployed. *Cancer.* 2011 PMID: 21732335
169. Lughezzani G, **Shariat S**, Sun M, Karakiewicz P.: Reply to Joan Palou, Oscar Rodríguez and Noel Clarke's Letter to the Editor re: Umberto Capitanio, Shahrokh F. Shariat, Hendrik Isbarn, et al. Comparison of Oncologic Outcomes for Open and Laparoscopic Nephroureterectomy: A Multi-Institutional Analysis of 1249 Cases. *Eur Urol* 2009;56:1-9.
170. Isbarn H, Capitanio U, **Shariat S**, Karakiewicz P: Laparoscopic or open nephroureterectomy? Which is the more efficient way to go? *Eur Urol.* 2009 May 3.
171. Capitanio U., **Shariat S.**, Karakiewicz P.: Reply. *Urology.* 2008 Dec;72(6):1212-3.
172. Svatek R., **Shariat S.**: Words of wisdom. Re: Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. *Eur Urol.* 2008 Sep;54(3):690-1. PMID: 18792446.
173. **Shariat S.**, Bolenz C., Karakiewicz P.: Words of wisdom. Re: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

- Escudier B, Pluzanska A, Koralewski P, et al., for the AVOREN Trial investigators. *Eur Urol.* 2008 Oct;54(4):948-9. PMID: 18953756.
174. **Shariat S**, Karam J., Raman J.: Urine cytology and urine-based markers for bladder urothelial carcinoma detection and monitoring: developments and future prospects. *Biomarkers Med* 2(2): 165-80, 2008.
175. Capitanio U., Briganti A., **Shariat S.**, Karakiewicz P.: The importance of the quantification of the extent of cancer in prostatic biopsies in prediction of biochemical recurrence: a global perspective. *Eur Urol.* 2008 Jul 21.
176. Gupta A., **Shariat S.**, for the Bladder Cancer Research Consortium: Reply by authors. *Urology.* 2008 Oct 7;
177. Svatek R., **Shariat S.:** Editorial Comment on: Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. *Eur Urol.* 2008 Jul 14.
178. **Shariat S.:** Editorial Comment on: Large-scale real-time reverse transcription-PCR approach of angiogenic pathways in human transitional cell carcinoma of the bladder: identification of VEGFA as a major independent prognostic marker. *Eur Urol.* 2008 May 23.
179. **Shariat S.:** Editorial Comment on: Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer. *Eur Urol.* 2008 May 21.
180. **Shariat S.**, Skinner E., Montorsi F.: A tribute to John P. Stein (1962-2008): surgeon, scientist, teacher, and humanist. *Eur Urol.* 2008 Aug;54(2):479. 2008
181. **Shariat S.**, Karam J., Raman J.: Urine cytology and urine-based markers for bladder urothelial carcinoma detection and monitoring: developments and future prospects. *Biomarkers in Medicine* 2 (2), 165-180, 2008.
182. Karakiewicz P., Capitanio U., **Shariat S.:** Editorial Comment on: Prostate growth and prevalence of prostate diseases in early onset spinal cord injuries. *Eur Urol.* 2008 Feb 8.
183. **Shariat S.**, Svatek R.: Editorial Comment on: Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsy. *Eur Urol.* 2008 May 15. (Epub ahead of print)
184. **Shariat S.**, Margulis V., Karakiewicz P.: More nomograms or better evidence of efficacy: what do we need in urologic oncology? *Eur Urol.* 2008; 54:11-12.
185. **Shariat S.**, Karakiewicz P.: Perspectives on prostate cancer biomarkers. *Eur Urol.* 2008 Jul; 54(1):8-10.
186. **Shariat S.**, Karam J., Lotan Y.: Critical evaluation of urinary markers for bladder detection and monitoring. *Abstracts in Hematology & Oncology* 10(2), 2007.
187. **Shariat S.**, Karakiewicz P.: Screening for prostate cancer in 2007: the PSA era and its challenges are not over. *Eur Urol.* 2008 Mar;53(3):457-60.
188. Nielsen M., **Shariat S.**, Lotan Y.; on behalf of the Bladder Cancer Research Consortium (BCRC) Investigators: Reply to Vincent Fradet and Badrinath R. Konety. *BJU Int.* 2008 Jan; 101(2):258-259.
189. **Shariat S.:** Blasenkarzinom: Was der Praktiker wissen sollte! *Avicenna* 2(1): 24-9, 2007.
190. **Shariat S.**, Karam J., Roehrborn C.: Novel biomarkers for prostate cancer. *Abstracts in Hematology & Oncology* 10(3):21-30, 2007.

191. **Shariat S.:** Facing the challenges of T1 bladder cancer. *Issues in Urology*, 19(2): 54-55, 2007.
192. **Shariat S.:** Editorial: Will volume-based referral strategies reduce costs or just save lives? *European Urology*, 50(1): 62–63, 2006.
193. **Shariat S., Casella R., Lerner S.:** Answer to letter from C. Sier and F. Blasi RE: Urinary level of urokinase-type plasminogen activator and its receptor in the detection of bladder cancer. *Cancer*, 98(9): 1995-6, 2003.
194. **Shariat S., Slawin K.:** Peripheral blood RT-PCR assays for detection and prognosis of prostate cancer. *Reviews in Urology*, 5(1): 54-58, 2003.
195. Slawin K., **Shariat S., Canto E., Kattan M., Wheeler T.:** Beyond PSA: new serum markers for improved diagnosis and management of prostate cancer. *Recent Advances and Research Updates* ISSN-0972-4699, 3(2): 175-186, 2002.
196. **Shariat S., Lerner S.:** Editorial -The use of molecular markers for diagnosis, staging and prognosis in bladder cancer, *Oncology*, November; 15(11): 1479-80, 2001.
197. **Shariat S., Sadeghi F., Slawin K.:** Vaccine-based immunotherapy for prostate cancer. *Reviews in Urology*, 2(4): 222-7, 2000.
198. **Shariat S., Slawin K.:** Gene therapy for prostate cancer. *Reviews in Urology*, 2(2): 81-7, 2000.

ABSTRACTS over 2000; available on request

BOOK EDITOR

1. **Shariat S., Xylinas E.:** *Advances in Bladder Cancer Management*. 220 pages. October, 2015. Future Medicine Ltd. doi: 10.2217/9781780844237 eISBN (PDF): 978-1-78084-423-7
2. **Shariat S., Xylinas E.:** *Upper Tract Urothelial Carcinoma*. Springer 2014. ISBN: 978-1-4939-1500-2 (Print) 978-1-4939-1501-9 (Online) Downloaded over 3,102x (status 6/12/2017)

BOOK CHAPTERS

1. Operative standards for cancer surgery urothelial from Smerican College of surgerons snd the alliance for clinical trials in oncology, volume 3, 2023
2. Comperat E., Oszwald A., Wasinger G., **Shariat S., Amin M.:** Update on flat and papillary urothelial lesions: genitourinary pathology society consensus recommendations. *Surgical Pathology Clinics* 15:4 629-441, 2023
3. Kardoust Parizi M., **Shariat S.:** Risk Stratification of Upper Tract Urothelial Carcinoma for Kidney-Sparing Surgery Pages 387-402. . *Bladder Cancer: A Practical Guide*. 2021
Editors: Kamat, Ashish M., Black, Peter (Eds.)

4. Korn S., **Shariat S.**: Gender Differences in Bladder and Kidney Cancers. Editor Marianne J. Legato Principles of Gender-Specific Medicine. 2017
5. D'Andrea D., **Shariat S.**: Urothelial tumors of the upper urinary tract. Textbook of Urology edited by Peter Nyirady. Semmelweis Publishers, Budapest, 2016.
6. **Shariat S.**, Xylinas E.: Advances in Bladder Cancer Management. October 2015, Pages 2-5. Doi: 10.2217/fmeb2013.14.150
7. Xylinas E., Mitra A., Daneshmand S., **Shariat S.**: Molecular markers for screening, detection and prognosis of bladder cancer. In Advances in Bladder Cancer Management. October 2015, Pages 62-88. Doi: 10.2217/fmeb2013.14.157
8. Rieken M., **Shariat S.**, Robinson B.: Nonurothelial cancers of the bladder. In Advances in Bladder Cancer Management. October 2015, Pages 192-204. Doi: 10.2217/fmeb2013.13.314
9. Lee D., **Shariat S.**, Holzbeierlein J.: bladder cancer. Geriatric Urology. Ed T. Griebing. Springer 2014.
10. Xylinas E., Novara G., Remzi M., Karakiewicz P., and **Shariat S.**: Prognostics Factors, Molecular Markers, and Predictive Tools in Upper Tract Urothelial Carcinoma. *Upper Tract Urothelial Carcinoma*, Springer 2014
11. **Shariat S.** and Bochner B.: Urinary diversion. UpToDate. 2009-present
12. Lee R. and **Shariat S.**: Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. In Essentials and Updates in Urologic Oncology (2 Volume Set) 2012. Editor: P.E. Spiess In Essentials and Updates in Urologic Oncology (2 Volume Set) 2012. Editor: P.E. Spiess. ISBN: 978-1-62081-494
https://www.novapublishers.com/catalog/product_info.php?products_id=33161
13. Lee R. and **Shariat S.**: Urinary diversions. In *Textbook of Urologic Oncology*. Spiess P. (eds), 2011.
14. Chromecki T., Margulis V., **Shariat S.**: Upper tract urothelial carcinoma. Editor: P.E. Spiess In Essentials and Updates in Urologic Oncology (2 Volume Set) 2012. Editor: P.E. Spiess. ISBN: 978-1-62081-494 https://www.novapublishers.com/catalog/product_info.php?products_id=33161
15. Bensalah K., **Shariat S.**, Patard J.: Prognostic factors for localized and metastatic renal cell carcinoma. In *Recent Advanced In Renal Cell Carcinoma*. Molins J. (eds), 2008.
16. **Shariat S.** and Roehrborn C.: Prostate cancer detection. In: *Textbook of Prostate Cancer*. Su L. (eds), 2009. **ISBN13**:9781416045755; **ISBN10**:1416045759; Elsevier Science Health Science div
17. **Shariat S.** and Kattan M.: Nomograms for prostate cancers. In: *Textbook of Prostate Cancer*. Thompson I. (eds), 2008.
18. **Shariat S.** and Kattan M.: Risk assessment in prostate cancers. In: *Textbook of Prostate Cancer*. Tewari A. (eds). Springer Verlag, Germany, 2008.
19. **Shariat S.**, Canto E., Slawin K.: Molecular genetics of BPH. In: *Textbook of Benign Prostatic Hyperplasia*. Chapter 9, Vol.2. Kirby R., McConnell J., Fitzpatrick J., Roehrborn C., Boyle P. (eds). Oxford, UK, Isis Medical Media Ltd, 2005.
20. M.Sun, **S.Shariat**, C. Cheng, V. Ficarra, M. Murai, S. Oudard, A.J. Pantuck, R. Zigeuner, P.I. Karakiewicz: Prognostic factors of renal cell carcinoma: A contemporary review. *Kidney Cancer*, (Eds: Z. Kirkali and P. Mulders) 2011 Edition, page 75-98.